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The headroom method proposes to offer medical device developers a simple way to integrate 
health economics into the decision of whether or not to develop a device, so that only 
commercially viable innovations are pursued.  The aim of this PhD research is to evaluate the 
headroom method on this basis.  A mixed-methods approach is used to assess both its 
prognostic ability and its usability by developers. 
Two prospective case studies demonstrate the method‘s early application, whilst efficacy is 
assessed by twenty further case studies where the headroom method is applied retrospectively.  
The headroom method predicted NHS uptake with a sensitivity of 92% and a negative 
predictive value of 67%; however, results reflect the close-to-market context of the study 
sample.  When numerical headroom assessments were considered alongside qualitative 
factors identified (relating to the clinical and market context), the method generally offered a 
good indication of future market potential.  Interviews with twelve potential users of the 
method identified practical issues around time, expertise and objectivity, which varied 
according to the participant‘s involvement in the innovation process.  The headroom method 
is demonstrated to be a flexible approach, which could ground development choices in the 
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CHAPTER 1 INTRODUCTION 
Over the past decade, the UK‘s growing healthcare budget has supported the development of 
many innovative technologies from the medical device industry.  In light of the (ongoing 
2007- 2012) economic downturn and the tightened public spending that has followed, the 
National Health Service (NHS) is now expected to make huge spending cuts, placing 
unprecedented strain on healthcare resources and activity.  Rather than this connoting ruin for 
the medical device industry, device developers have an important part to play in ensuring that 
these savings are made through the increased efficiency of spending, and not at the expense of 
the quality of care received by patients; the market is therefore ripe for innovation.  In 
acknowledging that cost-effectiveness is an important criterion for purchasing decisions, now 
more than ever, the headroom method proposes to integrate consideration of health service 
value into early device development decisions.  Thus, the aim is to better inform the go / no-
go decision to develop a device, which is critical to get right.  This thesis evaluates the 
headroom method in relation to this goal. 
 
1.1  Introduction of concepts 
1.1.1  Economic evaluation in healthcare 
In the context of healthcare, an economic evaluation is simply the comparison of two clinical 
interventions (generally current practice versus its proposed replacement) in terms of their 
costs and consequences (Drummond, O'Brien, Stoddart, & Torrance 1997).  The way in 
which consequences are measured determine whether an economic evaluation is a cost-
effectiveness analysis (CEA: outcome generally measured in natural units such as number of 
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hospital days avoided or life years gained), a cost-utility analysis (CUA: outcome measured in 
terms of [health-related] utility), or a cost-benefit analysis (CBA: outcome measured in 
monetary terms).  Despite these commonly accepted definitions, the often interchangeable use 
of these terms in the literature can be confusing; the reasons for this will be described in 
chapter 4. 
The economic evaluation of a medical product or healthcare intervention is included as 
part of the health technology assessment (HTA)
1—or ‗technology appraisal‘—process of The 
National Institute for Health and Clinical Excellence (NICE).  In the UK, NICE develop 
evidence-based guidelines on the effectiveness of medical interventions, and consider whether 
they are likely to represent a cost-effective use of NHS resources.  A cost-utility approach is 
employed (though it is often labelled a CEA), where benefit is measured in quality adjusted 
life years (QALYs): a measure which accounts for both the duration of health outcome as well 
as the health-related utility experienced.  Thus, a life year is adjusted for health-related quality 
of life (HRQoL), a quality weighting on a scale of 0 to 1: one QALY is equivalent to one year 
in full health. 
By considering the trade-off between the cost and QALY implications of two different 
interventions, NICE consider the new intervention‘s incremental cost-effectiveness ratio 
(ICER) (cost per QALY), which helps determine whether any increase in cost can be justified 
by the health benefit.  In order to make this judgement NICE apply a threshold ICER, the 
derivation of which will be explained in chapter 4, which is based on the opportunity cost of 
health service spending in terms of the health gain that could be generated elsewhere in the 
                                                 
1
 HTA and economic evaluation are sometimes used synonymously in the literature, with the former often being 
used to describe the CEA of a new technology.  In reality, whilst determining cost-effectiveness is an important 
feature of an HTA, an HTA will consider other aspects of the innovation or its impact which are not captured (or 
not fully captured) by its cost-effectiveness, but which are nevertheless important to the decision-maker. 
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system.  The ICER threshold range applied by NICE is £20,000 - £30,000 per QALY, 
implying that an intervention where each extra QALY costs less than £20,000 is considered to 
be cost-effective.  If this health benefit is generated at a cost to the health service of over 
£30,000, however, the intervention is perceived to be too expensive; the same investment 
could buy more health elsewhere.  This is represented in the cost-effectiveness plane in Figure 
1.1, where delta (∆) denotes incremental costs or benefits (as compared with current practice 
which represents the baseline).  The incremental cost represents the net cost implication for 
the health service of the intervention, and the incremental QALY effect is equal to the total 
health utility impact.  The ICER threshold, also referred to as the ‗willingness to pay‘ (WTP), 
is represented by a single threshold value for simplicity.  The implied coverage decision is 
either to reject the proposed technology (shaded area) or to accept it. 
 
Figure 1.1 The cost-effectiveness plane 
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The north-west and south-east quadrants of the cost-effectiveness plane produce intuitive 
coverage decisions: if the intervention is more costly and less effective (is dominated by 
current practice) it will be rejected, and if it is more effective and less costly (dominates 
current practice) it will be accepted.  The south-west and north-east quadrants require a more 
discerning judgement to be made on value for money.  Whilst a new product located in the 
south-west quadrant would technically provide a cost-effective use of resources if it were 
located to the right of the ICER line, it may be ethically or politically unpopular to introduce 
such an intervention.  For a new product or intervention to be situated in the north-east 
quadrant is a common proposition for new medical interventions, and the WTP threshold 
provides the means to judge whether the increased cost can be justified by its health benefit to 
patients. 
1.1.2  Medical devices 
The term ‗medical device‘ covers a huge range of healthcare products and equipment, from 
tongue depressors to body imaging scanners to prosthetic heart valves; they play a vital role in 
preventing, diagnosing, monitoring and treating ailments and diseases (European Commission 
2012).
2
  The main differentiating factor between medical devices (often used synonymously 
with the term ‗medical technologies‘ in the literature and in this thesis) and other healthcare 
products is their mechanism of action, which is physical rather than biochemical.  As apparent 
                                                 
2
 According to the European Commission‘s medical device directive 93/42/EEC:  
„Medical Device‟ means any instrument, apparatus, appliance, software, material or other article, whether used 
alone or in combination, including the software intended by its manufacturer to be used specifically for 
diagnostic and/or therapeutic purposes and necessary for its proper application, intended by the manufacturer 
to be used for human beings for the purpose of: 
- diagnosis, prevention, monitoring, treatment, or alleviation of disease, 
- diagnosis, monitoring, treatment, alleviation of or compensation for an injury or handicap, 
- investigation, replacement or modification of the anatomy or of a physiological process, 
- control of conception, 
and which does not achieve its principal intended action in or on the human body by pharmacological, 
immunological or metabolic means, but which may be assisted in its function by such means. 
 (The council of the European Communities 2007, pp. 5-6) 
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from the European Commission‘s definition, products with a diagnostic function are a sub-
category of medical device, and in this thesis are considered as such (though will be discussed 
specifically where relevant).   
1.1.3  The headroom method 
The headroom method of early economic evaluation, which will be described in detail in 
chapter 4, allows device developers to incorporate consideration of the demand-side 
reimbursement process (decision to buy) into supply-side investment decisions (decision to 
develop).  By grounding the development decision in the potential future value of a device to 
the purchaser, it is thought that development decisions can be better informed.  The method is 
intended to be applied as early as possible, ideally at ‗concept stage‘.  It optimally provides an 
estimation of the maximum reimbursable price (MRP): the greatest price at which the 
healthcare provider might fund the device, which represents the total value of the product to 
the health service based on early expectations of health and cost impact (Girling, Chapman, 
Lilford, & Young 2012).  The method is simple and intuitive, which may be particularly 
important for small businesses who dominate the industry and who are likely to lack the 
resources and health-economic expertise of larger companies (a discussion of the industry 
landscape is presented in chapter 3). 
Whilst the headroom method could be applied within the context of any healthcare 
provider, the context chosen for this thesis is that of the UK, in order to maintain consistency 




1.2  Motivation for the study 
Whilst economic evaluation is well developed in the context of late-stage HTA and coverage 
decisions by providers, its use to inform the early stages of development for industry is less 
well developed, and applied mainly to pharmaceuticals in the literature.  The scene-setting 
chapters 2 and 3 will highlight the gap for the headroom method, both in the literature as well 
as in relation to the device industry‘s composition and structure.   
Whereas in the past, evaluation activity in the health sector was based almost entirely on 
concerns of quality, safety and efficacy—known as the three ‗hurdles‘ to market (Cookson & 
Hutton 2003)—demonstrating a product‘s cost-effectiveness is now increasingly emphasised, 
such that it has become known as the fourth hurdle to market (Taylor, Drummond, Salkeld, & 
Sullivan 2004).  This project explores the potential for cost-effectiveness considerations to be 
incorporated into routine decision-making by industry using the headroom method, thus 
converting this so-called fourth hurdle to market into the first.  The potential benefit of this is 
twofold: reduced spending by developers on ultimately unsuccessful products, and the 
speedier development and uptake of those innovations that could benefit patients and the 
healthcare system. 
The motivation for this particular study—an evaluation of the headroom method—derives 
from the absence of a critical appraisal of this or any other method of early economic 
evaluation in the literature.  By evaluating the method in terms of its ability to usefully inform 
early investment decisions made by device developers, the study provides guidance around 
how useful the method might be and in what ways.  The research questions upon which the 




1.3  Research questions 
The current literature base for the headroom method, outlined in the forthcoming literature 
review chapter, mainly describes the method and applies it to a small number of case studies 
(Cosh et al. 2007;McAteer et al. 2007;McAteer 2011).  By purporting its value to the device 
industry, the implicit hypothesis made by these publications is that the headroom method will 
improve decision-making.  The evaluation presented in this thesis makes this hypothesis 
explicit and, in doing so, matches the study‘s design with the research questions necessary to 
understand the whether this hypothesis is correct: 
Research question 1:  Does the headroom method ‘work’? 
Research question 2:  Is the headroom method ‘usable’ by device developers? 
The first of these questions relates to whether or not the headroom method can usefully 
predict future uptake (the method‘s efficacy), whilst the second relates to whether it could 
feasibly be incorporated into the decision-making practices of device developers (its 
usability).  The efficacy and usability of the headroom method therefore form the key 
evaluation criteria for this study, the definition of which are described in greater detail in the 
methodology chapter 5.  
 
1.4  Methodological approach 
A mixed-methods approach is employed to consider the headroom method‘s potential value to 
device developers.  By adopting this pluralist stance, method choice and design is guided by 
the research questions, which underpin the whole study.  Case study analysis and interviews 
are undertaken, which address not only the predictive capacity of the method and its 
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compatibility with the intended users, but also what pertinent factors are left out and in what 
additional ways it could be useful to device developers.   
1.5  Structure 
A review of the literature is presented in chapter 2, which sets both the headroom method and 
this evaluation within of the wider research landscape.  Further background and rationale for 
the research is presented in chapter 3 in relation to the UK‘s medical device market.  The 
chapter explores the distinguishing features of medical devices and how they mould the 
landscape for innovation as well as its late-stage economic evaluation, which underwent 
reorganisation in the UK in 2009/10 to better reflect these device-specific considerations. 
The theoretical underpinning of economic evaluation in healthcare is provided in chapter 
4, which describes how these health economic principles can be embedded into early 
commercial decisions using the headroom method.  A detailed exposition of the headroom 
method and the way it is applied within this thesis is then presented, which also describes how 
its application has been advanced by the present study.  The methodological approach to the 
project is then presented in chapter 5, which describes the research questions in detail and 
how these will be addressed by the mixed-methods evaluation design. 
The first of two prospective case studies—the near-patient monitor for chronic obstructive 
pulmonary disease (COPD)—is presented in chapter 6, and provides a headroom analysis of a 
device in the very early stages of development.  The retrospective case study investigation is 
then presented in chapter 7, in which 20 devices (identified from the national horizon 
scanning centre (NHSC)‘s 2000-2009 database) are retrospectively evaluated using the 
headroom method, with information searches date restricted to mimic the concept stage of the 
developer.  The method is applied systematically using a pre-specified approach and time 
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limit (under the principle of ‗headroom in a day‘).  These are then followed-up to the present 
day to observe actual market uptake, from which the predictive value of the method is 
considered.  This is followed by the final prospective case study presented in chapter 8, which 
considers the headroom for a protective stocking for leg ulcers, and is conducted using the 
same systematic approach as that developed for the retrospective studies. 
Chapter 9 presents the thematic analysis of interviews with 12 stakeholders, representing a 
range of the method‘s potential users spanning from small and large businesses, to those 
involved in innovation within the NHS, to consultants and individual innovators.  These 
provide a deeper insight into the method‘s value and explore its potential role in device 
development.  In chapter 10, the thesis discussion, results across the whole evaluation are 
synthesised and the convergence of findings is explored.  A critique of this study is presented, 
and implications of the research discussed.  The chapter finishes with a conclusion of the 
headroom method‘s potential use in informing medical device development decisions. 
 
1.6  Summary 
This thesis, for the first time, assesses the possible implications of basing device development 
decisions on early expectations of reimbursement value.  It investigates whether using the 
headroom method to explore commercial viability is feasible or even desirable for device 
developers, and in what ways this may differ according to the type of device or the type of 
developer.  By grounding the research in its real-life context and its real-life implications, the 
study assesses the potential impact of the headroom method, and in what form it should be 
carried forward.  
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CHAPTER 2  LITERATURE REVIEW 
2.1  Introduction 
The health economics literature is continually growing, and at an ever-increasing rate.  Cost-
effectiveness analysis within HTA has long been recognised as a compelling way to ascertain 
value for buyers.  The remit of this project is to explore the use of health economics at the 
beginning rather than the end of the development process: to embed its principles into the 
innovator‘s decision to develop.  This overview of the literature provides a summary of the 
wider on-going dialogue in the subject area, noting some of the key influences and setting out 
the gaps that this project intends to address. 
After describing the origins and impact of health economic evaluation, the current state of 
play in the early economic evaluation literature will be explored.  This is followed by an 
overview of the studies relating specifically to the headroom method.  Consideration of this 
literature base reiterates and substantiates the goals presented in the introduction, by 
describing the current knowledge base and, more importantly, outlining its omissions. 
 
2. 2  Health economic evaluation 
In the leading article of the research journal Pharmacoeconomics‘ first issue, Wells (1992) 
describes the UK healthcare landscape of the late 1980s, where 80% of medicines expenditure 
was in primary care.  In an effort to contain expenditure, the UK Department of Health 
responded by issuing personalised spending targets to GPs (Wells 1992).  This inclination 
toward cost containment has always been a priority for commissioners, and if anything will 
only be prioritised further in the future (the recent plans to make GPs responsible for their 
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own budgets could be seen as a further step in this direction).  However, it is only when 
outcomes are considered in conjunction with costs that true efficiency can be considered; this 
is the basis of health economics.  This section briefly presents its application over recent 
decades. 
It is generally accepted that the free market would lead to a suboptimal allocation of 
healthcare resources due to reasons of equity, uncertainty surrounding future need, 
externalities, uninformed customers and potential for collusion between providers (Sloman 
2003).  Moreover, health is regarded as a merit good whose provision should be on the basis 
of need rather than willingness or ability to pay; that is, we should be regarded as citizens, 
rather than consumers of healthcare (Williams 1997).  In the UK these considerations have 
inspired healthcare services to be organised centrally by the set-up of the publicly funded 
NHS in 1948. 
Health economics deals with the relationship between input and output, input being 
healthcare spending and output being improved outcomes for patients.  In 1971 Archie 
Cochrane described this relationship as unsatisfactory, declaring that large increases in NHS 
spending were not being accompanied by markedly improved outcomes (Cochrane 1971).  
Based on the proviso of a limited budget, health economic evaluation offers decision-makers 
the tools to maximise output relative to a fixed budget input. 
Economic evaluation within healthcare has developed rapidly over the past 50 years.  
Drummond and colleagues (1997) provide a much cited overview of the topic in their book 
‗Methods for the economic evaluation of health care programmes‘.  Economic evaluations (in 
the form of CEA/CUA/CBA) have applications in many subject areas; one fundamental 
requirement for their use to assess healthcare interventions is clinical outcome data on which 
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to base comparisons.  Although the principles of randomised controlled trials (RCTs) were set 
out as early as the 1930s, they were not carried out widely until many years later.  The use of 
CEAs within healthcare developed momentum in the mid-sixties with the availability of such 
RCT data, and the term health technology assessment (HTA) was first coined in 1967 (Banta 
2003).  Previous to this, the use of economic evaluation within the sector was not well 
established, and used crude measures of outcome such as labour productivity (Blumenschein 
& Johannesson 1996).  HTA activity has continued to grow, in response to ever increasing 
healthcare costs and rapid technological developments. 
The speed of development in HTA activity has been especially pronounced in countries 
with publicly funded health services such as Canada, Australia, the UK and Sweden (Banta 
2003;Hutton et al. 2006).  Established in 1999, NICE was the first example within Europe of 
an explicit HTA decision-making body, and is regarded internationally to be the most 
organised and generously funded HTA body in the world (Banta 2003;Hutton et al. 2006).  
Substantial progress has been made toward ensuring that decision-making is as systematic and 
transparent as possible, which has been facilitated by the continual discussion and debate 
around the appropriate stance, methods, and analytical framework of HTA and economic 
evaluation within it (Hutton 2012). 
Although in the UK a specific threshold range for WTP for health benefit in HTA 
decisions has been stated (see chapter 4), this is not the case for all countries.  Whilst those 
countries with a similar approach tend to have a comparable threshold to that employed by 
NICE, others do not explicitly set such a threshold (Vernon, Goldberg, & Golec 2009).  In 
Germany, for example, economic evaluations undertaken by the Institute for Quality and 
Efficiency in Health Care (IQWiG) do not consider an explicit trade-off between costs and 
QALYs; indeed, no specific instrument to measure health benefit is recommended over any 
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other.  The MRP (used to make coverage decisions rather than set prices) is determined by 
information on existing alternatives within specific therapeutic areas (generating ‗efficiency 
frontiers‘), and not within the context of healthcare spending in general (Caro et al. 
2010;IQWiG 2009).  Efficiency is therefore judged on the ability to provide equivalent or 
increased benefits at equal or lower costs (much like the new medical technology committee 
within NICE, which is discussed further in the next chapter). 
Although economic evaluation is applied in various forms across different healthcare 
systems, there is no doubt that consideration of value for money is increasingly prioritised by 
today‘s healthcare purchasers.  As described, demonstrating evidence of cost-effectiveness is 
now commonly labelled the ‗fourth hurdle‘ to market approval (Hutton et al. 2006;Taylor, 
Drummond, Salkeld, & Sullivan 2004).  This assumes, however, that purchasers routinely 
perform economic evaluations in all coverage decisions, which is not the case in practice: 
NICE evaluate a very small proportion of NHS activity.  Hoffman and colleagues (2002) 
investigate the use of economic evaluation by decision-makers within two UK health 
authorities, and identify three main barriers: inflexibility of budgets, poor understanding of 
health-economic outcomes, and the preference that appraisals should be performed and 
disseminated by a trusted source.  Whilst the expansion of NICE‘s appraisal activity over the 
past decade go some way to addressing the last concern, a more recent assessment finds that, 
at a local level, cost-effectiveness still plays a minor role in decision-making (Williams, 
McIver, Moore, & Bryan 2008).  Whilst this is of huge practical importance, these issues are 
for now left to one side and decision-makers are presumed to be rational.  Reconsideration of 
these issues will appear later in the thesis when headroom results are compared with actual 
uptake of new medical devices.  
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Economic evaluation has been presented here in its capacity to inform demand.  These 
evaluations are often organised by industry, to demonstrate the value of their products.  
Pharmaceutical companies pump many more resources into conducting late-stage economic 
evaluations than do medical device companies (Cookson & Hutton 2003).  This tendency 
exists for many reasons, reflecting the commercial makeup of the industry and the nature of 
the products themselves: their lifespan, cost impact, relationship with current practice, and 
compatibility with the clinical trial and economic evaluation process.  The factors that set 
devices apart are well documented in the literature (Siebert et al. 2002;WHO 2010b).  A 
detailed discussion of these issues and how they interrelate is reserved for the next chapter. 
In 1991 Drummond investigated the use of economic evaluation by the pharmaceutical 
industry, finding the activity to be more akin to marketing than scientific investigation due to 
the lack of rigorous standards and bias being common as a result (Drummond 1991).  There 
has been much development in health economic methods since then, and the critical lens 
through which economic evaluations are appraised is increasingly well defined.  The use of 
economic evaluation by industry at the early stages of development is what interests me, and 
is explored from section 2.3 onwards. 
 
2.3  Early health economic evaluation 
„Economics is the science which studies human behaviour as a relationship between ends 
and scarce means which have alternative uses.‟  
                                                                                                              (Robbins 1945, p. 16) 
We have seen that economic evaluation can help buyers determine value for money, based on 
the premise of maximising health subject to a budget constraint.  The use of economics to 
maximise the output of scarce resources must also have a role in the allocation of research and 
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development (R&D) resources by companies.  This section describes the literature relating to 
economic methods applied in the early stages of development.  Competing methods of early 
economic evaluation are presented in section 2.3.1, which is followed by a summary of the 
literature that explores their application in practice (section 2.3.2).  The literature on early 
economic evaluation for medical devices specifically is then summarised in section 2.3.3. 
2.3.1  Methods of early economic evaluation 
The supply-side of the health economy is a long way from optimising the use of 
pharmacoeconomics
3
 in the early stages of development (Miller 2005).  However, the 
increased use of economic evaluation to inform demand has given rise to the development of 
sophisticated early economic modelling techniques.  In the literature, these methods have 
been discussed mainly in relation to pharmaceuticals, partly reflecting their substantial 
commercial value, but also due to the vested interest of the NHS and national agencies in big-
impact new drugs.  The incorporation of economic evaluation into the early stages of 
development can be considered under many relevant headings.  The term ‗early economic 
evaluation‘ renders limited results in a literature search.  However, incorporating search terms 
such as investment appraisal, net present value, decision-support, and R&D brings to light a 
wealth of significant intellectual input. 
In a study of (general) new product development, Cooper and Kleinschmidt (1986) 
conclude that more emphasis should be placed on the initial screening of ideas (the go/no-go 
decision to allocate funds to a proposed project), finding this activity to be both poorly 
executed and highly related to the overall success of a project.  Whereas the headroom 
method (as applied in this thesis) considers product value at the preliminary go/no-go decision 
                                                 
3
 Traditionally referring to the health economic evaluation and technology assessment of pharmaceuticals, the 
term pharmacoeconomics is now often used to refer to health economic activity in general, for any type of 
healthcare product or intervention. 
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stage, the methods presented in the literature relating to the ‗early‘ use of economic evaluation 
refer to its employment anywhere along the development process. 
Sculpher and colleagues (1997) present a framework of iterative economic evaluation, 
applied initially in the early stages of development (once the basic science has been 
investigated), and with estimates being firmed up progressively as more information is 
gathered (though this is explored within the context of publicly funded HTA rather than 
specifically by industry).  These authors were not the first to promote this iterative approach.  
Banta and Thacker (1990) likewise noted the importance of continual reassessment.  
Grabowski (1997) and Fenwick et al. (2000) also emphasise that early health economic 
analyses should be refined iteratively, and that new data should be incorporated as it becomes 
available using Bayesian methods.  Rather than representing a method in itself, a Bayesian 
approach involves estimating prior distributions (e.g. around cost-effectiveness) based on 
current information from available statistical data or from experts and their personal beliefs, 
which can be later updated and transformed into a posterior distribution when more 
information becomes available (Briggs 1999). 
The net present value (NPV) of a project, assessed by valuing the future flow of costs and 
benefits in today‘s terms, is a widely employed framework to assess project viability.  The 
NPV exercise has been advocated for investment decision-making within the healthcare 
industry for many years (Long 1979).  Consideration of a product‘s potential value within the 
healthcare market is unique, as it is not the consumer who determines value but a third-party 
payer.  Backhouse (1998) outlines how drug companies can use NPV and profit 
considerations to optimally design clinical trials.  To this end, the author presents a demand 
and revenue function which, given its date of publication, does not employ a collective WTP 
threshold which is now implicit (even explicit) in many countries.  Indeed, Vernon and 
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colleagues (2009) describe the use of NPV to determine maximum WTP using payer 
reimbursement signals (such as cost-effectiveness thresholds).  This approach is closely 
related to the proposed framework provided by the headroom method, and will be elaborated 
in section 2.4. 
Uncertainty inevitably surrounds any product development decision, so the objective of 
some economic models is to incorporate this parameter into decision-making.  Palmer and 
Smith (2000) describe the use of ‗option value‘ (also ‗real options‘) for HTA decisions, to 
extend allowance for uncertainty from simple bounds (within which actual cost-effectiveness 
is expected to lie) to incorporate the possibility of decision deferral.  Miller (2005) describes 
this framework in relation to NPV calculations for drug development decisions, and goes on 
to set out four more pharmacoeconomic approaches for use in the early phases of drug 
development: clinical trial simulation (CTS), investment appraisal, threshold analysis and 
value of information (VOI).  Whilst CTS and ‗investment appraisal‘ require a synthesis of 
available knowledge (usually from phase I/II clinical trials) and manipulation of these using 
Monte Carlo simulation, Miller‘s description of ‗threshold analysis‘ seems more intuitive but 
still requires partial information about the drug‘s performance.  VOI is described by Miller 
and others as identifying the returns of future research, i.e. evaluating the cost of current 
uncertainty by estimating the expected value of perfect information (Dong, Coyle, & Buxton 
2007).  VOI has traditionally been used to improve the cost-effectiveness of research 
spending, from a societal perspective (Fenwick, Claxton, Sculpher, & Briggs 2000), but has 
been suggested for adaptation to commercial decisions by comparing the cost of making the 
wrong decision to the cost of collecting further information to reduce uncertainty (Vallejo-
Torres et al. 2008). 
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Bartelmes and colleagues (2009) provide perhaps the most comprehensive account of 
assessment methods for innovative healthcare products in the early stages.  The authors 
present the results of a systematic literature search as well as an extensive manual search, the 
executive summary of which is available in English.  The 379 references demonstrate that 
research around development-accompanying assessments is extensive.  Specific methods 
identified include the innovation assessment algorithm for drug innovation, expert systems, 
fuzzy-logic, and the analytical hierarchy process (AHP) (Bartelmes et al. 2009).  Most are 
discussed in relation to drugs, and are not intended for pre-development decisions.  However, 
those that are commonly discussed in the literature, along with their potential limitations, are 
summarised in Table 2.1 (discussion of which is largely informed by a MATCH research 
paper by Johal and Williams (2005)). 
Table 2.1 Summary of development-accompanying methods of economic evaluation 
Method Description Limitations 
NPV Making decisions based on the net present value of a 
project is a generic approach to project assessment 
(and is what the headroom method proposes to 
facilitate).  By estimating the (monetary) value of future 
benefits and costs, identifying when these are likely to 
be realised / incurred, and applying a relevant discount 
rate based on the time-value of money, the net present 
value of the project may be assessed. If this is positive, 
this would indicate a favourable development decision. 
This technique does not account 
for possibility of decision deferral, 
and does not explicitly 
incorporate any uncertainty 
valuation.  Additionally, the 
appropriate discount rate will vary 
between users and may be 
difficult to estimate. 
Real 
Options 
The real options approach derives from the financial 
market, where the holder of an option has the right (but 
not the obligation) to hold on to it in the future.  In a 
similar respect, product development can be seen as a 
series of investments, where the decision to abandon 
(or adjust) a project may be made in the future (Johal, 
Oliver, & Williams 2008).  By allowing for this decision 
deferral option, the present value of an investment 
opportunity is increased. 
The approach is complicated and 
difficulties are likely to arise in 
applying it to the product 
development setting.  The 
requirement of a volatility value (a 
measure of economic 
uncertainty), for example, may be 
unrealistic in practice. 
AHP The analytical hierarchy process is one form of 
multicriteria decision analysis, where both quantitative 
and qualitative factors may be combined.  A hierarchy 
of relevant decision inputs can be created, which are 
weighted by making pair-wise comparisons and using 
mathematical techniques (which can be consolidated 
into computer programmes) to create weightings 
(Hummel, Van Rossum, Verkerke, & Rakhorst 2000). 
As well as potential 
inconsistencies in the numerical 
scales utilised, no theoretical 
foundation for their imposed link 
with the verbal descriptions exists 
(Johal & Williams 2005). 
Additionally, the approach makes 
choices between alternatives, 
rather than determining whether 





Fuzzy logic allows decision-making to incorporate 
current knowledge, past experience, and subjective 
judgements.  It does this by transforming descriptive 
linguistic values or qualitative statements into fuzzy 
numbers (called ‗fuzzification‘). These are then 
assigned weights and aggregated to assess value. 
The concept and application of 
fuzzy logic is quite abstract, and 
requires expert input. 
Expert 
systems 
An expert system is an artificial intelligence technique, 
which uses an imputed knowledge base and inference 
engine to solve a problem.  It has been applied in the 
pharmaceutical sector to assess the chances of 
success of a novel pharmaceutical product (Akoka & 
Leune 1994). 
The knowledge base required by 
the system is time consuming, 
and it may be difficult for experts 
to express and input their 
knowledge in terms of specific 
rules and confidence factors 
(Johal & Williams 2005). 
Information adapted from a MATCH research paper (Johal & Williams 2005) 
2.3.2  The use of early economic evaluation in practice 
Many question the applicability to industry of the methods described due to their conceptually 
challenging nature and reliance on a strong set of assumptions.  Mayhew (2009), for example, 
finds only limited use of the options approach in practice, whilst Bartelmes et al. (2009) note 
that despite the wide methodological literature, methods are generally described vaguely and 
seldom proceed beyond pilot implementation.  The limitations described in Table 2.1 suggest 
practical usability issues for industry.  Annemans and colleagues (2000) outline methods of 
early modelling for drug therapies, and describe their capacity to inform go/no-go and priority 
setting decisions.  Whilst presenting some of the difficulties associated with early modelling, 
the authors offer no guiding framework, but stress that early models must be designed to meet 
the requirements of ‗full-blown‘ (late stage) models (Annemans, Genesté, & Jolain 2000).  
The stance taken in this thesis is that this is not practical or even desirable for very early 
decisions; I aim to investigate whether so called ‗quick and dirty‘ models can offer a useful 
insight into potential value.  
The contribution of early economic evaluation to decision-making within industry has 
been reviewed by Hartz and John (2008), who searched for both methodological contributions 
and empirical studies using early data.  The review reflects the main body of research in the 
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area, where ‗early‘ refers to any stage pre-market.  Even those methods described to 
accompany ‗go/no-go‘ decisions incorporate data from early clinical trials.  The headroom 
method fits most appropriately into the short section relating to the business opportunity 
within pre-clinical market assessment.  Others refer to this as the ‗early value proposition‘ 
(Davey et al. 2011).  Hartz and John (2008) emphasise the importance of identifying 
unsuccessful products as early and accurately as possible, and find that the value of early 
modelling for this purpose is not fully exploited. 
The industry‘s use of early economic evaluation is, perhaps unsurprisingly, not well 
documented (Annemans, Genesté, & Jolain 2000;Hartz & John 2008).  Nevertheless, the 
benefit of terminating the development of unsuccessful products early is clear.  DiMassi 
(2002) finds that if one quarter of all decisions to abandon drug development were shifted 
from phase II to phase I, cost savings of around 8% per approved new drug could be realised.  
The consequences may be even greater for medical devices, whose industry is dominated by 
small companies which rely on a very small number of products.  
2.3.3  Early economic evaluation of medical devices 
As with the findings from the wider literature for early economic evaluation, where the 
timescale of intended application ranges from early clinical trials (Álvarez 2001) to its later 
role in informing pricing (Dranitsaris & Leung 2004), the methodological literature relating to 
devices specifically is wide in scope.  The use of iterative health economic modelling for 
medical devices specifically has been advocated by Vallejo-Torres and colleagues 
(2008;2011), who explain how Bayesian methods can be used to incorporate all available 
information at the various stages of development.  However, the increased complexity of this 
approach as the stages of development progress may pose difficulties to its use in practice by 
device companies (Vallejo-Torres et al. 2008). 
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Dong and Buxton (2006) describe an early assessment of cost-effectiveness for computer-
assisted knee replacement in the absence of formal evidence from clinical trials, based on 
early cost and outcome data which are manipulated using transition probabilities in a Markov 
model.  A year later they supplement this with a VOI analysis to assess the returns of further 
research, though this is addressed from a societal rather than commercial perspective (Dong, 
Coyle, & Buxton 2007).  Research into the use of early HTA has also been provided by 
Craven and colleagues (2009), who describe a straightforward decision-tree spreadsheet tool, 
which was used with the intention of establishing a common understanding of value between 
device developers and the NHS National Innovation Centre.  Whilst many highlight that the 
integration of health economics into early decisions is particularly absent from the device 
industry (Craven, Morgan, Crowe, & Lu 2009), even in large pharmaceutical companies 
pharmacoeconomics is employed to a much greater extent for marketing and reimbursement 
than for R&D, despite economic factors being the second leading cause for research 
termination (DiMasi, Caglarcan, & Wood-Armany 2001;Grabowski 1997). 
Pietzsch & Paté-Cornell (2008) provide a model of early technology assessment for new 
medical devices.  The model considers risk attitude and current information on relevant 
technologies, and builds these into a quantitative model to explore potential effectiveness, 
safety and superiority over existing treatments.  Although presenting a sophisticated approach 
to engineering risk analysis, the model only explores investment ‗value‘ in terms of physical 
device performance, despite listing cost-effectiveness in the critical components of an early 
HTA.  Ijzerman & Steuten (2011) provide a recent overview of the potential for HTA to 
inform decisions made by medical technology developers.  The authors suggest a framework 
of development stages, within which the headroom method would fit into ‗very early HTA‘; 
indeed, the authors incorporate a brief reference to the early work presented on the headroom 
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method by Cosh et al. (2007).  The authors go on to indicate that the method requires the 
existence of a prototype for the product, and that it should be adapted so as to incorporate a 
‗clinical case analysis‘ (Ijzerman & Steuten 2011).  The headroom method‘s application, as 
explained and implemented in this thesis, will demonstrate that early views on clinical 
potential are an integral part of the method, and that it is suggested for the most preliminary of 
feasibility decisions (pre-prototype). 
I have identified limited research into the use of early economic evaluation methods by 
the medical device industry.  Since the inception of MATCH
4
, two studies have been 
undertaken to investigate the decision-making practices of MATCH‘s industry partner base.  
The first, reported in 2005, provides the findings of a postal questionnaire sent to six 
companies: five ‗large‘ (turnover greater than £200 million) and one ‗small‘ (fewer than 15 
people) (Johal & Williams 2005).  The authors found five to incorporate formal economic 
evaluation in product development, but only three at the concept stage.  Four companies used 
an NPV approach (though no details around the derivation of value are provided).  One 
company incorporated a real options approach, and four used internally-developed scoring 
checklists (Johal & Williams 2005).  More recently Craven and colleagues (2009), through a 
series of interviews with MATCH‘s industry partners (12 in total), note that few used health 
economics in early development decisions and none amongst the start-ups or small and 
medium enterprises (SMEs) (no description of the sample is provided).  Though not strictly 
comparable, the divergent findings may reflect the changing industry partner base of the 
organisation, which in the earlier days of MATCH seemed to be much larger companies with 
                                                 
4
 MATCH (the Multidisciplinary Assessment of Technology Centre for Healthcare) is the research collaboration 
within which this PhD has been undertaken.  The research collaboration is between four UK universities 
(Birmingham, Brunel, Nottingham and Ulster) as well as a cohort of industrial partners. 
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more developed processes (reflected in the job roles of the questionnaire respondents, which 
included an R&D director, technology valuation manager and health economics manager). 
As illustrated, early health economic methods have generated substantial research, though 
investigations into their use at the concept stage are largely absent, and their relevance to 
developers remains unaddressed.  The next section describes the literature relating to the 
headroom method specifically. 
 
2.4  The Headroom Method 
The literature reviewed thus far relates to decisions made throughout the development 
process, relies on fairly complex models, and has been mainly explored in relation to 
pharmaceuticals.  The headroom method, which will be explained in detail in chapter 4, aims 
to quantify the reimbursement prospects of a device idea, to allow the developer to compare 
this with projected costs of production and development.  The feasibility of profit may 
thereby be considered before any substantial investment is made.  The basis of this approach 
is by no means novel, but its perspective is distinct.  It represents the application of heath 
economics where effect is supposed rather than known.  The outcome, rather than a cost-
effectiveness ratio, is the identification of the maximum cost to the health service at which the 
device would be cost-effective.  In this context, the term ‗headroom‘ was coined in Cosh et al. 
(2007) and appears in several publications that have emerged from the MATCH collaboration  
(Davey et al. 2011;Girling, Young, Brown, & Lilford 2010;McAteer et al. 2007). 
The theoretical underpinning of the headroom method is most frequently described in 
relation to Sculpher et al.‘s description of the ‗effectiveness gap‘ (Sculpher, Drummond, & 
Buxton 1997), which describes the extent to which current practice could be improved (which 
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is what the headroom method seeks to quantify).  However, the current headroom literature 
largely fails to identify some important parallels with other relevant research, due probably to 
differences in terminology used by this other research and its focus on pharmaceuticals.   
One paper discusses the potential implication of cost-effectiveness thresholds on the 
commercial viability of new drugs, and conceptualises this in a very similar way to headroom 
(Vernon, Goldberg, & Golec 2009).  By describing the cost of a new therapy as the sum of its 
price and associated costs, the authors set out the ICER inequality, and disaggregate the 
maximum price at which the therapy would be cost-effective: ‗...by decomposing a new 
drug‟s price from the total costs of the intervention, firms may “solve” for product price 
levels that satisfy a given threshold...‘ (Vernon, Goldberg, & Golec 2009, p. 800).  They go 
on to describe societal efficiency in R&D investment being achieved where products attract 
investment based on their NPV to the company.  Jena and Philipson (2008) also consider the 
implications of CEA on innovation incentives, whilst Danzon and Towse (2002) identify a 
similar ‗Pmax‘ (maximum price) as that illustrated by Vernon and colleagues.  In the latter, 
which considers the novel use of gene therapy, the authors also outline a useful transformation 
of the maximum price equation into the producer‘s break-even profit constraint (Danzon & 
Towse 2002).  Similar outlooks can be found in both older research (e.g. Grabowski‘s 
‗simulation model‘ (Grabowski 1997)) and new (such as a recent presentation at the European 
Conference on Health Economics titled ‗Early health economic evaluation and value based 
pricing in the development phase of medical products‘ (Koerber 2012)). 
The derivation of an MRP using the headroom method is conceptually akin to a term that 
is now rife in the literature: value based pricing (VBP).  VBP was recommended by the Office 
of Fair Trading in 2007 for the pricing of pharmaceuticals to the NHS, and is to be rolled out 
by 2014 (Department of Health 2010b;Office of Fair Trading 2007).  This has inspired much 
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debate in the literature, reflecting widely varying shades of opinion.  Under VBP, the whole 
‗value‘ of an innovation would be reflected by its price, meaning that all surplus would accrue 
to the producer until patent expiration.  As a concept, VBP has been addressed by others 
under different names, for example the use of cost-effectiveness as a ‗price control‘ (Jena & 
Philipson 2007).  Although not being suggested in this thesis as a pricing tool for medical 
devices, the headroom method is based on the same principle, assuming that the health service 
should be willing to pay up to the maximum ‗value‘ of a device—its MRP.   
In introducing the headroom method, McAteer et al. (2007, p. 344) pose the question: 
‗would it be cost-effective if it works as well as we hope?‘.  Whilst acknowledging that 
sufficient headroom does not guarantee commercial success, for example where a product 
turns out to be less effective than expected, the authors propose that its utilisation as a rule-out 
tool (for those technologies which will never be cost-effective to buyers) will reduce the risk 
of pursuing failures.  To inform the headroom analysis of tissue engineered products, the 
authors supplement a literature search with ‗technical updates‘ from companies and the input 
of expert urologists.  Two potential tissue engineering applications are identified: a bowel 
substitute in cystoplasty for bladder carcinoma, and for urethroplasty in place of buccal 
mucosa (lining of the cheek).  They find headroom to be large for the first indication, but 
possibly too small for the second.  Utilities are elicited using the time trade-off method from 
four clinicians in the first case, and from members of the public in the second.  This time-
intensive means of HRQoL elicitation, which is at odds with the remit of the headroom 
method (to provide a quick and simple overview of market potential), is addressed by 
McAteer in her thesis (McAteer 2011), in which she applies the headroom method to four 
areas of regenerative medicine (two of which are outlined above).  In recognition of the utility 
elicitation problem, she provides an alternative approach: the ‗utility ladder‘.  This will be 
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discussed further in chapter 4, where I present an alternative method of intuitive HRQoL 
estimation. 
Cosh and colleagues (2007) present the same two case studies, and place the headroom 
method within a wider ‗decision framework‘, beginning with considerations of strategic fit.  
As in the paper by McAteer et al. (2007), the QALY benefit for the tissue engineered bladder 
is not discounted despite its ten year duration.  The headroom method has also been applied to 
two health service interventions, the first of which considers the cost-effectiveness of a ‗deep 
cleaning‘ initiative in UK hospitals (Brown & Lilford 2009), and the second of which 
estimates the value to the health service of improved patient handover of care between 
hospital and the community (Yao et al. 2012).  Application of the headroom method outside 
of the MATCH program of research is presented in a discussion paper by Latimer and 
colleagues (Latimer et al. 2011), who assess the cost-effectiveness of a new neck collar for 
patients with motor neurone disease.  Girling and colleagues (2010) extend the concept of 
headroom to incorporate developmental uncertainty, finding that, when combined with the 
flexibility offered by later decision gates, uncertainty enhances early stage valuations.  The 
authors also relate the theory clearly to some of the relevant terms that have been overlooked 
by others (such as the NPV and VBP).  A pricing model is proposed by the same authors 
(Girling, Lilford, & Young 2011).  Although interesting mathematically, the incorporation of 
uncertainty considerations into the headroom method‘s application within this thesis is limited 
to the exploratory testing of alternative assumptions or scenarios.  This is so the method is 
kept straightforward, and as intuitive and accessible as possible to device developers. 
Vallejo-Torres and colleagues (2011) present an important study which builds on the 
literature advocating the incorporation of Bayesian methods into iterative HTA.  The authors 
undertake a retrospective analysis of absorbable pins for treating hallux valgus (bunions), 
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calculating its perceived cost-effectiveness at the early, mid and late stages.  The authors 
restrict literature searches to information that would have been available at the various stages 
of development, an approach also taken in the retrospective case studies presented here 
(chapter 7).  Early headroom/‗effectiveness gap‘ analysis is used to place an upper bound on 
the MRP, which can be compared to expected costs.  The authors assumed that the need for 
surgical removal of metallic pins would be eliminated and half of all stress fractures and 
infections would be avoided, leading to a cost saving of £465.  A QALY impact of 0.05 was 
elicited from five experts and assumed to last for the patient‘s remaining lifetime, leading to 
overall headroom of £21,306, deemed to be sufficient to warrant development.  Probabilistic 
sensitivity and VOI analysis is incorporated into the mid-stage evaluation, and more detailed 
data from clinical trials into the late stage, all of which provided a positive case for the 
innovation (though early expectation of outcome was too optimistic); the device has achieved 
commercial success.  A similar approach (though not retrospective) is presented by van de 
Wetering and colleagues (2012), who employ a step-wise approach to the early HTA of a 
point-of-care diagnostic test for heart failure patients, beginning with a headroom assessment 
and, given favourable results, following this with progressively more sophisticated models. 
Some important contributions have been made in the literature surrounding early 
economic evaluation.  The next section outlines the ways in which this project contributes to 
the current knowledge base. 
 
2.5  How this project fits into the literature 
The motivation for this project was described in the introduction.  An outline of the relevant 
literature demonstrates the gaps in the current research base that this thesis intends to address.  
28 
 
This concluding section of the literature review offers a recap of (a) how the headroom 
method complements or differs from other methods of early economic evaluation, and (b) 
how this project contributes to this field of research.  
The main divergence of the headroom method from other methods of early economic 
evaluation in the literature is in the definition of ‗early‘, which in much of the literature refers 
to any stage pre mass-market.  In the context of this research, the focus is on the concept-stage 
of development.  The various methods presented above aim to increase the efficiency of R&D 
spending by the ‗faster termination of uneconomic projects‟ (Miller 2005, p. 11).  In this 
thesis I consider a framework whereby the projects that could never be cost-effective are 
never embarked upon.  Of course, very early estimates of value will inevitably be speculative, 
and may be seen as lacking the sophistication of other more rigorous approaches that can be 
used in the later stages of development.  However, this thesis aims to evaluate the headroom 
method according to its ability to provide a useful and pragmatic approach to investment 
decisions by device developers.  
The current headroom publications, outlined above, offer only a small handful of 
examples of the method‘s application, therefore providing limited insight into the 
methodological issues and considerations which may vary according to device type, 
relationship with current practice (which is not always a direct replacement), clinical area, etc.  
By drawing upon a relatively large number of case studies—two prospective and twenty 
retrospective—these methodological issues can be explored further, in order to identify any 
barriers or qualifications for the successful application of the method.  By following up the 
retrospective case studies, an initial validation of the method is presented, something that 
Bartelmes and colleagues (2009) describe as largely absent from the literature.  Additionally, 
there is a strong call for an investigation into the value and usability of early decision-making 
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tools for stakeholders (Ijzerman & Steuten 2011;Vallejo-Torres et al. 2008).  As well 
evaluating the method according to considerations of validity, the project also considers 
whether the headroom method might feasibly be integrated into real decision-making by 




CHAPTER 3  THE UK’S MEDICAL DEVICE MARKET—THE 
LANDCAPE FOR INNOVATION AND ITS EVALUATION 
3.1  Introduction 
As this project focuses on medical devices, it is appropriate to describe what sets devices 
apart from other healthcare products.  In doing so, this chapter outlines the wider medical 
device landscape and thereby describes the context within which the headroom method is 
proposed to be applied.  The background of and progress towards recent changes in the 
evaluation of medical devices in the UK is also explored, and will be shown to be sensitive to 
the particular characteristics of the device industry. 
The importance of the life sciences sector—covering pharmaceuticals, medical technology 
and biotechnology—cannot be overstated, given its contribution to both the UK economy and 
the health of the population.  The ever-increasing demand for health and healthcare products 
in the UK is demonstrated in Figure 3.1 by the upward trend in healthcare spending since the 
1960s.  Total healthcare expenditure in 2010/11 was £151.3 billion, equivalent to 10.3% of 
gross domestic product (GDP) (Hawe, Yuen, & Baillie 2011). 
 
Figure 3.1 Health expenditure in the UK as percentage of GDP 
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The ageing of the population and ever higher standard of living expectations means that 
this upward growth in demand is likely to continue, despite constraints to public expenditure.  
The wider fiscal situation suggests that the large yearly increases in inflation-adjusted NHS 
spending which have set the precedent over the past six decades will not continue in the 
immediate future.  However, this does not imply a reduced demand for the output of the life 
sciences industry.  The NHS is in fact reliant on the sector‘s innovative output to make current 
spending go further, and to achieve the ‗efficiency savings‘ that are required of it—£20 billion 
by 2014 (Department of Health 2010b).  This dependence is reciprocated; according to OECD 
health data, 83% of total health expenditure in the UK in 2010 was publicly funded (OECD 
2012), implying that the NHS is a very important customer for the healthcare industry.  This 
interdependency means it is essential that both industry and those making NHS procurement 
decisions are mindful of each other‘s norms, processes and concerns. 
The headroom method offers a mechanism by which industry, at a very early stage, can 
consider the future NHS demand for their products.  As a means of providing some context to 
the topic, this chapter considers the two ends of a spectrum for medical devices in order to 
then observe how they interact: the industry and decision-makers—supply and demand.  By 
considering the market environment for medical devices, and then the process by which 
devices are evaluated, we will see how this second system is adapting to suit the first.  This 
complements the basic premise of this thesis which is essentially to do the opposite: to align 
industry behaviour with the adoption process. 
The chapter is divided into four parts.  Firstly, the distinguishing characteristics of devices 
are presented in section 3.2 by comparing them to pharmaceuticals in terms of their process of 
innovation, with section 3.3 considering the impact of these differences on industry structure.  
Section 3.4 explores the ensuing difficulties in evaluating and regulating medical devices, and 
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includes a review of national appraisal activity over the past ten years.  In section 3.5 the 
response to these difficulties as reflected by changes in the UK‘s appraisal system is 
investigated, and an initial critique of the new evaluation pathway for devices is presented. 
 
3.2  What makes devices different? 
Devices and pharmaceuticals have the same primary objective: to improve patient health.  
They differ in their mechanism of action; whereas pharmaceuticals generate biochemical 
reactions, a device relies on its physicality to treat patients (Campbell 2008).  For this reason, 
drugs interact directly with patients whilst devices do so through a third party—the operator 
(which could be a clinician or even the patient themselves) (Taylor & Iglesias 2009).  This 
dissimilar mechanism of action is the fundamental distinction between drugs and devices, and 
holds important implications for all of the issues explored in this section and indeed the rest of 
the chapter. 
3.2.1  Process of Innovation 
Whereas advances in pharmaceuticals derive from a discovery of new chemical entities or 
combinations, new devices are invented (Campbell 2008).  The innovative proposition of new 
medical devices is therefore wide in scope, ranging from an incremental development of an 
existing technology, to a completely new treatment modality which solves a problem that is 
not managed by existing treatment options.  Of course there are many types of device 
innovation in between, which will be demonstrated by the wide variety of ways in which the 
20 case studies presented in chapter 7 propose to change or supplement current practice. 
Although the scope for pharmaceutical innovation is also wide, the inherent difficulty in 
identifying new chemical entities and developing them for commercial use means that there 
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are relatively few novel pharmaceutical products; there are 218 drug targets
5
 (Imming, 
Sinning, & Meyer 2006).  This contrasts with the medical device sector which is in a state of 
constant development, and is currently made up of around 500,000 products (Campbell 
2008;Eucomed 2011).  Being user-driven, a single medical device may be subject to 
continuous iterative improvements or modifications, and often stem from individual 
clinicians, researchers, or engineers.  This is in contrast to drugs, where innovation is 
generally a result of laboratory work by large teams of scientists and the discovery of new 
compounds with limited scope for alteration.  Once approved, a drug may remain on the 
market for many years with no fundamental changes (World Health Organisation 2010b). 
Whilst there are of course examples of medical devices that become and remain the ‗gold 
standard‘ of treatment for a long time, the trend within the sector of continual redesign and 
replacement means that the typical lifecycle of a device has been estimated to be around 18 
months (Eucomed 2011).  Minor modifications allow others to produce products outside the 
original patent terms, as designs are visible and thus easy to replicate.  By contrast, the patent 
protection of a chemical entity allows companies to maximise the lifetime of their products: 
the EU has the highest level of market protection for pharmaceuticals in the world, with 
patent regimes stretching to 25 years (Lowe 2004).  An investigation into the historical 
lifetimes of 455 drugs in England identified a mean lifetime of 57 years (Hoyle 2010).  
Spending on R&D in the UK device industry is relatively high: £300 million in 2007/8, 
accounting for 5.5% of sales (BIS 2009a).  For the same year, however, the pharmaceutical 
and biotechnology sector spent 15.3% of sales on R&D, contributing over a quarter of all 
industrial R&D in the UK (ABPI 2011b;BIS 2009b).  This disparity reflects industry 
                                                 
5
 A drug target is the native protein or cell structure in the body which can be targeted and modified by a drug, to 
produce a therapeutic effect. 
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structure.  As the lifecycle of a product is also its investment recovery period, pharmaceuticals 
have far greater scope for recouping the vast resources they direct towards R&D, although 
there is a significant lag period—on average 10 to 12 years (ABPI 2011b)—before returns can 
be realised.   This is one reason why the pharmaceutical industry is better suited to large scale 
firms that can afford to invest large amounts into this R&D process, and indeed the sector is 
dominated by large multi-national corporations (MNCs).  This differs to the situation for 
devices whose investment recovery period tends to be much shorter and more immediate.  
Section 3.3 demonstrates that although the device industry has some big players, there is a 
high proportion of SMEs in this sector. 
 
3.3  UK Market Composition 
The outputs of both the pharmaceutical and medical devices industries are increasingly 
important for society‘s wellbeing.  Their contribution to the health of the population is 
obvious, but they also provide a valuable contribution to the British economy, not least by 
fostering a more healthy and productive workforce.  A brief consideration of the nature / 
application of devices and drugs, and what constitutes ‗innovation‘ in the two industries, has 
indicated why their set up should be so different.  This section demonstrates the translation of 
these differences into market composition, which is explored quantitatively.  It is split into 
four parts: demand in the UK, how the national industries fit into the global marketplace, their 
size and structure, and their contribution to the UK economy. 
3.3.1  Demand for devices and pharmaceuticals in the UK 
Aneurin Bevan, the Minister for Health in post-war Britain, is acknowledged to have 
orchestrated the creation of the NHS, which was established in 1948 with the belief that 
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health should be a fundamental right for all citizens.  Bevan believed that, within a few years 
of running, a healthier population would lead to diminished healthcare needs and reduced 
expenditure requirements (George & Julious 2006).  As outlined above, spending on 
healthcare has actually risen consistently over the past 60 years, and now stands at around 
£151 billion in the UK, 83% of which is from public expenditure (Hawe, Yuen, & Baillie 
2011;OECD 2012).  The NHS is now the world‘s largest publicly funded healthcare supplier 
(NHS Choices 2011), and thus a major buyer of healthcare products in the UK.  However, 
(perhaps as a result) the UK is considered to be remarkably slow in the uptake of new 
healthcare technology, especially for new medicines (ABPI 2011a).  
As well as the growing life expectancy and raised expectations in standard of living, 
technological advances in the life sciences sector are also considered to place upward pressure 
on healthcare expenditure.  However, the direction of this relationship is contested by many, 
as the net outcome of technological progress is based on a complex interplay of effects, which 
can be both cost-reducing as well as cost-increasing (Pammolli et al. 2005).  Spending on 
devices and drugs represents a significant portion of spending, though not equally so.  Of total 
healthcare expenditure in the UK, around 12% is spent on pharmaceuticals, which is nearly 
three times as large as device spending at just over 4% (OECD 2012;Wilkinson 2011).  This 
demonstrates the large economic impact of both sectors but particularly the pharmaceutical 
industry, which is corroborated by further statistics presented below. 
3.3.2  ‗Global players‘ 
The pharmaceutical and medical device sectors are huge global industries.  Based on global 
sales, the pharmaceutical industry is nearly four times as large as the medical device industry 
whose global market is estimated to be worth between £150 and £170 billion (BIS UKTI DH 
2011;IMS 2011).  Both industries are expected to grow, but the predicted magnitude of this 
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growth is larger for medical devices than pharmaceuticals—10% versus 3-6% over the next 
five years (BIS UKTI DH 2011;IMS 2011).  In fact, the global pharmaceutical market has 
exhibited a steady decline in sales growth, which was 11.8% in 2001, and which has 
decreased year on year, standing at 4.1% in 2010 (IMS 2011). 
The UK representation within both industries is similar, making up around 4% of global 
sales and 13-14% of European sales (Office for Life Sciences 2010;Wilkinson 2011), 
implying a UK market size of around £6 billion for devices and £23 billion for drugs.
6
  
Annual turnover (income from sales) in 2011 was £15 billion for medical devices and £31.8 
billion for pharmaceuticals (BIS UKTI DH 2011).  These figures, however, do not tell the full 
story.  For example, the UK‘s sales share of the world‘s top 100 prescription medicines is 
16% (higher than any other country after the USA), and 20% of them were discovered and 
developed in Britain (ABPI 2011b).  Both sectors have two UK representatives in the top 10 
global firms according to sales: GE Healthcare and Covidien for devices and 
GlaxoSmithKilne and Astrazeneca for pharmaceuticals (IMS 2010;Quotec Ltd. 2009).  The 
UK is thus a large stakeholder in both of these healthcare sectors. 
3.3.3  Contribution to the UK economy 
Table 3.1, adapted from a document produced by the Pharmaceutical Industries Task Force 
(PICTF 2001) outlines some of the ways in which national and foreign owned health 
technology companies, both home and abroad, contribute to the UK‘s economic welfare.    
  
                                                 
6
 This is based on the global market value estimates presented above.  The difference between sales value and 
turnover is not clear in the sources indicated, or indeed in the wider literature; it can be seen from the figures 
reported that estimated turnover appears to be significantly larger than sales value (or ‗market size‘).  It is 
presumed, therefore, that turnover is equal to the total income from sales, whereas sales value refers to the net 
revenue from those sales.  
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Table 3.1 National economic contribution of device and drug companies 
  OWNERSHIP 










Benefits to patients 
Gross profits 
Employment income 
Better terms of trade 
R&D spill overs in UK 
Benefits to patients 
Tax revenues in UK 
Employment income 
Better terms of trade 
R&D spill overs in UK 
Overseas 
Net profits 
Employment income of 
UK nationals 
 
Source: Pharmaceutical Industry Task Force (PICTF 2001) 
Both sectors contribute positively to the UK‘s balance of payments.  In 2008 the medical 
device sector ran a trade surplus of £300 million and that of pharmaceuticals was £6 billion 
(BIS 2009a;PICTF 2010).  However, other sources suggest that the UK is a net importer of 
medical devices (BIS UKTI DH 2011;Wilkinson 2011). 
A key metric of productivity is value added per employee, which measures the average 
contribution to the economy by each employee in a particular sector.  The Department for 
Business Innovation and Skills (BIS 2010) report that the gross value added per employee for 
the medical technology sector was £49,000 in 2007 (similar to that of ‗All Manufacturing‘), 
compared to pharmaceutical‘s £121,000. 
3.3.4  Size and structure 
The differing size and composition of the device and pharmaceutical industries are largely due 
to the differences in innovation described above, and the resulting scale and duration of 
market capture.  The regulatory frameworks of the two industries are undoubtedly another key 
influence, which is discussed further in section 3.4.1.  Along with the lower regulatory 
hurdles for devices which lead to lower R&D spend, the fast-paced and competitive nature of 
the device industry and the user-led provenance of many innovations (which often 
incrementally develop previous models), mean that there is an important role for small 
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businesses in the sector.  In contrast, the investment required to bring a new pharmaceutical 
product to market (about £1 billion (ABPI 2011b)) means that drugs are more feasibly 
developed and marketed by larger companies.  This is reflected by the data presented below. 
Within the UK there are 3,113 device companies, which employ 64,000 people in total 
(BIS UKTI DH 2011).  An estimated 99% of these (3,082) are SMEs (companies that employ 
less than 250 people), with 42% (1,307) employing four people or less (BIS UKTI DH 2011).  
Figure 3.2 illustrates this dominance of small businesses. 
 
Figure 3.2 The UK's distribution of medical device companies (total:3,113) by number of employees 
Data from  Government report ‗Strength and Opportunity‘ of the Life Sciences industry (BIS UKTI DH 2011) 
This offers a contrast to the UK‘s pharmaceutical sector which consists of around 365 
companies and nearly 78,000 employees (BIS UKTI DH 2011).  Whilst 81% of 
pharmaceutical companies are SMEs, the remaining 19% employ 89% of the UK 
pharmaceutical sector workforce (BIS UKTI DH 2011).  The pharmaceutical sector has 
become increasingly concentrated over the years, with the top ten global companies sharing 
62% of total UK turnover in the sector (BIS UKTI DH 2011).  Pharmaceutical companies also 
tend to be more mature than medical technology companies, with 67% being over 10 years 
old versus devices‘ 52% (BIS UKTI DH 2011). 
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The Government‘s report on the life sciences sector also offers a breakdown of the 
medical technology industry by sector (BIS UKTI DH 2011).  The largest sector in relation to 
turnover is single use technology, followed by wound care and orthopaedic devices.  
Professional services (consultancy) is the biggest sector in terms of employment and number 
of companies, which is followed by in vitro diagnostics and single use technology in terms of 
employment, and by assistive technology and singe use technology for number of companies. 
Table 3.2 provides a summary of the main comparisons drawn through section 3.3. 
Table 3.2 Headline comparative statistics for the UK's Device and Pharmaceutical Sectors 
 Medical Devices Pharmaceuticals 
Products (estimated number 
available globally) 
500,000, belonging to 10,000 
generic groups                               
(Eucomed 2011) 
218 ‗Drug targets‘                         
(Imming, Sinning, & Meyer 2006) 
Lifecycle of product Around 18 months                       
(Eucomed 2011) 
Mean lifetime: 57 years  
(Hoyle 2010) 
R&D spend as % of sales, 
2007/8 
5.5%                                                  
(BIS 2009a) 
15.3%                                                
(BIS 2009b) 
Spending as % of UK’s total 
expenditure on health, 2006 
4.5%                                                
(Eucomed 2007) 
12.3%                                              
(OECD 2010) 
Turnover, 2011 £15 billion  
(BIS UKTI DH 2011)                                     
£31.8 billion                                   
(BIS UKTI DH 2011) 
Value (sales) of global 
market, 2010; Forecasted 
growth per annum over next 5 
years 
£150-170 billion; 10%                    
(BIS UKTI DH 2010) 
£589 billion; 3-6%                       
(IMS 2011)
1 
UK presence on the world 
market, 2009 
4% of global sales;                         
13% of European sales                   
(Wilkinson 2011) 
4% of global sales;                    
14% of European sales                 
(Office for Life Sciences 2010)
2 
Trade surplus, 2008 £300 million                                     
(BIS UKTI DH 2009) 
£6 billion                                         
(PICTF 2010) 
 Value added per employee, 
2007 
£49,000                                            
(BIS 2010) 
£121,000                                          
(BIS 2010) 
Number of companies, 2011 3,113                       
(BIS UKTI DH 2011)                            
365                                                   
(BIS UKTI DH 2011) 
Employment, 2011 64,000                                               
(BIS UKTI DH 2011) 
77,795                                             
(BIS UKTI DH 2011) 
Size distribution, 2010 99% SMEs                                        
(BIS UKTI DH 2010) 
81% SMEs 
(BIS UKTI DH 2011) 
Figures refer to UK statistics unless otherwise stated 
1Converted from U.S. dollars to pounds using the exchange rate: £0.673 to the $, the average exchange rate of 2010 
2This is noted to exclude over-the-counter drugs 
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The British medical devices industry is, in general, on a smaller scale to that of the 
pharmaceutical industry.  Nevertheless, the sector is important for the economy and provides 
a large number of jobs, not to mention the crucial contribution it makes to patient care.  The 
pharmaceutical sector is dominated by larger companies, the advantages of which include 
economies of scale, more established marketing distribution channels, steady funding, and a 
greater collection of expertise and experience (Scully, Van der Walde, & Choi 2002).  Smaller 
companies can face some unique challenges, especially with regards to providing evidence for 
HTA.  However, device companies face more than financial barriers in demonstrating clinical 
/ cost-effectiveness.  These barriers are outlined in the next section and, like the industry 
structure described in this section, are intrinsically linked to the nature and application of 
devices. 
 
3.4  Evaluation Issues 
The way healthcare products are brought to market is undoubtedly affected by the system of 
regulation and adoption.  In this section devices are again compared with pharmaceuticals: 
after describing regulation in the UK, the prevalence of device appraisal by NICE is outlined, 
followed by a consideration of why devices do not lend themselves easily to providing 
evidence for evaluation.  This then sets the scene for section 3.5 which describes the response 
to these issues by the formation of a new evaluation pathway specific to devices. 
3.4.1  Regulation 
Regulation should ensure that products are safe and that they function for their intended use, 
which is of particular importance in the healthcare market where the consequence of a fault or 
drop in standards could be fatal.  However, it has long been recognised that the models of 
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regulation for drugs and devices cannot and should not be interchangeable.  Historically, a 
significant development in medical device legislation in the U.S. arose from a report 
submitted by the Cooper Committee in 1970.  The committee recommended that a regulatory 
approach specific to devices be created, which would be sympathetic to their differences to 
pharmaceuticals (Link 1972;Pilot & Waldmann 1998).  The EU regulatory system for medical 
devices was established 25 years after that of the U.S., and was some 25 years behind the 
European regulation of pharmaceuticals (Altenstetter 2003). 
Until the early 1990s each EU member state ran its own system of device regulation.  This 
was seen to be an unnecessary barrier to trade, and so in 1993 regulation across Europe was 
harmonized by the implementation of the European Medical Device Directive (McAllister & 
Jeswiet 2003).  This is now supplemented by two related directives: Active Implantable 
Medical Devices Directive and the In Vitro Diagnostic Device Directive.   In the EU medical 
devices are categorised into four classes according to risk: class I, class IIa, class IIb and class 
III (see (European Commission 2010) for full classification rules).  The directives are 
implemented by private sector ‗notified bodies‘, which issue a mark of Conformité 
Européenne (CE) to devices that are approved.  This is in contrast to pharmaceuticals which 
in the UK are approved directly by the  Medicines and Healthcare products Regulatory 
Agency (MHRA), an executive agency of the Department of Health (MHRA 2011).  Once on 
the market, the system of market vigilance for devices and drugs in the UK is similar, both 
being overseen by the MHRA.  The scale and profitability of the industries, as described in 
the previous section, is reflected in the way the MHRA‘s regulation activity is funded: 
principally by public monies for device regulation and by fees from the pharmaceutical 
industry for the regulation of medicines. 
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Whilst the regulation policies for devices and pharmaceuticals both aim to ensure that 
only safe and effective products are approved, the level of clinical evidence required is much 
more rigorous for pharmaceuticals (World Health Organisation 2010a).  The licensing of 
pharmaceuticals generally requires clinical trial evidence, whereas the EU regulation of 
devices is founded upon quality management.  This includes a specification of the design 
process, a risk assessment, and a clinical evaluation which need not necessarily be a clinical 
trial, depending on device type and risk classification (this could for example be lab test data, 
data for similar preceding devices, etc.) (Carlisle 2011).  The differential evidence 
requirement reflects a device‘s (generally) more predictable outcome, though the topic is 
controversial.  Particular sources of contention include the manufacturer being allowed to 
choose the notified body, as well as the private nature of the CE mark decision which is not 
made publicly available (Cohen & Billingsley 2011). 
Many new products generated by the devices sector represent minor developments of 
previous models; to demand a randomised controlled trial (RCT) for each would be unfeasible 
and would discourage companies from making these improvements.
7
  Obtaining approval for 
devices that are ‗substantially equivalent‘ is therefore purposefully straightforward (Avorn 
2010).  However, many incremental changes may together lead to new functions or risks, 
which if untested may compromise effectiveness or safety (Garber 2010).  The balance 
between fostering innovation and ensuring safety is therefore delicate, and different interested 
parties have competing perspectives.  Predictably, device companies believe that UK 
regulation is cumbersome and restrictive, whilst doctors and patients often consider the rules 
to be too lax (Watts 2012).  This trade-off is given the spotlight when faulty devices cause 
                                                 
7
 Reed, Shea and Schulman, for example, demonstrate how altering the regulatory environment of devices to be 
in line with pharmaceutical regulation would significantly decrease the value derived by a company for 




adverse events, as exemplified by metal-on-metal hip replacements which have been found to 
have high failure rates (Smith et al. 2012), or the defective silicone breast implants which 
have inspired news articles to liken the regulation of an implantable medical device to the 
regulation of a yo-yo (Boseley 2012).  This places under real scrutiny the differential evidence 
requirement for devices, especially those that are implanted into the body.  Indeed, whereas 
drugs may simply be discontinued if harmful side-effects are identified, the irreversibility of 
some implantable devices can be problematic. 
Conditions for innovation are considered more favourable in the EU than in the U.S., 
whose regulatory system is often accused of being too risk-averse, leading to unnecessarily 
slow adoption and thus impeding technological progress (Cohen & Billingsley 2011;Kramer, 
Xu, & Kesselheim 2012).  The safeguarding of patients is certainly an issue of high interest 
and debate; difficulties are inevitable, especially in a sector whose regulation system is 
relatively young.  As medical technology gets increasingly more sophisticated, the risks posed 
by certain products are higher than ever.  Altenstetter and Permanad (2007) suggest that the 
differences between the device and pharmaceutical sectors in this respect are starting to blur, 
implying that the regulation systems may eventually adapt to reflect this. 
Before a medical device can be sold in the UK it must work and be safe.  The system 
which aims to ensure this in the UK has been described.  However, regulation considers the 
risk-benefit relationship in order to justify whether a device can be sold, not whether it should 
be bought (not least with public money).  In the UK the NHS charge NICE with the task of 
considering the cost-benefit relationship, in order to determine value for money.  The next 
sub-section explores the prevalence of device evaluation by NICE, and is followed by a 
presentation of some of the pertinent challenges that devices pose to the evaluation process.    
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3.4.2  NICE technology appraisals 
The formal incorporation of economic analysis into healthcare decision-making is a relatively 
recent phenomenon.  Having first been incorporated into Australian drug evaluation in 1993, 
economic analysis is now a part of decision-making across New Zealand, Canada and half of 
Europe (Drummond 2012).  Across Europe and Canada, Hutton (2012) finds that the 
Canadian Coordinating Office for Health Technology Assessment (CCOHTA) and NICE are 
the only national-level assessment systems to appraise devices and procedures, with all other 
systems focusing solely on funding decisions for innovative drugs. 
NICE ‗provides independent, authoritative and evidence-based guidance on the most 
effective ways to prevent, diagnose and treat disease and ill health, reducing inequalities and 
variation‘ (NICE 2012a).  NICE guidance falls into three main areas: Public Health, Clinical 
Practice, and Health Technologies, the last of which includes Technology Appraisals (TA), 
Interventional Procedures Guidance (IPG), and additionally Medical Technologies Guidance 
and Diagnostics Guidance which were introduced in 2010.  In order to appreciate the 
evaluation scene from which the new medical technologies pathway has arisen, all TAs 
conducted by NICE since the first in 2000 until the close of 2009 (from which point the new 
evaluation pathway considers medical devices specifically) have been reviewed and classified 
(data collected from NICE published TAs (NICE 2012e)). 
Over the ten years considered, NICE produced 178 TAs, 153 of which were new 
appraisals (the 25 remaining were reviews of previous TA decisions).  Of the new appraisals, 
21 (14%) were for medical devices.  The total number of (new) TAs by year is shown in 
Figure 3.3, which also exhibits the breakdown of technology type appraised.  The appraisal of 




Figure 3.3 NICE Technology Appraisals by technology type 
* Surgical procedures, Imaging/screening, Behavioural therapies, Training/education programmes & Process. 
The decision outcomes of technology appraisals were largely favourable; 88% of non-
devices were approved (either for routine or restricted use), compared with a 95% approval 
rate for devices.  Of those devices approved, 40% (eight) were approved for routine use and 
60% (twelve) for restricted use.  For all other TAs, 34% of those approved were for routine 
use.  The decision to reject the one medical device that was not approved was on grounds of 
clinical ineffectiveness.  Overall, cost-effectiveness played a role in 61% of all rejection 
decisions.  NICE now publishes a summary of all TAs and decision outcomes on their 
website, though these are not categorised by technology type (NICE 2011c). 
Others have also considered the preponderance of pharmaceuticals in NICE appraisals.  
Linden and colleagues (2007) find a similar overall proportion of drug and device TAs for the 
years 2000 to 2006 (75% and 14% respectively).  These authors also describe the tendency for 
NICE appraisals to address new rather than existing technologies, highlighting concerns that 
neglecting to appraise existing ineffective / inefficient technologies means forgoing 
significant NHS savings, and placing an upward pressure on spending (Linden, Vondeling, 







NICE Technology Appraisals 2000-2009 
T A s : Other* 
T A s for Drugs 
T A s for Devices 
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The tendency for NICE to appraise drugs over other health technologies is clear, but is 
this irrational?  It can be partly explained by the market factors already described.  Drugs 
expenditure is nearly three times that of devices, implying that new and more efficient drugs 
could have a big impact on overall spending, making them particularly relevant for national 
evaluation.  Additionally, the costs and benefits arising from an approved drug are generally 
immediate; some devices may have a more delayed or less direct impact on budgets, 
sometimes requiring training or service reorganization (Drummond, Griffin, & Tarricone 
2009).  Another factor is the continual redesign and replacement of devices, making their 
lifetime short and thus making the time and resource intensive appraisal process less relevant 
and less valuable (Linden, Vondeling, Packer, & Cook 2007).  Furthermore, the lower 
evidence requirement for regulatory approval means that the data required to conduct a device 
appraisal may not be available.  The characteristics of the industries further explain the better 
provision of evidence for pharmaceutical appraisals, but for medical devices, evidence 
generation is further complicated by specific issues beyond the financial constraints of the 
companies that produce them.  These are described in the next subsection. 
3.4.3  Hurdles to providing evidence for HTA 
HTA activity has increased substantially over recent years, but particularly so for 
pharmaceuticals.  It could be that pharmaceutical companies, keen to make claims of cost-
effectiveness, have driven this trend.  However, this is further compounded by their ability to 
produce trial data.  The difficulties that arise in the generation of evidence for medical devices 
relate to their nature and application (described in section 3.2) and are outlined below. 
The HTA of a product is an essential component of an informed reimbursement decision.  
By comparing the new technology to current practice, its impact on overall costs and health 
outcomes can be observed.  Two essential criteria for this are (a) to identify the ‗gold 
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standard‘ in current clinical practice, and (b) to generate evidence upon which a comparison 
can be based.  These both present difficulties for device manufacturers. 
Standard clinical practice for pharmaceuticals tends to be better established than for many 
devices.  Devices (like other manufactured goods) are often tailored to user preference, with 
many co-existing devices designed for the same purpose.  Clinical practice can therefore vary 
from place to place—even doctor to doctor—making the question of a ‗gold standard‘ 
comparator difficult.  Moreover, individual device manufacturers may stand less to gain from 
the HTA process, as even a positive decision is unlikely to lead to full market capture. 
Clinical trials play a fundamental role in the generation of evidence.  According to the 
‗Clinical Trial Magnifier‘ there were 1,107 industry-sponsored medical device trials globally 
between October 2005 and June 2009, equivalent to only 7% of trials for drugs and biologics 
(Karlberg 2009).  This can be partly explained by the lower evidence requirement (in the 
main) for devices compared to drugs, but also reflects the set-up of the industry described in 
section 3.3.  European pharmaceutical manufacturers spend vast amounts on evaluating new 
products, more in fact than total European spending on evaluating all other health 
technologies, procedures and policies (Cookson & Hutton 2003). 
Aside from the financial context and structural set-up of the industries, the very nature of 
devices makes performing an RCT—thought to be the most rigorous way to provide evidence 
of the cause-effect relationship between treatment and outcome—difficult, biased or even 
unfeasible.  Three specific issues are especially problematic: confounding factors, recruitment 
/ drop out, and blinding. 
That devices are administered by a third party (generally the clinician or patient) can act 
as a confounding factor, being itself responsible for some variation in clinical outcome.  
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Effectiveness thus depends not on the device alone but also on the skills and experience of the 
user, or the context of its use (Cookson & Hutton 2003).  For example, a clinician‘s skill is 
paramount in the outcome of a surgical intervention, compared with the formulaic and 
replicable process of prescribing medicines (Lilford, Braunholtz, Harris, & Gill 2004).  This 
provokes a second, related issue: the skill of a clinician using a new technology is likely to 
improve over time.  This ‗learning curve‘ phenomenon may result in an unfair comparison 
between a new technology and a ready established technique (Drummond, Griffin, & 
Tarricone 2009;Taylor & Iglesias 2009). 
One fundamental mechanism by which RCTs minimise bias is the random allocation of 
treatment.  This randomisation should lead to equivalent treatment groups, maximising the 
chance that observed differences in outcome are the result of treatment effect rather than 
differing baseline characteristics of the groups.  Any CE marked device (which must be 
obtained before a trial) is in the public domain, making preconceptions a real threat (Medilink 
UK Review 2009).  Where these preconceptions exist for patients, there may be difficulty in 
recruiting the required sample size, or drop-out may be high.  If clinicians act on their own 
pre-conceptions, then allocation bias may occur (Wittes 2001).  A quotation from Cochrane 
(1971, p.68) draws an eloquent picture of the difficulty in this randomisation aspect of an 
RCT: „On one occasion I was trying to persuade a senior consultant to participate in an RCT.  
He told me that the protocol was morally and ethically unacceptable as he knew what the 
result would be.  On another occasion I was trying to persuade a headmaster to randomise 
caning and detention for boys who were caught smoking.  He answered by claiming that the 
trial was unnecessary as he always knew which boy should be caned and which should not.  I 
checked as far as I could later and it looked as though his method was quite simple.  He 
caned them all.‟ (Cochrane 1971). 
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Lack of blinding (or ‗masking‘) is another important source of bias for RCTs, which 
involves the patient / clinician / third party observer being aware of treatment allocation, and 
adjusting behaviour (either consciously or subconsciously) as a result.  Whereas the masking 
of drugs is usually easy, devices can look very different and involve dissimilar procedures.  
This has been noted to be especially problematic in surgical trials (Ergina et al. 2009;Lilford, 
Braunholtz, Harris, & Gill 2004).  For example, while placebo-controlled drug trials are 
straightforward, sham surgery is ethically undesirable (Becker & Whyte 2006;Lilford, 
Braunholtz, Harris, & Gill 2004). 
HTA for medical devices can also be problematic outside the issue of evidence generation 
specifically.  The perspective of the decision-maker must in some cases be broad, where new 
devices pose wide health or economic implications or require local service reorganisation 
(Drummond, Griffin, & Tarricone 2009); the COPD case study to be presented in chapter 6 
provides an example of this.  Whilst in an economic evaluation it is possible to account for 
cost impact seen in other parts of the health service, NHS budgets are in reality not so 
transferable, thus making the outcome of an HTA theoretically sound but less directly 
applicable (Buxton 2006).  A long time perspective is often required, particularly for pieces of 
equipment which may require large upfront costs (Ferrusi, Ames, Lim, & Goeree 2009).  
Additionally, some device benefits are not fully captured by the standard HTA framework, 
such as the utility associated with the process of healthcare—‗process utilities‘ (Donaldson & 
Shackley 1997).  For example, a non-invasive treatment option which yields the same health 
outcome as an invasive alternative will produce a similar QALY gain.  The multiple potential 
applications of some devices further complicates the valuation of new technologies for HTA 
(Drummond, Griffin, & Tarricone 2009).  Many of these issues are illustrated through the 
course of this thesis. 
50 
 
The output of a NICE appraisal is an ICER (Δ Cost ÷ Δ QALY), which establishes the 
cost-effectiveness of a new technology over current practice.  However, for medical devices 
the real ICER is rarely static due to the variability of both numerator (costs) and denominator 
(QALYs), making the timing of an HTA worryingly important.  The operator‘s influence and 
learning curve phenomenon demonstrate the potential inconsistency of outcome, which may 
imply that an HTA conducted early in a product‘s lifecycle may underestimate its QALY 
impact and therefore cost-effectiveness (Holmes, Jr. et al. 2008).  As regards the numerator, 
unlike drugs whose price remains reasonably constant until the patent expires, the price of a 
new device tends to fall quickly given its short lifetime.  However, the price of the technology 
that it replaces is likely to fall even faster (Drummond, Griffin, & Tarricone 2009;Holmes, Jr. 
et al. 2008).  This affects perceived cost-effectiveness and may even imply that a decision to 
fund a new device based on its cost-effectiveness should be reversed soon after it is made. 
  
„Adopting a pharmaceutical paradigm, based on expectation of multiple RCTs being 
available at the time of launch, may lead to restrictions on access to many new medical 
technologies.  A device specific paradigm must be recognised.‟ (Eucomed 2008, p. 2).  This 
quotation reiterates the need for drugs and devices to be regarded separately.   In section 3.4 I 
have addressed why UK national appraisal activity has focused on pharmaceuticals, and why 
the TA system can be problematic, unnecessary or unfeasible for device manufacturers.  The 
topic has been explored from its very roots: the characteristics inherent to a medical device; 
its mechanism of action; the resulting industry size, structure, and operations; and subsequent 
difficulties in providing evidence for HTA.  The new system of evaluation that intends to 
address these issues is described in the next section, which focuses exclusively on devices and 
describes the progress towards this change, and what it might mean for industry. 
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3.5  Response: How the evaluation landscape has adapted 
Innovation is imperative for the continual development and improvement of a healthcare 
system.  New cost-effective medical technologies have a substantial impact on patient quality 
of life, the health budget, and the wider economy; slow uptake means these important benefits 
are delayed.   Whilst having a globally recognised industry scene, as illustrated in section 3.3, 
the delayed adoption of new medical technology within the NHS was highlighted in the 
Wanless Report in 2002 (Wanless 2002).  The underuse of new devices was also stressed by 
the House of Commons Health Committee (2005), who blamed the fragmented nature of the 
NHS and its preference for short-term savings over long-term gains.  Together with the 
difficulties for industry described above, this slow and often misdirected procurement 
landscape was the backdrop for the work which began in 2003 to review the medical 
technology scene in the UK, and identify ways to maximise its potential.  
3.5.1  The development of strategic dialogue 
With so many interested parties in the devices sector, any progress needed to be collaborative.  
An attempt at such a collaborative venture was first made possible by the Health Industries 
Task Force (HITF) in October 2003, a year-long initiative and the first Government / 
healthcare industry collaboration of its kind in this sector.  It aimed to facilitate the common 
understanding of problematic issues, to suggest ways to address them, and to encourage wider 
adoption of new technologies (HITF Market Access- Working Group 1 2003).  This strategic 
dialogue is what, six years later, would ultimately pave the way for a new system of 
evaluation for devices.  Figure 3.4 sketches the development of implementation groups and 




Figure 3.4 The development of strategic dialogue between government and industry 
The organisation of the HITF into four working groups demonstrates the array of issues 
important to the health technology industry and government, for which it was believed 
progress needed to be made.  During the first meeting of UK Market Access working group in 
December 2003, some of the pertinent points raised (as detailed in the meeting minutes) were: 
timeliness of procurement, the understanding of ‗value‘, the increasing demand for evidence 
(and the troubles this posed for SMEs), and the need to streamline and speed-up the process 
of adoption (HITF Market Access- Working Group 1 2003).  These concerns all reflect the 
matters highlighted in this chapter, and clearly demonstrate the developing need for a new 
system of evaluation. 
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3.5.2  Early HITF output and the Next Stage Review 
The initial impact of the HITF report included a shift in emphasis to adoption (the Device 
Evaluation Service turned into the Centre for Evidence-Based Purchasing), and changes in 
procurement approaches, e.g. Payment by Results (Wilkinson 2005).  The National 
Innovation Centre was created to stimulate demand for technology and to support industry 
(especially SMEs), R&D capacity was built up in the NHS, and funding was provided to train 
professionals in using new products (Secretary of State for Health 2005).  To advance the 
progress made by the HITF, the Strategic Implementation Group (SIG) made a series of 
recommendations relating to increased uptake of innovation, support for SMEs, consistent 
decision-making, and continued collaborative engagement (SIG 2007). 
Significant changes were made in response to Lord Darzi‘s report, High Quality Care for 
All: NHS Next Stage Review (NSR) (Department of Health 2008a), in which he reiterated the 
slow-uptake of technology.  Darzi advocated the creation of a new, single evaluation pathway 
for medical technologies which would “...simplify the pathway by which they pass from 
development into wider use‖ (Department of Health 2008a, p. 13).  The Ministerial Medical 
Technology Strategy Group (MMTSG), successor of the HITF and SIG, identified four work 
streams to deliver on NSR output: the new evaluation pathway, ‗intelligent demand‘ from the 
NHS, more receptive procurement, and metrics to measure uptake (MMTSG 2009).  There is 
a clear connection between the industry‘s concerns relating to those problems outlined in 
sections 3.3 and 3.4 of this chapter, and these recent efforts to modernise the system. 
3.5.3  Single Evaluation Pathway for Devices and Diagnostics 
NICE was asked to lead the evaluation pathway programme for medical technologies in 
winter 2008/9, which was later rebranded as the Medical Technologies Evaluation 
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Programme (MTEP).  Subsequent development has been fairly rapid; recruitment for the 
Medical Technologies Advisory Committee (MTAC) took place over summer 2009, the 
programme was officially announced late autumn, MTAC‘s inaugural meeting took place in 
November, the Methods and Process guides were issued for consultation in June 2010, and 
the first Medical Technology Guidance was published for consultation in July 2010. 
The principal aims of MTEP are to (a) simplify access to evaluation and subsequent 
adoption, (b) to speed up this process, and (c) to increase capacity.  It provides a single entry 
point for manufacturers to submit products for evaluation, which are then routed (if eligible) 
to the appropriate evaluation programme within NICE: TA, clinical guidelines, interventional 
procedures, diagnostic assessment programme (DAP, also a new programme), or, if fulfilling 
certain criteria, to MTAC‘s own evaluation and subsequent ‗medical technologies guidance‘. 
The suggested timeframe is around 10 weeks from notification to routing, and a further 38 
weeks for in-house evaluation by MTAC for those selected (NICE 2011b).  Building on its 
founding principles, the new pathway is seen to be an opportunity for collaboration and 
increased understanding between industry and the NHS (NICE 2009d).  The committee 
comprises academics, practitioners, industry, regulatory experts, NHS trust members and lay 
members (NICE 2009d), who have a particular focus on fostering future research for new 
medical technologies where this is required (Campbell 2011). 
To be eligible for MTEP a device must have attained a CE mark (or equivalent), be within 
the remit of a NICE evaluation programme, be new or a significant modification of a previous 
technology, and have clear benefits for patients or the NHS.  The scope for MTAC‘s own 
guidance was eventually defined in June 2010: medical technologies guidance will deal 
exclusively with products ―...for which the case for adoption in the NHS or social care is 
based primarily on improvements in the efficient use of resources‖ (NICE 2010d). 
55 
 
The concerns of industry have played an important role in MTEP‘s development, which is 
evident in the Process and Methods guides (NICE 2011b).  For example in section 2.3 of the 
Methods guide, the characteristic innovation process and limited clinical data for devices are 
acknowledged, as well as issues relating to the context of trial setting.  As a result, the 
evidence requirement compared with the TA programme is reduced, and includes 
consideration of observational trials and expert advice (Medilink UK Review 2009;NICE 
2011b).  Additionally, the prevalence of co-existing versions of certain devices is 
acknowledged: ‗The specific recommendations on individual technologies are not intended to 
limit use of other relevant technologies which may offer similar advantages‟ (Campbell 
2011;NICE 2012c). 
The creation of MTEP and the form it has taken has attempted to be sensitive to industry-
related issues.   Another major stakeholder in devices, however, is the NHS, and it is perhaps 
for this reason that medical technologies guidance deals specifically with cost saving/cost 
neutral devices.  This remit has not always been so clear.  When the pathway was first 
announced, guidance was to be issued on ‗clinically effective‘ technologies (NICE 2009c); 
the more discriminatory criterion was not even discussed at the plenary session for the new 
pathway at NICE‘s 11th annual conference in December 2009.  The selection criterion for 
medical technologies guidance is now explicit: only a technology which will ‗provide 
equivalent or enhanced clinical outcomes for equivalent or reduced cost‘ will be considered 
(NICE 2012b).  With the economic downturn and huge public debt as a backdrop, the NHS 
must now invest in treatments that are not only cost-effective, but also cost-saving.  Cost-
consequence analysis rather than the cost/QALY approach will therefore be used to issue 
guidance on technologies that have the potential to dominate current practice.  Those that 
offer patient benefits but at an additional cost (not offset by the release of other NHS 
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resources) will be directed to another NICE programme.  This is in contrast to the diagnostic 
technologies routed to DAP, for which a comprehensive cost-benefit analysis will be 
undertaken. 
3.5.3 (i) Potential Impact of MTAC 
As the programme is still relatively young, it is difficult to predict its effect on manufacturers 
and the speed of NHS adoption.  The first pertinent question to consider is: What is the 
benefit of submitting a product to MTAC—does it increase uptake?  Whilst NICE does issue 
reports relating to guidance compliance within the NHS (NICE 2011a), at the time of writing 
no implementation uptake reports had been produced for guidance produced by MTAC.  
NICE medical technologies guidance only applies to England, and recommended technologies 
are not subject to mandatory funding (NICE 2010f).  So, whilst the ramifications of a positive 
(or negative) MTAC recommendation are not yet fully known, this section provisionally 
assesses the degree to which the pathway might achieve what it set out to: (a) simplify access 
to evaluation, (b) speed up the process, and (c) increase evaluative capacity for devices within 
NICE. 
To notify a medical technology to NICE for evaluation does appear straightforward.  
Sponsors complete a short pre-specified form covering general information about the 
technology along with the claimed patient benefit and cost implications (NICE 2012d).  
Although medical technologies guidance is unequivocal in only considering devices that are 
cost-saving or cost-neutral and at least as beneficial to patients, ascertaining clinical 
equivalence is not a simple task, and industry may have difficulty in providing data on the 
cost-saving potential of their products (Hogan 2009). 
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The premise of the pathway is to provide a ‗fast track‘ to evaluation for those products 
which dominate current practice.  In comparison with NICE‘s single technology appraisal 
guidance (NICE 2011d), the production of medical technologies guidance seems no quicker 
(both around 38 weeks), so it is perhaps the (presumably shorter) 10 week ‗routing/selection‘ 
process duration, and the increased capacity where the real benefit will lie.  Nevertheless, a 
total time of 48 weeks is almost two-thirds of the average product‘s lifecycle8 and, given the 
need for a CE mark prior to notification, the clock is already ticking at this point. 
The review of NICE TAs (in section 3.4.2) demonstrated the underrepresentation of 
medical devices in the national evaluation process.  The intended capacity of MTAC is not 
clear.  One source indicates that NICE is expected to handle 50 device and diagnostic 
submissions per year (Yeo 2009).  The target number of assessments to be published in 
MTAC‘s first year was 15, with capacity expected to rise in future years (NICE 2010g).  Only 
four were published in the first year of MTAC
9
, and six in the second.  Within the context of 
such a large market, this clearly is still just the tip of the iceberg.  Additionally, it is probable 
that the new appraisal system will continue to attract only a narrow subset of devices: mainly 
implantable and other class III devices (though it may be argued that this is appropriate, given 
their greater attributable risk and larger cost and outcome implications). 
As very few medical devices were appraised by the previous TA system, the industry will 
be keen to understand the benefit of subscribing to the MTEP process; the programme is 
expected to publish evidence on the impact of guidance on uptake in due course. 
 
                                                 
8
 Arguably, the lifetime of the sorts of product that would be submitted to MTAC may be longer, given the 
implicit requirement that the technologies submitted to the committee are novel and represent more than a minor 
modification to current practice. 
9
 Here, I consider the first year to start from the meeting date in which MTAC discussed specific technologies 
for the first time (NICE 2010e): June 2010 to June 2011. 
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3.6  Summary 
This chapter has attempted to set medical device innovation within the context of the wider 
social and economic landscape of the sector.  Whilst the new evaluation pathway represents 
an important step in the direction of fair assessment for devices, some provisos have been 
explored.  The current economic landscape explains the committee‘s focus on cost-saving 
technologies.  However, some may question whether this is the best long-term strategy.  The 
commentary and criticism that fed into Lord Darzi‘s Next Stage Review (Department of 
Health 2008a) was slow uptake, underuse of new technologies, and preference for short-term 
savings over long-term gains.  The cost-saving criterion of MTAC guidance therefore has the 
potential to undermine the review‘s key recommendations, particularly if capacity for device 
evaluation in the TA work stream is not increased simultaneously. 
The adoption and diffusion of new health technology within the NHS is still regarded to 
be inexcusably slow (Department of Health 2011a).  Looking forward, there will be many 
organisational changes within the decision-making structures of the NHS taking place over 
the next few years, the impact of which is difficult to predict.  For example the more advisory 
role which was demanded of NICE in the NHS White paper issued in 2010, which detailed 
non-mandatory funding of technologies with positive TA decisions (Department of Health 
2010b;Department of Health 2010c), has since been overturned.  In fact, in order to reduce 
variation in care across the NHS, the importance of NICE guidance implementation is now 
being emphasised, and the Department of Health will implement a ‗NICE compliance regime‘ 
to safeguard the funding direction attached to TAs (Department of Health 2011a) (there is no 
indication that MTAC recommendations will be made mandatory in the future).  Value based 
pricing will be adopted for pharmaceuticals by 2014 (Department of Health 2010c), though 
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the exact form of this has yet to be determined.  Additionally, the remit of NICE will be 
extended beyond health to include social care (Department of Health 2011a). 
In this chapter I have described and linked the characteristics of the health technology 
industry and innovation with the national evaluation of devices, and by doing so, have implied 
that this in an important link to make.  However, how important is economic evaluation for 
the success of medical technologies and their manufacturers?  It has already been shown that 
very few devices are actually evaluated by NICE.  Even for those technologies that are 
appraised, the implications of an approval are not well understood. 
In studying the use of economic evaluation in NHS decision-making, Williams et al. 
(2008) find that, at a local level, committees consider clinical benefit and cost implications 
separately.  This is consistent with the literature which notes that, whilst NICE is able to 
evaluate cost-effectiveness by adopting a removed, holistic stance, at the local level the 
inflexibility of budgets distorts this motive for efficiency (Buxton 2006).  Those that have 
explored the implementation of NICE guidance specifically have generally found 
implementation to be patchy (Moore 2005;Sheldon et al. 2004), probably due to the local-
decision-making context noted above (Spyridonidis & Calnan 2011).  
Despite the reservations outlined, NICE is still recognised internationally as a pioneer in 
the incorporation of health economics into decision-making.  As in any economic model, the 
only assumption that can be made is that decision-makers are rational, and it is on this basis 
that the headroom method incorporates the NICE decision-making framework into the 
consideration of potential value. 
 




Table 3.3 Summary: Innovative medical devices and their evaluation 
The Medical Device 
Landscape: what makes 
devices different? 












 Short product lifecycle: TAs 
quickly outdated 
 Many similar devices 
 Lower spend on R&D 
 
 
 Faster turnaround of 
guidance and greater 
capacity 
 Notification by 
manufacturers 
2. UK Market composition 
 
Supply  
 Principally SMEs, with limited 
financial capacity 
Demand 
 Budget impact lower and more 
delayed than pharmaceuticals 
 Slow adoption by NHS 
 
 
 Improve accessibility to the  
evaluation process 
 Accelerate the uptake of 
innovative technologies 
within the NHS 
 
 
3. Providing evidence 
 
 Difficult to identify the ‗gold 
standard‘ treatment 
comparator 
 Lower regulatory hurdle: 
rigorous evidence not required 
for market approval 
 Third party administration: 
confounding factors and the 
‗learning curve‘ phenomenon 
 Recruitment and drop out 
 ‗Blinding‘ often impossible 
 Willingness to consider 
evidence from non-RCT 
sources  (i.e. not based on 
levels of evidence required 
when evaluating drugs) 
 Encourage collaborative 
research (help 
manufacturers to make 
links with academic groups 




The new MTEP seeks to clear the pathway to the NHS for new and cost-efficient medical 
devices, an important objective not only for industry and patients, but also to help the NHS 
make the £20 billion of efficiency savings it needs to by 2014.  As MTAC is still in its first 
few years of operation, it is impossible to tell exactly how the new programme will affect 
manufacturers and the procurement landscape; processes and expectations are likely to adapt 
with experience, and according to the wider social context.  The increased speed, capacity and 
accessibility of device evaluation and increased uptake of new technologies within the NHS 
are commendable goals, and success of the programme must be judged on this merit. 
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With 60% of medical device manufactures being micro firms (fewer than 10 people), the 
majority of companies can neither afford costly investment in health economic expertise, nor 
can they afford to lose money on the development of products that will not find a place on the 
market.  The headroom method aims to provide a simple approach to ensuring that funds are 
directed to those products for which the chance of reimbursement is most likely. 
It has been suggested that the early application of economic evaluation is even more 
important for devices given their short life cycles, making it crucial for assessments of likely 
cost-effectiveness to be early and rapid (Vallejo-Torres et al. 2008).  Additionally, the nature 
of innovation for devices, as described in this chapter, demonstrates their particular 
applicability to the headroom method, which requires an estimation of potential impact on 
patient outcome and NHS resource implications.  This is likely to be better predicted for a 
new device, having been developed from an engineering process rather than a discovery and 
whose interaction with the patient is physical rather than pharmacological.  Furthermore, the 
literature review demonstrated a focus of early evaluation methods on pharmaceuticals, 
meaning that there is a larger contribution to be made for exploring this in the context of the 
device sector, which is the faster growing of the two industries. 
The objective of this chapter was to set the scene for device innovation within the wider 
market context.  It also described how national evaluation is adapting to meet the needs of the 
device industry, to ensure that the NHS is making the most of the industry‘s output.  Moving 
forwards, the emphasis is on the inverse relationship.  The next chapter, which describes the 
headroom method in detail, explains how the method offers a way by which industry may 
adapt their behaviour to suit the demands of the NHS, in turn ensuring sensible and informed 
development decisions.  
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CHAPTER 4 THE HEADROOM METHOD 
4.1  Introduction 
The previous two chapters have set this project within its wider context: first academically, 
and then in relation to the medical device marketplace.  The literature demonstrates the 
notable development of health economics as a topic over the past 50 years and the increasing 
maturity of its application.   The embedding of these principles into the commercial, supply-
side of the market is less well advanced, particularly for medical devices.  The previous 
chapter provided some explanation for this, describing an industry landscape which is 
dominated by small enterprises that may lack the resources, time and expertise to spend on 
long and costly decision-making processes.  Combined with the short period over which 
development costs can be recovered, the potential benefit of a simple health economic tool 
which could distinguish between good investments and bad becomes clear. 
The headroom method aims to embed the principles of health economics into an 
innovator‘s development decision.  Therefore, the first section (4.2) of this chapter outlines 
the methodological basis of health economic reimbursement decisions.  Section 4.3 describes 
the method, and also explains how it can be extended to consider plausible levels of 
development costs.  Section 4.4 describes the specific framework of the method‘s application 
in this thesis, before a summary of the chapter is presented. 
 
4.2  NICE’s decision-making framework 
Although most medical devices will not be appraised by NICE, the institute‘s concept of 
value should, in theory, extend to any rational decision-maker.  At the very least, their concept 
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of ‗value‘ provides solid grounds to justify the worth of a new product (for example for 
marketing purposes).  NICE‘s decision-making framework therefore forms the basis of the 
headroom approach, which is explained in section 4.3.  The following describes the 
theoretical underpinning of economic evaluation, and outlines the main schools of thought in 
this area. 
4.2.1  Welfarism versus extra-welfarism  
Economic evaluation offers a framework to manage the trade-off between costs and 
outcomes.  How this trade-off is optimally applied is a matter of judgement, and can vary 
according to ideological stance.  Two major schools of thought prevail: welfarist and extra-
welfarist.  Welfarists contend that utility should be measured in its broadest sense (i.e. not 
restricted to health-related utility / outcome), and that this is best captured by individual WTP 
(Hutton 2012) (this would allow for a direct CBA).  This is also called a Paretian approach, 
and is ruled exclusively by questions of economic efficiency (Sugden & Williams 1978).  
Whilst this approach is intuitive, individual WTP alone offers no practical means of making 
allocation decisions within a centrally funded decision-making scenario, where one group of 
patients may be treated at the expense of another (Coast, Smith, & Lorgelly 2008).  The 
Paretian approach therefore employs the compensation principle, first described by Kaldor 
and Hicks (Hicks 1939;Kaldor 1939), which asserts that a global improvement is achieved 
where those individuals benefiting could compensate those who lose out, and still be better 
off (a potential pareto improvement).  Of course, this transaction would not actually take 
place in the healthcare scenario, but would still be consistent with welfare maximisation by 
achieving a net social benefit.   
Arguments against the Paretian approach are similar to those against the free-market 
provision of healthcare: as well as the impracticality of basing healthcare resource allocation 
64 
 
decisions around individuals‘ valuations, there are many reasons why these valuations may 
not optimally reflect social benefit (for example the merit goods argument, externalities, the 
influence of ability to pay, etc).  Accordingly, the extra-welfarist argues for a decision-making 
approach, whose objective is to maximise health (and/or some other measure of well-being 
that is not strictly utility), and where the relevant outcomes may be compared across people 
and across programmes (Brouwer, Culyer, van Exel, & Rutten 2008;Culyer 1989).  The 
decision-making approach is therefore guided by optimisation theory, the criticisms of which 
revolve mainly around the credibility of a decision-makers‘ objectives, which may be self-
serving (Sugden 2008). Welfarists face a similar optimisation problem, the difference being 
that the decision-making approach assumes that someone (other than the economist) has the 
ethical authority to stipulate the objective of a system, for example to base provision on need 
(Culyer 2008).  Whilst accepting this approach to be a form of management consultancy, 
Williams (1972) insists it to be as scientific an endeavour as any analytic aid, and that it 
should be carried out systematically and transparently, with the objective of helping the client 
to conceptualise its problem in order to assist choices (rather than to make them) (Williams 
1972).  
4.2.2  The decision-making approach 
NICE‘s approach to economic evaluation is consistent with the decision-making approach: a 
pragmatic method to consider the efficiency of healthcare spending in relation to the health-
related outcomes it generates.  For conventional CBAs the trade-off between costs and 
benefits (both measured in monetary units) is straightforward, as is the comparison of net 
benefit between alternative uses of that money.  This is more complicated in a setting where 
‗health‘, a much less tangible concept than money, is the outcome of interest.  Given the wide 
distribution of health afflictions and the diverse objectives of healthcare interventions, 
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allocation decisions must be based on a universal measure of health: enter the QALY.  For 
NICE, ‗the QALY is considered to be the most appropriate generic measure of health benefit 
that reflects both mortality and HRQL effects‘ (NICE 2008b, p. 33), and is used to ensure 
consistency. 
The assertion that the QALY (in its current form) provides the best measure of health 
outcome is contested by many.  For example, its failure to reflect equity issues has been noted 
as an important omission of the current evaluative framework (Culyer & Bombard 
2011;Nord, Enge, & Gundersen 2010;Williams & Cookson 2006), along with issues around 
the relativity of time (for example whether extra value should be placed on the final moments 
of life) (Chochinov 2011) and its narrow interpretation of health (Coast, Smith, & Lorgelly 
2008).  These are all important concerns, some of which have been acknowledged in NICE 
evaluation practices, for example by extending the threshold cost/QALY range for end of life 
treatments (NICE 2009a).  However, arguably the bigger controversy, which may be more 
difficult to resolve, is the appropriate way to determine value for money in paying for QALY 
improvements. 
4.2.3  The cost-effectiveness threshold 
Constrained optimisation theory allows economists to maximise output in relation to a fixed 
input (Pemberton & Rau 2001).  For NICE, the decision-maker, the objective function is to 
maximise health (measured in QALYs) subject to a fixed health budget (set externally by 
Government: the client).  Mathematically, the optimisation problem for just two healthcare 
interventions (1 and 2, used for x1 and x2 number of patients), spending on which is set to 
exhaust income (m), would be as follows, where p1 and p2 are their prices and U is the (health-
related) utility resulting from their implementation: 
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Maximise U(x1,x2)  subject to budget constraint  p1x1 + p2x2 = m                      (Eq. 4.1)   
A Lagrangian function can be employed to solve this problem: 
 L(x1,x2, λ)=U(x1,x2) – λ(p1x1 + p2x2 – m)                                                          (Eq. 4.2)   
Where λ (lambda) is the Lagrange multiplier, and represents the marginal value of the 
constrained resource (money).  In order to solve for the point of maximum utility, the first 
order conditions (differentiating with respect to x) would be equated zero, and thus solved for 
x1, x2 and λ.  Equations 4.1 and 4.2 demonstrate that the optimum choice for x1 and x2 is a 
function of p1, p2 and m: the prices of both healthcare interventions, and the overall health 
budget.  The Lagrange multiplier, lambda, represents the opportunity cost of spending at the 
margin (Gafni & Birch 2006;Weinstein & Zeckhauser 1973), also referred to as the ‗shadow 
price‘ of the NHS budget constraint (Claxton et al. 2006;Sugden & Williams 1978;Williams 
2004).  Lambda therefore provides the theoretical foundation of the threshold ICER.  
Equivalently, this threshold ICER can be conceptualised as follows: if a list was complied of 
all technologies available to the NHS in order of efficiency (with that generating the most 
health per pound at the top), the threshold ICER would be equal to the cost per QALY of the 
last technology on that list before the health budget is used up (Culyer et al. 2007).  The 
threshold ICER would therefore be set so that, at the margin, any adopted technology would 
have a more favourable cost-effectiveness ratio than that of any technology that is not 
adopted, or that is displaced as a result (Buxton 2006). 
NICE employs a threshold ICER range by which to judge the cost-effectiveness of a 
treatment: 
„Below a most plausible ICER of £20,000 per QALY gained, the decision to recommend 
the use of a technology is normally based on the cost-effectiveness estimate and the 
acceptability of a technology as an effective use of NHS resources. [...] Above a most 
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plausible ICER of £30,000 per QALY gained, the Committee will need to identify an 
increasingly stronger case for supporting the technology as an effective use of NHS 
resources‟ 
               (NICE 2008b, pp. 58-59) 
The explicit setting of this threshold range implies that NICE believes it to represent the 
approximate opportunity cost of NHS spending on one QALY.
10
  The main controversy 
becomes apparent when considering the parameter inputs required to determine the optimal 
ICER threshold (lambda), as demonstrated in Eqs. 4.1 and 4.2.  To consider the true 
opportunity cost of resources for the whole NHS would require an understanding of the cost 
and health implications of all current and potential interventions (Birch & Gafni 2006).  
Additionally, such a threshold should theoretically be dynamic, as the opportunity cost of 
investment is never constant given the ever-changing budget and basket of interventions (a 
basket which would change every time a new decision is made).
11
  Whilst this partly explains 
the adoption of a threshold range rather than a definitive threshold ICER, no particular 
justification has been given for the value of this range, which is said to have been based on the 
‗collective experience and knowledge of the Committee‟ who felt that it was a „reasonable, 
defensible threshold‘ (NICE 2009e, p. 12). 
Although NICE does not set the healthcare budget, affordability cannot be completely 
dissociated from the matter.  To consider the ‗opportunity cost‘ of healthcare spending at the 
margin is meaningless if that ‗opportunity‘ is not in fact foregone.  There has been no real 
attempt by NICE to disinvest in cost-ineffective practices (Culyer et al. 2007;McCabe, 
Claxton, & Culyer 2008;Towse & Pritchard 2002), which has caused an upward pressure on 
                                                 
10
 The range also offers more discretion for the committee to bring other considerations into the analysis where 
appropriate.  For example, for ICERs between £20,000 and £30,000 the committee consider in detail the 
certainty around the ICER, the adequacy of HRQoL measurement, and the innovative nature of the technology 
(NICE 2008b).  
11
 One strong criticism is that the threshold should surely at least have risen with inflation (Ubel, Hirth, Chernew, 
& Fendrick 2003), which rose 40% between 1999 and 2007, with the NHS budget having risen 90% in the same 
time frame (Raftery 2009). 
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spending, seen as a major shortfall of the current appraisal system (Birch & Gafni 2006).  
Bryan and colleagues (2007) conducted a qualitative study of NICE decisions by interviewing 
members of the appraisal committee.  Whilst finding economic analysis to be of central 
importance to the decision-making process, many committee members claimed to feel 
uncomfortable with the threshold, expressing concerns regarding both its theoretical 
foundation and its affordability implications for the NHS (Bryan, Williams, & McIver 2007).  
Some argue that the threshold is too low (Towse 2009;Ubel, Hirth, Chernew, & Fendrick 
2003), blaming it for damaging the biotechnology industry and innovation (Moran 2009).  
However, the general consensus suggests it to be too high (Raftery 2009;Williams 2004), 
implying that NICE guidance may lead to the displacement of more cost-effective 
technologies.  Some authors have tried to estimate the actual (implemented) threshold 
empirically, by trying (albeit unsuccessfully) to observe PCT-level investment and 
disinvestment decisions (Appleby et al. 2009), or using a discrete choice analysis of NICE‘s 
appraisal results (finding the threshold to be somewhat higher than the stated range) (Devlin 
& Parkin 2004).  Others have shown the relationship between a product‘s cost-effectiveness 
ratio and its likelihood of rejection (Rawlins & Culyer 2004). 
Whilst imperfect, NICE‘s decision-making approach is pragmatic, transparent, and 
evidence-based and—theoretically at least—represents the framework of any rational 
decision-maker within any healthcare system (though the appropriate threshold will differ 
according to budget size and current healthcare activity).  Before showing how this 
framework is translated by the headroom method into the conceptualisation of development 
decisions, it seems appropriate to outline the difference between CE-, CU- and CB-analyses.  
I believe their often interchangeable use within the literature to be as illuminating as it is 
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confusing; by outlining their differences and similarities, it is hoped that some clarity will be 
imparted. 
4.2.4  CEA, CUA and CBA: What‘s the difference? 
In health economics textbooks, the line between these three approaches to economic 
evaluation is clear, and relates to the outcome of interest: CEAs consider outcomes in natural 
units (e.g. number of hospital days avoided or number of cured cases), a CUA considers 
utility, and CBAs value benefits in monetary terms so that these may be compared directly 
with costs (Drummond, O'Brien, Stoddart, & Torrance 1997).  This sounds intuitive, but with 
NICE being referenced (according to the source) as performing all three, it seems useful to 
outline why.  According to NICE:  
„For the reference case, cost-effectiveness (specifically cost–utility) analysis is the preferred 
form of economic evaluation. This seeks to establish whether differences in costs between 
options can be justified in terms of changes in health effects. Health effects should be 
expressed in terms of QALYs.‟ 
                      (NICE 2008b, p. 33)  
In these terms, CUA is seen as a sub-set of CEA, where health units are measured in QALYs.  
The employment by NICE of this terminology may reflect its desire to appear pragmatic, not 
wishing to be perceived as attempting to grasp overall utility. 
Can NICE‘s approach be construed as a CBA in any way?  It is understandably unpopular 
for NICE to be considered as placing a monetary value on human life.  By describing the 
premise of the cost-effectiveness threshold, it was shown that the decision-maker—whilst 
making implicit value judgements about the relative social value between healthcare 
interventions—makes no judgement about the overall social (monetary) value of health in 
relation to other goods and services in the economy.  Rather, by facing an exogenously 
determined healthcare budget, the decision-maker‘s task is simply to maximise the value 
70 
 
derived from it.  To argue that the appropriate ICER threshold for NICE should be based on 
actual social value, as reflected by individuals‘ WTP (the welfarist approach), is to contend 
that NICE should have the power to set the healthcare budget.  These arguments have led 
Culyer and colleagues (2007) to appropriately label NICE a ‗threshold searcher‘ rather than 
threshold setter. 
Despite the decision-maker in this scenario being detached from making an explicit health 
valuation, the government, in setting the healthcare budget, reveals its valuation of health 
implicitly (Sugden & Williams 1978).  The threshold ICER thus represents a postulated value 
of the QALY (albeit by the government presumably on behalf of the citizenship, rather than 
the decision-maker), and therefore ‗can be regarded as a form of cost-benefit analysis‘ 
(Sugden & Williams 1978, p. 193).  Hence, although it is a two-step process, the same 
outcome is achieved by conceptually using the threshold ICER to value the QALY.  It is for 
this reason that the ICER is often labelled (both within this thesis and the wider literature) as 
the ‗willingness-to-pay‘, and why the headroom method uses this directly to inform the 
demand function for a new product, by attaching this monetary value to potential QALY 
gains.  This CBA approach is supported by NICE‘s own words: ‗…expected net monetary or 
health benefits can be presented using values placed on a QALY gained of £20,000 and £30,000.‘ 
(NICE 2008b, p. 45), as well as the imminent move to VBP for pharmaceuticals. 
 
By framing the decision-maker‘s objective as the assessment and comparison of costs and 
health benefits, both valued in monetary terms, a reformulation of the cost-effectiveness 
problem has been proposed, so as to generate a ‗net-benefit‘ or ‗net-monetary-benefit‘ value 
(Hoch, Briggs, & Willan 2002).  The net-benefit to the decision-maker is simply calculated by 
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subtracting the extra cost of an intervention from the extra health that it generates (valued in 
pounds).  This is entirely equivalent to standard considerations of a product‘s ICER, but has 
been proposed to overcome some statistical difficulties in handling uncertainty (Briggs, 
Sculpher, & Claxton 2006).  This type of re-organisation of the ICER equation, to suit the 
needs of the user, will be shown to closely relate to the formulation of ‗headroom‘. 
4.2.5  A summary of NICE‘s ‗reference case‘  
To ensure consistency of their technology appraisals, NICE provides a ‗reference case‘ in its 
methods guide, describing the most appropriate parameter inputs.  The preferred measure of 
HRQoL (the quality adjustment for a QALY) is one described by the patient, but considered 
by a representative sample of the public using a choice-based method of valuation (e.g. the 
time trade-off method) (NICE 2008b).  This contrasts with the welfarist ideal which would 
consider the individual to be the best judge of their own welfare.  The EQ-5D (EuroQol 
2012c), a standard instrument which has been validated by many patient populations, is the 
preferred method of quantifying HRQoL.  Costs are considered relevant if they relate to NHS 
and personal social services (NICE 2008b).  Both costs and health effects are discounted at a 
rate of 3.5%. 
 
4.3  The headroom method 
In the same way as demand-side economic evaluations, the objective of the headroom method 
is to maximise the efficiency of spending: to ensure that investments are only directed 
towards products that could generate returns for the company (or, where there are competing 
product ideas, that those with the highest likely value are pursued).  This section describes the 
headroom method, and section 4.4 provides details of its application in this thesis. 
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In short, the headroom method offers a simple way for manufacturers to investigate the 
commercial viability of a new medical device, by applying the principles of health economic 
evaluation early on—ideally when the product is first conceived.  Clinical data verifying 
effectiveness is absent at this stage, but the innovator‘s ideas around what the device could 
mean for patients (impact on health) and the NHS (cost impact for services) can be used to 
estimate its potential reimbursement prospects.  Thus, the method uses early predictions of 
potential impact (which should be optimistic but plausible) to estimate what the NHS should 
be willing to pay for the device if it works as well as hoped.  This places a ceiling on the 
reimbursement opportunity. 
The method re-arranges the standard ICER formula: 
ICER = 
               
                
  ≤ £20,000                                                                   (Eq. 4.3)   
For ease of illustration I take here the lower bound of NICE‘s threshold range, which is 
consistent with the interpretation that £20,000 represents the actual ‗threshold‘, above which 
other factors must persuade the buyers (McCabe, Claxton, & Culyer 2008).  In the 
forthcoming headroom case studies, the £20,000 threshold is generally used for the headline 
headroom estimate, but calculations according to a WTP of £30,000 are also presented.  
Equation 4.3 can be re-written as: 
  Maximum WTP = £20,000 = 
     
     
                                                        (Eq. 4.4)   
Where   denotes impact (i.e. compared with current practice), and the ‗maximum WTP‘ 




 Maximum ∆Cost = £20,000 x ∆QALY         (Eq. 4.5) 
The right hand side of the equation represents the impact on health (improvement in health 
utility multiplied by the duration of this improvement in years) multiplied by the WTP 
threshold, to give us the value of the health improvement.  The Maximum ∆Cost is the 
‗Headroom‘, and represents the maximum additional cost (to the health service) of the new 
technology over the comparator, at which the technology is cost-effective (Cosh et al. 2007).  
This must include all costs relevant to the NHS, which can be broadly divided into service 
costs (SC: staff time, hospital bed occupation, etc) and the price (P) of the new or replaced 
technology.  If, based on early estimations of potential effectiveness, the manufacturer deems 
it feasible to produce the new device at a price which will keep costs to the NHS within this 
threshold, then development would appear viable (Cosh et al. 2007).  If not, then even using 
optimistic early assumptions, the reimbursement opportunity is not sufficient to warrant 
development. 
4.3.1  Isolating the Maximum Reimbursable Price 
In order to be useful for manufacturers, I believe a further iteration must be made: to 
disaggregate from the equation the maximum reimbursable price (MRP) of the new 
technology.  As outlined, the effect on total NHS costs must include service cost impact 
(∆SC: SC2 – SC1) as well as any difference in price between the new and old device (if there 
was one) (∆P: P2 – P1).  From Eq. 4.5: 
 
Maximum ∆Cost = £20,000 x ∆QALY                                                                          (Eq. 4.6) 
      ∆SC + ∆P 
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The maximum price that the new technology could fetch within this framework (P2: 
henceforth called MRP) is therefore: 
MRP = £20,000 x ∆QALY - ∆SC + P1                                                                           (Eq. 4.7) 
Where P1 is (where relevant) the price of the current technology that would be replaced (thus 
representing a disinvestment [saving] for the NHS).  The service cost impact would detract 
from MRP if that impact were positive (SC2 greater than SC1), or add to MRP if it were to 
introduce a service cost saving.  This can be mapped onto a traditional cost-effectiveness 
plane, where the axes represent QALY and cost impact per unit (device).  For example, 








In Figure 4.1 the baseline (centre of the graph) represents the current gold standard.  The 
coordinates of technology two (our new device idea) are plotted according to expected health 
benefit (QALY2-QALY1) and expected impact on service costs (SC2-SC1).  Thus, the only 
variable left unaccounted for is P2: this is what we want to identify the ‗headroom‘ for, which 
will be known as the MRP.  First, costs and QALYs must be put onto the same (monetary) 








Figure 4.3 MRP for device (a): reduces costs and improves health 
 
 
By aggregating the cost and health effects of device (a), the vertical distance between the 
plotted coordinates of the new device and the WTP line represents the MRP, and can be 
related directly to (Eq. 4.7).  Alternatively, if a device (b) was more costly but more effective; 
or (c) equally effective but less costly than current practice, then MRP would be as shown in 




Figure 4.4 MRP for device (b): costs more and improves health 
 
Figure 4.5 MRP for device (c): reduces costs, with no impact on health 
 
This focus on MRP turns the headroom method into a more conceptually useful decision 
proposition.  If the innovator thinks that that device can be developed and produced at a cost 
which would allow for the price to be within this MRP, then it may present a viable 
development opportunity.  If not, then it is unlikely that the device, once developed, would 




Due to the pre-specified definition of ‗headroom‘ in the literature and its corresponding 
equation (Eq. 4.5), this has been described as the value of the health benefit, and therefore 
represents the maximum total cost impact to the NHS for a product to be cost-effective.  This, 
of course, is not directly of interest to a device developer, who instead must consider the 
proportion of that NHS cost impact that may feasibly be allocated to the purchase of the 
device itself.  It is for this reason that ‗MRP‘ has been defined and explained as it has above, 
which essentially represents the headroom for price (or ‗commercial headroom‘ (Girling, 
Chapman, Lilford, & Young 2012)).  However, in practice this distinction becomes more 
fuzzy, as an MRP cannot always be calculated.  This may be the case when the full potential 
impact on service costs cannot be estimated, or where particular characteristics of the device 
(its longevity, for example) are not known.  In such cases, the monetary value calculated 
cannot be attached directly to the device, as either the value estimation is not complete or is 
expressed as a value per year or per patient, for example.  Therefore, the term ‗MRP‘ is used 
in this thesis when the monetary value calculated relates directly to the device being 
considered.  The term ‗headroom‘ (rather than being used only to describe the value of health 
benefit) is employed as a more general description of the reimbursement gap identified, and is 
used to label the evaluation output in cases where MRP cannot be identified explicitly. 
4.3.2  The headroom method for decision-making:  a cost-benefit analysis 
Although the literature provides some examples of the headroom method‘s application (Cosh 
et al. 2007;McAteer et al. 2007), its placement into the decision-making context of the 
manufacturer has not been explored in much depth.  Until now, case studies have simply 
demonstrated the generation of a headroom figure, followed by an assertion of whether or not 
this seemed feasible to the developer. 
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The first step to turning the headroom method into a concrete decision-making framework 
is (where possible) the isolation of the MRP, as demonstrated above.  For the developer, 
however, this is just half the story, and simply informs the potential future ‗benefit‘ of the 
developer‘s own CBA.  Put simply, if the expected benefits of a project outweigh the 
expected costs (to develop and manufacture the device), then the project may be worthwhile.  
Technically, benefits and costs (both monetary) should be expressed in terms of their present 
value, which involves discounting these according to the company‘s own internal rate.  This 
may be important because much of the cost of development is likely to be incurred early on, 
whereas the benefit (revenue from sales) may be accrued some years in the future, and thus 
eroded more by discounting.  For a project to be viable, the net present value of the whole 
project should be greater than zero. 
NPV ≥ 0                        (Eq. 4.8) 
NPV = NPV (Benefits) – NPV (Costs)              (Eq. 4.9) 
As the relevant discount rate is likely to vary on a case-by-case basis (depending on the 
financial position and preferences of the manufacturer), this is left to one side here, and it is 
assumed that the developer will incorporate consideration of this into their decision.   
4.3.3  Calculating allowable development costs 
The isolation of MRP has been described, and represents the potential unit value of a new 
device idea.  However, potential volume of sales is also an important consideration for 
business decisions.  The relevant market size will directly affect the per unit cost of a device 
to a manufacturer; the larger the market size, the greater the capacity to spread the costs of 
development over more units (or to recoup these more quickly), as well as allowing the 
manufacturer to exploit economies of scale for production.  The following analysis will 
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demonstrate that, if future production costs can be estimated, the developer can use the 
headroom estimate to determine how much they can afford to spend on development (in order 
to consider whether this seems feasible).   
In keeping with the method‘s approach—to estimate the theoretical limits—the value of a 
development project can be equated to zero in order to determine the maximum viable costs to 
the developer.   
 NPV = 0             (Eq. 4.10) 
When combined with Eq.4.9: 
NPV (Benefits) = NPV (Costs)         (Eq. 4.11) 
There are two major components of total cost (TC): fixed (FC) and variable costs (VC).  By 
introducing volume of sales into Eq. 4.11, we have:      
NPV (Benefits) = MRP*volume 
          = NPV (Costs) 
                                 TC= FC + VC         (Eq. 4.12) 
Table 4.1 defines total, fixed and variable costs. 
Table 4.1 Total costs in the development decision 
TC: Total cost Total cost for the purposes of this exercise will be equal to total revenue 
(MRP*vol.)  It is the sum of fixed and variable costs. 
FC: Fixed cost 
(development 
costs) 
This is the element of total cost that does not vary with the amount of output 
produced.  Fixed costs may include things like the purchase of machinery, land 
rent, etc.  An important fixed cost is sunk cost of development for devices: the 
investment in R&D required to get the product ready for market.  I will therefore 
refer to this set of costs as ‗development costs‘, but consideration of this must 
include other such fixed costs as land rent and capital upkeep. 
VC: Variable cost Variable costs are those that do vary with the amount of output produced.  This 




By estimating the maximum total revenue and thereby assessing the maximum allowable 
costs for the developer, we can explore the trade-off between development costs and variable 
costs, where:  
Maximum total development cost = TC – VC                                                           (Eq. 4.13) 
Where TC is (MRP * volume) and VC is total variable cost (variable cost per device * 
volume).  Thus, if the likely variable production costs can be estimated, then the maximum 
cost of development can be considered.  This will be demonstrated in chapter 6 where it is 
described in relation to the development of a near-patient COPD monitor.  It will also show 
how this analysis can be used to compare target market considerations.   
 
The current literature base for the headroom method lacks a practical focus.  The description 
above therefore places the method within the decision-making context of the manufacturer.  
However, to calculate ‗headroom‘ in the first place requires certain research skills and an 
understanding of the resources available.  With this in mind, the next section outlines an 
approach to help the user of the method hone in on the important change proposition of the 
new product, and to extract the relevant information from the literature to furnish these 
assumptions and quantify their value.   
 
4.4  Finding values for the headroom method 
Through the course of this study, materials have been generated to guide the conducting of a 
headroom analysis.  As well as making its application clearer for a developer, this also allows 
for a more systematic approach to its application for the purposes of this study. 
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4.4.1  Pro forma and headroom method template 
Although every new device is different in the way it might impact current practice (its change 
proposition), there are certain questions to be asked and resources to draw upon which allow 
assumptions to be as informed as possible.  For this purpose, a pro forma has been developed, 
as well as a headroom method template to be used in conjunction with it (see Appendices 1 
and 2).  The pro forma is divided into seven categories: description of the technology, 
comparator, market size, health service impact, patient impact, developments in the area 
(clinical and healthcare context) and research questions.  The template breaks these categories 
down further and outlines the pertinent questions, as well as providing the potentially relevant 
online resources for each category.  This is followed by a more detailed description of some 
of the categories where identifying the numbers might be difficult, especially for those not 
used to identifying or manipulating the figures in this way.  This includes a description of 
some relevant databases (e.g. HES Online and NHS reference costs), the provision of 
particularly useful statistics (costs per hospital bed day, inflation rates, etc) as well as how to 
adjust for inflation, apply discount rates, approach QALY calculations, and so on. 
These materials were compiled through a familiarity with the method and experience 
gained from the first major case study: the near-patient monitor for COPD.  The pro forma 
and template were developed before the 20 retrospective case studies were undertaken, but 
extra resources were added to the latter during the work.  The documents are not intended as 
stand-alone material, but can help the user to conceptualise and quantify the potential value of 
their product.  Whilst the identification of costs is reasonably objective (once the appropriate 
assumptions have been decided upon), QALY estimations are often more difficult due to the 
paucity of HRQoL data in the literature.  In the headroom method template I propose three 
approaches for this, which are outlined in the next subsection. 
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4.4.2  Identifying HRQoL weights  
Whilst there are many useful resources for identifying HRQoL studies, they are available for 
only a finite number of health conditions.  Therefore, I propose three approaches (in order of 
preference): 
1) HRQoL estimates in the literature 
As mentioned in the summary of NICE‘s reference case (section 4.2.5), the preferred method 
of HRQoL estimation is with the EQ-5D questionnaire (to be completed by those affected by 
the condition), and the use a choice-based method of valuation (such as time trade-off) from a 
representative sample of the general population (NICE 2008b).  HRQoL estimates derived 
from the EQ-5D therefore represent the first choice (though others are considered by NICE). 
The headroom method template, which acts as a resource guide, lists some useful HRQoL 
resources in the literature.  Particularly useful is the CEA registry (TMC Research 2012): a 
database of CEAs across a wide spectrum of treatments and diseases.  Others include the 
Cochrane library (which has specific search outputs for technology assessments and economic 
evaluations) (Cochrane Collaboration 2012), the NHS economic evaluation database (CRD 
2012), the National Institute for Health Research (NIHR) HTA programme (NIHR 2012), as 
well as medical journal searches such as Medline and previous NICE technology appraisals.   
2) Manipulating the five health dimensions of the EQ-5D questionnaire 
When estimates in the literature do not exist, it may be appropriate to consider the EQ-5D 
questionnaire directly.  This has not been proposed for use in the headroom method before, 
but seems intuitive in cases where the developer has a clear idea of the product‘s potential 
areas of benefit. 
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The EQ-5D‘s five health dimensions (mobility, self-care, usual activities, pain/discomfort, 
and anxiety/depression) are each divided into three levels: (1) no problems, (2) some 
problems, and (3) severe problems.  There are therefore 243 possible health states.  A large 
survey of a representative sample of the UK population (3,395 participants) was conducted in 
1993, through which 42 of these ‗health states‘ were directly valued (Dolan 1997;Williams 
1995).  Dolan (1997) modelled the results to interpolate values for the remaining 201 states, 
for which he found the best fit for the data was from a main effects model, which attached a 
value to each separate deviation from perfect health.  This set of national EQ-5D ‗tariffs‘ or 
‗value sets‘ have not been updated since, and remain the reference standard for UK QALY 
valuation (EuroQol 2012a;Karlsson et al. 2011).  Table 4.2 summarises the findings of this 
study, by showing the coefficient values of all possible deviations from 1 (‗full health‘). 
 
Table 4.2 UK health state valuations for the EQ-5D based on the time trade-off method 
Dimension Coefficient 
Constant  0.081 
Mobility Level 1: No problems walking about 
Level 2: Some problems walking about 




Self-Care Level 1: No problems with self-care 
Level 2: Some problems washing or dressing self 




Usual Activities Level 1: No problems with performing usual activities 
Level 2: Some problems with performing usual activities 




Pain/Discomfort Level 1: No pain or discomfort 
Level 2: Moderate pain or discomfort 




Anxiety/Depression Level 1: Not anxious or depressed 
Level 2: Moderately anxious or depressed 




N3  0.269 
Data from Williams (1995) 
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This information allows us to calculate the value of any single combination of the three levels 
of the five health states, by subtracting the coefficients presented in Table 4.2, from 1.  The 
‗constant‘ (0.081) should be subtracted from any deviation from full health, and N3 (0.269) 
should be subtracted from the overall value if one or more health states are in level 3.  For 
example: 
For health state 11221:  1 – 0.081 – 0.036 – 0.123 = 0.76                               (Eq. 4.14) 
 For health state 13312:  1 – 0.081 – 0.269 – 0.214 – 0.094 – 0.071 = 0.271   (Eq. 4.15) 
This could be useful in estimating the effect of a one-step change in a particular health 
parameter.  Whilst the potential health implications of many new health technologies is 
complicated, for particular cases it may be intuitive to attribute the desired effect of a new 
device idea to one of these categories (see for example the Ulcer Protector in chapter 8).  If, 
for example, a new device could plausibly reduce pain/discomfort from level 2 (some 
pain/discomfort) to level 1 (no pain/discomfort), then this could be valued at 0.123, and 
should be multiplied by the time (in years) for which this change is sustained (and then 
discounted at 3.5%) in order to calculate QALY impact.  
The EuroQol group have recently developed a new instrument called the EQ-5D-5L, 
which will eventually replace that described above, where each of the five health states is split 
into five rather than three levels (Rabin et al. 2011).  However, new value sets (of which there 
will be 3,125), will take several years to generate.  EuroQol provide an estimate of what these 
values might be, using a ‗crosswalk‘ model and existing data for the EQ-5D-3L (EuroQol 
2012b).  As this five-level instrument has not yet been used for many studies and validated 




Although this strategy should not be considered a substitute for later-stage HRQoL 
investigations, it could at a very early stage offer some insight into the potential value of 
particular changes in certain HRQoL parameters, in cases where this is intuitive.    
3) Utility ladder 
Alternatively, HRQoL may be estimated by relating the health state in question to other 
comparable health states, for which a HRQoL estimate does exist.  McAteer (2011) proposes 
this in her PhD thesis, to overcome problems she encountered in eliciting HRQoL in the 
absence of literature estimates.  By pulling together a range of HRQoL values from various 
conditions derived from NICE technology appraisals, McAteer places a selection of these on a 
utility hierarchy (‗utility ladder‘), which can act as a frame of reference (see Template in 
Appendix 2 for a visual depiction of these utility ladders). 
The solution described above is not completely novel, and other attempts to build such a 
catalogue of health states date back nearly 20 years.  The Beaver Dam Health Outcomes 
Study predates NICE by around seven years; by providing HRQoL measures for various 
chronic conditions, the aim was for these to act as reference statistics in a world where there 
were relatively few HRQoL studies (Fryback et al. 1993).  Indeed, one example of its 
application is in a cost-effectiveness study for a pneumococcal vaccine: ‗Because the 
literature includes no assessments of utility for in-patient and out-patient pneumonia, we 
estimated them on the basis of comparisons with various health states for which published 
utility data exist‘ (Vold Pepper & Owens 2000, p. 160). 
 
Previous attempts to apply the headroom method in the absence of HRQoL estimates in the 
literature include an opinion-poll of four urologists, and a survey of 112 members of the 
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public using a questionnaire (Cosh et al. 2007;McAteer 2011); these methods are time-
consuming, resource-intensive, inconsistent with standard utility measures, and above all are 
unlikely to be feasible for most device developers
12
.  The approaches outlined above may help 
to overcome this, by offering a relatively quick and simple way to make an informed estimate 
of potential QALY impact.  This would appear to be more straightforward, intuitive, and 
consistent with the framework employed by the decision-makers.   
 
4.5  Summary 
In order to understand the basis of and the need for the headroom method, it was important to 
demonstrate the objective function of the healthcare decision-maker.  By presenting the 
headroom method within the framework of a traditional economic evaluation on the cost-
effectiveness plane, the direct translation of the demand-side health economic framework into 
these early decisions by developers is evident.  Consideration of the developer‘s decision as a 
CBA has clarified how ‗headroom‘ fits into a development decision, as well as allowing the 
developer to reflect on the allowable development costs of the project.  Along with the pro 
forma and template, these help to make the headroom method and its application more 
tangible.  Section 4.4 demonstrated how the method‘s application has been made as practical 
as possible, by providing guidance on navigating the relevant sources of information and 
outlining pragmatic approaches to overcome information scarcity. 
                                                 
12
 For example, the headroom analysis for a tissue-engineered substitute of buccal mucosa (cheek lining) to treat 
a urethral stricture utilised a time trade-off questionnaire distributed to 112 members of the public, which 
described the pain of buccal mucosa donation and asked participants to specify the time and money they would 
be willing to sacrifice to avoid this (McAteer 2011).  Approach two described above (utility estimation using the 
EQ-5D questionnaire) could have been employed to very quickly estimate the potential value of avoiding 
moderate pain for five weeks.  This would have rendered a higher disutility estimate: 0.0123 QALYs saved 
rather than 0.006 estimated by McAteer. 
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Given the highly competitive nature of the device industry and the short time over which 
developers can recover costs, it is important that reimbursement potential is considered early 
on.  Of course, actual reimbursement at this threshold level implies that the full value of the 
innovation would accrue to the manufacturer rather than the NHS which, whilst not socially 
inefficient, might be a high-risk strategy
13
.  However, these considerations are not paramount 
at such an early stage, and instead the focus should be on the feasibility of containing costs 
within this theoretical MRP. 
Section 4.2 of this chapter explored NICE‘s approach to decision-making, which for the 
purposes of the headroom method is considered to be a CBA approach.   The headroom 
method aims to predict the outcome of this late-stage CBA, which can then be used to inform 
the ‗benefit‘ element of a developer‘s own CBA for a device development decision.  The aim 
of this thesis is to evaluate the headroom method: to consider the costs involved (How long 
does it take? What are the resources required?) and the benefits (Is it a good predictor of NHS 
uptake? Is it useful to manufacturers?) of the headroom method itself.  The next chapter 
describes the methodology employed to tackle this evaluation.  
                                                 
13
 Girling and colleagues discuss the optimal pricing of medical devices under coverage uncertainty, and suggest 
that the price should be set to cover production costs and to recover 84% of the anticipated economic surplus 
(Girling, Lilford, & Young 2011). 
89 
 
CHAPTER 5 METHODOLOGY 
5.1  Introduction 
A medical device that is developed with no real attempt to study its effect on and 
compatibility with patients is arguably of no use.  Whilst it may have a sound theoretical 
justification, real life rarely upholds this perfectly, and with no attempt to test for its actual 
consequences the device is likely to be left on the shelf.  In the same way, a decision-making 
tool that is not studied in relation to its effectiveness and suitability to the intended user is not 
well understood.  The previous chapter outlined the headroom method and explained its 
theoretical underpinning and method of application.  This chapter sets out how the method is 
evaluated in this research project. 
Whilst there are examples in the literature of the application of headroom and other 
methods of early economic evaluation, these studies fail to evaluate the methods.  This 
omission has been noted by many but addressed by few: ‗The field must critically appraise 
the relevance of early HTA for its stakeholders‘ (Ijzerman & Steuten 2011, p. 342); ‗Further 
research, however, is needed to investigate the practicality and likely value of the 
approach...to medical device companies and the wider healthcare society‘ (Vallejo-Torres et 
al. 2008, p. 463).  This project makes the crucial steps from application of the headroom 
method to an evaluation of it, for which a mixed-methods research design is appropriate.   
The review of the literature and market scene-setting chapter alluded to the ‗Why‘ of this 
research.  This chapter outlines the ‗How‘.  In a perfect study the headroom method would be 
applied to a multitude of new devices at concept stage by the developers themselves, and 
would be followed up in real time to observe the actual market uptake or cost-effectiveness of 
the devices studied (or better still, an RCT approach through which the method‘s employment 
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would be randomised).  Time and resource constraints inhibit this ideal, but the approach 
outlined here aims to make best use of information that is attainable, and with it to offer a 
novel insight into the usefulness of the headroom method. 
The research questions underlying this project were outlined in the introduction, and were 
concerned with the method‘s efficacy and usability.  Put simply, I ask: Does the tool facilitate 
appropriate decisions, and is it applicable in practice?—two questions that remain unanswered 
by the current literature.  These core questions form the basis of my methodological choices, 
so that a ‗chain of evidence‘ (Yin 1994) can be constructed, allowing each part of the study to 
be clearly linked to all other parts, and conceptually bound to the original research questions. 
The chapter is organised as follows.  The first section (5.2) describes the philosophical 
grounding of the project, and the objectives of evaluation research are presented in section 
5.3.  The prospective case studies, retrospective case studies and interviews are then outlined 
in sections 5.4 and 5.5.  The overall mixed-methods design of the study is then discussed in 
relation to the specific research questions (section 5.6).  Finally, a summary is offered. 
 
5.2  Research Philosophy 
Before describing the evaluation literature, this section briefly introduces the epistemological 
grounding of this and other types of research.  As suggested by Burrell and Morgan (1979), 
all research is based on a philosophy of science and implicit assumptions about how the world 
can be investigated.  In its widest and most polarised sense, research may ascribe to an 
objective or a subjective paradigm, hereafter referred to as ‗Positivist‘14 or ‗Relativist‘15.  
                                                 
14
 Also referred to in the literature as scientific, experimentalist, empiricist, traditional and conventional 
15
 Also called subjectivist, humanistic, constructivist, anti-positivist and interpretive 
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These are delineated by several core assumptions concerning what reality is (ontology) and 
the theory of knowledge (epistemology) (Holden & Lynch 2004). 
From an ontological perspective, a positivist believes that the reality to be investigated is a 
given, objective thing which is external to the individual (Burrell & Morgan 1979).  A 
relativist, on the other hand, believes that reality is a product of individual cognition and of 
groups who construct their own version of truth, believing there to be no single reality that 
can be objectively measured (Burrell & Morgan 1979;Clarke 1999).  These opposing theories 
of nature give rise to opposing theories of knowledge.  A positivist aims for personal 
detachment of the researcher from the researched so that knowledge can be gained by 
measurement and observation, whereas a relativist researcher believes that knowledge cannot 
be discovered but is subjectively explored (Clarke 1999;Holden & Lynch 2004).  These 
epistemological stances guide evidence generation, the raw material of research, of which 
there are two main types—quantitative and qualitative—the first of which suits the aims of 
the positivist, and the second the relativist (Gillham 2000). 
Of course, there are standpoints in between these two extremes, the differences between 
which many authors believe to be overstated (Crossan 2003).  Whilst some purists (see for 
example Guba and Lincoln (1988, pp. 89-115)) believe that methodologies are meaningless if 
they are not rooted to one (non-divisible) paradigm, others believe that by utilising both 
paradigms for a particular enquiry, convergences (or divergences) in the stories they tell can 
be explored, offering a more revealing understanding of the research problem (Greene, 
Caracelli, & Graham 1989;Kidder & Fine 1987;Patton 1988).  I believe the latter perspective 
to be particularly pertinent to evaluation and to the purposes of this project.  Perhaps a more 
appropriate philosophical stance for this research, therefore, is offered by ‗critical realism‘, 
which sits between the two extremes and believes there to be an independent and objective 
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reality, but which is critical of our ability to know it with certainty, thus emphasising the 
importance of multiple approaches (Clark, Lissel, & Davis 2008;DeForge & Shaw 
2012;Trochim 2006).  I believe that this pragmatic stance most successfully allows the 
research methodology to be guided by the research questions, and therefore to generate the 
most useful findings. 
 
5.3  Evaluation Research 
„Evaluation is an applied inquiry process for collecting and synthesizing evidence that 
culminates in conclusions about the state of affairs, value, merit, worth, significance, or 
quality of a program, product, person, policy, proposal or plan.  Conclusions made in 
evaluations encompass both an empirical aspect (that something is the case) and a 
normative aspect (judgement about the value of something).  It is the value feature that 
distinguishes evaluation from other types of inquiry such as basic science research, 
clinical epidemiology, investigative journalism or public polling.‟ 
                                                            (Fournier 2005, p. 140) 
 
Evaluation research tends primarily to address social programmes or policy.  However, the 
object of an evaluation, as demonstrated in the Encyclopaedia of Evaluation‘s definition 
presented above, can be almost anything.  The various definitions of an evaluation in the 
literature demonstrate some unifying themes, most notably the necessary ‗systematic‘ nature 
of evidence generation (Rossi, Freeman, & Rosenbaum 1979;Stufflebeam & Shinkfield 
1985), which should relate to an object‘s ‗merit or worth‘ (Clarke 1999;House 1993;Trochim 
2006).  The use of the term systematic alludes to the strive for impartiality and 
reproducibility, whilst the words merit and worth suggest a consideration of efficacy, but in 
relation to those who have a stake in the object or program.  Generally, an evaluation is said 
to be ‗summative‘ if its aim is to draw conclusions around a program‘s effectiveness, or 
‗formative‘ if the intention is to support the program‘s improvement (Scriven 1967). 
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One of the most salient features of an evaluation is its underlying purpose: to influence 
decision-making.  This sets this type of research apart from others, both justifying and guiding 
its use of multiple approaches.  In the early days of program evaluation an experimentalist‘s 
approach prevailed, but is argued to have produced poor results with little impact, mainly due 
to an experiment‘s incompatibility with non-hard science subjects, and its failure to account 
for the context of the evaluation and the views of the stakeholders (Pawson & Tilley 
1997;Simons 2009).  Now, the main body of evaluation literature advocates epistemological 
and methodological pluralism (Fetterman 1988), stressing that the methods chosen should be 
determined by the nature of the research rather than pre-existing methodological biases (Chen 
1990;Chen & Rossi 1983;Clarke 1999;Weiss 1997).   
Although discussed mainly in relation to sociology and criminology, the literature relating 
to ‗realist evaluation‘ provides some particularly pertinent objectives of evaluation research 
which chime with the goals of my own evaluation.  Realist evaluation was introduced by the 
seminal work of Pawson and Tilley (1997), who suggest that an evaluation should consider 
not only whether a programme works, but should also address why, by considering what 
works, for whom, and in what circumstances.  The authors emphasise that evaluation research 
should be based on hypothesis testing, and stress the importance of context in shaping 
outcome (Pawson & Tilley 1997;Pawson & Tilley 2004).  Whilst not forming the central 
focus of this study, the realist evaluation approach described briefly here offers some guiding 
questions which, when it comes to the discussion of results presented in chapter 10, will 
demonstrate the explanatory power of the evaluation, providing a deeper appreciation of the 
study results. 
The purpose of evaluating the headroom method is to understand its potential to improve 
decision-making by developers: to reduce expenditure on the development of devices which 
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will ultimately be unsuccessful, and/or to increase expenditure on devices with the potential 
for health service uptake.  This is the ‗outcome‘ of interest, and the headroom method‘s 
description in the last chapter set out the theory of why its use by device developers should 
improve decision-making.  The mixed-methods strategy to this evaluation has been designed 
to test this hypothesis, whilst acknowledging that outcome is likely to be affected by the 
context within which the headroom method is applied. 
As outlined in the introductory chapter, the two key research questions are: 
Research question 1:  Does the headroom method ‘work’? 
Research question 2:  Is the headroom method ‘usable’ by device developers? 
The methods employed within this study all aim to address different elements of both of these 
questions.  The way in which the overall mixed-method strategy achieves this is described in 
section 5.6.  First, the individual methods—case studies and interviews—are outlined.  
However, a detailed account of the precise procedures employed and the implications of 
decisions made is reserved for the relevant chapters themselves.  
 
5.4  Case studies 
The purpose of this section is to briefly outline the procedure of data collection and analysis 
of the case studies, of which there are two types: prospective and retrospective.  
5.4.1  Prospective case studies 
Although it has not been possible to interact with developers at true ‗concept‘ stage, the two 
prospective case studies offer a useful insight into the application of the headroom method 
early on, before major development has taken place.   
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5.3.1 (i) Near-patient monitor for COPD 
The first case study is a near-patient monitor for COPD whose innovator, Professor Monica 
Spiteri, had initiated the very first stages of product conception and development when we 
first met in early 2010.  The collaboration with Professor Spiteri, a respiratory clinician, was 
facilitated by a mutual contact who was also involved in the development of the monitor.  The 
sampling technique here was clearly one of convenience, and the Professor‘s association with 
an academic institution may have influenced her interest in pursuing the collaboration and 
understanding the benefit of the research.  However, the source of this innovation, having 
been motivated by the experience of a clinician working in the field, is typical of the device 
and diagnostic sector, and so offers a unique insight into this type of innovation. 
The case study was carried out by independent work that was ongoing for over a year, and 
whose direction was facilitated by various meetings with the innovator.  It involved extensive 
reference to the literature; the headroom assumptions were generated through both this 
literature work and discussions with the expert: Professor Spiteri.  The process offered an 
invaluable learning experience in familiarisation with the available literature and resources, in 
working with the innovator to generate assumptions, and in guiding my understanding of the 
headroom method at a practical level.  Additionally, it is through this case study that the 
approach to development cost consideration, described in chapter 4, was developed. 
This case study (presented in chapter 6), acted as a ‗pilot‘ of sorts, and informed much of 
the later work.  The headroom analysis was time-intensive, which is clearly contrary to the 
intended use of the method.  This therefore inspired the rest of the study and in some ways 
shaped the whole research design, motivating me to consider the type of evidence required to 
evaluate the headroom method (rather than simply offering another example of its 
application).  Therefore, whilst not reflecting the intended form of the method‘s application, 
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this case study formed an important part of the research process and design, as well as 
providing an insightful interview opportunity (to be discussed in section 5.5).  
5.4.1 (ii) Protective stocking for leg ulcers 
The analysis for the protective stocking for leg ulcers is presented in chapter 8, as it was 
conducted after the retrospective case studies.  The collaboration was facilitated by a mutual 
contact who had been advising the innovators: two individuals who had set up a new business 
to develop this device.  An appreciation of the proposed product was facilitated by a meeting 
which took place in November 2011, after which emails were exchanged in order to confirm 
my understanding of the topic and the feasibility of assumptions drawn.  All other work was 
conducted independently.  One additional meeting took place, in which results were presented 
and discussed (and an interview conducted).  
The principal benefit of this case study was to illustrate the prospective application of the 
headroom method, using the framework and resource set which had been developed during 
the retrospective case studies.  This included the (loosely defined) principle of ‗headroom in a 
day‘.  The total time taken for the case study was recorded and reported back to the 
developers.  The application of the headroom method to this particular product type offered 
additional insight into the method‘s use, which is analysed alongside the other elements of the 
project in the discussion chapter.  
Although these case studies were by no means randomly selected, they offer examples of two 
very different innovation types.  As well as demonstrating the method‘s early use, they also 
provided the opportunity to understand the relative merits, disadvantages, and impact of the 
headroom method in real-life.  Additionally, unlike the retrospective case studies described 
below, these are less biased toward successful or big-impact innovations.  
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5.4.2  Retrospective case studies 
As described, the preferred scenario of following-up case studies to which the headroom 
method had been applied prospectively (at ‗concept‘ stage) is inhibited by the time restraints 
of this research.  Additionally, if headroom results had influenced the development decision, 
the appropriateness of that influence would not always have been traceable.  Therefore, as a 
surrogate for the prospective application of the method, the method is applied retrospectively 
to medical technologies that were conceived in the past, but whose success or failure on the 
market has already been determined.   
The source for these case studies was the National Horizon Scanning Centre (NHSC‘s) 
medical technology briefing database, which provides an overview of technologies that are 
yet to be introduced into clinical practice (see chapter 7 for further details).  All briefings 
produced by the organisation between 2000 and 2009 were considered for inclusion on the 
basis of clarity, and focus on a specific technology.  As explained in chapter 7, of the 83 
briefings 54 were excluded, and of those remaining 20 were randomly selected.  After the pro 
forma was developed, and a framework of application designed, the Fibro-Test Acti-Test was 
used as a pilot study which served to consolidate and refine the approach. 
The method was applied on the premise of ‗headroom in a day‘, and searches for the 
relevant data and literature were restricted to mimic as far as possible the information base 
available to the developer at around its point of conception.  After the headroom analysis was 
undertaken, the technology was followed-up to confirm whether headroom would have 
indicated a favourable development decision (based on up-to-date information and actual 
price where available), and the market uptake of the device was identified.  In chapter 7, 
uptake of the medical technology is described to three extents: (a) Evidence of any uptake 
within the NHS for the specified indication, (b) Evidence of widespread uptake within the 
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NHS for the specified indication, and (c) Evidence of any uptake (globally of for other 
clinical indications).  The headroom method aims to quantify the potential value of a new 
product to the NHS, for a specific clinical application; therefore, definition of uptake (a) 
above is used as the main measure of success, to which headroom analyses are compared.  
However, consideration of the headroom method‘s performance using the other definitions of 
uptake will also be explored. 
As the headroom method values the gap in the market based on current market conditions 
and (optimistic) expectations for the technology, the value of this ‗gap‘ may reduce as time 
goes on (e.g. due to the introduction of new competitors, revision of efficacy expectations 
etc.)  Therefore, it may be reasonable to assume that some devices whose headroom indicated 
a favourable development decision may in the end be unsuccessful.  However, where 
headroom indicates a no-go decision, and the product turns out to in fact be a successful one, 
this may imply a problem with the method.  It is for this reason that the headroom is primarily 
suggested as a ‗rule-out‘ method.  Results and subsequent analysis considered each case study 
in terms of the technology type, regulatory class, relationship with current practice, and 
clinical area, in order to relate these factors to the headroom results. 
The limitations of the NHSC database as a source of case studies is clearly important, and 
the implications for the results are discussed in chapter 7.  Most notably, the sample does not 
include any devices that have been dropped pre-launch, and is likely to be biased toward 
successful and big-impact products.  The headroom method was applied in a systematic way, 
and the situation of the developer was imitated as far as possible in terms of information 
availability and likely time restrictions.  A significant part of the analysis is found in the 
‗headroom lessons‘ that arise from the case studies and their follow-up, such as 
appropriateness of scope, intrinsic limitations and extra considerations required. 
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Whilst in the retrospective studies I have tried to some extent to reflect the situation of the 
developer, I recognise that I, personally, have both disadvantages (limited clinical or in-depth 
knowledge pre evaluation) and advantages (previous experience and educational background) 
in applying the headroom method.  The pro forma and template, as well as providing the 
materials to apply the method systematically in this evaluation, also offer the novice health 
economist (device developers wishing to apply the headroom method) a starting point and a 
way into the topic.  The objective of this research is not to understand how well a PhD 
researcher can apply the headroom method, but rather to understand its potential application 
in real life.  For this reason, consideration of the context of developers is paramount, and this 
is the subject matter of the interviews.  
 
5.5  Interviews with potential users of the headroom method  
„The most important purpose of evaluation is not to prove but to improve… We cannot be 
sure that our goals are worthy unless we can match them to the needs of the people they 
are intended to serve‟  
                                                                                (Stufflebeam & Shinkfield 1985, p. 151)  
  
The goal of this research study is to improve the decision-making practice of medical device 
developers.  As well as exploring for whom the method may be most useful / appropriate, the 
interviews with stakeholders facilitate an understanding of its usability and in what way it has 
the potential to impact decision-making in real life.   
Whilst the case studies consider the causal potential of the headroom method, it must be 
recognised that outcome is contingent upon the contextual conditions and attitudes of the 
method‘s user.  It is for this reason that information and insight are sought from the potential 
users of the method.  Participants were selected based on a purposive sampling technique, and 
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were identified through either ready-established contacts made through the course of the 
project or through colleagues.  Twelve participants were interviewed through the course of 
seven interviews, and interviewees covered a wide range of potential users, including a start-
up business, a large multi-national medical technology company, business and design 
consultants, a clinician, an academic, and an NHS innovations manager.  The semi-structured 
interviews were transcribed and thematically analysed. 
 
5.6  A mixed-methods evaluation of the headroom method 
The main perceived benefit of a mixed-methods research design derives from the recognition 
that all individual methods have error and are susceptible to bias (Trochim 2006;Williamson 
2005).  Moreover, by employing a mixed-methods approach, the strengths of each approach 
can be exploited and their combined results can provide a wider and more informative 
exposition of the issues (Creswell 2009;Yin 1994).   The combining of methods has risen in 
popularity both within evaluation research and more widely, reflecting the development in 
legitimacy of many different approaches, as well as the recognition that each contributes a 
distinct and useful perspective (Clarke 1999;Creswell 2009).  The philosophical grounding of 
adopting a mixed-methods approach was set out in section 5.2, along with the rationale for its 
use within this particular enquiry.   
Greene and colleagues (1989) provide a useful outline of the various purposes of a mixed-
method strategy to evaluation: triangulation, complementarity, development, initiation and 
expansion.  These five distinct purposes are explained in chapter 9, where the methodological 
contribution of the qualitative interview investigation to the overall study design is described 
in more detail.  Triangulation in particular is regularly stressed in the literature to be an 
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important output of mixing methods.  A term originally deriving from nautical navigation, 
triangulation refers to the establishment of location (or meaning in this case) using inferences 
obtained from various methods or measurements (Stake 1995).  This allows for the improved 
validation of research results by exploring the convergence in findings from the various 
methods (Campbell & Fiske 1959;Simons 2009;Stake 1995). 
5.6.1  Study design 
The first most obvious criterion for the headroom method‘s assessment is its ability to 
discriminate between good projects and bad.  This addresses method efficacy, and is dealt 
with primarily by the 20 retrospective case studies and their follow-up.  The word ‗efficacy‘ 
has been chosen purposefully here as it refers to the ability of something to produce the 
desired effect or outcome under controlled conditions (e.g. within a clinical trial), as opposed 
to effectiveness which considers the effect of an intervention in practice (Osterholm, Kelley, 
Sommer, & Belongia 2012).  Although this contribution is novel (the outcome of the 
headroom method‘s use has not previously been investigated), an understanding of efficacy 
alone is insufficient to appreciate the potential effectiveness of the method. 
As described in the literature review, current studies of early HTA methods for developers 
lack an evaluative approach (Bartelmes et al. 2009).  McCabe and Dixon (2000) acknowledge 
the desirability of identifying the predictive value of economic models, whilst noting that their 
validity cannot be determined exclusively on that basis; the value of a model should be 
assessed in relation to the decision-maker for whom it is intended (McCabe & Dixon 2000).  
Usability is explored primarily through the stakeholder interviews, although both methods are 
designed to address both research questions in different ways.  The implicit assumptions of 
the headroom method must also be addressed.  For example, by assuming that the headroom 
method could improve decision-making, we implicitly assume that health economics is not 
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currently incorporated into development decisions, or is done so sub-optimally; this must be 
investigated.  The ways in which each method contributes to the evaluation is summarised in 









2 x Prospective case 
studies 
20 x Retrospective case 
studies 
Interviews 
Does it work? 
(i) Is it novel? 
 
  The method may only improve 
decision-making if it adds to 
current practice. This is 
investigated in the interviews. 
(ii) Is it a good 
predictor of market 
uptake? 
 Follow-up of the retrospective 
headroom analyses allow the 
implied development decision to 
be matched with later market 
uptake. Given the diverse 
characteristics of the study 
sample, patterns may be sought. 
 
(iii) What is left out of 
the analysis? 
Later interviews with the 
developers of the prospective 
case study devices offer a 
unique insight into their views 
on the completeness of the 
analysis, and the usefulness 
of its output. 
The headroom analyses and 
follow-up allow for pertinent 
omissions (that had an impact 
on future market uptake) to be 
noted.  These are presented in 
chapter 7 as ‗headroom 
lessons‘. 
Interviewees are asked to discuss 
any important omissions from the 
headroom approach, which may 
be as / more important at 
development decision stage. 
Is it usable by 
device developers? 
(i) Can it be utilised at 
‗concept‘ stage? 
These case studies 
demonstrate the method‘s 
application in real time to 
devices in the very early 
stages of development. 
Information searches are date-
restricted to mimic the concept 
stage of the developer. 
Headroom should be related to 
expected costs in order to inform 
the development decision. 
Interviewees are asked whether 
costs can be conceptualised at 
such an early stage. 
(ii) Can the method be 
applied by device 
developers? 
 A pro forma and resource 
template offer non-specialists a 
framework to follow in applying 
the method.  
Interviews investigate whether the 
method is understandable and 
what the biggest barriers might be 
to its application. 
(iii) Could it practically 
be incorporated into 
decision-making? 
 Time spent per headroom 
analysis is guided by ‗headroom 
in a day‘. 
Practical barriers are explored, 
including time available and 
expertise, and how barriers may 
vary according to the user. 
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The break-down of method choice and design presented in Table 5.1 demonstrates the 
multiple ways in which efficacy and usability of the headroom method are considered in this 
research.  The strategy employed for the evaluation is aligned most clearly with what 
Creswell (2009) describes as a ‗sequential explanatory design‘.  Rather than the methods 
being applied concurrently, I first analyse the case studies (which represents a quantitative-
leaning method), which then informs the secondary qualitative data collection.  This allows 
for the interview questions to build upon (and sometimes make reference to) the results or 
output of the initial stage of research.  It is important to note that the weight attached to each 
phase of the research need not be equal, and in fact a sequential explanatory design normally 
places priority on the initial, quantitative stage (Creswell 2009). 
This section has described the merits of a mixed-methods approach to evaluation, and has 
introduced my own research design in relation to these.   
 
5.7  Summary 
The practical focus of the research design described in this chapter has at its core the desire to 
understand the potential impact of the headroom method on decision-making in the medical 
device industry.  This is the novel contribution of this research methodology, which is 
grounded in the need to critically evaluate the headroom method in relation to its 
consequences and its viability; the review of the literature showed this to be absent from the 
current literature base. 
The consideration of philosophical paradigms is important for a research project, both 
allowing the researcher to open their mind to other possibilities, to explain the approach 
chosen, and also to ‗enhance their confidence in the appropriateness of their methodology to 
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the research problem which, in turn, enhances confidence in their research results‘ (Holden 
& Lynch 2004, p. 406).  I have shown that I take a sequential explanatory mixed methods 
approach, and by doing so increase the strength of the overall study by approaching the 
research questions from various angles.  This triangulation will enrich the synthesis of results 
presented in the discussion chapter, enhance the conclusions drawn, and improve the validity 
of the overall study. 
This chapter has sought not to provide precise detail of each research method, but rather to 
tie up the whole thesis and frame it within its stated objective: to evaluate the headroom 
method.  By assessing the method in this way, an improved understanding of its potential 
impact is sought, thereby providing the foundation for recommendations concerning its 




CHAPTER 6 HEADROOM ANALYSIS FOR A NEAR-PATIENT 
MONITOR FOR COPD 
6.1  Introduction 
Chronic obstructive pulmonary disease (COPD) is a far-reaching and costly disease for the 
NHS.  The innovation under consideration, which proposes to improve patient care and 
streamline services, is a near-patient monitor for COPD.  This portable device for point-of-
care management (for use by patients in their own homes) would combine a biosensor which 
would detect levels of COPD-relevant biomarkers in saliva, with symptom-related health 
question responses.  This would facilitate a record of progression and detect the onset of acute 
inflammation / infective episodes (exacerbations), to allow for prompt treatment. 
This case study acts as a foundation for the approach taken in ensuing case studies, and 
demonstrates some opportunities as well as difficulties associated with early economic 
evaluation using the headroom method.  It also introduces and demonstrates further functions 
of the method, for example in assessing different scenarios or target markets, and considering 
the costs of development.  Section 6.2 provides the background, explaining the current model 
of COPD care and how the near-patient monitor might change this.  Using this information as 
a platform, section 6.3 presents the headroom analysis based on three clinical scenarios.  
Possible interpretation of the analysis is then provided, followed by a summary which outlines 




6.2  Background 
This section describes COPD and its care in the UK.  After outlining the key characteristics of 
the disease and the way it affects patients and the NHS (section 6.2.1), the current model of 
care is described, alongside the deficiencies in this model that the near-patient monitor could 
address.  The third sub-section (6.2.3) presents the device and its change proposition in more 
detail, before the relevant data and literature are outlined, setting the scene for the headroom 
analysis that is presented in section 6.3.  
6.2.1  COPD: Prevalence and Relevance 
This section briefly outlines the clinical and economic burden of COPD in the UK. 
6.2.1 (i) Definition 
COPD is a lung disease characterised by airflow obstruction which interferes with a patient‘s 
breathing.
16
  The disease is progressive in nature and is not fully reversible, and symptoms 
include breathlessness and chronic cough.  Predominant causes include smoking and 
occupational exposures (smoking is the cause of 85% of COPD deaths (NICE 2010a)).  
COPD is associated with a significantly impaired QoL and can cause premature death (NICE 
2010a;WHO 2010a).  Although unable to reverse the disease, treatment is important in 
controlling symptoms and avoiding or ameliorating exacerbations (a flare-up in symptoms), 
which are associated with increased inflammation in the airways and are mainly triggered by 
respiratory viruses and bacteria (Wedzicha & Seemungal 2007).  Exacerbations cause 
significant QoL loss, and can trigger further irreversible damage to lung function, often 
causing disease severity to have progressed when the patient returns to their ‗stable‘ state.  
                                                 
16
 COPD is the term now used for patients with airflow obstruction of the lungs, and includes patients who 
would previously have been diagnosed with chronic bronchitis and emphysema.  
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Therefore, patients with more frequent exacerbations tend to exhibit worse health status and 
quicker disease progression.  
6.2.1 (ii) Burden of disease 
COPD is the fourth most common cause of death worldwide, and is predicted to become the 
third by 2020 and to rank fifth in terms of worldwide burden of disease (Burney 2006;Rabe et 
al. 2007).  Within the UK, COPD causes approximately 30,000 deaths each year.  Around 
900,000 people in the UK are diagnosed with COPD (accounting for around 1.5% of the 
population in 2007/08), though the actual number affected is more likely to be around 3 
million (Healthcare Commission 2006;NICE 2010a).  Prevalence is significantly biased 
towards older patients, and there is a strong association with level of deprivation (Burney 
2006;NICE 2010a).   
6.2.1 (iii) Economic burden 
As well as its important clinical impact, COPD is a very costly disease for the NHS.  Total 
direct healthcare costs are estimated to be over £800 million per year, which excludes the 
huge productivity loss associated with the disease, said to be 24 million working days or £2.7 
billion per annum (Department of Health 2004).  The disease accounts for 1.4 million 
consultations in primary care each year.  Exacerbations experienced by COPD patients 
represent the second most common cause for emergency admission to hospital in the UK, 
accounting for around one million hospital bed days per year (Burney 2006;Lung & Asthma 
Information Agency 2003;NICE 2010a).  Over half of the total direct costs of COPD are 
attributable to these hospital admissions (Burney 2006;NICE 2010a).  This means that 
recognising the early signs of an exacerbation and treating symptoms before they escalate is 
crucial, not only for the health of the patient but also in reducing resource use.  The average 
cost per patient is highly dependent on disease severity (NICE 2010a), as is quality of life, 
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implying that any treatment or disease management strategy that could slow the progress of 
the disease would be hugely beneficial.  
6.2.2 Current care for COPD patients:  ‗Standard practice‘ & national initiatives 
In response to the high impact of the disease, there have been a number of national schemes 
and initiatives which encourage improvements in COPD patient care: the Chief Medical 
Officer‘s report ‗It takes your breath away: The impact of COPD‘ (Department of Health 
2004); the Healthcare Commission‘s national study of COPD ‗Clearing the air‘ (Healthcare 
Commission 2006); a new National Strategy for COPD from the Department of Health 
(2010d); and also an updated NICE clinical guideline (NICE 2010a).  All of these initiatives 
aim to make care more responsive to patients‘ needs.  This section briefly explains current 
best practice for diagnosis, day-to-day management, patient follow-up, and exacerbation 
response, and is mainly guided by NICE‘s clinical guideline for COPD  (NICE 2010a).  The 
deficiencies of current care in reality (informed by both the reports listed above and Prof. 
Spiteri)—deficiencies which could potentially be addressed by the proposed near-patient 
monitor—are presented in boxes alongside the relevant text. 
6.2.2 (i) Diagnosis 
Diagnosis should be considered in patients who: are over 35, smoke (or have another risk 
factor) and who present symptoms such as chronic cough, breathlessness, or regular sputum 
production (NICE 2010b).  Airflow obstruction is confirmed by spirometry which measures 
lung volume (forced expiratory volume in one second FEV1) which, combined with clinical 
judgement, determines the diagnosis.  Airflow obstruction is categorised by severity as shown 




Table 6.1 Definition of COPD severity stages 
FEV1 % predicted* (Post bronchodilator) COPD severity** 
≥80% Stage 1- Mild 
50-79% Stage 2- Moderate 
30-49% Stage 3- Severe 
<30% Stage 5- Very severe*** 
*Measured FEV1 of the patient, as a percentage of the average FEV1 in the population for similar age, sex, etc. 
**Note that this classification system differs to that used in NICE 2004 guidance, of which CG101 is an update.   
***Or FEV1 < 50% with respiratory failure 
Under-diagnosis is mainly due to patients ignoring the symptoms of mild COPD, dismissing 
the warning signs as a smoker‘s cough and not seeking medical help.  Early, proactive 
diagnosis is therefore a feature in all the national guidelines for improved care (often labelled 
‗finding the missing millions‘).  
6.2.2 (ii) Day-to-day management (for stable COPD) 
All patients are encouraged to stop smoking and to be vaccinated against illnesses that could 
aggravate symptoms, e.g. the annual influenza vaccination.  To treat symptoms, NICE 
recommends the prescription of short-acting bronchodilators as needed in the first instance, 
followed by long-acting bronchodilators and potentially adding inhaled corticosteroids 
according to severity.  Medications are scaled up according to treatment response. 
 
Patients are encouraged to undertake pulmonary rehabilitation.  Lung volume surgery and 
transplantation are only considered for severe COPD patients who do not respond to ‗maximal 
medical therapy‘. 
Whilst this progressive prescription of drugs is necessary to gauge the level of treatment 
required for each individual patient, and to tailor their management accordingly, analysis 
of the response to a patient‘s initial management plan can be difficult and somewhat 
subjective.  This is because ‗response‘ to treatment may not be based on improved lung 
function, but on symptom improvement. Additionally, there is no clear timeframe for the 
treatment plan.   
Box 1 Difficulties measuring treatment response 
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Delivery of care should be by a multidisciplinary team of experts who ensure that the 
patient receives the right treatment at the right time. 
 
 
6.2.2 (iii) Follow-up and review 
Patients with mild, moderate or severe manifestations of COPD should be followed-up in 
primary care at least once a year to assess symptom control, and very severe patients at least 
twice a year.  Regular hospital review is not normally required, but preparations should be in 
place to allow for rapid hospital assessment when necessary.  Measurements to be taken in 
primary care consultations include FEV1, forced vital capacity (FVC), body mass index 




Much of the recommendation for follow-up is based on expert opinion rather than 
research studies, due to the lack of evidence in this area.  Response to treatment is 
difficult to measure, and having year-long gaps between reviews can mean that the need 
for incremental treatment is not recognised early enough.   This is why patient education 
and self-management strategies have been emphasised in all of the national initiatives to 
improve care.  For example:  
 Recommendation 16 in the COPD strategy document (Department of Health 2010d);  
 The provision of integrated care recommendations within the healthcare commission 
report (Healthcare Commission 2006, p.32); 
 The emphasis on patients taking control of their own care in the CMO report 
(Department of Health 2004), and;  
 A persistent emphasis on self-treatment strategies in NICE‘s clinical guideline 101 
(NICE 2010a). 
In reality, COPD care is patchy across the country.  More effort is needed to make care 
consistent and available to all those that need it.  This equity concern is highlighted in the 
Chief Medical Officer‘s report (Department of Health 2004) which demonstrates the large 
national variations in the re-admission rate to hospital, average length of stay, specialist 
staff numbers, and mortality rates. 
Box 2 Inconsistent care 
Box 3 Unresponsive care 
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6.2.2 (iv) Exacerbations 
A timely response to the early signs of an exacerbation (worsening of breathlessness, cough 
and sputum production) is very important, and includes the use of corticosteroids, antibiotic 
therapy if sputum is purulent, and adjusting broncholidator therapy.  Recovery should be 




Section 6.2.2 has provided a brief summary of current care guidelines for COPD patients and 
some shortfalls in current practice.  The recurrent themes in many of the national COPD 
studies/ recommendations are that: (a) care is currently reactive rather than proactive, with a 
structure of care which treats patients when things have already gone wrong; (b) care is 
inconsistent across the country; (c) treatment should be tailored to individual patients; (d) 
acute episodes should be dealt with in a timely manner, and; (e) patients should be 
The initial signs of an exacerbation are often ignored by patients, meaning that they do not 
receive crucial treatment which can prevent the episode from progressing.  The National 
COPD audit found that before admission to hospital for an exacerbation, two thirds of 
patients (68%) indicated having suffered a respiratory infection or flu-like symptoms in the 
month leading to admission, and 57% noted a change in phlegm (colour/volume) within the 
week prior to hospital admission (RCP 2008c).  Additionally, the report on COPD by the 
Healthcare Commission (2006, p. 38) noted a large variability in hospital admission rates, 
suggesting that many admissions are avoidable. The following quotation is drawn from 
Report 4 of the National COPD Audit 2008 (Patient Survey), and highlights the 
opportunity for earlier identification and treatment of exacerbations: 
‗The results suggest that the lead-in, or pro-dromal, phase of exacerbation is quite 
long and imply there is ample opportunity to make earlier interventions to prevent 
hospital admission in a selected group of patients who exacerbate frequently.  
There is also a need for improved self-management and the value of personal 
COPD plans should be explored in this context‟ 
                                                                                                         (RCP 2008c, p. 6) 
Self-management and providing patients with the means to recognise and react to early 
symptoms is therefore at the top of the agenda for all national initiatives. 
Box 4 Delayed treatment of exacerbations 
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empowered to self-manage.  The following section describes an innovation for the monitoring 
of COPD, and demonstrates its potential to tackle all of these issues. 
 
6.2.3  Smart Biosensor: A near-patient monitor of COPD status 
The near-patient monitor would be a portable handheld device which would provide the 
patient and their healthcare team with a clear and comprehensive picture of COPD status and 
progression over time, in the form of patient-driven bio-clinical profiling.  The home-use 
device would capture and combine subjective clinical metrics (from self-reported wellbeing 
scores) and the objective measurement of COPD relevant biomarkers in the patient‘s saliva 
(using lab-on-a-chip technology).  Results (which would ideally be generated daily) would be 
telecommunicated to the patient‘s clinic, thus alerting the healthcare professionals to any 
sudden changes.  The headline advantages of the innovation are threefold: (1) it acts as a 
personalised monitor of COPD status with respect to the patient‘s own baseline, (2) it allows 
for better, more objective and more sensitive monitoring of response to initial management 
plans, and (3) it can act as an early warning for exacerbations, ensuring prompt treatment.   
These proposed advantages would optimise the delivery of care, and improve clinical 
outcome by doing so.  A key economic driver would be the reduction in hospital visits, 
resulting from the earlier recognition and treatment of acute episodes.  Additionally, the 
device could differentiate between the viral or bacterial cause of a COPD exacerbation, 
ensuring antibiotics are prescribed more intelligently.  Table 6.2 provides a summary of 
patient management best-practice, shortfalls in current care, the key recommendations made 
by the national initiatives discussed, and alongside these how the near-patient monitor might 
improve patient care in these areas. 
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Shortfalls of current 
practice 
Comments/ recommendations in 
the various national initiatives 
How the near-patient monitor addresses these 
issues 









Analysis of response 
to the patient‘s initial 
management plan can 
be difficult /subjective. 
- PCTs must ensure that COPD 
patients receive structured and 
personalised care (Healthcare 
Commission 2006). 
-Clinicians should be supported 
locally with an appropriate team and 
the right tools and evidence to do 
their jobs (Winter 2010). 
Allows for treatment to be guided specifically by 
patient‘s own health. Step-up in medication can be 
informed by regular data on patient wellbeing and 
objective biomarker observation (changes in which 







There lacks a clear 
timeframe to monitor 
response, and review 
meetings are 
infrequent. 
-Care should be integrated and more 
personalised with better information 
to guide changes in treatment 
(Winter 2010). 
The device acts as a tool for clinicians to personalise 
management, and as a record of temporal changes in 
symptoms and biological indices.  These can thus be 
picked up and acted upon quickly. 
Delivery of care 
should be by a 
multidisciplinary 




receive the right 
treatment at the right 
time. 
Care is inconsistent 
and not available to all 
those that need it.  
Access to specialists 




Patients contact the 
health service when 
things have already 
gone wrong. 
 
-Care should be standardised 
(Department of Health 2010d). 
-Optimal care requires partnership 
between the COPD patient and the 
healthcare professional associated 
with regular review (Department of 
Health 2010d). 
 
-The current model of care is reactive 
(Department of Health 
2010d;Healthcare Commission 
2006). 
-Care should be more accessible and 
closer to home (Winter 2010). 
Allows all COPD patients, regardless of location, to be 
monitored and managed according to their own needs. 
Provides a means of communication and understanding 
between patient and healthcare professional. 
 
Offers a means to make care proactive. By monitoring 
their own progress, patients are empowered to manage 
their condition and take control of their treatment. This is 
in keeping with the general shift away from care in 
hospital and into the home. Fewer hospital and primary 










annually for very 
severe patients. 




Long gaps between 
reviews can mean that 
the need for treatment 
changes is not 
recognised early 
enough.    
-COPD patients should be 
empowered to self-manage 
(Department of Health 
2010d;Department of Health 
2004;Healthcare Commission 
2006;NICE 2010a;Winter 2010). 
-Care should be supported by 
actionable data, that is clinically 
owned (Winter 2010). 
-Regular review should reduce the 
demand for unscheduled care 
(Department of Health 2010d). 
The near-patient monitor acts as a tool for self-
management. It would allow patients to monitor their 
health, and critically would also provide advice on self-
treating.  By combining data from biomarkers and self-
reported indicators of wellbeing, the device will alert the 
patient and healthcare team to the need of a change in 
treatment.  By making the patient part of this process 
and allowing review to be consistent rather than 
periodical, treatment can be better targeted and 
effective. 
Exacerbations 
The best way to 
avoid an 
exacerbation is to 
ensure that the 
patient is adequately 
managing symptoms.  
A patient should 
react immediately to 
the early signs of an 
exacerbation, by 
treating with a step-
up in current 
medication, or the 
use of corticosteroids 
or antibiotics, as 
appropriate. 
Initial signs of an 
exacerbation are often 
ignored by patients.  
Many current hospital 
admissions for COPD 
are avoidable (due to 
lack of recognition of 
early signs, or lack of 
knowledge/means to 
self-treat).  
-Exacerbations are associated with a 
significant worsening of prognosis 
and very high costs.  Timely and 
appropriate treatment is important for 
reducing the impact of acute 
episodes (all reports listed above). 
The number of people admitted to 
hospital should be reduced, by: 
-  Better identification of 
exacerbations(Department of Health 
2010d, Recommendation 17); 
-  Providing patients with the means 
to self-treat in response to an acute 
episode (Department of Health 
2010d). 
By identifying abrupt changes in longitudinal data 
(based on patient‘s own baseline), the biosensor can 
alert the patient to the early signs of an exacerbation 
and provide advice on what to do about it. 
The device will facilitate the early identification and 
treatment of acute exacerbations.  The patient may then 
administer the treatment which could prevent the 
episode from progressing, thus reducing its impact in 
the: 
- Short term- exacerbation is less severe if treated early 
- Long term- slows the rate of progressive lung function 
decline 
Lowered costs to the NHS would result from fewer 
hospitalisations and slower disease progression. 
The treatment of episodes that do require hospitalisation 
could be made more efficient if a consistent and 
comprehensive picture of a patient‘s health status over 




There is clearly room for improvement in the management of COPD patients, a gap which the 
headroom analysis to follow in section 6.3 aims to value.  Along with the national reports 
already outlined, Table 6.3 provides details of additional initiatives in the UK (both for 
COPD specifically and more widely), which illustrate not only the demand for the type of 
improvements that the biosensor could generate, but also the demand for this specific format 
of management.   




Interest in the use of saliva as a non-invasive means to monitor health status, 





The HICF, an initiative set up by the Wellcome Trust and Department of Health 
to stimulate innovation (Wellcome Trust 2010), issues thematic calls for 
proposals. At the time of analysis (2010), this call was for innovative 
technologies addressing the ‗monitoring of chronic illness in the home and 
remote settings’. This illustrates the current relevancy of this topic.  
The following ‗desirable qualities‘ were expressed (Wellcome Trust 2010): 
- ‘Methods that engage the patient on an ongoing basis and motivate 
the patient to take the appropriate self-management action. 
Methodologies that prevent the patient escalating to the next care level 
are particularly important’ 
- ‘Systems that offer improved front-end data capture’ 
- ‘Achieving optimal balance between the amount of face-to-face care and 
remote monitoring by health professionals’ 
NHS White 
Paper 
Within the NHS White Paper there is a strong emphasis on focusing care around 
patients‘ needs, and empowering them to take control of their own care 
(Department of Health 2010b).  In particular, they emphasise: 
 ‘…increased self-care and the use of new technologies for people with long-term 




The Lung Improvement Programme supports local improvement of respiratory 
services (NHS Improvement 2010). They identify ‗four winning principles of 
transforming inpatient care‘ which, for lung cancer care, have lowered hospital 
admissions, reduced length of stay, and encouraged earlier discharge, and which 
should be applied to the management pathway of COPD (Duncan 2010): 
(1) Daily decision-making; (2) Encourage self-management; (3) Defined inpatient 




The Department of Health‘s (2010d) recommendation no.16: ‗People with COPD 
should be encouraged to learn how to manage their condition themselves…‘ (p.80) 
includes a case study of a telehealth project.  The benefits of remote monitoring are 
highlighted, and are similar to those attributable to the near-patient monitor. 
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The near-patient monitor seems to chime well with key national objectives in COPD care.  
Having presented how the innovation fits in with current practice, it was demonstrated how 
such a device would make care more proactive, patient-centred and efficient.  The focus now 
shifts to the practical areas of benefit that might be valued using a headroom analysis.  In any 
economic evaluation, the proposed technology is compared with current practice by assessing 
its impact on health and resource use.  For a medical device that will directly replace another, 
this comparison is relatively straightforward.  For this innovation, the anticipated 
improvement would result from altering the care pathway, rather than changing the model of 
treatment per se.  This makes valuing its impact more challenging. 
Figure 6.1, below, provides a visual summary the natural progression of COPD, and how 
the near-patient monitor may affect this.  
 












Short Term: by ensuring 
the patient is receiving 
the appropriate treatment 
and reacting early to 
flare-ups, patients have 
the best chance of 




Long term: By managing 
symptoms and limiting 
exacerbations before they 
escalate (presenting a 
greater risk of further 
damaging the lungs), the 
natural course of disease 




COPD‘s progressive nature is represented in the diagram.  At any level of severity, 
patients may be in either a stable or an unstable condition.  The unstable state (which may 
manifest as an exacerbation) poses a greater risk of generating further irreversible damage to 
the lungs, thus progressing to a higher severity category.  This risk of exacerbation and 
reduced lung function becomes progressively greater (as represented by the thickening of the 
transition arrows).  The paler dotted arrows represent the target improvements of the near-
patient monitor, aiming in the short term to maintain stability of symptoms, and thereby in the 
long term reducing the pace of disease progression.  As more severe manifestations of COPD 
are associated with higher morbidity and increased resource use, having a greater control of 
the disease‘s progression would improve both quality of life prospects and NHS costs.  
To economically evaluate these suggested improvements fully would require a complex 
Markov model, for which cost and QALY estimates would be attached to each disease state, 
along with transition probabilities and estimates of how these would be affected by the near-
patient monitor.  The approach taken for the headroom analysis is explained in section 6.3, 
which necessarily involves a simplification of this scenario.  Before this, the pertinent 
statistics which are relevant to this clinical problem are outlined, along with the literature 
which provides evidence for the relationships that are either assumed in the headroom 
analysis, or not quantified in the model but which should be considered to understand the 
wider potential impact of the device. 
6.2.4  Data and the literature 
6.2.4 (i) Data 
The data presented in Table 6.4 and Table 6.5 describe the current clinical and economic 
landscape for COPD care in the UK.  Whilst not all of the data will be used specifically in the 
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subsequent headroom calculations, they highlight the room for improvement in current care 
and may be beneficial at a later stage when clinical data for the near-patient monitor are 
available and a more complex model could be built.  All data can be found in the full NICE 
clinical guideline (NICE 2010a). 
Table 6.4 Data: Clinical context 
People affected 3 million 
Diagnosed 900,000  (1.5% population) 
Mortality 30,000 deaths each year in UK 
Inpatient mortality rate (2008) 7.7% 
Leading cause of death 5
th
 in UK, 4
th
 worldwide 
Number of patients on the 
practice list for the average GP 
(who cares for 7,000 people) 
200 COPD patients per practice 
GP consultations per year 1.4 million 
Healthcare contact for patients 
admitted to hospital, and 
exacerbation history 
In the month prior to 
admission 
In the 12 months prior to 
admission 
74% make contact with 
GP  
31% have 3 or more 
contacts 
Median of 12 contacts with GP 
Median of 3 exacerbations 
51% have no contact out-of-hours 
Symptoms before admission 68% reported respiratory infection/flu-like symptoms in the 
month prior to admission 
57% noticed change in colour/volume of phlegm, of whom: 
 46% 2-5 days before 
 26% 6 or more days before 
Emergency admissions to 
hospital 
Though representing a small proportion of the COPD patient 
population, hospitalized COPD patients account for:  
1 in 8 emergency admissions (130,000 per year), which 
represents: 
 The second largest cause of emergency admission; 
 One of most costly inpatient conditions treated by NHS; 




Median length of stay in hospital 5 days 
Within 3 months after admission 34% re-admitted to hospital 
14% die 
Mean age of admission 73 (men) 72 (women) 
Patient occupancy 90% live at home (36% on their own) 
39% receive care at home (whether paid or unpaid) 
Lung capacity Median predicted FEV1 = 38% (for those with spirometry 
recorded in the last 5 years) 
Source of data: NICE (2010a)  Clinical Guideline 101 
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Table 6.5 Data: Economic impact 
Total cost to NHS (2000/1) 
 
Total cost to NHS (2004) 
(according to CMO report 
(Department of Health 2004)) 
£491,652,000 direct healthcare costs 
 
‗Over  £800million’ direct healthcare costs (more than half of 
which relates to provision of care in hospital) 
 
Average cost per patient 
 p.a. (2000/1) 
£819.42, of which: 
 54.3%- inpatient hospitalization 
 18.6%- treatment 
 16.4%- GP and specialist visits 
 5.7%- A&E visits and unscheduled contacts with GP/specialist 
 5%- laboratory tests 
Indirect costs of COPD p.a. 
(2000/1) 
24 million working days lost per annum 
Total direct and indirect costs: £982,000,000 
Source of data: NICE (2010a)  Clinical Guideline 101 
Of note from the data presented, there is a clear time window between the initial signs of an 
exacerbation and subsequent hospitalisation.  High readmission rates indicate suboptimal 
community care after an acute episode, which will become especially important as hospitals 
start to be penalised for re-admissions.  The high economic impact indicates a strong case for 
measures to prevent exacerbations.  
6.2.4 (ii) The Literature  
The literature base for COPD care is vast, especially relating to new drug treatments.  The key 
themes from this evidence base are outlined in this sub-section, which is divided into 
exacerbations, self-management, quality of life, and finally evidence around biomarkers.  
These will substantiate claims made or relationships inferred in the headroom evaluation. 
Exacerbations  
Due to the significant role of exacerbations in COPD management, these play a big part in the 
economic evaluation described in the next section.   Table 6.6 provides a summary of the 
main assertions from the literature, accompanied by the reports or investigations that 
explicitly verify or quantify these themes.   
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Table 6.6 Literature for exacerbations 
Assertion  Sources 
Exacerbations cause un-recoverable impairment of 
health status.  
Strategies that extend a patient‘s time free of 
exacerbation by recognising and reacting to 
exacerbations early are crucial. 
Miravitlles (2005); Anzueto (2010); 
Wedzicha & Seemungal (2007). 
Exacerbations, especially those requiring 
hospitalisation, lead to quicker lung function decline 
(decline in FEV1). 
Cote, Dordelly & Celli (2007); Anzueto 
(2010); Anzueto, Leimar & Kesten (2009); 
Donaldson et al. (2002); Silverman (2007); 
Spencer et al. (2004); Soler-Cataluña et 
al.(2005); Almargo et al. (2002); Celli et al. 
(2008); Miravitlles et al. (2000); Quint et al. 
(2008) 
Higher exacerbation rates are associated with a 
significantly worse patient quality of life. 
Osman et al. (1997); Spencer & Jones 
(2003); Seemungal et al. (2000); Miravitlles 
et al. (2004); Miravitlles et al. (2007); 
Kessler et al. (2006); Doll & Miravitlles 
(2005); Haughney et al. (2005); Wang & 
Bourbeau (2005); Connors et al. (1996); 
Anzueto (2010); Seemungal et al.(1998); 
Quint et al. (2008); Budweiser (2008); Llor 
et al. (2008) 
Many exacerbations go unreported, and therefore 
untreated.  These ‗ignored‘ exacerbations have a very 
detrimental impact on patient health, so strategies to 
increase recognition and early treatment of these 
exacerbations is paramount.  
Prompt treatment of an exacerbation is associated 
with improved recovery, reduced hospitalisations and 
greater quality of life. 
Seemungal et al.(1998); Xu et al. (2010); 
Koff et al. (2009); Langsetmo et al. (2008); 
Wilkinson et al.(2004); Wedzicha & 
Donaldson (2003); Paggiaro (2004) 
The cause of an exacerbation is difficult to determine, 
and could be either bacterial or viral.  A means to 
differentiate between the two would limit the over-
prescription of antibiotics, along with the associated 
costs and health risks of unnecessary usage. 
Stolz et al. (2007); Brusse-Keizer et al. 
(2009) 
 
Moving care to the patient 
The literature contains many investigations into the benefits of more proactive care.  Table 6.7 
is split into three parts, which present the main conclusions of studies investigating (1) home 
hospitalisation, (2) self-management strategies, and (3) remote monitoring devices.  The 
ambitions of the near-patient monitor relate to all three of these. 
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Table 6.7 Literature for self-management and home care initiatives 
Assertion  Sources 
Home hospitalisation 
offers equivalent or 
improved outcomes 




exacerbation at home, 
or early discharge from 
hospital.  Patients are 
usually supported by 
home-visits or phone 
consultations] 
 Puig-Junoy et al. (2007): The magnitude of cost saving increases with 
the patient‘s disease severity. For the ‗average‘ patient, a 36% 
reduction in cost was associated with home hospitalisation. 
 NICE CG101 (2010a, p. 365)—Recommendation 138: ‗Hospital-at-
home and assisted-discharge schemes are safe and effective and 
should be used as an alternative way of caring for patients with 
exacerbations of COPD’. 
 Ram et al. (2004): Readmission rates and mortality are not 
significantly affected, but the hospital at home scheme reduces health 
service costs (about 50% reduction in cost). 
 Hernandez et al. (2003):  Home care intervention is cost-effective, 
leading to better outcomes and at lower costs than conventional care 





and reduces costs 
 
[Self-management: 
patients are given 
education (and 
sometimes medicines) 
to react to changes in 
symptoms] 
[Integrated care: 
individually tailored care 
and coordination among 
care teams] 
 Effing et al. (2009): Self-treatment of exacerbations incorporated into 
a self-management program leads to fewer exacerbation days and 
lower costs (23% fewer exacerbation days). 
 Bourbeau et al. (2003): Self-management compared with standard 
care resulted in: 39.8% fewer hospital admissions for 
exacerbations, 41% fewer A&E visits, 58.9% fewer unscheduled 
physician visits, and greater quality of life. 
 Gadoury et al. (2005):  Provision of education in self-management 
leads to significant reduction in hospitalisations (26.9% reduction in 
all-cause hospitalisation). 
 Casas et al. (2006): Integrated care lowers hospitalisation rate 
 Garcia-Aymerich et al. (2007): Integrated care reduces hospital 
readmissions. 
Remote monitoring 
systems foster the 
earlier detection and 
treatment of 
exacerbations  
 Koff et al. (2009): The ‗Health Buddy‘ was given to the ‗proactive 
integrated care‘ (PIC) arm of the trial, which combined disease-
specific education, self-management techniques, enhanced 
communication and remote home monitoring (measuring daily 
symptoms, oxygen saturation, FEV1 and exercise capacity).  
Compared with the control group, patients experienced both improved 
QoL, and reduced healthcare costs (not statistically significant). 
 Alonso (2004):  A Spanish pilot of the ‗e-Vital‘ project, which monitors 
patients‘ vital signs to detect symptom deterioration. Early results are 
encouraging: fewer emergency visits, improved QoL and lower costs. 
 Sund et al. (2009):  A feasibility study investigating patient compliance 
for remote daily monitoring of COPD patients, by means of an 
electronic diary and portable spirometer. The results were favourable: 
on average 77% of total study days had recordings, and COPD-
related hospitalisations were significantly reduced compared with the 
previous year (57% reduction). However, the sample size was small. 
 Trappenburg et al. (2008): A non-randomised study on the effect of a 
home based telemonitoring device, offering daily symptom 
surveillance. Hospital admission rates and exacerbations were 
reduced, as were hospital days (no significant changes in HRQoL). 
 COPD National Strategy case study (Winter 2010, p. 79): The case 
study involved a telephone-based self-management service for people 
with chronic conditions (including COPD). The trial reported high 
patient satisfaction, and ―substantial savings‖. 
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Although the remote monitoring systems described above have produced positive results, the 
use of salivary diagnostics by the near-patient monitor would have the capacity to predict 
acute flare-ups before these are reflected in a patient‘s symptoms, thus providing earlier 
warning and facilitating prompter treatment.  
Quality of Life 
A search of the CEA registry (TMC Research 2012) was undertaken to identify utility weights 
associated with COPD.  See Appendix 3 for details of all studies found in this search.  The 
most commonly cited utility weights are those originally reported by Borg et al. (2004), 
summarised in Table 6.8. 
Table 6.8 Utility weights according to disease severity 
Mild   (GOLD* I) Moderate    (GOLD II) Severe    (GOLD III) V. Severe    (GOLD IV) 
0.897 0.755 0.748 0.549 
*GOLD: The Global Initiative for Chronic Obstructive Lung Disease 
For utility loss during an exacerbation, the most frequently cited estimates are those originally 
reported by Paterson et al. (2000) and Spencer & Jones (2003), as described in Table 6.9. 
Table 6.9 Utility loss during an exacerbation 
 Utility loss 
Moderate exacerbation* 15% drop in utility 
Severe exacerbation** 50% drop un utility 
*An exacerbation requiring systematic corticosteroids and/or antibiotics 
**An exacerbation requiring hospitalisation 
 
Sin and colleagues (2004) report a quality of life loss of 0.32 per acute episode, with mild 




Biomarkers and COPD management 
Three biomarkers are to be targeted by the biosensor.  For the near-patient monitor to 
accurately anticipate the onset of an exacerbation pre-symptoms—distinguishing it from other 
remote monitoring devices—there must be a direct and established link between pathological 
changes reflected by the selected biomarker levels (as measured with the device), and a 
subsequent acute episode.  This relationship will be directly investigated in clinical trials in 
due course, but the literature, outlined in Table 6.10, provides some indication of its 
feasibility. 




Discussion of biomarkers and their use as a marker for COPD and disease 
progression. 
Cazzola et al. 
(2008) 
A summary of the pulmonary biomarkers to have been associated with COPD in the 
literature.  The author emphasises the need to elicit more information on the 
reproducibility and relevance of such measurements.  
Christ-Crain et 
al. (2006) 
Results are presented for an RCT in which procalcitonin concentration (a biomarker 
which is elevated in the presence of bacterial infections) in the blood is used to guide 
antibiotic prescription for patients with community-acquired pneumonia.  
Procalcitonin guidance (compared with the control group which received antibiotics 
according to usual practice) reduced total antibiotic exposure, prescriptions, and 
treatment duration. Outcomes in both groups were similar.  
Stolz et al. 
(2007) 
Results are presented for an RCT which compares standard antibiotic treatment of 
patients admitted to hospital with a COPD exacerbation, with procalcitonin-guided 
therapy (guided by serum procalcitonin levels, as above).  Procalcitonin guidance 
significantly reduced antibiotic prescription and exposure.  Clinical outcome was 
similar in both groups. 
Yamamoto et 
al. (1997) 
The results of this cohort study indicate that interleukin-8 (IL-8) concentration in 
sputum is closely associated with degree of airflow obstruction in COPD patients, so 
may serve as a marker for airway inflammation. 
Nadel (2000) This paper discusses Neutrophil elastace (ELA2) and its important role in the 
pathogenesis of COPD and its exacerbation. 
Barczyk et al. 
(2004) 
A study in which two markers—IL-8 and neutrophil activation marker 
myeloperoxidase (MPO)—are measured in induced sputum to investigate why 
inhaled glucocorticosteriods may decrease exacerbations.  
Broekhuizen 
et al. (2006) 
An investigation into C-reactive protein (CRP) levels as a clinical marker for acute 
systematic inflammation. 
Vignola et al. 
(1998) 
A study which shows that airway inflammation in chronic bronchitis and asthma is 
associated with high levels of active elastase.  
Man et al. 
(2006) 
This paper shows that (Serum) CRP measurements provide greater prognostic 





The headroom analysis that follows is based on the optimistic (but plausible) beliefs of the 
innovator, which support the predictive capacity of the near-patient monitor.  
 
6.3  Identifying the ‘Headroom’ for development 
The headroom method considers the economic case for an innovation, by comparing it to 
current practice in terms of its cost implication to the health service and its health benefit (to 
which a monetary value is attached by using NICE‘s cost-effectiveness threshold).  By 
considering the net effect of these two parameters, the potential reimbursement value of the 
innovation is estimated.  This can, however, be an iterative process.   It is possible to initially 
consider the cost saving effect of a device in isolation, to observe whether this generates 
sufficient ‗headroom‘.  This seems appropriate in this instance for three reasons: 
1.  The key economic and clinical driver of this innovation is the reduction in 
emergency admissions, achieved by monitoring health status and reacting early to 
flare-ups.  Exacerbations treated in hospital make up over 50% of the overall 
economic burden of the disease, so shifting treatment to an earlier stage where events 
can be treated at home would offer significant savings. 
 
2. The device could provide cost-savings and health benefit both in the short term 
(reducing the impact of exacerbations) and long term (slowing disease progression).  
Whilst important, the long term effects are less immediately tangible, and are likely to 
be realised a long time into the future.  Therefore, it is perhaps more pertinent for 
today‘s decision-maker with today‘s budget and today‘s cohort of COPD patients, to 
take a more short-term perspective.  
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3. Thirdly, the current climate surrounding NHS procurement is that of tightened budgets 
and cautious spending.  Therefore, justifying the case for the cost-saving potential of a 
device (coupled with equivalent or improved health outcomes) will be important.  That 
health outcomes would be at least equivalent by using the device is easily justifiable, 
as it simply provides more information on which to base treatment decisions. 
The following analysis thus considers the short-term cost-saving potential of the device from 
the reduction in emergency hospital admissions, to see whether this generates sufficient 
‗headroom‘ to justify development. 
As the near-patient monitor does not represent a simple replacement of a current 
technology, the potential scale of distribution is not clear-cut; despite resonating well with 
current ideals for change within COPD care, it would likely represent a significant shake-up 
in the pathway.  Therefore, headroom is considered under three scenarios of deployment.  The 
first two scenarios consider the headroom for the near-patient monitor based on a reduction in 
hospital visits: in scenario one the device is distributed according to yearly exacerbation rate, 
and in scenario two according to average yearly hospitalised exacerbation rate.  This is 
followed by the more aspirational scenario three, where the device is rolled-out to all those 
diagnosed with COPD, the value of which is explored in terms of savings in primary care 
resources as well as hospital care.   
The analysis is split into three sections.  The first presents the data which inform the base-
case assumptions for all forthcoming scenario evaluations.  Section two provides the analysis 
for the three scenarios described.  Where previous applications of the method have stopped at 
the headroom calculation, section 6.3.3 ‗Headroom: The Decision‘ extends the analysis by 
interpreting the headroom output, considering, for example, the trade-off between 
development and production costs, and presenting further analysis of distribution strategies. 
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6.3.1  Data: Base-case assumptions 
The data used for headroom calculations are summarised in Table 6.11, and described below.  
Table 6.11 Summary of base-case assumptions for COPD patients in the UK 
Number of diagnosed COPD patients 900,000 
Average number of exacerbations per year per patient 1 
Proportion of exacerbations that are hospitalised 20% 
Cost of an exacerbation £36 – Non-hospitalised 
£2,539 – Hospitalised 
Breakdown of average cost per patient (for Scenario 3) See Table 6.13 
 
 COPD patient population (diagnosed): 900,000 
(Healthcare Commission 2006;NICE 2010a) 
 
 Average yearly exacerbation rate: 1 
Based on the data presented in Table 6.12 and the opinion of the clinical expert, this is 
suggested to be an appropriate (and conservative) initial estimate. 











0.79 1.22 1.47 
Notes: This study uses slightly different disease stage categorisation (given here are their ‗mild, 
moderate and severe‘ exacerbation estimates: mild: ≥50%, moderate:35-49%, severe: <30%.   
Quint  
(2010) 
2 2.16 2.52 2.73 





Notes: This figure represents the baseline average exacerbation rate in the previous 12 months 
prior to screening (self-reported) over all treatment groups in the TORCH study
17
. This is cited 
frequently in the literature (NICE 2010a;Wedzicha & Seemungal 2007). Average FEV1%predicted 
in this study was around 44, indicating that the average patient in this cohort falls within (the less 
serious end of) the ‗severe‘ category. 
 
                                                 
17
This was the ‗Towards a Revolution in COPD Health (TORCH) trial: a double-blinded RCT which compared 
combination therapy of salmeterol and inhaled fluticasone propionate, with usual care. 
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 20% of these exacerbations are hospitalised 
In describing the baseline characteristics of participants in a large COPD trial (the ‗TORCH 
study), Calverley et al. (2007) find an average of 0.2 exacerbations per year per patient 
requiring hospitalisation, representing 20% of the average annual exacerbation rate.  This 
source is also used to populate NICE‘s CG101 cost-effectiveness model (NICE 2010a, p. 
566). 
Hospitalisation rate estimates elsewhere in the literature are inconsistent.  In reality this 
rate will vary between patients, as the severity of an exacerbation is strongly associated with 
disease staging (Almagro et al. 2002;Miravitlles et al. 2000).  From the information available 
at the time of writing, this 20% estimation seems the most validated and cited estimate.
18
  
 Cost of an exacerbation: £36 (non-hospitalised) or £2,539 (hospitalised) 
The source of these estimates is the NICE clinical guideline for COPD (NICE 2010a), inflated 
using UK healthcare inflation indices to 2009/10 prices (last indices available at the time of 
analysis)
19
.  The cost estimate for non-hospitalised exacerbations was based on a UK costing 
study, whereas that for a hospitalised episode was a weighted average for all categories of 
COPD hospitalisations, principally using 2007/8 NHS reference costs (see Appendix M of the 
NICE guideline for more details (NICE 2010a, p. 576)). 
 Breakdown of the overall costs for the average COPD patient 
This data (source: (NICE 2010a)) will relate to scenario three—the community roll-out— 
which considers the ‗average‘ COPD patient and their cost of care.  There are 1.4 million GP 
consultations for COPD every year (about 1.5 per patient) (Healthcare Commission 
                                                 
18
Note: Spencer et al. (2005) report a hospitalisation rate for exacerbations of only 10% for severe patients and 
lower for those with less severe COPD. 
19
 The Hospital & Community Health Services (HCHS) Pay & Prices Index (PSSRU 2010) is used to inflate to 
current prices throughout this evaluation 
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2006;NICE 2010a), but a reliable and consistent estimate of their cost has been difficult to 
obtain.  Britton (2003) provides a useful breakdown of costs which is used in the NICE 
COPD clinical guideline (NICE 2010a).  These data are summarised in Table 6.13, presented 
in their original form (in 2000/1 prices), alongside their adjustment to 2009/10 prices (all 
rounded to nearest pound). 
Table 6.13 Breakdown of cost per patient attributable to particular services 
Average cost per 




£819  (2000/1 prices) 
 
£1,132 (2009/10 prices) 
a) Inpatient hospitalisation 54.3% £445 £615 
b) Treatment 18.6% £152 £211 
c) GP and specialist visits 16.4% £134 £186 
d) A&E visits and 
unscheduled contacts with 
GP / specialist 
5.7% £47 £65 
e) Laboratory tests 5% £41 £57 
 
 
6.3.2  Headroom analysis 
Using the base-case assumptions outlined, the headroom offered under three distribution 
scenarios is considered.    
6.3.2 (i) Scenario 1: Distribute according to number of exacerbations per year 
The value of the near-patient monitor will vary according to its user.  Table 6.14 describes the 
exacerbation-related costs for the ‗average‘ COPD patient, who experiences one exacerbation 










The total cost of hospitalised exacerbations (£457 million) provides some reassurance that 
these base-case estimations are feasible; hospitalisations represent just over half of total 
COPD healthcare costs (Burney 2006;NICE 2010a;Soler-Cataluña et al. 2005), which in 2004 
was around £800 million (Department of Health 2004)—£935 million when inflated to 
2009/2010 prices. 
The headroom analysis is based on one main assumption: the near-patient monitor will 
halve hospitalisations.  By treating flare-ups earlier, 50% of acute episodes will be treated at 
home rather than in hospital.  This was thought by the innovator to be a realistic consequence 
of the device‘s proactive patient management approach, considering also that full compliance 
would not be achieved.  The literature presented in section 6.2.4 included studies of specific 
education programs or management schemes, which reported reductions in hospitalisation rate 
or cost that ranged from 23% to 57%.  Although most estimates were below 50%, it is thought 
that the added predictive capacity of this technology makes this assumption feasible.      
 Average exacerbations per year Cost (£) 
Non-hospitalised 0.8 £36  
Hospitalised 0.2 £2,539  
   
 Average cost per patient £537 
   
 
Total cost of exacerbations 
(based on a COPD population of 
900,000): £482,940,000 
   
 




The device may, in addition, make hospital care more efficient, by providing richer patient 
data and thereby allowing treatment to be more timely and appropriate.
20
  By also improving 
patient supervision in the community (allowing for earlier hospital discharge), hospital length 
of stay (LOS) should be significantly reduced.  As a result, a 50% reduction in the average 
cost of a hospital episode was initially considered to be a reasonable expectation.  However, 
this could involve double-counting; if hospitalisations are reduced by half, then the cohort of 
exacerbators still attending hospital will be the more serious (and more costly) patients.  
Therefore, halving the cost of hospitalisations implies cutting LOS by much more than half 
(the ‗average‘ LOS of those still attending hospital will be higher than the average of the 
previous, larger cohort).  By assuming that the average cost of a hospitalised exacerbation 
remains constant, we are indicating a (more feasible) reduction in LOS for those more serious 
patients with whom we are left. 
Results 








                                                 
20
 Currently, very little clinical data are available to clinicians treating patients in hospital for a COPD 
exacerbation.  The National COPD Audit 2008 found that only 55% of those admitted to hospital had spirometry 
results recorded in the last 5 years (RCP 2008b). 
 Average exacerbations per year Cost (£) 
Non-hospitalised 0.9 £ 36  
Hospitalised 0.1 £2,539  
   
 Average cost per patient £286 
   
 Total cost of exacerbations: £257,670,000 
   
 % of original cost 53% 
                                                                                                                                                                          
 Headroom (£): £225,270,000 
 
Headroom per person or device 
(£ / year)  £250 
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The average headroom per device (per year) is £250 when distributed to all 900,000 COPD 
patients.  Of course, its value will be higher when used by patients who experience more 
frequent exacerbations.  Table 6.16 provides the headroom per patient based on their yearly 
exacerbation rate: 
Table 6.16 Headroom based on number of exacerbations per year 
 
These figures represent the headroom (per device per year) generated for each group 
individually.  However, a real decision-maker is likely to offer the device to those with a 
yearly exacerbation rate of X or more.  To calculate the cost saving effect of this strategy 
(which would be a weighted average), one would require the distribution of exacerbation rates 
in the target population.  Due to the strong regional differences in COPD severity, this would 
                                                 
21
 There will obviously be some patients who experience zero exacerbations per year.  As the device would 
imply no cost saving for these patients, this is omitted from the table.  The ‗average of one exacerbation per 
year‘ scenario described initially, includes these patients.   
Base-case    






Total cost per 
person 
1 0.8 0.2 £537  
2 1.6 0.4 £1,073 
3 2.4 0.6 £1,610  
4 3.2 0.8 £2,146  
With device (hospitalisations halved) 












1 0.9 0.1 £286  £250  
2 1.8 0.2 £573 £500  
3 2.7 0.3 £859 £750  
4 3.6 0.4 £1,145  £1,000  
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be more appropriately considered locally (Department of Health 2004;Healthcare 
Commission 2006;NICE 2010a).  
It should be noted that illustrating ‗headroom‘ by patient subgroup predicates perfect price 
discrimination.   In reality this is unlikely, and the price may be based on the subgroup with 
the fewest exacerbations (further discussion of this is reserved for section 6.3.3). 
Rationale for this approach 
The most obvious way to categorise COPD patients is by disease severity (lung capacity 
based on FEV1% predicted); the literature finds severity to be strongly associated with (a) 
frequency of exacerbations and (b) severity of exacerbations (see literature section 6.2.4 (ii)).  
The analysis presented here, however, divides the patient population according to their 
predisposition to experiencing exacerbations.  Despite the strong association between lung 
capacity and exacerbations, a large observational trial
22
 presented by Hurst et al. (2010) 
demonstrates that the most important predictor of frequent exacerbations is a history of 
exacerbations, indicating there to be an ‗exacerbation-susceptibility phenotype‘ that may be 
independent of underlying disease severity.  This should be reflected in how interventions that 
target exacerbations are directed (Hurst et al. 2010).  The trial also finds exacerbation 
frequency to be relatively stable, further complementing the approach taken. 
6.3.2 (ii) Scenario 2: Distribute according to number of hospitalised exacerbations per 
year 
Given the huge costs attributable to hospitalised COPD episodes, commissioners will be keen 
to limit these.  However it may be appropriate (at least initially) to focus resources on patients 
who place the largest financial burden on the health system: those who regularly have 
                                                 
22
 The Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECPLIPSE). 
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exacerbations requiring hospitalisation.  Three situations are explored: a) 100% of 
hospitalisations are avoided, b) 75% avoidance and c) 50% avoidance (turning these episodes 
into non-hospitalised exacerbations, for which there is a significantly lower cost). 
As in the previous scenario, it is assumed that the cost of an ‗average‘ hospitalised episode 
remains constant. 
Results 
Table 6.17 Headroom based on number of hospitalised exacerbations per year 
*Example of calculation: £2,539 (cost of avoided exacerbation) - £36 (cost incurred of a non-hospitalised 
exacerbation = £2,503 
Table 6.17 displays the headroom per device per year according to a patient‘s yearly 
hospitalisation rate, and the degree to which these admissions are reduced.  This differs from 
scenario one only in that the COPD patients being considered are those who are more 
regularly hospitalised.  Whilst this strategy generates much higher headroom per device, the 
fixed costs of development must be spread between fewer units.  Consideration of this trade-
off is presented later. 
Rationale for this approach 
The literature suggests that the lead-in phase of an exacerbation provides sufficient 
opportunity to treat early and avoid admissions.  The value of this will be higher for those 
patients who are currently hospitalised more regularly. 
 
A patient‘s current 
number of hospitalised 









1 £2,503 * £1,877  £1,252  
2 £5,006  £3,755  £2,503  
3 £7,509  £5,632  £3,755  
4 £10,012  £7,509  £5,006  
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It should be noted that for scenarios one and two, value is calculated based on the number 
of exacerbations a patient would experience in the next year.  Clearly the device cannot be 
assigned retrospectively, but as described previously, exacerbation rate is strongly associated 
with previous exacerbations. 
6.3.2 (iii) Scenario 3: Community Roll-out 
Improving self-management is likely to reduce demand of both primary and secondary 
services. The community roll-out strategy is an extension of scenario one which considered 
the ‗average‘ COPD patient (assuming full distribution), but widening the perspective beyond 
hospitalisations.  Whilst inpatient hospitalisation poses the most substantial economic burden 
within COPD, A&E visits and unscheduled contact with GPs or specialists also represent 
important contributors to the cost of unscheduled emergency care.  Additionally, the data 
from a national COPD audit suggest ‗frequent exacerbation and high usage of primary care 
health resources in the 12 months leading up to admission‟ (RCP 2008a, p. 11).  74% of 
patients hospitalised for an exacerbation within the audit period had made contact with their 
GP in the month prior to admission; 31% had made three or more contacts in that time. 
The break-down of costs for the ‗average‘ COPD patient (as presented in the NICE 
clinical guideline) is used as the base-case for this scenario (see Table 6.13 on page 129).  It 
suggests that 16.4% of the COPD budget is attributable to GP and specialist visits, 5.7% to 
A&E visits and unscheduled contacts with GP/specialist, and 5% to laboratory tests.  The 
near-patient monitor could reasonably create savings in all of these areas, particularly for 
unscheduled healthcare visits.  However, due to the paucity of information on the regularity of 
(scheduled) GP contacts across the whole COPD population, estimating potential impact on 
these would be too speculative (though the innovator believes that GP/specialist visits would 
be reduced, due to the constant monitoring and more informed GP-patient interactions).  
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Treatment costs are presumed to remain constant.
23
  The following assumptions are made for 
the community roll-out scenario: 
 Reduction in hospitalisation costs associated with COPD by half; 
 Elimination of A&E visits and unscheduled contacts with the GP / specialist (or to be 
reduced by 75%); 
 Significant reduction in the need to send samples for laboratory tests (generally 
diagnostic in nature), resulting in negligible lab costs, or a reduction by 75%. 
Results 




100% cut in 
emergency 
contacts / lab 
tests  
With Device: 
75% cut in 
emergency 
contacts / lab 
tests 
Costs relating only to 
hospitalisations (as in 
scenario 1) 
a) Inpatient hospitalisation 
(costs cut by 50% with 
device) 
£615 £308 £308 £308 
b) Treatment £211 £211 £211 £247*    
c) GP and specialist visits £186 £186 £186 £186 
d) A&E visits and 
unscheduled contacts with 
GP or specialist 
£65 £0 £16 £65 
e) Laboratory tests £57 £0 £14 £57 
Average cost per patient p.a £1,132 £704 £734 £863 
HEADROOM per person 
per year  
- £428 £398 £269 
*£36 added for incurred treatment cost for treating exacerbation at home as in scenario 1 
                                                 
23
 Although earlier treatment at home may increase ‗Treatment‘ expenditure, this may be cancelled out by the 
reduced spending on antibiotics where these are not appropriate.  The cost of a non-hospitalised episode used for 
the last scenario is not used here, as no assumptions about frequency of exacerbation are made in this case, and 
inconsistency in data sources may invalidate the analysis. 
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Table 6.18 describes the savings associated with the community roll-out scenario based on 
100% or 75% cuts in the cost of unscheduled primary / secondary care visits and lab tests, 
which generate £428 and £398 of ‗headroom‘ (per device per year) respectively.  Presented 
alongside this is a re-estimation of the model assumptions for scenario 1.  That the headroom 
figures derived are relatively similar (£269 versus £250) provides some assurance in the two 
sources of data. 
Rationale for this approach 
The community roll-out scenario represents most comprehensively the advantages developed 
in section 6.2 of such a technology.  The Primary Care Respiratory Society (previously the 
General Practice Airways Group) outlined three key aspects of optimal exacerbation 
management, all of which are addressed in scenario three (GPIAG 2008): 
1) The key cost-contribution of those exacerbations requiring unscheduled care is noted, 
which includes GP visits, out-of-hours visits and A&E attendance, as well as hospital 
admission. 
2) ‗…reducing the frequency and severity of an acute exacerbation of COPD by adopting a 
proactive approach centred on the patient will have benefits not only to the patient but also 
makes good financial sense.‟  (GPIAG 2008, p. 1). 
3) A ‗proactive‘ approach should be managed in primary care, and should aim to reduce the 
frequency of exacerbation, provide self-management advice, assess and manage the 
exacerbation, and ensure appropriate follow-up post-exacerbation.   
The strategy also fits in with the imminent changes to the NHS which will force hospitals to 
become leaner and to transfer services into the community (Department of Health 2010b). 
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6.3.3  Headroom: The Decision 
Table 6.19 summarises the headline headroom figures, based on the most conservative of the 
assumptions considered in each scenario. 
Table 6.19 Summary of headroom figures under three scenarios 
Scenario Key assumptions Headroom per person 
(device) per annum 
1. Distribute according 
to number of 
exacerbations 
Cost-saving based on avoided 
hospitalisations alone. 
Hospitalisations halved 





2. Distribute to those 
who exacerbate 
regularly in hospital 










3. Community Roll-out  
(This is the extended 
version of scenario 
one‘s ‗average‘ 
patient) 
Distributed to all 900,000 patients 
diagnosed with COPD. 
Break-down of spending on ‗average‘ 
COPD patient as estimated in the NICE 
CG101 
Device allows a) hospitalization costs to 
be halved, and b) A&E visits, unscheduled 
contact with GPs/specialists, and lab 






To support a favourable development decision, headroom must exceed total costs to the 
manufacturer.  These must include manufacturing costs, any consumables, and making back 
the fixed costs in its development and production.  For all three strategies described, 
headroom has been presented as a monetary value per patient (or device, assuming individual 
use) per year.  By accounting for the expected device lifetime, we can consider the headroom 
per device (thus estimating the MRP under the assumptions utilised). 
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The innovator expects the device to last around five years.  The present value (PV) of the cost 
saving (applying a discount rate of 3.5%) 
24
 for scenario one‘s ‗average‘ patient is therefore: 
                    
    
          
 
    
           
 
    
          
 
    
          
                  
         
Table 6.20 presents a summary of headroom figures per device, representing the (discounted) 
value over five years for each scenario. 
Table 6.20 Headroom per device under three scenarios 
Scenario Headroom per device (life expectancy: 5 years) 
1. Distribute according to 
number of exacerbations 





2.  Distribute to those who 
exacerbate regularly in 
hospital 





3.  Community Roll-out  £1,860 
 
Whilst in the literature the analysis ends here, this section explores the potential interpretation 
of these results and some specific trade-offs that can be considered.  The decision of if / under 
what circumstances the device should be developed must include the following 
considerations: 
1. How many people will you give it to? This will be important because the size of the 
target market will represent the number of units over which the fixed costs of 
                                                 
24
 The NICE ―reference case‖ stipulates that cost-effectiveness results should reflect the present value of the 
stream of costs and benefits accruing over the time horizon of the analysis.  The annual discount rate should be 
3.5% for both costs and benefits (NICE 2008b). 
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development / production can be shared.  The more serious the condition of a patient 
the greater the headroom per device, but the more limited the scope for sharing sunk 
costs and making use of economies of scale.  
2. Expected device costs.  This must include the expected cost of the near-patient monitor 
itself once in ‗full‘ production, and also the annual cost of consumables. 
If the reimbursement potential is sufficient to cover costs, a favourable decision for 
development can be justified.  If not, then it must be considered by how much the 
reimbursement need falls short of the projected MRP for the application considered.  If this 
were the case, further quantification of additional value may be sought by considering 
improvements in quality of life and slowing disease progression, to see whether these would 
turn the project into a viable investment.   
6.3.3 (i) Decision-making for manufacturers: Some economic analysis 
Although savings within primary care services are anticipated, these are less easily quantified 
than the effect of reduced hospitalisations alone.  The roll-out of such a device (in any of our 
scenarios) will incur additional costs within primary care, for example from providing patient 
training in its use, and monitoring its output which may additionally require some re-
organisation of services.  Even though these additional costs are expected to be more than 
offset by reduced GP visits (scheduled and unscheduled), these are difficult to quantify at this 
stage.  Therefore, the analysis below considers the simpler scenarios one and two, where the 
impact on primary care services is overlooked and it is assumed hospitalisations are halved.  
Firstly, the potential trade-off between fixed and variable costs at different levels of headroom 
is outlined.  This is followed by a value-based pricing exercise, considering headroom to 




Mapping ‘headroom’ in terms of its component costs 
The approach to exploring the trade-off between the fixed costs of development and the 
variable costs of production was outlined in chapter 4.  By equating the MRP to the maximum 
total cost per device, the NPV of the project would be zero.  This therefore represents the 
maximum cost to the manufacturer per device for its development to be feasible, and must 
cover both the variable costs of production (materials, production, labour, selling costs etc. 
once in full production) and also the fixed development costs (including land rent, capital 
upkeep, and crucially the costs of development
25
).   
At such an early stage, there will clearly be uncertainty around these costs, but as an 
exercise it is possible to map the relationship between the two.  By inputting various potential 
levels of variable cost, Table 6.21 considers the maximum allowable development cost of the 
device under scenario one (device is given to a 900,000 COPD population who has on 




Table 6.22 considers scenario two, where the device is distributed according to 
hospitalised exacerbation rate.  Unfortunately, patient numbers stratified by hospitalisation 
rate were difficult to obtain, so I use the assumptions described in scenario 1 to estimate total 
number of hospitalised exacerbations (1*0.2*900,000=180,000), and assume these all 
represent different patients (one hospitalised exacerbation per year; headroom: £5,851 per 
                                                 
25
 At this early stage, investment in R&D can be considered a fixed cost to the manufacturer, which only 
becomes sunk at launch (and must therefore feature in the decision to develop).   
26
 As explained, the headroom figure of £1,168 has been calculated by adding the discounted value accumulated 
over the 5 year lifetime of the device.  Although this represents the value of the device to the buyer when they 
purchase it at time ‗t‘, using this to represent the future monetary benefit to the manufacturer now (at time t-1) 
may be misleading, as these benefits are to be accrued later than the development costs incurred at t-1.  This 
means that relatively more weight should be attached to the sunk costs of development; although the headroom 
figure should therefore be discounted at an appropriate rate—the internal rate of return of the company—this 
will vary according to the developer, and therefore is not attempted here.  
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device).  This is clearly a simplification as among those admitted will be repeat 
hospitalisations, implying a market size of less than 180,000.  However, for illustrative 
purposes, a comparison of these two scenarios is presented. 
Table 6.21 Headroom1: Distribute to all COPD patients 
Headroom (per unit per year): £250  
Headroom over 5 year expected device lifetime [MRP]: £1,168 
Number of patients: 900,000 
Total cost per unit 
(TCPU) 
Variable cost per unit 
(VCPU) 
Maximum development costs  
Total fixed costs= TC [TCPU*900,000] – TVC [VCPU*900,000] 
£1,168 £0 £1,051,200,000 
£1,168 £100 £961,200,000 
£1,168 £250 £826,200,000 
£1,168 £500 £601,200,000 
£1,168 £750 £376,200,000 
£1,168 £1,000 £151,200,000 
£1,168 £1,168 £0 
£1,168 £1,250 - £73,800,000 
£1,168 £1,500 - £298,800,000 
 
Table 6.22 Headroom 2: Distribute to those who experience a hospitalised exacerbation (one per year) 
Headroom (per unit per year): £1,252  
Headroom over 5 year expected device lifetime [MRP]: £5,851 
Number of patients: 180,000 
Total cost per unit 
(TCPU) 
Variable cost per unit 
(VCPU) 
Maximum development costs 
Total fixed costs= TC [TCPU*180,000] – TVC [VCPU*180,000] 
£5,851 £0 £1,053,180,000 
£5,851 £500 £963,180,000 
£5,851 £1,000 £873,180,000 
£5,851 £2,000 £693,180,000 
£5,851 £3,000 £513,180,000 
£5,851 £4,000 £333,180,000 
£5,851 £5,000 £153,180,000 
£5,851 £5,851 £0 
£5,851 £6,000 - £26,820,000 
 
A result of the simplification made for scenario 2‘s population size is that both scenarios 
actually consider the same population of exacerbators, the difference being that scenario 2 
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involves supplying the device to this group only (and charging a higher price to reflect its 
higher value), and scenario 1 involves supplying the device to everyone and charging its 
average value.  This means that permissible development costs given a zero variable cost (this 
is also equal to total revenue: price*quantity) should be the same for both scenarios (the 
reason they are not must be due to rounding in the calculation of prices).  If better information 
were available on the population size for scenario 2, it would be evident that restricting the 
target market would increase headroom but limit the ability to share the fixed costs of 
development, and the optimum strategy would depend on the variable costs of production.  
However, given the assumptions made above (and that the price is set at the theoretical MRP 
for both groups) scenario 2 is more attractive: for any given variable cost, what‘s left over for 
development (or future profit) is larger.  Figure 6.2 depicts this graphically. 
 
Figure 6.2 Relationship between variable cost per device and maximum allowable development costs (assuming 
NPV=0) 
The wide distribution strategy lies everywhere below the second scenario, meaning that for 
any given variable cost, the maximum allowable development cost is greater for ‗Headroom 
2‘ than ‗Headroom 1‘.  If, for example, the developer believes that the variable cost per device 
































Variable cost per device (including consumables) (£) 
Price: £1,168 (Headroom 1: 
Distribute to all 900,000 COPD 
patients) 
Price: £5,851 (Headroom 2: 




scenario 1 and £873 million for scenario 2.  This assumes full uptake (unrealistic in reality), a 
revision of which would simply pivot the curves in Figure 6.2 downwards, implying lower 




6.4  Summary 
Assuming that the near-patient monitor will allow for the accurate monitoring of a patient‘s 
symptoms and pathological changes, the literature suggests that this would improve patient 
prognosis.  In its exacerbation-predicting function, the device may be viewed as a diagnostic 
test.  The analysis has implicitly assumed sensitivity and specificity to be 100%, but the 
impact of false positives (patients taking extra medication unnecessarily), and false negatives 
(being assured no action is needed when the patient should in fact receive medical treatment) 
should be considered in the future when clinical data are generated.  Compliance issues 
should also be explored. 
The second crucial assumption was that hospitalised exacerbations would fall by 50%.  As 
well as being supported by the literature, the innovator believed this to be realistic based on 
her experience treating COPD patients within the current care pathway (the baseline).  One 
issue, however, is the possibility of a changing baseline.  The positive results from other 
studies demonstrate the magnitude of work being undertaken in the area that could lead to real 
benefits in the system.  Although these initiatives are currently not widespread, developments 
may eventually alter the baseline, in which case the ‗headroom‘ for the near-patient monitor 
may be reduced.  
                                                 
27
 As an exercise, one could calculate the additional QALYs required to make the reimbursement potential equal 
for both scenarios.  For example, if the variable cost were £1,000 and we assume a WTP of £30,000 per QALY, 
then for scenario 1 to fill the reimbursement gap (so that the allowable development costs are equal to scenario 
2) the wider distribution strategy would have to generate 24,066 extra QALYs. 
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Throughout the scenarios presented in section 6.3.2, headroom was expressed per patient 
(or device) per year, in terms of the value created for the NHS and therefore the maximum 
reimbursement opportunity, which should include any net change in service costs.  In 
subsequent analysis where development costs are considered (section 6.3.3), the headroom is 
considered to be maximum reimbursable price of the device itself.  However, if extra service 
costs associated with the device (e.g. maintenance, training, safety checks, a clinical member 
of staff to monitor results, etc.) exceed primary care cost savings (e.g. from fewer GP 
contacts), then this may not be appropriate, and the net effect of these should be considered 
alongside the ‗headroom‘ in order to isolate price.  In the analysis these two effects were 
implicitly assumed to be of equal magnitude; this will require further research when more is 
known about the technology, its exact form, and how disruptive it would be to the current 
pathway.  
The final section of this chapter considered distribution strategies, and how targeting 
different subgroups would impact MRP and allowable development costs.  From June 2014 
value based pricing (VBP) will come into effect; evaluating bodies for new pharmaceuticals 
will stipulate the price at which they would buy a new drug, based on the value it creates for 
the NHS (Department of Health 2010a).  Price will therefore be set at the maximum WTP— 
the parameter that the headroom exercise aims to predict.  Indeed, the VBP literature explores 
the concept of cost-effectiveness differing by patient subgroup, and the possibility of 
manufacturers being able to choose a level of coverage which would maximise revenue 
(Claxton 2007).  The distribution exercise performed above was illustrative only, as altering 
the market size assumptions would alter the results.  Additionally, although distribution 
scenario 1 was intended to be illustrative of an inclusive strategy, 100% market capture is 
very unlikely.  As well as the near-patient monitor representing a complex example of the 
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headroom method‘s application—posing a change in the whole clinical pathway rather than a 
simple exchanging of treatments—this may also present a potential barrier to adoption, 
requiring a large shake-up in service provision. 
The potential ‗scenarios‘ are extensive, and it would be unreasonable to attempt to 
quantify them all.  One high-value application may be its use as a tool for GPs or specialists 
to monitor patients during visits.  This could be especially important considering the 
imminent changes to the NHS, where care is moving out of hospitals and into the community.  
Specialists will travel to local surgeries, making high-tech equipment (easily on hand in a 
hospital setting) less accessible.  The value per device in this scenario, which would no longer 
be on a per-patient basis, could be very high. 
Largely ignored by this analysis is the QoL impact of ameliorating exacerbations.  The 
summary of the literature showed that these benefits are likely to be positive and tangible, and 
so should contribute to the case for the near-patient monitor (and possibly be quantified later 
on).  However, this case study demonstrated that a complete analysis may not be necessary to 
support an investment decision; there was no need to extend beyond the initial simplified 
scenario, as (according to the developer) sufficient headroom was identified to warrant 
development when considering costs alone.  Other factors omitted from the analysis, being 
currently outside the remit of healthcare decision-makers, include the wider benefits to society 
(e.g. fewer lost working days, less burden on carers, etc.). 
COPD is a notoriously difficult disease to assess in terms of the potential cost-
effectiveness of treatments.  The headroom analysis dealt only with the short-term cost-saving 
prospects of the near-patient monitor.  A much more complicated modelling approach would 
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be required to consider the long term effects of slowing disease progression.
28
  Mapel and 
Roberts (2012) provide a recent review of the literature, finding half of the cost-effectiveness 
studies identified to be based on observational data, a quarter on RCTs, and the remaining 
quarter to be modelling studies.  A substantial problem identified by the authors in relation to 
modelling in COPD is the use of FEV1 severity stages to model disease progression; due to 
the heterogeneity within disease state populations, in particular relating to propensity to 
exacerbate, dividing the population in this way could be misleading (this has now been 
acknowledged in the 2011 GOLD strategy: ‗FEV1 is an unreliable marker of the severity of 
breathlessness, exercise limitation, and health status impairment.‘ (GOLD 2011, p. vii)).  The 
literature fails to provide many good alternatives to markov modelling for COPD; although 
patient-level simulation may provide the best way to model outcomes (as this can incorporate 
a patient‘s history of events), this would require a huge data input.  
The analysis provided in this chapter presents a (necessarily) very simple model of 
potential cost savings, which only deals with the short term.  The headroom method aims to 
tap into the reimbursement opportunity, and the (sub-optimal) reality is that purchasers can be 
by nature at least somewhat short-sighted.  As evidence for the technology accumulates, 
assumptions and estimates may be updated in order to paint a more accurate picture of its 
impact.  However, by presenting an initial estimate of the reimbursement potential, 
development may be informed by this value. 
 
                                                 
28
 Rutten.van Mölken and Lee provide a review of COPD-related economic models (Rutten-van Mölken & Lee 
2006). At that time, there had been five studies using cost-effectiveness models in COPD, all of which were 
Markov models: Sin, Golmohammadi & Jacobs (2004), Borg et al. (2004), Spencer, Briggs, Grossman & Rance 
(2005), Oostenbrink, Rutten-van Mölken, Monz, & FitzGerald (2005), and Hoogendoorn et al. (2005).   
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In relation to her own projected costs, the innovator believes the headroom analysis to provide 
a favourable case for development.  The utility of the method, its scope, and the impact it has 
had for the innovator is discussed in the interviews chapter 9.   
This case study was in some ways exploratory, both illustrating the application of the 
method to a complex pathway-changing device early on, as well as exploring possible 
interpretations of headroom.  The ensuing case studies benefit from the experience gained in 
this one, in: approaching the literature, the data sources utilised, and the consideration of the 
wider context of the new device.  This headroom analysis also had an important impact on the 
research direction, in particular shaping the need for and the design of the retrospective case 





CHAPTER 7 RETROSPECTIVE CASE STUDIES 
7.1  Introduction 
The aim of this chapter is to shift the paradigm from application of the headroom method to 
its evaluation.  There are three principal novelties to this retrospective case study 
investigation:  a large sample, a systematic approach, and the ability to follow-up headroom 
decisions.  Given the huge range of products encompassed by the term ‗medical device‘, any 
lessons drawn from the headroom method‘s application may be specific to the type of device 
under evaluation.  By evaluating 20 case studies, the range of different perspectives and 
outcomes these individual examples contribute can be capitalised.  The approach to each case 
study aims to be as systematic, informed, and transparent as possible, which is assisted by the 
use of a pro forma, a template of resources, and a rough time limit for each case study.  
Furthermore, until now the ramifications of favourable or unfavourable headroom in terms of 
subsequent uptake have not been explored.  The headroom method is applied to the case 
studies retrospectively, by basing calculations on primitive expectations for the device and 
information from the literature that would have been available at the time the idea for the 
device was conceived. 
The chapter is set out as follows.  After describing the database used to identify case 
studies, the selection strategy is outlined.  The strategy of evaluation is presented in the 
methods section (7.3).  The results of each case study are then summarised in section 7.4, 
along with the principal messages that can be taken away from each in terms of the method‘s 
applicability.  Section 7.5 considers the overall findings, and relates the products‘ 
characteristics to the analysis and results, in order to identify relationships and to draw firmer 
conclusions around the headroom method‘s potential value. 
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7.2  The database: National Horizon Scanning Centre 
As described previously, the ideal strategy for evaluating this decision-support tool would be 
to: (1) elicit early expectations for a new product idea in real time; (2) calculate headroom and 
consider its adequacy for development; and (3) follow-up the device and observe its success 
or lack thereof.  The COPD case study offers an example of the first two steps, but to follow 
this up to an eventual reimbursement decision would require a time-frame beyond that of a 
PhD.  However, for a decision-support tool not to be related to the potential implications of 
that decision seems amiss, and whilst the question ‗does the headroom method work?‘ cannot 
be answered definitively in this academic setting, there is certainly more to be learnt about the 
method by exploring this path. 
The use of retrospective examples, whilst associated with inherent limitations that will be 
discussed, offers an opportunity to tackle this time constraint.  The National Horizon 
Scanning Centre (NHSC) provides technology briefings on emerging health technologies that 
may have a significant impact on NHS healthcare provision (NHSC 2012b).   Funded by the 
NIHR, the centre‘s remit is to provide timely information to policy and decision-makers 
within the NHS.  These short briefings (which can be found on their website) describe: the 
technology, the related patient group, current treatment alternatives, suggested impact, and 
any early evidence.  From 2000 until the close of 2009, the NHSC produced 83 medical 
device and diagnostic briefings (2009 was chosen as an end point to allow adequate 
opportunity for follow-up).  These were all considered for inclusion, according to the 
selection strategy described in the next subsection.   
Of course, the selection strategy of the NHSC itself completely defines the sample of 
medical technologies available to evaluate, even before these are filtered further for inclusion 
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in this study.  The NHSC‘s identification process is designed to pick up new technologies 
across a wide spectrum of clinical areas, which are evaluated for urgency and impact.  Their 
selection criteria reflects the remit described above, and explicitly excludes any minor or 
incremental developments, and products that would not be purchased by the NHS (NHSC 
2012a) (though as the analysis will demonstrate some of these seem to have slipped through).  
This is indicative of their role, which has often been to alert NICE of relevant new 
technologies.
29
  Although briefings are intended to be broad in topic coverage, the obvious 
caveat is that only technologies with high impact potential are considered.  Those that 
represent only minor changes or additions to current options, or those with a small cost 
impact, are likely to have been excluded; as discussed in chapter 3, these represent an 
important portion of the medical devices sector.  Also, given the timing of the briefings 
(around the time of launch) the sample contains no examples of devices whose development 
was aborted somewhere between ‗idea stage‘ and launch.  The implications of this are 
discussed further in the chapter‘s discussion.  
7.2.1  Selection strategy 
It was decided that 20 case studies would provide a good range of examples and subsequent 
insights, while being manageable within this PhD study.  All 83 medical technology briefings 
were considered for inclusion, according to criteria that developed organically from the 
process of reading and summarising all briefings.  Table 7.1 provides a list of the exclusion 
criteria.  
  
                                                 
29
 More recently, the NHSC have started to produce ‗news briefs‘ for medical devices rather than full technology 
briefings. These are shorter, simpler, and directed at NHS commissioners, health professionals, hospital and 
community care providers, and patient groups. This shift in emphasis is a result of the new Medical Technology 
Evaluation Programme within NICE, which no longer wishes to be notified of new technologies by the NHSC, 




Table 7.1 Case study exclusion criteria 
Reason for Exclusion Number of devices 
excluded on this basis 
1 Its application or advantages are not clearly set out.  For example, 
the relevant patient population is not well specified, or benefits over 
current practice not clearly expressed. 
22 
2 The briefing is on a general topic: it incorporates multiple devices, or 
is applicable very broadly. 
9 
3 It is very similar to a previous briefing. 8 
4 It represents a complex change in the clinical pathway with no 
estimate of overall impact on patients (e.g. screening test). 
5 
5 The report is a technology ‗note‘ rather than a ‗briefing‘.  Notes are 
very short, quite general, and have no real detail. 
4 
6 More of an evolving technique.  No developers indicated. 3 
7 It is likely to be a patient purchase. 2 
8 NICE guidance was issued on the procedure in the three years prior 
to the briefing.  It is not clear if/how the procedure involved for this 
device is any different. 
1 
 Total Excluded: 54 
 
It is worth considering what these exclusion criteria reveal about the headroom method.  
Every attempt was made to ensure that exclusion was not based on the likely difficulty of the 
case study, by ensuring the criteria for exclusion were functional rather than preference based; 
not doing so may mean missing some potentially important caveats of the method.  The vast 
majority of devices were excluded on the basis of insufficient information on which to base 
assumptions.  This was pertinent for criteria 1, 2, 5, 6 and 8 in Table 7.1, which represented 
39 cases of exclusion (72%).  The information provided for these examples was either unclear 
or not specific; headroom analysis would therefore have been too speculative.  Whilst this 
implies that the method‘s application requires a good understanding of the technology, this 
has more to say about the design of this investigation (a briefing note cannot be interrogated).  
Eight cases were excluded in order to maintain breadth of examples (criterion 3).  Five were 
excluded on the basis of complexity (criterion 4); this was especially problematic for 
screening tests.  Whilst this highlights a potential deficiency of the method, the COPD case 
study illustrated that it is possible to reduce a complex change in the clinical pathway to a 
simple proposition of impact.  The expert insight required to make such simplifications was 
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not available for these retrospective case studies.  The remaining two exclusions were due to 
the device not being relevant for health service purchase (criterion 7)
30
.  
A total of 54 devices were excluded, leaving 29 for consideration.  To investigate the 
possible implications of the selection process, Table 7.3 and Table 7.4 summarise the headline 
characteristics of those selected and excluded.  The availability for each of NICE guidance for 
follow-up is also indicated.  First, Table 7.2 outlines the categories used to describe the type 
of innovation: ‗relationship with current practice‘. 
Table 7.2 Definition of terms: Relationship with current practice 
Relationship with current 
practice 
Explanation 
Incremental Development (ID) These could fit into the ‗replacement‘ category, but relate 
specifically those that represent a small or straightforward 
change to an existing device that is used in current practice. 
Another Option (AO) The new product represents another option for the treatment of 
patients within a specific clinical area.   
Replacement (R) Whilst there is some overlap with AO, replacement innovations 
refer to those that will displace current practice, even if this is for 
a specified subset of the patient population.  
Addition (A) The new medical technology will be used alongside / in 
conjunction with current clinical practice. 
New Indication (NI) There are currently no treatment options for technologies that 
address a ‗new indication‘.  No current clinical practice or 
procedure is displaced by the introduction of NIs.  
Mix (M) This label is for those new medical technologies that fit into 
more than one of these categories. 
 
Table 7.3 Comparing the characteristics of those selected and excluded: devices and diagnostics 
 Total number Devices (%) 
[Total:45] 
Diagnostics (%)  
[Total:38] 
For which there is 
NICE guidance for 
follow-up (%) 
Selected 29 20 (44%) 9 (24%) 12 (41%) 
Excluded 54 25 (56%) 29 (76%) 11 (20%) 
                                                 
30
 Despite being itself an exclusion criteria of the NHSC, a small number of NHSC briefings related to 
technologies that were not likely to be NHS purchases.  Although these were excluded from this investigation, it 
transpired after starting to evaluate one device (the ‗SpeechEasy‘) that this would be a consumer purchase.  The 
case study was left in the sample in order to illustrate the difficulties encountered when applying the headroom 
method to those devices that would not be offered reimbursement by the health service.  
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Table 7.4 Comparing the characteristics of those selected and excluded: Relationship with current practice 
 Total number Selected (%) Excluded (%) For which there is 
NICE Guidance (%) 
Incremental 
Development 
6 6 (100%) 0 (0%) 0 (0%) 
Another Option 23 3 (13%) 20 (87%) 7 (30%) 
Replacement 13 10 (77%) 3 (23%) 5 (38%) 
Addition 18 2 (11%) 16 (89%) 2 (11%) 
New Indication 7 5 (71%) 2 (29%) 5 (71%) 
Mix 16 3 (19%) 13 (81%) 4 (25%) 
 
Aside from the exclusion criteria themselves, a closer look at the characteristics of those 
selected and excluded—and how they differ—is revealing.  A much larger proportion of 
diagnostics were excluded from the sample than devices.  Most technologies selected 
represent a more straightforward change in clinical practice, such as incremental 
developments or replacement technologies.  The majority of those developed for a new 
indication were selected.  On the other hand, most of those representing another option, an 
addition, or a mix, were excluded.  This may be because their fit within clinical practice was 
less clear.  This is in contrast to the other three categories for which the comparator is much 
clearer: a specific product (IDs and Rs) or ‗nothing‘ (NIs). 
The headroom method is simply a manipulation of the NICE framework of economic 
evaluation, applied early.  This strong association is emphasised by the availability of NICE 
guidance for follow-up, which is double for those selected compared with those excluded.  
The category for which proportionally there is most NICE guidance is new indications, 




The 29 technologies that were left after the exclusion process were placed in a random 
order and the first 20 selected for review.  
 
7.3  Methods 
As far as possible, the design of this investigation aspires to reflect the context of the 
method‘s intended use: by the device developer.  This includes consideration of the time 
available to conduct such an analysis, which is unlikely to be akin to the months of work 
involved in the COPD case study.  Therefore, a guiding policy of ‗headroom in a day‘ was 
employed (though not always achieved), and time taken was recorded for each case study.  
The methods employed are explained below; by outlining the significant potential problems 
with the study, I describe how the design of this investigation seeks to overcome these 
problems and minimise their influence on the results. 
7.3.1  The problem of ‗too much information‘ 
As the medical technologies under examination were conceived in the past, it is important that 
the retrospective application of the headroom method does not profit from any information 
that has become available more recently.   
NHSC medical technology briefings are generally produced in the six months pre-launch 
to six months post-launch window
31
 (NHSC Associate Director 2011).  The NHSC team 
contact developers directly with a pro forma (see Appendix 4), which is then supplemented by 
a limited literature search (NHSC 2012a).  The potential impact of the technologies reported 
in the briefings is therefore guided by the developer‘s own expectations. 
                                                 
31
 This differs from NHSC briefings for pharmaceuticals, which are produced two to three years pre-launch. 
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The time it takes to develop a device is clearly variable, depending among other things on 
the type of device and the situation of the developer.  Dixon and colleagues (2006) estimate 
mean development time to be 24 to 34 months.  Conservatively, I take a date restriction for 
information searches of three years before the NHSC briefing publication (or three years 
before launch date if this is known to predate the briefing); that is to say, any information 
utilised must have been available three years prior to the briefing‘s publication date.  This is 
scaled down to two years for incremental developments, for which development time is likely 
to be shorter.  Any data or information provided either within the briefing or in the wider 
literature whose source postdates this restriction is ignored (this includes any clinical trials 
outcomes which are sometimes reported in the briefings).  Any deviation from this rule in 
specific cases is explained in the headroom pro forma.  Although the date restriction limits the 
information searches significantly, this is important in making the headroom analysis as 
realistic as possible.  As well as excluding any information relating to the performance of the 
device itself, it is appropriate to reflect the state of knowledge in the general literature, which 
may be more limited before significant technological advances generate considerable research 
in a clinical area.   
7.3.2  Removing the researcher from the research 
To test a tool that is meant for device developers, it is important to set out a scheme that could 
be followed by someone other than an academic researcher.  The approach to the headroom 
analyses—described below—is therefore set out explicitly, which should make the 20 case 
studies as systematic and repeatable as possible, as well as accessible to others.   
7.3.2 (i) Template 
The template was designed as an overview of the steps required to calculate headroom, along 
with useful resources to furnish these.  This is supplemented by further specific reference to 
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sources of information on market size data, cost data, and patient QoL elicitation, along with 
guidance on the appropriate ways to manipulate these figures (discounting, inflation rates, 
etc).  The framework was designed before the commencement of the case studies, but the 
resources were built upon throughout the study (see Appendix 2).   
7.3.2 (ii) Pro forma 
The template is to be used alongside the pro forma (see Appendix 1), which is completed for 
every case study.  The pro forma helps to tease out the necessary information to estimate 
headroom: an explanation of the product and disease area, a description of the comparator, an 
estimate of market size, the likely impact on health service costs, the effect on patient health, 
a description of developments or changes in the area (clinical and healthcare context), and 
research questions that the analysis has inspired. 
As far as possible, the headroom assumptions were based on an interpretation of the 
aspirations for the technology expressed in the briefing notes, combined with an appreciation 
of the relevant literature in order to judge what might reasonably be expected from the new 
technology.  Depending on the level of information provided, some required more speculative 
assumptions than others.  
7.3.2 (iii) Headroom calculations  
‗Headroom‘ represents the maximum incremental cost to the health service of a new 
intervention (per unit), up to which point it would provide value for money.  More 
conceptually useful to the manufacturer, as explained in the headroom method chapter, would 
be an MRP which requires one further iterative step: netting the headroom of the relevant cost 
impact to the health service.  Many potential sources for eliciting healthcare costs are 
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provided in the template, but in the absence of implementation information (not always 
offered in the briefing notes) it was not possible to turn all headroom estimates into an MRP. 
The output is calculated according to the following formula, as explained in chapter 4:  
MRP = [WTP x ∆QALY] - ∆SC + P1                                                                           (Eq. 7.1) 
The output is expressed as ‗headroom‘ rather than MRP in cases where service cost 
implication is missing or incomplete, or where the headroom value identified could not be 
matched directly with the device (e.g. expressed as a yearly value when longevity is not 
known or as a per patient treated value in cases where the number of units required to service 
the relevant population was unknown).  The headroom or MRP output is presented in the 
results tables for each case study as a range, according to a WTP of £20,000 and £30,000. 
Where the appropriate assumptions required for the headroom analysis are not clear, a 
range of values is presented according to various scenarios, which are explained.  Where 
possible, development cost decision analysis is presented, as in the COPD case study.  These 
are presented in graphic form in the full case study documentation provided in the Appendix.  
7.3.3  Headroom: Decision Outcomes 
Although confirmation from the developer would be required to know for sure whether the 
level of headroom estimated would have been perceived as adequate, this can often be 
gleaned intuitively by comparing headroom with actual cost or price where this is available 
(e.g. where subsequent price is set below MRP, it seems likely that headroom would have 
indicated a favourable development decision).  The development decision analysis can then be 
compared with evidence of uptake.  This information is elicited from the current (up-to-date) 
literature, information available from the internet, and attempts to contact the relevant 
companies or interested parties.  The strategy for follow-up is presented in Appendix 5.  It 
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must be noted that the declaration of a favourable/unfavourable development decision, whilst 
as informed as possible and explained in the analysis, is still speculative and should be read as 
such. 
7.3.4  Presentation of results  
Each case study is presented individually in section 7.4, in which the main properties of the 
devices are outlined, a summary of the results and follow-up presented, and pertinent lessons 
described.  Due to space constraints, explanations behind the assumptions made and details of 
the data used (including references) are not presented in the main text.  This information is 
provided in the full case study documentation, attached in Appendix 6.  For each case study, 
the time perspective for the ‗description‘ and ‗headroom analysis‘ is that from which the 
headroom analysis was conducted (usually three years prior to launch).  This perspective 
shifts to 2012 for the ‗follow-up‘ and ‗headroom lessons‘ sections. 
These case studies explore the feasibility of conducting an early economic evaluation 
using only the information available at concept-stage and the most preliminary of 
expectations for the product (as deduced from the NSHC briefing).  By following these case 
studies up to the present day, the degree to which the headroom analysis reflected actual 
market opportunity can be explored.  All these elements of the analysis and results are then 
considered together in section 7.5, which reflects on what has been learnt about the headroom 





7.4  Case study results: The Data 




 is a non-invasive alternative to liver biopsy for assessing fibrosis 
(liver damage) in people with hepatitis C.  The test evaluates biomarkers from a blood sample, 
and a patented algorithm predicts the level of fibrosis and necroinflammatory activity in the 
liver.  This can assess disease staging prior to antiviral treatment.  The current gold standard 
for assessment of fibrosis is an invasive liver biopsy. 
Table 7.5 Summary of headroom analysis and follow-up for FibroTest-ActiTest 
Key 
characteristics: 
Clinical area Liver Disease (HepC) 
Technology type In Vitro Diagnostic.   
Relationship with current 
practice/ comparator 
Replacement 




Time perspective taken 2001 
Market size (per year) 3,600 
Service cost impact* £438 [saving] 
QoL Impact* 0.005 QALYs 
Headroom (per test) QoL impact included: £538 - £588** 
QoL impact not included: £438 
Important extra considerations  Adequate sensitivity and specificity will be key.   
 There may be a gradual move away from routine 
testing (currently with biopsy) prior to treatment for 
Hep C.  This could limit the potential market. 
Allowable development costs 
calculated?  
Given the variable and consumable cost per test is likely 
to be small, the maximum allowable development cost is 
huge (in the millions of £s). 
Time taken for headroom  6 hours 
Follow-up: 
Would the headroom analysis 
have indicated a favourable 
development decision? 
Headroom indicative of favourable development 
decision. 
Is the device used in the UK 
or the rest of the world? 
(Limited) availability in UK identified.  Laboratories 
performing the test are located globally. 
*Average per person treated 
**Depending on a WTP by the health service of £20,000-£30,000 per QALY 
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 As noted in the methods chapter, this case study acted as the pilot, through which the approach and resources 




FibroTest-ActiTest could directly replace biopsy in 90% of cases, and accuracy is presumed 
to be equivalent to biopsy.  Headroom (per person or test) is the average cost of a liver biopsy 
(£438), plus the value of disutility saved from avoiding invasive biopsy (0.005 QALYs); both 
parameters were elicited from the literature.  Insufficient information was provided to 
estimate the likely service costs involved in providing the test.  The figure presented is a 
‗headroom‘ (per test): between £438 and £588. 
Follow-up 
The unit cost to the NHS per FibroTest-ActiTest performed would be £70, indicating that the 
headroom would have presented an attractive proposition for development.  The test is offered 
by three UK laboratories and in 49 countries across the globe.  FibroTest-ActiTest has been 
recommended for reimbursement in France as first-line fibrosis assessment, but I have found 
no evidence of its systematic use across the NHS.  Cost-effectiveness studies indicate that 
FibroTest-ActiTest may be cost-saving but at the expense of reduced diagnostic accuracy 
(sensitivity, specificity and accuracy are 84%, 87% and 86% respectively).  In the UK biopsy 
remains the reference standard, but increasingly is not considered necessary before initiating 
treatment (NICE 2006); this has reduced the demand for disease-staging tests. 
Main lessons learnt 
Given its low price compared with its estimated (headroom) value, FibroTest-ActiTest should 
have achieved wide-spread adoption across the NHS.  The main factors to have impeded this 
are: diagnostic accuracy, a change in clinical practice, and the prevalence of direct 
competitors (these were all identified as potential threats in the headroom analysis). 
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7.4.2  Molecular adsorbent recirculating system (MARS®) — Teraklin Ltd. 
Description 
MARS is a mechanical blood detoxification system which would offer liver support therapy 
to patients with acute and chronic liver failure (much like dialysis for renal patients), 
potentially acting as a bridge to transplantation.  Liver transplantation is currently the only 
option once supportive measures have failed.  By considering NHS organ donation statistics, I 
estimate that an extra 10% of the approximately 1,000 patients on the waiting list would 
survive long enough to receive transplantation if all 1,000 have access to the MARS liver-
support system in this bridging period.  An estimate of 5% was also considered. 
Table 7.6 Summary of headroom analysis and follow-up for MARS 
Key 
characteristics: 
Clinical area Liver Failure 





Relationship with current 
practice/ comparator 
New Indication 




Time perspective taken 1997 
Market size (per year) 1,000 
Service cost impact* - 
QoL Impact* 0.69  (Assumption 1: 10% more survive until transplant) 
0.34 (Assumption 2: 5% more survive until transplant) 
Headroom (yearly value per 
patient) 
Assumption 1: £13,800 - £20,700 **  
Assumption 2: £6,800 - £10,200 ** 
Important extra considerations  Competitors: research is currently underway into 
liver-assist systems that also fulfil the metabolising 
function of the liver.  
Allowable development costs 
calculated? 
- 
Time taken for headroom  12 hours 
Follow-up: 
Would the headroom analysis 
have indicated a favourable 
development decision? 
Headroom indicative of favourable development 
decision. 
Is the device used in the UK 
or the rest of the world? 
NICE IPG does not recommend MARS, on the basis of 
insufficient evidence of efficacy.  The system has been 
used in various UK centres and across the world.  In the 
U.S. it is indicated for the treatment of drug overdose and 
poisonings rather than for liver conditions. 
*Average per person treated 
**Depending on a WTP by the health service of £20,000-£30,000 per QALY 
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 Equipment refers to medical technologies that are not used on a per patient basis 
34
 Devices have been classified using the rules outlined in the European medical device directive documentation 




Headroom is presented per patient per year, given the uncertain service provision costs and 
device longevity.  QALY impact is based on the average life years saved per patient treated 
with MARS, adjusted for HRQoL after liver transplantation (inferred from the literature).  
Headroom is estimated to be between £6,800 and £20,700 (see Appendix 6 for explanation). 
Follow-up 
Considering the £16,000 price tag for MARS, its intended use (for multiple patients) and 
likely longevity (more than one year), the headroom analysis is likely to have indicated a 
favourable development decision.  One cost-effectiveness study finds a QALY gain from 
MARS very similar to that estimated above, but in general there is insufficient evidence of 
clinical effectiveness (NICE 2009b).  The device is sold (both in the UK and globally), but 
has not achieved complete diffusion in the UK.  
Main lessons learnt 
Some potentially important benefits of MARS were ignored, simply because there was no 
easy way to estimate, quantify and incorporate these.  To estimate health-economic value of 
equipment requires some understanding of distribution, patient throughput, and device 
lifetime.  These may be difficult to envisage early on, even for the developer.  The headroom 
calculation, which involved a transformation of survival rates into expected life years 
remaining, may have been difficult for someone with no background in 
statistics/epidemiology.  The assumptions made for this analysis felt particularly speculative, 
and very open to alternative approaches. 
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7.4.3  SpeechEasy — SpeechEasy International 
Description 
The ‗choral effect‘ describes the phenomenon that stammering often improves when a person 
is singing or talking in unison with others.  The SpeechEasy is a prosthetic device that fits into 
the ear (much like a hearing aid), which stimulates this choral effect by providing altered 
auditory feedback (AAF) of the person‘s own voice, into their ear.  Other AAF devices exist, 
but this would be the first wireless AAF device, and thus the least conspicuous.   
Table 7.7 Summary of headroom analysis and follow-up for Speech-Easy 
Key 
characteristics: 
Clinical area Stammer 
Technology type Device. Class IIa 
Relationship with current 
practice / comparator 
Incremental Development 




Time perspective taken 2005 
Market size (per year) - 
Service cost impact* [Price of most expensive current model: £1,827] 
QoL Impact* [0.071 to 0.152 per year]- illustrative and not included 
Headroom/MRP [£1,827] 
Important extra considerations This is likely to represent a patient purchase, and so is 
unsuitable for headroom evaluation. 
Allowable development costs 
calculated? 
- 
Time taken for headroom  6 hours 
Follow-up: 
Would the headroom analysis 
have indicated a favourable 
development decision? 
- 
Is the device used in the UK 
or the rest of the world? 
The device is available across the world. 
*Average per person treated 
 
Headroom analysis 
The simple baseline MRP for a device that incrementally develops an existing model is the 
price of that comparator (£1,827).  After seeking information from The British Stammering 
Association and contacting a local NHS speech and language therapy clinic, it became 
apparent that, whilst occasionally used within clinics, AAF devices are not provided to 
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patients by the NHS (see Appendix 6 for further explanation).  HRQoL impact was explored 
using a manipulation of the anxiety level in the EQ-5D, but only for illustrative purposes. 
Follow-up 
The estimated MRP was £1,827, plus some premium that consumers should be willing to pay 
for the discrete nature of SpeechEasy.  The headroom method provides no means with which 
to estimate this premium.  The actual price of SpeechEasy is £2,450, and is available globally.  
Main lessons learnt 
Many economic methods exist to elicit the value a consumer would place on particular 
product characteristics, but this falls outside the scope of a headroom analysis.  Whilst the 
health value of this incremental development was explored, this cannot be used to estimate 
incremental WTP for SpeechEasy, as the ‗QALY tariff‘ (NICE‘s ICER threshold) has been 
designed specifically with the NHS and its inherent budget prospects in mind.  Although 
comments made in the pro forma and the general surface analysis transpired to be pertinent 
upon follow-up, they are unlikely to have provided additional insight; the headroom method is 
not applicable to consumer products. 
 
7.4.4  SLF Bypass Graft — Tayside Flow Technologies 
Description 
Peripheral arterial disease (PAD) involves stenosis (narrowing) of a peripheral artery.  This 
leads to insufficient blood supply to muscles and other tissues, causing pain and weakness.  
Spiral laminar flow (SLF) describes the natural pattern of blood flow through arteries, which 
is disrupted by stenosis.  The turbulent energy caused by this disruption contributes to 
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restenosis following bypass surgery.  An autologous vein graft is the first choice for surgeons, 
and is the most effective option but is not always available.  Where an autologous vein is 
unavailable, synthetic grafts are used, though these have a lower patency rate (become 
blocked more frequently).  The SLF bypass graft has a flow-inducer at the distal end which 
restores natural SLF, potentially improving graft patency compared with standard synthetic 
grafts.  I assume that the SLF graft could achieve equivalent patency rates to vein grafts. 
Table 7.8 Summary of headroom analysis and follow-up for SLF Bypass Graft 
Key 
characteristics: 
Clinical area Peripheral arterial disease 
Technology type Device. Class IIb 
Relationship with current 
practice / comparator 
Incremental Development 




Time perspective taken 2006 
Market size (per year) - 
Service cost impact -  [various estimates presented] 
QoL Impact - [given the strong possibilities of reimbursement on the 
cost side alone, and the fact that improved patency could 
only benefit patients, no attempt to quantify QoL benefit 
was made.] 
Headroom/MRP The case for development is intuitive 
Important extra considerations  Other innovations in this area were identified, 
including various direct competitors.  If proven 
effective, these could change the baseline of 
effectiveness. 
Allowable development costs 
calculated? 
- 
Time taken for headroom  8.5 hours 
Follow-up: 
Would the headroom analysis 
have indicated a favourable 
development decision? 
A favourable development decision is indicated. 
Is the device used in the UK 
or the rest of the world? 
The SLF graft is sold in over 20 countries, and is used in 
some NHS hospitals. 
 
Headroom analysis 
The potential value of the SLF bypass graft arises from a reduced burden of restenosis (which 
must be followed by repeat intervention or amputation).  Whilst some relevant literature was 
identified—one source suggesting that such an improvement in patency could be worth 
£4,400 per case (Cheshire et al. 1992)—data were scarce and any calculation would be 
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tenuous.  There is a strong indication that the potential reimbursement opportunity would far 
outweigh the cost of this incremental development. 
Follow-up 
Headroom indicated an intuitively favourable development decision.  The device is sold and 
marketed across the world (the company confirm that it is used within some NHS hospitals).  
Early indications of clinical function suggest reduced vessel occlusion following bypass with 
SLF grafts, but no economic evaluation was identified. 
Main lessons learnt 
Considering the expectation of improved patency and the straightforward change proposition 
of this device, the economic case for the SLF graft was a ‗no brainer‘.  It is difficult to say 
whether the headroom exercise would have been useful, even though it was not incorrect.  
This case demonstrated that even where the relevant information should be available (the cost 
implications of two existing options), this was lacking in the literature, highlighting that the 
headroom method‘s output is only as informed as the research undertaken by others. 
 
7.4.5  Meniett — Medtronic Xomed 
Description 
Ménière‘s disease is a pressure condition of the inner ear which can affect hearing and 
balance, causing vertigo attacks, hearing loss and tinnitus.  The Meniett device is proposed as 
an alternative to current approaches for the treatment of refractory cases: surgery or ablative 
treatment.  Meniett is a non-invasive portable patient-administered device which delivers low 
pressure pulses into the inner ear via a tympanostomy tube (grommet) which must first be 
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inserted under local anaesthesia.  I assume that Meniett will work as well as current methods 
of treating refractory cases, but may be better accepted by patients.  
Table 7.9 Summary of headroom analysis and follow-up for Meniett 
Key 
characteristics: 
Clinical area Ménière‘s disease 
Technology type Device. Class IIa 
Relationship with current 
practice/ comparator 
Another Option 




Time perspective taken 1999 
Market size (per year) 172 – 3,452 per year 
Service cost impact* £1,474 [saving] 
QoL Impact - 
MRP £1,474 
Important extra considerations  Local injection as a means of treatment seems to be 
well supported by the literature; if this becomes more 
widespread it might displace other treatment options 
(and is likely to be much less costly). 
 Would there be an improvement in hearing 
preservation compared with current surgical options? 
 Might the device be a patient purchase?  
Allowable development costs 
calculated? 
For a variable unit cost of between £50 and £550, 
maximum development costs ranged from £160,000-
£250,000 for the lower market estimate (172 patients) to 
£3.2 million-£5million for the higher market estimate 
(3,452 patients) 
Time taken for headroom  9 hours 
Follow-up: 
Would the headroom analysis 
have indicated a favourable 
development decision? 
Uncertain- possibly unfavourable.  Price for Meniett has 
been set above MRP at £2,000. 
Is the device used in the UK 
or the rest of the world? 
NICE does not recommend the procedure on the grounds 
of insufficient efficacy and safety evidence. Meniett does 
not seem to be available on the NHS, and appears to be 
mainly funded by patients themselves.  
*Average per person treated 
 
Headroom analysis 
Health service cost impact is calculated by subtracting the cost of grommet insertion 
(including one hospital day) from the current cost of surgical treatment (which would be 
avoided)
35
: £1,474.  This is the MRP for Meniett over a patient‘s lifetime (i.e. price per 
                                                 
35
 Costs were difficult to obtain.  In the absence of literature estimates predating 1999, I used the estimates 
provided in the NHSC briefing.  These were not referenced, so I assume were provided by the manufacturer.  
Given the paucity of cost data predating 1999, I used more recent sources to estimate generic hospital costs (and 
deflated these, using the HCHS Pay & Prices index). Whilst breaking the date restriction rule, it was surmised 
that whilst effectiveness / quality of life estimates capture a knowledge base that changes over time (which is 
important to mimic), costs are objective, and would probably have been identifiable by those in the field.  
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device, if it lasts a lifetime).  HRQoL estimates are not attempted.  Development cost analysis 
produces a wide range of estimates given the large uncertainty in market size. 
Follow-up 
At launch, Meniett was priced at £2,000, above the MRP.  Interventional procedures guidance 
by NICE finds insufficient clinical evidence upon which to recommend the therapy, and it is 
not reimbursed by the NHS.  As predicted, local injections have become the gold standard, 
thus reducing the potential headroom.  Meniett is mainly purchased by patients, and cheaper 
devices with similar function have become available. 
Main lessons learnt 
Although a not-entirely-convincing headroom case was indeed followed by a not-entirely-
convincing health service uptake, the product still seems to be viable for Medtronic, mainly 
from patient purchases.  This, and other factors that have affected the market environment, 
were highlighted in the headroom analysis, and show that the MRP must be considered 
alongside these other important factors, which can generally be predicted at an early stage.  
 
7.4.6  AmpliChip CYP450 — Roche Diagnostics Ltd. 
Description 
Tamoxifen is the main hormonal treatment for early-stage oestrogen receptor positive (ER+) 
breast cancer.  The AmpliChip CYP450 is a laboratory array-based prediction test that can 
detect the levels of a certain marker gene thought to influence the rate at which patients can 
metabolise tamoxifen.  The test is proposed to identify poor metabolisers who would not 
benefit from tamoxifen treatment.  
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Table 7.10 Summary of headroom analysis and follow-up for AmpliChip 
Key 
characteristics: 
Clinical area Early Breast Cancer 
Technology type In Vitro Diagnostic 
Relationship with current 
practice/ comparator 
New Indication 




Time perspective taken 2004 
Market size (per year) 29,500 
Service cost impact - 
QoL Impact - 
Headroom/MRP - 
Important extra considerations  Aromatase Inhibitors have been found by some to be 
more cost-effective than tamoxifen.  If this is proven 
further, they may in the future replace tamoxifen as 
first-line adjuvant treatment for early stage ER+ 
breast cancer. 
 Some studies indicate that this particular gene in 
isolation may not be the most useful predictor of 
tamoxifen metabolic function. 
 The gene detected by AmpliChip relates not only to 
the metabolism of tamoxifen, but also other types of 
drugs.  Therefore the commercial opportunity of 
AmpliChip is likely to be far wider than that 
investigated here. 
Allowable development costs 
calculated? 
- 
Time taken for headroom  8.5 hours 
Follow-up: 
Would the headroom analysis 
have indicated a favourable 
development decision? 
No headroom was delivered, but significant threats were 
identified.  
Is the device used in the UK 
or the rest of the world? 
AmpliChip is available in the UK and across the world (at 
a cost of £200 per test).  It is indicated more widely than 




Although tamoxifen is currently the gold standard, aromatase inhibitors (AIs) provide an 
alternative chemoprevention method that is more costly but more effective.  Amplichip could 
personalise chemoprevention, allowing for continued use of tamoxifen for good metabolisers, 
and identifying poor metabolisers whose treatment can then be modified (e.g. to AIs).  The 
required parameters for a headroom calculation include: the proportion of tamoxifen users 
that are poor metabolisers, their prognosis, the proportion of AI users who would be good 
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metabolisers of tamoxifen, etc.  The literature provides no estimates of these parameters, 
inhibiting a headroom estimate.  Important considerations are summarised in Table 7.10.   
Follow-up 
Whilst lacking a monetary estimate of market opportunity, the exercise did highlight some 
important considerations.  NICE now finds AIs to be more cost-effective than tamoxifen (but 
do not suggest the removal of tamoxifen from clinical practice).  The literature includes some 
favourable results for AmpliChip, but most (including the MHRA, a technology evaluation, 
and a systematic review) do not recommend genetic testing prior to tamoxifen treatment.  Its 
application to other disease areas has been important for the success of AmpliChip. 
Main lessons learnt 
This case study demonstrated that sometimes the necessary parameters for headroom cannot 
be elicited.  AmpliChip was a ‗new indication‘—there is no other test for poor tamoxifen 
metabolism—so prevalence estimates do not exist.  As AmpliChip is applicable for other 
indications, to base a development decision on this evaluation alone would have been 
inappropriate.  Although no numbers were presented, the analysis correctly identified the 
significant barriers to adoption/reimbursement in its use for breast cancer patients. 
 
7.4.7  Agento I.C. — Bard Limited 
Description 
Ventilator associated pneumonia (VAP) is acquired in hospital by mechanically ventilated 
patients, when the endotracheal tube (ETT) that delivers this ventilation becomes colonised 
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with bacteria.  The Agento I.C is a silver-coated ETT, whose antimicrobial properties may 
prevent VAP in patients who require prolonged mechanical ventilation (>24 hours).  
Table 7.11 Summary of headroom analysis and follow-up for Agento I.C. 
Key 
characteristics: 
Clinical area Ventilator associated pneumonia (VAP) 
Technology type Device. Class IIa 
Relationship with current 
practice/ comparator 
Incremental development 




Time perspective taken 2005 
Market size (per year) 62,000 
Service cost impact* 100% reduction in VAP: £3,111 [saving] 
50% reduction in VAP: £1,556 [saving] 
25% reduction in VAP: £778 [saving] 
(Max) Price of standard ETT: £55 [saving] 
QoL Impact* 100% reduction in VAP: 0.0005 QALYs 
50% reduction in VAP: 0.00025 QALYs 
25% reduction in VAP: 0.000125 QALYs 
MRP** 100% reduction in VAP: £3,167 - £3,181 
50% reduction in VAP: £1,616 - £1,619 
25% reduction in VAP: £836 - £837 
Important extra considerations  Other means of tackling VAP have been found to be 
effective, e.g. laying the patient in a semi-recumbent 
position, use of antibiotics, etc. One study found that 
an educational program for ICU nurses and 
respiratory care practitioners, on the risk factors and 
prevention strategies of VAP, reduced VAP 
incidence by 46%.  If in the future recommendations 
are better implemented, this could reduce the 
potential impact of the Agento I.C.  
Allowable development costs 
calculated? 
For the least optimistic scenario (MRP: £836), a variable 
cost of £0-£250 would allow for development costs in the 
region of £40-£50 million.  For the most optimistic, these 
reach nearly £200 million. This is based on a market size 
of 62,000, which may be an overestimate. 
Time taken for headroom  10 hours 
Follow-up: 
Would the headroom analysis 
have indicated a favourable 
development decision? 
Headroom indicative of a favourable decision (price of 
Agento IC falls well below the most pessimistic estimate 
of MRP). 
Is the device used in the UK 
or the rest of the world? 
Based on trial sites, it is available in the U.S. and Spain. 
The company‘s UK headquarters confirms that Agento IC 
is not sold in the UK. 
*Average per person treated 
**Depending on a WTP by the health service of £20,000-£30,000 per QALY 
 
Headroom analysis 
The impact of the Agento IC is estimated according to three scenarios: a 100%, 50%, and 





), which lasts 11.5 days (the average additional days spent in hospital for 
VAP patients).  MRP ranges from £836 to £3,181, depending on assumptions and WTP. 
Follow-up 
The price of Agento IC is around £100; the headroom analysis would have indicated a 
favourable development decision.  The product is not sold in the UK.  Most trials are located 
in the U.S. or Spain, the largest of which attributes a 36% relative risk reduction in VAP to 
Agento IC (Kollef et al. 2008).  Some studies indicate that Agento IC is cost-effective (though 
not to the extent imagined in the headroom analysis). 
Main lessons learnt 
Although the device appears to be cost–effective, uptake by the NHS has not followed.  This 
may relate to a limited awareness of VAP due to the difficulty in its diagnosis, or the 
implementation of other recommendations to combat the illness (as identified during the 
headroom analysis).  Most assumptions were based on information from a single source, 
deemed by me to be the most reliable/consistent.  The huge spread of data in the literature 
means that speculation was required; bias may therefore creep in.  Indeed, more recent 
estimates of VAP cost are more modest but, perhaps unsurprisingly, Bard Ltd. make reference 
only to the older, more generous estimates.  
 
 
                                                 
36
 This estimate was provided by Vold and Owens ―...on the basis of comparisons with various health states for 
which published utility data exist‖ (Vold Pepper & Owens 2000).  This is strikingly similar to the philosophy 
behind the ‗health utilities ladder‘ put together by McAteer (McAteer 2011). 
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7.4.8  Cool-Cap — Olympic Medical Corp 
Description 
Perinatal asphyxia is the deprivation of oxygen to a newborn baby, usually resulting from an 
interruption of blood flow to the brain during delivery.  Normal causes include placental 
infarction, a drop in maternal blood pressure, uterine rupture or umbilical cord complications.  
Hypoxic-ischaemic brain damage is a serious risk of perinatal asphyxia, which can cause 
infant death and impair neurological development.  20% of cerebral palsy cases are caused by 
perinatal asphyxia, which can also cause mental retardation, learning disabilities and epilepsy. 
The cool-cap would reduce a newborn‘s core brain temperature, to prevent continuing damage 
to the brain cells and their environment.  Although whole body cooling has been found to 
improve cerebral outcome, this is not used systematically in clinical practice.  The cool-cap 
provides focal cooling of the head, and is the first commercial product for neonatal cooling. 
Table 7.12 Summary of headroom analysis and follow-up for Cool-Cap 
Key 
characteristics: 
Clinical area Perinatal asphyxia 
Technology type Device. Class IIa 
Relationship with current 
practice/ comparator 
New Indication 




Time perspective taken 1997 
Market size (per year) 600 
Service cost impact - [assumed to be very high] 
QoL Impact - [assumed to be very high] 
Headroom/MRP - 
Important extra considerations  The significance of brain temperature on the outcome 
of cerebral ischaemia is well recognised. The 
systemic cooling of patients undergoing heart surgery 
is often employed to avoid ischaemic brain damage.  
Whilst this confirms the likelihood of improved 
outcome from the cool-cap, other methods of cooling 
may be just as effective (e.g. whole body cooling). 
Allowable development costs 
calculated? 
- 
Time taken for headroom  7.5 hours 
Follow-up: 
Would the headroom analysis 
have indicated a favourable 
development decision? 
Headroom analysis is indicative of a favourable 
headroom decision (intuitive), but should consider the 
potential change in the counterfactual. 
Is the device used in the UK 
or the rest of the world? 




The NHS cost impact of avoiding even a small percentage of hypoxic-ischaemic brain 
damage cases would be difficult to quantify, but must be large.  Savings may be seen in 
medical costs, nursing care, physiotherapy, and transportation, as well as limiting pay-outs (in 
the millions of pounds) for litigation cases where clinician error was the cause.  By the same 
token, QALY gains would be vast.  Cooling by other means should be considered, but given 
the lack of current alternatives, the development case for cool-cap seems obvious.   
Follow-up 
The high value of the cool-cap indicated a strong case for development, but should be 
considered alongside the research questions generated, namely: would it be better than whole 
body cooling?  NICE recommends therapeutic hypothermia for hypoxic perinatal brain injury, 
either by whole body cooling or with a purpose-made cap (all evidence presented for cooling 
caps pertain to Olympic Medical Corp‘s product) (NICE 2010c).  Both methods of cooling 
are clinically and cost-effective, and both are used within the NHS. 
Main lessons learnt 
The cool-cap proposed to commercialise a known therapeutic technique which was not yet 
part of routine clinical practice.  Being the first commercial device for hypothermic therapy 
gave the product (and its case for development) an advantage.  From a health economic 
perspective, costs and effectiveness alone dictate the preference of one intervention over 
another.  Even though other methods seem more cost-effective, many techniques and products 
for cooling co-exist in the market, indicating the strong influence of other factors, including 
personal preference.  The commercial opportunity and the external threats identified in the 
headroom analysis turned out to be pertinent and indicative of the future market opportunity. 
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7.4.9  ChondroCelect — TiGenix 
Description 
Cartilage damage in the knee can occur spontaneously or from injury, and is associated with 
knee pain, knee locking, and weakness.  ChondroCelect is a somatic cell therapy product, 
developed from a patient‘s own cartilage-forming cells and expanded ex-vivo prior to 
implantation.  ChondroCelect (the ‗product‘) is administered as part of an autologous 
chondrocyte implantation (ACI), a ready-established procedure that was appraised by NICE 
in 2000 (re-visited in 2005) and not recommended
37
 (NICE 2005).  The proposed advantage 
over standard ACI is the improved cell culturing technique, leading to more effective cultured 
chondrocytes.  Other treatment options include symptomatic relief, matrix-guided ACI 
(MACI), microfracture, mosaicplasty, knee lavage and knee replacement.  At the time of 
analysis, microfracture was the standard treatment for cartilage defects.  
 
Table 7.13 Summary of headroom analysis and follow-up for ChondroCelect 
Key 
characteristics: 
Clinical area Knee cartilage defects 
Technology type Advanced therapy medicinal product (ATMP).
38
  Includes 
elements of medicine, surgery and medical device 
implantation.  
Relationship with current 
practice/ comparator 
Incremental development 
Relationship with current 
company portfolio 
- 
                                                 
37
 Although ACI is not the gold standard in clinical practice, is it the most relevant comparator in this example.  
As NICE have already produced a technology evaluation on the procedure, it is important to consider 
ChondroCelect in relation to this, to determine whether it might be possible for the product to warrant a different 
reimbursement decision outcome. 
38
 There is some disagreement around the appropriate classification of somatic cell therapy / tissue-engineered 
products; from a regulatory perspective, they pose quite different risks issues to devices and medicines.  They are 
officially classified as ATMPs.  Within the European Medicines Agency (EMEA), the ‗Committee for Advanced 
Therapies‘ will provide scientific advice of ATMPs, and at least two members of this committee must have 
medical device expertise (Department of Health 2008b).  Although products of this nature fit more closely into 
the ‗medicines‘ category, at least from a regulatory perspective (evident from their consideration within the 
EMEA), this was classified by the NHSC as a medical technology rather than pharmaceutical, and was kept 
within the analysis as it may provide some useful insight into the headroom method.  It represents a bit of a 
special case that is worth exploring, as the procedure contains elements of medicine, surgery and medical device 




Time perspective taken 2006 
Market size (per year) 900 – 1,200 
Service cost impact* -   [Price of current ACI: £3,710] 
QoL Impact* -   [an estimate was provided regarding what this needed 
to be] 
Headroom/MRP - 
Important extra considerations  If the ChondroCelect procedure is able to keep its 
cost to the health service within that of arthroscopic 
ACI, then in the short term  (two years) it would have 
to show at least 70% better outcomes than 
microfracture (but there are indications that it might 
be much more expensive and thus require even 
greater improvement in outcome).  From their 
technology appraisal, it is clear that NICE will not 
consider a longer term perspective until clinical data 
are available (which may require at least 20 years). 
Allowable development costs 
calculated? 
- 
Time taken for headroom  8 hours 
Follow-up: 
Would the headroom analysis 
have indicated a favourable 
development decision? 
Potential for reimbursement seems unlikely 
Is the device used in the UK 
or the rest of the world? 
ChondroCelect is reimbursed on a case by case basis in 
Belgium, Germany, the UK, and soon Finland. 
*Average per person treated 
 
Headroom analysis 
Although ChondroCelect may improve the effectiveness of ACI, to estimate the service cost 
and QoL implications of this is very complex: no headroom was estimated per se.  However, 
as an HTA relating to ACI has been published within the relevant timeframe, some precise 
qualifications for reimbursement are identified, and outlined in the ‗research questions‘ 
section of the pro forma.  
Follow-up 
Although I am unable to predict whether the qualifications set out would have appeared 
feasible to ChondroCelect developers, this seems unlikely due to the extra costs involved over 
arthroscopic ACI, and therefore the huge improvement in outcome that would be required to 
make it cost-effective.  ChondroCelect is reimbursed in Belgium, Germany, and the UK on a 
case-by-case basis.  Although ACI is not recommended by NICE, TiGenix is ‗working with 
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orthopaedic surgeons to obtain Pass-Though Payment
39
 from individual PCTs, and also 
working with private insurance: very positive initial reception from BUPA‘ (Meurgey 2010).  
Results of clinical and cost-effectiveness studies for ChondroCelect are mixed;  a long term 
time horizon is certainly required before the product may appear cost-effective, and the data 
required to confirm these longer terms outcomes have still to be generated. 
Main lessons learnt 
ChondroCelect was the first ATMP to receive European market authorisation.  The 
‗headroom analysis‘ was simply derived from an HTA that had been produced for ACI just a 
year earlier.  Therefore, nothing novel is likely to have been added to the decision-making 
process here.  Despite its uncertain cost-effectiveness, alternative methods of reimbursement 
are available for novel and expensive products such as this one.  Regenerative medicine 
products present a particular challenge to health economists, due to the long time horizon 
required to capture their value, and therefore the difficulty in generating the required 
evidence.  In the closing remarks of a presentation on ChondroCelect, Meurgey (V-P 
Commercial Development of TiGenix) says: ‗Unless national authorities demonstrate 
willingness to experiment with conditional reimbursement, there is a real risk that 
regenerative medicine will remain a nice idea without any routine clinical use (or a luxury 
reserved for the rich)‘ (Meurgey 2010).   
Other headroom analyses 
Helen McAteer (2011) uses ACI as one of four examples in her PhD thesis on the headroom 
method for regenerative medicine products.  ChondroCelect is one of the products considered 
                                                 
39
 Pass-Through Payments are additional payments that can be used to support (reimburse) a particular device 
over and above the relevant tariff. These are sometimes used to support the use of new products (Pate 2009). 
Special arrangements for reimbursement are similarly proposed for other countries, being on the ‗expensive 
drugs list‘ in the Netherlands, and obtaining ‗innovative status‘ in Belgium.   
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within this thesis.  To inform her headroom analysis, all relevant evidence was reviewed and 
synthesised, producing three models of potential outcome and ‗headroom‘.  This diverges 
from the approach taken here in two major ways: firstly, evidence available for the product 
itself is used to inform its headroom, and secondly, complicated models of potential 
effectiveness are produced in order to consider the headroom value.  Her concluding remarks 
relate to the paucity and discrepancy in the available data for ACI, and that without long term 
data evidence-based modelling is impossible.  This does not seem appropriate for a tool 
intended to be integrated into development decisions, and one whose approach is intended to 
be straightforward.  It is also proposed that ‗...supply side analysis has been used to calculate 
the incremental benefit required if the technology is to cost the same as ACI‘ (McAteer 2011, 
p. 231).  The approach taken in this analysis has provided a similar result, but elicits this 
directly from the literature. 
 
7.4.10  KRYPTOR compact — Brahms AG 
Description 
A lower respiratory tract infection (LRTI) can cause symptoms such as shortness of breath, 
fever, cough and fatigue, and is principally associated with acute bronchitis, COPD and 
pneumonia.  LRTIs can be of bacterial or non-bacterial (viral) cause.  Antibiotics are only 
useful for bacterial infections, but are currently over-subscribed; clinical examination is the 
only widely used method to distinguish between viral and bacterial causes, and is often 
unreliable.  Levels of the biological marker procalcitonin (PCT), detectable in the blood, can 
indicate the cause of an infection.  The Brahms Kryptor assay (classic version), available 
since 1997, is a sensitive assay that measures levels of PCT in a blood sample, and is used for 
various diagnostic purposes (primarily prenatal screening).  The Kryptor compact is based on 
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the same reagent system, but would be smaller, less costly, and easier to maintain.  Data for 
the Kryptor classic (trialled for LRTIs but not used routinely) can inform the headroom of the 
compact version, assuming that the barriers to uptake for Kryptor classic may be overcome by 
its compact version. 
Table 7.14 Summary of headroom analysis and follow-up for KRYPTOR compact 
Key 
characteristics: 
Clinical area Lower respiratory tract infection (LRTI) 
Technology type In Vitro Diagnostic (Equipment) 
Relationship with current 
practice/ comparator 
New Indication 




Time perspective taken 2005 
Market size (per year) 1.7 million 
Service cost impact* £0.83 [saving if £2 per antibiotic course: First line 
treatment of a patient presenting with LRTI] 
£4.16 [saving if £10 per antibiotic course] 
£8.32 [saving if £20 per antibiotic course] 
£20.80 [saving if £50 per antibiotic course] 
£41.60 [saving if £100 per antibiotic course] 
£62.40 [saving if £150 per antibiotic course: Approximate 
cost of a course of antibiotics for hospitalised pneumonia 
patients] 
QoL Impact - 
Headroom (per patient) £0.83 - £62.40 
Important extra considerations  A reduction in antibiotics resistance is an important 
world-wide goal, for which more appropriate 
prescribing is key. 
 One very important question is: Why is the original 
Kryptor assay not used in routine clinical practice? Is 
it anything to do with issues that the new model 
would address / change (supposedly cheaper, smaller, 
and easier to maintain)? 
 Does the Kryptor compact represent a simple product 
evolution that should happen regardless, in order to 
keep products up-to-date? 
 What other clinical areas would a PCT test be useful 
for? 
Allowable development costs 
calculated? 
- 
Time taken for headroom  11 hours 
Follow-up: 
Would the headroom analysis 
have indicated a favourable 
development decision? 
Headroom is likely to have indicated a favourable 
development decision, but with the knowledge that the 
market is likely to be limited to serious LRTI patients in a 
hospital setting, and not as part of routine clinical practice 
for all LRTI patients. 
Is the device used in the UK 
or the rest of the world? 
Yes (though I am unsure about the extent to which it is 
available on the NHS for LRTI). 





Antibiotics prescription in LRTI patients can be reduced by 40% when guided by PCT levels, 
and its cost cut by 52% (from shorter treatment duration resulting from better targeting) 
(Christ-Crain et al. 2004).  Table 7.14 presents the headroom according to various antibiotics 
prices (as these vary greatly across settings), and ranges from £0.83 to £62.40.  
Follow-up 
The reimbursement opportunity varied greatly according to treatment setting, fetching a 
higher price in settings with higher antibiotics costs (e.g. the hospital).  The actual Kryptor 
cost (per tested patient) is £30.  This indicates that headroom would only have appeared 
favourable for patients prescribed antibiotics costing £70 or above.  This would be feasible in 
a secondary care setting, but not in primary care.  NICE (which has not reviewed this device) 
now recommends limiting antibiotic prescriptions for LRTIs in primary care (NICE 2008a).  
Results of clinical and cost-effectiveness studies confirm the headroom results: blood tests are 
viable only when the infection is severe.  The Brahms product range is vast, and the Kryptor 
compact is directed at many different clinical areas.  Brahms holds licensing agreements with 
other companies, to provide the PCT assay compatible with various systems. 
Main lessons learnt 
The ‗baseline‘ for reimbursement value was ‗no test‘, but for the development decision the 
baseline was a previous model, implying lower development costs and lower risks.  Such an 
evolution may in any case be natural.  Additionally, for a diagnostic test whose applications 
are wide, basing headroom on just one seems spurious in the context of a development 
decision.  Furthermore, the headroom method cannot value the worth of additional features 
such as ease of use or size, other than to propose that these may encourage uptake. 
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7.4.11  Aquadex FlexFlow — CHF Solutions 
Description 
A sufferer of congestive heart failure may readily decompensate, a state in which the heart 
fails to maintain adequate blood circulation.  Acute decompensated heart failure (ADHF) is a 
common cause of respiratory distress, and can cause excess fluid accumulation in the blood.  
Fluid overload in ADHF is principally managed with diuretics, but there are limited options 
for diuretic-resistant patients.  Ultrafiltration with Aquadex FlexFlow is suggested for 
refractory patients with severe fluid overload.  It is a portable trolley-based device which 
removes excess water and salt from a patient‘s circulation, can be performed in a hospital 
ward or outpatient department, and uses lower blood flow rates than conventional 
ultrafiltration (which must be performed in intensive care units). Conventional ultrafiltration 
has existed for many years, but is not an established component of clinical practice. 
Table 7.15 Summary of headroom analysis and follow-up for Aquadex FlexFlow 
Key 
characteristics: 
Clinical area Acute decompensated heart failure 
Technology type Device (Equipment). Class IIb 
Relationship with current 
practice/ comparator 
Incremental Development / Addition 




Time perspective taken 2004 
Market size (per year) 60,000 
Service cost impact* £1,786 per patient [saving] 
(plus) £2,930 per readmission avoided [saving] 
QoL Impact* 0.0022 QALYs  per readmission avoided 
Headroom (per patient) A selection or combination of the estimates provided 
above.  For patients who would currently experience 
(one) readmission, headroom could be as much as 
£3,284 if Aquadex can reduce these by half. 
Important extra considerations  The suggested barriers to adoption of conventional 
ultrafiltration have been:  
1) It must be delivered in an ICU (expensive); 
2) Cardiologists are accustomed to considering 
pharmacological rather than mechanical means 
of treatment for their patients. 
Whilst Aquadex could overcome the first barrier, it is 
difficult to know whether it would overcome the second. 
 How many refractory patients are there? Some 
reviews do not indicate that an alternative to 
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currently available drug therapy is required.  
 As (conventional) ultrafiltration has been around for 
many years, and is similar to other filtration systems 
(e.g. haemodialysis technology), cheaper alternatives 
may pose a threat to the Aquadex. 
Allowable development costs 
calculated? 
- 
Time taken for headroom  14.5 hours 
Follow-up: 
Would the headroom analysis 
have indicated a favourable 
development decision? 
The headroom figures may have indicated a favourable 
development decision, but should have been considered 
alongside the ‗development and research questions‘, 
which highlighted potential barriers to uptake. 
Is the device used in the UK 
or the rest of the world? 
Ultrafiltration still does not seem to be part of mainstay 
clinical practice for ADHF patients, but its use (and the 
use of Aquadex specifically) is rising. There is evidence 
of a UK user base. 
*Average per person treated 
 
Headroom analysis 
The appropriate comparator is difficult to ascertain (pharmacological therapy to which the 
patient does not respond, or conventional ultrafiltration), but the literature suggests that a 
reduction in ICU stay of two days—to be spent in the coronary ward instead—may be 
appropriate for both comparators (cost saving: £1,786).  There would be a saving of £2,930 
per readmission avoided.  The QALY impact of one hospital admission is estimated to be 
0.0022 (derived from a combination and manipulation of various literature sources).  
Readmission rates are unclear so presented separately.  The cost of provision must be 
considered within the headroom presented. 
Follow-up 
The Aquadex FlexFlow system costs £12,000; consumables cost £600 per session.  As the 
distribution factors are unknown, the system cost cannot be amortised per patient.  However, 
even if one system is used for twelve patients and lasts just one year, the estimated headroom 
for treating refractory patients outweighs the transpiring cost of the system (ignoring 
readmission savings, and before considering staff time), indicating a favourable development 
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decision from the headroom analysis.   The main clinical trial for Aquadex reports a reduced 
LOS and reduced rehospitalisation (18% vs. 32%) (Costanzo et al. 2007).  Some cost-
effectiveness analyses indicate that HRQoL benefit may have been underestimated in the 
headroom analysis.  Aquadex FlexFlow is available in many countries (including the UK), 
and is indicated for fluid overload associated with ADHF, kidneys, lungs, burns and trauma.  
Ultrafiltration is still not mentioned within UK clinical guidelines for ADHF, but is supported 
by US, Canadian, and European guidelines. 
Main lessons learnt 
Due to so many unknowns, the analysis was speculative and difficult to interpret, though it 
did identify cost and QALY estimations which could have been manipulated according to the 
expectations of the developer.  The threats identified in the research questions have transpired 
to be pertinent, especially in relation to the cheaper alternatives to Aquadex, which are very 
cost-effective.  This analysis was time-intensive due to the scarcity of relevant information in 
the literature. 
 
7.4.12  E-medICS — QinetiQ 
Description 
The Electronic Medical Integrated Care System (e-medICS) would provide online decision 
support for paramedics at the scene of emergencies.  A touch-screen panel PC with voice-
enabled commands provides diagnostic aids and treatment protocols across the spectrum of 
acute medical emergencies.  It could also act as an electronic report form (ePRF), in which a 
patient‘s vital signs and digital images can be recorded and relayed to the A&E department 
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before arrival.  This would be the first system to combine: decision support for paramedics, 
better and more advanced warning for A&E, and also supporting the national movement 
toward electronic patient records.  
Table 7.16 Summary of headroom analysis and follow-up for E-medICS  
Key 
characteristics: 
Clinical area Pre-hospital care 
Technology type Device. Class I 
Relationship with current 
practice/ comparator 
Addition 




Time perspective taken 1999 
Market size (per year) 2,900 ambulances 
1 million patients per year 
Service cost impact* [P1≈ £2,230 per patient (current average cost of pre-
hospital care).  Service cost of implementing e-medICS 
must be considered in addition to this.] 
QoL Impact - 
Headroom/MRP - 
Important extra considerations  Extra time at the scene incidents may adversely 
affect outcomes.  One study compares the outcome of 
patients attended by emergency medical technicians 
or (more qualified) paramedics, finding that for those 
attended by paramedics, the mortality rate was 
higher. This was thought to relate to the increased 
length of time at the scene in the paramedics group, 
and may be indicative of the impact that e-medICS 
would have.  
 This product belongs to the highly dynamic and fast-
moving technology sector, where competition is high 
and development will need to be continual.   
 The success of e-medICS will rely most crucially on 
its acceptance by ambulance staff, and whether they 
consider it a help or a hindrance. This must be 
explored as soon as possible.  
 E-medICS would also require the backing of the 
hospitals‘ A&E departments, which may require 
some reorganisation to be receptive to incoming 
information and images from the ambulance service. 
 The up-front cost of installing e-medICS across the 
system would be large. 
Allowable development costs 
calculated? 
- 
Time taken for headroom  10 hours 
Follow-up: 
Would the headroom analysis 
have indicated a favourable 
development decision? 
Unclear- many barriers identified. 
Is the device used in the UK 
or the rest of the world? 
No evidence of the product‘s existence found for the past 
ten years. 





The value proposition of e-medICS is the provision of more appropriate initial management 
for emergency patients.  To quantify its effect, it is necessary to understand the deficiencies of 
current practice.  Studies that consider the health outcome effects of staff training for 
ambulance staff (specifically for cardio-pulmonary arrest and trauma patients) find either 
moderately beneficial or insignificant results, but results vary according to the study, and 
cannot be generalised.  Whilst no headroom value is delivered, the bulk of the analysis is 
conveyed in sections six and seven of the pro forma (summarised briefly in Table 7.16), 
which raises many clinical, economic and practical questions that should be considered.  
Follow-up 
Significant culture and change management issues were reported after a brief trial by the 
Surrey ambulance service of E-medICS.  Post-dating the early 2000s I identified no mention 
of e-medICS, which is no longer on QinetiQ‘s website.  Whilst the main barrier for e-medICS 
is (as anticipated) a culture one, an unpredictable context factor has been the dismantling of 
the NHS IT programme. 
Main lessons learnt 
Quantification of headroom was inhibited by the huge scope of incidents attended by 
ambulances.  Instead, relevant developments in the clinical landscape were identified.  Where 
users are highly and intrinsically involved in device effectiveness, these users must back the 
concept for it to be feasible practically.  Although many questions raised by the analysis 
transpired to be fundamental for its case, whether it would have added anything unique to 
QinetiQ‘s development considerations is difficult to know.  
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7.4.13  HeartSmart — HeartSmart Ltd. 
Description 
Due to the strain placed on a patient‘s heart when undergoing major surgery or in intensive 
care, cardiac output (volume of blood pumped by the heart in one minute) must be monitored.  
HeartSmart is a piece of software encoded with algorithms defining the relationships between 
all key blood flow variables (which can be measured by pre-existing hospital equipment), the 
results of which could help optimise blood flow and fluid management.  Currently, the 
reference standard for cardiac monitoring is pulmonary artery catheter thermodilution 
(PACTD).  The literature for PACTD paints a mixed picture, at best indicating significantly 
reduced morbidity, and at worst demonstrating increased mortality, morbidity, and LOS.  The 
headroom analysis considers HeartSmart to be of equal effectiveness as PACTD in its 
capacity to monitor cardiac output, and presents two scenarios: (1) Patient outcome and 
hospitalisation costs are equivalent, so only the procedural cost of PACTD is saved, and (2) 
the negative impact of PACTD on patient outcome (mortality) and hospitalisation costs (LOS) 
may be avoided by using HeartSmart.  
Table 7.17 Summary of headroom analysis and follow-up for HeartSmart 
Key 
characteristics: 
Clinical area Cardiac monitoring 
Technology type Diagnostic Device. [Class IIa] 
Relationship with current 
practice/ comparator 
Replacement 




Time perspective taken 2004 
Market size (per year) 200,000 
Service cost impact* Scenario 1 & CVC
40
 used with PACTD: £145 [saving] 
Scenario 1& additional expenditure on CVC required: 
£118 [saving] 
Scenario 2 & CVC used with PACTD: £12,256 [saving] 
Scenario 2&additional expenditure on CVC required: 
£12,229 [saving] 
                                                 
40
 A central venous catheter (CVC) is required to provide an input measurement for the HeartSmart.  It was not 
clear from the literature whether PACTD already involves a CVC, and so whether this was included in its cost.  
Therefore, headroom is presented for both contingencies.  
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QoL Impact* Scenario 1: 0 





Least Optimistic (scenario 1, added CVC 
required):£118 
Most optimistic (scenario 2, CVC already used 
alongside PACTD): £14,456 - £15,556 ** 
Important extra considerations  HeartSmart would require no investment in capital 
costs, consumables, and no maintenance 
requirements. 
 There are a great number of options for cardiac 
monitoring, and more on the horizon.  HeartSmart 
would be competing against all of these options 
rather than PACTD alone.  A change in baseline 
comparator would have a dramatic effect on the 
perceived headroom, especially non-invasive options.  
 Are the risks associated with CVCs prohibitive to 
their future use? 
 How does the output of HeartSmart relate to the use 
of CVC alone? 
Allowable development costs 
calculated? 
The maximum development costs indicated by the 
headroom analysis seem large for the HeartSmart 
software (£3 million to 23 million if the maximum price 
were charged per patient usage) 
Time taken for headroom  13.5 hours 
Follow-up: 
Would the headroom analysis 
have indicated a favourable 
development decision? 
Headroom indicative of a favourable development 
decision. 
Is the device used in the UK 
or the rest of the world? 
HeartSmart is available in the UK, and used by some 
centres. 
*Average per person treated 
**Depending on a WTP by the health service of £20,000-£30,000 per QALY 
 
Headroom analysis 
For scenario two, the saved cost of PACTD (£145) is added to by the (evaded) LOS costs 
attributable to PACTD.  One study finds PACTD to be associated with a two-fold increase in 
mortality.  The average age of the relevant HeartSmart population is around 60, the life 
expectancy of whom (22 years) I halve to reflect underlying illness, and weight according to 
the average HRQoL of this age group (0.78).  This is then discounted and multiplied by the 
potential reduced mortality rate.   Headroom ranged from £118 to £15,556 per patient.   
 
                                                 
41
 It is unclear how this product would be priced, and whether this would be on a per patient or per package 




The wide range of headroom estimates reflects the divergent literature base.  Set-up and 
installation of HeartSmart costs £400, and £10-£15 per HeartSmart measurement (three to 
four measurements are required per patient); headroom would have indicated plenty of room 
for development.  Current literature indicates that scenario one is the more appropriate.  
PACTD is still the reference standard, though alternative methods are increasingly employed.  
HeartSmart is available in the UK, and used by various isolated centres.  The reasons for only 
partial uptake may be the availability of effective alternatives, and the required insertion of a 
CVC, both of which were identified during the analysis. 
Main lessons learnt 
Where evidence from the literature is so inconsistent, it is not possible to produce a definitive 
estimate of the monetary opportunity.  Although the headroom was clearly large, this example 
was time-intensive, mainly reflecting my desire to quantify the analysis.  This quantification 
may not have been essential for the development decision.   
 
7.4.14  CT Angiography — [various developers] 
Description 
Angiography describes a medical imaging technique used to diagnose coronary artery disease 
(CAD) and guide treatment.  The reference standard is invasive coronary angiography (ICA), 
which involves coronary catheterisation.  Multi-detector CT angiography (MDCTA) could 
offer a non-invasive and lower risk alternative to ICA, and represents the newest potential 
development in CT scanners.  The headroom analysis investigates whether the potential 
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reimbursement opportunity would be sufficient to cover the investment required to make a CT 
scanner good enough to replace ICA for first-line investigation of CAD.  Where severe 
occlusion (requiring revascularisation) is indicated—in about half of patients—MDCTA 
would need to be followed by ICA to guide treatment.  Therefore, I assume that half of all 
ICAs may be avoided. 
Table 7.18 Summary of headroom analysis and follow-up for CT Angiography 
Key 
characteristics: 
Clinical area Coronary Artery Disease 
Technology type Diagnostic (Equipment) 
Relationship with current 
practice/ comparator 
Replacement 




Time perspective taken 2003 
Market size (per year) - 
Service cost impact* £710 [saving] 
QoL Impact - 
Headroom (per patient) £710 
Important extra considerations  MDCTA involves high-dose radiation. 
 Omitted from the analysis is the benefit (QoL and 
reduced risk) associated with avoiding half of all 
ICAs, which are invasive by nature. 
 Where angiography indicates that revascularisation is 
required, this can be performed in the same sitting in 
cases where disease staging was performed by ICA, 
thus reducing overall costs.  This may indicate an 
overestimation of potential savings.  
 There are many non-invasive angiography techniques 
in development. 
 Sensitivity and specificity has been ignored. 
 More modest costs of ICA exist in the literature, 
which would reduce headroom dramatically. 
Allowable development costs 
calculated? 
- 
Time taken for headroom  9 hours 
Follow-up: 
Would the headroom analysis 
have indicated a favourable 
development decision? 
Headroom analysis indicative of a favourable 
development decision. 
Is the device used in the UK 
or the rest of the world? 
Yes, but the models have already been updated to ‗new 
generation‘ CT scanners. 







The impact on service costs of avoiding half of all ICA procedures (cost: £1,419) would be 
£710 per patient.  Consideration of an MRP per unit (rather than patient) would require a 
patient throughput estimation, as well as the service cost of provision (e.g. hospitalisation, 
labour costs, etc).  
Follow-up 
An MDCTA scanner costs around £600,000 to £1.2 million.  If a scanner lasted five years, 
this would require an expected patient throughput of 170 to 340 patients per year for 
headroom to look attractive, just to cover equipment costs.  One systematic review (Mowatt et 
al. 2008) indicates a cost per MDCTA session of £206, falling well short of estimated 
headroom (£710), possibly indicating favourable development prospects. Most clinical studies 
find MDCTA to be an effective ‗rule-out‘ strategy, and estimates of avoided ICAs range from 
none to 86%.  NICE recommends MDCTA as an option for patients with a low risk of CAD.  
The scanners considered are already out of date; ‗new generation‘ CT scanners (quicker, more 
accurate, and with less radiation) are updates of the previous MDCTA models, and now 
provide first-line imaging for a subset of CAD patients (and are also used outside of CAD). 
Main lessons learnt 
This analysis considered the reimbursement opportunity for further developing an existing 
technology.  Encouragingly, a large UK-based HTA for MDCTA utilised the same evidence 
sources as those used in this quick, date-restricted headroom analysis.  Most of the issues or 
uncertainties expressed in the research questions transpired to be important, and when 
considered alongside headroom, offered a good assessment of market opportunity.  This case 
exemplified the fast-moving nature of the medical device industry. 
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7.4.15  Stapled Haemorrhoidectomy — Ethicon Endosurgery (J&J) 
Description 
Haemorrhoids are swollen blood vessels in or around the anus which can cause itching, 
mucus discharge, pain and bleeding.  Third and fourth degree haemorrhoids involve prolapse, 
and may be indicated for surgical removal; the Milligan-Morgan technique is the most 
commonly employed method of surgical haemorrhoidectomy.  Stapled haemorrhoidectomy is 
a less painful and less invasive alternative, during which an intraluminal circular stapling 
device is introduced into the anal canal, the staples applied, and the redundant tissue removed. 
Table 7.19 Summary of headroom analysis and follow-up for Stapled Haemorrhoidectomy 
Key 
characteristics: 
Clinical area Haemorrhoids 
Technology type Device. Class IIb 
Relationship with current 
practice/ comparator 
Replacement 




Time perspective taken 1995 
Market size (per year) 10,300 
Service cost impact* Scenario one (baseline estimate): £540 [saving] 
Scenario two (testing the effect of improvement in current 
practice): £300 [saving] 
QoL Impact* 0.00912 QALYs 
MRP Base-case estimate: £772 - £814 ** 
[Improvement in current practice]: £482 - £574 ** 
Important extra considerations  Is it feasible for all stapled haemorrhoidectomy 
procedures to be undertaken as day cases?  
 Might stapled haemorrhoidectomy be associated with 
a greater recurrence rate than surgery? 
 Cost of pain management in primary care may be 
reduced following stapled haemorrhoidectomy 
compared with conventional surgical removal. This 
cost-saving potential is overlooked here. 
Allowable development costs 
calculated? 
For a variable cost of stapled haemorrhoidectomy of £0 to 
£100, maximum development costs range from around 
£7.4 million to £8.4 million (MRP: £814), or from £4 
million to £5 million for an MRP of £482 (which assumes 
further improvements in current practice) 
Time taken for headroom  7.5 hours 
Follow-up: 
Would the headroom analysis 
have indicated a favourable 
development decision? 
MRP appears sufficient to have inspired a favourable 
development decision. 
Is the device used in the UK 
or the rest of the world? 
Stapled haemorrhoidectomy has been recommended by 
NICE, and is available across the world (but has not 
replaced conventional haemorrhoidectomy entirely). 
*Average per person treated 
**Depending on a WTP by the health service of £20,000-£30,000 per QALY 
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  Headroom analysis 
Conventional haemorrhoidectomy usually involves three days in hospital; by reducing pain 
and shortening recovery time, stapled haemorrhoidectomy could be carried out as a day-case 
procedure.  Two scenarios are presented.  Scenario one reflects today‘s (1995) state of affairs: 
10% of conventional haemorrhoidectomies are undertaken as day cases (i.e. stapled 
haemorrhoidectomy would reduce LOS by two days in 90% of cases, at a cost saving of £300 
per day).  Scenario two incorporates the possibility of future improvements in current 
practice, for which 50% of conventional haemorrhoidectomies are day cases.  QALY impact 
is estimated to be the value of two fewer weeks in a health state involving ‗some problems 
performing usual activities‘ and ‗moderate pain or discomfort‘: 0.00912 QALYs per person.  
Assuming variable costs of production are £100 or less, the maximum allowable development 
costs would be £7.4 million in the base-case (assuming full market coverage). 
Follow-up 
The price per procedure of stapled haemorrhoidectomy is £256 according to the NHSC, or 
£420 according to a NICE technology appraisal; the headroom analysis would have indicated 
ample room for development.  NICE now recommends stapled haemorrhoidectomy using 
Ethicon‘s stapling device, considering it to be both clinically and cost-effective (NICE 
2003;NICE 2007).  Trial results indicate that early assumptions were correct—stapled 
haemorrhoidectomy involves less pain and shorter hospital stay—though the risk of prolapse 
is greater.  The model submitted to NICE by manufacturers estimates an additional 0.009 
QALYs from stapled haemorrhoidectomy (elicited directly from patients), incredibly close to 
that estimated in the headroom analysis; NICE deemed this estimate to be plausible.  The two 
factors that hinder cost-effectiveness were both raised as potential issues in sections six and 
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seven of the pro forma (not all are carried out as day cases, and subsequent prolapse and re-
intervention is increased). 
Main lessons learnt 
This example demonstrated that early estimates can offer useful predictions.  Where HRQoL 
information is not supplied by the literature, a simple manipulation of the EQ-5D value sets 
can usefully estimate health impact, in this case leading to an exact match (though the 
influencing factors differed, so this could be considered a fluke).  The follow-up also revealed 
the flexibility of NICE‘s decision-making approach.  Although NICE‘s base-case economic 
evaluation found stapled haemorrhoidectomy to be dominated, consideration of other factors 
(such as patient/clinician preference and potential for primary care savings) influenced their 
decision. 
 
 7.4.16  Transpupillary Thermotherapy — Iridex 
Description 
Age-related macular degeneration (AMD) is a significant cause of blindness, and can be of 
dry or wet-form.  Wet-form AMD, also called choroidal neovascularisation (CNV), is where 
new blood vessels grow beneath the retina which can leak and bleed, eventually forming a 
scar which causes a blind spot in a person‘s central vision.  CNV can be classic (well defined 
stalk of vessels and localised leak) or occult.  Conventional photocoagulation is standard 
practice for CNV, which uses an intense light beam to burn the blood vessels and seal the 
leak, but is not indicated for patients with occult CNV (who currently have no treatment 
options and who represent around 88% of all CNV patients).  Transpupillary thermotherapy 
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(TTT) uses a low intensity infrared laser beam with a large spot slit lamp adaptor to heat the 
problematic blood vessels, and aims to preserve central vision.  It would offer a treatment 
option for all CNV patients (classic or occult). 
Table 7.20 Summary of headroom analysis and follow-up for TTT 
Key 
characteristics: 
Clinical area Age-related macular degeneration 
Technology type Device (Equipment). Class IIb 
Relationship with current 
practice/ comparator 
New Indication 




Time perspective taken 2000 
Market size (per year) 217,000 
Service cost impact* £207 [additional cost incurred] 
QoL Impact* 0.186 QALYs 
Headroom (per patient) £3,513 - £5,373 ** 
Important extra considerations  A treatment option for the previously un-treatable 
would be well sought after by the health service, 
which may be willing to pay a premium for this. 
 The equipment indicated for TTT is the same as that 
developed by this company (and others) for 
conventional photocoagulation, with a small 
adaption.  This means that there are likely to be many 
competitors if it is found to be useful for occult CNV 
patients, and would probably be cheap to produce. 
 Would more than one treatment session be indicated 
per patient?  Headroom is per patient rather than per 
procedure. 




Time taken for headroom  6.5 hours 
Follow-up: 
Would the headroom analysis 
have indicated a favourable 
development decision? 
Headroom analysis would probably have indicated a 
favourable development decision. 
Is the device used in the UK 
or the rest of the world? 
NICE has not recommended TTT for wet AMD, based on 
deficient clinical efficacy and safety evidence.  The 
procedure is used elsewhere in the world.   
*Average per person treated 
**Depending on a WTP by the health service of £20,000-£30,000 per QALY 
 
Headroom analysis 
The headroom analysis considers the impact of TTT on patients suffering from occult CNV.  
The principal assumption is that TTT will be as useful for occult CNV as conventional 
photocoagulation is for classic CNV.  Given the procedural similarities, resource utilisation 
 196 
 
outside of the treatment session itself (consultation, angiography, follow-up appointments, 
etc.) are assumed to be similar: £207.  As TTT would be indicated for those with no current 
treatment options, these resource costs would represent additional costs to the NHS.  Data for 
QALY gain is elicited directly from a study on the impact of conventional photocoagulation 
(versus the natural course of CNV).  Headroom is presented per patient: £3,513 to £5,373.   
Follow-up 
The cost for the TTT laser and delivery device is £25,000.  Although no cost per patient or 
treatment was identified, headroom is likely to have indicated a favourable development 
decision, given: the cost per patient of photodynamic therapy (which is likely to be more 
expensive), its Medicare reimbursement per procedure (U.S.), and noting the relatively few 
patients that need to be treated to make back equipment costs (as well as the fact it represents 
an incremental development to the company‘s own product).  NICE has not recommended 
TTT, on the basis of safety and efficacy evidence.  TTT is reimbursed for wet AMD in some 
parts of the U.S., and for other specific indications elsewhere.  Treatment options have grown, 
and a drug ranibizumab (injected into the eye) is now recommended for most CNV patients. 
Main lessons learnt 
Unlike replacement or ‗another option‘ devices, this represented an example of treating the 
previously untreatable, meaning service costs would be incurred rather than saved/redirected, 
thus detracting from its cost-effectiveness.  Although this is counter-balanced by the effect 
size (large additional QALYs), it does show that only considering the ‗cost-savers‘—as 
MTAC does—favours new treatment options for those patients that are already addressed by 
current means of management.  The headroom analysis felt somewhat artificial, as the main 
component of the device was already used for other ophthalmic applications.  Given the 
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(presumably) small costs of adapting the laser equipment to TTT, this development would 
probably have been worth pursuing if it had even the remotest chance of working. 
 
7.4.17  Citrasate Dialysate — Advanced Renal Technologies 
Description 
People with chronic or acute renal failure require the assistance of a dialysis machine to 
remove waste products and water from their blood.  A dialysis solution is used within the 
extracorporeal circuit and often contains heparin, an anticoagulant that prevents clotting of the 
circuit, but which is contraindicated in some patients (around 100 patients in the UK).  
Citrasate dialysate is a citric acid concentrate which could be used as part of standard 
bicarbonate dialysis solutions.  It could improve the efficiency of dialysis, and also work as an 
anticoagulant for patients who cannot tolerate heparin.  Where heparin is contraindicated 
currently, measures include periodic line flushes, regional citrate anticoagulation, and 
danaparoid (probably the most relevant comparator). 
Table 7.21 Summary of headroom analysis and follow-up for Citrasate Dialysate 
Key 
characteristics: 
Clinical area Chronic or acute renal failure 
Technology type Device. Class IIb
42
 
Relationship with current 
practice/ comparator 
Incremental Development 




Time perspective taken 1999 
Market size (per year) Scenario 1: 4,500 
Scenario 2: 100 
Service cost impact* Scenario 1(a): £3.00 
Scenario 1(b): £3.50 
Scenario 2: ? (cost of danaparoid)  
QoL Impact* - 
                                                 
42
 There is some confusion in the literature regarding the categorisation of dialysis fluids.  However, within the 
rules set out for the classification of medical devices by the European Commission (European Commission 
2010), ‗haemodialysis concentrates‘ are included under Rule 3: Non-invasive devices that modify biological or 
chemical composition of blood, body liquids, other liquids intended for infusion.  These belong to Class IIb. 
 198 
 
MRP (per patient per session) Scenario 1: £3.00 - £3.50 
Scenario 2: ? (cost of danaparoid) 
Important extra considerations  Other alternatives to heparin are being investigated, 
including low molecular weight heparins which may 
perform better than current anticoagulants, and not be 
contraindicated in patients who currently do not 
tolerate unfractioned heparin.  
Allowable development costs 
calculated? 
- 
Time taken for headroom  6 hours 
Follow-up: 
Would the headroom analysis 
have indicated a favourable 
development decision? 
Prices were difficult to obtain, but overall, headroom is 
likely to have indicated a favourable development 
decision (especially if scenario two was deemed feasible). 
Is the device used in the UK 
or the rest of the world? 
Citrasate dialysate is available globally.  It is not used 
systematically across the NHS, but does seem to be a 
viable treatment option (currently procured by 6 NHS 
hospitals). 
*Average per person treated 
 
Headroom analysis 
Two approaches are described.  Scenario one considers Citrasate simply to substitute current 
acid additives for bicarbonate dialysate fluids (for use in all patients), and is split into two 
approaches: (a) considers Citrasate to be worth the price of current acid additions to 
bicarbonate solutions—£3, and (b) adds to this the value of a potential improvement in 
dialysis efficiency, around £0.50 per session.
43
  Scenario two considers its use exclusively in 
those patients for whom heparin is contraindicated, for which the headroom would be the 
price per session of danaparoid (whose precise cost could not be identified, but is indicated to 
be large).  Citrasate dialysate is unlikely to pose any significant / measurable impact on QoL. 
Follow-up 
Given the very specific nature of this analysis, follow-up was difficult; prices were not readily 
available and the quantity required per session was unclear.  One source indicates a price for 
Citrasate higher than the MRP in scenario 1, whereas the company‘s own website implies a 
                                                 
43
 This is based on an HTA which compares two dialysate fluids (bicarbonate and acectic), one of which 
(bicarbonate solutions) is more efficient and associated with smaller complications costs (MacLeod et al. 1998). 
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much lower price.  Citrasate is almost certainly cheaper than danaparoid.  Citrasate is 
available widely in the U.S. and across the world (though received EU clearing seven years 
after it was available in the U.S.).  The (limited) literature indicates positive results for 
Citrasate in terms of efficiency of dialysis and anticoagulation. 
Main lessons learnt 
The diffusion of this product demonstrates how slow uptake can be.  It offered an example of 
a product with a very specific application, for which prices were difficult to identify.  This 
may have posed less of a problem for the developer. 
 
7.4.18  Tension free vaginal tape (TVT) — Ethicon 
Description 
Stress incontinence is the involuntary loss of urine upon physical exertion.  After conservative 
treatments in women have failed, the bladder neck is repositioned in a surgical procedure 
called Burch colposuspension.  Tension free vaginal tape (TVT) would be a less invasive and 
quicker alternative to colposuspension, involving a mesh tape being attached under the urethra 
via the vaginal wall like a sling.  This minimally invasive technique, which will be assumed to 
achieve the same long-term outcomes as surgery, is likely to lower the threshold for 
intervention.  Therefore the headroom analysis considers two groups: those for whom TVT 
directly replaces colposuspension (‗group 1‘-around 4,000 per year in England), and a wider 
group that includes patients who are currently treated conservatively (‗group 2‘-potentially up 




Table 7.22 Summary of headroom analysis and follow-up for TVT 
Key 
characteristics: 
Clinical area Stress incontinence in women  
Technology type Device. Class IIb 
Relationship with current 
practice/ comparator 
Replacement 




Time perspective taken 1996 
Market size (per year) Group 1:4,000 
Group 2: 100,000 (96,000 when considering only those 
                that currently do not undergo surgery) 
Service cost impact* Group 1: £2,700 [saving] 
Group 2: £66 [saving] 
QoL Impact* Group 1: - 
Group 2: 0.1 to 0.2 QALYs 
Headroom (per procedure) Group 1: £2,700 
Group 2: £4,066 - £6,066 ** or  £2,066 - £3,066** 
Important extra considerations  QoL impact of TVT versus colposuspension was 
ignored, but may be important for patients and their 
clinicians.   
 Less invasive methods of colposuspension are 
beginning to emerge, which could change the 
relevant comparator for TVT. 
 Success rate for TVT in those previously managed 
conservatively has been implicitly assumed to be 
100%.  This may not be appropriate. 
 Full recovery of HRQoL may not be an appropriate 
baseline for health outcome estimations. 
Allowable development costs 
calculated? 
- 
Time taken for headroom  10 hours 
Follow-up: 
Would the headroom analysis 
have indicated a favourable 
development decision? 
Favourable development decision 
Is the device used in the UK 
or the rest of the world? 
TVT is now widely considered to be the gold standard in 
surgical management of stress incontinence. 
*Average per person treated 
**Depending on a WTP by the health service of £20,000-£30,000 per QALY 
 
Headroom analysis 
The main cost-saving potential of TVT versus colposuspension is in hospital costs (shorter 
operation time and reduced LOS—six hours as opposed to three days).  Due to the limited 
data predating 1996 on hospital service costs (to estimate the procedural cost of TVT and 
thereby net this from headroom), service cost impact is simply presented as the cost of 
colposuspension for group one (£2,700) and the average cost of conservative treatment for 
 201 
 
group 2 (£66).  There is assumed to be no HRQoL impact for group 1, and a HRQoL gain of 
between 0.1 and 0.2 QALYs for group 2 (who used to receive conservative management).  
This was estimated by manipulation of the relevant EQ-5D health state parameters—a one 
year timeframe is taken.  Headroom (which must include the procedural and hospital costs of 
TVT) is £2,700 for group one, and between £2,066 and £6,066 for group two, depending on 
the developer‘s beliefs of potential effectiveness. 
Follow-up 
Total TVT procedure costs fall below headroom estimates, indicating that these may have 
appeared viable for development.  TVT is used widely within the NHS and has been 
recommended by NICE; it now replaces colposuspension as the gold standard surgical 
intervention for stress urinary incontinence.  The procedure has been found to be cost-
effective, and has increased the number of patients undergoing surgical intervention (but not 
to the extent proposed in the headroom analysis).  Ethicon have expanded their portfolio of 
products, now selling five variations of TVT. 
Main lessons learnt 
When considering the potential impact of TVT versus colposuspension on hospital stay, then 
this alone presents a clear case for TVT development (without spending 10 hours identifying 
numbers).  QALY implications were overestimated using the EQ-5D parameter manipulation 
approach.  Although the estimated HRQoL for incontinent women of 0.8 was identical to that 
identified in a later study used by NICE (Cody et al. 2003), the return to a baseline of full 
health was misjudged.  The case study demonstrates that companies are always developing 
new versions of their own products, in order to stay dominant in the market. 
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7.4.19  Penile cuff test, CT3000 — MediPlus Ltd. 
Description 
Lower Urinary Tract Symptoms (LUTS) in men include problems with both storing and 
voiding urine; the decision to intervene surgically (by means of a prostatectomy) is dependent 
on symptom severity and responsiveness to conservative treatment.  The CT3000 penile cuff 
test offers a non-invasive pressure flow analysis, which could indicate the appropriateness of 
prostatectomy.  The current ‗gold standard‘ diagnostic test is an invasive urodynamic study, 
which is costly and requires urinary catheterisation and a rectal manometer.  The best non-
invasive method is peak urinary flow rates, but these cannot distinguish between obstruction 
(which would indicate prostatectomy) and bladder muscle weakness.  Misclassification is a 
common reason for prostatectomy failure; around a third of men who currently undergo 
prostatectomy do not benefit from the procedure.  I assume that the provision of this extra 
diagnostic test for urologists (to be used as an option/as well as/instead of current bladder 
function tests) would increase the overall success rate of prostatectomy from 70% to 90% by 
improved targeting. 
Table 7.23 Summary of headroom analysis and follow-up for Penile cuff test, CT3000 
Key 
characteristics: 
Clinical area Lower Urinary Tract Symptoms (LUTS) 
Technology type Diagnostic device (Equipment) 
Relationship with current 
practice/ comparator 
Another Option 




Time perspective taken 2002 
Market size (per year) 550 [number of units required to cover all relevant 
patients] 
Service cost impact £10,000,500 [saving: total per year] 
£18,183 [saving: per unit per year] 
QoL Impact - 
Headroom (per unit per year) £18,183 
Important extra considerations  In order to keep the analysis simple, I have not 
considered the costs that could be saved from a 
potential reduction in other urodynamic 
investigations (average cost: £114), or quantified the 
extra costs required to provide the CT3000 test (15 
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minutes preparation/operation time by a junior 
technician, and 5 minutes per day from a senior 
technician for calibration).  
 Although the avoidance of undergoing invasive 
surgery would be important for patients, the value of 
this has not been incorporated into headroom. 
Allowable development costs 
calculated? 
- 
Time taken for headroom  5 hours  
Follow-up: 
Would the headroom analysis 
have indicated a favourable 
development decision? 
Headroom is larger than actual prices, indicating that the 
analysis would probably have presented a sufficient 
reimbursement opportunity at the early stages. 
Is the device used in the UK 
or the rest of the world? 




6,667 prostatectomy procedures could be avoided per year in England and Wales by better 
targeting of the procedure.  This would generate a saving of £10,000,500 in total; if 550 units 
are required to test all relevant patients, each unit would be associated with £18,183 of cost 
savings per year.  Whilst not impacting long term outcomes, short term QoL benefits are 
likely to arise from avoiding the disutility associated with (unnecessary) invasive 
prostatectomy; this is not quantified in this analysis. 
Follow-up 
Given the actual equipment (£11,000) and consumables (£5.50 per test) costs associated with 
the CT3000, the headroom surpasses these (in the first year alone), indicating that the 
development opportunity is likely to have appeared favourable based on this analysis.  The 
CT3000 is used in various NHS trusts (at least six across England), and also in Spain, 
Switzerland and the U.S.  The centre for evidence-based purchasing (CEP) provide a 
favourable report on the CT3000 (CEP 2007).  The assumptions made in the headroom 
analysis appear viable; a clinical study (Harding et al. 2007) has shown a prostatectomy 
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success rate of 87% following targeting with the CT3000, and the company confirm that it is 
to be used as an adjunct rather than a replacement of current methods of diagnosis. 
Main lessons learnt 
Despite being a piece of equipment, a headroom per device was achievable as an estimate of 
the number needed to service all relevant patients was provided in the NHSC documentation.  
Although longevity was unknown, this offered a better idea of value per device for this piece 
of equipment.  It also offered another example of sufficient headroom being identified in its 
cost-saving potential, limiting the need to quantify HRQoL impact.  
 
7.4.20  PFO Closure — NMT Medical / St.Jude Medical 
Description 
Patients who suffer from migraine with aura experience painful migraine episodes that are 
accompanied by visual and other neurological disturbances (light flashes, clouded vision, pins 
and needles, hearing, vertigo, etc).   
In the womb, babies have a small opening between the right and left atria of the heart, 
allowing blood to bypass the lungs; this hole usually closes soon after birth.  A person has a 
patent foramen ovale (PFO) when this hole remains patent throughout life, which is 
reasonably common and usually causes no problems, but is a well-established risk factor for 
ischaemic stroke.  PFO closure (which has already been used for stroke patients), may also be 
useful for people who suffer from refractory migraine with aura.  An umbrella-like closure 
device is placed to seal the PFO, which may reduce the frequency and impact of migraine 
attacks.   
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Table 7.24 Summary of headroom analysis and follow-up for PFO Closure 
Key 
characteristics: 
Clinical area Migraine 
Technology type Device. Class III 
Relationship with current 
practice/ comparator 
New indication 
Relationship with current 
company portfolio 
Device already developed, for other indications.  The 
headroom method is being applied to explore its value in 
this market, in order to inform the decision of whether to 
invest in the research required to prove its clinical merit 
for migraine. 
Analysis: 
Time perspective taken 2005 
Market size (per year) - 
Service cost impact* Time horizon- 1 year: £843 [cost incurred] 
Time horizon- 5 years: £391 [cost incurred] 
Time horizon- 10 years: £93 [saving] 
Time horizon- 20 years: £843 [saving] 
QoL Impact* Time horizon- 1 year: 0.021 QALYs 
Time horizon- 5 years: 0.0981 QALYs 
Time horizon- 10 years: 0.1808 QALYs 
Time horizon- 20 years: 0.3089 QALYs 
MRP Time horizon- 1 year: -£423 to -£213 ** 
Time horizon- 5 years: £1,571 to £2,552 ** 
Time horizon- 10 years: £3,709 to £5,517 ** 
Time horizon- 20 years: £7,021 to £10,110 ** 
Important extra considerations  An association between PFO and migraine has been 
identified, but whether there is a causal link remains 
to be proven.  This will be critical. 
 PFO closure devices have been found to be 
efficacious at sealing PFO for stroke patients.  
However, there has been no conclusive evidence to 
show that this has reduced the risk of stroke (and 
therefore is not recommended in a NICE IPG). 
 The effect of migraine on productivity is large, which 
has a big knock-on effect for the whole economy.  
These indirect costs are between ten and fifty times 
those incurred directly by the health service.   
 The process and cost that would be associated with 
PFO investigation has gone unmentioned.  As it is 
likely that only around half migraine with aura 
patients may have PFO, investigative screening and 
its associated cost should be considered. 
Allowable development costs 
calculated? 
- 
Time taken for headroom  8.5 hours 
Follow-up: 
Would the headroom analysis 
have indicated a favourable 
development decision? 
Uncertain 
Is the device used in the UK 
or the rest of the world? 
PFO closure in migraine patients has not been integrated 
into clinical practice, on the grounds of clinical 
ineffectiveness.  
*Average per person treated 






In this case, headroom is calculated not for a development decision per se, but to ascertain the 
potential value of PFO closure devices in a new clinical area, to observe whether this could 
accommodate the devices‘ price (additionally, targeting this market would require costly 
research to prove effectiveness).  I assume that the relevant migraine with aura patients cost 
the NHS £245 per year, and that this could be halved after PFO closure.  The procedure may 
have similar resource implications as angiography (£1,221), but involve just one hospital bed 
day rather than two (average cost for an excess bed day in this area: £255).  The resultant 
service cost for providing PFO closure would be around £966 (one-off cost).  As a proxy for 
QALY impact, the result of an HTA on acupuncture therapy for migraine is used, which 
generates 0.021 QALYs over a year. Whilst procedural costs are one-off and incurred today, 
savings in treatment costs and impact on HRQoL would accumulate over a patient‘s lifetime.  
MRP is presented for one, five, ten, and twenty year time perspectives, and range from -£423 
(NHS would need to be given money to consider the procedure) to £10,110.   
Follow-up 
In the headroom analysis, the initial investment required to undertake the PFO procedure 
more than outweighed the combined value of health benefit and saved medication costs seen 
in the first year, even before the device price is incorporated.  Given an actual price of around 
£4,000 per PFO closure device, the NHS would need to take at least a ten year time horizon 
before the procedure has a net health economic gain, given the assumptions made in the 
headroom analysis.  The result of headroom in terms of decision to pursue this market is 
uncertain, but it should be noted that the health economic case for the product hinged 
crucially on its proposed health impact (the net cost of the procedure is high), and even with 
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optimistic efficacy assumptions, the decision to pursue this market was unclear.  Important 
caveats were the potential cost of screening, investment required for research, and the 
uncertainty surrounding the relationship between PFO and migraine.  PFO closure seems no 
longer to be indicated for migraine patients, and NICE does not recommend the procedure due 
to insufficient evidence.  NMT Medical undertook the only RCT for PFO in patients with 
migraine, which did not produce favourable results (and was shrouded in controversy and 
expensive libel suits, see Appendix 6 for details); the company has since gone bust.  St. Jude 
Medical began an RCT which has subsequently been abandoned.  As this company has a 
larger product portfolio than NMT medical, this is likely to have been less critical for them. 
Main lessons learnt 
Although PFO closure turned out not to be viable clinically, the case study brought up some 
interesting considerations: (a) the method can be used to investigate the potential of an 
existing product within a new market; (b) the timeframe willing to be considered by the 
reimburser can be critical; (c) interventions for clinical areas in which most costs are born by 
the patient are less likely to appear cost-effective; (d) strategic issues such as the free-riding of 
research might be important; (e) RCTs that involve sham surgery can be difficult and; (f) 
targeting new markets can be risky (but less so for larger companies).  Specific costs and 
prescription guidelines were difficult to identify during the analysis, but this may have been 
easier for the manufacturer.  Although clinical efficacy cannot be predicted with certainty, 
information that is currently available should influence an early judgement.  The interesting 
follow-up for this case study showed that companies are predisposed to bias, and this can 
even extend to misinterpretation and misrepresentation of results in RCTs (whose very design 
should eliminate biases). Given the subjective nature of a headroom analysis, might 
companies always find a favourable case for development?  
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7.5  Headroom Results 
This section presents the principal lessons drawn from the application of the headroom 
method to these 20 case studies.  Firstly, overall characteristics of the technologies and 
headroom results are outlined, and potential relationships between these are explored.  This is 
followed by a list of the main headroom lesson themes, and the strength of support for these 
themes from the data. 
The explanation of potential decision outcome was given for each case study in the 
summary section.  In most cases the decision outcome was not absolutely clear cut, but an 
inclination was presented and explained.  For illustrative purposes, I generally err on the side 
of certainty in this presentation of results (except in two cases where this would have been too 
speculative), describing the headroom decision outcome as favourable, unfavourable, or 
intuitively favourable/unfavourable in cases where no headroom number was generated.  
Evidence of uptake of the technologies is used as a proxy for commercial success.  Three 
levels of uptake are considered: (a) evidence of any uptake within the NHS for the specified 
indication, (b) evidence of widespread uptake within the NHS for the specified indication, and 
(c) evidence of any uptake (globally or for other clinical indications).  It is important to 
reiterate that the favourability or otherwise of the development decision informed by the 
headroom analysis (as summarised in the third column of Table 7.27) is based only on the 
numerical assessment that was generated by the headroom analysis (with the exception of the 
four cases that were made intuitively).  It therefore does not encompass the suggestions or 




Table 7.25 Summary of NHSC case studies: Characteristics 
Characteristics 
    Relationship with   
 Type* Regulatory 
class 
Equipment** Comparator*** Company 
portfolio 
Clinical area NICE 
guidance?**** 
1. FibroTest IVD - - R - Liver disease - 
2. MARS Device IIb Equipment NI - Liver failure IPG 
3. SpeechEasy Device IIa - ID - Stammer - 
4. SLF bypass graft Device IIb - ID - PAD - 
5. Meniett Device IIa - AO - Ménière‘s disease IPG 
6. AmpliChip IVD - - NI - Breast cancer - 
7.Agento I.C. Device IIa - ID - VAP - 
8. Cool-Cap Device IIa Equipment NI - Perinatal asphyxia IPG 
9. ChondroCelect Other: ATMP - - ID - Cartilage defect - 
10. Kryptor compact IVD - Equipment NI ID LRTI - 
11. Aquadex FlexFlow Device IIb Equipment NI/A - ADHF - 
12. E-medICS Diagnostic device I Equipment A - Pre-hospital care - 
13. HeartSmart Diagnostic device [IIa] Equipment R - Cardiac monitoring - 
14. CT angiography Diagnostic device [IIa] Equipment R ID CAD CG 
15. Stapled haemorrhoidectomy Device IIb - R - Haemorrhoids IPG & TA 
16. Transpupillary thermotherapy Device IIb Equipment NI ID AMD IPG 
17. Citrasate dialysate Device IIb - ID - Renal failure - 
18. TVT Device IIb - R - Urinary incontinence CG 
19. Penile cuff test Diagnostic device [I] Equipment AO - LUTS - 
20. PFO closure device Device III - NI Already 
developed 
Migraine IPG 
*In the selection strategy section presented at the beginning of the chapter, medical technologies were either defined as ‗device‘ (labelled ‗Device‘ in this column) or 
‗diagnostic‘ (which includes ‗IVD‘ [in-vitro diagnostic] or ‗diagnostic device‘ in this column).  Whilst diagnostic devices technically belong to the devices category from a 
regulatory perspective, they have been set apart here due to their use for diagnostic purposes, which makes the health economics approach distinct. ATMP is an advanced 
therapy medicinal product.  
**Describes whether the product is a piece of equipment (used for multiple patients) 
***Replacement (R); New indication (NI); Incremental development (ID); Another option (AO); Addition (A). 
****This describes whether (and what type of) NICE guidance was available for follow-up: Interventional Procedures Guidance (IPG); Clinical Guideline (CG); Technology 
appraisal (TA).  
 210 
 
Table 7.26  Summary of NHSC case studies: Analysis 
Analysis 
  Estimate provided?  
 Date perspective Market size ∆ Service costs * ∆QALYs ** Development cost analysis Time taken (hours) 
1. FibroTest 2001 Yes Yes (incomplete) Yes (lit) Yes 6  
2. MARS 1997 Yes No Yes (lit) No 12  
3. SpeechEasy 2005 No No (unnecessary) No (unnecessary) No 6 
4. SLF bypass graft 2006 No No No (unnecessary) No 8.5 
5. Meniett 1999 Yes Yes No Yes 9 
6. AmpliChip 2004 Yes No No No 8.5 
7.Agento I.C. 2005 Yes Yes Yes (lit) Yes 10 
8. Cool-Cap 1997 Yes No (unnecessary) No (unnecessary) No 7.5 
9. ChondroCelect 2006 Yes No (unnecessary) No (unnecessary ) No 8 
10. Kryptor compact 2005 Yes Yes (incomplete) No (unnecessary) No 11 
11. Aquadex FlexFlow 2004 Yes Yes (incomplete) Yes (lit) No 14.5 
12. E-medICS 1999 Yes No No No 10 
13. HeartSmart 2004 Yes Yes Yes (lit) Yes 13.5 
14. CT angiography 2003 No Yes (incomplete) No No 9 
15. Stapled haemorrhoidectomy 1995 Yes Yes Yes (EQ-5D) Yes 7.5 
16. Transpupillary thermotherapy 2000 Yes Yes (incomplete) Yes (lit) No 6.5 
17. Citrasate dialysate 1999 Yes Yes (incomplete) No No 6 
18. TVT 1996 Yes Yes (incomplete) Yes (EQ-5D) No 10 
19. Penile cuff test 2002 Yes Yes (incomplete) No (unnecessary) No 5 
20. PFO closure device 2005 No Yes Yes (lit) No 8.5 
*Service cost estimates were either provided in full—‗Yes‘; provided but incomplete—‗Yes (incomplete)‘; not provided as it was unnecessary or inappropriate to do so—‗No 
(unnecessary)‘; or not provided, usually due to the complex nature of potential impact—‗No‘. 
**Impact on QALYs was either not provided because of the difficulty in doing so—‗No‘; not provided as it was unnecessary or inappropriate to do so—‗No (unnecessary)‘; 
estimated by manipulating the EQ-5D health parameters—‗Yes (EQ-5D); or estimated using data derived from the literature—‗Yes (lit)‘.  
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Table 7.27  Summary of NHSC case studies: Results 
Results 





Evidence of any uptake 
within the NHS for the 
specified indication? 
If ‗Yes‘ to previous, is there 
evidence of widespread 
NHS uptake?** 
Evidence of any 
uptake? (Globally or 
for other clinical 
indications?) 
1. FibroTest Headroom Favourable Yes No Yes 
2. MARS Headroom Favourable Yes No Yes 
3. SpeechEasy Headroom method not fit for consumer products 
4. SLF bypass graft - Intuitively favourable Yes No Yes 
5. Meniett MRP Unfavourable No - Yes 
6. AmpliChip - Intuitively unfavourable No - Yes 
7. Agento I.C. MRP Favourable No  - Yes 
8. Cool-Cap - Intuitively favourable Yes No Yes 
9. ChondroCelect - Intuitively unfavourable Yes No Yes 
10. Kryptor compact Headroom Favourable Yes No Yes 
11. Aquadex FlexFlow Headroom Favourable Yes No Yes 
12. E-medICS - Uncertain  No - No 
13. HeartSmart Headroom Favourable Yes No Yes 
14. CT angiography Headroom Favourable Yes No Yes 
15. Stapled 
haemorrhoidectomy 
MRP Favourable Yes Yes Yes 
16. Transpupillary 
thermotherapy 
Headroom Favourable No - Yes 
17. Citrasate dialysate MRP Favourable Yes No Yes 
18. TVT Headroom Favourable Yes Yes Yes 
19. Penile cuff test Headroom Favourable Yes No Yes 
20. PFO closure device MRP Uncertain No - No 
*Note:  This development decision indication is taken from the numerical part of the headroom analysis only (apart from the intuitive decisions). As explained in the 
description of each case study, the research questions were always pertinent. See below for discussion of this.  




7.5.1  General observations and trends 
Table 7.25 outlines the main characteristic of the study sample.  Of the 20 medical 
technologies analysed, twelve were devices, four were diagnostic devices, three were in vitro 
diagnostics and one was an ATMP.  Their regulatory classes, which generally reflect risk, 
ranged from I to III, but were mainly IIa or IIb.  The paucity of class I devices (only two) 
reflects the NHSC‘s remit.  Whilst this is not representative of the industry as a whole, it may 
be representative of those devices for which headroom would be most useful.  Nine case 
studies were pieces of equipment.  There was a variety in change proposition: five 
replacements, six new indications, five incremental developments, two ‗another option‘s, one 
addition and one mixed.  There were four case studies for which the company‘s own baseline 
was not ‗nothing‘ (i.e. they represented incremental developments or ready-established 
products), and eight had NICE guidance for follow-up (only one was a technology appraisal).   
Table 7.26, which describes the analysis inputs and outputs, shows that UK market size 
could not be identified in four cases.  Service cost impact was not estimated in seven cases, 
but three of these were because this was unnecessary or inappropriate.  Incomplete service 
cost estimations were usually a result of not understanding the suggested implementation of 
the new device; this was mainly due to lack of clarity or detail in the briefing.  Estimates may 
have been more complete had they been elicited from the developer.  QALY impact was 
estimated for nine cases, and just over half of the missing QALY estimates were due to their 
inclusion being unnecessary.  Only five case studies were accompanied by development cost 
analysis.  The mean time taken per headroom analysis (pre follow-up) was 8.85 hours 
(median: 8.5; range: 5 to 14.5).  Although the case studies with the date perspective further 
back in time felt more difficult, this was not reflected in time taken, which was actually a 
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mean of 8 hours for the earlier half (those dated pre-2002—the average year), and 9.3 hours 
for the later ones. 
The results table (Table 7.27) shows the categorical outcomes of each case study: the 
principal output (MRP, headroom or nothing), the likely decision to have been made from 
this, and the degree of its subsequent uptake.  Five case studies generated an MRP, nine a 
headroom estimate, and six produced no numbers.  However, only one of the case studies that 
produced no headline monetary estimate resulted in an ‗uncertain‘ development decision; the 
rest resulted in intuitively favourable/unfavourable headroom decisions, based on an 
exploration of the relevant numbers and other factors.  Headroom analysis led to what was 
considered to be a favourable development decision in fourteen cases, unfavourable in three 
cases, and uncertain in two cases (SpeechEasy is the missing case here).   
The anomaly within the sample was SpeechEasy, which was a consumer purchase.  
Although this was an exclusion criterion, this only became apparent after some investigation.  
The case study was left in as it was deemed to be a pertinent example, both highlighting the 
difficulty in evaluating technologies whose demand will be consumer (patient)-led, and being 
an example of a typical offering of innovation in the device sector: a small change to an 
existing technology.  That the headroom method would encounter difficulties in evaluating a 
device whose customer is not the health service is no surprise—such a device is not likely to 
ever undergo an economic evaluation, at least not by NICE.  ChondroCelect was another 
outlier as this was neither a device nor a diagnostic.    
7.5.1 (i) Are there any characteristics of a good headroom candidate? 
The characteristics of the medical technologies for which headroom/MRP/no estimate were 
calculated may indicate the type of medical technology to which the headroom approach is 
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best suited.  Overall, the analyses that resulted in an MRP took a mean of 8.2 hours (median: 
8.5), those that provided a headroom estimate took 9.7 hours (median: 10), and those for 
which no monetary estimate was calculated took a mean of 8.1 hours (median: 8.25). 
Categorising all technology disease areas according to whether headroom/MRP/no 
estimate was generated reveals no obvious patterns; all three categories contain examples of 
chronic and transient medical problems.  60% of case studies for which an MRP was 
generated had NICE guidance for follow-up, versus 45% for those with headroom and 17% 
for those with no monetary estimate.  This reflects the greater ease of analysis for those 
technologies that are relevant for national economic evaluation.  There was no clear pattern in 
how the change proposition (relationship with current practice) related to outcome type, apart 
from the fact that all ‗replacement‘ technologies generated either headroom or MRP.  
Unsurprisingly, none of the ‗equipment‘ technologies resulted in an MRP, as the briefing 
notes lacked detail regarding the distribution and patient throughput parameters of these.  In 
terms of regulatory classification, 60% of MRPs were for devices of class IIb or above, 
compared with 57% for headrooms and 25% for those with no monetary estimates.  The time 
perspective taken for the analyses had no impact on output type.  All five case studies that 
were able to generate an MRP were devices.    
The above analysis indicates that whilst some factors seem to be significant in the ability 
to estimate value, no individual characteristic appears overwhelmingly prohibitive.  The 
biggest factor seems to be technology type: no MRPs were generated for the diagnostic 
technologies (though most were able to produce a headroom estimate).  This may relate to the 
greater difficulty in understanding the potential health and cost impact for diagnostics.   
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7.5.1 (ii) Relating headroom to subsequent market uptake 
The potential implications of using the NHSC database as the source of case studies were 
described early in the chapter, and are confirmed by the ‗evidence of uptake‘ results.  Whilst 
the primary aim of follow-up was to determine the NHS uptake of a product for the clinical 
application investigated by the headroom analysis, evidence of any uptake (globally) provides 
a better indication of general product viability.  For all but two of the products, some evidence 
of uptake was identified.  This is unsurprising, since the NHSC database provided a close-to-
market sample of case studies.  This should be taken into account when interpreting the result 
statistics presented below, along with the fact that the postulated decision to develop is in 
relation to quantified headroom only.  Additionally, though informed by the literature, the 
implications of the headroom analyses in terms of the suggested decision outcomes (which 
were generally informed by their follow-up) were speculative.  Whilst these three factors may 
make the statistics generated somewhat artificial, by exploring what they convey we can 
explore the possible implications of using a numerical headroom assessment (as the headroom 
method has traditionally been described) to explore the feasibility of uptake. 
Figure 7.1 summarises graphically the uptake results in relation to whether headroom was 
perceived to be favourable, unfavourable, or uncertain.  As headroom considers the potential 
for a product‘s reimbursement within the NHS context specifically (and for the clinical 
indication originally specified), the medium-grey lines show the total number of products 
which achieved NHS uptake; the dashed box indicates the proportion of these that achieved 
widespread uptake (becoming the gold standard for the clinical scenario considered)
44
.  The 
number of products which did not achieve NHS uptake is shown underneath this in white.  
                                                 
44
 Widespread uptake was determined in both cases by favourable NICE recommendations, as well as the current 
clinical literature (which implies that these are the new reference standard) and indications from wider patient-
facing information sites and manufacturers‘ websites. 
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Presented alongside these is the number of products which turned out to be viable, which is 
shown by the light-grey lines and represents the total number of products for which there has 
been evidence of some uptake (including international uptake and use of the product outside 
of the original clinical specification). 
 
 
Figure 7.1 Summary of headroom decisions and subsequent uptake 
 
If product success was defined by becoming the gold standard in clinical practice, then Figure 
7.1 demonstrates that this was only achieved for two products (headroom was considered to 
be favourable for both: stapled haemorrhoidectomy and TVT).  However, the market 
landscape described in chapter 3 demonstrated that this is rarely achieved for medical 
technology, due to strong product competition and the important role of user preferences.  
Therefore, it may be more appropriate to judge the relevance of headroom against evidence of 
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any NHS uptake (in relation to the clinical application considered by the headroom analysis); 
this is the definition of NHS uptake utilised for the performance statistics outlined below. 
Figure 7.1 shows that 12 of the 14 products for which headroom appeared to be 
favourable achieved some level of NHS uptake.  The two that did not were due to clinical 
ineffectiveness (TTT) or what appears to be a change in clinical practice (Agento IC: follow-
up indicated that this device may indeed be cost-effective, but has not achieved NHS uptake 
due possibly to the implementation of other guidelines of best practice; these were highlighted 
descriptively in the headroom analysis).  The headroom decision outcome was described as 
uncertain in two cases: E-medICS (for which no number was generated) and PFO closure (for 
which an MRP was generated).  These represent the two products in the study sample which 
appear not to be viable products.  The headroom analyses for these two products offered 
strong caution around the case for development, but as I cannot be sure how these would have 
been interpreted, it may be unwise to infer that they would have engendered an unfavourable 
decision.  The effect on the summary statistics of having interpreted these uncertain decisions 
as unfavourable ones will be discussed briefly below.       
At the outset of the project, it was thought that a headroom analysis that was indicative of 
a favourable development decision would hopefully lead to subsequent uptake, but this may 
not always be the case, e.g. where early expectations of clinical effectiveness transpire to be 
too optimistic.  This led to the perhaps more appropriate definition: that the headroom method 
should be used to ‗rule-out‘ technologies that will never be cost-effective.  Headroom was 
considered unfavourable in three cases, two of which have not achieved NHS uptake (and 
thus were successfully ‗ruled-out‘).  However, by this logic, any headroom analysis that 
would have indicated an unfavourable development decision but that actually has achieved 
NHS uptake, may disprove the method.  This was the case in one headroom analysis: 
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ChondroCelect.  Although no monetary headroom was presented, the case for development 
was intuitively unfavourable, given the necessary requirements of clinical effectiveness or 
cost for ChondroCelect, based on NICE‘s evaluation of the technology that ChondroCelect 
was incrementally developing.  These did not seem feasible, and indeed the product has not 
proven to offer such large benefits.  However, ChondroCelect (an ATMP rather than a device 
or diagnostic) is offered by some specialists, due to alternative methods of reimbursement 
(e.g. pass-through payments by the NHS for some new technologies). 
The Contingency Table 7.28 describes the relationship between the headroom result and 
NHS uptake (the reference).  The ‗uncertain‘ headroom decisions are omitted (as well as 
SpeechEasy), making the denominator 17. 
Table 7.28 Headroom and NHS Uptake contingency table 
  REFERENCE  
  NHS Uptake No NHS Uptake  
HEADROOM 
Favourable 12 2 14 
Unfavourable 1 2 3 
  13 4 17 
 
Based on the data presented, Table 7.29 provides the common measures of test performance 
for the headroom method.  
Table 7.29 Summary headroom performance statistics and their interpretation 
Sensitivity 0.92 Of those that achieved NHS uptake, the proportion for which 
headroom was favourable 
Specificity 0.50 Of those that did not achieve NHS uptake, the proportion for 
which headroom was unfavourable 
 
Positive predictive value 0.86 Of those for which headroom was favourable, the proportion that 
went on to achieve NHS uptake 
Negative predictive value  0.67 Of those for which headroom was unfavourable, the proportion 
that were unsuccessful in achieving NHS uptake 
 
Accuracy 0.82 ‗Getting it right‘: the proportion of case studies whose subsequent 
NHS uptake was correctly predicted 
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The low specificity of the headroom method (50%) reaffirms the fact that a favourable 
headroom result does not guarantee future uptake, meaning that false positives are not 
uncommon (two out of the four that did not achieve NHS uptake had been considered 
favourable, and thus represent false positives).  The use of optimistic early assumptions 
(which may reasonably transpire to be too optimistic) intends to rule-out the perusal of device 
ideas that could never be cost-effective, and therefore it is no surprise that specificity is low.  
More importantly therefore, the headroom method should not rule-out technologies that have 
some chance of future uptake.  It is for this reason that sensitivity is the more important 
measure here.  Sensitivity was found to be not 100% but 92%, due to the one case described 
above for which alternative means of reimbursement has led to the uptake of a technology 
which, by NICE standards, cannot (currently) be considered cost-effective: ChondroCelect.  
The positive predictive value of 0.86 indicates that 86% of those products for which a 
favourable headroom case was provided later achieved NHS uptake.  More interesting, 
however, is the negative predictive value which shows how predictive the headroom method 
is as a rule-out tool; this illustrates that just 67% of those for which headroom appeared 
unfavourable did not achieve NHS uptake (two out of three).  This, again, is driven by the 
ChondroCelect case only.  Due to the very small number of ‗unfavourable‘ headroom 
outcomes in the study sample, these figures should be interpreted with caution.  Overall, the 
headroom method and its suggested decision outcome correlated with subsequent NHS uptake 
in 82% of cases (representing the ‗accuracy‘ of the headroom method for these retrospective 
case studies). 
Table 7.30 and Table 7.31, show the same analysis as above, except the uncertain 
headroom decision outcomes are now re-categorised as unfavourable.  
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Table 7.30 Headroom and NHS Uptake contingency table: re-classifying 'uncertain' headroom as 'unfavourable' 
  REFERENCE  
  NHS Uptake No NHS Uptake  
HEADROOM 
Favourable 12 2 14 
Unfavourable 1 4 5 
  13 6 19 
 
Table 7.31 Summary headroom performance statistics and their interpretation: re-classifying 'uncertain' headroom 
as 'unfavourable' 
Sensitivity 0.92 Of those that achieved NHS uptake, the proportion for which 
headroom was favourable 
Specificity 0.67 Of those that did not achieve NHS uptake, the proportion for 
which headroom was unfavourable 
 
Positive predictive value 0.86 Of those for which headroom was favourable, the proportion that 
went on to achieve NHS uptake 
Negative predictive value  0.80 Of those for which headroom was unfavourable, the proportion 
that were unsuccessful in achieving NHS uptake 
 
Accuracy 0.84 ‗Getting it right‘: the proportion of case studies whose subsequent 
NHS uptake was correctly predicted 
 
By assuming that the cautionary headroom analyses described for E-medICS and PFO closure 
would have been interpreted by the developer as unfavourable, the summary statistics become 
slightly more favourable for the headroom method (as it successfully ruled out two further 
technologies).  In particular, the negative predictive value rises to 80%, and the method 
becomes more specific.   
As discussed previously, the two most important caveats to the interpretation of the result 
statistics outlined above are: (a) the close-to-market nature of the sample, meaning that 
unsuccessful products are underrepresented, and (b) that the headline ‗result‘ in terms of 
headroom favourability (to which subsequent uptake was compared) relates only to the 
numbers that were generated in the analyses, rather than the exercise as a whole.  The case 
study documentation demonstrates that, even at a very early stage of development, by 
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considering and researching the parameter inputs required to calculate headroom, the relevant 
threats to uptake can be brought to light, as well as the additional opportunities for a product 
that have not been characterised by the numerical headroom assessment.  By considering 
these factors alongside the monetary headroom assessments, subsequent market uptake was 
generally well predicted. 
It has been shown that the viability of product development is not captured by simply 
considering uptake within the NHS; even the two medical technologies that were successfully 
‗ruled-out‘ by the headroom method in terms of NHS uptake turned out to be viable products 
(one transpiring to be a patient purchase and another used within a different clinical context).  
Therefore, the numerical headroom calculations described should not be used directly to 
consider the viability of product development, and to rule-out development based on this.  
However, I have demonstrated that the exercise as a whole does get much closer to an 
assessment of development viability. 
The reason for headroom analyses and results not being entirely straightforward are 
largely explained by the factors presented below, which outline some of the important lessons 
learnt regarding the headroom method and its application.    
 
7.5.2  Main headroom lessons 
As an exercise undertaken to evaluate the headroom method, some of the most useful findings 
of this investigation are insights into the headroom method itself.  Table 7.32 outlines the 
important lessons learnt, in an attempt to understand better how useful the headroom method 
might be in practice.  The particular case studies to which they relate are noted in brackets. 
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Table 7.32 Summary of Headroom Lessons learnt 
1. APPROPRIATENESS OF SCOPE 
A global market 
(general observation) 
The focus of these case studies was the UK market: a) using the NICE perspective 
on health gain ‗value‘ and b) exploring the context of the UK market specifically 
(e.g. market size, NHS costs, etc).  Of course, the device market is a global one, 
and the results may not translate directly to other settings.  Often, uptake by the 
NHS was non-existent or limited, but the product was still viable given its use in 





Where the application of the medical technology turned out to be relevant for a 
wider spectrum of clinical areas, the headroom analysis underestimated the 




A product can be perfectly profitable in the absence of its widespread use across 






By adopting the NICE decision-making framework, the headroom method 
considers a product‘s cost-effectiveness to dictate its reimbursement prospects.  
The ChondroCelect case study demonstrates that a product can be viable even 
where NICE regards the intervention unfavourably.  The procurement landscape 
is infinitely more complicated than the simple approach taken by the headroom 
method, and schemes such as pass-through payments and reimbursement by 
private insurance companies can widen the purchasing landscape.  




Changes in the clinical context can be unpredictable, for example the dismantling 
of the NHS IT programme for e-medICS.  Additionally, current practice (the 
comparator) can change rapidly, which alters the headroom of a new product 





A common difficulty in estimating the MRP for devices that are not used on a 
per-patient basis was a lack of practical understanding around their likely 
distribution.  This sets devices apart from pharmaceuticals, and requires an 





The ‗value‘ identified by the headroom method does not incorporate non-health 
related preferences.  This is a limitation of much health economic analysis, as 
currently practiced, and can be an important issue for medical devices and their 




The fundamental notion that all decision-makers are rational is mistaken.  There 
are many other factors that go into these buying decisions, which cannot 





Providing evidence can be particularly difficult for new medical devices.  This 
was clear from the follow-up of case studies, where often the provision of RCT 
data was limited.  The RCTs that were conducted often demonstrated the intrinsic 
difficulties of generating this evidence, e.g. the use of sham surgery for the 








The headroom method is only as informed as the information that informs it.  
Where the literature base is thin or contradictory, the ability of the method to offer 
a useful insight into the market opportunity is compromised.  Obtaining relevant 
information for the headroom of new indications was particularly difficult.    
[In some cases, the lack of information in the literature did not pose too much of a 
problem in getting a good idea of headroom.] 
No single ‘gold 
standard’ 
(13,14,17) 
Often there is not one single reference standard, but many options at the disposal 
of medical professionals in the treatment of their patients.  This makes the relative 




For assumptions to be made in a headroom analysis, a simplification of the 
clinical scenario is usually required.  In some cases this can be useful, for example 
where a development decision can be based on a partial headroom (e.g. from the 
cost-saving effect alone).  In other cases, this simplification may omit important 
value-affecting factors, simply because these are too difficult to quantify. 
3. IMPORTANT EXTRA CONSIDERATIONS 
User input 
(12) 
Where users are intrinsically involved in the effectiveness of a device, those users 




The time horizon willing to be considered by purchasers is crucial for headroom 
results in some cases.  Whilst this should be the number of years for which benefit 
and cost impact are applicable, some procurement decisions might have a shorter 
timeframe in mind.  This should be explored pre-development. 
Strategic factors 
(most) 
Strategic considerations are not dealt with by the headroom method.  These might 
relate to how the product is priced (especially for equipment), willingness to 
accept reduced market share, licensing agreements, and strategic competition 
considerations.  
First to market? 
(8,20) 
In the cool-cap example, the headroom turned out to be a ‗no-brainer‘, as it was 
the first intervention proposed for this clinical area; headroom was huge.  
However, if the relevant comparators that exist now were available at the time of 
analysis, headroom would have been unfavourable (cool-cap is less cost-
effective).   The co-existence of many cooling options demonstrates not only that 
user preferences matter, but that being the first to market may be an advantage.  
On the other hand, companies can free-ride on the research of the market leaders. 
4. WHERE THE HEADROOM METHOD MAY BE LESS APPROPRIATE 
Model updates 
(10,11,14,16) 
Where new products are simply incremental developments of a company‘s 
previous model, then health economic matters may not be of unique relevance in 
the decision to develop.  For example, the update may represent a natural 
evolution in product design, and be necessary for the company to keep its product 
portfolio up-to-date and competitive (especially relevant for the constantly 
evolving high-tech sector).  The development cost of these modifications may be 




Where products are applicable for many clinical indications, valuing it from the 








The headroom method is simply the application of the NICE technology appraisal 
framework, applied early on to inform development rather than procurement 
decisions.  Therefore, those technologies that are not ‗NICE‘-able, are not easily 
evaluated with the headroom method either.  





Many of the analyses felt very speculative, or required some creativity in finding / 
manipulating the relevant information.  Where there were big discrepancies in 
literature estimates, personal judgement and bias could creep in, which will have a 
large impact on the perceived headroom.  Companies may be predisposed to 
overestimate the potential impact of their innovations.  Two of the follow-ups 






The headroom method is an approach rather than a strict set of rules.  In many of 
the case studies, an MRP could not be calculated (usually due to too many 
unknowns), but it was still possible to get a feel for whether the prospects for the 




Although MRP is estimated exclusively by estimating its health-economic value, 
this might not represent a feasible or sensible reimbursement price (for example 
where this MRP is an awful lot larger than the treatment it replaces).  It may be 
that the MRP of a new device should be scaled in some way to the baseline 






Although this investigation intended to apply the headroom method to 
development decisions, it has also demonstrated its direct applicability to other 
investment decisions, such as new market entry (for which investment in clinical 
trials and marketing would be required). 
The analyses also demonstrated that where impact was uncertain, the headroom 




A critical finding has been that the reimbursement perspective alone is too narrow 
to inform a development decision, but set within the context of other factors, can 





Nearly all of the caveats, limitations, and observations outlined in this table can 
be (and were) picked up in the individual headroom analyses, in the 
‗developments‘ identified and ‗research questions‘ posed.  These sections (six and 
seven of the pro forma), which outlined the relevant external or unquantifiable 
factors, turned out to be pertinent in all examples, and must be considered 
alongside the headroom value when considering the investment opportunity of 
product development.  In some instances, this meant that a seemingly 
unfavourable headroom value would actually have implied a favourable 
development decision.  However, these extra considerations mainly proposed why 
the reimbursement opportunity might not be as favourable as calculated (i.e. 
presenting the suggestions from the literature of why the ‗best case‘ assumptions 
might not be met).  When combining the economic case made in the headroom 
analysis with the factors described in sections six and seven of the pro forma, an 
accurate description of market opportunity was generally presented. 
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The lessons outlined in Table 7.32, which are divided into five themes, should contribute to 
our appreciation of the place for the headroom method in business decision-making, and its 
potential limitations.  A consideration of the appropriateness of scope reveals that the 
headroom method can both over and underestimate the market size and value, and that this 
may invalidate the findings of any development cost decision analysis (though this was only 
presented in five cases).  It is because of the global nature of the device industry that many 
technologies that are unsuccessful in the UK are actually viable products, due to their uptake 
elsewhere across the world.  The intrinsic limitations described are largely problems 
associated with health economic evaluation more generally, and specifically the difficulty of 
its application to medical devices; these findings corroborate the distinguishing features of 
devices outlined in chapter 3.  The ‗important extra considerations‘ relate to critical elements 
in the success of a medical technology that are out of the scope of a headroom analysis, as 
they relate to unquantifiable factors or strategic concerns.  The fourth theme offers three 
examples of where the headroom method may not be appropriate or feasible: model updates, 
multiple applications, and those technologies unsuitable for national evaluation by NICE.  
Finally, specific factors relating to the method‘s application and interpretation are outlined, 
especially important being the incorporation of the clinical and market context factors 
(identified during the analysis) into development decisions.  Consideration of these factors or 
threats that cannot be quantified would have been useful in all cases, and should be 
considered alongside the monetary case. 
7.5.2 (i) Headroom lessons: Costs and QALYs 
Using the resources and approaches outlined in the headroom template (see Appendix 2), 
these case studies have shown that, even prior to development, the literature can often supply 
some useful estimates that help to quantify the potential impact of a new technology, both in 
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relation to costs and QALYs.  By outlining the relevant sources of information available and 
describing the appropriate strategies of approach, it is hoped that the application of the 
headroom method may be amenable to developers themselves (this is considered more 
formally in chapter 9).  There is a wealth of cost data available in the literature (especially 
nowadays) though estimating service cost impact does sometimes require some creativity (and 
therefore may be subject to bias). 
The estimation of HRQoL in these case studies raised some interesting issues, and 
demonstrated that much can be gleaned from manipulating information that is already 
available.  The ‗QALY ladder‘ developed by McAteer (2011) was not utilised, as it contained 
up-to-date estimates of HRQoL that went beyond the relevant timeframe of most of these case 
studies.  In most cases, either: (a) there was no need for an estimate of HRQoL as the benefit 
was clearly large enough, or there was sufficient headroom in costs alone; (b) there were 
relevant HRQoL studies in the literature, or (c) I manipulated the relevant health parameters 
from the EQ-5D questionnaire, and used the work by Williams (1995) to quantify these.  The 
EQ-5D manipulation approach was applied formally in two cases, to stapled 
haemorrhoidectomy and TVT.  For stapled haemorrhoidectomy the estimated HRQoL impact 
turned out to be surprisingly accurate upon follow-up.  Whilst the impact estimate provided 
for TVT overestimated its potential, the HRQoL associated with people suffering from 
urinary incontinence was well predicted; the presumption that symptoms would be alleviated 
completely was incorrect.  Although just two examples are not sufficient to provide a well-
balanced impression of efficacy, this has shown that this approach can offer at least some 
insight into the potential value of a new product. 
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7.5.3  Potential confounding factors 
This investigation was designed to mimic as far as possible what might be achievable by 
industry in applying the headroom method, including a template to follow, a pro forma to fill 
in, and a reasonable time limit for the analysis.  However, it is of course impossible to 
completely ‗remove the researcher from the research‘.  Whilst completing the 20 case studies, 
a log was kept regarding the aspects of the investigation itself that might have offered me, the 
researcher, an artificial advantage or disadvantage in eliciting headroom. 
There were many aspects of the (necessary) design and context of this investigation that 
may have made the headroom method more readily applied compared with its use by 
developers.  One obvious factor is my research background, both from previous academic 
endeavours and practice in applying the method to a number of case studies.  This may mean 
that the relevant information was more easily or quickly obtained due to previous experience 
in applying the tool (though time taken per analysis showed no downward trend through the 
20 case studies).  Industry members with no background in health economics may, even with 
the provision of the necessary resources, find the problem difficult to approach (I was forced 
to seek advice in one instance, regarding a statistical challenge presented by the MARS case 
study).  Interpretation of the literature would be more difficult for someone not experienced in 
reading information in such a format, and access to this literature may be problematic outside 
of an academic institution.  I found that a non-research background may have posed a barrier 
to headroom elicitation particularly for case studies 7, 11, 13 and 20.  Given the large 
discrepancies in parameter estimates in the literature (especially the case for 7, 11, 13, 14, 17 
and 20), conducting the analysis from the viewpoint of third party independent researcher 
(such as myself) may have reduced the potential for bias in these instances.  This may have a 
big impact on the size of the investment opportunity identified. 
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As well as advantages, there were also many artificial disadvantages relating to the 
application of headroom within this study.  These mainly related to the provision of 
information on which to base appropriate assumptions for potential impact, as the NHSC 
briefings were sometimes unclear or offered limited detail on the aspirations of the developer 
(which is why a range of headroom was presented in many cases).  Direct elicitation of impact 
expectations from the developer would have been much more straightforward.  The other 
critical disadvantage was my knowledge base within the specific clinical and treatment areas.  
Having no medical/clinical background, all understanding was informed only by the literature 
and background searches.  The developer is much more likely to have a deeper appreciation 
of the relevant issues.  I felt that my own (lack of) clinical knowledge hindered the potential 
for more useful estimates in some cases in particular (2,11,16,17 and 20) or made the process 
much slower (13 and 20).  Patient throughput for equipment (uncertainty of which often made 
an MRP difficult ascertain) may have been better understood by the developer.  Given the 
date restrictions for searches, the earliest being 1995, relevant information was sometimes 
limited, especially relating to cost data (though according to the analysis above this does not 
seem to have had an impact on ability to estimate headroom).  Information available today is 
much richer and wider in scope, so applying the headroom method from today‘s perspective 
may well be more straightforward or meaningful. 
Interpreting headroom values was difficult where the available information for follow-up 
was limited (attempts to contact the manufacturers were largely unsuccessful).  In some cases, 
estimates of potential impact were offered not out of necessity (it would not have changed the 
decision outcome), but simply to show that it was possible.  In these instances, the ability of 
headroom to inform a development decision is likely to have been much simpler and quicker 
had it been undertaken by the developer, who would have a more pragmatic approach. 
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7.6  Summary and discussion 
The results of this investigation go some way to determining the headroom method‘s use as 
an early gauge of market opportunity.  As far as possible, the application of the headroom 
method aimed to reflect what might be achievable by a device developer, and differs in this 
respect from the (headroom method related) investigations of others.  It also offered the 
possibility of follow-up, which for the first time has given an insight into the possible 
implications of basing a development decision on the outcome of a headroom analysis.  The 
results have shown that a lot can be learnt about the market opportunity for a device early on, 
and in a reasonably short space of time.  The importance of having a large sample of case 
studies was confirmed by the fact that each offered a new and unique insight into the method 
(but also implies that there may be more to learn). 
The biggest impact on the generalisability of these findings is the source for the case 
studies evaluated: the NHSC.  Crucially, this limited the potential for evaluating medical 
technologies whose development was abandoned pre-launch.  The sample was also biased 
towards the bigger-impact technologies.  Another potential restriction on generalisability is 
the time perspective adopted in the case studies; the real aim of the thesis as a whole is to 
investigate how useful the headroom method might be to developers in the future.  This 
investigation considers the usefulness of the headroom method in the past, and may 
underestimate its potential given the ever-increasing information base at the disposal of the 
investigator, which may make headroom analyses easier or more accurate. 
There was a lot to be learnt about the method by studying the characteristics of those 
technologies excluded from the study or for which difficulties arose in estimating headroom.  
These showed that a clear understanding of the application and potential consequences of a 
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new medical technology is necessary, though where this clarity does not exist, some 
exploratory elicitation of headroom according to various scenarios can be useful.   Diagnostic 
technologies are often more problematic than others, though collaboration with the developer 
in the COPD case study (chapter 6) showed that estimates can still be made.  Headroom 
analyses that painted an unfavourable investment opportunity have in some cases turned out 
to be viable, investable products (even where headroom accurately ‗ruled-out‘ those that have 
not been bought by the NHS).  All of the limitations and caveats outlined above offer 
potential explanations for this, and mainly reflect the narrow perspective taken.  Whilst the 
headroom method considers the viability of national reimbursement, it is clear that the market 
for medical technology is a global one, and not restricted to national purchasing agencies. 
It is within the nature of early evaluations that uncertainties around potential impact or 
changes in the clinical and procurement landscape are inevitable.  However, the case studies 
evaluated here have demonstrated that these factors can often be predicted from a very early 
stage.  In this respect, the headroom approach has been furthered, and should no longer be 
considered a ‗back of the envelope calculation‘, as described previously (McAteer 2011).  The 
present study has shown that important factors can be missed if this approach is taken (either 
missing potential investment opportunities, or investing in the un-profitable).  It should not be 
forgotten that the headroom method of early economic evaluation is, just as the name 
suggests, a method of evaluation rather than a prognostic tool per se.  The method has 
demonstrated its ability to generate a good idea of reimbursement opportunity, and this study 
has highlighted some important considerations in its use. 
The word ‗useful‘ has been intentionally omitted from any declaration of value of the 
headroom method, the reason being that such a tool can only be considered useful if its output 
is valued by its intended user: the developer.  Chapter 9 considers this question explicitly. 
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CHAPTER 8 HEADROOM ANALYSIS FOR A LEG ULCER 
PROTECTIVE STOCKING 
8.1  Introduction 
This chapter describes the second of two prospective case studies which, like the first, 
involved interaction with its innovator at an early stage of development.  The approach to the 
headroom analysis, however, is more akin to that of the retrospective case studies, where the 
time is limited and the analysis follows a pre-determined approach (using the pro forma).  By 
keeping to this format for a prospective study I demonstrate the use of this approach in real 
time.  An understanding of the innovation was developed through just one meeting and a few 
confirmatory emails.  Subsequent work was independent.  The product is kept generic for 
commercial reasons and is referred to as the Ulcer Protector throughout this chapter, which is 
divided into three parts: the first (section 8.2) explains the headroom analysis; section 8.3 
offers a brief interpretation of the results; and a summary is provided in section 8.4. 
 
8.2  Headroom Analysis 
The headroom analysis is presented in the format that it was conducted, using the pro forma. 
8.2.1  Description 
A leg ulcer is a chronic (non-healing) wound, which develops on the leg or foot and takes 
longer than six weeks to heal (NHS Choices 2010). There are various types of leg ulcer, 




Table 8.1 Types of leg ulcer 
Leg ulcer type Description 
Venous leg ulcer A venous leg ulcer is the most common type, accounting for 80-85% of 
all cases. This is where increased blood pressure in the veins of the 
lower leg causes damage to the skin.  This problem mainly affects older 
people, especially women. 
Arterial leg ulcer An arterial leg ulcer is caused by poor circulation (which also prevents 
them from healing). 
Diabetic foot/ leg ulcer Diabetic foot/ leg ulcers are caused by high blood sugar. 
Vasculitic leg ulcer These are related to inflammatory disorders such as rheumatoid arthritis 
and lupus. 
Malignant leg ulcer Malignant leg ulcers are caused by skin tumours. 
Source: (NHS Choices 2010) 
Venous leg ulcers alone are thought to affect 1 in every 500 people in the UK, but 1 in 50 
over the age of 80 (NHS Choices 2010).  The biggest risk factors are immobility, obesity and 
varicose veins. 
Treatment for leg ulcers can involve various methods.  Where an ulcer does not have 
circulatory causes (such as peripheral arterial disease), a compression bandage/sock is often 
used.  Ulcers are initially washed before a dressing is applied to promote healing, which is 
initially changed at least weekly by a nurse (The British Association of Dermatologists 2010).  
The cleansing and dressing of ulcers is principally to avoid cross-infection with sources of 
contamination rather than the removal of bacteria from the site (Royal College of Nursing 
2006).  Antibiotics are prescribed if the ulcer becomes infected.  
Patients are advised to keep ulcer dressings dry. Failure to do so impedes wound recovery; 
if the dressing gets wet and is left to dry of its own accord, infection can occur.  This makes 
washing very difficult, and showering/bathing impossible.  
The Ulcer Protector is a completely waterproof protective stocking that allows a patient 
with a leg ulcer to bathe or shower whilst keeping the ulcer site completely dry.  Given the 
impact this could have to a patient‘s QoL, and also the NHS resources that could be saved 
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from the reduced redressing of ulcers, it is thought that the product could and should 
eventually be made available on the NHS. 
8.2.2  Comparator 
There is much research and innovation in the area of wound dressing and ulcer treatment.  
The Ulcer Protector is not intended as a treatment for leg ulcers, nor does it replace anything 
in the current treatment pathway.  Rather, it acts as an aid for patients who must live with a 
leg ulcer, by providing the means to wash properly.  This would promote general hygiene, 
reduce ulcer infection and redressing, and—crucially—boost QoL.  
To the knowledge of the developers, there had been no other product developed 
specifically to help protect ulcers and their dressings and allow for contact with water.  This 
would imply that the appropriate comparator for the Ulcer Protector is ‗nothing‘.  My own 
searches identified some potentially relevant comparators, outlined in Table 8.2, though none 
seem to be embedded into the current clinical management of leg ulcer patients in the UK. 
 
Table 8.2 Comparator products for the Ulcer Protector 
Comparator product Description 
Seal-Tight This seems to be the most relevant comparator for the Ulcer Protector, given 
its proposed benefits to patients and the NHS.  The developer of seal-tight, 
Autonomed, is a company based in West Yorkshire that has developed a 
number of products to help patients with practical solutions to common 
medical problems.  Seal-tight is marketed as a cast and bandage protector, 
but has also been targeted specifically at diabetic foot patients and their 
clinicians as a ‗waterproof woundcare protector‘ (Autonomed Ltd 2009).  The 
product is available on NHS prescription, but it is difficult to know the extent 
to which this has been picked up—some sources indicate that it may only be 
available to NHS Lancashire patients (Stang 2010). 
 
Cast protectors There are various makes and models of waterproof ‗cast protectors‘ 
available, that are principally targeted to help patients keep their casts dry 
after having injured or broken a limb.  Various medical supplies websites 
provide links to the various offerings on the market (Betterlifehealthcare Ltd. 




The developers believe (having been made aware of Seal-Tight) that, compared to all other 
products available, the Ulcer Protector offers a much newer and more compatible material and 
design.  Practically, this means a safer, more flexible and easy to use product.  It would also 
be marketed more specifically toward leg ulcers, as compared to the majority of products 
available whose proposed application is very wide (and mainly targeted toward people with 
casts and bandages).  
Two approaches are therefore considered: 
1) To consider Seal-Tight as the appropriate comparator, being the most closely matched 
competitor and already having achieved reimbursement from the NHS. 
2) Taking the stance that  most leg ulcer patients today have no appropriate means of 
protecting their ulcer dressing, making washing or being around water very difficult. 
8.2.3  Market size 
In 1983, Dale and colleagues estimated (for the Scottish population) that around 1% of adults 
suffer from a chronic leg ulcer (Dale et al. 1983).  Callam et al. (1985) estimated that active 
leg ulceration (i.e. those being treated) represents 1.5/1,000 of the population at any one time.  
This estimate is upheld by Royal College of Nursing statistics, which estimate a UK 
prevalence of active leg ulcers of 1.5 to 3 per 1,000 of the population (Cheater et al. 2001).  
Considering a UK population of about 60 million (and England: 50 million), this equates to 
around 90,000 to 180,000 for the UK (and 75,000 to 150,000 for England).  Other estimates 
identified in the literature tend to fall within this range.   I will conservatively assume the 
lower bound of these estimates. 
Market size per year (UK) 90,000 




8.2.4  Health service 
In 2004 the annual treatment cost of leg ulcers in the UK was £300-£600 million, with 
nursing time being the main cost driver of leg ulcer care (Soares et al. 2009).  It was estimated 
that in 1988 the cost of caring for leg ulcer patients was around £1,200 per patient per year 
(Budgen 2004) (this is equivalent to about £3,260 in today‘s prices45).  Another source 
estimates that each unhealed leg ulcer costs the NHS £1,067 per year, the largest element of 
which is district nurse time (Skene et al. 1992) (£2,161 in today‘s prices46).  Some other 
estimates are more modest, with one more recent one being £1,500 to £1,800 per patient per 
year (Chuang et al. 2011). 
From an NHS perspective, the main cost saving that could reasonably be associated with 
the Ulcer Protector is in nursing time, which is the main cost driver for leg ulcer care 
(Anderson 2010;Callam, Ruckley, Harper, & Dale 1985;Iglesias, Nelson, Cullum, & 
Torgerson 2004).  The Ulcer Protector could reduce the utilisation of nursing services by a) 
improving the general hygiene of a patient by allowing them to bathe or shower properly, and 
b) decreasing the number of re-dressings by reducing the incidence of accidental wetting of 
the dressing (which, according to the developer, would always prompt a re-dressing). 
By taking the perspective of approach one, the headroom (and MRP) would simply be 
equal to the price of Seal-Tight, if we assume equivalent performance.  Approach two 
requires an estimation of the potential cost saving from a reduction in nursing visits. 
                                                 
45
 The Hospital & Community Health Services (HCHS) Pay & Prices Index (PSSRU 2010) is used to inflate: 
Inflation rate: P&P Index (present year) ÷ P&P Index (year of cost data) 
= 271.5/100 
= 2.715 
£1,200 * 2.715 = £3,258 
46
 As above:  
 = 271.5/134.06 
 = 2.03 
£1,067 * 2.03 = £2,161 
 236 
 
An economic evaluation was undertaken alongside a UK clinical trial, which considered 
the impact of a new type of bandage for leg ulcers (Iglesias, Nelson, Cullum, & Torgerson 
2004).  The number of nursing visits per patient per month was recorded; for one type of 
bandage the mean number of nurse visits was 6.03 per month (median of 5) and for the other 
5.14 visits (median of 4).  Across all centres, most of these were home visits.  It may be 
reasonable to presume that the Ulcer Protector may (like the better style of bandage) allow for 
one fewer nursing visit per month, from around five to four.  This is consistent with the 
recommended care advice, that re-dressing should occur weekly.  This monthly perspective 
also matches the expected lifetime of the product, which is likely to last around one month. 
NHS reference costs for 2009/10 (Department of Health 2011b) provide the average cost 
of community nursing services, in its various forms.  The national average unit cost for 
district nursing services (face to face) is £39, £42 for ‗health visiting services: all other 
services‘, and £41 for ‗health visiting services: core services‘.  I use £40 as the approximate 
value of a community nursing visit.  By assuming that one nursing visit is saved per month, 
the Ulcer Protector may save £40 per month in healthcare costs. 
 
Approach 1- Comparator: Seal-Tight  
By taking Seal-Tight as the comparator, I assume no impact on service costs.  Autonomed 
promote Seal-Tight for £19.99, and stipulate that it should last for 6 to 8 weeks.  About £10 
therefore represents its monthly price. 
(Total) ∆SC £0 





Approach 2- Comparator: Nothing  
By assuming there is no relevant comparator, there may be a cost saving of £40 per person:   
(Total) ∆SC £3,600,000* 
(Av. per person) ∆SC £40 
P1 £0 
*£40 multiplied by 90,000, the estimated number of patients being treated for leg ulcers in the UK 
 
8.2.5  Patients 
There is a strong need for QoL assessment in wound care (Teare & Barrett 2002).  A 
‗Technical Guide‘ published in the online journal Wound Essentials emphasises the impact of 
not being able to bathe / shower properly on QoL and general hygiene (Lindsay 2007).  The 
importance of understanding the HRQoL implications of leg ulcers, and incorporating these 
issues into patient care, has been underlined in the literature (Budgen 2004), and in 2011 
González-Consuegra and Verdú (2011) presented a review of the relevant studies.  Three of 
those twenty-one studies reviewed use the EuroQoL EQ-5D questionnaire to elicit the 
HRQoL of people with leg ulcers, and find this to be 0.6 to 0.7 (Iglesias, Nelson, Cullum, & 
Torgerson 2004;Michaels et al. 2009).  However, I am interested in the difference that the 
Ulcer Protector could make on a patient‘s HRQoL rather than the average HRQoL of leg ulcer 
sufferers. 
Autonomed present research of their own on the impact of Seal-Tight on HRQoL for 
diabetic foot ulcer patients (Autonomed Ltd 2009).  Using a disease-specific measure, the 
Cardiff Wound Impact Schedule (CWIS), they find that physical functioning is improved by 
27%, well-being by 44%, and overall QoL was improved by nearly 20%. 
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In order to consider this from a reimbursement perspective, I consider the five health 
dimensions of the EQ-5D questionnaire, and use the results of a large UK study to estimate 
potential QoL benefit (Dolan 1997;Williams 1995).  It seems reasonable to assume that the 
main health state of relevance to the Ulcer Protector is self-care.  Presuming that having a leg 
ulcer would cause ‗some problems with washing or dressing‘, and that using the Ulcer 
Protector could turn this into ‗no problems with self-care‘, then the impact of this on a 
patient‘s QoL weighting47 would be 0.104.  As the product will last one month, each Ulcer 
Protector would provide (0.104/12): 0.0087 QALYs.  
Approach 1- Comparator: Seal-Tight  
∆QALY* 0 
(Av. per person) ∆QALY 0 
*This assumes equivalent effectiveness between the Ulcer Protector and Seal-Tight.  
Approach 2- Comparator: Nothing  
∆QALY 783 
(Av. per person) ∆QALY 0.0087 
 
8.2.6  Developments (clinical and healthcare context) 
Table 8.3 lists some of the relevant developments in the clinical and healthcare context, 
alongside ‗Red‘ if it poses a significant threat to the opportunity identified in the market, 
‗Amber‘ if it represents a potential threat, and ‗Green‘ if it further supports the case for the 
new technology.  
                                                 
47
 I will not add to this the intercept estimation, which is a constant that should be added for any deviation from 
‗full health‘, as I presume that, given the likely age of the relevant patient population, their baseline would 
probably not be a HRQoL of 1 (perfect health). [See headroom method chapter 4 for a more detailed explanation 
of this approach].  
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Table 8.3 Developments in the clinical and healthcare context that may affect the headroom for the Ulcer Protector 
[Green] Patient-facing websites such as NHS Choices offer no guidance or information on looking 
after ulcer dressings, and how to adapt normal everyday routines to accommodate for them 
(NHS Choices 2010).  This (along with accounts from people working in the field) 
demonstrates that these problems go largely unaddressed; the Ulcer Protector offers a 
simple way to overcome an everyday problem. 
[Amber] Competitors: As well as Seal-Tight, it is clear from the many websites that offer waterproof 
cast protectors, that similar types of product are available (Betterlifehealthcare Ltd. 
2012;CastCoversNow 2012). 
[Green] An article in the Nursing Times highlights the costly nature of leg ulcer care when patients 
are not managed properly (Anderson 2010).  It emphasises that costs can be reduced if 
nurses are provided with appropriate training.  This demonstrates that there is room for 
improvement in the care provided for leg ulcer patients, and the Ulcer Protector could 
provide a cheap way to make care more effective, involving no extra investment in training 
or staff time.  Clinical practice need not be altered. 
[Red] The fact that Seal-Tight is already available on prescription may represent a barrier to 
adoption for another similar product. Some sources indicate that Seal-Tight is available 
across the UK (Autonomed Ltd 2009).  The significance of this barrier should be 
investigated.  If the product is widely available, then ‗approach 1‘ taken above is likely to 
be the more appropriate, with the price of Seal-Tight providing a cap on the Ulcer 
Protector‘s MRP.  One source indicates that Seal-Tight is available on prescription to all 
patients who wear bandages or plaster casts (Lindsay 2005).  The product received the 
Nursing Times product gold award in Product Awards 2010 in the ‗Dignity and Daily 
Living‘ category (Nursing Times 2010). 
[Green] On the other hand, the fact that a product of a similar nature has been successful in 
achieving reimbursement indicates that the NHS is willing to reimburse this sort of product. 
Research undertaken for Seal-Tight has also shown the large potential impact on QoL of 
protective ulcer stockings.  
[Amber] One source finds that just 4% of dressing changes arise from accidental wetting (Stang 
2010).  In the analysis presented above, I have assumed this rate to be 20% by estimating 
that one nursing visit could be saved each month (from five to four).  It could be argued, 
however, that the general improvement in hygiene of patients who would now be able to 
wash, may further contribute to the reduced demands on nurses and healthcare resources.   
[Green] The Ulcer Protector will have applications outside of those indicated in this analysis, and 
the innovators already have ideas around these. Leg ulcers have been chosen as 
professional opinion indicated that there was a real gap in the market here.  However, future 
models could be developed and targeted to different areas, and may add to the business case 
for this product. 
 
8.2.7  Research Questions 
 To what extent has Seal-Tight been picked up by clinicians?  Would the NHS be 
prepared to offer both Seal-Tight and the Ulcer Protector on prescription? 
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 If Seal-Tight is offered at a discounted rate to the NHS, then this should be identified 
and used as the base-case. 
 The introduction of other similar products on the market should be monitored. 
 Is it reasonable to assume that the Ulcer Protector could save one nursing visit per 
month, or is this an over/under estimation? 
8.2.8   Headroom 
Table 8.4 and Table 8.5 illustrate the MRP for the Ulcer Protector under approaches 1 and 2. 
Table 8.4 MRP for Approach One 
Comparator: Seal-Tight  NHS willing to pay £20,000 per QALY 
Impact on Health 
(QALY2-QALY1) 






0 £0 £10 £10 
 
Table 8.5 MRP for Approach Two 
Comparator: Nothing  NHS willing to pay £20,000 per QALY 
Impact on Health 
(QALY2-QALY1) 






0.0087 - £40 [saving] £0 £214 
 
The high value of improved self-care is represented by the high reimbursable price in 
approach two (which would reach £310 for a WTP of £30,000).  However, if the closely 
matched competitor is deemed to be the more appropriate baseline, then this MRP is reduced 
to £10.  Using the graphical representation presented in the headroom chapter, Figure 8.1 and 




Figure 8.1 Ulcer Protector: Graphical MRP for approach one 
 
 
Figure 8.2 Ulcer Protector: Graphical MRP for approach two 
 
8.3  Interpretation 
The headroom exercise is meant to allow the developer to observe the reimbursement 
potential for a new device idea, in order to then decide whether this makes it worth 
developing.  This does not mean that the MRP should directly inform pricing decisions in the 
future (even if early expectations are confirmed).  In this case, the higher of the two MRP 
estimates (£214) would represent an unreasonably high price for this type of product.  Not 
only is there a comparable and much cheaper device on the market (which probably 
represents the more reasonable price cap), but also the costs of production would be relatively 
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low.  Indeed, the developers indicate that the headroom analysis provides plenty of room for 
development and that price is likely to be set on the basis of cost plus reasonable profit, which 
would be below the competitors‘ prices. 
The headroom analysis considered the NHS to be the target customer, and therefore used 
NICE‘s WTP threshold to value health impact in the second approach.  In reality, such a 
product (very simple and with low costs) would never be evaluated by NICE, and so 
conducting such a valuation may seem artificial.  However, although the price in the future 
will be set independently of this, it could act as a good marketing tool, demonstrating that the 
value obtained from its use far outweighs any investment required for its purchase. 
Although the headroom analysis considered the potential value of the product from a 
health service perspective (as the main aim is for product to be available on prescription), the 
Ulcer Protector may be targeted directly to patients.  In this case the headroom analysis would 
not be applicable and, like other consumer products, value would be determined by the 
buyers.  Competing products would be particularly important in this case. 
 
8.4  Summary 
This headroom analysis, which utilised the resources developed for the retrospective case 
studies, illustrates the use of this approach in a real-life prospective example.  The analysis 
and write-up took a total of 10.5 hours, thus adhering (loosely) to the notion of ‗headroom in 
a day‘.  Analysis of development costs, which makes use of the total market size estimate to 
explore the likely room to re-coup costs of development assuming full market coverage, was 
not pursued for this example given the nature of the company and its likely capacity (a very 
 243 
 
small start-up), and also the unrealistic notion in this case of the MRP being the actual price 
charged in the future.   
The value of the method for the innovators is explored in the next chapter, where potential 
stakeholders (including the developers of the two prospective case studies) are asked to 
consider the value and practicality of the approach.  However, what this chapter has 
demonstrated is that, in a reasonably short space of time, understanding of impact can be 
communicated (through just a two hour meeting) which, when combined with literature work, 
was able to produce realistic assumptions and to quantify these into monetary values.  The 
process also brought to light some direct competitors, an important finding at an early stage.  
The work also showed that the headroom method is less relevant to consumer products, 
although the interviews chapter explores this and other questions in more detail by consulting 





CHAPTER 9  QUALITATIVE INVESTIGATION INTO THE VALUE 
AND USABILITY OF THE HEADROOM METHOD FOR ITS 
POTENTIAL USERS 
9.1  Introduction 
As an evaluation of the headroom method, this thesis aims to assess if and in what ways the 
method provides medical device developers with a useful indication of product viability.  
Having applied the method prospectively to two case studies and retrospectively to twenty, 
issues relating to its application have been exposed, and its predictive value explored.  
However, the method—a tool to facilitate decision-making by medical device developers—
has so far been assessed outside the context of its intended users.  Whilst elements of the 
study design, particularly for the retrospective case studies, attempted to replicate the 
potential constraints of device developers and to provide resources for its implementation, 
without capturing the views of the intended user, any results would lack a grounding in / 
translation into the real world.  Through thematic analysis of semi-structured interviews with 
12 stakeholders, this chapter explores the potential value of the headroom method, and 
thereby provides a deeper understanding of its merits and limitations as a method of early 





9.2  Contribution of this investigation to the mixed methods 
research design 
As described in the methodology chapter, the research methods employed for this project 
were based on their capacity to address the prominent research questions.  The inclusion of 
this qualitative study was grounded in the desire both to validate the assumptions made and 
the conclusions drawn by other methods (in the case studies), as well as to further the 
evaluation by exploring factors that cannot be assessed by the techniques used so far. 
The hypothesis underlying the set-up and design of this research is that by integrating the 
headroom method into early development decisions, innovators could improve the efficiency 
of development expenditure by only pursuing those ideas with feasible reimbursement 
prospects.  To evaluate the headroom method, the implied assumptions of this hypothesis 
must be tested.  The first implicit assumption is that economic evaluation of this nature does 
not currently feature in early decision-making by developers; determining the novelty of the 
approach was therefore one important objective of the interview process.  Whilst the potential 
efficacy of the method was addressed by the retrospective studies, the conditions which 
facilitated its application may not be representative; the usability and practicality of the 
method in the eyes of potential users are therefore also explored.  Additionally, consideration 
of the usefulness of the method‘s output is investigated, as well as any important omissions. 
An outline of the various motivations for a mixed-methods evaluation design is given by 
Greene and colleagues (1989), all of which relate in different ways to my motivation to 
incorporate this qualitative investigation into the study.  A summary of these is provided in 
Table 9.1.  ‗Expansion‘ relates to the underlying reason for taking a mixed methods approach, 
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whilst ‗Development‘ relates to how this was done.  ‗Complementarity‘, ‗Triangulation‘ and 
‗Initiation‘ describe what the mixing of methods contributes to the overall research findings. 
  
Table 9.1 Rationale for including interviews: Purposes of mixed-method evaluation design 
Purpose Rationale for inclusion of interviews 
EXPANSION. To extend the 
breadth and range of inquiry, 
by using different methods for 
different components of the 
inquiry.   
In the methodology chapter, two distinct components of the 
headroom method‘s evaluation were outlined, which related to its 
efficacy and usability.  The interviews permit an investigation of 
elements of usability that cannot be tested through the case 
studies, as well offering the chance to examine other components 
of its proposed ‗value‘ that remain unaddressed by other methods. 
E.g.: Does the method add / is it different to what developers 
already think about?; Can costs (which must be considered 
alongside headroom) be projected at such an early stage? 
DEVELOPMENT. Uses the 
results from one method to 
inform the other, to increase 
the validity of constructs and 
results by capitalising on 
inherent method strengths. 
Both the process of and results from the prospective and 
retrospective case studies shaped the interview inquiry and the 
types of questions asked, as well as the material provided and the 
participant sample. 
E.g.: Interviews with developers of the prospective case studies; 
 Is nine hours a useful / feasible time to allocate to this sort of 
analysis?; Does the simplification process render the analysis 
ineffectual? 
COMPLEMENTARITY. Seeks 
to elaborate, enhance, 
illustrate and clarify the results 
from one method with the 
results from the other, thus 
increasing the interpretability 
and meaningfulness of results.   
The context chapter outlined the diverse nature of innovation and 
innovators in the medical device market.  The anecdotes provided 
by the varied sample of potential users, relating to their thoughts on 
the method in relation to their own roles and experiences, can 
complement the case study findings as well as placing these 
findings into a real-life setting, thereby increasing their 
meaningfulness.  
E.g.: Is the method intelligible (and by who)? What would the real 
barriers be to its implementation? 
TRIANGULATION. Seeks 
convergence, corroboration 
and correspondence of results 
from the different methods, 
thereby increasing the validity 
of constructs. 
The discovery of convergent results between interviews and case 
studies, relating to headroom method implementation issues and 
the extra factors considered, substantiates and provides validity for 
the conclusions drawn. 
E.g.: Exploring the factors that are omitted by the method in the 
eyes of the user and cross-checking these with the findings of the 
case studies. 
INITIATION. Aims to discover 
contradiction or new 
perspectives. 
By exploring the interpretation of the method by different people 
with varying perspectives, new potential usages and roles for the 
method emerge, and patterns can be drawn from these findings.   
E.g.: The discovery of disagreement in responses, and provisional 
theorising of what works for whom and in what way. 




9.3  Methods 
Approval for this interview study was granted by the University of Birmingham‘s Science, 
Technology, Engineering and Mathematics Ethical Review committee on the 31
st
 of January 
2012 (ERN_10-0531, see appendix 7).  Details on the methods employed for both the 
collection and analysis of data are provided below.   
9.3.1  Sampling 
A maximum-variation purposive sampling technique was employed to select interview 
participants, for which the intention was to capture the perspectives and opinions of 
stakeholders with a broad range of insights, backgrounds, and roles in the innovation process.  
Two sets of interviewees were the developers of the prospective case studies described in 
chapters 6 and 8.  The remaining participants were contacts established either through their 
past or present contact with MATCH, through contacts established through the course of the 
project, or through the connections of colleagues.  Participants were approached and provided 
with a participant information sheet and consent form (see Appendix 8).  In exchange for their 
participation, interviewees were provided with a presentation of the headroom method, as 
well as the materials developed for the method‘s application (pro forma and resource guide).  
Generic names are used to refer to the interviewees, which are summarised in Table 9.2. 
Table 9.2 Characteristics of interviewees 
 Label Description 





[COPD case study] 
Clinician and Professor, specialising in respiratory 
medicine.  
 
Director of a (small) medical device technology 
consultancy company, and an academic medical 
device researcher. 
Interview 2 Start-up (1) 
Start-up (2) 
[Ulcer protector case study] 
The two staff members of a start-up micro business 
set up to develop and pioneer a product to help leg 
ulcer sufferers. 
Interview 3 SME 
 
 
Senior director of a medium sized company (around 
100 employees) with a global reach.  This medical 








Chief executive of company that provides business 
support to the heath technology sector, including 
strategic marketing, and business development. 




Research project facilitator 
Innovation manager for an NHS trust, providing 
support and advice to both NHS trust staff with new 
ideas and also small companies.  
 
Research management role within an NHS trust, 
facilitating collaborative projects and the development 
of new medical devices for urinary incontinence. 
Interview 5 Design consultant Director of a (small) company that provides 
consultancy in the design and development of medical 
(and other industrial) products, including prototyping.  
Interview 6 Large MNC (1) 
Large MNC (2) 
Head of scientific development (1) and global business 
development director (2), at a global company with a 
large multinational health technology division, which 
operates in 50 countries, employs 3-4,000 people and 
has a turnover of around €1.5 billion per year.   
Interview 7 Academic Teaching fellow at a UK university, interested in 
translating their research into a product for use in 
teaching and for clinicians in the NHS (has recently 
applied for a first round of i4i funding). 
  
 The intention was to interview a heterogeneous sample of potential users of the method, in 
order to gain an insight into the various perspectives they might offer.  Although probability 
sampling (involving a random sampling method) would be required to maximise the 
generalisability of results, this was neither feasible nor necessarily desirable.  Statistical 
representation is not the objective of this study, which instead aims to understand the 
headroom method‘s potential use within a range of settings.  This non-probabilistic sampling 
technique is widely acknowledged in the literature to allow the researcher to identify and 
include a wide range of key informants who enable an exploration of specific issues related to 
the research (Mays & Pope 1995).  As indicated, the participants were identified through 
connections made either through previous collaboration, or through the wider network of 
contacts provided by my academic setting or MATCH.  It must therefore be noted that the 
sample may be biased toward those with a more favourable appreciation of this sort of 
method, especially given their agreement to participate.  Two participants (business consultant 
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and design consultant) have had previous exposure to the headroom method (having attended 
MATCH courses) and claim to incorporate its principles into their thinking; whilst these 
participants can offer valuable insights, their willingness to engage with this interview process 
may reflect their (positive) attitude to the method.  
9.3.2  Interview design 
The seven interviews with twelve participants took place between February and June 2012.  
The semi-structured interview script (see Appendix 9) was designed to elicit pertinent factors 
relating to the current way development decisions are made or conceptualised by the 
participant, thoughts on the headroom method itself and its application, and the usefulness of 
its output.  The logic of these question topics was checked with the project supervisors, who 
agreed them to be appropriate and inclusive. 
All interview sessions followed a similar format, and were conducted at a location 
amenable to the participant.  The headroom method was presented to participants through a 
(20 minute) power point presentation followed by a discussion (see Appendix 10 for 
presentation slides).  After talking through the material provided and discussing any questions 
or uncertainties, consent forms were signed and the interviews were undertaken.  The 
interviews lasted around 20 minutes (minimum 13 maximum 35), and were tape recorded.  
All tape recordings were transcribed and these were checked for accuracy against the 
recordings at a later date.  
In an effort to ensure reliability of data and consistency of findings, the interviews were 
all conducted in a similar format, and the same presentation and materials were provided for 
each participant.  Furthermore, an attempt was made to ask non-leading questions, and the 
interviewees were informed that all comments (both positive and negative) were useful and 
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welcome.  All presentations and interviews were conducted by me.  Whilst this provides 
consistency, responses may have been affected by previous interactions (both within and 
outside the meeting).  I also transcribed all interviews, and although no external inspection of 
the transcriptions was carried out, these were double-checked for accuracy. 
9.3.3  Thematic Data Analysis 
The method chosen to organise and analyse interview data should suit the purpose of the 
qualitative investigation.  For this study, the intention was not to develop deep theories of 
underlying experiences and a constructivist account of behaviours and motivation, for which 
methods such as Interpretative Phenomenological Analysis (IPA) or Grounded Theory may 
have been appropriate.  Such methods are bounded by theory, and do not match the objectives 
of this research project.  Although thematic analysis has in the past been criticised as 
representing a very general notion of qualitative analysis, the method is increasingly discussed 
and used as a concrete method in its own right (Braun & Clarke 2006).  Thematic analysis is 
not bound to any particular theoretical framework, and so suits the stance of this research 
project, which for the purpose of these interviews seeks to report the meanings, experiences, 
and reality of the interviewees.  It is a method by which patterns (themes) within the data can 
be identified, analysed and reported, allowing the researcher to both organise data and 
interpret the research topic (Braun & Clarke 2006). 
Themes (and sub-themes) relate to patterns identified in the data which provide a 
significant insight.  Whilst the questions asked in the interviews were driven by my interest in 
the topic and what I wanted to find out (as described in section 9.2), the initial coding and 
organising of data extracts were simple and non-creative.  Coding and theme identification 
was based exclusively on what was said in the interviews, rather than being structured by the 
questions asked; this process should increase the reliability and validity of the subsequent 
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analysis, by not guiding the results or missing important information (Kvale 1996).  Data was 
interpreted on a semantic (explicit) level, where the surface meanings of the data were taken.   
9.3.3 (i) Thematic analysis: the process 
After the audiotapes were transcribed and checked, the scripts were re-read to gain further 
familiarity with the text.  Coding—the process whereby all data (individual sentences and/or 
chunks of text) are assigned a descriptive label—was then carried out by hand for all 
interview scripts.  Coding is referred to as ‗...the transitional process between data collection 
and more extensive data analysis‘(Saldaña 2009, p. 4), and at this stage helped to organise the 
data into meaningful groups.  The data extracts corresponding to each code (some data was 
given multiple codes), were then copy/pasted into a tabulated word document.  After all the 
data were coded and collated, the analysis was re-focused at a broader level and organised 
into four wider themes which captured the groups of codes and reflected the data within them.  
A table of the codes (grouped into themes) can be found in Appendix 11.  The findings 
section that follows describes the story that each of these themes tells, and how their messages 
relate both across themes and more broadly to the overall research questions.  
 
9.4  Findings 
Four themes emerged from the analysis: (1) the participant‘s guiding principles and 
motivation, (2) the practicalities of the headroom method, (3) its scope, and (4) its impact.  
The analysis that follows will demonstrate the individual importance of each theme, showing 
the first three to be intrinsically linked and which, together, shape the fourth. 
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9.4.1  THEME 1: Involvement in innovation: guiding principles and motivation 
The codes and data within this theme encapsulated the background or guiding principles of 
interviewees, reflecting their underlying motivations or involvement in the innovation process 
(which will be shown later to influence their interaction with the headroom method).  Across 
all interviews, participants brought in their own perspectives and personal experiences, 
expressing or relating comments or ideas to their own roles.  This was an encouraging signal, 
demonstrating a genuine engagement with the questions.  A slight exception was the 
interview with the business consultant and SME, who less frequently related the questions 
asked entirely to themselves (they therefore feature minimally in this theme).   
9.4.1 (i) Motivation 
The participants fell into two main groups: those looking to develop their own innovations 
(group 1: clinician, start-up and academic) and those who deal with the ideas of others (group 
2: consultants, MNC and NHS trust).  For the first group, discussion of underlying 
motivations centred mainly on improving patient care or services, and the desire to improve 
QoL or to reduce the cost of patient care.  The clinician in particular emphasised the scale of 
disease burden.  The motivation to develop a medical device appeared personal for this group 
of interviewees, with the academic describing the decision as such.  Although 
acknowledgement of the need for a project to be viable and to make business sense was made 
by the start-up and clinician, a much greater emphasis was placed on the innovators‘ belief in 
their products.  In response to their motivation to develop, the start-up noted:  
‗It was an ethical decision in a sense.  In as far as, we felt there was a need for this  
product, and it was a great shame people who suffer from leg ulcers actually couldn‟t 
bathe properly, which must have affected their quality of life terrifically‘. [Start-up]   
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This captures the strong passion the innovators feel for their products.  All noted their qualms 
around quantifying their products‘ proposed benefits, talking of their ‗fear of numbers‘ and 
their having ‗no idea where to start‘. 
The motivations of group 2—linked by their advising capacity or working with the ideas 
of others—appeared less personal, with a focus on a product‘s viability as a business 
proposition.  Rather than stressing numbers as the difficulty, this group highlighted their 
sometimes limited ability to influence decision-making (either that of their clients or, for the 
MNC, within their company): 
‗...sometimes a company wants to do what they want to do. You know, and it‟s their risk 
and it‟s their cost, and we‟re just an advisory base.‘ [NHS trust project facilitator] 
Likewise, the head of scientific development at the MNC noted that ‗...you can‟t choose the 
team‘, and suggested internal difficulties and a divergent set of opinions and perspectives 
within the decision-making team. 
9.4.1 (ii) Current feasibility checks 
Information relating to any current (economic) feasibility considerations was also collected.  
Group 1 indicated no concrete decision-making processes for the consideration of 
development opportunities.  Worthy of note, however, is the network of expertise available to 
the academic (which helped her to compose the cost-side of her i4i funding application).  This 
support and knowledge base is not likely to be replicated within an industry setting, especially 
for small companies. 
On the other hand, group 2 provided details of some fairly structured approaches to early 
opportunity assessment.  For the NHS trust employees this mainly revolved around their own 
feasibility to deliver a project, but the importance of market size was also stressed.  The large 
MNC gave a particularly informative account of their current screening process for new 
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innovations, which involves an initial rule-out process for which considerations include 
clinical feasibility, intellectual property (IP), regulatory situation, business fit, time to market, 
scale of development costs, and possibility (rather than size) of reimbursement; for those that 
pass this stage, a presentation is compiled for an innovation board who consider these factors 
in greater detail: 
‗The board will review each of those elements and make a decision which ultimately and 
usually is gut feel... I know they wouldn‟t like to agree to that, but that‟s the reality of it‘. 
[MNC] 
Both the MNC and the NHS trust employees noted the lack of formal incorporation of health 
economics at the early stage.  As indicated previously, both the design and business 
consultants incorporate the headroom approach into their current consideration of new 
products.  
 
9.4.2  THEME 2: Headroom Practicalities 
Exploring the practicality of the headroom method was an important motivation for 
conducting the interviews.  The method‘s accessibility, ease of use, usefulness of output, and 
feasibility of application are considered here, an appreciation of which necessarily precedes 
any understanding of the method‘s real potential.   
9.4.2 (i) Understanding 
All participants indicated a positive understanding of the method, considering it to be clear 
and often alluding to its presentation within the meeting: ‗…it looked very attractive as well 
because it was so neat‘.  Whilst this type of commentary may allude to the possibility of 
participants relating to me/the presentation, rather than the method alone (denoting potential 
partiality in responses), the topic seemed accessible to all interviewees. 
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‗…I‟m not an economist, I‟m not even a scientist, so if it‟s reasonably clear to me I would 
think it‟s reasonably clear to most people.‘ [SME] 
This quotation mirrors the sentiment of many responses, with participants asserting their own 
disparate backgrounds in relation to this understanding.  However, based on their experience 
or setting, the participants identified with the method in different ways.  The SME, for 
example, made reference to QALYs being the most obscure element, whilst the clinician 
indicated the method to become much more tangible when framed in this way.  
9.4.2 (ii) Barriers to calculating the ‘headroom’ 
Making appropriate assumptions for a product‘s potential impact was highlighted by many as 
a potential difficulty, though the possibility of making these assumptions iterative (as with the 
COPD case study), and testing ranges, were suggested.  The design consultant indicated (from 
experience) that innovators will ‗…always have rose-coloured spectacles on‘, potentially 
making realistic assumptions problematic.  The two prospective case study innovators 
(clinician and start-up) indicated that the assumptions made for the headroom analyses, 
although potentially underestimating benefit, were pragmatic and justified.  However, this 
does not mean they would have made the same assumptions themselves. 
‗All models are basically the same in that they function on garbage in garbage out.  If you 
don‟t have the right stuff to put in it doesn‟t matter how good your model is.‘ [SME] 
The template / resource pack and pro forma were compiled to aid the making of appropriate 
assumptions as well as to identify the data to furnish them.  Accessing the data was 
highlighted as a potential concern by all except the clinician, academic, and NHS trust, 
perhaps reflecting their background in research, signifying the potential importance of this.  
9.4.2 (iii) Can costs be conceptualised at an early stage? 
The premise of the headroom method‘s value is allowing developers to compare potential 
future value with their own costs of development, manufacture, and sales.  However, the 
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ability to predict these costs varied according to respondent type.  The businesses and 
consultants believed themselves to have a good grasp of future costs even at a very early stage 
(except, according to the MNC, where a product is truly novel), though according to the 
design consultant the small businesses he deals with overwhelmingly underestimate costs.  
Conversely, those in research roles (within the NHS and universities) expressed much greater 
uncertainty around costs.   
9.4.2 (iv) The feasibility of applying the method yourself 
Notwithstanding the existence of practical calculation difficulties for headroom (or lack 
thereof), the feasibility of the method being used by the developers themselves was explored.  
Two main issues were raised: expertise and time.  Whilst all interviewees understood the 
method, some consultants considered an impracticality to be the expertise of the innovator.  
Indeed, the academic indicated that she would probably not approach the analysis by herself, 
and the technology consultant (from the COPD case study) noted that it was useful having an 
‗expert‘ making you think about the right questions.  However, the business consultant 
stressed the virtue of the template / pro forma in this respect:  
‗The important thing which I thought was good about that is asking the right questions.  
Usually they know the answers but nobody‟s asking the right questions of them‘. 
[Business consultant] 
The MNC employees were able to articulate quite clearly what the barrier would be within 
their own company: time.  They therefore suggested that, as with their market research, they 
would look to outsource a headroom analysis as a service.  This highlights the fact that, 
however useful a tool, it must fit within a (ready-established) way of doing things, and even 
‗headroom in a day‘ may be too much to ask of a person‘s job role and task list which is 
already stretched.  Similarly, the start-up indicated that ‗…we‟re trying to run a business as 
well, so there‟s only so much time you can allocate to that‟, although they indicated their 
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surprise that the headroom analysis for their product had taken just 10.5 hours, suggesting it 
to be a very good use of time.  Others noted the importance of investing time in a method that 
considers future reimbursement prospects: 
‗If you spend a day assessing whether your product has legs, will run, then it‟s got to be 
worth doing.‘ [Design consultant];  
‗…of course it‟s worth investing in doing it no matter how long it takes.‘ [Academic] 
 
9.4.3  THEME 3: Headroom Scope 
All interviewees noted the importance of health economics, although their agreement to 
participate denotes their intrinsic interest in the subject.  Some important findings emerged 
around the method‘s scope: in what way the method is appropriate / reflective of the actual 
situation, how complete the message it presents is, and what the major omissions are. 
9.4.3 (i) The simplification process 
The case studies demonstrated that to make assumptions for potential technology impact, the 
clinical scenario must be (often greatly) simplified.  Despite the passion for their products 
described previously, the prospective case study innovators suggested that this did not render 
the analysis uninformative: ‗It was an informed, pragmatic approach for a clinically complex 
need‘ [clinician].  Similarly, the start-up proposed that, whilst they were always interested in 
‗…that little bit more‘, those to whom they would want to describe the product‘s value would 
only want that (straightforward) information.  From his experience working with innovators, 
the design consultant noted their temptation to go into minute detail, which can be counter-
productive at that early stage.  Other interviewees believed the simplification process to be 
necessary and useful, so long as the potential weaknesses were understood. 
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9.4.3 (ii) Actual reimbursement 
As well as simplifying the clinical story, the headroom method sets the development decision 
within a world where future product value is determined by a rational buyer, who utilises 
economic evaluation within an NHS system-wide decision-maker‘s framework (like that used 
by NICE).  The comments of those who have worked directly with the reimbursement process 
(in particular: business consultant, SME and NHS trust), cast doubt over this view.  The basis 
of this criticism lies in the reality that decision-makers‘ incentives are distorted by the 
organisation of the system; the main issues are neatly summarised by the SME director: 
‗…with the proviso that I‟m not sure you could ever address these with a model, the two 
major things are 1) fixed reimbursement tariffs…  If that‟s set then the willingness to pay 
is already determined and it‟s not a flexible scale at all, it‟s flat.  And the other one is… 
silo budgeting, which is to say… I don‟t care how good it is for everyone, if it‟s not good 
for me it‟s not happening.‘ [SME] 
Concerning reimbursement tariffs, the business consultant indicated that, to be attractive to 
commissioners, a new product (even if more effective) must match or better the monetary 
value of current practice which, in cases where cost to the NHS come under the tariff, provide 
a revenue stream for a hospital.  Together with silo budget problems, it is clear that individual 
decision-makers are not given the right incentive structure to allow for the optimisation of 
their own decisions to align with the optimal outcome for the NHS as a whole. 
Additionally, according to the NHS trust there is a great deal of variation within the NHS, 
which even for them presents a complex, confusing and fast-changing landscape. 
9.4.3 (iii) Completeness of scope 
Omissions of the method (in its direct computational sense) were noted to be: that the market 
is a global one, trends in care or health service targets, the market context, alternative buyers 
(e.g. private or end-user), and market size.  Overwhelmingly, however, interviewees 
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considered that broadening the scope of the headroom calculation would make the method too 
complicated, and those with screening processes in place indicated that these other factors 
would already be taken into account: ‗I think it‟s incredibly useful… It shouldn‟t be an answer 
in its own right.  That doesn‟t discount its value‘ [MNC].  This corroborates the findings of 
the retrospective case studies (for which there is much cross-over), and re-emphasises the 
result that consideration of sections six and seven of the pro forma, which consider the un-
quantified / un-quantifiable, are essential. 
The method‘s simplicity was widely acknowledged to be a strong asset of the approach, 
making it (necessarily) quick and simple.  The MNC illustrated this with an account of an 
internally developed project appraisal process, which was too detailed and complex to be 
useful in practice: ‗…they spent an enormous amount of time, money, and effort to put it 
together.  Looked fantastic, but nobody utilised it‘.  This resonates with a comment made by 
the NHS innovations manager, who had previously attended a MATCH course on the HE tool 
(an excel-based decision tree health economic analysis).  Having understood the tool on the 
day, and being keen to utilise it and share it with colleagues, she came up to a difficulty, ‗fell 
off‘ and has not returned to it since. 
9.4.3 (iv) Product versus application 
The headroom method requires a concrete vision of for what and whom a device will be used.  
A product and its application are considered to be one and the same, a result of taking a 
demand-side approach for which the product‘s application is of paramount concern.  
However, this notion is at odds with the perspective articulated by the SME, who indicated 
that (at least for biotechnology) innovation tends to be an ‗idea in search of an application‘.  
This standpoint is complemented by the retrospective case studies, where a product transpired 
to have multiple applications and headroom was valued in relation to only one of these.  This 
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highlights the potential incongruity in applying a demand-side approach to a business decision 
for product development. 
However, this product–application relationship differed according to the type of 
developer.  For example, where an idea has stemmed from an association or involvement with 
its end use, the direction appears to be opposite, with the application preceding (and 
informing) the product.  In the experience of the NHS research project facilitator: ‗… 
sometimes it‟s a concept and you‟re kind of designing a device for a problem.‘  This mimics 
the conception of the near-patient monitor for COPD, which was born from the desire of a 
clinician to improve the process of care for her patients. 
9.4.3 (v) Extra Scope 
Ideas around extra scope for the method or its interpretation, outside of its proposed remit (to 
inform go / no-go development decisions) arose from the interviews.  The first relates to the 
aforementioned product-application consideration: 
‗…if you know that maximum price, you ought to be designing your device to fit that to 
some degree.‘[Research project facilitator]. 
This suggests that, particularly where application ideas precede concrete notions of the 
product, design choices may be guided by the headroom value, e.g. the intended regulatory 
class of the device, materials used, whether it is durable or disposable, etc.  This was also 
suggested by the design and technology consultants.   
The impracticality of estimating headroom where thoughts on the product precede 
application ideas, or where multiple applications are indicated, was noted above.  However, 
just as a method benefit was considered by the clinician to be its ability to value different 
scenarios / distribution strategies within a specific application, exploring value between 
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applications was also noted by the SME as a potential strength rather than necessarily a 
limitation of the method:  
‗...in actual fact it [the product] is potentially going to be used in a wide range of different 
applications.  So it‟s actually not too late to apply that [the headroom method] to other 
indications, that one might or might not move into‘. [SME]  
This highlights the method‘s flexibility, illustrating its potential use in considering or 
comparing value across different markets. 
The headroom method was presented and discussed as a rule-out method for early 
development decisions, and all interviewees believed it to be useful in this respect.  However, 
consideration of the later stages of development arose in some interviews (particularly with 
the medium and large businesses).  The theoretical MRP was related to how pricing decisions 
are actually made: generally, according to the SME, on a ‗cost-plus‘ basis.  Indeed, the very 
high theoretical value of the ulcer protector discussed in chapter 8 would be an unreasonably 
high price to charge.  This demonstrates that although the method (within the remit of this 
project) is not proposed to set future price, it may be misguided to consider that the NHS 
would be willing to pay up to its maximum theoretical value.   
This brings to the fore a new potential role of the method: to communicate value in the 
later stages of development.  For example, where the headroom method indicates a clearly 
positive development decision (such as that of the ulcer protector), and the actual product 
price would be set well below MRP, this could be used to present an attractive case for buying 
it; the larger this difference, the bigger this willingness-to-buy factor should be.   
On top of its early and later applications, the research project facilitator considered its 
potential integration into the management process throughout a project: to review the case and 
update expectations.  Other comments alluding to the method‘s wider potential scope included 
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indications of its global relevance (clinician and technology consultant), and the MNC and 
design consultant considering the method, in its most simple conceptual form, to be 
applicable to all industry.  Improvements were suggested in the form of wider guidance on the 
reimbursement process, but were more directed to MATCH rather than this specific method. 
 
9.4.4  THEME 4: Headroom Impact 
 This theme captures the pertinent messages from all three themes discussed, and brings the 
observations and patterns identified forward to consider the method‘s (potential or realised) 
impact.  They cover the method‘s novelty, the motivation of the interviewees for carrying out 
a headroom analysis, for whom the method might be most useful, pertinent roles established, 
and evidence of actual or intended action. 
9.4.4 (i) Novelty 
To determine the novelty of an approach is to assess the extent to which it adds to or differs 
from current practice.  For many participants, the method provided a learning opportunity.  
This learning experience was, for some (clinician, start-up and academic), based on an insight 
into health economics in general: 
‗Well I certainly learnt a lot.  And I think any other clinician would learn a lot...  You will 
have read a lot about what clinicians think of NICE.  We don‟t usually see them as our 
friends, because we wonder why we can‟t use such and such a drug… But I now 
understand the workings behind that, you know, and the importance of that.  For me, it‟s 
given me a very healthy perspective of health economics and the work that NICE does on 
behalf of the NHS.  It was very useful.‘ [Clinician];  
‗It‟s been a huge insight into how it all works.‘ [Start-up].     
For the academic and those working with innovation in the NHS trust, learning about NICE‘s 
cost-effectiveness threshold was deemed particularly useful.  Whilst this does not convey 
much insight into the headroom method itself, it does highlight the gap in health economic 
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knowledge of many innovators, and also shows that this insight can be delivered in a short 
space of time using this framework. 
Interviewees already familiar with health economics, such as the SME, indicated that 
while they did not learn anything new, they may have learnt a ‗better way of looking at it‘, at 
that early stage.  All participants (apart from the business and design consultants who are 
already familiar with the approach) acknowledged that the method offered a novel 
contribution to current decision-making protocol (where there was one), and by expressing the 
value they saw in it, believed it to be useful despite the limitations or omissions described in 
the scope theme. 
I believe that the basis of this ‗novelty‘ in fact derives from the method‘s provision of  a 
way to better articulate the things that developers already think about; to transform notions 
into numbers: to back up assertions and quantify them.  This may be what makes the method 
accessible: ‗I think conceptually it‟s very similar [to what she was already considering], which 
is I think why I found it attractive because I thought „ooh‟, I recognise what to try and 
do.‘[Academic]. 
9.4.4 (ii) Motivation for employing the headroom method 
a) To ‘open the purse’: a practical motivation 
For the innovators—the ‗group 1‘ described in the first theme—the underlying motivation for 
engagement with me and with the method seemed practical.  Rather than to inform their 
decision to develop, they seemed driven by wanting to learn about health economics and the 
way in which value is perceived in the health sector, either because they were looking to 
promote their product to the NHS (start-up), or were applying for NIHR research / product 
development funding (clinician & technology consultant and academic): 
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‗I think the days of blue sky funding are gone... It has to be relevant economically.‘ 
[Academic] 
Additionally, the graphic presentation of the method was noted to potentially add some 
impact to this application process, being: ‗...sharper.  Instead of wordy text, it‟s just there, and 
it leaps out at you, and I think that sort of impact is hugely important.‘ [Academic] 
b) To assess viability at an early stage 
‗The main reason for using a headroom method it to try and decide whether an idea is 
viable.  To avoid me spending time working on a product which isn‟t going to go ahead.‘ 
[Design consultant] 
Comments of this nature, expressed by the business and design consultants (who already use 
the method), SME, and MNC align more closely with the method‘s traditional remit: to get an 
idea of the ‗prepared to pay‘ number, so that by comparing this to manufacturing costs, the 
viability of development can be explored.  By way of illustrating this, the MNC offered an 
example of an instance in the past where the company had invested significant time and 
resources into a product which was a no-goer from the start: 
‗...it was dire.  It had SWOT analysis, PEST analysis, god knows what, and it was 
garbage. Whereas something like this [the headroom method] ...might well have said, 
actually, that‟s what you‟re going to get.‘ [MNC] 
The head of scientific development noted that by incorporating the headroom method into 
their current system, this expense may have been avoided. 
c) Injecting some ‘objectivity’   
For those in advisory roles or dealing with the ideas of others—group 2 in the first theme—a 
real motivation was adding ‗objectivity‘ into early development decisions / interactions, with 
words such as ‗rigour‘, ‗something definitive‘, ‗formalised process‘, and ‗structure‘ being 
used extensively.  The reason for this becomes apparent when considering the earlier 
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exposition of guiding principles and current feasibility checks.  For example, to tackle the 
problems associated with a diverse innovation board and the subjective ‗gut feel‘ nature of 
decisions, the MNC suggests: 
‗... you can use this tool to get an objective point of view into a very open discussion‘; 
‗...you need some financial objectivity… this would give an element of that, that they [the 
innovation board] would find very very acceptable.‘ [MNC] 
It therefore seems that, even for those with set processes, there is a call for increased 
objectivity and structure to these early decisions, and early indication that the headroom 
method could fulfil this role. 
d) Further roles 
In considering the method‘s scope, some new roles for the headroom method were explored, 
outside of its original remit as a ‗rule-out‘ tool.  Most notably, these included informing 
product design, assessing new market entry opportunities, and its use for later marketing 
purposes.   
9.4.4 (iii) For whom might the method be most useful? 
In the opinion of most participants, the method would be most useful for small or young 
companies: as a reality check, to force them to consider the ‗unpleasant truth‘ about the 
potential value of their products.  The premise of this response is that (a) small companies 
have limited resource to apply to early decisions, but a lot to lose if the wrong decision is 
made, and (b) that ‗small companies tend to be driven by optimistic people because optimistic 
people found companies.‘ [SME].  This is consistent with the description of the innovators‘ 
guiding principles and motivation, which is grounded in a belief in their products and a 
passion to improve practice.  This optimism represents both a strong rationale for integrating 
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the method into early development decisions, as well as a potential barrier to doing so with 
detached objectivity. 
The above theory matches my own hypothesis going into these interviews, believing that 
large companies are likely to already consider the potential health economic value of their 
product early on (but that small companies dominate the sector).  This belief was reiterated by 
the SME and design consultant, who confirmed that very large medical companies have teams 
of in-house health economists and a good grasp of market opportunity early on.  However, 
these companies are few, and the interview exchange with the MNC (whose healthcare 
division has a global outreach and is worth €1.5 billion per year, employing 3-4,000) 
indicated an absence of health economic expertise within their own company.  When asked 
who would benefit most from the method: ‗I would say... anyone and everyone.  I think you‟d 
be surprised at large companies how badly some of them do this‘.  The method‘s use by 
manufacturers selling their ideas to large medical companies (whose product development 
often stem from acquisitions) was also suggested to hold promise. 
Despite the participants‘ focus on (usually small) companies being the most likely to 
benefit from the method, all interviewees discussed how they themselves could benefit from 
its application.  In particular, it appears to have a strong function for those dealing with the 
ideas of others.  Indeed, the two participants who already employ the method are both 
consultants.  The often limited influence on decision-making of people in consulting or 
advisory roles was noted in theme one.  However, rather than this hindering the method‘s 
potential, it was expressed that in fact the method could aid those interactions, making them 
more productive and successful.  This function relates to the method‘s suggested association 
with objectivity and its provision of a formalised approach, which was mainly discussed in 
relation to restraining enthusiasm.  For those dealing with innovation from within the NHS, it 
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was suggested that the method could help defend the position of the advisors when interacting 
with the subject experts, and by taking them thorough a formalised process, to put off those 
whose commitment is superficial. 
9.4.4 (iv) A tool for communication 
The headroom method‘s role in sharing information and communicating value with relevant 
interested parties and stakeholders was highlighted by all interviewees.  For the academic and 
clinician, this meant selling their ideas to funders. 
‗…which allows me to bridge the gap in the language that can be used not only to further 
my collaboration with the commercial partner, because after all the commercial partner 
needs to see whether this is going to be viable, but also… in talking with commissioning 
groups, the purchasers. … Because you don‟t want your product to end up on the shelf.‘ 
[Clinician]  
This demonstrates quite explicitly that the method is seen as something not only for justifying 
the case for development early on, but in carrying through to later conversations with buyers 
as well (which was also emphasised by the business consultant, in describing the use of 
‗headroom‘ to sell a new product based on the revenue stream it could provide for an NHS 
trust).  This communicative role is also reflected in the method‘s use to facilitate consultants‘ 
interactions with their clients, and in facilitating internal discussions around potential new 
projects within companies. 
9.4.4 (v) Action points 
Finally, impact (realised and potential) is considered in relation to actual action points.  
Evidence of the method‘s use is provided by the business and design consultants, who 
indicate its worth in considering the commercial viability of their clients‘ ideas; this offers a 
promising signal of the method‘s utility in this function.  Indeed, the NHS trust employees 
described their interest in utilising the method to appraise product ideas they are approached 
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with, both aiding the selection process—‗I want to see it as part of the tools that I use to make 
decisions. To either proceed or not proceed‘—as well as facilitating more productive 
interactions with their clients (NHS staff or small businesses). 
For the clinician and technology consultant (from the COPD case study) and the 
academic, their own decision to develop is dependent on their ability to successfully access 
funding opportunities.  Whilst the academic expressed her interest in using the approach in the 
future, the method‘s application to the COPD case study has had a practical output, in helping 
to secure a second round of i4i funding for the product by presenting its economic case: 
‗I think as well from the funding point of view it added a lot of credibility, and also a lot 
more confidence knowing that we had that on board from an early stage.‘ [Technology 
consultant] 
Both the SME and start-up expressed a desire to use the headroom method in the future, 
with the former looking to consider new market entry opportunities: ‗…it‟s not too late to use 
the tool, and I shall be passing it on to my colleagues.‘ 
The MNC saw value in the method‘s potential integration into their current screening 
process.  However, the form of this in their eyes would most feasibly be outsourced 
consultancy work, an option which NHS innovations also mentioned to be of consideration.  
Whilst this may reflect the previous contact with MATCH of these two sets of participants, it 
is also indicative of the limited time they have to allocate to the method.  Another shared 
characteristic is that both deal with the ideas of others, probably implying a lower level of 
intrinsic interest in the products themselves (and this interest is not financially incentivised in 
the same way it is for consultants). 
The potential impact of the headroom method is clear.  The form of this impact, however, 
has been shown to be diverse, and to vary according to the user. 
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9.5  Summary and discussion 
The purpose of this qualitative investigation was to elicit, from those involved in the 
development of medical devices, the potential limitations of and opportunities provided by the 
headroom method.  As described in the literature review, there has been limited research into 
the use early economic evaluation within the device industry, although two studies conducted 
by researchers within MATCH investigate the practices of their industry partner base (Craven, 
Morgan, Crowe, & Lu 2009;Johal & Williams 2005) (see literature review for description).  
More recently, MATCH academics have performed a survey of 19 academic staff involved in 
healthcare innovation, and find that participants had little or no knowledge of health 
economics (Lu, Martin, Craven, & Morgan 2012).  The current study set out to investigate 
this issue, intending not only to describe the potential gap for the headroom method, but also 
to explore its potential to fill that gap. 
The themes presented in this chapter were based on interviews with 12 participants, 
recruited to suit the goals of a maximum variation sampling frame.  New perspectives and 
insights were gained from each interview; although many of the themes and ideas were 
supported within the sample, it is unlikely that data saturation has been attained.  It would 
therefore be unwise to suggest that these results are generalisable.  Limitations of the study 
may include the pairing of some of the interviewees (see Table 9.2), which might have limited 
the diversity of potential responses.  Additionally it is possible that, through either previous 
interactions or discussions within the meeting, my own thoughts were conveyed which may 
have consciously or subconsciously influenced the responses of the participants.  Time and 




Despite its limitations, this qualitative investigation elicited the views of a wide range of 
informant types, who were able to impart a broad spectrum of ideas and insight.  The analysis 
of these views, both between participants and across themes, has revealed some important 
practical issues as well as further opportunities, and how both of these are likely to depend on 
the user‘s background and relationship with the innovation process.  Figure 9.1 summarises 
the themes and subthemes identified, and visually depicts the interrelationships between these.  
 
 




In relation to guiding principles, the sample was shown to be broadly dichotomised into (1) 
innovators, driven by a strong belief in their products and a desire to improve practice, and (2) 
those dealing with the ideas of others, who had a stronger commercial orientation.  These 
positions influenced potential practical problems, which included possible difficulties for the 
innovators in making appropriate and realistic assumptions.  Additionally, those with a 
research background specified fewer problems around finding data than did those in a 
commercial setting, whereas the costs of development (which were easily conceptualised by 
those in commerce), presented more difficulties for researchers.  Expertise and time to 
allocate to the method‘s application may present further barriers to implementation. 
The complexity of the actual reimbursement scene was noted, but overall the simplicity of 
the method‘s scope was considered to be a positive attribute.  By asking the right questions, 
the method was regarded to usefully estimate market potential, offering a novel contribution 
to the decision-making process of all interviewees, including the MNC.  The realised or 
potential impact of the headroom method differed according to the type of interviewee, and 
related fundamentally to their involvement in the innovation process.  The impact of the 
method was discussed in relation to two main functions: to make decisions, and to sell ideas.   
The first of these included the method‘s original aim—to help developers decide whether 
to invest in a new medical device idea, by grounding that decision in the consideration of 
potential value versus likely costs.  Its use by consultants and advisors to help their clients 
make these decisions was also identified.  However, in addition to this original remit, value 
was also seen in using the method to make further decisions: to inform product design, and to 
consider entry into new markets. 
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The second function—to sell ideas—was described in relation to the early and late stages 
of the development process.  Early on, the method can (and has) been used to communicate 
value to prospective funders.  This communicative role of the method was indicated to also be 
of value later on to make the case for a product‘s purchase, especially where price would be 
set below MRP. 
 
The purpose for the mixed methods design of this project was introduced in the methodology 
chapter, and elaborated in the introductory sections of this one.  The discussion chapter which 
follows considers the combined results of the various methods employed in this thesis, and 





CHAPTER 10  DISCUSSION 
10.1 Introduction 
The mixed-method approach to this evaluation was designed to overcome inherent method 
weaknesses, to expand the evaluation enquiry, and to confirm and elaborate findings across 
methods (Clarke 1999;Greene, Caracelli, & Graham 1989;Yin 1994).  So far in this thesis, 
interpretation of the results has been undertaken in relation to each of the evaluation‘s 
component parts as they have been presented.  This discussion chapter synthesises and 
interprets the evaluation‘s findings as a whole, and in doing so provides a firmer appreciation 
of the headroom method‘s potential contribution to the decision-making processes of device 
developers. 
Methodological triangulation, as described in the methodology chapter, allows the 
researcher to improve the validity of their research results by exploring any convergence in 
findings (Campbell & Fiske 1959;Simons 2009;Stake 1995).  This chapter presents the results 
of this triangulation, and is organised as follows.  Firstly, the evaluation and its outcomes are 
discussed in relation to the literature and the market context, which were described in the 
opening chapters.  The triangulation of findings is then presented, offering a synthesis of 
results across the whole evaluation.  Results are organised according to their capacity to 
address the initial research questions.  Following this, the study‘s findings are extended so as 
to consider the resulting form in which the headroom method is proposed to be most effective.  
A careful consideration of the study‘s limitations is then discussed along with suggested 
avenues of further research, which is followed by the overall implications of the research and 
final conclusions.   
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10.2 Triangulation: The literature and market context 
The literature review in chapter 2 demonstrated that, methodologically, the early application 
of HTA is still in its infancy—especially for medical devices.  Most research focuses on 
pharmaceuticals and relates to the integration of HTA considerations throughout the 
development cycle (Bartelmes et al. 2009;Hartz & John 2008;Ijzerman & Steuten 2011).  The 
academic literature relating specifically to the appraisal of medical devices pre-development 
is scarce, and the previous headroom literature fails to answer the calls of the field: to 
‗critically appraise the relevance of early HTA for its stakeholders‘ (Ijzerman & Steuten 
2011, p. 342), and to ‗investigate the practicality and likely value of the approach‘ (Vallejo-
Torres et al. 2008, p. 463).  Bartelmes and colleagues (2009), in reviewing the literature, note 
the lack of standardisation of any proposed method of early economic evaluation, which are 
mostly described vaguely and whose application rarely exceeds pilot implementation.  The 
authors additionally note that an evaluation and validation of any method in relation to its 
predictive capacity does not exist (Bartelmes et al. 2009).  The results presented in this thesis 
therefore offer a novel and important contribution to the field. 
 The market context within which device developers operate was described in chapter 3, 
setting out the landscape for innovation as well as its evaluation.  The interrelated themes that 
emerged from this account aimed to ground the research in its real-life subtext.  Subsequent 
findings from this study have substantiated many of the issues raised, including the 
methodological challenges in applying HTA to medical devices, which were frequently 
illustrated through the case studies.  It is no surprise that the difficulties surrounding device 
evaluation were also found in its early application, and often meant that headroom was 
problematic to calculate, that an MRP could not be estimated, that a range of options were 
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presented, or that the headroom case was made descriptively.  These methodological 
challenges are summarised in Table 10.1 
Table 10.1 Methodological challenges in the HTA of medical devices which were reflected in headroom case studies 
Methodological challenge Explanation 
Headroom for Equipment: 
patient throughput issues 
Where medical devices were not for individual use, estimating the 
headroom associated with an individual device (MRP) was difficult, as 
the number of units required to service the relevant patient population 
was unknown.  Additionally, an estimate of device longevity is required 
to estimate MRP.  This presented difficulties for nine of the 
retrospective case studies.  Although not prohibitive in most cases, 
this often meant that headroom per patient (and/or per year) was 




Where the impact of the proposed technology was potentially very 
wide, concrete assumptions were difficult to make.  In the case of E-
medICS, this resulted in no quantification of headroom, although the 
COPD case study demonstrated that such assumptions can be made 
with careful study of the literature and expert input. 
Non-health related 
preferences 
Due to the third party administration of medical devices, user 
preferences influence product demand.  Where health outcomes are 
not affected (e.g. from process utilities), these preferences are not 
captured in the economic evaluation.  This was relevant for six of the 
retrospective case studies, where these relevant user-related factors 
were described in sections six and seven of the pro forma. 
Providing evidence of health 
benefit 
The follow-up of retrospective case studies often demonstrated the 
evidence generation issues described in chapter 3.  These were 
exemplified by the limited availability of RCT data for follow-up, and 
specific device-related difficulties were identified in some of these (e.g. 
the problems associated with sham surgery for trials of the PFO 
closure device).  
No single ‗gold standard‘, or 
the comparator changes 
quickly 
As there are fewer guidelines for devices than drugs, there are often 
many co-existing options available to medical professionals. As a 
result, the reference standard (the ‗baseline‘ for an economic 
evaluation) was often difficult to define.  Relative impact may differ 
according to the chosen comparator.  Annemans and colleagues 
(2000) describe this selection problem in early health economic 
models for drugs, declaring that often more than one comparator 
should be considered (to potentially include different competitors as 
well as improvements in general medical practice).  I have shown in 
many of the case studies that this is often intuitive, and can be 
incorporated into a headroom range. 
The relevant comparator can also change quickly due to the short life-
span of a medical device.  The CT scanner case study, for example, 
had already been superseded by a newer model when it came to 
follow-up the case study. 
Long-term impact Often a long time frame is required to consider the real benefit of a 
medical device. This requires buyers to be willing to consider a long 
time horizon which, depending on the financial situation, may not be 
possible. This presented some uncertainty for the headroom analyses. 
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These methodological challenges, rather than presenting insurmountable barriers, introduced 
some methodological opportunities.  In particular I found that a complete analysis may not 
always be necessary to support an investment decision—often a partial headroom estimation 
sufficed.  Where the new technology would offer clear cost-savings, for example, these were 
often easier to quantify and justified development on their own; this also suits the landscape 
of tightened health service spending and the increased pressure on innovators to deliver 
interventions of equivalent (or improved) benefit but at reduced costs (a necessary 
qualification, for example, of attaining NICE‘s medical technology guidance).  This 
demonstrates the headroom method‘s ability to adapt to the prevailing procurement landscape.  
The case studies also demonstrated the potential negative ramifications of this cost-saving 
landscape, in noting that devices for new indications which deliver health benefits to 
previously untreatable patients are likely to be disadvantaged.  Additionally, follow-up of the 
retrospective case studies often illustrated the slow uptake of devices within the NHS 
described in chapter 3. 
Another opportunity presented was the ability to choose the target market by using the 
headroom method to identify where the net gains would be highest.  This was explored in 
depth through the COPD case study, which also demonstrated that important justification for 
a new innovation could be found by considering the wider clinical context, including sought-
after changes in clinical practice; the retrospective case studies showed that this wider market 
context should be investigated for its potential to curtail the case for development as well as 
promote it. 
The industry landscape, representing the cohort of potential headroom method users, was 
shown in the introductory chapters of this thesis to be diverse in nature and dominated by 
small companies.  The varied provenance of device innovation was demonstrated by the 
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sample of interviewees in the qualitative investigation, who were able to reveal the method‘s 
utility in relation to their particular roles.  The interviews also corroborated an underlying 
assumption which was articulated in chapter 3: small businesses lack time and health 
economic grounding, which may currently inhibit rational decision-making in the early stages.  
Moreover, it was demonstrated that even large businesses may not incorporate health 
economic considerations into development decisions, thus also standing to potentially benefit 
from the headroom method. 
The following results synthesis section presents the findings of this evaluation with 
respect to the initial research questions: does the headroom method work, and is it usable by 
device developers? 
 
10.3 Triangulation: Results synthesis 
Discussion of the study‘s findings in relation to the two main research questions are broken 
down into the subsidiary questions described in the methodology chapter (Table 5.1, page 
103). 
10.3.1 Does it work? 
To establish the efficacy of the headroom method, the evaluation sought to determine its 
novelty to developers and its predictive capacity, and to identify what is left out of the 
suggested framework. 
10.3.1 (i) Is it novel? 
Determining the novelty of the method in relation to current early feasibility checks for device 
development was a strong motivation for the interviews; even if the headroom method were to 
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‗work‘, it would not improve decision-making outcome if a similar method were to already be 
employed by developers.  The method provided a learning opportunity for many of the 
participants.  For those already familiar with health economics, its incorporation into the 
development decision stage was perceived to be novel.  Despite the MNC noting the novelty 
of the approach in relation to its own decision-making practices, other very large medical 
technology companies are likely to already systematically and comprehensively consider 
reimbursement prospects pre-development; the method is likely to be of less use to such 
companies. 
As indicated in the interview analysis, the method seemed to provide participants with a 
more concrete way to express and quantify the benefits of their innovations, of which they 
already had a general notion.  In four of the retrospective case studies, the headroom 
development decision was indicated to be either intuitively favourable (SLF bypass graft and 
Cool-cap) or intuitively unfavourable (AmpliChip and ChondroCelect).  In these cases 
headroom was not quantified, either because it was not possible or not necessary to do so.  
Whilst the prevailing research questions transpired to be pertinent, it is difficult to know in 
these cases whether the method‘s output would not have contributed an insight beyond that 
already perceived by the developer, or whether the analysis forces such insight to be 
recognised. 
10.3.1 (ii) Is it a good predictor of market uptake? 
There appeared to be no strict qualifications for an ideal headroom candidate, although those 
technologies that directly replaced the baseline treatment were most likely to generate a 
concrete monetary estimate.  Most difficulties in estimating headroom derived from the 
methodological challenges outlined in Table 10.1; diagnostics were the most problematic, due 
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to the less direct impact these technologies have on patient outcomes and future cost 
implications. 
The method‘s predictive capacity was addressed by the retrospective analyses and their 
follow-up; for the purposes of comparing the headroom decision to later success, the latter 
was judged primarily on its availability in the UK.  A favourable headroom decision outcome 
was followed by widespread NHS uptake for just two of the case studies, which became the 
‗gold standard‘ for the indications considered.  This re-emphasises the fact that a product need 
not achieve full market coverage to be viable, and in fact this is rare for medical devices (due 
to the market factors described in chapter 3).  Indeed, in assessing the business proposition of 
his clients‘ products the business consultant interviewed uses a 40% estimate of market 
coverage as a baseline.  In two of the case studies, the decision outcomes of the headroom 
analyses were uncertain (due partially to the inability to follow the products up), but strong 
caution was offered in relation to their health-economic case for development; these were the 
only two case studies for which no evidence of uptake (anywhere) has been identified.  The 
follow-up of all other case studies identified some evidence of uptake (either internationally, 
and/or for another clinical indication). 
Evidence of any NHS uptake (for the clinical indication specified) was used as the main 
outcome to which headroom decisions were compared.  Of the 17 headroom decisions that 
were followed-up (eliminating SpeechEasy due to it being a consumer product, and omitting 
the two cases for which headroom was uncertain), the headroom method ‗got it right‘ in 14 
cases—around 82%.  The remaining three decisions were contradicted (ChondroCelect, TTT 
and Agento IC).  The headroom for both TTT and Agento IC appeared to indicate a 
favourable development decision, but neither is used within the NHS for the proposed clinical 
indication, due to unsatisfactory clinical effectiveness for TTT and possibly changes in 
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clinical practice for Agento IC.  Before conducting the analyses, this scenario was considered 
to be the less disparaging of inaccurate predictions by the headroom method, as early 
expectations of clinical effectiveness may transpire to be too optimistic.  Therefore, if the 
method is seen primarily as an aid to ‗rule-out‘ the development of devices that will never be 
cost-effective, then the more discrediting scenario is for an unfavourable headroom decision 
to be followed by future uptake.  This was realised in the case of ChondroCelect.  This could 
imply that the headroom method may direct resources away from viable products which 
would otherwise have been developed.  In the case of ChondroCelect, this was due to the 
reimbursement perspective being too narrow, not acknowledging that the NHS allows pass-
through payments for some innovative high-cost technologies.  This one case of an 
unfavourable headroom decision being followed by subsequent NHS uptake led to the 
headroom method‘s sensitivity being recorded as 92%, and its negative predictive value (its 
performance as a rule-out tool) as 67%.  By re-categorising the uncertain headroom decisions 
as unfavourable, accuracy would be 84%, sensitivity would remain 92% (though the test 
would become more specific: 67% instead of 50%) and the negative predictive value would 
be 80%. 
The main limitation of the quantified headroom analyses in relation to the viability of 
product development (which must more appropriately relate to uptake anywhere and for any 
purpose) was the narrow reimbursement perspective taken.  However it was shown that, 
through the process of assessing headroom, the relevant barriers and opportunities to 
commercial viability can often be identified, and when considered alongside the monetary 
headroom analysis offer a good assessment of uptake prospects.  
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10.3.1 (iii) What is left out of the analysis? 
Economic evaluations form only part of an HTA when reimbursement is being considered.  
This was shown to be the case for Stapled Haemorrhoidectomy, where the result of the late-
stage cost-effectiveness analysis was marginally unfavourable, but where the NICE 
committee nevertheless recommended the procedure based on other factors.  This is crucial, 
and vindicates the necessary consideration of the peripheral factors which are noted but not 
quantified in the headroom analysis as well (such as user acceptability, likelihood of 
competitors, and potential changes in clinical practice).  Whilst this discounts the value of the 
headroom method as a strict decision rule, the retrospective case studies demonstrated that the 
pertinent additional factors can usually be predicted at a very early stage, and that when 
considered alongside headroom ‗value‘, always offered a useful prediction of market 
opportunity.  Unlike the suggestion by Girling et al. (2010) that early valuations need 
necessarily be deflated (due to lower actual cost-effectiveness compared with early 
predictions, healthcare provider budgetary constraints, effectiveness of the marketing 
campaign, and competing products that may arise during development) these exogenous 
factors were found to inflate as well as deflate perceived value.  The findings relating to 
omissions of (numerical) headroom are presented below, and where relevant supported by the 
views of the device developers interviewed. 
The reimbursement perspective was found to be too narrow and somewhat idealistic.  The 
most obvious caveat is that the device market is global.  Whereas six of the retrospective case 
study medical technologies did not became available within the NHS, only two of the 
products were not available anywhere upon follow-up (either in other countries or for 
different clinical indications).  This perspective was reiterated by the interviewees, who also 
mentioned alternative types of buyer such as private healthcare providers and the end-user.  
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Indeed, one case study was omitted from the results analysis as it turned out to be a patient 
purchase, and ChondroCelect has achieved funding by means of supplementary 
reimbursement specifically for novel products.  The Ulcer Protector described in chapter 8 
may in the future be made available directly for patient purchase.  Therefore, whilst the 
headroom analysis provided guidance on potential NHS value, if the result had been 
unfavourable it would have been unwise to rule out its development based on this alone.  The 
rationality of local decision-making within the NHS is regularly discussed in the literature, 
and has been found to differ from the perspective taken by NICE (Buxton 2006).  In the 
interviews, the non-alignment of actual reimbursement with the framework assumed by the 
headroom method was also raised. 
Both the case studies and interviews demonstrated the tension between a headroom 
analysis (intended to help investigate the commercial viability of a product) and a standard 
economic evaluation (intended to understand the health economics of a specific application).  
The difficulty of patent protection becomes important here; whereas for drugs the valuation of 
a therapeutic outcome is synonymous with the value of a particular drug (which in the early 
years is patent protected), device competition is much greater.  Additionally, the multiple 
application possibilities of some devices, especially diagnostics, means that their value to the 
health provider should be some weighted average of their impact across all relevant 
applications (Drummond, Griffin, & Tarricone 2009).  In such cases the headroom analysis 
felt somewhat artificial, and whilst the device‘s potential applicability to other markets was 
described within the case studies, basing the development decision on the monetary headroom 
figure for that market alone would have been misguided.  Despite this limitation, the ability to 
assess value by indication was regarded by the SME to be an advantage, proposing to use the 
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method to consider entry into new markets.  The PFO closure case study demonstrated the 
method‘s use in this capacity. 
Strategic factors also require specific consideration in the decision to develop, which may 
be especially relevant where the innovation is an incremental development of a company‘s 
own product; these considerations are not dealt with explicitly by the headroom method.  
Diagnostic devices were often assumed in the headroom analyses to either be completely 
accurate or equivalent to the comparator.  This kept analyses simple, but an extension of the 
method may involve incorporating sensitivity and specificity assumptions more explicitly.  
The omitted factors outlined provide justification for a remark made by the MNC: ‗It 
shouldn‟t be an answer in its own right.  That doesn‟t discount its value‘. 
 
10.3.2 Is it usable by device developers? 
Besides efficacy, the headroom method cannot improve current decision-making if it is not 
usable by those for whom it could provide benefit.  An understanding of its usability was 
attained by assessing: its use at concept stage, the possibility of its application by device 
developers, and the practicality of its incorporation into current decision-making practices. 
10.3.2 (i) Can it be utilised at ‘concept’ stage 
The two prospective case studies demonstrated the method‘s application at an early stage of 
development, and showed how the literature may be used alongside the developer‘s own 
thoughts to inform and furnish headroom assumptions.  The ‗concept‘ stage for the 
retrospective studies was modelled to be around three years pre-launch (or two years for 
incremental developments); whilst it is not known whether this accurately reflects the 
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development time for all of these technologies, it certainly restricted the potential to pick up 
any data relating directly to the product itself. 
In applying the headroom method across manifold medical technologies, the dependence 
of the method on the quality, consistency, and availability of the literature became clear.  
Whilst both this reliance on the literature (not being an expert in the clinical area) and its 
sometimes limited availability (especially where there were very early date restrictions) were 
probably exaggerated within the investigation, this posed a problem particularly for new 
indication devices.  The strategy used to overcome this was to present headroom under 
various scenarios or assumptions, a strategy in which the interview participants saw promise.  
A headroom analysis assesses the potential future monetary benefit of a medical 
technology, but in order to appraise the viability of a project (by considering profit prospects: 
net monetary benefit) this must be considered in relation to projected costs.  Of those 
interviewed, the businesses and consultants indicated very few problems in anticipating 
development and production costs, whereas those in research and clinical settings (and 
according to a consultant: small businesses) find these difficult to fathom, potentially 
underestimating their magnitude.  This may limit the ability of these developers to usefully 
appraise commercial viability, even if the headroom‘s assessment of future monetary benefit 
was accurate. 
10.3.2 (ii) Can the method be applied by device developers? 
The pragmatic approach taken for the retrospective studies and the ulcer protector aimed to 
mimic the restricted time available to device developers, and to make its application 
systematic and accessible by using the pro forma and template of resources.  There is an early 
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suggestion from the interviews that these resources may be useful in helping developers to 
take the method forward and apply it themselves.   
Two of those interviewed (business and design consultants) claim already to use the 
method; this indicates that the method (or some form of it) is usable, and their positive 
comments reveal its contribution.  All interviewees claimed to understand the headroom 
method, and believed its simplicity to be a strong virtue.  That is, despite the factors that were 
identified as being left out (discussed in 10.3.1 (iii)), the method should not be made more 
complicated.  However, some pertinent patterns emerged from the interview data and case 
studies which suggest two primary application difficulties: making the appropriate 
assumptions, and finding data to furnish them. 
On the assumptions side, the strong rose-tinted belief of the innovators in their products 
may lead to biased assumptions, whereas those acting in advising capacities may be more 
independent and objective (though may lack the experience in the clinical area that the 
innovators are likely to have).  The retrospective case studies illustrated that often 
assumptions were necessarily very speculative.  The interview analysis suggested that those 
users in research roles (or with a research background) may more easily identify data in the 
literature, whereas those in business may find this challenging.  The potential for bias extends 
to the identification of data, which regularly required a discerning approach where the 
literature base was wide; indeed, in some cases selecting a different source for data would 
have altered the implied development decision.  The follow-up of some case studies 
demonstrated that companies are indeed selective in the data they choose to report from the 
wider literature (this was particularly the case for the PFO closure device and the Agento IC), 
and this tendency may extend into early headroom estimates.   
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The above commentary should be considered in relation to the headroom method‘s 
application in this evaluation study.  Being both independent and a researcher, I may have had 
advantages in the method‘s application, the results of which may not be replicable in practice.   
On the other hand, being removed from the innovation and the innovator‘s field of expertise 
may have represented a disadvantage.  
10.3.2 (iii) Could it practically be incorporated into decision-making? 
The main practical barriers were identified to be expertise and time.  The issue of expertise 
relates in some ways to the ability to make assumptions and find data described above.  
Although this has not been tested directly in this evaluation, different parts of the headroom 
analysis were found to resonate more clearly with different users.  The positive understanding 
of the method from just a short presentation was encouraging.   
The time available to developers to allocate to researching the development opportunity is 
another matter which is not easily tested, and the assertion that this could pose a barrier to its 
implementation is difficult to argue against.  The retrospective case study analyses took a 
mean of nine hours; whilst most interview participants indicated this to be a reasonable and 
worthwhile use of time, others (most notably the MNC) indicated that to add this to their 
current job function would be unfeasible (and thus would look to outsource such analyses).  
The MNC also hypothesised that analyses would take longer, at least initially, for someone 
unaccustomed to applying it.  However, the time taken for each retrospective case study in my 
own investigation showed no downward trend, reflecting perhaps that each case was unique.  
The average time taken was slightly longer for retrospective studies with a later time 
constraint than those with earlier ones.  This may indicate that the exponential growth in the 
literature base—whilst helping to better inform assumptions and quantify benefits—may 
increase the time required to sift through it and identify the most useful sources; indeed, the 
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wealth of information available for the COPD case study was certainly time-consuming to 
manage.  
 
By summarising the results in relation to the research questions posed at the beginning of the 
project, an insight has been offered into the potential use of early economic evaluation in 
practice, which goes beyond any such understanding conveyed in the literature.  However, by 
exploiting the mixed-methods evaluation output, the lessons that can be drawn reach beyond 
the original remit.  These are summarised below. 
10.3.3 The method‘s form 
During the closing remarks of one stakeholder interview I was asked, in jest, whether I had 
considered the headroom for the headroom method.  Upon reflection, this eloquently 
describes the motivation for this study, and is what I believe to have achieved.  Echoing the 
elicitation of headroom for individual devices, the overall evaluation has taken on an inclusive 
approach, and as a result has extended the analysis beyond the initial research questions.  This 
has been achieved by guiding method choices and analysis around what Patton (1997) 
describes to be a utilisation-focused evaluation, informed by an overarching evaluation goal: 
intended use by intended users.  By broadening the scope and investigating the reasons behind 
the method‘s efficacy and usability, the results attend not only to ‗Does it work‘ but ‗What 
works for whom in what circumstances and in what respects?‘ (Pawson & Tilley 2004, p. 15): 
the objective of the realist evaluator.  The interpretation of results in relation to this 
explanatory perspective is presented over the next two pages. 
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10.3.3 (i)...What works? 
A unifying theme across all case studies was the need to be flexible and adaptive in the 
application of the headroom method.  Accordingly, the step-by-step guide offered by the pro 
forma and template of resources, rather than supplying the precise steps to calculate 
headroom, provided the right questions to work out the most appropriate approach, which will 
differ according to the product under evaluation.  The choices made for a headroom analysis 
must be conscious choices, for which the user should be aware of the underlying assumptions 
and potential limitations of these.  Additionally, other factors identified through the process, 
which are not quantified but which may (either positively or negatively) affect the chances or 
scale of reimbursement, should be recorded.  Together, these inform the research questions, 
which should be considered pre-development or, if it is decided that development should 
proceed, should guide future investigations.  When these were considered alongside the 
quantitative headroom gap, the headroom analysis provided a good assessment of future 
market potential, and thus may provide a useful aid to decision-making. 
10.3.3 (ii)...For whom? 
The stakeholder interviewees reflected just some of the diverse origins of innovation in the 
medical device sector.  Whilst previously considering small businesses to be the foremost 
potential beneficiaries of the headroom method, the interviews illustrated a much wider 
relevant user base.  It was found that even large companies may profit from the method, and 
that its potential use extends beyond industry to anyone involved in the process of innovation.  
However, the way in which different users derive (or perceive to derive) benefit varies 
according to their role and their relationship with that innovation process. 
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10.3.3 (iii)...In what circumstances and in what respects? 
For those looking to explore early indications of product viability, or to sell their ideas to 
funders who must make a similar judgement, the headroom method can be seen to hone in on 
the value proposition where previously reimbursement prospects were either not addressed or 
were considered in a vague or notional manner.  The case studies showed that a clear 
understanding of potential impact was necessary, which was particularly difficult for 
diagnostic devices or medical equipment used for multiple patients.  However, some 
exploratory testing of alternative scenarios can be useful where this clarity is lacking.  As well 
as ascertaining the method‘s capacity to inform very early development decisions, the 
evaluation identified further possible roles which fall beyond this original scope, relating to 
the timing of the assessment and the utilisation of its output. 
Whilst most case studies considered the development prospects of a new innovation 
(where headroom is compared with projected costs of development/production), others related 
to alternative decisions.  For example, some retrospective studies investigated the 
reimbursement value of upgrading a company‘s own device (where headroom must be 
compared with upgrade costs, e.g. CT scanner case study), or considered the reimbursement 
value of directing a current device to a new market (where headroom is compared with 
research and marketing costs, e.g. PFO closure case study, and SME‘s intentions). 
Economic models are described by Miller as the ‗interface‘, the ‗vehicle of 
communication with external decision-makers‘ (Miller 2005, p. 5).  The headroom method 
provides an economic model of a new innovation‘s value, and its use to communicate this 
value with decision-makers (be they funders, buyers, or in-company) was considered by 
interviewees to be important in the later as well as earlier stages.  For those involved in 
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innovation in an advisory capacity, the method was considered to be a useful tool to add 
rigour and structure to their interactions with clients or with those making the decisions. 
 
Having described the results of this evaluation—outlining the limitations of and opportunities 
provided by the headroom method—the next section considers the limitations of this study 
and the opportunities these may present in terms of future research.  
 
10.4 Limitations of the study and opportunities for further research 
The results and analysis of a research study are inextricably bound to the methodological 
choices made, either purposefully or for practical reasons.  Consideration of their potential 
limitations is therefore necessary, in order to judge the validity of results as well as to identify 
possible avenues of further research.  The discussion of these study design limitations and 
further research opportunities are presented below under four main categories: (1) study 
sample, (2) the headroom method‘s application, (3) the approach to the overall evaluation, 
and (4) the indirect nature of evidence. 
10.4.1 Study sample 
There were three sample groups in this thesis: the prospective case studies, the retrospective 
case studies and the interviewees, and for each the selection process was distinct.  Due to the 
research setting of this project, the identification of prospective case studies was in fact not a 
very selective process, and was more opportunistic.  Their contribution to the evaluation 
results were not as significant as the retrospective studies due to their lack of follow-up, 
although they played a strong role in informing the evaluation study design and both offered 
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unique methodological insights.  Although both prospective case studies provided particularly 
insightful interview opportunities, their contribution to the evaluation may have been greater 
had they been designed to address the study‘s research questions more directly.  As efficacy 
could not be addressed, our understanding of usability may have been advanced had the 
headroom analyses been carried out by the innovators themselves.  Although this was 
addressed indirectly through the interviews, a study of the method‘s direct application by 
developers would be the logical next step in future research. 
The selection process of the retrospective case studies from the NHSC database was 
described in detail in chapter 7.  Most notably, exclusion was on a practical basis, and was 
largely due to lack of clarity in the NHSC briefings.  However, the tendency for those 
excluded to be diagnostics and to represent non-replacement technologies may indicate an 
inherent difficulty in ascertaining their potential impact; this finding may have been under-
represented due to their exclusion.  The biggest source of bias for the retrospective case 
studies was their source, being selected from a database whose remit is to provide early 
warning of medical technologies which are close to launch, and which have the potential to 
make a big impact on the clinical or procurement landscape.  This was reflected in the fact 
that only two of the 20 case studies were class I devices.  As discussed, this is not likely to be 
representative of the sector, and most crucially it biased the sample toward successful 
products.  However, a study by Simpson et al. (2004) which assessed the accuracy of this 
forecasting by the NHSC (spanning across all types of briefings including those for drugs), 
found that of a sample of 117 technologies, 35 were initially predicted to make a big impact 
on the NHS but 30 of these (86%) transpired to be false positives.  Of my own case studies 
that were followed-up, six were not available on the NHS for the indication considered. 
 292 
 
The possible partiality of the interviewees, who were proactively sought but whose 
interest in taking part inherently reflects their interest in the subject, was discussed in chapter 
9.  Responses may therefore have been biased as a result.  Although the interviewees span a 
wide range of potential users, it is difficult to know whether their attitude is typical of their 
sector.  Certainly, if larger companies were better represented in the sample, then the 
investment appraisal techniques currently used by these could have been explored.  
Nevertheless, the presentation of the UK‘s medical device market landscape showed these 
larger companies not to be representative of the industry as a whole.  Moreover, the 
interviews did not intend to provide a thorough characterisation of current decision-making 
practice across the medical technology sector, but to develop a better understanding of some 
of the barriers and opportunities around the headroom method‘s use.  A postal survey directed 
at a large number of device developers may provide a way to better explore current practice, 
and presents a potential future avenue of research (although, as noted by Pike & Sharp (1989), 
this technique may be subject to response bias also, with those using more sophisticated 
investment techniques being more likely to respond). 
10.4.2 Headroom application 
10.4.2 (i) Uncertainty 
The application of the headroom method through this thesis has been described in some 
detail, and the development of materials (the pro forma and template) intended to make this 
application as systematic and reproducible as possible.  However, the precise approach taken 
was noted to vary case study by case study, according to the source of the technology‘s 
proposed value and the information available in the literature.  Uncertainty was not formally 
incorporated into the analyses, though a form of sensitivity analysis was often performed to 
test the effect of altering assumptions (with regards to comparators or magnitude of health / 
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cost impact) on the headroom outcome.  This lack of formal incorporation of uncertainty may 
be regarded as a limitation, especially given the inherent financial risks associated with 
product development. 
The development process for a new product comprises in reality not of a one-off 
investment decision made at the outset of a project which cannot be reversed, but a chain of 
decisions, considered to take place at a series of stage gates (Cooper 2009).  Although the 
initial concept-screening stage decision is perhaps the most critical but most difficult point for 
investment, the real options approach recognises the flexibility offered by adapting or revising 
budget allocation decision at a future date when some uncertainties have been resolved (Johal, 
Oliver, & Williams 2008).  The value provided by this flexibility (reflecting the ability to 
defer the decision to abandon development or to adapt to changing market conditions or 
technology performance) necessarily inflates early valuations so that, perhaps un-intuitively, 
‗the larger the amount of uncertainty, the greater the opportunity for value creation‘ (Johal, 
Oliver, & Williams 2008, p. 109).  Whilst much of the real options literature does not provide 
details on how the initial valuation should be made within the context of the healthcare sector, 
Girling and colleagues (2010) consider uncertainty alongside early headroom valuations, and 
simplify the options approach by considering there to be just two decision gates.  The authors 
reveal mathematically how a subset of these uncertainties could be considered, providing a 
partial valuation and therefore placing a lower bound on expected product value (Girling, 
Young, Brown, & Lilford 2010).  Further research into the formal incorporation of 
uncertainty into headroom may represent a potential future avenue of research.
48
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 As described in the literature review, Vallejo-Torres et al. propose integrating health economics into the 
product development of a medical device at the early, mid and late stages (Vallejo-Torres et al. 2011).  However, 
uncertainty is explored in the mid and late stages only (when some clinical evidence is available).  
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The decision not to formally incorporate uncertainty in this way lies in its impracticality.  
This options-style approach involves a complex mathematical manipulation and quantification 
of expectations and (stage-related) uncertainties, which may be unfeasible in practice.  The 
use of real options by businesses has been described more readily in relation to the 
pharmaceutical industry (see for example Nichols (1994) and Rogers, Gupta & Maranas 
(2002)).  One practical barrier to its use by device firms is the required numerical estimate of 
volatility, which in the case of larger and more established pharmaceutical firms may be more 
tangible: ‗Merck‟s experience with R&D has given us a database of information that allows 
us to value the risk or the volatility of our research projects, a key piece of information in 
option analysis‘ (Nichols 1994, p. 90).  Johal and colleagues (2008) indicate that the medical 
device industry face similar issues to the pharmaceutical sector early on, where early 
valuations are subject to considerable technological, regulatory and market demand 
uncertainty, which must be accounted for.  However, I demonstrated in the context-setting 
chapter 3 that, in fact, the uncertainties surrounding device development tend to be lower than 
for pharmaceutical innovation, due in part to their engineered design (which is often an 
incremental modification) rather than discovery process, lower regulatory hurdles, and shorter 
development time (thus limiting the uncertainty surrounding the changing market context).  
Indeed, the retrospective case study analyses demonstrated that the clinical and market 
context factors which did transpire to affect demand were largely predictable—though of 
course this is not always the case. 
By not accounting for the positive value of uncertainty and decision-deferral, the main 
concern is that an NPV approach (such as that proposed in this thesis) would lead to the non-
development of potentially successful products (Girling, Young, Brown, & Lilford 
2010;Johal, Oliver, & Williams 2008).  In my own test of headroom decision implications, 
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there was just one case for which the headroom analysis (though not quantified) implied an 
unfavourable development decision which was subsequently successful in achieving 
reimbursement: as discussed, ChondroCelect has achieved reimbursement via pass-through 
payments.  This highlights the ambiguity around reimbursement routes, which does represent 
a limitation of the naïve perspective of the headroom method.  This being said, the developer 
of the technology may have been better informed of alternative means of reimbursement, and 
could have incorporated this into his decision qualitatively. 
The interview analysis highlighted that, to impact current decision-making, the headroom 
method must be simple.  Formally incorporating uncertainty may therefore be prohibitively 
complex, though this could be investigated in the future. 
10.4.2 (ii) Expanding the analysis   
The HTA of new products by decision-makers has been shown to consider aspects of a 
technology‘s offering outside of its cost–effectiveness alone.   There has therefore been a call 
for appraisal committees to incorporate these other factors more transparently and consistently 
into coverage decisions, for which multicriteria decision analysis has been suggested (Tony et 
al. 2011).  First introduced by Saaty (1994), the analytical hierarchy process (AHP) (as 
presented in the literature review) is one regularly cited method of multicriteria decision 
analysis, which involves structuring a decision-problem into its key elements and attaching 
weightings to those elements based on their relative importance to the decision-maker.  This 
technique has been applied to various decision-making settings and scenarios in the literature, 
and may be relevant to device developers given the multiple strategic factors that must also be 
considered at the concept-screening stage.  Mayhew (2009), for example, describes other 
contributors of value to a company which would not be captured within a headroom analysis:  
human resources value, marketing value, reputation value and innovation value.  Thus, 
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incorporating these into a development decision systematically (e.g. using AHP) may 
represent a worthwhile methodological extension to the headroom method which could be 
investigated in the future.  As the relevant factors and their relative importance would vary 
according to the user, this was outside the remit of this particular evaluation, which aimed to 
evaluate the headroom method according to its capacity to provide a simple tool that could be 
applied across technologies and by any device developer. 
10.4.2 (iii) Approach to QoL estimations  
The recommended approach to HRQoL estimation was described in chapter 4, which 
described three methods in order of preference.  An original methodological contribution to 
the headroom framework was provided by the second of these methods: manipulating the five 
health dimensions of the EQ-5D.  This technique was applied to three case studies: stapled 
haemorrhoidectomy, TVT and the ulcer protector.  Whilst its application to the ulcer protector 
cannot be validated (though the innovators indicated that the approach contributed to their 
understanding of HRQoL), the other two were followed-up and compared with subsequent 
evidence.  The health impact valuation for stapled haemorrhoidectomy transpired to be fairly 
accurate.  In the case of TVT the impact was overestimated; although the baseline health state 
of urinary incontinence was well predicted, the assumed resumption to full health was not.  
This may be improved when validated value sets become available for the updated EQ-5D-
5L, where the increments will be smaller and thus sensitive to more moderate health impact  
(EuroQol 2012b).  This greater sensitivity to smaller changes in health may also be more 
appropriate for valuing the improvement in self-care modelled for the Ulcer Protector.  This 
updated instrument could be incorporated into future research. 
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10.4.2 (iv) Development cost analysis 
Another novel contribution of this study was to consider the allowable magnitude of 
development costs, in cases where MRP and market size could be estimated.
49
  This was 
demonstrated in some detail for the COPD case study, was deemed inappropriate for the Ulcer 
Protector, and transpired only to be possible for five of the retrospective case studies.  One of 
the main limitations in estimating these allowable development costs was the presumption of 
full market coverage.  As discussed, this is particularly unlikely for medical devices.  In order 
to more appropriately conform to the guideline of optimistic but plausible assumptions, the 
market size estimate should probably be revised downwards.   
Due to my limited understanding of the appropriate timeframe for companies to recover 
development costs, this was implicitly assumed to be the amount of time it would take for the 
company to sell the device to the full (estimated) market size (i.e. the number of relevant 
patients identified, which was often presented on a  per year basis).  This may be somewhat 
artificial, as companies are likely to have their own preferred timescales, which will be 
capped by the time it takes for the technology to be superseded by competitors (which may be 
within or beyond the timeframes used in this thesis). 
10.4.2 (v) The present value of costs and benefits 
NHS-relevant costs and benefits were discounted at the appropriate rate for the calculation of 
headroom throughout this thesis, in accordance with NICE‘s stated discount rate (3.5%) 
(NICE 2008b).  However, the objective of the headroom method has been described as 
estimating the future benefit to be considered within a developer‘s own CBA.  By comparing 
the NPV of commercial costs and benefits (benefit being the product‘s value, as estimated by 
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 In some retrospective case studies the allowable development costs were subjectively explored where a 
headroom rather than MRP was available. 
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the headroom method), the potential for profit may be explored from a very early stage.  An 
omission of this framework, as presented in this thesis, is therefore the failure to convert these 
costs and benefits into their present value (pre-development).  This has been explained by 
noting that the internal rate of return (the discount rate) required to convert the value of costs 
and benefits to their present value is likely to differ substantially by developer, and even 
throughout the period of investment (due to varying risks associated with different parts of the 
development process (Johal, Oliver, & Williams 2008)).  It is proposed, therefore, that this 
should be considered by the developers individually when they come to use the tool.  As a 
result, however, the effect of the cost-benefit timescale has been underestimated in this thesis, 
and the value of benefits accrued in the future by selling the device (i.e. headroom) would 
receive relatively less weight than the upfront costs of development, which must be incurred 
earlier. 
10.4.3 Approach to the headroom method‘s evaluation 
10.4.3 (i) Absence of investigator triangulation 
Investigator triangulation is where data is collected and analysed by more than one researcher 
(Clarke 1999).  The pro forma and template of resources aimed to reduce the inherent 
subjectivity of the headroom method.   However, to remove the effect of the researcher from 
this type of research was impossible, although I have attempted to make this possible effect as 
transparent as possible.  My background in research (and limited exposure to commercial 
endeavours), and the potential impact of this on results, was explored qualitatively in the 
analysis of interview data.  However, the validity of the retrospective case studies may have 
been improved if the case studies were repeated by another researcher, in order to better 
explore the subjectivity of analyses.  The same could be said for the interview analysis, which 
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was also conducted by one researcher only.  Time and resource constraints inhibited the 
duplication of research, which may present a worthwhile future research opportunity. 
One retrospective case study did duplicate one of four conducted by McAteer (2011) in 
her thesis on the use of the headroom method for regenerative medicine therapies.  In the 
current thesis, I aimed to replicate as far as possible the context of the developer at the 
concept stage, which included the information available in the literature as well as the 
potential time constraint of an early evaluation, and therefore differed from McAteer‘s 
approach.  Rather, McAteer (2011) provides three detailed health-economic models of the 
technology‘s potential cost-effectiveness, and the health benefit required to achieve a certain 
level of funding (an estimate of which already existed in the literature).  The overall results 
presented are similar (although McAteer concludes that headroom may be sufficient to 
warrant the treatment if a long-term perspective is taken, whereas I conclude with the same 
argument but note that NICE seems unwilling to take such a perspective).   
10.4.3 (ii) Lack of data saturation 
Saturation is achieved when the researcher no longer obtains new information or insight by 
pursuing further examples; the concept is often used in qualitative research to determine the 
appropriate sample size.  In both the case studies and interviews, information was certainly 
corroborated within the samples and trends in the data were apparent, but each case study or 
interviewee did seem to convey a fresh perspective and an opportunity for learning about the 
headroom method‘s application and potential limitations.  Saturation therefore may not have 
been achieved, and further insight may be gleaned from the perusal of additional examples.  
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10.4.3 (iii) Imperfect follow-up 
The follow-up of retrospective case studies aimed to determine the actual use of the products 
and their presence on the market.  However, as attempts to contact their developers were 
unsuccessful, this follow-up was also used to determine whether the headroom analysis would 
have appeared favourable to the developer, by comparing headroom to published evidence on 
price and/or costs associated with the device.  Whilst the decision implication was often 
intuitive, there was clearly an element of subjectivity in this follow-up, which also lacked 
details around the actual costs of development and most notably the predictability of these by 
developers.  Indeed, the interview analysis indicated that cost predictions may be difficult for 
developers without a strong commercial background.  The rapid price erosion of medical 
devices may imply that follow-up was also subject to error. 
The headline predictability of market uptake was judged in relation to a product‘s 
availability in the NHS.  This was because the headroom analyses were conducted with this 
market in mind, both in the threshold value of a QALY employed, as well as the perspective 
on the relevant comparators and service cost implications.  However, viewed globally, only 2 
of the 20 retrospective case studies appeared not to be available anywhere in the world.  This 
demonstrates that the headroom method should be used to provide an appreciation of the 
potential reimbursement prospects in the UK market, rather than to make the development 
decisions per se. 
10.4.3 (iv) The headroom method as a prognostic test? 
A validation of assessment methods for new product development in the medical sector has 
been noted to be largely absent from the literature (Bartelmes et al. 2009).  This thesis sought 
to address this for the headroom method, but does not treat such an assessment as a test of 
diagnostic validity.  The reason for this is largely due to the purpose of the headroom method, 
 301 
 
which is not exclusively to provide an accurate prediction of future cost-effectiveness, but 
rather to identify those products that may not be viable.  Whilst various statistics have been 
presented, most notably in relation to the method‘s proficiency as a rule-out method, these 
should be interpreted with caution and therefore have not been presented as the headline result 
of this evaluation.  This is due in part to the multiple other context factors and research 
questions that transpired to be important for each case study, the imperfect nature of the 
follow-ups, and perspective of the developer which is likely (and has been shown) to extend 
beyond the UK border. 
As noted in the methodology chapter, McCabe and Dixon (2000) provide a review of and 
recommendations for testing the validity of cost-effectiveness models, which serve to endorse 
the decision not to treat the headroom method solely as a prognostic test in this evaluation.  
The authors acknowledge that whilst the overarching purpose of all economic evaluation 
models is essentially the same—‗to help the decision-maker reach a better informed and 
rational decision‘ (McCabe & Dixon 2000, p. 508)—the specific way in which a model aims 
to achieve this differs according to the reason for which it is employed.  A framework is 
provided in the paper for assessing validity, which focuses on four main aspects of a model: 
structure, inputs, results, and the value of the model to the decision-maker.  With respect to 
the first criterion, a brief critical assessment of each case study‘s structure (the descriptive 
validity of the economic evaluation presented) accompanied all case studies.  In many cases 
the evaluations were acknowledged not to reflect the whole clinical story, but it was 
contended that increasing the complexity of the model would not impact the particular 
decision implication for that case. 
The second assessment of validity is of the model‘s inputs (internal validity) which relates 
to the selection of  data used to furnish the models (McCabe & Dixon 2000).  Nuijten (1998) 
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provides guidance on this topic, and notes that the modeller should ‗be able to evaluate the 
strengths, weaknesses and possible sources of bias that may be inherent in the data used‘ 
(Nuijten 1998, p. 314).  In the headroom analyses presented in this thesis, data selection was 
often opportunistic (I used what I could find), but the quality of data sources was assessed and 
their selection was based on this assessment where possible.  However, no strict guidelines 
relating to quality were used, and given the potential for bias discussed, internal validity may 
pose a genuine problem when the method is employed by innovators.  An assessment of the 
third criterion—comparing the results of the model with the real-life outcome (predictive 
validity)—was facilitated by the retrospective case studies, the results of which were 
summarised in section 10.3.1.  The fourth and final criterion contests that ‗the value of the 
model to the decision maker goes beyond its ability, or otherwise, to produce accurate 
predications‘, and underlines the need for models to be assessed according to their being 
‗appropriate to the decision making context‘, ‗understandable‘, and ‗believable‘ (McCabe & 
Dixon 2000, p. 510).  The evaluative approach taken in this thesis has addressed these 
important factors. 
10.4.4 The indirect nature of evidence 
The primary limitation of this study, from which the majority of other limitations discussed 
derive, is the indirect nature of the evidence used to critically appraise the headroom method.  
The inherent bias of device developers has already been discussed, which raises the question: 
would a developer ever formulate an unfavourable headroom assessment, or; would they take 
heed of an unfavourable headroom result?  The motivation of interviewees to engage with the 
headroom method was explored in chapter 9, and was shown for the innovators to revolve 
mainly around justifying to buyers or funders the value of their products.  This casts doubt 
over the questions posed above, though may reflect the timing of the interaction (well after 
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true ‗concept‘ stage).  For those in consulting roles the headroom method was considered to 
offer an opportunity to rein in the enthusiasm of innovators.  The positive views in this regard 
of the two consultants that claim to use the method are pertinent, although their insight was 
perhaps underexploited in the interviews, the format of which were kept relatively 
homogeneous across the whole sample.  
As discussed in chapters 3 and 4, the headroom method relies on a NICE decision-making 
framework which in reality is rarely applied to devices.  Therefore the assumption is that 
local-level purchasers are rational and also consider cost-effectiveness when making coverage 
decisions.  However, previous discussions within this thesis have revealed that this is not 
always the case, or that at least the perspective from which a cost-effectiveness judgement is 
made is not always a system-wide one.  Other factors certainly influence whether or not a 
device is successful once launched, outside of cost-effectiveness alone.  The retrospective 
case studies suggest that this situation is not as discouraging for the headroom method as it 
may seem, as applying the headroom method using the materials provided seems to pick up 
on the factors influencing uptake.  However, the identification of these factors—like 
headroom calculations—also requires an element of subjective judgement, and therefore it is 
unclear whether such assessments would have been made by the developer in the same way.  
As mentioned previously, it is also difficult to know whether these factors would be explored 
by developers in any case, or whether their identification was facilitated by the headroom 
method.  Although not possible to test through the retrospective case studies, the headroom 
analysis for the ulcer protector did identify a major competitor of which the innovators had 
not been previously aware.  
In addition to the question of how effectively the headroom method would be used in 
practice, perhaps an even more fundamental question is whether it would be used in practice.  
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Whilst all interviewees expressed their intention to take the method forward and use it in the 
future, the success of this cannot be surmised within this project.  The difficulty in engaging 
with industry for the identification of prospective case studies
50
 suggests an innate resistance 
to alter current practice (or may reflect an instinctive secretiveness).  Any future progress in 
understanding the impact of early economic evaluation must derive from research on its use 
by the stakeholders themselves.  
 
The most important future research questions motivated by the discussion of limitations in 
this section are summarised below. 
10.4.5 Summary of future research questions 
The limitations highlighted above in relation to the headroom method‘s application within this 
thesis have intimated a number of possible development opportunities and avenues for further 
research around the headroom method.  The incorporation of uncertainty into pre-market 
value considerations by companies continues to be on the MATCH research agenda (Girling, 
Chapman, Lilford, & Young 2012;Girling, Lilford, & Young 2011;Girling, Young, Brown, & 
Lilford 2010).  In terms of the very early stage setting considered in this thesis, deterministic 
sensitivity analysis was often used where input parameters were very uncertain.  These 
sensitivity analyses were exploratory, but a worthwhile avenue of future research may be to 
investigate the marginal benefit of additional modelling.  For example, in many case studies 
the totality of the clinical story was acknowledged not to be fully represented, but it was 
contended that further modelling would not alter the implied development decision (and thus 
                                                 
50
 In the earlier phases of the project, many (unsuccessful) attempts were made to engage with industry and 
thereby to foster collaborations which could serve as prospective case studies for the thesis.  These included: 
presenting the method and proposing collaboration on a MATCH partners day, placing an advert on the Medilink 
West Midland‘s website, and attending / presenting at various industry-facing conferences and forums (e.g. 
Knowledge Transfer Network conference, ABHI events and research galas). 
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would not be worth pursuing).  However, in cases where the decision implication is only 
marginally favourable or unfavourable, the value of additional modelling may be much 
higher.  This commercial application of value of information analysis has been discussed 
briefly by Vallejo-Torres et al. (2008), but could be investigated more formally in the context 
of very early decision-making. 
The development cost analysis proposed in this thesis would benefit from further 
investigation in terms of its value to device developers.  In particular, the time frame over 
which development costs could acceptably be recovered should be explored.  Likewise, 
appropriate discount rates to apply to headroom valuations (which are likely to differ by 
developer) could be elicited.  Another potential research question is whether other decision 
factors could be integrated into the headroom method, using multi-criteria decision analysis.  
Given the qualitative research results presented in this thesis, an important research question 
to be addressed concurrently would be how such an extension to the headroom method might 
affect its usability or likelihood of uptake. 
If the particular mixed-methods evaluative approach described in this thesis were to be 
taken forward, the design limitations outlined provide a platform for future research 
recommendations.  A particularly useful research question would be: how subjective is the 
headroom method?  Although this was explored qualitatively in the interviews and 
illustratively in the case studies, inter-researcher reliability of headroom estimates could be 
investigated by duplicating case studies (investigator triangulation (Clarke 1999)).  The same 
could be said for the thematic analysis undertaken of the interview data.  The biggest barrier 
to providing concrete performance results in this study was the source of retrospective case 
studies (the NHSC), which provided a close-to-market sample of medical technologies; this 
biased the study sample toward successful products, and also limited it to bigger-impact 
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technologies.  A less biased sample of retrospective case studies would therefore be beneficial 
for future research.  However, this may be limited by practical constraints, as it would require 
businesses to be open about medical technologies that have been abandoned somewhere along 
the development pathway.  More promising, therefore, may be a research strategy which 
employed numerous prospective case studies, which could be followed over a longer 
timeframe. 
A strategy that would mitigate most of the limitations outlined above would be one which 
investigated the use of the headroom method among device developers themselves.  This 
study has provided an early indication that the headroom method (as applied in this thesis) 
may be useful for developers; possible barriers to its use as well as further opportunities have 
also been identified.  In order to further the research and test these findings, direct evidence of 
the headroom method‘s use among developers will be required. 
 
10.5  Implications 
In the methodology chapter, it was briefly mentioned that evaluations could either be 
formative (if the aim is to support program improvement) or summative (drawing conclusions 
on a program‘s effectiveness) (Scriven 1967).  The discussion of results has hopefully 
demonstrated that this evaluation has contributed to the current state of knowledge in both of 
these capacities.  By outlining the formative and summative results of this evaluation, its 
implications are summarised. 
10.5.1 Implications for future applications of the headroom method 
A strong motivation for this project was to explore the feasibility of generating very early-
stage headroom estimates (in a way which might be replicable by industry).  By applying the 
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method to a wide spectrum of examples, the study offered methodological insights into; (a) 
how and for what the method worked best, and (b) how its application might be improved.  
Future applications of the method should be cognizant of these insights.    
The results synthesis presented earlier in this chapter described the form in which the 
headroom method‘s application appears to be most effective.  It also discussed for whom the 
method might be useful and in what ways, and highlighted its potential uses outside of its 
original remit (e.g. to consider entry into new markets or to communicate value with 
stakeholders).  The case studies demonstrated various pre-requisites for the successful 
application of the headroom method.  Firstly, there should be a major marketing opportunity 
among healthcare providers.  The technology and its application should be clearly set out, 
including the relevant patient population.  Additionally, the comparator treatment should be 
clear.  That said, the case studies demonstrated that sensitivity analysis can be used to alter 
assumptions relating to the relevant treatment comparator (e.g. modelling improvements in 
current clinical practice or anticipating the emergence of competitors), in order to present 
alternative headroom estimates or a headroom range. 
The case studies revealed what medical technology characteristics were conducive to 
straightforward evaluation using the headroom method.  Technologies whose relationship 
with current practice can be modelled clearly are most easily assessed: this includes 
replacement technologies, incremental developments, and in some cases new indications 
(whose comparator is ‗nothing‘).  Difficulties arise where value is dependent on complex 
changes in clinical pathways.  For such products, health economic benefit is contingent not 
only upon its main value proposition but also on its cost and resource implications, which 
may be seen across different parts of the health service and to disparate effect.  It is for this 
reason that many of the diagnostic technologies were excluded from the retrospective case 
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study sample, and why those that were selected rarely produced an MRP.  The E-medICS case 
study provides a good example of a complex (service delivery) intervention, for which no 
headroom was delivered.  The near-patient COPD monitor also represents a complex 
intervention, whose potential impact was greatly simplified and whose wider healthcare 
resource implications may not have been considered sufficiently.  For such scenarios, there 
should in the future be a stronger role for sensitivity analysis. 
Around half of the retrospective case studies considered products which would not be 
used on a per patient basis, and therefore whose value was dependent patient through-put 
considerations.  These implementation/distribution issues were difficult to interpret in the 
context of the retrospective case studies, and as a result values were not always expressed as 
MRPs.  In future applications of the method, where the developer is engaged with the 
headroom evaluation, these issues should be explored and incorporated into headroom 
estimates.  Implementation considerations also affect the developer‘s own cost benefit 
analysis; where the magnitude of allowable development costs was assessed in this study, 
uptake was usually considered to be 100%.  This should be revised downwards in the future, 
and should incorporate the developer‘s expectations of realistic market penetration.  
Additionally, the developer‘s internal rate of return should be used to calculate the net present 
value of the proposed product development project.  
The headroom method has been shown to be a flexible tool, for example allowing partial 
headroom estimates to support investment decisions where these partial valuations are 
deemed sufficient to cover costs.  The method‘s flexibility may also be important in the 
context of a changing procurement landscape.  In particular, the cost-saving criterion of the 
medical technology guidance stream within NICE may in the future be incorporated into 
headroom estimations.  In such a setting, headroom valuations would derive exclusively from 
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expectations of cost impact, whilst investigating the feasibility of at least equivalent health 
benefit.   
10.5.2 Wider effectiveness implications 
‗...the more complex reality is, the more dangerous it is to rely on intuitive short-cuts 
rather than careful analysis.‟  
               (Williams 2004, p. 14) 
The above quotation summarises the danger of relying blindly on the results of a headroom 
assessment.  The method (in its early use at least) proposes to usefully guide resources away 
from un-lucrative ventures, and so it is in the interest of the user to be realistic.  The 
headroom method has been found to be most effective when a wider perspective is taken, and 
the materials generated provide the resource for this.  By combining headroom estimates with 
the consideration of important contextual factors identified, the headroom method has been 
shown—even within this early framework—to helpfully assess reimbursement potential.  This 
should be considered alongside other strategic factors by device developers.  Accordingly, 
just as economic evaluation is employed by decision-makers at the demand-side to help 
clarify the resource allocation decision rather than to make the decision on its own, the 
headroom method and the CBA that it facilitates for the developer should be viewed as a 
useful tool to assist choice rather than to make it: 
‗I take the objective of CBA to be to assist choice (not to make choice, nor to justify past 
choice, nor yet to delay matters so that some previously chosen course of action has a 
greater chance of adoption, although I recognise that each of these purposes may also be 
served by the skilful employment of CBA). 
             (Williams 1972, p. 201) 
The above quotation also addresses a further role that has been identified for the headroom 
method through this evaluation, which is to justify a previous development decision or to 
increase the likelihood of funding or future adoption.  Whilst considered by many of the 
interviewees to represent a valuable function, a word of caution should be issued here.  In the 
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literature review, the development of economic evaluation within the healthcare sector was 
described, the standards of which were noted to have greatly advanced over time.  The use of 
economic evaluation in the past was more open to subjectivity, and its use as a marketing tool 
sometimes led to the inappropriate reporting of cost-effectiveness results (Drummond 1991).  
Whilst this is now better regulated, industry-sponsored cost-effectiveness analyses are still 
systematically found to report more favourable results than non-industry sources (Chauhan, 
Miners, & Fischer 2007;John-Baptiste & Bell 2010).  Thus, the danger is that the headroom 
method‘s use is guided entirely by the user‘s own agenda, which is not the intention of the 
method.  Employed carefully and honestly, however, it has been shown that the headroom 
method could assist development decisions and ground these in the potential value of the 
product.  
 
10.6  Conclusion 
The importance of health economics in informing coverage decisions is clear, and has 
prompted the institutionalisation of CBA in many countries.  With the strong technology push 
from industry and the concurrent strain on the healthcare budget, the role of economic 
evaluation in maximising the efficiency of spending is critical.  However, by the time a 
comprehensive HTA is undertaken it is too late to modify or terminate the development of 
medical technologies without huge costs to the manufacturer (Bartelmes et al. 2009).  In this 
thesis I have proposed that, in the very early stages of development, developers face a similar 
optimisation problem which can also be clarified by considering the decision to develop as a 
CBA.  With development opportunities competing for limited resources, this study set out to 
evaluate the headroom method according to its capacity to usefully assess market potential. 
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Research relating to methods of early economic evaluation in the literature lacked a 
critical lens and a pragmatic focus.  By considering the value of the headroom method in 
terms of its commercial implications, and in relation to the context within which the method‘s 
value will be realised, this study has provided an important methodological contribution to a 
relatively narrow literature base.  The mixed-methods design of this study was guided by its 
research questions, such that each part of the evaluation uniquely contributes to the better 
understanding we now have of early economic evaluation and its use in practice.  When 
considered together, the results provide a platform for recommendations regarding the future 
use of the headroom method. 
One of the main objectives of this study, as described in the introduction to this thesis, 
was to find out whether using the headroom method to explore commercial viability is 
feasible or even desirable for device developers.  The process of innovation and the 
accordingly short lifespan of a medical device, as described in chapter 3, mean that 
commercial viability checks (to be undertaken early and rapidly) are surely desirable.  Having 
initially considered small-scale developers to be the most likely to benefit from the headroom 
method, the user-related research conducted in this thesis demonstrates that the potential user 
base is wider than initially anticipated.  Involvement in the innovation process can take many 
forms; this research considered just some of these, but showed that the method may support 
not only the consideration of development value by innovators (whether these be individuals, 
health service staff, small companies or large companies), but also by those acting in an 
advisory capacity.  Health-economic value considerations were found to be largely absent 
from the decision-making processes of the developers interviewed, who suggested that 
integration of such considerations would be desirable: the gap for the method hypothesised in 
the early parts of this thesis has been confirmed. 
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The feasibility of the method‘s utilisation by developers was also investigated through the 
case studies and interviews.  The method‘s relatively simple nature was considered to be an 
asset—and indeed, a prerequisite for its adoption by developers.  All bar one of the case 
studies were conducted under the premise of ‗headroom in a day‘, and the method was found 
to be accessible to developers.  However, the practicality of its application may vary 
according to the user, with those from a research background more readily identifying the 
relevant data in the literature, and those in commerce having a firmer grasp of development 
and production costs (to which ‗headroom‘ must be compared).  In addition, the strong belief 
of innovators in their innovations could threaten the objectivity of their early headroom 
assumptions.  The thesis has demonstrated the headroom method‘s application to a wide range 
of medical devices, addressing a broad set of clinical problems and change propositions for 
the health service.  Some were more easily assessed than others.  In particular, those devices 
that posed a simple change to current practice were more easily evaluated than those whose 
health or cost impact was less direct (e.g. diagnostic tests). 
Another important objective (and the principal novelty) of this research was to assess the 
possible implications of basing development decisions on early expectations of reimbursement 
value.  This was facilitated by the follow-up of retrospective case studies, where headroom 
was estimated (based on information that would have been available at an early stage of 
development) and then followed-up to the present day to compare the headroom outcome with 
subsequent uptake.  (Numerical) headroom assessments predicted NHS uptake with a 
sensitivity of 92%; the negative predictive value of the method (proficiency as a rule-out tool) 
was 67% and, overall, NHS uptake was correctly predicted in 82% of cases.  These statistics 
should be interpreted with caution given the close-to-market context of the study sample, 
which limited its exposure to unsuccessful products.  The performance results indicate that 
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numerical headroom assessments should not be used directly to inform a development 
decision, primarily due to the narrow perspective with which reimbursement is considered 
(which was limited to the UK market and to the specific clinical application being 
considered).  It has been shown that early estimates of reimbursement value should be 
considered alongside the numerous (unquantifiable) factors which may affect the magnitude 
of that value (factors relating to the appropriateness of early assumptions, and potential 
changes in the clinical and market context).  However, the retrospective case studies 
demonstrated that these factors can often be predicted from an early stage, and that—by 
considering them alongside the monetary value identified—a good assessment of commercial 
opportunity can be provided.   
The evaluation identified a number of further opportunities provided by the headroom 
method.  As well as informing development decisions, its role was expanded to include 
identifying and comparing the most relevant sub-populations, informing a product‘s design, 
planning the focus of future data collection, and considering entry into alternative markets.  
Additionally, the method was found to offer a platform to communicate or discuss value.  
Indeed, its use as a tool for consultants was highlighted, and the headroom method‘s 
assessment of the near-patient monitor for COPD has helped to secure funding for its 
development. 
In conclusion, this study finds an important role for the early integration of health 
economics into decision-making by medical device developers.  The method worked most 
effectively when a flexible and inclusive stance was adopted, suggesting that using a ‗back of 
the envelope‘ calculation in isolation to rule-out development may be suboptimal.  However, 
this research suggests that the headroom method could offer a practical way to improve the 
efficiency of R&D spending, by grounding development choices around the potential 
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healthcare value of a product and by throwing into sharp focus the essential research 
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3. Market size   
Market size per year: 
 
4. Health Service 
 
Changes in resource use.  Any changes in 
service delivery costs to the NHS that will 
result from the application of the new 
technology, including the disinvestment in 
previous practice.  This could include: Staff 
time, hospital bed days, GP visits, A&E visits, 
etc.  It should not include services for which 
the NHS (and personal social services) is not 
financially liable (e.g. lost productivity and 
[non-health] social care costs), but these 
should be noted in writing below to add to 
the verbal case for the product (NICE may 
incorporate social care costs into cost-
effectiveness estimates in the near future). 
 
 If relevant and not included in service cost 
impact above, search for price of the 
currently used product (P1). 
 
Use HCHS index to inflate estimates to 
current prices * 
 
Describe any potential costs/savings that 
































Potential impact of the new device on 
patient health, as compared to current 
practice (preferred method of elicitation is 
from studies using the EQ-5D).   
Where NICE have not produced relevant 
economic analyses, search for cost-
effectiveness studies or systematic reviews 
within the disease area (the CEA registry 
offers a useful platform to identify these 
studies). 
 
Describe any impact on patient health that 













(Av. per person) ∆QALY= 
 
6. Developments (clinical & 
healthcare context) 
 
Consider the following questions to help you 
think about the space for your product 
within the market.  
 
Does the technology address any key national 
objectives for improving care in this area? 
 
How will the technology complement current 
practice? Is current practice likely to change? 
 
Are there any indications in the literature of 
potential effectiveness? 
 
Have you identified any direct competitors? (This 
could be another specific technology, or simply a 
different technique)  
 
 RED: Poses a significant threat to the 
opportunity identified in the market (i.e. 
works against current health service 
objectives, or there are other products 
being developed that are associated with 
better outcomes or are at a more advanced 
stage of development). 
 
AMBER: Potential threat 
 
GREEN: Further supports the case for the 






7. Research questions 
 
This should be a list of the things that the 
developer needs to find out or monitor 
during the process of development, relating 
to the function of the device or how it fits 
into the market place. 
 
From the research undertaken and reported 
above, what are the most important 
questions or uncertainties that must be 
addressed / tested? What factors or 
assumptions have the calculations / 
economic or clinical case hinged upon? 
What potential benefits or threats have you 
ignored in the calculation (see italicised 













* To adjust cost estimates identified to their present value (to the time perspective taken for this 
form), use the HCHS ‘Pay and Prices’ Index (PSSRU 2010). 
** These are so you do not forget about elements of the potential costs / savings you have ignored in the 
calculations and why.  If positive, they could either function as additional narrative support for the device, or if 
the quantified benefits do not present a sufficiently high MRP, these can be quantified later. If they have the 
potential to have a negative impact on the economic case, you should consider why these have been left out, 
and whether they might have an important role to play in the adoption case. 
These could also include costs/benefits that NICE do not currently consider as part of a healthcare economic 
evaluation, but which certainly have a societal impact, such as impact of social care services (this may in fact be 
incorporated into the remit of NICE’s cost analysis perspective in the future). One potential source for this is: 
‘Social Care Online’ (Social care institute for excellence 2011). 
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Before following the structure of investigation outlined in figure 1 (to be read 
alongside the Pro Forma), it is useful to interrogate the literature and identify the 
potentially relevant resources that could assist you in answering the questions that 
will follow.  Some may be more relevant than others, depending on the information 
already collected. 
When searching the literature use keywords that are relevant to the technology and
the clinical area.
The sources that may be of most use in addressing the specific stages of investigation 
are indicated as a guide  alongside fig.1, but are not intended to be definitive. 
Resources
A. NHS Evidence: Draws on many relevant resources. Search results can be filtered by type, e.g. 
HTAs, care pathways, evidence summaries, guidelines etc.  http://www.evidence.nhs.uk/
B. NHS Choices: Information for patients. http://www.nhs.uk/Pages/HomePage.aspx
C. NICE Guidance: Search NICE guidance by topic (will produce the relevant clinical guidelines/ 
Technology Appraisals, Interventional Procedures etc.). You can often find a lot of information 
on clinical practice for a particular condition even if the guidance has been produced in 
relation to another specific drug / device.   http://guidance.nice.org.uk/Topic
D. Department of Health: A search of the DH website will identify national targets and 
strategies.  http://www.dh.gov.uk/en/index.htm
E. National service frameworks and strategies: Presents the national strategies for certain 
disease areas (albeit a limited range). 
http://www.nhs.uk/NHSEngland/NSF/Pages/Nationalserviceframeworks.aspx
F. World Health Organisation: Search by topic. General information on condition, cause, 
diagnosis etc. http://www.who.int/topics/en/
G. NICE Pathways: Collates all relevant NICE guidance on certain topics, and presents these  
visually in pathway form.  http://pathways.nice.org.uk/
H. CEA Registry: This is an important  and useful source of cost-effectiveness studies. Note 
country of origin and  quality score.  The studies identified  here can help to identify relevant 
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I. Cochrane Library: A useful source which collates Cochrane systematic reviews, clinical trials, 
HTAs and economic evaluations. If  you are trying to find  patient benefit estimates, look 
under the “measure of benefit”  subheading on the summary to determine whether it will 
be relevant. http://www.thecochranelibrary.com/view/0/index.html
J. PubMed / MEDLINE: PubMed provides  access to the MEDLINE database for clinical studies, 
economic evaluations, policy issues etc. If you have access to this resource, it is a good place 
to locate and download studies that have been identified elsewhere. 
http://www.ncbi.nlm.nih.gov/pubmed/
K. CRD database: Centre for Reviews and Dissemination. This includes  a central  search point 
for reports from NHS EED (NHS Economic Evaluation Database) and DARE (Database of 
Abstracts of Reviews of Effects).  http://www.york.ac.uk/inst/crd/
L. NHS Reference Costs: NHS reference costs is a very large database with key cost schedules 
for NHS trusts and PCTs. 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuid
ance/DH_123459
M. Euroscan: Perform a technology search to identify new innovations in the clinical area. 
http://www.euroscan.org.uk/outputs/
N. NHSC: Search technology briefings by speciality or technology type to identify innovations in 
the area  since 2006 (or search the archive for 2000 – 2005) that the organisation have 
identified as having the potential to make an important  impact on patients or health 
services. http://www.nhsc-healthhorizons.org.uk/outputs/
O. Google and Google Scholar Search: Useful for general information searches
P. NIHR HTAs: The NIHR Health Technology Assessment Programme provides a journal series 
of comprehensive HTAs that have been conducted from an NHS perspective. 
http://www.hta.ac.uk/research/HTAjournal.shtml
Q. HES online: The hospital episode statistics database provides some useful information about 
the current number of patient episodes, particular procedures, outpatient visits, etc. 
http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID=889
R. PSSRU Unit Costs of health and social care.  The Personal Social Services Research Unit  
(PSSRU) provide statistics each year on unit costs for health and social care.  This resource is 
particularly useful for staff costs and specific service costs. 
http://www.pssru.ac.uk/uc/uc2011contents.htm
S. Social care online.  This site provides information that could go into the presentation of 













• What happens now and how does 
device X change this?
• What is the current gold standard, and its 
deficiencies?
• How does device X address these deficiencies?
Market size
• Who will the device be used for?
• What is the size of the relevant patient 
population?
• How does this differ to current practice?
Health 
Service
• What is the health service cost impact?
• Are there any saved or associated costs to the 
NHS in the application of the new device 
and/or  withdrawal of current practice?
Patients
• Are there any envisaged changes in 
patient outcome?
• Changes in quality or length of life?
• Over how long are any changes sustained?
Developmen
ts
• Are there currently many 
developments or changes in the area?
• Changes in clinical practice?










try utility search 
using H.
Changes or trends in 
the clinical 
landscape should 
have been identified 




Also try Q if 
appropriate
For competitors, possible 
sources include: C;M;N;O. 
Also see S for extra 
rationale for the product














Describe any impact on patient health that you haven’t quantified here
‘Research Questions’ should be a summary of those things that have 
come out of the analysis as the most important things to find out or 
monitor.  This could relate to the appropriateness of assumptions made, 








‘Finding the numbers’ : Extra resources
The possible sources of data available for identifying the 
relevant market size  are multiple. 
Where appropriate, one potentially useful source of data 
for potential market size is hospital episode statistics (HES):
• HES Online
For inpatient data according to Healthcare Resource Group (HRG) code:
http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID
=206
(note: HRG codes are related to the way in which hospitals are paid for the treatment of patients. 
Treatments are assigned a Healthcare Resource Group (HRG).  HRGs are groups of clinically 
similar activities which consume a similar amount of resources.  For costs related to HRG code, 
see NHS reference cost data below.)
To explore all the available data:
http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID
=889









The  following offers a list of some more specific resources 
to identify specific healthcare costs, where these are not 
identified from other studies. 
• Payment by results
The way in which NHS healthcare providers are paid is by a system of ‘payment 
by results’ (PbR).   
For a simple overview of payment by results, see:
http://www.medicine.ox.ac.uk/bandolier/painres/download/whatis/What_is_pay_by_res.pdf
This is a more detailed explanation of the system provided by the DH:
http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_
128864.pdf
HRGs are the basis of the NHS PbR system, and costs are often reported in 
relation to these codes (such as NHS reference costs, see below).
• NHS REFERENCE COSTS
Although the database of NHS reference costs (which is published on a yearly 
basis) is very large, it offers a wealth of information on NHS costs, if you know 
exactly what you are looking for:
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidan
ce/DH_123459
•The  cost of a hospital bed day
The cost of an ‘excess bed day’ can give an indication of the cost of a patient day 
in hospital, according to what the patient is in hospital for.  This can be useful in 
cases where the new device will affect a patient’s length of stay in hospital.  
These are offered in precise detail in the NHS reference cost database, but the 
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This table, presented by Jones (2008), gives the average cost of excess bed days by speciality (the cost 
of a stay in hospital beyond the expected maximum length of stay for a particular HRG).  Beyond the 
specified stay within a speciality code, these are paid  on a per day basis according to these tariffs.  
These can act as a good estimate that can be used to calculate the effect of increased/reduced hospital 
stay resulting from the application of a new technology.
 
 
Template and Resource Guide 
354 
 
Manipulating the cost data
•Exchange rates
Where the costs identified are reported in a different currency, HM Revenue 
& Customs provide the appropriate exchange rates:
https://www.uktradeinfo.com/TradeTools/Pages/ExchangeRates.aspx
•Inflation index
To adjust cost estimates found in the literature to their present value, use 
the HCHS (Hospital & Community Health Services) ‘Pay and Prices’ Index:
Source: Personal Social Services Research Unit (PSSRU), Unit Costs of Health and Social Care 2005  
Source: Personal Social Services Research Unit (PSSRU), Unit Costs of Health and Social Care 2010  
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P&P Index (present year)  ÷ P&P Index (year of cost data) = Inflation rate
£(cost found) x Inflation rate = Present (£) value
Patients
Quantifying the benefit to patients of a particular treatment or 
change in their management pathway can be challenging.  The 
following provides various approaches and sources of information 
that can help estimate patient health impact, and translate this into 
a quality of life (QoL) estimate. 
Where the device saves lives...
•Life expectancy
If the proposed new technology can expect to reduce mortality (save lives), then in 
order to value this effect you need to know the life expectancy of that life saved.  
The office of national statistics (ONS) provides data on the average period 
expectation of life at any given age:
http://www.ons.gov.uk/ons/taxonomy/index.html?nscl=Interim+Life+Tables
Under the ‘Data’ section, click on the appropriate link to access Interim Life tables.
The link called ‘United Kingdom, Interim Life Tables, 1980-82 to 2008-10’ (which was 
updated on 29/9/11), uploads an excel spreadsheet with the estimated life 
expectancy at various ages (the 2008-10 tab provides the most up-to-date 
estimates)
The column labelled ex provides the relevant life expectancy statistics, representing 
the “average period expectation of life at exact age x, that is the average number of 
years those aged x will live thereafter”.
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•Quality of Life weightings for the general population
If the new technology is expected to save lives and to return a person’s QoL (on 
a scale of 0 to 1) to match that of the general population, then it is important to 
weight those life years gained according to QoL experienced, in order to 
estimate a QALY impact. Kind et al. (1999) conducted a large survey of the UK 
general population, and provide estimates of the average QoL (using the EQ-5D 
index) for the general public, according to age (and many other parameters 
including sex, smoking status, marital status, region, social class, etc).
This report can be found here:-
http://www.york.ac.uk/media/che/documents/papers/discussionpapers/CHE%2
0Discussion%20Paper%20172.pdf
The following table provides the summary figures of weighted health-state 
index according to age and sex:
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Where the device affects the quality of life experienced by the 
patient...
Presented in order of ease and reliability, the following are  possible approaches 
to estimating the impact that a device might have on the QoL of a patient:
1) QoL estimates in the literature
2) Calculating the value by manipulating the appropriate health states in the 
EQ-5D questionnaire
3) Utility ladder
• 1) QoL estimates in the literature
The quantification of QoL is complex, and there are many methods that exist 
that try to do this.  For the purposes of a general QoL measurement that can 
be used across all states of health, NICE consider the elicitation of QoL to be 
most appropriately estimated by using the EuroQol EQ-5D questionnaire, 
and the time trade-off method to translate this into a universal QoL 
measure.  This QoL weighting (which will lie between 1 [perfect health] and 
0 [death]) is used to calculate QALY impact by multiplying this by the time 
(in years) for which this impact is sustained.
The simplest way to estimate QoL is to use data provided by other studies 
(preferably using the EQ-5D, but other methods are sometimes appropriate 
as well).  
• 2) Manipulating the five health dimensions of the EQ-5D questionnaire
When estimates in the literature do not exist, and the developer has a clear 
idea of the potential areas of benefit of the product, then it may be 
appropriate to consider the EQ-5D questionnaire directly.  A large UK study 
conducted by Williams (1995) used people’s valuations of various health 
states according to the five health dimensions of the EQ-5D questionnaire, 
in order to assign a value to each possible combination of levels (mild, 
moderate or severe) within each of these five dimensions (mobility, self-
care, usual activities, pain/discomfort, and anxiety/depression).
Dolan (1997) modelled these results and found that the best way to model 
changes in health state and actual QoL perceived, was to assign a value to 
each step-change in parameter.   We can use these results to estimate the 
change in QoL of a patient, if it is clear in our minds exactly how the device 
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‘Full’ health, represented by a QALY weighting of 1, is represented by level 1 of 
all these five parameters.
The combination 11221 represents: ‘Some problems performing usual activities’, 
‘moderate pain or discomfort’,  and no problems with any other health 
parameter.  The aforementioned study mapped each combination of these three 
levels of five health states, in order to present a QoL value for each combination.  
The results of this are presented below.
Source: Williams (1995) A measurement 
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This table presents the value of all possible deviants from ‘full health’ (which has 
a value of 1).  The ‘constant’ 0.081 should be subtracted from any deviation from 
full health,  and N3 (0.269) should be subtracted from the overall value 
whenever one or more health states are in level 3. For example:
11221: 1-0.081-0.036-0.123 = 0.76.
13312: 1-0.081-0.269-0.214-0.094-0.071 = 0.271
These  can be used to value the effect of a change in a particular health 
parameter.  If, for example, a new device could plausibly reduce pain/discomfort 
from level 2 (some pain/discomfort) to level 1 (no pain/discomfort) then this 
should be valued at 0.123, and should be multiplied by the time (in years) for 
which this change is sustained.
This should not act as a substitute for a later-stage QoL investigation when the 
product has been developed.  However, it can at an early stage offer some insight 
into the potential value of particular changes to QoL, in cases where this is 
intuitive.
Source: Williams (1995) A 
measurement and validation of 
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• 3) Utility ladder
Alternatively, QoL may be estimated by relating the health state in question to 
others.  For example, if it is considered that the QoL associated with the clinical 
problem of interest might be similar to another, for which a QoL estimate does 
exist, this could be used as a proxy.  McAteer (2011) presents a ladder of various 
health-related QoL values, so that the clinical area in question may be related to 
others, and be conceptually placed along this scale.
These ‘utility ladders’ are presented  over the next two pages, the first offering 
a hierarchy of QoL values (all derived from NICE technology appraisals) from 0 
to 1, and the next focusing on a spectrum of QoL values from 0.5 to 1.
These are taken directly from McAteer’s work: McAteer, H. 2011, The use of 
health economics in the early evaluation of regenerative medicine therapies. 
Ph.D. thesis, University of Birmingham.
 
 
















Discounting for costs and health 
benefits accrued in the future
In order to reflect the time value of money and health benefit, any impact on 
costs or health benefit that is accrued in the future must be discounted, at a 
rate of 3.5% for both costs and QALYS, as per the NICE reference case.  This is 
done in the following way:
If we want to determine the present value of eleven additional life years in a 
health state of 0.8, the following formula is used:
The same approach is used for costs.
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Appendix 3: Utility weights for COPD 
Definition of disease severities: Mild, Moderate and Severe COPD in line with NICE clinical guidance: 
Mild: FEV1 percent predicted ≥80% 
Moderate: 50% < FEV1 percent predicted < 80% 
Severe: 30% < FEV1 percent predicted < 50% 
V.Severe: FEV1 percent predicted < 30% 
Year Journal Title Primary 
Author 
COPD- related UTILITY Source of utility measure  
Mild Mod Sev V. Sev Exacerbations 









Oba (2009)  0.569-0.591. Not split into mild, moderate or severe states. Utility values were estimated by converting SGRQ 
(St George’s Respiratory Questionnaire) scores 






ol (500/50 microg) in 






0.897 0.755 0.748 0.549 Moderate: 15% 
↓ in utility, 
Severe: 50% ↓ 
in utility 
QALY weights for each disease severity are based 
on a study by Borg et al. (2004), whose source 
was a cost of illness study in northern Sweden 
which used an EQ5D questionnaire. QALY 
weights were estimated according to UK EQ5D 
index tariff. 
Exacerbation implications on utility from 
Oostenbrink et al. (2005) – who themselves get 
these from Paterson et al. (2000) and Spencer & 
Jones (2003). 
2008 Thorax Cost effectiveness of 
therapy with 
combinations of long 
acting 
bronchodilators and 
inhaled steroids for 
treatment of COPD. 
Najafzadeh 
(2008) 
Not made explicit. Moderate: 15% 
↓ in utility, 
Severe: 50% ↓ 
in utility 
Utilities were calculated from the SGRQ scores. 
Exacerbation implications on utility from 
Paterson et al. (2000) and Spencer & Jones 
(2003). 






























with bupropion, NRT, 
and nortriptyline for 
smoking cessation in 
the Netherlands. 
(Q.S.: 4.5) 




of varenicline versus 
existing smoking 
cessation strategies 
using the BENESCO 
Simulation model: 
application to a 
population of US 
adult smokers. 
(Q.S.: 4) 
Howard et al. 
(2008)  





Modelling the 5-year 
cost effectiveness of 
tiotropium, 
salmeterol and 
ipratropium for the 
Rutten-van 
Mölken et al. 
(2007)   
 
- 0.809 0.762 0.655  Utilities based on EQ-5D scores at baseline in a 
subset of patients randomly accepted in to the 
UPLIFT trial. Scores valued using the SPANISH 
tariff (which differ to UK preferences, see Badia 
et al. (2001)).  
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treatment of chronic 
obstructive 
pulmonary disease in 






of tiotropium and 
salmeterol in the 
treatment of chronic 
obstructive 
pulmonary disease 
(COPD) in Greece. 
(Q.S.: 5.5) 
Maniadakis      Unable to access 








pulmonary disease in 
the presence of 
missing data. 
(Q.S.: 5) 
Briggs et al.  
(2006) 
Not detailed SF-36 instrument used and converted to health 
utility scores. 










0.897 0.755 0.748 0.549  Utility weightings retrieved from Borg et al. 
(2004). 
2005 Value in 
Health 
Probabilistic Markov 
model to assess the 
cost-effectiveness of 
bronchodilator 
therapy in COPD 
patients in different 
countries. 
Oostenbrink 
et al. (2005) 
0.897 0.755 0.748 0.549 Moderate: 
15% ↓ in 
utility, 
Severe: 50% 
↓ in utility 
QALY weights at each disease severity based on 
study by Borg et al. (2004). 
Exacerbation implications on utility from 
Paterson et al (2000) and Spencer & Jones 
(2003). 







Development of an 
economic model to 








Spencer et al.  
(2005) 
 
Mild, Moderate and Severe COPD states based 
on a different definition, following that described 
by the American Thoracic Society: 
Mild: FEV1 ≥ 50% 
Moderate: FEV1 35-49% 
Severe: FEV1 < 35% 








according to disease 
severity. 
(Q.S.: 3) 
Sin et al. 
(2004) 
- 1 QALY 0.92 
QALYs 
0.84 QALYs  ↓ of 0.32 
QALYs for 
each episode 
(mild: 1 week, 
mod: 2 weeks, 
sev: 4 weeks) 
Definition of mild, moderate and severe as 
above, using the American Thoracic Society 
levels. 
2004 Value in 
Health 
A computer 
simulation model of 
the natural history 







Borg et al. 
(2004) 
0.897 0.755 0.748 0.549 Mild: 5% ↓ in 
utility, 
Moderate:15
% ↓ in utility, 
Severe: 70% 
↓ in utility 
Source: a cost of illness study in northern Sweden 
which used an EQ5D questionnaire. QALY 
weights estimated according to UK EQ5D index 
tariff. 
Exacerbation implications on utility: ‘Mild and 
Moderate’ based on assumption by “expert 
panel”: J. Wedzicha, A. Gulsvik, and S.D. Sullivan.  
Severe exacerbation figure derived from asthma 
data. 
Definitions of Mild, mod and severe 
exacerbations: 
Mild- if the patient can manage in his or her 
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normal environment.  Could include phone calls 
to a doctor that might be followed by a course of 
antibiotics or oral steroids; 
Moderate- if the patient must make an 
unscheduled visit to the doctor; 
Severe- if the patient requires hospitalization or 











Groen et al. 
(2004) 
     Utility scores were collected using the EuroQol 
questionnaire, but scores were not assigned to 
each of the different diseases individually, but 
collected over the whole group, 
‘averaged’, and categorised in relation to 
pre/post lung transplant. 













Añón et al. 
(1999) 
 
     Rosser Index score used as an estimate of quality 
of life.  Specific values adopted are not detailed 












Smith      Unable to access 




Appendix 4: NHSC information proforma Jul 10 V2 
Medical device information proforma  
 
The National Horizon Scanning Centre (NHSC) is funded by the National Institute for Health Research 
to provide advanced notice of health technologies and interventions that are likely to have a 
significant impact on patients and/or the NHS in the next 2 years. For more information on our 
methods and processes see www.haps.bham.ac.uk/publichealth/horizon.  
 
 Please fill in as much information as possible in as many relevant boxes as possible. For some 
early developments we understand that there will be little information available.  
 Please use a different proforma for each major patient group for which the product is CE marked 
and/or launched in the UK, or expected to be so in the next 12-18 months. 
 Please mark in the last column any rows with commercially confidential or sensitive information 
giving more details in the associated text box.   
 
Date:   Name:  









Technology description  Confidential 
information 
Name of the device/product   
 




Who are the commercial developers 
and/or distributors (if different)? 
  
Patient group and/or indication 
Please include stage of disease and 
targeted patient sub-groups (including 




Brief description of the device 
i.e. what it is and how it works  
  
What is the intended use of the device? 
e.g. prevention, treatment, susceptibility 
testing, or rehabilitation 
  
What is innovative about the device? 
e.g. new, novel  
  
What advantages does the device have 
over current options?* 




effects, shorter length of stay in 
hospital, fewer infections   
How will the device change the patient 
pathway?* 
  
Likely impact in terms of patient 
benefits* (please quantify where 
possible), e.g. health outcomes, clinical 
management, safety, patient 
acceptability/compliance 
  
Likely impact in terms of system 
benefits to the NHS* (please quantify 
where possible), e.g. net cost savings, 
reduced service use. 
  
Is the device already available for a 




Is it under evaluation (or been 
evaluated) by any national organisation 
in the UK, e.g. NICE? 
  
 
Stage of development, availability, 
licensing and launch plans 
 Confidential 
information 
Date of CE mark? 
If your device is not available or 
licensed, what are the CE mark and 
launch plans for England and Wales? 
e.g. Q4 2010* 
  
Is your device available in the NHS in 
England and Wales?  
If so, how widely is it available or used 
in the NHS?  
e.g. number of hospitals using the 
technology 
  
Is your device available, licensed or 
launched in the USA (e.g. FDA 
approval), Canada or Australia? 




Current alternatives  
Not essential at this stage 
 Confidential 
information 
What are the current treatment or 
management options for the patient 
group? 
  
Is the new device planned to be 
additional to current therapy or used as 
a substitute? 
  
Is there any evidence of a variation in 




Costs  Confidential 
information 
What is the unit cost of the technology, 
cost per treatment, or estimated cost 




Are there additional costs related to 
your product?  
e.g. days in hospital, extra out-patient 
visits  
  
What is the cost of current diagnostic, 
treatment or other management 
options for this patient group? 
  
 
Clinical need, burden of disease 
Not essential information 
 Confidential 
information 
What is the burden of disease in 
England and Wales (or the UK)?  
e.g. number of patients and sub-groups, 
survival, mortality, morbidity, and 
quality of life 
Please give references to any key 
epidemiological studies 
  
Estimated potential uptake of the 
technology amongst the relevant 




Are there likely to be any barriers to 
diffusion of the technology in the NHS in 
England and Wales? 
  
 
Research evidence  Confidential 
information 
Published clinical trials 
Please list references, and attach copies 
of relevant publications and abstracts 
from publications or conferences that 




Unpublished completed clinical trials  
 
Please give details of the following, 
and/or attach copies of protocols, press 
releases and abstracts: 
 trial number/name  
 location  
 trial funders, sponsors 
 study design  
 inclusion and exclusion criteria 
 treatment arms 
 length of follow-up 




 numbers of patients in trial 
 start date 
 date of full patient accrual  
 date of interim analysis 
 expected date of final analysis or 
publication 
 results  
 economic analysis included or not 
Ongoing clinical trials 
 
Please give details of the following, 
attaching copies of protocols, press 
releases and abstracts: 
 trial number/name  
 location  
 trial funders, sponsors 
 study design  
 inclusion and exclusion criteria 
 treatment arms 
 length of follow-up 
 primary and secondary endpoints 
 planned patient numbers 
 start date 
 anticipated date of full patient 
accrual  
 expected date of interim analysis 
 expected date of final analysis or 
publication 
 economic analysis included or not 
  
 
What is the potential or intended impact of the technology (speculative)? 
Copy this symbol  to the relevant boxes 
 
Patients  
 Reduced morbidity  Reduced mortality or increased 
survival 
 Improved quality of life for 
patients or carers 
 Other, please specify:   
 
Services 
 Increased use e.g. length of stay, 
out-patient visits 
 Service re-organisation required  Staff or training needs 
 Decreased  use e.g. shorter 
length of stay, reduced referrals 





 Increased unit cost compared to 
alternative 
 Increased - more patients 
coming for treatment 
 Increased - capital investment 
needed 
 New costs, please specify:  Savings, please specify:  Other, please specify: 
 
 
Please return to the NHSC member who requested this information, or email to: 







Appendix 5: Follow-up Strategy 
The following is a list of questions necessary to consider when following up the technology, to 
understand the usefulness of the analysis undertaken. The questions are followed by potential 
sources for answering them. 
Headroom Outcome and Market success 
Does the MRP look realistic? Would it have indicated a yes or no to development? 
This is bound to be subjective, and ideally such information would be obtained from the developer, 
to see whether the ‘headroom’ calculated would have been sufficiently large to warrant 
development.  
 Price is often indicated in the NHSC briefing. Compare MRP to this given price. 
 Search internet and webpage of the company for price, if the technology still exists. 
 Try to establish contact with manufacturer. 
Interpretive / Informed answer: Headroom positive / Headroom negative 
Has there been a decision made on it by NICE? What was the outcome? 
 Search NICE guidance, not only for a technology appraisal for the specific topic, but also for 
related IPG, CG or TA documents. These may give an indication of whether the technology 
type is within the radar of NICE, whether guidance has been issued on a similar product, or 
whether it isn’t considered / has been overtaken by other ideas (this will help in answering 
the next question). Search the ‘Do not Do’ recommendations. 
Is it sold in the UK or the rest of the world?(Or has it in the past) If so, who is it bought by? 
 Search company web page 
 NHS patient choices websites 
 Contact company if information not available 
 Identify geographic location of clinical studies undertaken 
 Check the MHRA website 
Have there been investigations into its clinical / cost effectiveness? 
 Some early clinical studies are reported in the NHSC briefings (ignored until now), as well as 
indication of future trials or cost-effectiveness studies. Find these. 
 Cochrane, Medline, etc, CEA registry 
 
Has the landscape described changed significantly? 
What is current gold standard clinical practice now? Has this changed? 





 Conduct a re-run of the literature search for clinical or economic studies, but remove date 
range restrictions. 
Are there now many direct competitors? 
 Search: Google, newer NHSC briefings, Eursocan, and ones that have been picked up from 
the literature searches.  
 
Conclusions: How useful might the headroom exercise have been? 
Would the analysis have been useful at the beginning?  
How pertinent did the identified ‘research questions’ turn out to be? 
What was important that was missed by the headroom analysis? 
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Appendix 6: Retrospective case study documentation 
The case studies are presented in the order they appear in the main text of the thesis.  For 
each case study, the initial pro forma is presented, followed by a description of the 
headroom calculation and subsequently their follow-up. 








No NICE follow-up. 
 
Date of briefing: Jan 
2004 
 
Time perspective of this 
report: 2001 
The FibroTest-ActiTest is a non-invasive alternative to liver biopsy for 
patients with the hepatitis C virus (HCV). It uses a (patented) algorithm to 
combine results from serum tests to predict the level of fibrosis and 
necroinflammatory activity in the liver. The biomarkers measured in the 
serum tests are: a2-macroglobumin, haptoglobulin, apolipoprotein A1, 
total bilirubin, gamma glutamyltranspeptidase (GGT) and alanine 
amonitransferase (ALT).  
 
Hepatitis C is an infectious disease, passed by blood or body fluids, for 
which there is no vaccine.  By the end of 2001 there were around 26,500 
patients in England known to be infected with HCV, although it is thought 
that in reality between 200,000 and 400,000 are infected. The virus 
causes chronic hepatitis in about 85% of cases, but disease progress is 
normally slow and silent over 20-50 years, with about 20-30% eventually 
developing advanced liver disease or cirrhosis.  The HCV infection usually 
presents no symptoms until significant fibrosis has developed. 
 
2. Comparator  Currently (2001), liver biopsy is the gold standard method used to assess 
disease staging prior to antiviral treatment.  Liver biopsy is an invasive 
procedure, and so associated with a (small) risk of adverse events due to 
bleeding and other complications. Biopsies are usually performed under 
local anaesthesia and require a short hospital stay. 
 
It is thought that FibroTest-ActiTest could have the same degree of 
diagnostic accuracy as biopsy. Given its non-invasive nature it is likely to 
be better accepted by patients and clinicians than biopsy. 
 
3. Market size  In NICE Guidance produced in 2000 for the appraisal of ribavirin and 
interferon alpha (drugs for the treatment of HCV), it was estimated that 
50% of those who have a liver biopsy receive therapy, and that about 
2,000 people are receiving interferon therapy for HCV each year (this 
NICE guidance—TA14—is no longer viewable as it was updated and 
replaced in 2004 by TA75). This means that about 4,000 people undergo 
liver biopsy each year. 
BioPredictive estimate that FibroTest-ActiTest could replace biopsy in 
90% of cases (3,600). 
 
Tests per year: 3,600 
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4. Health Service 
 
Changes in resource use.  Any changes in 
service delivery costs to the NHS that will 
result from the application of the new 
technology, including the disinvestment in 
previous practice.  This could include: Staff 
time, hospital bed days, GP visits, A&E visits, 
etc.  It should not include services for which 
the NHS (and personal social services) is not 
financially liable (e.g. lost productivity and 
[non-health] social care costs), but these 
should be noted in writing below to add to 
the verbal case for the product (NICE may 
incorporate social care costs into cost-
effectiveness estimates in the near future). 
 
 If relevant and not included in service cost 
impact above, search for price of the 
currently used product (P1). 
 
Use HCHS index to inflate estimates to 
current prices  
 
 
Describe any potential costs/savings that 
you haven’t quantified.  
(i) 
The FibroTest-ActiTest represents a direct 
replacement of liver biopsy, for 90% of those patients 
that currently undergo this procedure.  Therefore, 
the health service costs saved per patient will be 
equal to the cost of this liver biopsy procedure. 
A cost utility study from 1999 (Leal, Stein, & 
Rosenberg 1999) reports a cost per liver biopsy of 
£416, which is based on a day case procedure. They 
also estimate an adverse incident rate of 0.5%, which 
leads to an extra 1.5 days of inpatient treatment at 
£200 per patient. 
Inflated to 2001 prices (ii), this amounts to the 
following: 
 
3,600*£437 = £1,573,200 
(3,600*0.005)*£210 = £3,780 
 
Total savings from liver biopsy disinvestment: 
 
(Total) ∆SC= £1,576,980 




The potential service implications that would result 
from the introduction of FibroTest-ActiTest into 
clinical practice are not described in the briefing. 
Therefore, consideration of these costs should be 




Potential impact of the new device on 
patient health, as compared to current 
practice (preferred method of elicitation is 
from studies using the EQ-5D).   
Where NICE have not produced relevant 
economic analyses, search for cost-
effectiveness studies or systematic reviews 
within the disease area (the CEA registry 








BioPredictive believe that the FibroTest-ActiTest 
could replace liver biopsy, and work just as well.  
Therefore, the analysis will not consider a trade-off in 
diagnostic accuracy. 
 
A study identified on the CEA registry presents an 
estimate of the disutility (in QALYs) associated with a 
liver biopsy (Huber et al. 1997). This is thought to be 
a loss of 0.005 QALYs per year. 
 
By multiplying this by the number of biopsies that will 





(Av. per person) ∆QALY= 0.005 
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Describe any impact on patient health that 
you haven’t quantified.  
In the economic analysis to follow, I will also present 
the findings had we ignored this increase in QoL, as 
the impact on patients of liver biopsy does not seem 
to be emphasised in the literature, so for decision 
makers it may not be seen as significant enough a 
reason to invest in a different diagnostic test. 
(Additionally, I have not included the disutility that 
might arise from a blood test for patients!) 
 
6. Developments (clinical & 
healthcare context)  
 
Consider the following questions to help you 
think about the space for your product 
within the market.  
 
Does the technology address any key national 
objectives for improving care in this area? 
 
How will the technology complement current 
practice? Is current practice likely to change? 
 
Are there any indications in the literature of 
potential effectiveness? 
 
Have you identified any direct competitors? (This 
could be another specific technology, or simply a 
different technique)  
 
 RED: Poses a significant threat to the 
opportunity identified in the market (i.e. 
works against current health service 
objectives, or there are other products 
being developed that are associated with 
better outcomes or are at a more advanced 
stage of development). 
 
AMBER: Potential threat 
 
GREEN: Further supports the case for the 
new technology  
 [AMBER] There may in the near future be a move 
away from routine testing prior to treatment for 
Hepatitis C (with antiviral therapy). If this is the 
case, then the market for this test could be 
significantly reduced. 
 
 [AMBER] In searching the literature, a 2001 study 
was found that considered the predictive value of 
various biomarkers for fibrosis in patients with 
HCV (as compared with biopsy) (Imbert-Bismut et 
al. 2001). In this study they consider false 
positives and false negatives (which are not 
zero), and estimate that 46% of biopsies could be 
avoided (rather than 90% as estimated here). 
This presents two potential threats: 
1) That the assumptions made for this analysis 
may be too optimistic regarding market size 
and predictive value. 
2) There are others investigating the use of 
biomarker algorithms in the prediction of 
fibrosis. This may mean that there are other 




 [GREEN] If proven to be effective in this clinical 
area, the test could also be directed to other liver 
conditions, e.g. Hep B, and alcoholic and non-
alcoholic liver disease. This would widen the 
target market considerably.  
 
 
7. Research questions 
 
This should be a list of the things that the 
developer needs to find out or monitor 
during the process of development, relating 
to the function of the device or how it fits 
 The sensitivity and specificity of the technology 
must be investigated, to investigate its 
equivalence to liver biopsy. 
 Changes in standard clinical practice should be 
monitored regarding how clinicians decide to put 
patients on antiviral therapy (is there a 
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into the market place. 
 
From the research undertaken and reported 
above, what are the most important 
questions or uncertainties that must be 
addressed / tested? What factors or 
assumptions have the calculations / 
economic or clinical case hinged upon?  
decreasing trend in pre-testing before therapy is 
provided?) This will affect market size. 
 Keep a look out for other technologies with the 
same indication and their level of development, 
as this could affect return on investment 
calculations if the market size is subsequently 
decreased. 
 
Notes by AC 
Information used is from the NHSC briefing notes unless otherwise stated 
(i) Although the briefing gave quite precise estimates of the biopsy costs which would be 
displaced by using the new diagnostic test in its place, it wasn’t clear how these costs 
were identified: 
“In patients younger than 70 without complications, the mean average cost for an inpatient biopsy is 
£775 and for a day case £509”. Ref: HRG NHS Reference Costs, 2002. 
After looking at the HRG NHS reference costs database (for 2002 and earlier versions), 
these statistics could not be identified from this huge dataset.  In order to reflect the 
perspective of the user of this form, an alternative source was sought.  Cost-
effectiveness studies predating 2001 were searched on the CEA registry. One study was 
based on UK data, by Leal et al., 1999 (Leal, Stein, & Rosenberg 1999), and these are the 
biopsy costing figures I use here.  
 
(ii) To inflate prices from those issued in the report identified, to the time perspective taken 
for this form, I use the HCHS ‘Pay and Prices’ Index (PSSRU 2010), which date back to 
2000 (as the cost utility study was published late 1999, this seems appropriate): 
 
HCHS P&P Index 2000/01: 196.5 
HCHS P&P Index 2001/02: 206.5 
Inflation rate: 206.5/196.5= 1.05 
 
Cost of day-case liver biopsy: £416 * 1.05 =£437 
Cost of treatment after complications: £200 * 1.05 =£210 
 
 
Headroom Notes (FibroTest) 
 
 WTP: £20,000 WTP: £30,000  
QoL saving included £538 £588 
QoL saving not included £438 £438 
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The headroom for the FibroTest-ActiTest ranges from £438 (when the disutility of liver biopsy is 
ignored) to £588 (saved disutility included, WTP: £30,000).  The calculation presents a ‘headroom’ 
per test rather than an MRP per se, as this will need to include the cost of service provision (staff 
time, laboratory costs, etc).  Ideally these costs would have been included in the service cost 
implications, but there was insufficient information on which to base these estimates. As only a 
blood test is required, service costs should be minimal.  
 
Some development cost decision analysis was performed, to show the trade-off between various 
variable costs in relation to maximum development costs, for the most and least optimistic scenarios.  
 
This may be slightly deceiving as the figures calculated corresponded to a ‘headroom’ rather than an 
MRP.  However, if the likely service costs are included in the variable costs given, then the maximum 
development costs can be estimated. For example, a variable cost per test of £40 would equate to a 
maximum development cost of £1.4 million (least optimistic) up to nearly £2 million (most optimistic) 
(assuming no profit).  Clearly, given the nature of this in vitro diagnostic (a blood test whose results 
are input into a programmed formula), whose variable costs are bound to be small and whose 

























Variable cost per device (including consumables) 
Least optimistic 
Most optimistic 




Headroom Outcome and Market success 
Does the MRP look realistic? Would it have indicated yes or no to development? 
Headroom: £538 (assuming a WTP of £20,000) or £588 (assuming WTP of £30,000) (£438 if we ignore 
the utility impact associated with not undergoing a liver biopsy). This should be interpreted as a ‘unit 
cost’ to the NHS for the test. 
Although not verifiable without discussion with the developers of the FibroTest-ActiTest, this seems 
to be a large value per unit. Presuming a variable cost per test  of under £120 per unit, the allowable 
development costs reach over £1.5 million. Given that the FibroTest-ActiTest is a patented algorithm 
rather than a piece of kit, these estimates look generous. 
The NHSC briefing includes an estimated unit cost (to the NHS) for the FibroTest-ActiTest, which is 
£70.  This figure was estimated by the company, so it is assumed to include the estimated price of 
the technology and the time/person investment necessary for using the test. This indicates that the 
headroom probably would have seemed favourable. 
Interpretive answer: Headroom Favourable 
Has there been a decision made on it by NICE? What was the outcome? 
No NICE guidance has been issued relating to this technology. 
Is it sold in the UK or in other countries? (Or has it in the past) If so, who is it bought by? 
Once blood samples have been analysed in the lab, the data obtained (relating to the biomarkers) 
are downloaded by the biologist into the BioPredictive website (with a registered account), which 
then returns an immediate report of the results. The laboratories that practice the BioPredictive tests 
for each country are listed on their website; there are three in the UK. BioPredictive  is based in Paris, 
but laboratories that carry out the test exist in 49 countries across Europe, Africa, South America, 
North America and Asia (BioPredictive 2011). 
It is not clear exactly how wide spread the use of the test is, and who the main customer base may 
be1.  The test has certainly been (and continues to be) the subject of much research and many 
validation studies. Although I cannot find evidence of its systematic use within the NHS, there is 
certainly an indication in the literature that the test has been used within the NHS to non-invasively 
test for liver fibrosis (Mardini & Record 2005;NHSC 2004).  
FibroTest-ActiTest seems particularly well established in France; the French health authority has 
approved FibroTest, as well as FibroScan (see next section) as “first-line estimates of fibrosis in 
patients with chronic hepatitis C, with recommended reimbursement from the government” (Halfon, 
                                                          
1
 Contact has been made with the labs to establish the exact cost of the test, and how many they 
undertake. An enquiry has been sent to BioPredictive relating to the test‘s use in the UK. Responses 
were not received. 
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Munteanu, & Poynard 2008).  Liver biopsy is indicated as a second-line estimate, in cases where non-
invasive markers are non-interpretable.  
Have there been investigations into its clinical / cost effectiveness? 
There are many studies looking at the diagnostic value of biomarkers in the prediction of liver 
fibrosis, not only for hepatitis C patients but also for other liver conditions.  BioPredictive provide on 
their website the titles of 126 scientific publications from 2001 to 2010 relating to their diagnostic 
tests. The names ‘FibroTest’ or ‘Fibrosure’ (as marketed in the U.S.) appear in the title of 54 of these 
papers.  Most report favourable results for the FibroTest, and its use as a substitute for liver biopsy. 
A meta-analysis which included 30 studies looking at the diagnostic value of FibroTest in chronic liver 
disease was produced in 2007.  It concluded that FibroTest is an effective alternative to biopsy in 
patients with chronic hepatitis C and B, Alcoholic Liver Disease, and non-alcoholic fatty liver disease 
(Poynard et al. 2007). 
One cost-effectiveness study was identified, which was based in the U.S and assessed the clinical and 
economic outcomes of non-invasive strategies in the diagnosis of significant liver fibrosis compared 
with liver biopsy (Carlson et al. 2009).  FibroTest was found to be the most accurate non-invasive 
strategy, with a sensitivity, specificity and overall accuracy of 84%, 87% and 86% respectively. 
Compared to liver biopsy, the authors report a cost saving of about $770 per person, but a 14% 
decrease in accuracy. They conclude that, compared to liver biopsy, FibroTest could offer short term 
savings, but that the longer term costs of misdiagnosis might outweigh these.  (However, the study 
compares Fibrotest and the other non-invasive techniques directly to liver biopsy, implicitly assuming 
a 100% diagnostic accuracy for the latter, which clashes with a general consensus in the literature 
that important shortcomings of biopsy arise from sampling error and inter-observer variability). 
Has the landscape described changed significantly? 
What is current gold standard clinical practice now?  Has this changed? 
Although there have been many publications in the past 10 years investigating the use of non-
invasive diagnostic techniques for liver fibrosis, the majority still refer to biopsy as the baseline 
comparator (and no evidence has been identified of a change in this gold standard for the UK).  
However, the degree to which biopsy is used as a diagnostic technique pre-therapy seems to be 
reduced.  A technology appraisal by NICE for peginterferon alfa and ribavirin (drugs) for the 
treatment of HCV indicates that liver biopsy is no longer considered necessary before initiating 
treatment, which is now given at an earlier stage (NICE 2006c). No other forms of diagnostic aid are 
mentioned in this guidance. 
Are there now many direct competitors? 
There are two main approaches that have been developed to replace liver biopsy and its associated 
difficulties / risks: the ‘biological’ approach and the ‘physical’ approach (Castera 2011).   
The FibroTest seems to be the dominant test for the biological approach, being the most frequently 
studied and the best validated, but others include: Fibrometers (BioLiceScale, France), FibroSpectII 
(Promotheus Laboratory Inc, USA), ELF (iQur Ltd, UK), and Hepascore (PathWest, Austrailia) (the 
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NHSC produced a briefing on ELF – Enhanced Liver Fibrosis Test – in 2008). There are also non-
patented scores for liver fibrosis such as the Forns index, FIB-4 and APRI which, although having a 
slightly lower performance, are free and easy to calculate (Castera 2011).   
The other (‘physical’) approach is Transient Elastography, which measures liver stiffness using 
ultrasound (the NHSC produced a briefing on this device in 2008). The main Transient Elastography 
device (developed by Echosesns (France)) is FibroScan. 
Comparisons of the two approaches seem variable; Castera (Castera 2011) and Degos (Degos et al. 
2010) present findings that indicate Fibroscan to be the better diagnostic tool whereas Carlson 
(Carlson et al. 2009) finds FibroTest to be the most accurate test when compared to Fibrospect II 
(another biomarker approach) and Fibroscan. 
Conclusions: How useful might the headroom exercise have been? 
 
Results from the headroom analysis suggested that the potential value to the NHS of a non-invasive 
diagnosis tool for liver fibrosis could probably viably support the development of FibroTest-ActiTest 
for sale in the UK.  That the headroom estimated was very large compared to the actual cost of the 
test to the NHS, and the cost to BioPredictive of producing the results (simply through a computer-
generated algorithm) suggests that if our assumptions had been correct, the product should have 
achieved widespread success in the UK and be used systematically across the NHS, as it would have 
represented a better use of NHS resources.  Of course, reality is never this simple, and questions 6 
and 7 of the headroom pro forma aim to help identify the factors that could influence these 
parameters. 
Unfortunately, the lack of NICE guidance or UK based cost-effectiveness study means we cannot 
compare this vision with a more recent and better informed decision analysis from a UK healthcare 
reimbursement perspective.  It is clear, though, that BioPredictive has a global focus, and the UK is by 
no means their only or most important market.   The company have a much boarder perspective 
than that taken by the headroom analysis, which considers the case for adoption / sale in the UK 
(specifically, the NHS).  However, a positive endorsement from a UK perspective is likely to translate 
into a promising case in other settings as well. 
The following points offer potential explanations to the question of why the FibroTest-ActiTest is not 
in widespread use across the NHS, or caveats in the assumptions made that have not held in reality.   
1. Many studies have shown the diagnostic accuracy of the test not to be equivalent to that of 
biopsy, as assumed in the headroom analysis. This implies that the cost saving from biopsies 
avoided should be set against the extra cost and health implications of misdiagnosis, i.e. 
treating those who do not need to be treated or delaying the treatment of those who need 
it.  This has been attempted by Carlson et al. (2009) who show that this trade-off could swing 
the cost balance the other way in the longer term. 
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2. NICE perform fewer liver biopsies than they did in 2001, due to a change in clinical practice 
whereby treatment tends to be initiated earlier, and often without this sort of testing.  This 
reduces the potential impact (and market size) of the Fibrotest, and makes it less relevant for 
national evaluation as well. 
3. Direct competitors have filled the space which was previously less populated.  This obviously 
has implications for uptake. 
4. The headroom analysis considered only patients with hepatitis C.  The test has now been 
clinically validated for other liver conditions, thus increasing the potential market size 
(though this has implications for the return on investment decision rather than the marginal 
analysis used to determine value per patient). 
5. I have found no other studies that have considered and quantified the disutility associated 
with liver biopsy. This might suggest this disutility is not important enough to influence 
decision-making in this area, and that the MRP of £438 might be more appropriate. 
All of these points suggest potential problems associated with the headroom method (as applied in 
this case study), and put into question its prognostic ability (though, it has always been emphasised 
that the headroom method values the potential market for an idea under optimistic assumptions, 
and given the uncertainty of developments taking place in the future, this margin is more likely to get 
smaller than bigger).  
So, was the headroom exercise useful, given the subsequent lack of evidence for its widespread use 
across the NHS? Firstly, the headroom method identified a significant opportunity in this area, and 
the fact that this product (and others) have and still do sell in many countries, shows that this was an 
investable space.  Secondly, if we compare the 5 points listed above with the points raised in 
question 6 and 7 of the Headroom pro forma with the 2001 time perspective, we can see that all of 
those caveats were actually identified as potential threats or changes in the landscape, which should 
have been monitored through the development process.  This may show that the exercise of 
undertaking a headroom calculation allows the user to usefully identify important areas of 
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IPG follow up 
 
Date of briefing: Jan 
2003 
 
Time perspective of this 
report: 19972 
The Molecular adsorbent recirculating system (MARS®) is a liver support 
therapy for acute and chronic liver failure.  It is a mechanical 
detoxification system that selectively eliminates both water-soluble toxins 
and strongly albumin-bound toxins from the blood of patients with liver 
insufficiency. In other words, it is a blood purification system that filters 
toxins from the blood stream.  Blood from the patient’s femoral vein is 
pumped into the MARS circuit which passes the blood through a 
membrane, transferring albumin-bound toxins into counter-current 
albumin-enriched dialysate fluid. Treatment duration is likely to be 6-8 
hours. The MARS system will be used with a standard dialysis machine 
(available in renal units) or continuous venevenous hemofiltration (CVVH) 
machine.  
 
The MARS system will act as a support of liver function for those patients 
with acute or chronic liver disease, who are waiting for transplantation or 
capable of spontaneous recovery after some short-term support (and can 
also act as a temporary supportive role following transplant or liver graft). 
This could mean shorter hospital stay and better use of donated livers.  
Mortality from liver failure is 80-100% in the absence of transplantation. 
In the UK in 1997, 667 liver transplants were undertaken, and 180 
patients remained on the waiting list at the end of the year (NHS UK 
Transplant 2001). 
 
2. Comparator  Episodes of acute liver failure are fairly common in chronic liver disease 
patients, and supportive measures are used in the first instance for these 
episodes of encephalopathy. The measures include reduction/elimination 
of dietary protein, or administration of glucose, lactulose and neomycin. 
Once supportive measures have failed, liver transplantation is currently 
the only option available, and the definitive treatment for patients with 
severe liver failure. 
 
The MARS liver-assist device can provide therapy for patients where 
supportive measures have failed, and can act as a bridge to 
transplantation.  Although it is said to provide time for spontaneous liver 
regeneration or correction of precipitating event, it is not known for how 
many patients this might be relevant, and as such the MARS system will 
be viewed upon in this analysis as a bridge to transplantation only. 
 
Some estimates suggest that about half patients with fulminant hepatic 
failure (acute hepatic failure) will die awaiting transplantation (Kamlot, 
Rozga, Watanabe, & Demetriou 1996). However, it difficult to estimate 
what proportion of transplant patients in the UK (or on the waiting list) 
these represent.   
                                                          
2
 The NHSC briefing says that MARS was launched mid-2000 with diffusion still ongoing, so the time 
perspective chosen is three years prior to this date, rather than three years prior to briefing as normal 
(briefings are normally provided within 6 months of launch).  




For this analysis, I will use transplant statistics from NHS organ donation 
statistics for the year 2001 (NHS UK Transplant 2001)3.  These offer the 
outcome of patients waiting for a liver transplant. Of all 954 patients on 
the waiting list, 70% received transplantation, 17% were still waiting at 
the end of the year, 6% died, and 7% were removed from the list (the 
cause of a patient being removed from the list was not indicated in this 
report, but a 2010 version of the report by the same group indicates that 
typically patients are removed from the register because they become too 
unwell for transplant).   
 
As the prognosis for severe liver failure is poor in the absence of 
transplant, it could reasonably be assumed that the mortality rate for 
those removed from the waiting list (due to deterioration of symptoms) 
would be high. Adding together those on the waiting list that die and 
those that are removed, it is possible that a system of liver support could 
have made a significant impact on 13% of those on the waiting list. 
Unfortunately, cause of death for those that die waiting for a transplant is 
not given.  I will therefore assume that 10% of the 954 patients on the 
waiting list that would otherwise have died, might have survived long 
enough to receive a transplant if they had been given liver support in this 
bridging period (with the MARS device).  I will also run the assumption 
that 5% of these patients could be saved.  
 
3. Market size  If the MARS system were to be used as a bridging therapy for 
transplantation for all patients, then every year this could equate to 
around 1,000 patients (there were 954 patients on the waiting list in 
2001).  
Market size per year:1,000 
 
4. Health Service 
 
Changes in resource use.  Any changes in 
service delivery costs to the NHS that will 
result from the application of the new 
technology, including the disinvestment in 
previous practice.  This could include: Staff 
time, hospital bed days, GP visits, A&E visits, 
etc.  It should not include services for which 
the NHS (and personal social services) is not 
financially liable (e.g. lost productivity and 
[non-health] social care costs), but these 
If the 10% of waiting list patients that drop off the 
waiting list every year (due to removal or death) can 
be kept on the register until a liver transplant is ready 
for them, then this would increase the demand for 
liver transplant.  However, liver donor supply is 
clearly restricted and is unlikely to shift significantly 
in response to changes in demand.  Therefore, it will 
probably be the case that all patients would have 
longer waiting times until transplant. Although this 
may in turn increase the risk of death-while-waiting 
rate, the provision of liver support from MARS will be 
assumed to offset this. 
                                                          
3
 Although headline transplant and waiting list statistics for 1997 were found (from the same source), 
statistics relating to the characteristics and outcomes of transplant / waiting list patients were not found 
(including information on how many had died waiting for a transplant).  As such, the earliest date 
available for this data is used: 2001. The trend graph for NHS liver transplant activity between 1997 
and 2001 is fairly flat, indicating that 1997 statistics may well have shown similar characteristics. 
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should be noted in writing below to add to 
the verbal case for the product (NICE may 
incorporate social care costs into cost-
effectiveness estimates in the near future). 
 
 If relevant and not included in service cost 
impact above, search for price of the 
currently used product (P1). 
 
 
Use HCHS index to inflate estimates to 
current prices  
 
Describe any potential costs/savings that 
you haven’t quantified.  
 
If the MARS system were to be offered in ITU 
(intensive therapy unit) or renal units, then minimal 
reorganisation / training would be required.  As it 
would be very difficult to estimate the cost of the 
extra staff time that would be needed, this will have 
to be considered and accounted for within the 






The potential for the MARS system to offer an 
opportunity for spontaneous recovery (perhaps 
reducing the number of transplants required and 
leading to better allocation of transplants) has been 
ignored. Savings from fewer transplantations could 
be significant (a transplant costs between £11,000 
and £14,000 per patient).  
(Total) ∆SC=  - 
(Av. per person) ∆SC=  - 
 




Potential impact of the new device on 
patient health, as compared to current 
practice (preferred method of elicitation is 
from studies using the EQ-5D).   
Where NICE have not produced relevant 
economic analyses, search for cost-
effectiveness studies or systematic reviews 
within the disease area (the CEA registry 








From a headroom perspective, I will assume that the 
system is in equilibrium (i.e. the waiting list for 
transplants is not getting longer and longer all the 
time).  If 10% more people on the waiting list are able 
to survive until transplant, then the value of the 
additional benefit of the MARS system would be the 
value of those lives saved, taking into account their 
life-expectancy post transplant and for the quality of 
life they experience in that state4.  
 
Transplant survival rates are recorded in the liver 
activity report by the NHS UK Transplant Group (NHS 
UK Transplant 2001). The group estimate a one year 
survival rate of 80%, a three year survival rate of 73% 
and a 64% survival rate at 5 years.  This translates 
into an expected survival time for those receiving a 
liver transplant of around 10 years (i).  This must be 
adjusted for the quality of life experienced in those 
                                                          
4
 This actually poses a very complicated problem. One could argue whether it is reasonable to use the 
value of these extra lives saved when, in real terms, if supply of livers is exactly fixed every year, then 
the same number of people are being transplanted with or without the device. However, from this 
simple headroom approach, we can only assume that the system is in equilibrium, and that those kept 
alive until transplant will (eventually) receive one. 























































A report published in 1990 assessed QoL after liver 
graft. Although the unit of measurement was not an 
EQ-5D score but the ‘Nottingham Health Profile’ (a 
validated HRQoL measurement), results showed 
HRQoL to be high, and broadly similar to that 
expected in the general population (Lowe, O'Grady, 
McEwen, & Williams 1990). Kim (Kim et al. 1997) 
estimates a QALY weighting of 0.8 following 
transplant, and Bennet (Bennett et al. 1997) estimate 
a QoL weighting of 0.5 after first year and 0.7 
thereafter. Neither study is clear on how these values 
were elicited. 
As an estimate, I will use the middle of these three 
figures and apply a QALY weighting of 0.8 for the 10 
years of expected life following transplant.  
0.8*10= 8 QALYs 
This gives us a discounted health gain for this 10% of 
patients of 6.89 QALYs per patient (ii), and a total 
∆QALY of 689 QALYs 
 
10% of those on the waiting list represents 100 
patients, but as the MARS system will be used for all 
1,000 patients on the waiting list, the average QALY 
gain per patient will be (6.89*100)/1,000 = 0.689 
QALYs. 
∆QALY=689  
(Av. per person) ∆QALY=0.69 
 
If just 5% more patients could be kept alive until 
transplant with the MARS system, the figures would 
transform into the following: 
(6.89*50)/1,000 = 0.3445 QALYs 
 
∆QALY=345  
(Av. per person) ∆QALY=0.34 
 
The MARS system is a piece of equipment not for 
individual use, but to be used for many patients. 
Therefore, in order to think of a headroom per 
device, we require an estimate of average health gain 
per device, for which we need to know how many 
systems are needed to cover all of these patients 
(and therefore how many people will be serviced by 
each device in a year). There is no indication in the 
briefing notes as to how many patients can be 
treated by one device. However, this would be an 







Describe any impact on patient health that 
you haven’t quantified.  
essential parameter for calculating headroom per 
device (the conceptually useful number). 
(Av. per device) ∆QALY= ? 
 
Not included in this analysis is the potential for those 
patients who are currently not suitable for liver 
transplant (and therefore not on the waiting list), to 
benefit from liver function support. This would not 
only lead to a greater relevant patient population, 
but could provide enhanced quantity/quality of life 
for these patients. 
I have also not incorporated the disutility that may 
arise from longer waiting times.  
 
6.  Developments (clinical & healthcare 
context) 
 
Consider the following questions to help you 
think about the space for your product 
within the market.  
 
Does the technology address any key national 
objectives for improving care in this area? 
 
How will the technology complement current 
practice? Is current practice likely to change? 
 
Are there any indications in the literature of 
potential effectiveness? 
 
Have you identified any direct competitors? (This 
could be another specific technology, or simply a 
different technique)  
 
 RED: Poses a significant threat to the 
opportunity identified in the market (i.e. 
works against current health service 
objectives, or there are other products 
being developed that are associated with 
better outcomes or are at a more advanced 
stage of development). 
 
AMBER: Potential threat 
 
GREEN: Further supports the case for the 
new technology  
 [AMBER] A search of the literature identified a 
paper from 1975 entitled: ‘Artificial liver support 
based on haemoperfusion of adsorbents’ (Dunlop 
et al. 1975). A paper from 1986 also discusses 
haemoperfusion for this indication (Mito 1986). 
Although I was not able to access either paper, 
their existence shows that the idea for this sort of 
technology is not new. This could mean that: 
1) If it was a good idea someone would have 
made a successful product of it before now. 
2) There might be others developing a similar 
technology. 
 
 [AMBER] There is much talk in the literature of 
the acute need for systems that can help to 
support liver function, whilst patients await 
transplantation or (ideally) who could recover 
spontaneously if temporary support were 
available. Papers with this theme include Nyberg, 
1993 (Nyberg et al. 1993), Cattral, 1994 (Cattral & 
Levy 1994), Jauregui, 1996 (Jauregui, Roy 
Chowdhury, & Roy Chowdhury 1996) and Fouad, 
1996 (Fouad, Mamer, & Shahidi 1996).  However, 
all of these papers talk of the potential for 
artificial hepatic dialysis that makes use of 
hepatocytes to enable liver support, a function 
not dealt with by the MARS system. The MARS 
system mimics the capacity of the liver for 
filtering toxins from the blood stream. However, 
a normally functioning liver also metabolises 
drugs and synthesises bile and proteins. With the 
MARS system, this complex task of metabolism 
and regulation are left to the living hepatocytes 
within the liver (it is thought that removing toxins 
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from the blood can improve the environment for 
hepatocyte regeneration).  Liver support devices 
that are being developed to fulfil these 
metabolising functions include an extracorporeal 
liver assist device using human liver cells  
(Sussman et al. 1992), and a bioartifitial liver 
device containing porcine hepatocytes (Rozga et 
al. 1994). Sussman (1994,1996) discusses the 
advantages of biochemical liver assist devices 
over mechanical devices (i.e. MARS) (Sussman, 
Gislason, & Kelly 1994;Sussman & Kelly 1996). 
Although these alternatives have not yet entered 
the market, it is clear that (long-running) 
research is being undertaken on these systems, 
which may allow for increased function as 
compared with the MARS system.  
 
7.  Research questions 
 
This should be a list of the things that the 
developer needs to find out or monitor 
during the process of development, relating 
to the function of the device or how it fits 
into the market place. 
 
From the research undertaken and reported 
above, what are the most important 
questions or uncertainties that must be 
addressed / tested? What factors or 
assumptions have the calculations / 
economic or clinical case hinged upon?  
 The principal assumption, upon which all 
estimations of value are dependent, is that the 
MARS system has the potential to save lives, by 
supporting liver function and allowing more 
people to receive a life saving transplant. This will 
need to be verified by clinical trials. 
 In order to estimate the potential of the MARS 
system to allow for spontaneous recovery (which 
would be very valuable to the NHS in terms of 
saved life or reduced demand for liver 
transplants), the potential magnitude of this 
should be estimated (i.e. for how many patients 
might this be relevant?) 
 Given the large literature base for this technique, 
the company should be aware of potential 
competitors or changes in the market. 
 Research relating to the use of hepatocytes 
should be monitored carefully, as – if found 
viable – technologies employing such a function 
could prove to be more effective than the MARS 
system in its capacity to aid liver function.   
 In order to understand the economic and clinical 
value of a device, the company will need to work 
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Notes by AC 
(i) Mean survival was calculated in the following way: 
 
P (Survive T years) =       
 
Where mean survival = 1/d 
 
 One year survival rate of 80%: 
0.8=        
ln(0.8)= - d  
-0.223= - d 
Mean Survival = 4.5 years 
 
 Three year survival rate of 73% 
0.73=       
ln(0.73)= -3d 
0.105=d 
Mean Survival = 9.5 years 
 
 Five year survival rate of 64% 
0.64=       
ln(0.64)=-5d 
0.089=d 
Mean Survival = 11.2 years 
 
The estimate of a 10 year life expectancy post-transplant has been chosen, as the calculations 
from the three and five year survival rate are close to this figure.  Although the shorter-term risk 
of death is greater in the first year (presumably from the risk associated with organ rejection), it 
has been indicated that the MARS system could usefully be used in a temporary supportive role 
post-transplant, which may help to reduce this risk.  
 
(ii) Calculating discounted QALY gain 
Using a discount rate of 3.5% to calculate the value of future health gain, the following formula 
was used to calculate discounted health gain: 
           
   
     
 + 
   
        
 + 
   
        
 + 
   
        
 + 
   
        
 + 
   
        
 + 
   
        
 + 
   
        
 + 
   
        
 
= 6.89 QALYs 




Headroom Notes (MARS) 
 
 10% saved 5% Saved 
WTP: £20,000 / QALY £13,800 £6,800 
WTP: £30,000 / QALY £20,700 £10,200 
 
These headroom figures represent the value that using the MARS system on one patient presents to 
the NHS in a given year (I have not been able to infer an MRP given the absence of a service cost 
estimate, patient throughput, and device longevity).  
As MARS is a piece of equipment, the true value per device would be calculated by multiplying this 
headroom figure by the number of patients who would use it in a given year. Having calculated a 
headroom per device per year, this would be multiplied by the expected device lifetime (and 
subsequently discounted) in order to estimate a true headroom per device.  This estimate of 
maximum willingness to pay would need to cover: the cost to the NHS of the equipment itself 
(‘price’), extra NHS resource expenses (e.g. staff time), consumables (e.g. the albumin and disposable 
kit required for each use, multiplied by the number of times each patient would need to be treated), 
and costs for servicing the equipment. 
If we were to have all of these inputs, then the true MRP could be estimated and some decision 
analysis regarding development costs could be undertaken. An interesting aspect of conceptualising 
the ‘headroom’ for this particular type of device, is that this value could be recouped through various 
channels: equipment price, consumables price, and also annual servicing charges.  This is likely to be 
a strategic decision, and could mean dividing total MRP into multiple MRPs, rather than accruing the 
whole monetary value of the device as one lump sum upon sale of the device. 
 
Follow-up (MARS) 
Headroom Outcome and Market success 
Does the MRP look realistic? Would it have indicated yes or no to development? 
The MRP for this device was particularly difficult to identify, but what was calculated was a 
headroom per patient. If (unrealistically) one device would be used per patient then, according to 
these early estimates, the company could reasonably charge £6,600 (5% saved, WTP: £20K) to 
£20,700 (10% saved, WTP: £30K), which would need to cover all consumables and health service 
costs. If the device were to last five years, this would become £33,000 to £103,500.  
The price indicated for the MARS system is £16,000, with disposable cost per treatment of £1,300 
(£1,100 for the kit and £200 for the albumin). The number of treatments per patient is said to be 
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approximately 3 to 8.  A comprehensive service contract is £1,600 per year.  Even if we assume that a 
patient receives 8 treatments, this would cost the NHS (if it lasted 5 years): £16,000 + (£1,300 * 8) + 
(£1,600 * 5) + (health service costs) = £34,400 (+health service costs e.g. staff time). Considering this 
cost falls short of our lowest headroom estimate, and that in reality the fixed capital cost of £16,000 
and servicing would be shared among many patients rather than just the one, we can only assume 
that this headroom looks favourable5.  
Interpretive answer: Headroom positive  
Has there been a decision made on it by NICE? What was the outcome? 
In 2004 an Interventional Procedure Guidance was issued (IPG45) on extracorporeal albumin dialysis 
for acute-on-chronic liver failure, which concluded that the current evidence on safety and efficacy at 
that time was not adequate to recommend that the procedure be used without special arrangements 
for consent, audit and research.  In the update of this guidance produced in September 2009 entitled 
‘Extracorporeal albumin dialysis of acute liver failure’ (IPG316) the procedure was said to raise no 
major safety concerns, but that current evidence on its efficacy were still inadequate in quality and 
quantity. As such, if a clinician wishes to undertake the procedure, they should still inform clinical 
governance leads, make patients aware of uncertainties, and audit/review clinical outcomes. 
Although NICE IP guidance omits specific technology or company names, when looking through the 
evidence reviewed, it is clear that the majority consider MARS as the system to deliver this dialysis 
(NICE 2009a). In its guidance, NICE recommend further research be undertaken as to the short and 
longer term survival of patients ‘bridged to transplant’, as compared with current practice. 
 
Is it sold in the UK or the rest of the world?(Or has it in the past) If so, who is it bought by? 
Given the volume of clinical trials reported for the MARS system, it is clear that the device has been 
used for a number patients. Even in 2003, according to the NHSC briefing, the MARS system was 
being used occasionally in 20 UK centres and on a regular basis in 3 centres. A 2009 report 
commissioned by the North Trent Priorities Process, covering primary care trusts in the North 
Derbyshire, South Yorkshire and Bassetlaw areas, declared a commissioning policy: that the 
procedure would be funded for a maximum for four cases per year for the next three year period 
(Suckling 2009). This was based on that fact that apparently 3 to 4 patients per year with acute liver 
failure do not respond to standard medical therapy and may be considered suitable.  This indicates 
that the stance used in the analysis may well have overestimated a realistic distribution policy, and 
that using the liver transplant list may not have been the best estimate of the relevant patient 
population.   
Teraklin Ltd was acquired by Gambro in 2004. On the company website, it is indicated that in the U.S 
the MARS system is cleared for use in the treatment of drug overdose and poisonings only, and not 
for the treatment of liver conditions or as a bridge to transplant. It is clear, though, that the MARS 
                                                          
5
 To the other extreme, we could have assumed that there would be one MARS system per UK liver 
transplant centre, of which there are 7 (NHS UK Transplant 2001), and in which case the headroom 
could have been multiplied by around 140! 
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treatment kit has a global outreach. Research into the use of MARS in practice is undertaken globally, 
another indicator that the device has widespread interest. 
Have there been investigations into its clinical / cost effectiveness? 
There have been a great number of studies into the clinical and/or cost effectiveness of the MARS 
system.  A simple search of MEDLINE of ‘MARS’ AND ‘liver’ produces 403 studies.  On the efficacy 
side, the NICE review in 2009 showed that, although most studies reported clinical benefits for 
patients using the MARS system (including increased survival), most effects were not statistically 
significant.  
The CEA registry identifies three cost-effectiveness studies for MARS. The oldest, published in 2006 
by Hessel (Hessel 2006) presents a clinical cohort trial with a prospective follow-up of three years. 
Hessel found that, over the three years, MARS cost 40,000 EUR per patient treated, versus 12,700 for 
the controls. The three year survival rate was found to be 52% with MARS and 17% in controls (highly 
significant). He reports an ICER of 47,200 EUR. 
The second cost-effectiveness study is by the same author, reporting on study with a larger cohort 
(149 patients) with a three year follow-up, but having modelled longer-term costs and outcomes. 
They found an ICER of 43,040 EUR (Hessel, Bramlage, Wasem, & itzner 2010). 
The final cost-effectiveness study on the CEA registry is by Kantola et.al, who report on a trial 
conducted in Finland (Kantola et al. 2010). They find MARS to be both less costly and more effective 
than standard medical therapy, thus dominating current practice. It cost on average 10,928 EUR less 
than standard medical therapy. Interestingly, the number of QALYs gained per patient with the MARS 
system versus standard practice was 0.66 (this was elicited using the 15D generic HRQoL instrument). 
This is remarkably close to that used in the headroom estimate: 0.69.  
A paper by Hassenein et al.  (Hassanein, Schade, & Hepburn 2011) reports that nonbiological devices 
such as MARS, whilst effective in improving severe hepatic encephalopathy, have failed to show 
improvement in survival in RCTs. They also note that recent pilot studies for biologic devices 
(incorporating hepatic cells) show improved survival rates in some groups (but RCTs are needed to 
verify).  
Has the landscape described changed significantly? 
 
What is current gold standard clinical practice now? Has this changed? 
I have found no evidence to show that clinical practice has changed significantly for patients with 
acute liver failure, though assist devices such as MARS are becoming more prominent. 
Are there now many direct competitors? 
Many clinical trials compare MARS to other devices with a similar function (called liver detoxification 
albumin dialysis), particularly the Prometheus device. The single pass albumin dialysis (SPAD) is 
another simple alternative, using standard haemodialyisis machines without an additional perfusion 
pump system. 
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Conclusions: How useful might the headroom exercise have been? 
The seemingly positive headroom for the MARS liver assist device may have suggested development, 
and the product does seem to be sold across the world. However, there is nowhere near full-scale 
deployment in the UK, and unfortunately no technology appraisal has been undertaken by NICE to 
consider its economic as well as clinical impact.  This is due mainly to questions of effectiveness.   
The MARS liver assist device was viewed upon in the headroom analysis as an aid for liver function. 
The size of the relevant patient population may have been overestimated for liver disease patients.  
However, the technology has also been mentioned in relation to renal failure and drug poisoning, 
which could widen market significantly.  
The headroom analysis used increased survival rates as the key clinical and economic driver for its 
value case.  The story was over simplified, and the subsequent clinical data has shown that this 
parameter is not straightforward.  The need to provide evidence of impact on survival of MARS when 
used as a bridge to transplant was emphasised in the proposed research questions of the headroom 
analysis.  Ten years later, elicitation of this precise parameter was reiterated as a research 
encouragement by NICE.    
The information unearthed by the headroom analysis also uncovered some potential threats to the 
MARS system in terms of future competitors.  This threat remains, and has borne some direct 
competitors.  
Not all clinical studies on the MARS system have shown increased survival (upon which the whole 
headroom sum was based). There are other factors that were ignored by the headroom analysis and 
thus un-quantified, including potential reduction in time spent in an intensive care unit.  
The headroom analysis undertaken could not identify a true estimate of MRP per device, as I could 
not estimate the likely lifetime of the device, the number of patients treated per device, or the 
health service implication in terms of resources. Whilst the developer may be better equipped to 
estimate such parameters, these may be difficult to predict early on. 
 
 












Date of briefing: Sep 
2007 
 
Time perspective of this 
report: 20056 
It is estimated that 1% of adults have a stammer. Most stammering starts 
in early childhood, and is more common in males than in females. The 
‘choral effect’ describes the phenomenon that stammering is usually 
clearer when a person is singing or speaking in unison with others. 
 
The SpeechEasy is a prosthetic device that stimulates this ‘choral effect’ 
by providing altered-auditory feedback (AAF) of a patient’s own voice to 
themselves when they talk. This AAF can be in the form of delayed 
auditory feedback (DAF) or frequency-altered auditory feedback (FAF), 
and the SpeechEasy can provide a range of settings to combine these two, 
tailored to each user.  It is a wireless device that has three models: one 
that fits behind the ear, another which sits mainly in the inner ear canal, 
and a third that sits completely in the ear canal.   
 
2. Comparator Speech and language therapy is commonly used to help deal with 
stammering, which includes fluency modification techniques 
(slowed/prolonged speech), vocal fold management, and psychological 
approaches (counselling etc). Other strategies include anxiety control, 
hypnosis and narrative therapy.  
 
This device is intended as an adjunct to current stuttering7 therapy. 
However, the most pertinent comparator for this particular device is an 
alternative electronic device whose therapeutic goals and means are 
similar to that of SpeechEasy.  The use of AAF to improve stuttering is not 
novel, and investigations into its effect were published in the 1970s 
(Pollock, Gregory, & Shaw 1976;Stark & Pierce 1970). Low (1979) first 
talks of a body-worn AAF device, that broke from previous versions which 
all required desk-top equipment. Versions of devices providing this 
function have progressed significantly over the past 25 years.  SpeechEasy 
represents the first available wireless version of AAF devices, allowing for 
more discrete use.  
 
That this sort of device be cosmetically appealing is important, as 
conspicuous versions could discourage use and may cause some anxiety (a 
measure of anxiety is included in the health-related quality of life 
questionnaire EQ-5D). Other versions of AAF devices include models that 
use a headphone / microphone system (often connected by wires). Prices 
for these devices range from $350 to $3495.  
 
3. Market size  It is estimated that 1% of adults have a stammer (around 408,000 adults 
in England and Wales), though the severity and exact features vary 
greatly from person to person. There has been no estimate given as to 
                                                          
6
 More recent date chosen as the device represents a small change to its comparator, so the date is 
set to two years pre briefing rather than three. 
7
 The terms stutter and stammer are used interchangeably.  




the number of patients relevant for this device.  The BSA (British 
Stammering Association) indicates that these electronic devices tend to 
be more useful for those that suffer more severely from a stammer, but 
give no indication of the number of people this represents.  It is likely 
that the SpeechEasy could widen the current market for AAF devices 
given their more discrete nature. 
Market size per year: ? 
 
4. Health Service 
 
Changes in resource use.  Any changes in 
service delivery costs to the NHS that will 
result from the application of the new 
technology, including the disinvestment in 
previous practice.  This could include: Staff 
time, hospital bed days, GP visits, A&E visits, 
etc.  It should not include services for which 
the NHS (and personal social services) is not 
financially liable (e.g. lost productivity and 
[non-health] social care costs), but these 
should be noted in writing below to add to 
the verbal case for the product (NICE may 
incorporate social care costs into cost-
effectiveness estimates in the near future). 
 
 If relevant and not included in service cost 
impact above, search for price of the 
currently used product (P1). 
 



















Speech and language therapy is provided by the NHS 
through specialist clinics.  It is not clear to what 
extent such AAF devices are available on the NHS.   
The BSA indicate that ‘NHS funding for such devices is 
not generally available’ (The British Stammering 
Association (BSA) 2011).  In order to understand what 
role the technology plays in current clinical practice, 
if any, I contacted an NHS speech and language 
therapy clinic (i).  A community service that serves 
the North, East, and Heart of Birmingham localities 
owns two ‘VoiceAmps’ (devices that combine voice 
amplification with an altered auditory feedback 
function), which are used within therapy sessions to 
develop a patient’s skills. If a patient thinks that such 
a device could help them in everyday life, then they 
would have to purchase one.  It was noted that the 
situation with AAF devices varies up and down the 
country.   
 
This brings up two issues.  First of all, that the NHS 
probably represents a very small portion of the 
potential market for SpeechEasy; such devices are 
generally used in clinic rather than prescribed for 
everyday use.  Secondly, for those that are used 
within NHS clinics, there is likely to be little 
motivation to replace current devices with a more 
discrete model such as SpeechEasy. As it stands, it 
seems that the customer-base for SpeechEasy would 
be the patients themselves rather than the health 
service. 
 
Although indicated as an adjunct to speech therapy, 
it is suggested that SpeechEasy could eventually 
reduce the demand for these speech therapy services 
(which are provided on the NHS). However, to be 
prescribed systematically by the NHS, this would 
change the buyer from patient to health service, and 
change our comparator from ‘older version’ to 
‘speech therapy alone’.  Being such a small change to 
previous versions of an AAF device, it is difficult to 






















Describe any potential costs/savings that 
you haven’t quantified.  
understand why the NHS would decide to pay for 
these where they didn’t before; the potential 
resource saving from reduced speech therapy is 
unlikely to be offset by the cost of such a device per 
patient.  As such, the SpeechEasy must be considered 
as a patient purchase.  
 
In light of this, the question becomes not how much 
the NHS would be willing to pay for the device, but 
how much patients would be willing to pay.  
(Total) ∆SC=  n/a 




(this is the price of the most expensive existing 
model. NOTE: This is a patient expense rather than  
a Health Service expense) 
 
Speech and language therapy is provided by the NHS. 
It may be that, if SpeechEasy can offer an effective 
and long term aid for stammer, then the demand for 
these services may be reduced. However, the device is 
mainly indicated as an adjunct to current therapy, so 
this was not quantified in this analysis, but should be 




Potential impact of the new device on 
patient health, as compared to current 
practice (preferred method of elicitation is 
from studies using the EQ-5D).   
Where NICE have not produced relevant 
economic analyses, search for cost-
effectiveness studies or systematic reviews 
within the disease area (the CEA registry 
offers a useful platform to identify these 
studies). 
 
Describe any impact on patient health that 
you haven’t quantified.  
If SpeechEasy were to work as well as the most 
expensive version of what is currently available, 
which is sold for $3,495 (£1,827: Pocket Speech Lab 
by Casa Fortuna Technologies), then people should 
be willing to pay at least this much for SpeechEasy.  
However, people are likely to be willing to pay a 
premium for its more discrete appearance.  The 
question is: how much money could this premium 
represent? 
 
The value of this sort of change in current practice 
could feasibly be explored and estimated using the 
tools we use for NHS health valuation (ii). However, 
whilst interesting methodologically, this cannot be 
used to estimate incremental WTP for SpeechEasy, as 
this measure of health related quality of life and its 
valuation with a ‘QALY tariff’, have been designed 
specifically with the NHS and its inherent budget 
prospects in mind. There is nothing to indicate that 
this would reflect a patient’s WTP. 
                                                          
8
 Exchange rate ($1.9129 to the £) obtained from HM Revenue and Customs UK Trade Info for Jan 
2005 (HM Revenue & Customs 2011).  





Economic methods that aim to elicit the value a 
consumer places on particular product 
characteristics, which could be useful in valuing the 
magnitude of such a premium include: WTP methods 
(where individuals are asked to state maximum 
willingness to pay or willingness to accept) and 
discrete choice experiments (where the value of 
particular characteristics of a product are isolated by 
observing the trade-off between characteristics of 
commodities and performing a regression analysis).  
However, such techniques are outside the scope of a 
headroom analysis.  
∆QALY= n/a  
(Av. per person) ∆QALY= n/a 
(see notes (ii) for theoretical estimate) 
 
6. Developments (clinical & healthcare 
context) 
 
Consider the following questions to help you 
think about the space for your product 
within the market.  
 
Does the technology address any key national 
objectives for improving care in this area? 
 
How will the technology complement current 
practice? Is current practice likely to change? 
 
Are there any indications in the literature of 
potential effectiveness? 
 
Have you identified any direct competitors? (This 
could be another specific technology, or simply a 
different technique)  
 
 RED: Poses a significant threat to the 
opportunity identified in the market (i.e. 
works against current health service 
objectives, or there are other products 
being developed that are associated with 
better outcomes or are at a more advanced 
stage of development). 
 
AMBER: Potential threat 
 
GREEN: Further supports the case for the 
new technology  
 [AMBER] There is no NICE Guidance of any sort 
on stammer, indicating that it may not be an NHS 
priority. As SpeechEasy represents an 
incremental development to currently available 
models, it is unlikely to incite funding where it 
was previously unavailable for similar 
technologies. 
 
 [GREEN] The strong literature base supports the 
efficacy of such devices, and there is no reason to 
believe SpeechEasy should be any less effective.  
Therefore, from a therapeutic perspective, the 
device is likely to be well received. 
 
 [AMBER] There are many makes and models for 
AAF devices, and the number of direct 
competitors is not likely to diminish.  Although 
SpeechEasy is the first in-the-ear AAF device, it is 
unlikely to be so for long, as other companies will 
follow with yet more versions.  Projected market 
share should reflect this, and the time to make 
back development costs should also be set with 
this in mind. 
 




7. Research questions 
 
This should be a list of the things that the 
developer needs to find out or monitor 
during the process of development, relating 
to the function of the device or how it fits 
into the market place. 
 
From the research undertaken and reported 
above, what are the most important 
questions or uncertainties that must be 
addressed / tested? What factors or 
assumptions have the calculations / 
economic or clinical case hinged upon?  
 The sound literature base for AAF devices 
supports their use in people with a stutter. The 
SpeechEasy device will need to prove that it can 
perform this function up to the standard of 
current technologies. 
 An important parameter to identify is the extent 
to which patients would value / accept an in-the-
ear device. This is the key selling point of the 
SpeechEasy, and will likely dictate the price that 
consumers are willing to pay for it.  
 Investigate the likely lifetime of such a device, as 
this will inform the length of the development 
cost recovery period.  It is clear from the speed 
and extent of developments in this market until 
now that, as in many consumer markets, 
technology moves on quickly and models are 
soon outdated. 
Notes by AC 
 
(i) I emailed a contact supplied on the website of a speech/language therapy centre in 
Birmingham. I asked him whether devices such as SpeechEasy are provided for patients 
on the NHS, or whether they are a patient purchase.  I received an email in response to 
my query, advising me of the situation in their clinic: 
Dear Amanda 
  
Your request for information on altered auditory feedback equipment has been sent over to me, as 
Clinical Lead for fluency disorders.  I am delighted to hear that you are undertaking some research in 
to the field of stammering! 
  
The situation regarding altered auditory feedback devices for adults who stammer probably varies 
across the country. 
  
The adult community service in Birmingham, which covers the North, East and Heart of Birmingham 
localities, owns two VoiceAmp devices.  These are used in therapy as part of the process for some 
clients.  Clients are supported to use the device in the session, and can develop their skills in using 
them.  If they decide that the device could benefit them in their everyday life, they would have to 
purchase one. 
  
I hope this is useful. 
  
(ii) Interestingly, one of the 5 health dimensions in the EQ-5D questionnaire relates to level 
of anxiety / depression. Comparing SpeechEasy to ‘Pocket Speech lab’ (and assuming it 
works just as well), the only health-related quality of life parameter likely to be affected 
would be a one-level shift in anxiety (resulting from using a more discrete device), from 
moderately / slightly anxious or depressed, to slightly / not anxious or depressed.  The 
effect of this on total utility weighting should be easy to estimate. 
 
Williams (1995) lists all possible combinations of the EUROQOL classification system, and 
used interviews from a cohort of 3395 people in the UK to estimate each and every 
combination.  Each of the 5 health parameters contains three options: No problems, 




Moderate / some problems, or extreme problems. Dolan (Dolan 1997) models these 
results and provides a coefficient for each parameter (and the effect of a change in these 
on overall QoL) 
 
Using this scale, we could estimate the value of a shift-change in level of anxiety.  For 
example, if all other health parameters (mobility, self-care, usual activities, 
pain/discomfort) are held constant at 1 (no problems), a shift from moderately anxious 
to not anxious would be worth 0.152 (1 [with SpeechEasy] – 0.848 [with more visible 
device]) in a quality of life tariff.  If we imagine that the person does not return to ‘full 
health’ at baseline (in the model, there is a ‘constant’ which represents the reduction in 
health state for anything under 1: full health), then this change would be 0.071. 
Multiplied by £20,000 or £30,000, this would incite a WTP by the NHS of £3,040 - £4,560, 
or £1,420 - £2,130 per year.   
Headroom Notes (SpeechEasy) 
No calculation made 
Follow-up (SpeechEasy) 
 
Headroom Outcome and Market success 
Does the MRP look realistic? Would it have indicated yes or no to development? 
Rather than estimating a definitive maximum reimbursable price, in this instance, the headroom 
method has only provided a narrative argument for SpeechEasy over other similar AAF devices.  The 
MRP has thus been expressed as the price of the most expensive current technology (£1,827) plus 
some premium that consumers should be willing to pay for the discrete nature of SpeechEasy as 
compared with other models.  The headroom method provides no means with which to estimate this 
premium. 
Without knowing the cost of transforming the AAF function into such a small device, it is hard to 
know what a realistic MRP would be.  According to the NHSC briefing (2007), the actual price of 
SpeechEasy ranges from $4,100 (£2,050) for the behind the ear model to $4,900 (£2,450) for the 
completely-in-the-ear-canal model. The SpeechEasy website now indicates that prices range from 
$4,100 to $5,100 (£2,550 using the same conversion rate) (SEInternational 2011).  This price includes 
initial fitting and development of the mould to fit each person specifically, as well as ongoing device 
adjustments. 
This seems to fit well with the expectation that the company should be able to charge a price 
equivalent to the most expensive alternative, plus a premium for the discrete design. For the most 
expensive model (completely hidden), this premium seems to have been estimated at £623 - £723. 
Interpretive answer: Headroom lacked sufficient detail to answer this  




Has there been a decision made on it by NICE? What was the outcome? 
No NICE guidance relates to stammering. 
Is it sold in the UK or the rest of the world?(Or has it in the past) If so, who is it bought by? 
SpeechEasy is a U.S. based company, but with providers around the world, including all over North 
and South America, parts of Africa and Asia, and much of Europe. The website of Europe’s distributor 
MedSys indicates that the product is available in the UK. 
The British Stammering Association (BSA) make the SpeechEasy device available to its members for 
free for a five day trial, so people can see if it works for them. 
SpeechEasy has received a lot of international press, and among other media outlets has received air 
time on the Oprah Winfrey show, and SpeechEasy was also featured on the program ‘Inside Out’ for 
the BBC in 2009.  
Searching ‘stammer’ on the NHS choices website indicates AAF devices as a treatment option for 
stammer, but that these are still not provided on the NHS. 
Have there been investigations into its clinical / cost effectiveness? 
There have been a number of small trials for the SpeechEasy device, most of which are favourable. 
Armson (2006) reports on a trial (in laboratory conditions) with 13 people, which finds SpeechEasy to 
be beneficial to all patients in at least one of three speech tasks, though degree and pattern of 
benefit varied greatly across participants (Armson, Kiefte, Mason, & De Croos 2006). O’Donnell et al. 
(2008) tested SpeechEasy on seven adults who had responded positively to the therapy in a 
laboratory setting, to see if the benefit would hold in situations of daily living (O'Donnell, Armson, & 
Kiefte 2008). Five out of seven participants experienced some instances of reduced stuttering with 
the device compared to without.  SpeechEasy was also found to have (moderately) favourable results 
by Armson & Kiefte (2008) and Pollard et al. (2009) as well (Armson & Kiefte 2008;Pollard, Ellis, 
Finan, & Ramig 2009). 
 
No cost-effectiveness analyses were identified. 
Has the landscape described changed significantly? 
What is current gold standard clinical practice now? Has this changed? 
It seems (through information retrieved from the web, the BSA and a Birmingham-based speech and 
therapy clinic) that AAF devices still do not attract systematic NHS funding. 
Are there now many direct competitors? 
There are still many competitors in the market and, as anticipated, these have also developed and 
moved forward their technological developments, making them direct competitors to SpeechEasy. 
As an example, the competitor ‘next best’ device which was used in the headroom analysis which 
cost $3,495—the Pocket speech lab by Casa Fortuna—is now, according to their website, an 
‘obsolete model now marked down for clearance’, and costs $995 (CasaFortunaTechnologies 2011).  
They have developed a very small version AAF which they sell for $2,495 (though it doesn’t fit 




completely within the ear, and requires a small box nearby), and they have also developed an iPhone 
app which features AAF. 
Conclusions: How useful might the headroom exercise have been? 
 
As an NHS perspective could not be taken for this device, the headroom approach did not allow the 
isolation of an MRP; this is a shortcoming of the headroom method.  The eventual price set for 
SpeechEasy does seem to have aligned itself with expectations from the headroom exercise, and the 
research questions were pertinent.  Whether, though, this has anything to offer beyond what a 
company would have been investigating anyway, is probably unlikely.  
 
 












No NICE follow-up 
 
Date of briefing: Sep 
2009 
 
Time perspective of this 
report: 2006 
Peripheral arterial (or vascular) disease (PAD) is the narrowing of the 
peripheral arteries (primarily in the legs), leading to insufficient blood 
supply to the muscles and other tissues. It can cause leg pain and 
weakness when walking, but in advanced cases can develop into pain at 
rest.  
 
Critical limb ischaemia is when claudication progresses to Fontaine 
classification stages III (ischaemic rest pain) or IV (ulceration, gangrene or 
both). About 150-200 per million of the population in the UK progress to 
this critical limb ischaemia stage every year (Beard 2000). It is for these 
patients that revascularisation techniques are considered. In 2000 it was 
estimated that critical limb ischaemia cost over £200 million a year in the 
UK alone (Beard 2000). 
  
Spiral laminar flow (SLF) describes the normal spiral pattern of blood flow 
through the arteries (because of the twisting of the heart on its axis). This 
movement increases total pressure and velocity of the blood. Stenosis 
(narrowing) of the vessels interrupts this spiral flow and places pressure 
and stress on the vessel wall.   
 
The SLF peripheral bypass graft is a man-made graft which has a flow 
inducer at the distal end which restores natural SLF (and so reduces the 
laterally directed forces and turbulence caused by stenosis).  This should 
reduce neointimal hyperplasia (NIH) (thickening of a blood vessel, a 
natural response to vessel injury and a cause of vessel occlusion), and 
thus reduce the incidence of vessel occlusion.  
 
2. Comparator  
 
Management of PAD includes self-help measures such as smoking 
cessation and regular exercise, and the use of antiplatelet agents.  When 
PAD becomes more severe or persistent, options include: percuntaneous 
transluminal angioplasty (PTA) or—the most relevant comparator for the 
SLF bypass graft—bypass surgery with autologous saphenous vein or 
synthetic graft.  In a small number of cases amputation might be 
necessary. 
 
It is thought that where the flow of blood becomes non-spiral due to 
stenosis, the turbulent energy can increase dramatically (by about 700%) 
(Stonebridge et al. 2004). Lowering these forces acting on the vessel wall 
could reduce hyperplasia and subsequent occlusion. It is proposed that 
the SLF graft could achieve this stabilising effect. The SLF bypass graft is 
itself a man-made synthetic polytetrafluoroethylene (ePTFE) graft, but 
unlike traditional ePTFE grafts, has a flow inducer at the distal end which 
should improve graft patency (the chance of a graft remaining open). It is 
said to be an alternative to traditional ePTFE grafts or autologous vein 
grafting. 
 




Prosthetic grafts are usually considered only when an autologous vein is 
not available for revascularisation, as vein grafts are known to have higher 
patency rate than prosthetic grafts (Cheshire et al. 1992;Eidt et al. 
2006;Fisher et al. 2003;Londrey et al. 1991;Panayiotopoulos et al. 
1997;Pereira et al. 2006)9.  
 
There was no estimate in the NHSC briefing as to degree of improvement 
that could be expected for the SLF graft over other ePTFE grafts.  An 
optimistic but reasonable assumption for the purposes of this analysis 
could be that the SLF graft will work as well as an autologous venous graft 
(but will be used when a venous graft is not available)10. 
 
3. Market size  I have found no estimates in the literature regarding the number of 
patients undergoing a PAD bypass procedure every year. Nor have I 
found the proportion of patients for which autologous vein grafting is not 
possible. 
Market size per year: ? 
 
4. Health Service 
 
Changes in resource use.  Any changes in 
service delivery costs to the NHS that will 
result from the application of the new 
technology, including the disinvestment in 
previous practice.  This could include: Staff 
time, hospital bed days, GP visits, A&E visits, 
etc.  It should not include services for which 
the NHS (and personal social services) is not 
financially liable (e.g. lost productivity and 
[non-health] social care costs), but these 
should be noted in writing below to add to 
the verbal case for the product (NICE may 
incorporate social care costs into cost-
effectiveness estimates in the near future). 
 
 If relevant and not included in service cost 
impact above, search for price of the 
currently used product (P1). 
 
In the literature, vessel occlusion has been found to 
be common for PAD bypass grafts. In most studies, 
graft material has been found to be an important 
factor in patency rates, and the general consensus is 
that patency is improved with vein grafts over 
prosthetic ones. However, the degree of this 
improvement varies, with some saying that vein and 
ePTFE patency rates are broadly similar, going as high 
as 70 to 80%, where others find much lower patency 
rates.  Panayiotopoulos, in a UK prospective analysis 
of bypass grafts between 1991 and 1995, finds three 
year patency to be 55% for vein grafts and only 24% 
for ePTFE grafts (around half) (Panayiotopoulos et al. 
1997).  They estimate the cost to the health service 
of a successful bypass to be £4,320, and the cost of a 
failed bypass surgery which warrants later 
amputation to be £17,066. 
 
Whilst it seems feasible to estimate the change in 
cost to the health service of doubling patency rates 
for those who must use PTFE grafts (making them 
                                                          
9
 Although most studies estimate a much higher patency rate for vein grafts, one paper raises the 
question of whether the two graft options have been fairly compared, as ePTFE is usually used in 
trials when a venous graft is not an option; the risk factors and extent of arterial disease in the two 
treatment arms  could be very different (Panayiotopoulos & Taylor 1997). 
10
 This assumption has not been elicited from the developers own appreciation of the graft‘s potential 
(which was not expressed in the NHSC briefing), but from an appreciation gained from the literature of 
the disadvantages and reduced patency rates of ePTFE grafts. It would be unreasonable to assume 
that the SLF graft would achieve 100% patency, so assuming a patency rate equivalent to that of a 
venous graft (which would be the surgeon‘s first option anyway) seems appropriate.  




Use HCHS index to inflate estimates to 
current prices  
 
Describe any potential costs/savings that 
you haven’t quantified.  
similar to patency rates of venous grafts), to do so 
would mean understanding the number of graft 
revisions that take place, and how many go on to be 
amputated.  
 
Cheshire et al. estimate a patency rate of 72% for 
vein grafts and 48% for ePTFE grafts. Unfortunately 
the article is not accessible, but the abstract implies 
that the initial cost to the health service of both vein 
and ePTFE graft is $6898, which increases to $15,024 
and $20,416 respectively when considering the 
(three year) follow up period, due to higher 
reintervention rates for ePTFE grafts (Cheshire et al. 
1992). This theoretically means we could value a 
technology that increases patency rates of ePTFE 
grafts up to that of vein grafts could be worth about 
$5400 to the health service, per unit, over a three 
year time horizon (£4,400 after having inflated to 
today’s (2006) prices and converted from U.S. $ to 
the £).  
 
Given the paucity of data, any calculation made here 
would seem tenuous. However, to think of this 
problem logically, and given the assumption made, 
the case for development is compelling. From the 
literature, we have gathered that there is a big 
efficacy gap between ePTFE grafts and venous grafts. 
If we think that the SLF graft can work as well as 
venous grafts (the fact that it is proposed as a 
possible replacement for venous grafts implies that 
the developer believes this to be the case), then 
patency rates can be increased. This means fewer 
cases of graft revision (or amputation). The one 
estimate identified suggests that the cost saving 
potential for the NHS of this could be about £4,400.  
Even if this figure were actually to be far more 
modest, one can surmise that, as the SLF graft is a 
reasonably simple device that represents a small 
change to current ePTFE grafts, development costs 
shouldn’t be huge.  As there are many versions of the 
ePTFE grafts on the market (assumed to be in 
profitable business), then the extra reimbursement 
that could be achieved from producing a product that 
worked better could surely more than cover the cost 
of the modified mechanics of the SLF graft. 
(Total) ∆SC= 










Potential impact of the new device on 
patient health, as compared to current 
practice (preferred method of elicitation is 
from studies using the EQ-5D).   
Where NICE have not produced relevant 
economic analyses, search for cost-
effectiveness studies or systematic reviews 
within the disease area (the CEA registry 




Describe any impact on patient health that 
you haven’t quantified.  
It has been argued above that the economic case for 
a graft that works better than current prosthetic 
grafts is a strong one.  As it represents an 
incremental modification to current grafts, its 
increased cost per unit (if any) is unlikely to outweigh 
this potential. 
It is clear that patients would only benefit from a 
reduced vessel occlusion rate. Having established 
that the grounds for development are clear on its 
economic merit alone, there is no need to quantify its 
benefit to patients. 
∆QALY=  
(Av. per person) ∆QALY= 
 
The increased quality (and perhaps quantity) of life 
from reduced vessel occlusion and graft revision has 
not been quantified. 
 
6. Developments (clinical & healthcare 
context) 
 
Consider the following questions to help you 
think about the space for your product 
within the market.  
 
Does the technology address any key national 
objectives for improving care in this area? 
 
How will the technology complement current 
practice? Is current practice likely to change? 
 
Are there any indications in the literature of 
potential effectiveness? 
 
Have you identified any direct competitors? (This 
could be another specific technology, or simply a 
different technique)  
 
 RED: Poses a significant threat to the 
opportunity identified in the market (i.e. 
works against current health service 
objectives, or there are other products 
being developed that are associated with 
better outcomes or are at a more advanced 
stage of development). 
 
AMBER: Potential threat 
 
GREEN: Further supports the case for the 
new technology  
 [AMBER] There is much innovation in this area, 
including other modifications of ePTFE grafts 
which, if found to be better than current 
versions, could change the baseline. 
 
 [AMBER] One such development is the 
introduction of herapin-bonded grafts, which 
could improve resistance to thrombosis. A clinical 
investigation has been published on the 
incremental effectiveness of ePTFE grafts that are 
bonded with herapin over standard ePTFE grafts. 
Early patency and limb salvage results are 
promising, but longer term RCTs are required to 
confirm this (Bosiers et al. 2006). 
 
 [RED] The Distaflo graft by BARD is another graft 
that, like the SLF graft, has been developed to 
reduce intimal hyperplasia by improving 
hemodynamics (blood movement) at the distal 
end of the graft (Fisher et al. 2003). The ‘Miller 
cuff’ is also described for this purpose. It has 
been found to have an improved patency rate for 
below-the-knee bypass (Griffiths, Nagy, Black, & 
Stonebridge 2004).  
 
 [AMBER] It has already been found that 
precuffed grafts have benefits for improved 
haemodynamic forces which suppress 
hyperplasia and improve patency rates (Fisher et 
al. 2001b;Fisher et al. 2001a). 




7. Research questions 
 
This should be a list of the things that the 
developer needs to find out or monitor 
during the process of development, relating 
to the function of the device or how it fits 
into the market place. 
 
From the research undertaken and reported 
above, what are the most important 
questions or uncertainties that must be 
addressed / tested? What factors or 
assumptions have the calculations / 
economic or clinical case hinged upon?  
 Does it work as well as we thought it would? 
There is a wide body of literature aiming to 
assess the patency of different graft types.  In 
order to introduce and establish a viable new 
product in this market, the SLF graft must prove 
to work better than current ePTFE grafts. 
 Are there any other upcoming graft types for this 
indication, and how do they compare to SLF?  
 
Headroom notes (SLF bypass graft) 
No calculation made 
Follow-up (SLF bypass graft) 
Headroom Outcome and Market success 
Does the MRP look realistic? Would it have indicated yes or no to development? 
An MRP was not identified for this product, but an intuitive case was made for its development.  
Interpretive answer: Headroom positive 
Has there been a decision made on it by NICE? What was the outcome? 
A clinical guideline for lower limb peripheral arterial disease is in progress; Tayside Flow Technologies 
is not on the stakeholder list. 
Is it sold in the UK or the rest of the world?(Or has it in the past) If so, who is it bought by? 
The SLF bypass graft is CE marked and received FDA approval in 2009 (Bloomberg 2009). The 
company indicate that they are selling and marketing their SLF grafts in more than 20 countries 
across the world.  The United States seems to represent a big market for Tayside Flow Technologies, 
with as many as 10 distributors over there.  At the end of 2010, the SLF graft had already been used 
by 55 surgical centres in the USA (Tayside Flow Technologies 2010b).  Tayside Flow Technologies has 
since been renamed Vascular Flow Technologies (Vascular Flow Technologies 2013), and has 
expanded.  The company confirm that their SLF bypass graft is used within various NHS hospitals 
(confirmed through telephone communication with the company, whose headquarters are in 
Dundee, Scotland). 




Have there been investigations into its clinical / cost effectiveness? 
There have been many clinical investigations into the patency of different graft types, much along 
the same lines as those published before 2006. Cost-effectiveness analyses in this area are still few in 
number.  
One HTA considers the cost-effectiveness of balloon angioplasty versus bypass surgery, and finds that 
for those with a life expectancy of under two years, angioplasty is the more cost-effective solution, 
but where life expectancy exceeds two years, bypass is the best option (as patients are likely to 
experience the longer term benefits)(Bradbury et al. 2010). However, they also indicate that patients 
for whom a vein bypass is not possible would be better off attempting balloon angioplasty first, and 
advise that surgeons should view prosthetic grafts as a last resort.   This could represent a move 
away from revascularisation using prosthetic grafts in PAD. 
The literature relating to spiral laminar flow and its role in vessel occlusion has already been 
presented, showing the theoretical link between SFL and increased patency. As for the SLF graft 
itself, no studies were identified, but the company provide the results of some preliminary trials on 
their website.  Forty patients were implanted with the SLF graft, and ten (randomly selected) were 
subsequently assessed using ultrasound and were found to have this spiral flow pattern. The primary 
patency rate at 1 year was 88%. Another trial achieved 96% primary and secondary patency (at 11  
months) for a cohort of 36 patients in 2009-2010 (Tayside Flow Technologies 2010a). Another finds 
78% patency rates at 24 months (Tayside Flow Technologies Ltd. 2011).  
The following pictures show images of blood flow within a normal artery, one with vessel occlusion, 
and following an SLF graft: 
Natural blood flow              Turbulent blood flow from     Natural blood flow from 
within a healthy artery        a non SLF graft                     an SLF graft 
   
 
The clinical function of the SLF graft seems to have been demonstrated.  There are early indications 
that this leads to reduced vessel occlusions, but this needs independent confirmation by larger trials.  




Has the landscape described changed significantly? 
What is current gold standard clinical practice now? Has this changed? 
A Cochrane review published in May 2010 outlines the evidence for the various graft types for 
femoro-popliteal bypass surgery: autologous vein, polytetrafluoroethylene (ePTFE) or Dacron 
(another type of prosthetic material used for grafts) (Twine & McLain 2010). They conclude that vein 
bypass is the most effective, followed by the synthetic materials, but that using a vein cuff leads to 
improved patency rates over ePTFE alone. There was no mention of the SLF graft specifically within 
the ePTFE group.  
Current practice does not seem to have changed significantly since 2006.  
 
Are there now many direct competitors? 
In one large retrospective study published in 2009, herapin-bonded ePTFE grafts were found to have 
patency rates that were not significantly different from those of autologous saphenous vein grafts 
(Daenens et al. 2009).  The Distaflo graft continues to be marketed, and BARD have since developed 
other version of their ePTFE bypass graft.  No other grafts were identified which propose the 
restoration of spiral laminar flow.  
 
Conclusions: How useful might the headroom exercise have been? 
The main conclusion drawn from the headroom analysis was that, if the patency rates of the SLF graft 
could be shown to be equivalent to those of vein graft, then the economic case for product 
development would be strong. Early clinical investigations have shown promising results, and the 
company seem to be successfully expanding into markets across the world.  
As the headroom analysis really hinged on the clinical case for the SLF graft (the gap for which was 
identified in the literature), it is difficult to say whether this headroom analysis would have been 
useful, even if it wasn’t wrong.  The clinician to first develop this would have had this clinical case as 
the driving force for his research, and in this instance the economic case to follow was an obvious 
one (given the non-existent impact on service cost of actually implanting the graft, and the clear 















IPG in development; 
 
Date of briefing: July 
2003 
 




Ménière’s disease is a condition of the inner ear which can affect hearing 
and balance. It is thought to be linked with excess fluid in the inner ear, 
which affects pressure.  The main complaints of patients suffering with 
Ménière’s disease are: attacks of rotary vertigo (room spin), hearing loss, 
tinnitus (ringing in the ear), and a feeling of fullness / pressure in the ear.  
Although the disease is progressive, symptoms can fluctuate significantly 
and unpredictably, making it difficult to observe the effects of treatment.  
Generally, attacks of vertigo tend to be more frequent in the first few 
years, and following this, reduced frequency of attacks is accompanied by 
a sustained deterioration in hearing. 
  
Meniett is a non-invasive, portable patient-administered device for 
Ménière’s disease which delivers intermittent low-pressure pulses into 
the inner ear through a tympanostomy tube (grommet), which must first 
be inserted into the inner ear with the patient under local anaesthesia.  
The low-pulse generator is to be used three times a day until remission of 
symptoms, for patients who do not respond to medical therapy. 
 
2. Comparator  
 
Certain drugs can be used to improve symptoms of vertigo, and vestibular 
rehabilitation is used in some cases.  However, for those refractory cases 
where patients do not respond to medical therapy, an ablative or surgical 
procedure may be used to control symptoms. 
 
The Meniett low-pressure pulse generator is to be used instead of 
ablative treatment or surgery where medical therapy has failed.  
 
Research into the use of pressure as a treatment for patients with 
Ménière’s disease has been undertaken for many years. There are many 
early studies dating back to the 1970s and 80s which find changing air 
pressure within the ear to have an effect on hearing (Densert, Ingelstedt, 
Ivarsson, & Pedersen 1975;van Deelen, Hulk, & Huizing 1987).  Two 
academics with the name of Densert (O and B, who often co-author 
papers) have been prolific in this area since 1975 to the present day12 
(Densert 1987;Densert et al. 1997;Densert & Densert 1982;Densert, Sass, 
& Arlinger 1995;Densert, Ingelstedt, Ivarsson, & Pedersen 1975). The 
papers tend to show that pressure pulses to the middle ear improve 
electrocochleographic recordings (a technique of recording stimulus-
related responses or electrical potentials of the inner ear / auditory 
nerve). 
 
According to the NHSC briefing note, ablative treatment with 
aminoglycosides (called local intratympanic gentamicin), where an 
injection is given locally into the ear to deaden the inner ear, is the 
                                                          
11
 Product was launched in 2002 
12
 Barbara Densert writes an introduction to the Meniett device in the journal of Acta Otolaryngol in 
2000 (Densert, Arlinger, & Odkvist 2000) 




‘treatment of choice’ for refractory cases. Surgical techniques that are not 
destructive to hearing are endolymphatic sac surgery and vestibular nerve 
section. Destructive treatments such as labyrinthectomy are occasionally 
used in severe cases.  Pfeiderer (1998) reports that the local 
intratympanic gentamicin procedure is an effective treatment for patients 
with unilateral Ménière’s disease, and is associated with low morbidity 
and good hearing preservation, and indicates it is a potentially superior 
alternative to surgical treatment (Pfleiderer 1998). Atlas (1999) reports on 
a study in which 84% of the 83 patients showed complete vertigo control, 
and another 6% showed ‘substantial’ vertigo control. As a group, there 
was no statistically significant change in hearing parameters at 24 months 
(Atlas & Parnes 1999). Many other studies also show this to be the 
treatment of choice, and that these injections provide significant vertigo 
control, without the significant cost of a more invasive surgical procedure 
(Hirsch & Kamerer 1997). 
 
Some other studies talk of endolymphatic surgery as the treatment of 
choice, achieving (some degree of) vertigo control in 96% of cases, and 
gentamycin injection being an effective back-up treatment (Watanabe et 
al. 1995). 
 
We can surmise that the treatment of Ménière’s disease in refractory 
cases is far from formulaic. However, there does seem to be varied 
opinion, and scope for various procedures to be used as options, 
depending on clinician and patient preference.   
 
The NHSC briefing gives no indication of if/ by how much treatment of 
patients will improve by using the Meniett device as compared to current 
ablative / surgical procedures that conserve hearing. Therefore, I assume 
that the Meniett will work as well as other procedures.  
 
3. Market size  The Meniett device is thought to be applicable for one third of patients 
who do not respond to medical therapy (there is no source or 
explanation attached to this assertion, so this estimation is thought to 
come from the manufacturer).  The number of those affected by 
Ménière’s Disease is difficult to estimate, but this is thought to 
correspond to a relevant patient population for the Meniett device of 
between 172 and 3,432 patients (based on the Meniere’s Society 
estimates of total incidence).   
 
Market size per year: 172 – 3,452 patients per year 
 
4. Health Service 
 
Changes in resource use.  Any changes in 
service delivery costs to the NHS that will 
result from the application of the new 
technology, including the disinvestment in 
Although local intratympanic gentamicin (ablative 
injection into the inner ear) seems to be the 
reference standard, it is clear that surgical options 
are also considered for the treatment of these 
patients with refractory symptoms.  
 




previous practice.  This could include: Staff 
time, hospital bed days, GP visits, A&E visits, 
etc.  It should not include services for which 
the NHS (and personal social services) is not 
financially liable (e.g. lost productivity and 
[non-health] social care costs), but these 
should be noted in writing below to add to 
the verbal case for the product (NICE may 
incorporate social care costs into cost-
effectiveness estimates in the near future). 
 
 If relevant and not included in service cost 
impact above, search for price of the 
currently used product (P1). 
 
Use HCHS index to inflate estimates to 
current prices  
 
Describe any potential costs/savings that 
you haven’t quantified.  
The headroom method usually takes the ‘gold 
standard’ in current practice to be the relevant 
comparator. As there are so many different 
treatment options, we can only assume that, if the 
Meniett works just as well as / better than 
treatments that are currently funded by the NHS, 
then the health service should be willing to invest the 
same amount in this new device, especially if it is 
found to be better accepted by patients.   
 
Information regarding the cost of procedures for 
Ménière’s disease is not readily available on the 
internet. A cost estimate of surgical alternatives: 
endolymphatic sac surgery, vestibular nerve section 
and labrynthectomy are presented in the NHSC 
briefing: £750 to £1,500. No reference is given as to 
the source of these costs, so I assume that these 
estimates are from the developer’s own knowledge 
base.  These surgical techniques are said to be 
accompanied by a hospital stay of around three days. 
It is not absolutely clear whether the resource 
implication of these three days hospital stay are 
included within the £750-£1500 estimate, but 
intuitively I will assume that they are not, considering 
the cost of three days in hospital would make up a 
large portion of this estimate, and also given that 
costs indicated in the NHSC briefing for other 
procedures (namely, the grommet insertion for the 
Meniett device) is later revealed not to include 
hospital costs. 
 
Those service costs saved (per patient) by replacing 
surgery with Meniett treatment would be: 
 £1,500 for avoiding the surgery itself (taking the 
higher of the estimate range), and  
 3 days hospital stay, valued at £201 per day 
=£603   (i) 
 
Total saved per patient: £2,103 
 
Those extra service costs that must be incurred when 
switching from clinical practice to the Meniett device: 
 Grommet insertion: £428 
 Hospital costs (estimated one day): £201 
 
Total incurred per patient: £629 
(Total) ∆SC= £253,528 to £5,088,248 
(Av. Per person) ∆SC= £1,474 
P1= (included in above estimate)  






Potential impact of the new device on 
patient health, as compared to current 
practice (preferred method of elicitation is 
from studies using the EQ-5D).   
Where NICE have not produced relevant 
economic analyses, search for cost-
effectiveness studies or systematic reviews 
within the disease area (the CEA registry 




Describe any potential costs/savings that 
you haven’t quantified. 
As outlined above, there is no indication in the NHSC 
briefing that the Meniett device will work better than 












If treatment with the Meniett device were found to be 
more acceptable for patients, this could offer an 
increased incentive for its use. If the quality of life loss 
from the surgical procedure itself were to outweigh 
the frequent daily use of the Meniett device, then this 
could be quantified, and translated into a WTP for the 
health service, potentially adding to the headroom.   
 
If the Meniett device could enhance rather than 
simply preserve hearing, then this could also have an 
impact on the reimbursement opportunity. 
 
6. Developments (clinical & healthcare 
context) 
 
Consider the following questions to help you 
think about the space for your product 
within the market.  
 
Does the technology address any key national 
objectives for improving care in this area? 
 
How will the technology complement current 
practice? Is current practice likely to change? 
 
Are there any indications in the literature of 
potential effectiveness? 
 
Have you identified any direct competitors? (This 
could be another specific technology, or simply a 
different technique)  
 
 RED: Poses a significant threat to the 
opportunity identified in the market (i.e. 
works against current health service 
objectives, or there are other products 
 [RED] Local intratympanic gentamicin (injection 
into the ear) seems to be well supported by the 
literature. Although a cost estimate couldn’t be 
found, it is likely to be much less costly than 
surgery. If this is to become more widespread, 
this might displace other treatment options. 
 
 [GREEN] Considering that all other treatment 
options for patients with refractory Ménière’s 
disease are fairly invasive / destructive, a 
treatment option which is minimally invasive 
could present an attractive proposition to 
patients and clinicians. This may not be captured 
in a headroom calculation. 
 
 [GREEN] Early research into pressure therapy for 
Ménière’s disease indicates that it could actually 
improve hearing, rather than simply preserve it. 
 
 [AMBER] As noted above, the use of pressure 
therapy has been under investigation for many 
years. This could mean that direct competitors 




being developed that are associated with 
better outcomes or are at a more advanced 
stage of development). 
 
AMBER: Potential threat 
 
GREEN: Further supports the case for the 
new technology  
may emerge.  
 
 
7. Research questions 
 
This should be a list of the things that the 
developer needs to find out or monitor 
during the process of development, relating 
to the function of the device or how it fits 
into the market place. 
 
From the research undertaken and reported 
above, what are the most important 
questions or uncertainties that must be 
addressed / tested? What factors or 
assumptions have the calculations / 
economic or clinical case hinged upon? 
What potential benefits or threats have you 
ignored in the calculation (see italicised 
points in Qs 4&5, and ‘developments’ 
section)? 
 The headroom analysis has been based on 
assumption that it will work as well as surgical 
techniques (in terms of vertigo control and 
hearing preservation).  This must be investigated 
in trials. If it transpires that it could work better 
than current surgical techniques, the headroom 
should be adjusted accordingly, as current 
estimates could have underestimated its value 
(potential for a positive effect on hearing could 
be a big factor here, if found to be significantly 
affected by the Meniett pulse generator).  
 Would the device be well tolerated by patients? 
Its minimally invasive nature could be attractive 
(perhaps adding a premium to the reimbursable 
price), but this should set against patients’ 
feelings towards the frequency of treatment 
required for therapy using the Meniett pulse 
generator (3 times daily until remission, and 
thereafter depending on duration and severity of 
symptoms). If this treatment schedule were to be 
indicated for a long time, a one-off surgical 
intervention may seem more attractive. 
 Would the Meniett pulse generator be procured 
on a per patient basis (for home use, as 
indicated), or might the devices be made 
available centrally in primary care? This could 
increase the value per device, though 
practicalities must be considered, given the 
optimal frequency of treatment. 
 Is there scope for the Meniett to be a patient 
purchase? It may well be that the value to 
patients of this minimally invasive procedure 
outweighs what the NHS might be willing to pay 
for it. 
 Be mindful of other emergent devices using the 
same sort of technology, which deliver pressure 
therapy for sufferers of Ménière’s disease. 
 




Notes by AC 
(i) Identifying the average cost of an excess bed day (either in general or for individual 
specialities) represents one way in which hospital bed day costs can be estimated.  
Having not been able to find any such estimates predating 1999 (from the Department of 
Health or any literature within the clinical area), I use the table presented by Jones 
(2008), for speciality-specific national average cost per (excess) bed days. For ENT, this is 
£268 for adults. Jones uses the NHS Reference Cost database for 2006-07. Using the 
HCHS Pay&Prices index, this would be worth the following in 1999 prices: 
 
HCHS P&P Index 1999/00: 188.5 
HCHS P&P Index 2006/07: 249.8 
Deflation rate: 188.5/249.8= 0.75 
 
Cost of ENT bed day: £268 * 0.75 =£201 
 
Although from a practical perspective, this particular resource did not exist in 1999, it is 
thought that given time and experience within the area, this would have been a findable 
number.  
 
Headroom Notes (Meniett) 
 
MRP: £1,474 
It must be noted that the value created by disinvesting in the one-off surgical procedure is, (unlike 
most headroom analyses for pieces of equipment that have been undertaken), not a yearly value. 
Therefore, the assumption we are making here is that the Meniett pulse generator will last a 
patient’s lifetime.  
It is indicated that only a small amount of patient training is required, and that this is provided by 
Medtronic. The cost of this training must be included in this price (the device is said to have no 
maintenance costs). 
The huge gap between the lower and upper estimates of market size reflect the high uncertainty in 
the number of people suffering from and being treated for Ménière’s disease. However, given the 
MRP estimated of £1,474, the following graph shows the relationship between variable cost per unit 
and maximum allowable development costs, if this price can be achieved when the Meniett pulse 
generator is put on the market, assuming the lower distribution estimate of 172 (blue curve) and the 
higher estimate of 3,452 (red curve).  






In the case of a small market size, the allowable development cost does not vary greatly according to 
variable cost, and ranges from about £160,000 when variable cost per unit is £550, to about 
£250,000 if a unit cost of £50 could be achieved. The wider distribution could support much larger 
development costs, ranging from £3.2 million to about £5 million, given the variable costs presented 
here.  
It should be noted that, as this device is indicated as ‘another option’ the relevant market size is 
difficult to estimate, and will depend greatly on patient and clinician preference. The analysis 
presented above is illustrative of potential market size, according to the NHSC briefing.  
Follow-up (Meniett) 
Headroom Outcome and Market success 
Does the MRP look realistic? Would it have indicated yes or no to development? 
The MRP, indicated by the estimated magnitude of disinvestment in current surgical procedures (and 
considering the extra health service investment required to undergo the grommet insertion), was 
£1,474 for the Meniett low-pressure pulse generator.  The allowable development costs were also 
estimated, at various levels of unit production (variable) cost. 
It was acknowledged that surgical intervention represents one group of treatment options for 



































but that other interventions (e.g. the injection of gentamicin  into the ear) were also used, and are 
probably cheaper. However, it was thought that if the case for surgical intervention was sufficient to 
warrant their use and reimbursement on the NHS, then this higher reimbursement opportunity 
would represent the price up to which the health service should be willing to pay for an equivalent 
treatment.  
The Meniett device was priced, at launch, at £2000. This is clearly above the MRP estimated. We 
cannot tell whether, from the company’s perspective, this MRP of £1,474 would have appeared early 
on to be sufficient to cover development and unit cost of production, and therefore, cannot say for 
sure whether this would have suggested a go or a no-go development decision.  When price turns 
out to be below MRP, we can reasonably assume that it would have provoked a ‘go’ decision; this 
case is less clear, as we do not know by how much actual price exceeds what they could actually 
afford to charge, and also what their prediction of this might have been.  However, if the NHS does 
fund the device at a price of £2,000, then: either the headroom approach is flawed, or the 
assumptions employed to calculate the MRP appear to have underestimated its potential.  
Interpretive answer: Headroom decision unsure.  Possibly negative 
Has there been a decision made on it by NICE? What was the outcome? 
An interventional procedures guideline is currently ‘in progress’ by the NICE IPG team (expected to 
be published November 2011), for ‘Micropressure therapy for refractory Ménière’s disease’. An 
overview was compiled in April 2011 and provisional recommendations were subsequently made in 
July 2011 (subject to potential revision after the public consultation). Having examined the literature 
upon which provisional recommendations are made, all trials refer to the Meniett device as the 
system used to deliver this therapy. 
Provisionally, NICE state that the current evidence on the safety and efficacy of micropressure 
therapy is inadequate in quantity (NICE 2011f). As such, it should only be used with special 
arrangements for clinical governance, consent, and audit or research. They encourage further 
research into the therapy. 
Is it sold in the UK or the rest of the world?(Or has it in the past) If so, who is it bought by? 
At the time the NHSC briefing was produced (July 2003), thirty Meniett devices were in use in the 
NHS. It was also stated that several had been purchased privately.  
A forum set up in 2008 on the Ménière’s Disease UK website, shows some patients exchanging 
thoughts on the Meniett device (Meniere's Disease UK Forum 2008). The (small number of) patients 
in this forum have mixed reviews regarding the efficacy of the device; it seems that most patients 
bought the product themselves (sometimes after trying it on loan from a consultant).  
Pressure therapy is not included among the list of treatments for Ménière’s Disease on the NHS 
Choices website. The section of Medtronic’s website dedicated to the Meniett device refers 
specifically to the U.S. market, and indicates that the device is mainly a patient purchase and may not 
be covered by medical insurance. They do not provide information about the global reach of product 
sales. 




Have there been investigations into its clinical / cost effectiveness? 
Well tolerated by patients? 
The first UK study into the effectiveness of the Meniett device was presented by Buchanan in 2010 
(Buchanan, Rai, & Prinsley 2010). Thirty retrospective questionnaires indicated that the device was 
well tolerated by patients, useful, and minimally invasive. Only 19 of the patients (63%) felt it had 
alleviated their vertigo and tinnitus.  
Clinical effectiveness 
Most clinical studies for the Meniett device show positive results regarding vertigo control, though 
many of these are quite small, or with a short follow up period (Barbara et al. 2001;Densert & Sass 
2001;Dornhoffer & King 2008;Huang, Liu, Gao, & Zhou 2009;Thomsen, Sass, Odkvist, & Arlinger 
2005). Although many studies found that a (usually small) proportion of patients tested did not 
respond to the therapy, I have come across none that report negative effects. Although some early 
trials indicated a significant positive impact on hearing, a recent study by M. Barbara finds this not to 
be the case (Barbara et al. 2010). 
No individual clinical study compares the Meniett device directly with other treatment options. 
A Cochrane review to assess the effects of the Meniett device on the symptoms of Ménière’s disease 
is underway but has not yet been published. 
Cost effectiveness 
I could not find any cost-effectiveness studies relating to the Meniett device, or indeed to any other 
treatment for Ménière’s disease.  In 2003 Bjorne published an article relating to the social cost of 
Ménière’s disease (Bjorne & Agerberg 2003).  Though the treatment was unrelated to the Meniett 
device, Bjorne showed that the societal cost of Ménière’s disease (in terms of time off work) is 
significant.  
Has the landscape described changed significantly? 
What is current gold standard clinical practice now? Has this changed? 
A national survey of UK otolaryngologists regarding the treatment of Ménière’s disease was 
undertaken and presented by Smith in 2005 (Smith, Sankar, & Pfleiderer 2005). Smith concludes that 
a wide range of medical and surgical management technically are undertaken, much of which has 
little or no evidence base. He notes in particular that there is an increasing trend in the use of 
intratympanic gentamicin, which is now used by two thirds of correspondents, despite only being 
introduced to UK clinical practice 10 years previously. The Meniett device, and pressure therapy in 
general, is not mentioned in this report.   
In the headroom analysis, the Meniett device was presented as an alternative to surgery (as this was 
considered the most expensive of the options available to clinicians, and thus the maximum 
reimbursement opportunity). In the Interventional Procedures Guidance outline document, the 
specialist advisers consider intratympanic gentamicin (the injection), or placement of the grommet 




alone, to be the most pertinent comparators.  Changing the baseline comparator to this intervention 
could have brought the headroom down further. 
Studies into the effectiveness of intratympanic gentamicin tend to be very positive, some recent ones 
being Delgado (Delgado, Rodrigo, & Peña 2011) and Katzennel (Katzenell, Gordon, & Page 2010). A 
Cochrane review conducted in 2011 concludes that intratympanic gentamicinid is effective (produces 
significant reduction in vertigo complaints), but that it does carry a risk of hearing loss. I could not 
find any cost or cost-effectiveness analyses (Pullens & van Benthem 2011). 
 
Are there now many direct competitors? 
Given the attention that pressure therapy has received in the literature for many years, the 
headroom pro forma brought up the possibility of other devices being developed for the same 
purpose.  I have identified one other device that delivers low pressure pulse therapy, and is similar to 
the Meniett device: the P100-Meniere, by Enttex (Enttex 2011).  The manufacturer claims that this 
manually operated hand-held device works just as well as the Meniett device, but costs a fraction of 
the price.  One clinical trial compares the two devices, and finds that both to be equally successful, 
and confirms the efficacy of pressure therapy for sufferers of Ménière’s disease (Franz & van der 
Laan 2005). However, the P100 was the preferred device given its significantly lower cost. 
In the literature considered by NICE’s interventional procedures group, the only device for which 
evidence was presented was Meniett by Medtronic. This suggests that Meniett is still the dominant 
technology in the market, or that the P100 has not been around long enough to have undergone 
many clinical effectiveness studies. 
Conclusions: How useful might the headroom exercise have been? 
We cannot draw firm conclusions regarding the development decision that would have come out 
from the headroom analysis had it been undertaken early on in the lifecycle of the Meniett device. 
What we do know is that the MRP was significantly below the subsequent asking price, even though 
we took as a comparator the most expensive of treatment options.   
Clinical studies exploring the effectiveness of the Meniett device are favourable, but not decidedly 
more so than other treatment options, including the less expensive injection therapy.  According, 
then, to the headroom framework, the health service should not be willing to pay above this MRP of 
£1,474, unless: 
1) Some Meniett benefits were left unquantified. 
2) Procurement decisions made by the health service are not always strictly rational (in the 
sense that NICE consider decisions to be rational). 
3) The device could be used by more than one person, thus boosting the per unit value (though 
this doesn’t seem to be the case, given its impracticality – the NICE IPG document also 
regards the Meniett device for home use). 
However, the Meniett device does not seem to have achieved many sales to the NHS, according to 
anecdotal evidence on chat forums, the paucity of UK-specific research and trials that have been 




undertaken, and the failure of pressure therapy to be mentioned at all in a 2005 national survey of 
otolaryngologists (although the NHSC briefing indicated that 30 were in use in the NHS in 2003). 
Pressure therapy has not been recommended by NICE in a recent interventional procedures guidance 
document, though this was based on its insufficient clinical support in the literature (quantity of, 
rather than results).  As the IPG group look only at safety and efficacy rather than issues of cost-
effectiveness, one would assume that, had the evidence been sufficient to support the therapy from 
a clinical perspective, then it would have been recommended to clinicians. This puts into question 
the influence of cost-effectiveness issues on purchase decisions (though simply knowing that a 
procedure is safe and effective may not guarantee that it will actually be procured and incorporated 
into routine clinical practice).  Unlike TAs, there is no obligation to fund procedures based on a 
positive IPG.  
So, would the headroom exercise have been useful? Results wise, the headroom analysis delivered 
an unconvincing case for Meniett, which has been followed by poor heath service uptake. However, 
the device is still available for purchase, and seems to be a viable product for Medtronic. This could 
be for a number of reasons: 
1) The headroom method, and indeed health economics in general, has difficulty in estimating 
the value patients and clinicians place on parameters (preferences) that are not directly 
related to health and health costs, but which may indeed affect willingness to buy, and even 
willingness to pay. 
2) Given its minimally invasive nature, it is reasonable to assume that this might be something 
patients are willing to pay for, in order to potentially avoid more destructive means to 
control their symptoms. Indeed, the Meniett device seems mainly to be a patient purchase. 
Both of these factors were outlined in the research questions that were identified in the process of 
the headroom analysis, and this highlights the importance of this section of the pro forma (other 
issues raised by the research questions also turned out to be pertinent, namely emergent 
competitors and the use of intratympanic gentamicin in clinical practice).  The factors that emerge 
from sections 6 and 7 of the headroom pro forma should be considered by the developer in 
conjunction with the concrete number output (MRP), as this could invariably affect the product’s 
uptake and thus its potential as a viable investment.  This has come through as the major lesson from 
this example.  Although the not-entirely-convincing headroom was followed by a not-entirely-
convincing health service uptake (a positive result for the headroom method itself), separate factors 
such as the possibility of Meniett being a patient purchase (which was identified in the research 
questions) have made this a viable, investable product. 
 











No NICE follow-up. 
 
Date of briefing: Sep 
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Tamoxifen is the most commonly used form of hormonal treatment, and 
is widely used as an adjuvant therapy for patients with early-stage 
oestrogen receptor positive (ER+) breast cancer.  It acts by blocking the 
tumour’s ability to use oestrogen (which provides stimulus to the cancer 
cells).  
There is a CYP450 marker gene—CYP2D6—that is thought to influence the 
rate at which a patient can metabolise tamoxifen (Dehal & Kupfer 1997).  
Poor metabolisers tend to show poorer clinical outcome in terms of 
disease recurrence and survival, than do extensive or ultra-rapid 
metabolisers. 
 
The AmpliChip CYP450 is a laboratory array-based prediction test that can 
detect variations in this gene, and thus identify those breast cancer 
patients that would not benefit from tamoxifen treatment. The clinical 
pathway of these poor metabolisers may then be more appropriately 
managed.  
 
The AmpliChip is based on a polymerase chain reaction, and is to be used 
on the GeneChip microarray platform (from Affymetrix Inc). The test uses 
whole blood and takes 8 hours. 
 
2. Comparator  
 
There is no comparator for the AmpliChip device itself, as there is 
currently no prognostic test for response to tamoxifen (that does not use 
tumour cells).   
 
Five years of tamoxifen represents the standard adjuvant treatment for 
breast cancer (adjuvant therapy aims to prevent recurrence).  However, 
Aromatase inhibitors (AI) provide an alternative hormonal treatment, 
which rather than blocking the tumour’s ability to use oestrogen as 
tamoxifen does, actually reduces the amount of oestrogen that the body 
produces. Three types of AIs have market authorisation in the UK: 
Anastrozole, Exemestane and Letrozole. They are more expensive than 
tamoxifen, and are sometimes used after tamoxifen has not been 
effective (Campos 2004).  Where patients are predicted by the AmpliChip 
to be poor metabolisers of tamoxifen, it may be that AIs are used instead. 
 
3. Market size  I could not find any estimates in the literature of the number of patients 
currently treated with tamoxifen who may be poor metabolisers of the 
drug (not surprising, as there is no routine test currently available to test 
for this). However this test is proposed to be performed on all users / 
potential users of tamoxifen. In England and Wales there were 39,214 
new cases of breast cancer diagnosed in 2003. Tamoxifen is considered 
for those 75% of breast cancers that are ER+. This gives a potential 
market size of up to around 29,500 per year. 
Market size per year: 29,500 
 




4. Health Service 
 
Changes in resource use.  Any changes in 
service delivery costs to the NHS that will 
result from the application of the new 
technology, including the disinvestment in 
previous practice.  This could include: Staff 
time, hospital bed days, GP visits, A&E visits, 
etc.  It should not include services for which 
the NHS (and personal social services) is not 
financially liable (e.g. lost productivity and 
[non-health] social care costs), but these 
should be noted in writing below to add to 
the verbal case for the product (NICE may 
incorporate social care costs into cost-
effectiveness estimates in the near future). 
 
 If relevant and not included in service cost 
impact above, search for price of the 
currently used product (P1). 
 
Use HCHS index to inflate estimates to 
current prices  
 
Describe any potential costs/savings that 
you haven’t quantified.  
Many clinical studies find tamoxifen to be an 
effective (Early Breast Cancer Trialists' Collaborative 
Group 1998) and a cost-effective (Cykert, Phifer, & 
Hansen 2004;Smith & Hillner 2000)  way to reduce 
breast cancer recurrence and increase survival for 
breast cancer patients. 
The hypothesis upon which the worth of the 
AmpliChip CYP450 is based is that the prognosis of 
patients determined (by the CYP2D6 gene) to be poor 
metabolisers is not significantly improved by 
tamoxifen, and so whose treatment regime should be 
re-thought.  
 
Megestrol acetate used to be the standard second-
line treatment after tamoxifen, but this has been 
replaced by AIs. 
More recently, attention has turned to AIs and their 
use as an alternative first line treatment, i.e. instead 
of tamoxifen.  There are many studies which propose 
that AIs are more effective (costs aside) than 
tamoxifen (Bonneterre et al. 2001;Fentiman 
2004;Goss & Strasser-Weippl 2004). 
 







Some early investigations consider the cost-
effectiveness of AIs as a first-line adjuvant treatment 
versus tamoxifen. A UK-based study finds letrozole to 
be a cost-effective alternative to tamoxifen as a first-
line hormonal therapy with a cost per QALY gained 
with letrozole between £2,927 and £3,969 (the two 
authors of this paper are sponsored by Novartis 
Pharmaceuticals UK, the manufacturers of letrozole) 
(Karnon & Jones 2003). A cost-utility study of AIs 
from the perspective of the Italian national health 
service concludes that anastrozole and letrozole are 
both cost-effective alternatives to tamoxifen for first-
line therapy (Marchetti, Caruggi, & Colombo 2004). A 
computer simulation study by Hillner estimates that 
the cost-effectiveness of adjuvant anastrozole is 
acceptable for patients who are expected to live 12 
years or longer (Hillner 2004). Another U.S. study 
finds that anastrazole compared with tamoxifen 
produces a higher quality-adjusted time to disease 




progression, and lower healthcare resource 
utilisation (due to reduced hospitalisations, 
chemotherapy, outpatient visits etc.), thus making 
anastrazole the cost-effective option (Simons, Jones, 
& Buzdar 2003). Other studies also provide support 
for AIs as a cost-effective alternative to tamoxifen 
(Dranitsaris, Verma, & Trudeau 2003).     
 
Leaving to one side issues of treatment cost-
effectiveness for now — In order to understand and 
calculate the overall benefit and cost per patient of 
using the AmpliChip test to personalise 
chemoprevention, the following information would 
be required: 
 What proportion of patients is likely to be poor 
metabolisers, and thus switched to treatment 
with AI from tamoxifen (all patients would be 
tested with AmpliChip, but not all will have their 
treatment changed as a result)? 
 How many people treated with AI currently are 
likely to be good metabolisers of tamoxifen, and 
thus indicated for tamoxifen treatment by 
AmpliChip (the NHSC briefing indicates that 
savings could be made in this direction)? 
 How much worse is the prognosis (in terms of 
disease recurrence and survival) for poor 
metabolisers of tamoxifen compared to good 
metaboliser tamoxifen users? Without knowing 
this, we don’t understand the baseline situation 
properly (presumably poor metabolisers respond 
to tamoxifen, just not as well as good 
metabolisers). 
 
Without this information, we cannot estimate the 
likely impact of AmpliChip CPY450 on health care 
costs.  
 
Some studies, outlined above, have shown that AIs 
are more cost-effective than tamoxifen. If this is the 
case and if this can be proven beyond reasonable 
doubt, then first-line adjuvant treatment with AI may 
become routine clinical practice, in which case there 
would be no need for a test of tamoxifen 
metabolism.  There are two caveats to this: 
1) If poor metabolisers were to be taken out of the 
cohort of patients receiving tamoxifen 
(achievable using the AmpliChip), then the 
(average) percevied effectiveness of tamoxifen 
may rise. This would change the effectiveness 




comparison between tamoxifen and AIs, and 
perhaps make tamoxifen the more cost-effective 
option for good metabolisers. 
2) Tamoxifen has been used for many years for the 
adjuvant treatment of breast cancer, with proven 
results. Given this, and the fact it is the much 
cheaper option, changing clinical practice entirely 
may be met with some resistance.  
(Total) ∆SC=? 






Potential impact of the new device on 
patient health, as compared to current 
practice (preferred method of elicitation is 
from studies using the EQ-5D).   
Where NICE have not produced relevant 
economic analyses, search for cost-
effectiveness studies or systematic reviews 
within the disease area (the CEA registry 
offers a useful platform to identify these 
studies). 
 
Describe any impact on patient health that 
you haven’t quantified.  
The literature provides estimates of the utility 
experienced by patients receiving hormonal therapy 
for breast cancer if they are responding to treatment 
(utility: 0.8) or if their breast cancer is progressing 
(utility: 0.6) (Marchetti, Caruggi, & Colombo 2004).  
However, for the same reasons as those bullet 
pointed above in box 4, we cannot estimate the likely 
change in patient outcomes if we do not know in 
what way tamoxifen prescription or effectiveness 
might change as a result of the AmpliChip. What 
might also need to be taken into account is the 
unwillingness of some patients to take tamoxifen due 
to its potential side effects (Port, Montgomery, 
Heerdt, & Borgen 2001) (in the United States it has 
been estimated that as little as 5% of patients eligible 
for tamoxifen choose to take the therapy, due to fear 
of side effects (Ozanne & Esserman 2004)). This could 
potentially be improved by the AmpliChip device, as 
one study shows tamoxifen self reported side-effects 
to be related to tamoxifen metabolism (Gallicchio et 
al. 2004).  This could add to the potential rise in 
overall effectiveness of tamoxifen that may result 
from removing the poor metabolisers from the 
cohort of tamoxifen users.    
∆QALY=?  
(Av. per person) ∆QALY=? 
 
6. Developments  (clinical & healthcare 
context) 
 
Consider the following questions to help you 
think about the space for your product 
within the market.  
 
Does the technology address any key national 
 [AMBER] When searching the literature I came 
across some studies that investigate the 
relationship between gene expression and the 
benefit of tamoxifen in ER+ breast cancer 
patients.  Bièche et al. find that 7 out of the 27 
genes investigated were found in significantly 
higher levels in ER+ breast tumours than in 
normal breast tissue (Bièche et al. 2004). 




objectives for improving care in this area? 
 
How will the technology complement current 
practice? Is current practice likely to change? 
 
Are there any indications in the literature of 
potential effectiveness? 
 
Have you identified any direct competitors? (This 
could be another specific technology, or simply a 
different technique)  
 
 RED: Poses a significant threat to the 
opportunity identified in the market (i.e. 
works against current health service 
objectives, or there are other products 
being developed that are associated with 
better outcomes or are at a more advanced 
stage of development). 
 
AMBER: Potential threat 
 
GREEN: Further supports the case for the 
new technology  
However, only the NAT1 gene was found to have 
prognostic significance for relapse free survival, 
thus a candidate predictor of tamoxifen 
responsiveness. Another investigation finds the 
CYP3A gene to be the predominant determinant 
of tamoxifen metabolism, along with CYP2D6 
which has some catalyzing effect (Desta, Ward, 
Soukhova, & Flockhart 2004). These may call into 
question whether the CYP2D6  gene in isolation is 
the most useful predictor of tamoxifen metabolic 
function. 
 
 [RED] AIs tend to be supported in the literature.  
This supports the notion that patients for whom 
tamoxifen does not work should have their 
treatment pathway adjusted, and AIs seem like 
an effective alternative for these patients.  
However, if it is decided that AIs are definitely 
the most cost-effective option for patients, then 
this could curtail the need for a tamoxifen 




7. Research questions 
 
This should be a list of the things that the 
developer needs to find out or monitor 
during the process of development, relating 
to the function of the device or how it fits 
into the market place. 
 
From the research undertaken and reported 
above, what are the most important 
questions or uncertainties that must be 
addressed / tested? What factors or 
assumptions have the calculations / 
economic or clinical case hinged upon? 
What potential benefits or threats have you 
ignored in the calculation (see italicised 
points in Qs 4&5, and ‘developments’ 
section)?  
 No headroom has been calculated here, as not 
enough information was available in the briefing 
or the literature upon which to base any 
meaningful assumptions for costs and health 
outcomes. The ‘developments’ section above 
allows us to articulate how the clinical and 
research context into which the new device will 
fit, may have an impact on the feasibility of the 
new product. The two major issues are: 
1) Is the CYP2D6 gene the most appropriate marker 
of tamoxifen response? 
2) With the growing body of research supporting AIs 
as the adjuvant therapy of choice, will tamoxifen 
continue to be prescribed? 
The developer should bear in mind these factors 
when deciding whether to proceed with 
development. 
 The AmpliChip CYP450 is based on indirect 
evidence, that links: a) genotype with tamoxifen 
metabolism and b) genotype with outcome. In 
order to prove itself to be a useful test, a direct 
link between tamoxifen metabolism and 
outcome must be made.  
 




 If it is decided that the case for development is 
strong enough, the following things need to be 
investigated in order to provide a sound clinical 
and economic case for AmpliChip (these are the 
things I did not know that prohibited a 
preliminary economic evaluation from being 
undertaken): 
1) Around what proportion of patients is likely to be 
poor metabolisers of tamoxifen?  
2) How many people treated with AI currently, are 
likely to be good metabolisers of tamoxifen? 
3) How much worse is the prognosis (in terms of 
disease recurrence and survival) for poor 
metaboliser tamoxifen users compared to good 
metaboliser tamoxifen users?  
4) Is the overall effectiveness of tamoxifen likely to 
rise as a result of AmpliChip’s ability to isolate 
those that are poor metabolisers and direct them 
to an alternative treatment? If so, would this 
increase the cost-effectiveness of tamoxifen in 
relation to AIs? 
5) What effect might a reduction in side effects 
have on the cost-effectiveness of tamoxifen?   
 The CYP2D6 gene relates not only to the 
metabolism of tamoxifen, but also other types of 
drug.  This means that potential applications of 
AmpliChip may extend, into other disease areas.  
This would clearly have a large impact on the 
commercial opportunity provided by AmpliChip.  
 
Headroom Notes (AmpliChip) 
No headroom calculated. Not enough information to make useful assumptions. 
Follow-up (AmpliChip) 
Headroom Outcome and Market success 
Does the MRP look realistic? Would it have indicated yes or no to development? 
A headroom analysis in numbers was not achieved for this device.  There were too many unknown 
parameters for any useful assumptions to be made.  The process revealed a few key questions and 
developments in the area that should have been key considerations in the decision to develop.    
Of particular importance was the emergence of AIs as the adjuvant treatment of choice for patients 
with breast cancer. The universal acceptance of this should mean that there would no longer be a 




place for tamoxifen in clinical practice, and therefore no need for a pharmacogenetic test for this 
application.  
According to the NHSC briefing, the UK cost of AmpliChip is £200 per test.  
Interpretive answer: Headroom unknown – substantial threats identified (see ‘research questions’) 
 
Has there been a decision made on it by NICE? What was the outcome? 
The AmpliChip was considered for potential technology appraisal by NICE but was rejected by the 
panel. 
There are many NICE guidance documents relating to breast cancer treatments, showing the 
continual development in the clinical area and its importance to the health service. 
Is it sold in the UK or the rest of the world?(Or has it in the past) If so, who is it bought by? 
On Roche’s website, the AmpliChip CYP450 test is indicated as providing ‘comprehensive detection of 
gene variations for the CYP2D6 and CYP2C19 genes’ (Roche 2011) (this second gene was not 
mentioned in the NHSC briefing, so might be a new addition, or one that is not relevant to tamoxifen 
specifically). Specific clinical applications are not mentioned, but Roche indicate that these genes play 
a role in the metabolism of 25% of all prescription drugs. 
The NHSC indicate that, by 2007, the AmpliChip was already being used in psychiatry, cardiology, and 
pain management.  Indeed, searching for AmpliChip in the clinical literature returns studies 
pertaining to psychiatry in greater number than any other clinical indication. Given the diverse 
countries of origin of research, the AmpliChip seems to have a global reach. 
Have there been investigations into its clinical / cost effectiveness? 
The changing landscape of hormone therapy prescription was highlighted in the headroom analysis 
as being of key importance for the feasibility of such a test as AmpliChip.  Many early studies 
indicated that aromatase inhibitors (AIs) are probably a cost-effective alternative to tamoxifen; if this 
had turned out to be the case and tamoxifen were no longer used as first-line adjuvant therapy for 
ER+ breast cancer, then there would be limited use for a test that measures the tamoxifen metabolic 
potential of a patient.  A technology appraisal conducted by NICE in November 2006 on hormonal 
treatments recommended anastrozole, exemestane and letrozole (the three AIs with UK market 
authorisation) as possible treatments for women with ER+ breast cancer (post-menopausal) (NICE 
2006d).  Having reviewed the relevant literature and data submitted by the manufacturers, NICE find 
all three to be cost-effective alternatives to tamoxifen (all had ICERs under £20,000, given the most 
probable assumptions considered by the experts).  They do not, however, suggest that tamoxifen be 
removed from standard clinical practice.  
Ramón y Cajal et al. (2010) find that genotyping patients using the AmpliChip CYP450 according to 
CYP2D6 variants, is associated with improved disease free survival of those patients (Ramón y Cajal 
et al. 2010). Serrano et al. also note the relevance of pharmaco-genomics (using the AmpliChip 
CYP450) for tailoring tamoxifen treatment (Serrano et al. 2011). The use of (measuring) CYP2D6 




genetic variants for personalising treatment strategy for breast cancer patients is also supported in a 
review conducted by Brauch & Jordan (Brauch & Jordan 2009). 
A study by Abraham et al. finds that the reported association between CYP2D6 genotype and 
treatment response in breast cancer may not be valid, according to the results from the case-cohort 
study examined (Abraham et al. 2010).    
As indicated in the headroom pro forma, the AmpliChip is based on indirect evidence that links 
genotype with tamoxifen metabolism, and genotype with outcome.   The MHRA indicate that the 
evidence linking poor metaboliser genotypes with tamoxifen treatment outcome is mixed and 
inconclusive, and therefore do not recommend genetic testing before treatment with tamoxifen 
(MHRA 2010). One technology evaluation published in 2008 also say that the hypothesis that CYP2D6 
poor metabolisers have reduced tamoxifen metabolism, and have poor outcomes as a direct result, is 
not yet supported by evidence (BlueCross BlueShield Association 2008). A systematic review 
published in September 2011 on ‘The clinical and cost-effectiveness of genotyping for CYP2D6 for the 
management of women with breast cancer treated with tamoxifen’ concludes that the data is limited 
and conflicting, and it is therefore not possible to recommend pharmacogenetic testing (Fleeman et 
al. 2011).  
Has the landscape described changed significantly? 
What is current gold standard clinical practice now? Has this changed? 
There is still no form of pharmacogenetic predictive testing in standard clinical practice for breast 
cancer management. 
Are there now many direct competitors? 
I have not found any direct competitors in my searches, though the NHSC briefing mentions that 
another CYP2D6 test is available for research purposes (TaqMan Allelic Discrimination Array from 
Applied Biosystems).  
Conclusions: How useful might the headroom exercise have been? 
The headroom evaluation did not produce any numbers with which to consider the development 
opportunity. The task did, though, bring to light some important factors for its development case.  
Although AIs have been found to be cost-effective, this does not seem to have pushed tamoxifen out 
of the market, and tamoxifen still seems to be the reference standard of treatment for women with 
ER+ breast cancer (Fleeman et al. 2011) .  Although the evidence so far has not been sufficient to 
allow AmpliChip to be recommended, it is clear that the interest in idea of pharmacogenetic testing 
remains; this is evident from the substantial body of research that is still being undertaken on this 
topic.  
Something that was also brought up in the research questions was the applicability of the test to 
other disease areas. It seems that this has turned out to be very important for the success of 
AmpliChip, given its limited use for breast cancer. 
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 Ventilator associated pneumonia (VAP) (a subset of hospital-acquired 
pneumonia), can occur in patients that require mechanical ventilation in 
hospital.  Mechanical ventilation (MV) is delivered via an endotracheal 
tube (ETT); when this becomes colonised with bacteria, the patient can 
breathe these bacteria into their lungs, thus causing VAP which can lead 
to feverish symptoms and low body temperature (though diagnosis can 
be difficult).  Those patients who receive MV for 24 hours or longer are 
particularly susceptible to VAP. The presence of the mechanical device 
inhibits first line defences against such an infection by providing access to 
the airways for bacteria, and eliminating the cough reflex.       
 
The Agento I.C. is a silver-coated ETT, which has been designed to prevent 
VAP in patients who require prolonged MV (24 hours or more). Silver is 
widely known for its antimicrobial properties, reducing bacterial adhesion, 
and blocking biofilm formation (which offers a protective environment for 
bacteria).  
 
2. Comparator  
 
The comparator device for the Agento I.C. is a standard ETT. The company 
estimate that the cost of these range from £1.50 (for those used for short-
term use) and £55 (those used in a specialist intensive therapy unit). 
 
Other means of preventing VAP include altering body position (semi-
recumbent positioning), and oral antiseptics. 
 
Silver and its antimicrobial qualities have been researched in other clinical 
contexts for many years. For example,  the use silver for urinary catheters 
has been found to significantly reduce the adhesion of bacteria that cause 
urinary tract infections (Ahearn et al. 2000;Gabriel, Sawant, Simmons, & 
Ahearn 1995). It has also been used to promote healing for burns (Dunn & 
Edwards-Jones 2004).  One study tests ETTs that were internally coated 
with silver-sulfadiazine and chlorhexidine in polyurethane and used in 
mechanically ventilated sheep for 24 hours. Compared with those sheep 
that were intubated with uncoated ETTs, all 8 of which were heavily 
colonized with bacteria after the 24 hours, those with silver treated ETTs 
largely showed no growth of bacteria (7 out of 8 – the one remaining 
showed low growth) (Berra et al. 2004)14.  Before making assumptions on 
how the Agento IC might impact the occurrence of VAP, it is appropriate 
to first identify the incidence and impact of VAP in current clinical practice 
(where patients are mechanically ventilated using standard ETTs).  
 
 
                                                          
13
 For devices that represent an incremental development of an existing model, a two year date back 
is usually employed. However, having come across a paper relating to the device from 2006, I have 
chosen 2005 as my reference date. 
14
 No company was mentioned in this report, so it is unclear whether this might have been early tests 
for Bard‘s ETT or not. 




The incidence of VAP among mechanically ventilated patients is difficult 
to estimate, given the hazy diagnostic criteria and because it could 
overlap with other lower respiratory tract infections. The NHSC estimate 
that it could range between 10% and 30%.  The largest and best designed 
study I have found for VAP incidence and outcome is from 2002 by Rello 
et al., who present an analysis of VAP from a large U.S. database study 
(Rello et al. 2002b). The study sample included patients that were 
admitted to an ICU (not admitted with pneumonia already), and received 
MV for more than 24 hrs (9,080 patients in all). This seems appropriate as 
the Agento IC is indicated for use in ICU, for those needing ventilation for 
24 hours or more. These were the main findings on interest:  
 
 VAP developed in 842 patients (9.3%)15.  
 63.2% of VAP developed within 48hrs; 16% within 48 to 96hrs; 
20.8% after 96 hrs 
 Case-control analysis: There was no statistically significant 
difference in hospital mortality among patients with and without 
VAP. (30.5% vs 30.4% respectively). No attributable mortality. 
 Patients with VAP had significantly longer duration of MV (14.3 ± 
15.5 vs 4.7 ±7.0 days); greater number of ICU days (11.7 ±11.0 
days vs. 5.6 ±6.1 days); longer hospital length of stay (25.5 ±22.8 
days vs. 14.0±14.6 days) 
 Mean billed hospital charges: $104,983 with VAP, $63,689 
without 
 
As this was a case-control analysis, the specific outcomes attributable to 
VAP could be identified. Other studies report mortality rates for VAP 
patients at around 30% (Kollef et al. 2005) (the NHSC indicate that 
estimates range between 24-50%). However, this may be misleading as 
those needing MV are likely to have relatively poor outcomes and 
substantial risk of death anyway.  Like Rello, Bregeon (Bregeon et al. 
2001) also finds VAP not to be an independent risk factor for death, 
though some others disagree (Kollef, Silver, Murphy, & Trovillion 1995).  
As such, I will not assume that the Agento IC would have an impact on 
mortality, though this may be a conservative assumption. 
  
Using Rello’s estimates, the attributable effect of VAP on some important 
outcome parameters are: 9.6 addition days of mechanical ventilation, 6.1 
additional days in ICU, 11.5 additional days in hospital, leading to a total 
additional cost per VAP patient of more than $40,000 to the health 
service. 
 
The properties of silver and its use in other clinical indications to date give 
reason to believe that the Agento IC could reasonably have a substantial 
impact on the incidence of VAP.  Without knowing the exact potential for 
VAP avoidance, I will calculate the value of the Agento IC under three 
scenarios: 
                                                          
15
 This is the lowest incidence rate that I have come across, but seems to be the most reliable.  




1) VAP is completely avoided (unlikely, but represents the upper 
limit of potential effectiveness) 
2) VAP burden is reduced by half 
3) VAP burden is reduced by 25% 
 
3. Market size  The NHSC briefing contains an estimate of ICU patients on ventilation in 
England, Wales and Northern Ireland of 62,000 per year (out of 122,000 
admissions to critical care units in total). This estimate was said to be 
from a source supplied by the company, so I will use this figure. 
Market size per year: 62,000 
 
4. Health Service 
 
Changes in resource use.  Any changes in 
service delivery costs to the NHS that will 
result from the application of the new 
technology, including the disinvestment in 
previous practice.  This could include: Staff 
time, hospital bed days, GP visits, A&E visits, 
etc.  It should not include services for which 
the NHS (and personal social services) is not 
financially liable (e.g. lost productivity and 
[non-health] social care costs), but these 
should be noted in writing below to add to 
the verbal case for the product (NICE may 
incorporate social care costs into cost-
effectiveness estimates in the near future). 
 
 If relevant and not included in service cost 
impact above, search for price of the 
currently used product (P1). 
 
Use HCHS index to inflate estimates to 








Given the paucity of UK data on costs, I will assume a 
cost saving per avoided VAP episode of $40,000.  
Although this sum was calculated in the context of 
intensive care units in the U.S., it is the best estimate 
that I have found.  Converted to pounds and inflated 
to 2005 prices, this represents a cost saving of 
£31,113 16 (see note (i)).   
 
The company estimate that those ETTs used in 
specialist ICUs cost the NHS £55 per unit.  
 
I assume that the Agento IC will be used for all 62,000 
patients in critical care that are mechanically 
ventilated17 . 
 
Given our three scenarios (100%, 50% and 25% 
reduction in VAP incidence), the impact on service 
costs are calculated below, using the following 
information: 
 MV patients per year: 62,000 
 Incidence of VAP in MV patients ≈ 10% 
 Additional service cost for VAP: £31,113 
 




2) 50% reduction in VAP: 
½ (62,000*10%)*£31,113  
                                                          
16
 Exchange rate ($1.4497 to the £) obtained from HM Revenue and Customs for Jan 2002 (HM 
Revenue & Customs 2011). This was then inflated to 2005 prices using HCHS Pay&Prices Index. See 
note (i) for workings.  
17
 It is thought that the Agento IC will be used for those who are ventilated for 24 hours or more. 
Without having access to the source of this figure, I cannot discern whether this figure corresponds to 
those ventilated for over 24 hours (the target market indicated by the company, and the situation for 
which the estimates from Rello pertain), or all those that are ventilated in ICUs for however long. 





























Describe any potential costs/savings that 
you haven’t quantified.  
=£96,450,300 
 




These estimates should be divided by 62,000 to get 
the value per patient. 
 
 
Scenario 1: 100% reduction in VAP 
(Total) ∆SC=  £192,900,600  
(Av. Per person) ∆SC=  £3,111 
 
Scenario 2: 50% reduction in VAP 
(Total) ∆SC=  £96,450,300  
(Av. Per person) ∆SC=  £1,556 
 
Scenario 3: 25% reduction in VAP 
(Total) ∆SC=  £48,225,150 
(Av. Per person) ∆SC=  £778 
 
 
P1=  £55 
 
The estimate of cost saving per VAP episode retrieved 
from Rello et at (Rello et al. 2002b), is thought to 
contain all relevant costs, and be generally equivalent 
to what such costs would be in the UK. This estimate 
should be updated if any more relevant data becomes 




Potential impact of the new device on 
patient health, as compared to current 
practice (preferred method of elicitation is 
from studies using the EQ-5D).   
Where NICE have not produced relevant 
economic analyses, search for cost-
effectiveness studies or systematic reviews 
within the disease area (the CEA registry 







The exact impact of VAP on patient health is very 
difficult to estimate, because the morbidity caused 
by the underlying illnesses that have led them to be 
mechanically ventilated is probably high and varies 
greatly from patient to patient (this is also a reason 
why the effect of VAP on mortality is difficult to 
estimate).  
 
The only estimate that I have found is from two cost-
effectiveness analyses of VAP treatment with 
linezolid, which use a QALY weighting of 0.92 for 
patients for the years that follow mechanical 
ventilation, until death,  which they (arbitrarily) 
reduce by a further 10% (‘to be conservative’) to get 
0.83 (Grau et al. 2005;Shorr, Susla, & Kollef 2004). 
Having traced the source of the 0.92 figure, the basis 
of this does not seem reliable as the study actually 





















































relates to mechanical ventilation of those admitted 
for acute respiratory failure due to pneumonia (or 
acute respiratory distress syndrome) in the first 
place, and this comes from a 6 month follow up 
survey, and seems to simply assume that all patients 
were in perfect health (QoL weighting of 1) at 
baseline (Hamel et al. 2000).  
 
We would ideally like an estimate of the QoL loss 
experienced by patients in those days in hospital 
during which they were suffering from VAP.  
 
One study that considers the cost-effectiveness of 
pneumococcal conjugate vaccination in England and 
Wales uses a QALY loss of 0.006 per inpatient 
pneumonia episode (not VAP specifically) (Melegaro 
& Edmunds 2004). Tracing the source of this estimate 
brings up a cost-effectiveness study for the 
pneumocococcal vaccine in US navy and marine 
corps by Vold Pepper and Owens (Vold Pepper & 
Owens 2000).  Because the literature at the time 
(2000) did not include any assessments of utility for 
(hospitalised) pneumonia, they estimate this on the 
basis of comparisons with other health states, at 0.85 
(utility loss of 0.15).  Although the baseline for 
mechanically ventilated patients is likely to be well 
below 1 (full health), we can use this utility loss of 
0.15 during the VAP episode to estimate the likely 
QALY loss of patients experiencing VAP whilst being 
mechanically ventilated, versus those not acquiring 
VAP. 
 
Patients experiencing VAP on average spend an 
additional 11.5 days in hospital compared with non-
VAP mechanically ventilated controls (Rello et al. 
2002b). If these extra days (due to VAP) are 
experienced in a utility state that is 0.15 lower than 
their non-VAP counterparts, then that would lead to 
a QALY loss of 0.005 per VAP patient (0.15 * 0.035 
years).  
 
In other words, there would be a gain of 0.005 QALYS 
per avoided VAP patient (as per cost estimations, the 
three scenarios consider an incidence rate of 0%, 5% 
and 7.5%). 
 
Scenario 1: 100% reduction in VAP 
∆QALY= 31 
(Av. per person) ∆QALY= 0.0005 













Describe any impact on patient health that 
you haven’t quantified.  
 
Scenario 2: 50% reduction in VAP 
∆QALY=15.5  
(Av. per person) ∆QALY= 0.00025 
 
Scenario 3: 25% reduction in VAP 
∆QALY= 7.75 
(Av. per person) ∆QALY= 0.000125 
 
This estimate should be revised if any quality of life 
data pertaining to VAP specifically, and based on 
actual clinical investigation come to light. 
 
6. Developments  (clinical & healthcare) 
 
Consider the following questions to help you 
think about the space for your product 
within the market.  
 
Does the technology address any key national 
objectives for improving care in this area? 
 
How will the technology complement current 
practice? Is current practice likely to change? 
 
Are there any indications in the literature of 
potential effectiveness? 
 
Have you identified any direct competitors? (This 
could be another specific technology, or simply a 
different technique)  
 
 RED: Poses a significant threat to the 
opportunity identified in the market (i.e. 
works against current health service 
objectives, or there are other products 
being developed that are associated with 
better outcomes or are at a more advanced 
stage of development). 
 
AMBER: Potential threat 
 
GREEN: Further supports the case for the 
new technology  
 [GREEN] Hospital acquired infections have and 
continue to be recognised as important 
contributors to patient and service costs, and 
therefore measures to reduce such infections will 
be well received and are likely to be viewed as a 
priority. 
 
 [AMBER] There has been lots of research 
undertaken to investigate the factors and actions 
that can reduce VAP incidence (e.g. semi-
recumbent positioning of patients in their beds, 
use of antibiotics, etc) (Dodek et al. 2004;Kollef 
2004). Putting all these into place may improve 
baseline management of VAP, and thus reduce 
the potential impact of the Agento IC. For 
example, one study considered the effect of an 
educational initiative which involved a self-study 
module for ICU nurses and respiratory care 
practitioners on risk factors and prevention 
strategies for VAP. Fact sheets and posters were 
posted across ICU to reinforce the information. 
Across the four hospitals in the study, the 
combined VAP incidence dropped by 46% 
following the intervention (Babcock et al. 2004). 
 
 [GREEN] The Agento IC represents a 
straightforward and easy way to reduce VAP in 
mechanically ventilated patients. Rello (Rello et 
al. 2002a), in a survey based study of 
international experts, investigated why 
physicians do not follow evidence-based 
guidelines for the prevention of VAP; he found a 
non adherence rate of 37%. The most common 
reasons were disagreement with interpretation 
of clinical trials, inavailability of resources, and 




costs. He found that nonadherece was largely 
uninfluenced by degree of evidence (Rello et al. 
2002a). The Agento IC would be an easy way to 
improve outcomes, without changing clinician 
behaviour (which seems to be a particular 
stumbling point in this area). 
 
7. Research questions 
 
This should be a list of the things that the 
developer needs to find out or monitor 
during the process of development, relating 
to the function of the device or how it fits 
into the market place. 
 
From the research undertaken and reported 
above, what are the most important 
questions or uncertainties that must be 
addressed / tested? What factors or 
assumptions have the calculations / 
economic or clinical case hinged upon? 
What potential benefits or threats have you 
ignored in the calculation (see italicised 
points in Qs 4&5, and ‘developments’ 
section)?  
 The majority assumptions on the current state of 
affairs for VAP incidence, outcome, and cost, 
come from one American study.  These should be 
revised and updated if more relevant (UK?) data 
comes to light. 
 The market size of 62,000 may overestimate the 
market for Agento IC, as it is not known what 
proportion of these are mechanically ventilated 
for 24 hours or over. 
 Currently, research has shown that the 
recommendations in place for reducing VAP are 
not very well implemented. Over time, this may 
improve. The result of this on the baseline 
situation should be monitored (i.e. if uptake 
improves, then the relative impact of the Agento 
IC may become smaller). 
 Research must be undertaken to ascertain the 
likely impact of Agento IC on VAP incidence. 
 
Notes by AC 
 
(i) The cost saving of $40,000 needed to be converted into pound sterling, and then inflated 
to 2005 prices  
Exchange rate Jan 2002 (HM Revenue & Customs 2011): $1.4497 to the £  ≈ £27,600 
 
HCHS P&P Index Inflation rate = P&P Index (present year) ÷ P&P Index (year of cost data) 
    = 240.9/213.7  
    = 1.127 
     £27,600 * 1.127 = £31,113 
Headroom Notes (Agento I.C) 
 MRP 
 WTP: £20,000 WTP: £30,000 
100% reduction in VAP £3,176 £3,181 
50% reduction in VAP £1,616 £1,619 
25% reduction in VAP £836 £837 




In this case, I was able to estimate both the impact on service costs of the Agento IC as well as the 
potential impact on patient quality of life; this has allowed me to calculate an MRP for the Agento IC, 
given the assumptions specified. 
These ‘assumptions’ cover a wide spectrum of effectiveness for the Agento IC, ranging from a 25% 
reduction of VAP incidence for mechanically ventilated patients, to a 100% reduction in VAP 
incidence (VAP eliminated).  It is likely that the developer would pin-point a more precise estimate of 
potential effectiveness, based on their expertise in the area.  However, the MRPs estimated range 
from £836 (25% reduction in VAP; NHS WTP £20,000) to £3,176 (100% reduction in VAP; NHS WTP 
£30,000). It is likely that the developer would have made assumptions that would result in an MRP 
between these two prices. 
In order to practically consider whether this represents sufficient potential to warrant development, 
the trade-off between development costs and variable costs for both the least and most optimistic 
scenarios are presented; 
 
Because of the low variable costs chosen (relative to MRP), the large development costs do not vary 
a great deal in response to changes in these variable costs. These are of course speculative, and 
simply aim to demonstrate the likely magnitude of return at different variable costs.  This is based on 
the assumption that the Agento IC would be used on 62,000 mechanically ventilated patients.  As 
indicated in the headroom pro forma, this may be an overestimation of the market. It also assumes 

























Variable cost per device 
Least Optimistic: MRP= 
£836 
Most Optimistic: MRP= 
£3,181 




Follow-up (Agento IC) 
Headroom Outcome and Market success 
Does the MRP look realistic? Would it have indicated yes or no to development? 
The estimated MRP for the Agento IC lay somewhere between £836 and £3,181 (a large difference, 
that reflects my uncertainty of potential product performance.  If the product were to cost below 
£836 to produce then, so long as the unit cost for production was not at the very top of this range, 
the investment opportunity for this product is likely to have been considered attractive.  The 
headroom analysis estimated the allowable development costs for given variable costs, and these 
ranged a great deal depending on how optimistic we are about the potential effectiveness; if the 
Agento IC were to cost £100 to make, maximum allowable development costs would be between £45 
million and £190 million. This seems large considering that it incrementally develops a current 
medical device. Profit prospects would therefore be large. 
The actual price for the Agento IC has been difficult to obtain. However, I did find one American 
website (Great Medical Supplies 2011) which prices a box of 10 at  $2,201, indicating a price per 
device of about $220—around £145 (it may well be that prices charged to a health service would be 
somewhat lower than the price charged online). A 2009 publication that considers the cost-
effectiveness of silver coated endotracheal tubes considers the device to cost $90 in their model, the 
source of which is stated to be “an assumption”(Shorr, Zilberberg, & Kollef 2009).  Despite the fact 
that neither of these sources provides confidence in the exact price of the Agento IC, they indicate 
that the device seems to have been priced well below our most pessimistic scenario for the 
headroom analysis, of £836.   
Interpretive answer: Headroom positive  
Has there been a decision made on it by NICE? What was the outcome? 
No NICE guidance has been issued in the Agento IC. NICE did produce a patient safety guidance 
document in 2008 for ventilator associated pneumonia, but alternative ETTs were not mentioned in 
the guidance (this would have been pre launch in the UK) (NICE National Patient Safety Agency 
2008). 
 
Is it sold in the UK or the rest of the world?(Or has it in the past) If so, who is it bought by? 
Bard received clearance from the US Food and Drug Administration to market the Agento IC in 
November 2007 (BARD 2007). The Agento IC and its launch in the USA is reported in its 2008 annual 
report, but in no subsequent annual reports (C.R.Bard Inc. 2008). The NHSC briefing indicated that 
the device was expected to receive CE marking by mid-2009, but I haven’t been able to find evidence 
of this.  Additionally, Bard do not seem to be in the list of brands for endotracheal tubes on the NHS 
product supply chain catalogue.  Research and trials that I have identified for the device seem mainly 
to be based in the U.S., but I have also come across Spain as a site for clinical trials. The Bard 
customer services team confirmed by telephone that the Agento I.C. is not sold in the UK. 




Have there been investigations into its clinical / cost effectiveness? 
Clinical effectiveness  
Some early studies that considered the effect of Agento IC on bacteria colonization of an ETT 
reported favourable results (Rello et al. 2006). 
The biggest and most cited clinical trial has been the North American Silver-Coated Endotracheal 
Tubes trial (NASCENT), the results of which were published in 2008 (Kollef et al. 2008). This RCT was 
conducted in 54 centres of North America, and included 9,417 patients screened between 2002 and 
2006 (this indicates that my headroom perspective date of 2005 was too late and that BARD would 
actually have conducted such an early economic evaluation before 2002). They found that the silver-
coated ETT was associated with a 36% relative risk reduction in VAP (4.8% versus 7.9%), but no 
statistically significant impact on hospital / ICU stay, duration of intubation, or mortality was found. 
Bard uses the findings from this trial in their product information literature, citing the fact that the 
Agento IC reduces the incidence of VAP by 36% (48% risk reduction within 10 days of intubation) 
(BARD Medical Division 2008).   
A protocol has been written for a Cochrane review of effectiveness studies for the silver-coated 
endotracheal tube, but this has not yet been published. I did not find any estimates of quality of life 
associated with VAP. 
Cost effectiveness 
In 2009, Shorr et al. produced a cost-effectiveness analysis for the Agento IC (Shorr, Zilberberg, & 
Kollef 2009).  They use the findings of the NASCENT trial to model the effectiveness of the device, but 
use cost saving estimates from another study (Warren et al. 2003). Indeed, the NASCENT trial found 
no statistically significant impact of the Agento IC on hospital length of stay, whereas the cost saving 
figures from the study used (Warren et al. 2003) base the attributable cost of VAP on reductions in 
length of hospital stay; there is some contradiction here.  Shorr’s cost-effectiveness study uses the 
‘assumption’ that the Agento IC costs $90, and that a normal ETT costs $2 (based on ‘expert 
opinion’). The assumed marginal VAP cost is $16,620, and the break-even cost of the Agento IC was 
found to be $388.  
In response to a ‘letter to the editor’ in JAMA, the author of the NASCENT trial paper, Kollef,  
discusses the reasons for the statistically insignificant impact on hospital stay, and proposes that it is 
due to the lower than expected incidence of VAP (around half of most other published estimations) 
(Kollef 2008). He goes on to present a break-even cost (from a healthcare perspective) for the Agento 
IC using, like Shorr, the cost of VAP from another study ($25,072); the break-even cost estimated is 
$678. 
My assumptions 
We can see just from these two cost-effectiveness studies (which base their effectiveness estimates 
on the same trial) that there is a very wide spectrum of costs presented in the literature for VAP, 
which would present a very different value for the Agento IC.  The attributable cost of VAP that I 




found and used for the headroom calculation ($40,000 per case) was much higher than other 
estimates I have found since.  Unsurprisingly, this relatively high estimate of attributable VAP cost is 
that which the company itself now also uses in the Agento IC product information.  Since completing 
the headroom analysis, I have come across one cost of illness study that was published in 2003 (so 
which could have been considered when completing the pro forma using the time perspective 
taken), which produces a much lower estimate of cost attributable to VAP.  After adjusting for 
severity of illness, Warren (Warren et al. 2003) finds an incremental cost per VAP episode of just 
$11,897. If I had used this estimate instead, the headroom would have been reduced by about 70%.  
I assumed an incidence of 10% of mechanically ventilated patients. One UK estimate of incidence for 
an intensive care unit in Sheffield was 18% for all mechanically ventilated admissions, indicating that 
I may have underestimated this parameter (Lwin A, Temple A, & Heap M 2008). Though the 
incidence level reported in the NASCENT trial is quite low (7.9% at baseline), other sources tend to 
report incidence rates at around the 15% mark.  
Additionally, I used the price of a standard ETT estimated by the company and reported in the NHSC 
briefing of £55.  In one cost-effectiveness study, a $2 ETT price is used, based on ‘expert opinion’ 
(Shorr, Zilberberg, & Kollef 2009).  
 
Has the landscape described changed significantly? 
What is current gold standard clinical practice now? Has this changed? 
Initiatives to reduce the time that patients spend with mechanical ventilation are being implemented 
across the health service with varying degrees of success (Blackwood et al. 2010).  These measures 
are increasingly prioritised; VAP is a large contributor to healthcare acquired infection in the NHS.   
Evidence-based research has progressed in this area, and the ‘bundling’ of care practices known to 
reduce the risk of VAP has been found to decrease its incidence (O'Keefe-McCarthy, Santiago, & Lau 
2008). However, there is substantial variation in VAP prevention strategies across the UK (NICE 
National Patient Safety Agency 2008). 
NICE have issued a patient safety solutions document for VAP recommending that patients should be 
positioned with their upper body elevated, and that oral antiseptics should be included as part of the 
oral hygiene regimen for patients receiving mechanical ventilation (NICE National Patient Safety 
Agency 2008).   
The diagnosis and management of VAP in the UK in 2007 is summarised in a paper by Hunter et al 
(Hunter, Annadurai, & Rothwell 2007). They report widespread variation in diagnosis methods, and 
over utilization of antibiotics.  
Torres et al write a special article on ‘Defining treating and preventing hospital acquired pneumonia: 
European perspective’ (Torres A, Ewig S, Lode H, & Carlet J 2009). They provide a table of 
recommended measures for prevention of VAP, according to what experts in Europe believe to be 
best practice.  Silver-coated endotracheal tubes are among the ‘additional measures which might be 




helpful in distinct settings and populations’. This report was produced in 2009 (CE marking for the 
Agento IC was said in the NHSC briefing to be expected mid 2009).  
Are there now many direct competitors? 
I have not come across any direct competitor to the Agento IC; all trials / published articles for silver-
coated endotracheal tubes, where the company or product has been mentioned, have all been in 
reference to Bard’s Agento IC. 
 
Conclusions: How useful might the headroom exercise have been? 
 
The headroom calculated for the Agento IC was very high, and is likely to have indicated a positive 
development decision.  By presenting its value to the health service under various levels of 
effectiveness, we were able to examine the impact this would have on MRP. Even at the lowest 
effectiveness estimate of 25%, the investment proposition still looked attractive (the actual 
effectiveness of the Agento IC found in clinical trials is higher than this).  It is clear from the wide 
spectrum of cost estimations that VAP is a particularly difficult disease to accurately monitor and 
review in clinical trials, probably due to diagnostic difficulties. Such challenges in trial design are 
outlined by Niederman (Niederman 2010).   Although subsequent estimates in the literature on the 
cost-effectiveness of the Agento IC have been more modest than that estimated in the headroom 
analysis, they have still shown that the Agento IC is likely to represent a cost-effective purchase. 
Although the headroom method indicated that the Agento IC would generate substantial value to the 
health service, and the more recent literature also indicates that the Agento IC is cost-effective, the 
purpose of the headroom method is to estimate future cost-effectiveness in order to present the 
opportunity for uptake. 
The Agento IC is not sold in the UK. Without knowing why, this makes drawing conclusions about the 
usefulness of such an exercise difficult. The ‘developments’ in the clinical context identified in the 
pro forma and the research questions articulated may have been useful. The method’s use to 
demonstrate the value of the Agento IC at various levels of effectiveness may also have been helpful.  











Follow up NICE IPG 347. 
 
Date of briefing: Dec 
2000  
 
Time perspective of this 
report: 1997 
Perinatal asphyxia is the deprivation of oxygen to a newborn baby, usually 
resulting from an interference with blood flow to an infant’s brain during 
delivery. It can be caused by placenta issues, maternal blood pressure, 
uterine rupture or umbilical cord complications. Hypoxic damage (damage 
resulting from deprivation of oxygen) can affect most organs in the infant, 
but the most common and serious risk is brain damage (hypoxic-ischaemic 
brain damage). Neonatal encephalopathy is another clinical term 
associated with this condition. It is estimated that about two in every 
thousand babies born in England will have some degree of asphyxia 
(Volpe 1995) (the incidence rises dramatically in preterm neonates).  
 
Perinatal asphyxia is a significant cause of infant death and impairment of 
neurological development; it is the cause of about 20% of all cerebral 
palsy cases (Patel & Edwards 1997). Other outcomes include mental 
retardation, learning disability and epilepsy (Vannucci 1990).  
 
The Olympic Medical Corp ‘cooling cap’, which is to be initiated within 6 
hours of birth and for up to 48 hours, aims to bring down the baby’s core 
brain temperature in an effort to prevent continuing damage to the brain 
cells and their environment. Although (whole body) cooling is not 
systematically used in clinical practice, it has been found to have a 
positive impact on cerebral outcome in newborn animals. The cooling cap 
provides focal cooling on the baby’s head, and is the first commercial 
product for neonatal cooling. 
 
The cooling cap will be used for neonates believed to have hypoxic-
ischemic brain damage, but this can be difficult to determine. Certain 
indicators are thought to help determine the outcome. Some frequently 
used indicators have been found to be non-specific, for example obstetric 
information and clinical examination.  Simple electroencephalographic 
methods (EEG), magnetic resonance spectroscopy and MRI can have 
positive predictive values when used soon after birth (Patel & Edwards 
1997). One study finds EEG to have excellent sensitivity (94.7%) but a less 
satisfactory specificity (68.4%) (Selton & André 1997).  The NHSC briefing 
indicates that an aEEG device (amplitude integrated EEG), which is a 
cerebral function monitor, would be used to screen for eligibility for 
treatment with the cooling cap.  Although this will play a role in the 
overall pathway change from introducing the cooling cap into clinical 
practice, I will consider this to be external to this particular analysis, and 
simply assume that it does the job for which it is intended correctly. 
 
2. Comparator  
 
The NHSC briefing indicates that there is no comparator treatment for the 
prevention of birth asphyxia leading to permanent damage, or the 
treatment of hypoxic brain damage; they indicate that so far other 
techniques have proved unsuccessful.   
Indeed, a 1990 review of current management strategies for perinatal 




hypoxic-ischaemic encephalopathy reported that these ranged from no 
therapy at all, to the extensive use of a variety of medications to treat 
brain swelling, such as fluid restriction, sedation, hyperventilation, and 
others (Vannucci 1990). There is no uniform standard of care, and 
inappropriate drugs are often prescribed. Seven years later, the situation 
remains largely the same. An article by the same author but written in 
1997 indicates that, one by one, drugs that appeared promising have 
been discarded, such that ‘no agent has proven useful to ameliorate 
perinatal hypoxic-ischaemic brain damage in the clinical setting’ (Vannucci 
& Perlman 1997).  
 
Vannucci and Perlman estimate that approximately 15-20% of 
asphyxiated infants who exhibit hypoxic-ischaemic encephalopathy die 
(during the newborn period), and 25% of survivors will exhibit permanent 
neurological deficits (Vannucci & Perlman 1997). 
 
The cooling cap does not symbolise a revolutionary new clinical method; 
the significance of brain temperature has long been recognised to 
influence the outcome of cerebral ischaemia.  For example, experiments 
on rats have shown that cooling of the brain by just a few degrees has a 
protective effect against brain damage after transient ischaemia (stroke) 
(Busto et al. 1987).  Similarly, outcomes of brain cooling in rats have been 
tested after experimental traumatic brain injury; mortality was 
significantly reduced in those cooled to 30 degrees C, and long-term 
behavioural defects were also reduced (Clifton et al. 1991). Induced 
hyperthermia of the brain (raising the temperature by as little as one or 
two degrees) has been found to have the opposite effect, accentuating 
brain damage (Vannucci & Perlman 1997).  The use of systemic cooling in 
patients undergoing heart surgery has long been recognised and 
employed to protect their brains from ischaemic damage (Greeley, 
Ungerleider, Smith, & Reves 1989;Vannucci & Perlman 1997).  
So, the relationship between brain temperature and outcomes is well 
supported in the literature. 
 
Hypoxic-ischaemic brain damage in relation to perinatal asphyxia 
specifically has also been investigated in early experiments on animals.  
Induced hypothermia has been found to reduce brain damage in newly 
born rats (Yager, Towfighi, & Vannucci 1993;Young, Olenginski, Yagel, & 
Towfighi 1983) and pigs (Laptook et al. 1994). Additionally, focal cooling 
of the head has been found to be effective in  rats (Towfighi et al. 1994) 
and sheep (Gunn et al. 1997).  One study has shown that brain 
temperature measured in newborn babies is related to level of brain 
injury in that baby (Simbruner, Nanz, Fleischhacker, & Derganc 1994).  
 
The NHSC briefing does not indicate that the cooling cap would be more 
effective than whole body cooling (with cold air or a cooling mattress—
which would probably be cheaper). However, we do know that whole 
body cooling is not part of standard clinical practice at this time.  Also, it 
could be assumed that selective head cooling would reduce the adverse 




effects of hypothermia for babies18. 
 
Without having found any effect estimates of infant cooling on 
neurological outcome, I do not know the degree to which this could affect 
death / impairment.  However, the long term costs and morbidity of 
hypoxic ischaemia are so high that any improvement in outcome for those 
babies is likely to have a high value to the NHS. This is discussed further 
below. 
 
3. Market size  Asphyxia affects about two in every one thousand babies born in England 
every year.  This equates to around 1,200 babies (out of 600,000 born in 
England per year).  In the NHSC briefing, it is indicated that all 1,200 
would probably be eligible for aEEG screening, and out of these an 
estimated 600 babies may benefit from treatment with the cooling cap.  
 
Market size per year (NHS England): 600 
 
4. Health Service 
 
Changes in resource use.  Any changes in 
service delivery costs to the NHS that will 
result from the application of the new 
technology, including the disinvestment in 
previous practice.  This could include: Staff 
time, hospital bed days, GP visits, A&E visits, 
etc.  It should not include services for which 
the NHS (and personal social services) is not 
financially liable (e.g. lost productivity and 
[non-health] social care costs), but these 
should be noted in writing below to add to 
the verbal case for the product (NICE may 
incorporate social care costs into cost-
effectiveness estimates in the near future). 
 
 If relevant and not included in service cost 
impact above, search for price of the 
currently used product (P1). 
 
Use HCHS index to inflate estimates to 





The cost to the NHS of hypoxic-ischaemic brain 
damage as a result of birth asphyxia is likely to be 
huge, though I have not found a direct estimate.  
Cerebral Palsy, a potential outcome for babies that 
suffer from perinatal asphyxia, is thought to cost 
$503,000 per new case (based on 1992 U.S. data, 
which includes both direct medical costs and indirect 
costs such as specialist education services and lost 
productivity) (Centers for Disease Control and 
Prevention (CDC) 1995).  
 
Additionally, brain injury following birth asphyxia is a 
common cause of litigation (Goldsmith 1989); 
lawsuits taken out against the hospital often result in 
very large financial settlements. These can cost the 
NHS millions of pounds per case.   
 
The likely health service impact of avoiding even a 
small percentage of hypoxic-ischaemic brain damage 
in newborns would be difficult to quantify but must 
be very large.  Savings are likely to be seen in medical 
costs of treatment, nursing care, physiotherapy, 
transportation, and the provision of many other 
services, as well as pay-outs following court cases for 
perinatal asphyxia that resulted from mistakes made 
by clinicians.  
 
                                                          
18
 One study conducted in 1978 on the effectiveness of neonatal transport found that those babies that 
arrived in hospital with a core temperature of below the optimal (36 to 37 degrees C) had a 
significantly higher mortality rate (Gunn & Outerbridge 1978).  





Describe any potential costs/savings that 
you haven’t quantified.  
 
The cost of brain injury to families and social care 
services is huge. The impact of childhood brain 
damage on parents’ work and family finances was 
investigated in one paper; trouble maintaining 
regular work schedules, and resulting financial 
problems were a big problem for families with 
children suffering brain injuries (Osberg et al. 1997). 
 
(Total) ∆SC= 






Potential impact of the new device on 
patient health, as compared to current 
practice (preferred method of elicitation is 
from studies using the EQ-5D).   
Where NICE have not produced relevant 
economic analyses, search for cost-
effectiveness studies or systematic reviews 
within the disease area (the CEA registry 
offers a useful platform to identify these 
studies). 
 
Describe any impact on patient health that 
you haven’t quantified.  
As well as the substantial health service costs of 
hypoxic-ischaemic brain damage, the QALY loss to 
the infant can be huge.   
 
Birth asphyxia is a major cause of neonatal mortality; 
a recent study conducted in India found a neonatal 
mortality among asphyxiated neonates of 24.7%, 
which was 35 times that of the non-asphyxiated 
population (Paul, Singh, Sundaram, & Deorari 1997).  
 
The adverse QoL outcomes of neonatal 
encephalopathy are widespread.  A retrospective 
cohort study in the Oxford Regional Health Authority 
found that children with cerebral palsy at age 5 who 
have the condition as a result of neonatal 
encephalopathy were more likely to have developed 
spastic quadriplegia, have visual impairment and to 
be non-walking compared to those without neonatal 
encephalopathy (Gaffney et al. 1994).  Another study 
finds subtle learning differences (particularly in 
auditory pathway, attention, and short-term recall) in 
school children who had moderate hypoxic-ischemic 
encephalopathy at birth versus the mild 
encephalopathy group (Robertson & Finer 1993). 
 
An intervention that could reduce the incidence of 
hypoxic-ischaemic brain damage and thus reduce the 
incidence (or degree) of cerebral palsy, mental 
retardation, and neonatal death that can follow, 
would be highly regarded and would likely incite a 
very high willingness to pay (especially as the 
patients in question are babies, with all of their ‘life 
years’ ahead of them). 
∆QALY=  
(Av. per person) ∆QALY= 




6. Developments (clinical & healthcare 
context) 
 
Consider the following questions to help you 
think about the space for your product 
within the market.  
 
Does the technology address any key national 
objectives for improving care in this area? 
 
How will the technology complement current 
practice? Is current practice likely to change? 
 
Are there any indications in the literature of 
potential effectiveness? 
 
Have you identified any direct competitors? (This 
could be another specific technology, or simply a 
different technique)  
 
 RED: Poses a significant threat to the 
opportunity identified in the market (i.e. 
works against current health service 
objectives, or there are other products 
being developed that are associated with 
better outcomes or are at a more advanced 
stage of development). 
 
AMBER: Potential threat 
 
GREEN: Further supports the case for the 
new technology  
 [AMBER] Cooling as a way to reduce neurological 
damage is not a new idea, though this is the first 
commercialisation of such a technique. Research 
into the effect of cooling on neurological damage 
has used other means to reduce the core brain 
temperature.  Some experiments tested selective 
head cooling, using a tube coiled around the 
head of an animal with cold water running 
through it.  Thereofore, even if proven effective, 
there are other ways to achieve perform cooling,  
and that other products could be developed.  
 
 [RED] Whole body cooling may be as effective in 
reducing core brain temperature, and is likely to 
be cheap to perform. 
 
 [GREEN] As indicated by the overview of 
literature supporting cooling methods, the 
technique and its clinical benefit is recognised.  
Whole body cooling is apparently an effective 
way to bring down core brain temperature.  Why, 
then, has it not been brought into clinical 
practice already?  It may be that the 
development of a specific product for this 
indication is what it needed in order for it to be 
integrated into clinical practice across the NHS.  
 
 [AMBER] Other possible treatments for hypoxic-
ischaemic brain damage are under investigation. 
Some pharmacologic agents which are under 
experimental investigation are: oxygen-free 
radical inhibators and scavengers, excitatory 
amino acid antagonists, calcium channel 
blockers, inhibitors of nitric oxide production, 
monosialogangliosides, glucocorticosteroids, and 
combination therapy.  Nonpharamacologic 
interventions under investigation (aside from 
induced hypothermia) include hyperglycemia, 
carbon dioxide and  hypoxic preconditioning 
(Vannucci & Perlman 1997). If any of these are 
found to be effective, they could alter the 
incremental effectiveness of the cooling cap 
which, at this time, is being compared to no 
treatment.  
 
 [GREEN] There is likely to be strong societal 
pressure for the introduction of technologies that 
can save the lives / improve the outcome of 
babies at risk of brain damage.   




7. Research questions 
 
This should be a list of the things that the 
developer needs to find out or monitor 
during the process of development, relating 
to the function of the device or how it fits 
into the market place. 
 
From the research undertaken and reported 
above, what are the most important 
questions or uncertainties that must be 
addressed / tested? What factors or 
assumptions have the calculations / 
economic or clinical case hinged upon? 
What potential benefits or threats have you 
ignored in the calculation (see italicised 
points in Qs 4&5, and ‘developments’ 
section)?  
 Given the fact that cooling is an established 
technique, the potential of the cooling cap for 
perinatal asphyxia as a viable medical device and 
commercial opportunity could hinge on the 
following:  
1) Are other products for the same purpose 
being developed? 
2) Is this commercial product a sensible / 
attractive alternative to non-commercial 
cooling? What is the price differential likely 
to be? 
 If the cooling cap is found to have the same 
effect on core brain temperature as whole body 
cooling, what are the benefits of selective head 
cooling? To what extent does induced 
hypothermia present a risk to newborns? 
(Anecdotal evidence presented above suggests 
that small reductions in a newborn’s body 
temperature can have an impact on mortality). 
 How many devices would be required per 
hospital? It may be that 600 cases per year would 
require the cooling cap, but how many would 
need to be purchased in order to ensure 
adequate coverage?  
 How much would the aEEG testing cost for those 
estimated 1200 babies per year who are likely to 
need the screen if this were to become common 
practice?  
 
Headroom Notes (Cooling Cap) 
Given the lack of current (clinically proven) alternatives for newborns with hypoxic-ischaemic brain 
damage, the cooling cap seems to be a ‘no brainer’ from a headroom perspective (its potential health 
economic case is clear, if it works as we think it will and if our comparator (no treatment) does not 
change).  The potential impact of perinatal asphyxia on outcomes and costs makes this case seem 
obvious, without having to articulate the numerical value of this (which the literature does not supply 
readily). A long term view will need to be taken to realise the full value of such a product.  
The literature indicates that it will work, but the pertinent question is whether it works better than 
whole body cooling which, whilst not currently part of standard clinical practice, may offer a cheap 
easy way to realise the same therapeutic benefit.  This must be a key consideration when deciding 
whether to develop the product, as if it is thought that whole body cooling could feasibly become 
part of routine clinical practice, then the cooling cap must prove to work better than this (or be 
cheaper- which is unlikely).  Alternatively, the company would have to have some confidence in the 
fact that by selectively cooling the head only, outcomes for the baby would be improved or the risks 
reduced. 




If a headroom were to be calculated in the future, the number of cooling caps needed to cover all 
those babies at risk would need to be considered, as well as the longevity of the device. The likely 
market share should also be considered given the likelihood that other means of cooling may also 
have a place in clinical practice.  
 
Follow-up (Cooling Cap) 
Headroom Outcome and Market success 
Does the MRP look realistic? Would it have indicated yes or no to development? 
As indicated in the headroom notes, the (unquantified) MRP for the Cool-Cap (now its official name) 
would have been very high.  The indications in the literature of potential effectiveness were very 
positive.  The associated costs, morbidity, and mortality associated with hypoxic-ischaemic brain 
damage due to perinatal asphyxia are large, meaning that the value of this device would be high. 
This was based on the assumption that: 
1) The strong body of research into cooling as a way to reduce / prevent brain damage would 
translate into favourable effectiveness results for the Cool-Cap. 
2) The comparator, which in 1997 was ‘no treatment’, would remain so.  It was identified that 
whole-body cooling using mattresses or cool air may achieve similar results, and if this was 
found to be more acceptable / affordable than the Cool-Cap, then the business case could be 
at risk. The two caveats to this are that: 
a. Selective head cooling could reduce the risk to the baby posed by hypothermia, by 
achieving a reduction in core brain temperature without subjecting the rest of the 
body to low temperatures. 
b. A concrete device designed specifically for this indication may be what is needed to 
raise the profile of therapeutic cooling, and clinicians may prefer the Cool-Cap to 
other methods of cooling 
Although I have been unable to find the actual price of Cool-Cap, I feel that, from a headroom 
perspective, this was a ‘no brainer’, but the decision should have been made with consideration of 
the‘developments’ and ‘research questions’ presented. 
Interpretive answer: Headroom positive 
Has there been a decision made on it by NICE? What was the outcome? 
In 2007, ‘Whole body cooling for the treatment of neonatal hypoxic ischaemic encephalopathy’ was 
considered by the Interventional Procedures team but deemed ‘Not In Remit’ as it was not an 
interventional procedure. Three years later in 2010 NICE produced IPG347 on ‘Therapeutic 
hypothermia with intracorporeal temperature monitoring for hypoxic perinatal brain injury: 
guidance’ (presumably overcoming the remit issue by describing the way in which temperature is 
monitored) (NICE 2010c). NICE pronounce that current evidence on the safety and efficacy of 




therapeutic hypothermia is adequate to support its use in the NHS.  They go on to briefly present the 
evidence from the literature of decreased mortality following cooling as well as reduced incidence 
and severity of neurodevelopmental disability. They describe hypothermia to usually be induced by 
cooling the whole body with a blanket or mattress or sometimes by cooling the head only with a 
purpose-made cap. Having looked through the sources of evidence used, those considering a cooling 
cap refer exclusively to the Olympic Cool-Cap.  
Is it sold in the UK or the rest of the world?(Or has it in the past) If so, who is it bought by? 
The Olympic Cool-cap received FDA approval in December 2006 (FDA 2006b); Olympic Medical Corp. 
was merged into Natus Medical Inc. in December 2007 (both American companies) (Bloomberg 
2008). Although information provided on their website is focused toward an American audience, the 
Cool-Cap is used within the NHS (though it is not clear to what extent).  There have been many 
clinical trials testing cooling methods (see next section).  A study from 2009 looking at how cooling is 
managed in the UK outside of clinical trials follows hospitals that had been involved in the TOBY trial 
(Total Body Hypothermia for Neonatal Encephalopathy trial); a few of these infants were treated 
with the Cool-Cap (Azzopardi et al. 2009b).   
Considering the positive trial results, and the fact that improving the outcomes of babies at risk of 
long-term brain damage (and death) is a poignant issue, there has unsurprisingly been a lot of press 
and media coverage on this issue (Kaiser 2004;One True Media 2011;VanderbiltHealthNews 2011). 
The British media specifically have also reported on the big potential impact of cooling, with 
headlines like ‘Cooling cuts baby brain damage ‘ (Walsh 2009), ‘Cooling “cure” averts infant brain 
damage’ (Laurance 2009), ‘Cooling babies could reduce brain damage’ (Alleyne 2009) and ‘Cold cuts 
baby brain damage’ (NHS Choices 2009). 
Clinical trials for the device are international in location, suggesting a global reach.  
 
Have there been investigations into its clinical / cost effectiveness? 
Clinical effectiveness 
There have been many clinical trials for the use of cooling in human neonates with perinatal asphyxia 
and suspicion of hypoxic-ischaemic brain damage since 1997 (the time perspective taken for the 
headroom analysis).  As in the animal trials, cooling for newborn infants has been shown to have a 
positive impact on mortality and neurodevelopment, with no adverse effects.  A Cochrane review 
published in 2007 confirmed this, though reported that adverse events linked to hypothermia 
included an increase in the need for intorope support (of borderline significance) and significant 
increase in thrombocytopaenia. They conclude that the benefits outweigh the risks (Jacobs et al. 
2007). A 2010 meta-analysis draws the same conclusion, stating that moderate hypothermia is 
associated with a consistent reduction in death and neurological impairment at 18 months (Edwards 
et al. 2010). The biggest cooling trial undertaken in the UK is the ‘TOBY’ trial, which was a multicenter 
randomized trial comparing intensive care plus total-body cooling for 72 hours versus intensive care 
alone. The results showed that induction of moderate hypothermia in infants who had perinatal 




asphyxia did not significantly reduce the combined rate of death or severe disability, but did improve 
neurological outcomes in survivors (Azzopardi et al. 2009a). 
As for Cool-Cap specifically, the results of the biggest trial to estimate clinical effectiveness was by 
Gluckman et al, published in 2005 (Gluckman et al. 2005). They conclude that the cool-cap could 
reduce disabling neurodevelopmental sequelae of neonatal encephalopathy, except in the most 
severely encephalopathic infants.  
I have found no study that compares head cooling with whole body cooling directly. 
Cost-effectiveness 
A cost-effectiveness study of therapeutic hypothermia after cardiac arrest finds cooling to be cost-
effective (cost-effectiveness ratio of $47,168).  The cost and benefit improvement is likely to be more 
favourable when used for babies, especially as cooling has also proved to have a significant impact on 
mortality. 
One cost-effectiveness study for cooling, which combines the effectiveness estimates of the TOBY 
trial, NICHD trial and Cool-Cap trials, and costs found from the TOBY trial, find that the probability 
that cooling is cost-effective is finely balanced at 18 months, but increases to 99% when the 
throughput of infants was increased to reflect national incidence of neonatal encephalopathy, or 
when a longer time horizon was taken (which is probably appropriate for this intervention) (Regier et 
al. 2010). 
A U.S. study published in 2008 simulates the cost-benefit scenario of various strategies of 
deployment of selective head cooling and aEEG use for treatment allocation (Gray, Geva, Zheng, & 
Zupancic 2008). They find that the package of aEEG and selective head cooling is an economically 
desirable intervention.    
 
Has the landscape described changed significantly? 
What is current gold standard clinical practice now? Has this changed? 
Clinical practice has changed substantially in response to clinical trials and general awareness of 
cooling as an effective way to improve neurological outcome for asphyxiated babies. Whereas before 
there was no routine treatment, induced hypothermia is becoming increasingly common. 
A survey conducted in 2009 by Ponnusamy et al. questioned all 214 neonatal units in the UK with 
regards to the availability of cerebral function monitoring (CFM) and hypothermia therapy 
(Ponnusamy et al. 2010).  CFM was available in 41% of units, and 28% had dedicated cooling 
equipment.  16% of those without CFM were planning to acquire it, and 14% of those without cooling 
equipment were planning to procure it soon. In level three units CFM and cooling equipment 
availability was 87% and 78% respectively. There is no indication in the report what type of cooling 
equipment is used in these units. 




Olympic Medical now produce and sell their own cerebral function monitor, the Olympic CFM 6000 
(their own aEEG device to diagnose hypoxic-ischaemic damage and indicate whether cooling is 
appropriate (Natus 2011)). 
Whole body cooling is probably more widely used in the UK than selective head cooling.  Robertson 
et al. estimate that under 3% of units in the UK use selective head cooling (though the source of this 
estimate dates back to 2007) (Robertson, Kendall, & Thayyil 2010).  Robertson also suggests that 
servo-controlled devices, which have only recently come to the market, offer improved stability of 
temperature and minimal nursing input compared to other whole body cooling devices (such as the 
CriticoolTM and the Tecotherm servo).  
Though comparative data does not exist, the company highlight the benefit of the Cool-Cap: that the 
baby is not subjected to the adverse effects of hypothermia during treatment. However, Azzopardi 
reports that clinical complications that had arisen during the cooling period (using whole body 
cooling) were not considered related to the hypothermia therapy (Azzopardi D et al. 2009).  It is 
thought that eventually the cool-cap may provide cooling therapy portably (for example in 
ambulances) (Kaiser 2004) – this may be more feasible with this device than other means of cooling. 
 
Are there now many direct competitors? 
There has been continued research into whether any pharmacologic agents can prevent mortality 
and morbidity in newborn infants with suspected hypoxic-ischaemic encephalopathy. Recent reviews 
show that alloupurinol (Chaudhari & McGuire 2008), naloxone (McGuire, Fowlie, & Evans 2004), 
anticonvulsants (Evans, Levene, & Tsakmakis 2007), and dopamine (Hunt & Osborn 2002) still do not 
have sufficient evidence to support any clinically important benefit. 
In their hypothermic therapy guidance, NICE also reiterate that no other specific pharmalogical 
agents or interventions have been shown to prevent neuronal damage.  In the literature, the only 
commercial device I have come across for selective head cooling is that of Olympic Medical Corp 
(now Natus). This is consistent with the declaration on their website that the Cool-Cap is the only 
device for this indication with FDA approval (Natus 2011).  
Commercial devices that have been developed to allow for whole body cooling include:  
 Blanketrol cooling blanket (Cincinatti Sub-Zero);  
 CritiCool whole body cooling system (CritiCool, Charter Kontron, Milton Keynes, UK), and; 
 Tecotherm (Tecotherm, Inspiration healthcare, Leicester, UK). 
I have also come across the use of simple ice /gel packs, fans, and water bottles. 





Conclusions: How useful might the headroom exercise have been? 
The Cool-Cap was an example of commercialising a device for which the mechanism of action already 
has an established clinical case, but turning it into a marketable product. The question of whether it 
would work better than other methods has not been answered explicitly by the literature to date, 
but current practice and research indicate that other means of cooling may be just as effective as the 
Cool-Cap. 
When comparing the therapeutic benefit of the cooling cap to ‘no treatment’ (which was current 
practice in 1997), the headroom for development was really a ‘no brainer’. The evidence for cooling 
that has been produced over the past decade supports the notion that both clinically and 
economically, cooling is the optimal form of treatment for newborns with suspected hypoxic-
ischaemic encephalopathy. The media has probably served to propel changes in clinical practice with 
increased vigour and speed.   
To our knowledge, the Cool-Cap was the first commercial device for this indication.  An interesting 
parameter in this example is clinician preference. From a health economic perspective, effectiveness 
and costs alone dictate the cost-effectiveness of one intervention over another.  Comparing the Cool-
Cap to no intervention led to a straightforward positive case, but if we were to have considered that 
cheap alternatives were just as effective, the cool-cap may have been dominated.  However, as 
therapeutic cooling did not yet have a place in widespread clinical practice, a commercial device may 
have been what was needed to raise awareness and promote wider support for the intervention.  
The fact that the Cool-Cap was the first commercial device, may have benefited the company and 
provided support for the development case; the research interest generated and the clinical trials 
undertaken would mean that the company could make early contacts and alliances with individual 
hospitals/clinicians.  This is not the case with new or alternative versions of currently ‘established’ 
devices, as there would be limited need for trials.  
As is the nature with devices, especially in an area where the therapeutic benefit is known and the 
methods of cooling are multiple, the market has become crowded with competitors. This was 
highlighted as a significant and likely threat for the development opportunity. It is clear though that 
different devices which achieve the same therapeutic effect but by different means can co-exist in 
the same market.  This exemplifies the fact that customer choice (in this case that of the clinician) is 
of importance here.  It may reflect clinician’s having different ideas/interpretations of clinical 
effectiveness, or a predisposition toward gadgets. 
So, the headroom method and the signals it provided with regards to the commercial opportunity of 
cooling and the external threats to that opportunity, turned out to be applicable. Would a headroom 
analysis have been needed to give us this information? Maybe not. 
 
 












No NICE follow-up. 
 
Date of briefing: Aug 
2008 
 
Time perspective of this 
report: 2006 
 Cartilage damage is associated with knee pain, knee swelling, knee 
locking, and giving way of the knee joint. It can be caused by injury (and is 
often a result of sporting activity), or can happen spontaneously 
(osteochondritis dissecans).  It mostly occurs in young adults. Incidence is 
not very well known, but it is estimated that about 10,000 patients in the 
UK suffer from cartilage damage that warrants repair (NICE 2005b) . 
 
ChondroCelect is a somatic cell therapy product, which will be developed 
from a patient’s own cartilage-forming cells (from a lesser weight-bearing 
area of the joint), and expanded ex-vivo prior to implantation. It is 
administered as part of an ‘autologous chondrocyte implantation‘(ACI)20. 
The procedure consists of three steps, which are performed over 4 to 6 
weeks:- 
a) An arthroscopy is undertaken to assess the cartilage lesion and to 
take a biopsy from a lesser-weight bearing part of the joint 
b) Cells are harvested from the cartilage biopsy and expanded to 
make ChondroCelect. 
c) Arthrotomy: a biodegradable cover (a periosteal cap or collagen 
membrane) is joined over the cartilage defect, under which the 
cultured cells (ChondroCelect) are injected. 
The combination of ChondroCelect (the product) and ACI (the procedure) 
is called Characterised Chondrocyte Implantation (CCI™). 
 
2. Comparator  
 
There is no one uniform approach to managing knee cartilage defects. 
Options include:  
 Symptomatic relief 
 ACI. Also available is ‘MACI’: Matrix-guided ACI. This is where the 
extracted chondrocytes are cultured within a collagen matrix 
before being implanted.  Implantation can be done by 
arthroscopic injection (less invasive, uses a collagen membrane so 
avoids the need for a periosteal cap).  
 Microfracture: This is a marrow stimulation technique, and 
involves breaching the sub-chondral bone to cause bleeding. The 
blood clot that develops is thought to create the right conditions 
for stem cells to build new tissue 
                                                          
19
 There is some disagreement around the appropriate classification of somatic cell therapy/tissue-
engineered products; at least from a regulatory perspective they pose quite different issues from 
devices and medicines.  Regulation of European Parliament on such products classify them as 
‗advanced therapy medicinal products (ATMPs)‘. In a summary of the new directive, it is said that ‗a 
Committee for Advanced Therapies (CAT) will be established within the European Medicines Agency 
(EMEA) to provide scientific advice on ATMPs of which at least two members must have medical 
devices expertise‘(Department of Health 2008) . This exemplifies the unique nature of tissue 
engineered products that means they lie somewhere between a device and a medicine.   The NHSC 
classify them under medical devices, which is the reason for its inclusion.   
20
 The NHSC document refers to this procedure once as ‗autogenous cartilage implantation‘ procedure 
(ACI), though I cannot find this term used anywhere else. The company itself refers to the 
ChondroCelect as being used for ‗autologous chondrocyte implantation‘.  




 Mosaicplasty: Cylinders of normal cartilage and bone are removed 
from non-weight-bearing areas of the affected knee, which are 
then placed into the areas of effective cartilage. Mosaicplasty was 
reviewed by NICE as an interventional procedure in 2006, which 
concluded that there are no major safety concerns for the 
procedure but that data on long-term efficacy was inadequate 
(NICE 2006b) 
 Knee lavage 
 Knee replacement. 
 
NICE produced a technology appraisal for ACI in 2000. This was revisited 
in 2005, and became:  ‘TA89 Cartilage injury – autologous chondrocyte 
implantation (ACI) (review): Guidance’(NICE 2005b) .  ACI was not 
recommended for treating knee problems caused by damaged cartilage 
(unless designed to produce good quality research data for the 
procedure). The re-appraisal made the following modifications to the 
original guidance: 
o The recommendation that ACI should not be used for routine 
primary treatment was expanded to include all treatment levels.  
o All patients receiving ACI should be enrolled in clinical studies 
o Patients should be fully informed of the uncertainties about the 
long term effectiveness and potential adverse effects of the 
procedure. 
 
The ACI procedure described in this NICE technology appraisal seems 
identical to that described for ChondroCelect. When describing the 
‘Innovation and/or advantages’ of ChondroCelect in the NHSC briefing, it 
is said to be (if licensed) the “first advanced autologous chondrocyte 
therapy product developed for this indication”21.  We can only assume 
that the cell culturing technique differs to those used already for this 
procedure, leading to more effective cultured chondrocytes 
(ChondroCelect), and thus improved effectiveness. 
 
NICE considered four relevant RCTs in order to ascertain ACI 
effectiveness: two comparing ACI to Mosaicplasty and two comparing it to 
Microfracture. Compared with Mosaicplasty, one trial showed equivalent 
results whilst the other found greater improvement in knee function and 
symptoms in the ACI group (this difference was statistically significant).  
Compared with Microfracture, one trial found that after two years, a 
slightly greater number of ACI patients experienced less pain compared 
with Microfracture, but the physical component of the SF-36 was 
improved more with Microfracture. The other shows no statistically 
                                                          
21
 By the time this (the NHSC briefing) had been written, the NICE technology appraisal for ACI had 
been available for three years, and the original appraisal had actually been issued five years before 
that.  Whilst the brief does not indicate what it is that makes the ChondroCelect any different to ready-
established ACI procedures, it can only be assumed that what makes this the first ―advanced‖ ACI 
must be something in the cell culturing process (perhaps these details are omitted for reasons of 
confidentiality). The NHSC briefing also neglects to mention that the ACI procedure was not 
recommended by NICE. 





A Swedish longer-term observational study found that ACI had good or 
excellent results in 82% to 92% of patients. 
NICE conclude that the clinical effectiveness evidence for ACI is 
inconclusive.  
 
The HTA that was undertaken to support the NICE guidance was published 
in late 2005 (Clar et al. 2005). They state that microfracture is the ‘current 
standard treatment of cartilage defects’. Combining this with 
mosaicplasty’s problem of damage to donor sites meaning that the 
procedure is limited to smaller lesions (Clar et al. 2005), and that in their 
2006 guidance on mosaicplasty NICE declare that effectiveness data for 
mosaicplasty was insufficient, I will assume that microfracture is most 
appropriately considered the ‘gold standard’ in clinical practice’22. 
 
3. Market size  Although incidence is not well known, it is thought that 10,000 patients in 
the UK suffer cartilage damage that warrants repair. It is anticipated that 
9-12% of these patients would be suitable for treatment with 
ChondroCelect.  
Market size per year: 900 to 1,200 
 
4. Health Service 
 
Changes in resource use.  Any changes in 
service delivery costs to the NHS that will 
result from the application of the new 
technology, including the disinvestment in 
previous practice.  This could include: Staff 
time, hospital bed days, GP visits, A&E visits, 
etc.  It should not include services for which 
the NHS (and personal social services) is not 
financially liable (e.g. lost productivity and 
[non-health] social care costs), but these 
should be noted in writing below to add to 
the verbal case for the product (NICE may 
incorporate social care costs into cost-
effectiveness estimates in the near future). 
 
 If relevant and not included in service cost 
impact above, search for price of the 
currently used product (P1). 
 
Use HCHS index to inflate estimates to 
current prices  
 
ACI is thought to offer relief of symptoms in the short 
term, and reduced incidence of subsequent 
osteoarthritis and later knee replacement in the long 
term. For all of the associated benefits (both in terms 
of health and health service cost) to be incorporated, 
a long-term view must be taken. 
 
In NICE’s technology appraisal, four companies are 
mentioned in relation to the ACI procedure, which 
provide the cell culture service. They estimate the 
cost by company, which includes the cell culturing, 
shipping, and training of hospital staff. They also 
provide details of the one trust that use in-house 
methods of chondrocyte culture: The Robert Jones 
and Agnes Hunt Orthropaedic & District NHS Trust 
(RJAH) is Oswestry. 
 
Genzyme Ltd UK and Ireland: £4,000-£5,000 
BBraun/TeTec AG: £4,000 
Verigen UK Lts: £3,200 
Geistlich Biomaterials: £3,500 
RJAH: £2,000 
(It was noted that acquisition cost may vary 
according to local agreements). NICE then added to 
                                                          
22
 Additionally, the HTA for ACI finds mosaicplasty to be dominated by ACI and microfracture in nearly 
all scenarios. 
















































this the health service costs involved. They chose to 
use the Verigen UK cost of cell culture in their cost 
model.  
 
NICE undertook illustrative modelling of the cost-
effectiveness of ACI, and argue that there was 
insufficient evidence to produce a robust cost per 
QALY. They modelled cost-effectiveness in the short 
(2 years), medium (10 years) and long term (50 years) 
(the latter being the most speculative). It is only 
when taking a 50 year time horizon that ACI 
appeared cost-effective, but as the relative 
effectiveness of ACI was still experimental, NICE 
concluded that there was insufficient information on 
which to base long term effectiveness and quality of 
life gain estimates.  
 
The HTA report that informed this analysis provides 
more detailed information behind that modelling. 
Even though the modelling was illustrative because 
of the lack of long term data on ACI, the HTA team 
used what they thought to be reasonable 
assumptions; these well-informed ‘guesses’ fit the 
purposes of a headroom calculation. 
 
The report provides explicit costs for each procedure, 
which include procedural costs (length of stay, 
theatre time, physiotherapy) and cell culture cost for 
ACI (at £3,200). For arthroscopic ACI this is said to be 
£6,384, and for open knee ACI it was £8,646 (due to 
the increased recovery time in hospital). Although 
not completely clear in the NHSC briefing, it seems 
that the ChondroCelect procedure would use open 
knee surgery to implant the cultured cells, rather 
than an arthroscopic procedure which only uses a 
small incision23. The NHSC briefing indicates that 
ChondroCelect “may be a cheaper alternative”, but 
gives no indication of why this might be the case (this 
would have been especially useful information 
considering that ChondroCelect would be applied as 
an open knee ACI, which is the more costly version). 
Mosaicplasty costs £3,710.  
 
Taking a short time horizon, these differences in 
                                                          
23
 The NHSC briefing provides average costs of both open knee and arthroscopic ACI, but does not 
indicate where the ChondroCelect system fits into this picture. When describing the procedure, they 
say that the cultured cells are implanted via ‗Arthrotomy‘, which refers to a process of creating an 
opening in the joint. Upon further investigation, I find that in the context of ACI this refers to open knee 
surgery, which is the traditional method of surgically opening the knee with long incisions.  




















Describe any potential costs/savings that 
you haven’t quantified.  
intervention cost would have a great deal of 
influence on relative cost-effectiveness of the 
treatments.   
 
As the procedure for ChondroCelect looks to be the 
same as conventional ACI, service costs involved in 
the procedure itself are likely to be the same.  
Although it is proposed that ChondroCelect may be 
more effective, the assumptions required to quantify 
this improvement on longer term service costs are 
not provided.  
(Total) ∆SC= 




Although of limited relevance to the NICE reference 
case, Lindahl et al present the estimated impact of 
ACI on productivity (Lindahl, Brittberg, & Peterson 
2001). They find that for the 10 years pre-ACI 
procedure, absenteeism costs reach £74,352 per 
person. For the 10 years following an ACI procedure, 




Potential impact of the new device on 
patient health, as compared to current 
practice (preferred method of elicitation is 
from studies using the EQ-5D).   
Where NICE have not produced relevant 
economic analyses, search for cost-
effectiveness studies or systematic reviews 
within the disease area (the CEA registry 
offers a useful platform to identify these 
studies). 
 
Describe any impact on patient health that 
you haven’t quantified.  
Given the long term impact of knee problems, we 
would ideally have estimates of health status 
following intervention spanning many years.  
However, quality of life valuations in the literature 
using generic instruments such as SF-36 or EQ-5D are 
limited to just two years (Clar et al. 2005). 
 
The HTA performed by Clar et al. presents a simple 
short-term model which shows that the required QoL 
gain from switching from microfracture to ACI must 
be between 70 and 100% over two years in order to 
be cost-effective ( the evidence so far does not 
indicate gains of this magnitude) (Clar et al. 2005). If, 
however, this QoL gain could be maintained for a 
decade, ACI would need to provide a QoL increment 
of just 10-20% over microfracture in order to justify 
its higher cost. However, this has been calculated for 
arthroscopic ACI. Clar et al. assume open knee and 
arthroscopic ACI to be of equivalent effectiveness, 
meaning that (more expensive) open-knee ACI is 
dominated by arthroscopic ACI in all scenarios. They 
present the incremental cost-effectiveness ratio of 
open knee ACI versus microfracture (assuming a QoL 
gain of 0.1 for microfracture and 0.2 for ACI) which at 
year 1 is £62,980 but only £7,317 at year 10. 




However, the same calculations for arthroscopic ACI 
render an ICER of £40,360 at year 1 and just £4,689 
at 10 years. 
 
In the long-term model, Clar et al. consider the base-
case to be where ACI (successful cases) offers a QoL 
increment of 0.1 compared with microfracture, and 
once considering the relative impact on future health 
and service costs (including knee replacement), find 
the cost-effectiveness of switching from 
microfracture to ACI to be between £3,500 and 
£5,500 per QALY (very favourable). Again, however, 
they  assume arthroscopic ACI, which the 
ChondroCelect isn’t: “since open-knee ACI is more 
expensive than arthroscopic ACI, in the absence of 
any data suggesting it to be more cost-effective than 
arthroscopic ACI, open-knee ACI is dominated in 
terms of cost-effectiveness and has been largely 
disregarded in this section” (p.36, (Clar et al. 2005)).   
 
It seems now that the most pertinent comparator 
from a development decision perspective is 
arthroscopic ACI, even though this is not yet current 
practice.  In order to present an attractive case for 
NHS purchase, the benefits arising from ACI with 
ChondroCelect would need to be greater than those 
incremental benefits needed for arthroscopic ACI to 
be cost-effective, that were estimated in the HTA.  
∆QALY=  
(Av. per person) ∆QALY=  
 
6. Developments (clinical & healthcare 
context) 
 
Consider the following questions to help you 
think about the space for your product 
within the market.  
 
Does the technology address any key national 
objectives for improving care in this area? 
 
How will the technology complement current 
practice? Is current practice likely to change? 
 
Are there any indications in the literature of 
potential effectiveness? 
 
Have you identified any direct competitors? (This 
could be another specific technology, or simply a 
different technique)  
 [RED] ACI has been reviewed by NICE, who issued 
a recommendation that ACI should not be used in 
the clinical treatment of knee cartilage defects. 
 
 [RED] This non-recommendation was based on 
the fact that short-term data showed ACI to be 
dominated by alternative treatments, and that 
long-term data on which to base effectiveness 
estimates did not exist.  Data of this nature will 
take at least 20 years to collect. Until then, unless 
the current clinical landscape changes, it is likely 
only to be used as part of clinical trials in the UK. 
  
 [AMBER] There are a number of device 
manufacturers named on the ‘Consultees’ list for 
NICE’s ACI technology appraisal (TiGenix is not 
one of these). This suggests that there are many 





 RED: Poses a significant threat to the 
opportunity identified in the market (i.e. 
works against current health service 
objectives, or there are other products 
being developed that are associated with 
better outcomes or are at a more advanced 
stage of development). 
 
AMBER: Potential threat 
 
GREEN: Further supports the case for the 
new technology  
companies with an interest in producing products 
for ACI, so competition may be fierce.  
 
 [RED] Clar et al. showed that open knee ACI was 
dominated by arthroscopic ACI given its more 
expensive intervention cost, and the fact it has 
not been proven to be more effective. 
[AMBER] ChondroCelect would need to prove to 




7. Research questions 
 
This should be a list of the things that the 
developer needs to find out or monitor 
during the process of development, relating 
to the function of the device or how it fits 
into the market place. 
 
From the research undertaken and reported 
above, what are the most important 
questions or uncertainties that must be 
addressed / tested? What factors or 
assumptions have the calculations / 
economic or clinical case hinged upon? 
What potential benefits or threats have you 
ignored in the calculation (see italicised 
points in Qs 4&5, and ‘developments’ 
section)?  
 Would ACI using ChondroCelect generate more 
than a 100% utility benefit in the two years 
following intervention, as compared with 
microfracture (and is this impact greater than 
other versions of ACI)? This would be necessary 
to ensure short-term cost-effectiveness, unless 
the ChondroCelect procedure could be cheaper 
than current ACI. 
 Would the use of ChondroCelect lead to better 
outcomes in the long term compared to available 
methods of arthroscopic ACI? This would be 
necessary to ensure its long-term health 
economic case. 
 Significant barriers have been identified. In order 
for NICE to recommend ACI it would first need 
long term evidence of effectiveness as compared 
with microfracture. If this could be achieved, 
then ChondroCelect would need to prove to be 
more effective than arthroscopic ACI, as 
procedure costs are likely to be greater (longer 
hospital stay). 
 Can the company afford to develop a product 
which is likely to be launched into a market 
where (at least initially) ACI products are only 
being used as part of clinical trials? 
 Could the ChondroCelect procedure be 
undertaken using arthroscopic means of 
implanting the cultured cells rather than an 
Arthrotomy, as currently indicated? This would 
reduce the service costs involved in undertaking 
the procedure, and put it on an even keel with 
other arthroscopic ACI systems. 
 




Headroom Notes (ChondroCelect) 
No MRP has been calculated, but as an HTA relating to ACIs has already been published within the 
relevant timeframe (the ChondroCelect represents an ‘incremental development’ to other ACI 
procedures), some quite precise qualifications for the reimbursement opportunity have been 
identified.   
If the ChondroCelect procedure could be undertaken by the NHS for the same cost as arthroscopic 
ACI, then the required effectiveness and QoL impact to make it cost-effective would be the same as 
that identified in HTA by Clar et al (Clar et al. 2005) (see pro forma). Although open-knee ACI (which 
is supposedly the method of implantation for ChondroCelect) is a more costly procedure due to 
longer lengths of hospital stay, the NHSC briefing indicates that the procedure could be cheaper 
(though it does not indicate how this would be the case, and compared to what).  If the 
ChondroCelect procedure were to be more expensive than arthroscopic ACI, it would need to prove 
itself to be more effective (by some margin depending on how much more expensive it is).  
As no MRP is delivered, the headroom analysis and what it has to offer to a development decision is 
most concretely presented in the ‘Research Questions’ section.  The output of this section is 
summarised below: 
 If purchasers were to take a short-term perspective, arthroscopic ACI would need to prove with 
two year data to have at least 70% better outcomes than microfracture (at the moment the 
literature does not show this to be the case).  If ChondroCelect is more expensive, it would need 
data to show it is even more effective than that. 
 If this is seen by the developer as feasible, then there is a reasonable case for development.  
However, this should be with the knowledge that the lack of long-term data at the moment 
means that NICE aren’t willing to recommend the procedure unless in the short term ACI is 
proven to be more effective than the current literature suggests. It should also be kept in mind 
that it will probably be 20 years or so until that long term data might become avaialbe, until 
which time ACI is only recommended as part of clinical trials.  
 
Follow-up (ChondroCelect) 
Headroom Outcome and Market success 
Does the MRP look realistic? Would it have indicated yes or no to development? 
No MRP as such was delivered by this analysis. What it did identify was the price and total cost of 
current ACI procedures, and the increased effectiveness over microfracture that would need to be 
achieved (or more pertinently, shown by clinical trial data) for ACI to be the more cost-effective 
treatment, and thus reimbursable by the NHS.   
The purpose of a headroom analysis is to get a better idea of the reimbursement opportunity for a 
specific product which is to be developed in the context of a specific market. ChondroCelect is an 




incremental development of established ACI procedures; in this case a lot of work had already been 
done to collect and summarise the relevant clinical and economic data for the procedure versus 
current practice.  There was even a NICE decision on ACI (which was unfavourable), and a full HTA 
regarding its actual and potential cost-effectiveness. The main lessons and questions generated by 
the headroom pro forma to inform a development decision were those presented in the ‘research 
questions’ section. 
It is difficult to know whether or not the developer would have considered that the criteria given for 
a positive reimbursement case (from a NICE perspective) would have been feasible.  One could 
suppose that as the information used to generate these criteria came from a published HTA and NICE 
guidance, then the developer would have considered this information, and decided to develop in 
light of these potential barriers.  
As indicated by the analysis: if the ChondroCelect procedure were to cost the same as arthroscopic 
ACI, then in the short term it would have to show benefits over microfracture of over 70% (the fact 
that consideration of the procedure alone (open-knee) would cost more than arthroscopic ACI 
suggested that ChondroCelect would probably be more expensive).  As for the long-term, NICE will 
not recommend the procedure for widespread clinical use until long term data is available.  
I cannot guess the thoughts of the developer at the beginning of the development process on the 
potential effectiveness of ChondroCelect over microfracture and other ACI procedures.  However, the 
product does not seem to present a cost-saving case in the short term. A cost-utility analysis 
performed in 2010 by Gerlier et al. presents the costs of microfracture versus ACI using 
ChondroCelect (Gerlier et al. 2010). According to this recent cost-utility analysis, Microfracture costs 
(the Belgian health service) a total of €1,035, compared to ACI using ChondroCelect which costs 
€24,879 (including the whole three step procedure, hospital stay, and cell culture). 
It seems that the use of ChondroCelect poses much higher costs that arthroscopic ACI.  With this 
information, and according to this analysis, the outcomes from the procedure would have to have 
been predicted as much better than microfracture and arthroscopic ACI to warrant investment in the 
current landscape.  
Not able to predict headroom decision with any certainty, but based on its headroom value, and 
realistically what ChondroCelect might achieve, potential for reimbursement seems unlikely.  
 
Has there been a decision made on it by NICE? What was the outcome? 
NICE have not developed new guidance or revisited the guidance on ACI since it published its review 
on the procedure in 2005 (NICE 2005b).  It was due to be considered for review in May 2008, but no 
changes have been made. 
 




Is it sold in the UK or the rest of the world?(Or has it in the past) If so, who is it bought by? 
TiGenix headquarters are in Belgium, but other offices are in Madrid (Spain), Sittard-Geleen (the 
Netherlands) and Cambridge (UK)24.  
ChondroCelect received EU market authorisation in October 2009 (EU/1/09/563/001). The therapy 
has been classified as a tissue-engineered product: ‘a type of medicine containing cells or tissues that 
have been manipulated so that they can be used to repair, regenerate or replace tissue’ (EMEA 
(European Medicines Agency) 2009) 25.  ChondroCelect represented the first Advanced Therapy 
Medicinal Product (ATMP) to be approved and receive European marketing authorisation (ATMP is 
defined as any medicinal product prepared industrially or manufactured by a method involving an 
industrial process (Gerlier et al. 2010)). On their website TiGenix reveal that ChondroCelect is 
reimbursed in Belgium, Germany and the UK (on a case by case basis in the case of Germany and the 
UK) (TiGenix.Living Medicines 2011). A news article from October 2011 reveals that TiGenix have also 
signed an agreement for ChondroCelect distribution in Finland (4-traders 2011).  
In a presentation for the UK National Stem Cell Network in Nottingham, Francois Meurgey presented 
some slides on the difficulty of achieving reimbursement for regenerative medicine products in 
general, and ChondroCelect specifically (Meurgey 2010). In this presentation he says that “in some 
countries the procedure is reimbursed (often as part of DRG26), in most it is not”. Going into more 
detail about the situation in some European countries, Meurguey revealed that negotiations and 
national evaluations were underway, often being proposed to be on the ‘expensive drugs list’ 
(Netherlands), or to obtain ‘innovative status’ (Belgium).  In the UK, he confirms that NICE did not 
recommend ACI and that TiGenix would need to request an STA (single technology appraisal) to be 
reviewed independently by NICE. In the meantime, however, the company are “working with 
orthopaedic surgeons to obtain Pass-Through Payment27 from individual PCTs, and also working with 
private insurance: very positive initial reception from BUPA” (Meurgey 2010).  
ChondroCelect is on the MHRA’s ‘Black Triangle List’, which consists of UK marketed drugs for which 
there is limited clinical trial evidence, and so which are under intensive surveillance by the MHRA 
(MHRA 2011). It first came onto this list in August 2010.  
 
Have there been investigations into its clinical / cost effectiveness? 
What was unclear in the NHSC briefing was the way in which ChondroCelect improved the cell 
culture process that is used for conventional ACI.   Rather than simply expanding the cells that are 
                                                          
24
 Email enquiry sent to the company regarding use of ChondroCelect here in the UK.  Response 
pending. 
25
 Having considered initially that this product might be classified as a medicine, I decided to review 
this anyway as: a) the NHSC had considered it a device, and b) the procedure contains elements of 
medicine, surgery and medical device implantation, so is representative of complex procedures that 
involve many elements. 
26
 DRG: Diagnosis-Related Group. This looks similar to the UK version- HRG (Healthcare Resource 
Groups). They are used as a classification system to aid reimbursement. 
27
 Pass-Through Payments are additional payments that can be sued to support (reimburse) a 
particular device over and above the relevant tariff. These are sometimes used to support the use of 
new products (Pate 2009). 




harvested, this autologous characterised therapy uses characterised viable autologous cartilage cells 
which are expanded, and which express specific marker proteins that reflect their capacity to form 
hyaline-like cartilage (hyaline is the most robust and natural form of cartilage, as opposed to 
fibrocartilage which has poor histological outcome) (Gerlier et al. 2010). It is thought that 
microfracture produces a fibrocartilage repair, which can jeopardise longer term outcomes.  
Saris et al. report on the one RCT that has been performed for ChondroCelect, which is compared to 
microfracture (Saris et al. 2008). Follow-up at 12 and 18 months show no significant difference in 
outcome scores between the two treatments, though use of ChondroCelect was said to be 
associated with superior tissue regeneration, which they hypothesise could lead to improved long-
term clinical benefits.  Indeed, a follow-up at 36 months was published in 2009 which showed that 
improvement in clinical outcomes was greater in the ChondroCelect group compared to 
microfracture (Saris DB et al. 2009).  Van Assche et al. find that two years after surgery, patients’ 
activity levels were similar between the ChondroCelect and microfracture group (Van Assche et al. 
2009). 
A Cochrane review from 2010 considers the evidence for ACI versus other procedures (Vasiliadis & 
Wasiak 2010).  Whilst highlighting the positive outcomes of ChondroCelect at 36 months, they also 
present results from a trial comparing MACI (matrix-guided ACI) to microfracture, which reports 
more favourable outcomes and within a shorter time period (in the ChondroCelect trial improvement 
in functional outcomes was only detected at 36 months). When referring to the Saris report, they 
highlight potential risks of bias because of incomplete outcome data, selective reporting and conflict 
of interest (trial was sponsored by TiGenix and eight of the authors declared a conflict of interest).   
They conclude that there is still insufficient evidence to draw conclusions on the use of ACI, with 
further good quality RCTs with long-term functional outcomes needed (Vasiliadis & Wasiak 2010).  
One discussion paper emphasises the potential adverse effects of the ChondroCelect procedure (and 
ACI in general), and also stress the need for more data ([No authors listed] 2011). 
One cost-utility analysis has been produced for ChondroCelect, using effectiveness data from the 
Saris trial (Gerlier et al. 2010). The perspective taken is that of the Belgian healthcare payer.  Long 
term outcomes are projected, based on the hypothesis that success rates (and risk of long-term 
problems) will relate to presence of hyaline or hyaline-like cartilage (which was found in 44.9% of 
patients at 12 months in the ChondroCelect group and 23.2% in the microfracture group).  They 
derive a utility score from SF-36 questionnaires which were sent to those who participated in the RCT 
two years after randomization.  Using their base-case assumptions, the forty year ICER (€ per QALY) 
was €16,229.  Taking a shorter-term horizon (5 years) this ICER increases to €394,812.  They conclude 
that the relatively high cost of the ChondroCelect procedure should be considered against the longer-
tem benefits. 
 




Has the landscape described changed significantly? 
What is current gold standard clinical practice now? Has this changed? 
Given the fact that the longer-term data (or indeed any short term data that shows ACI to be 
considerably better than other techniques) do not exist, ‘gold standard clinical practice’ has not 
changed.  Although ChondroCelect and ACI in general have been found to have the potential for 
improved outcome, no study or review has provided the evidence to confirm the potential benefits 
of ACI that would make the intervention attractive from a health service perspective.   
In this clinical setting there is still no one intervention that is considered to outperform all others, 
and as such various options exist, both non-surgical and surgical (NHS Choices 2011a).  The fact that 
ChondroCelect is on the MHRA’s surveillance list shows that the product has UK market 
authorisation, and is being utilised in some settings (though perhaps not outside of clinical trial given 
NICE’s recommendations). 
Are there now many direct competitors? 
There are still many companies that provide the cell culture service for an ACI procedure, but the 
only product I have found in the context of characterised chondrocyte implantation is 
ChondroCelect. 
 
Conclusions: How useful might the headroom exercise have been? 
In this example, a health technology assessment produced just one year before the time-perspective 
taken for the headroom analysis meant that much of the work relating to the feasibility of ACI being 
a cost-effective alternative to microfracture had been done. The usefulness of the exercise then rests 
on whether this information would have been picked up by the company anyway (very likely).  
From purely a reimbursement perspective, I believe that the product would not have appeared 
viable (at least if reimbursement was required within the next 20 years or so). This was based on the 
(unrealistically) high comparative benefit that it would have needed to have over microfracture in 
the short term (especially as it is much more expensive even than other ACI procedures), and the un-
willingness of NICE to recommend the procedure without long term effectiveness data.  The 
subsequent evidence has not altered this situation. 
However, this conclusion is based on the supposition that if NICE do not consider it to be cost-
effective, then no UK healthcare provider will provide it.  This seems not to be the case.  As 
mentioned, TiGenix are working with orthopaedic surgeons in the UK to obtain Pass-Through 
Payment from individual PCTs, and also with private insurance companies.  This demonstrates that 
there are alternative methods of reimbursement; these are difficult to grasp in the context of a 
headroom analysis. 
The difficulty of pricing and reimbursement for medical products and the uncertainty of these issues, 
especially for a product like ChondroCelect, is an issue for the developer as well as the headroom 
method.  Meurgey (V-P commercial development of TiGenix) emphasised this in his talk to the UK 




National Stem Cell Network (Meurgey 2010). He said that gaining regulatory approval was the ‘easy 
part’, and that the so-called ‘4th hurdle’ that is Pricing & Reimbursement is possibly the most difficult, 
especially considering the diverse healthcare systems (and languages!) across Europe.  As indicated 
in the above section, there are some special allowances and reimbursement support for novel / 
expensive products, but these of course vary from country to country.  This makes negotiating the 
system very difficult for companies. 
This reimbursement landscape is especially challenging for products such as ChondroCelect, which 
makes use of regenerative medicine.  From an ‘evidence required for reimbursement’ perspective, 
this product has been regarded in the same light as medicines. However, the time horizon needed to 
demonstrate its full benefit may be many years.  This makes the health-economics very difficult. 
Meurguey closed his presentation with the following words: “Unless national authorities 
demonstrate willingness to experiment with conditional reimbursement, there is a real risk that 
regenerative medicine will remain a nice idea without any routine clinical use (or a luxury reserved 

















No NICE follow-up. 
 
Date of briefing: April 
2007 
 
Time perspective of this 
report: 2005 
A lower respiratory tract infection (LRTI) can cause symptoms such as 
shortness of breath, fever, weakness, cough and fatigue.  An LRTI is 
principally associated with acute bronchitis, chronic obstructive 
pulmonary disease (COPD) exacerbation, and community-acquired 
pneumonia.  
 
Using a clinical examination only, it is very difficult to distinguish between 
bacterial and non-bacterial (viral) LRTI.  Levels of the biological marker 
procalcitonin (PCT), which can be detected from blood samples, can 
indicate whether an infection is bacterial, and so whether antibiotics are 
appropriate.  The Brahms Kryptor assay (classic version), which has been 
available since 1997, is a sensitive assay to measure levels of PCT; it can 
produce quantitative results in 19 minutes. Antibiotics can then be 
prescribed or withheld on this basis. 
The Kryptor compact is based on exactly the same reagent system, but is 
smaller, less costly, and easier to maintain that than the classic version. 
 
The Kryptor assay is already used for other diagnostic purposes, especially 
prenatal screening. 
 
2. Comparator  
 
There are no reliable clinical tools to distinguish between bacterial and 
non-bacterial LRTI. Current means of diagnosis (which are not routinely 
indicated) are: sputum culture, viral or atypical organisms’ serology, chest 
x-ray, and C-reactive protein (another biomarker).   
 
The Kryptor compact looks as though it would have the same expected 
effectiveness as the classic version, which isn’t currently used 
systematically for this indication.  This is why the technology represents 
both a new indication (no prognostic tool is currently used: clinical 
examination is the only widely used method of distinction, which is often 
unreliable), and an incremental development (of Brahms’ original version 
of the Kryptor assay).  Therefore, it is possible to use trial results for the 
assay, to try to identify the maximum reimbursable price (for this 
particular clinical indication), and consider whether the new system could 
possibly fit into this space.  
  
The main hypothesis, upon which the usefulness of such a test is based, is 
that currently antibiotics are not being prescribed appropriately to 
patients who present with an LRTI.  In other words, antibiotics are not 
being given to those who would benefit from them (when their LRTI is 
caused by a bacterial infection) and/or patients who would not benefit 
from antibiotics (as the cause of the infection is viral) are being prescribed 
antibiotics.  The large body of literature on this matter paints a picture of 
the latter being the main problem in this area (over-prescription of 
antibiotics) (Gonzales, Steiner, & Sande 1997;SIGN (Scottish 
Intercollegiate Guidelines Network) 2002).  Antibiotics are in too many 




cases used as first-line therapy with no justification. The problem with this 
is three-fold: 
1. Over-prescription means unnecessary costs for the NHS 
2. Unnecessary use increases the risk of patients developing 
bacterial infections in the future that are resistant to antibiotics. 
3. Side-effects associated with antibiotics include nausea, vomiting 
and diarrhoea, so should be avoided unless necessary. These side-
effects also commonly cause repeat visits to the GP (SIGN 
(Scottish Intercollegiate Guidelines Network) 2002).  
 
It is thought that as much as 75% of all antibiotic doses are prescribed for 
respiratory tract infection, even though they are mainly viral in cause 
(Christ-Crain et al. 2004). The World Health Organization (WHO) estimate 
that only 20% of respiratory infections are of bacterial cause (and thus 
warrant antibiotics) (Brundtland 2000).  
 
A prospective, cluster-randomised, RCT that tested the use of the Kryptor 
assay to guide antibiotic treatment for patients presenting with LRTI in 
the University Hospital of Basel, Switzerland, found that antibiotic 
prescription was reduced by about 40% in the procalcitonin guided group 
compared with routine clinical practice (44% versus 83%).  It was also 
found not to compromise clinical and laboratory outcome (Christ-Crain et 
al. 2004). 
 
Two caveats to using this 40% estimate as our assumption for Kryptor 
compact effect on antibiotic use are that: 
1) Clinical practice in LRTI treatment varies from country to country 
(Halls 1993). 
2) The estimate from this trial is derived from an acute hospital 
setting.  It may be that antibiotic use is lower or higher in a 
primary care setting, so the impact may be different (though from 
the studies that I have come across, this initial 83% estimate does 
not seem too far off the situation in primary care also). 
However, it makes sense to use this as an estimate of value for this 
headroom analysis. 
Although it has been mentioned that the side-effects associated with 
antibiotics can be a major cause for repeat visits to the doctor, the data I 
have found for this effect in the literature seem to indicate that this may 
not have a big impact.  One study finds the 30% repeat consultation rate 
that was found for patients with LRTI was not related to whether or not 
they were initially prescribed antibiotics (Holmes, Macfarlane, 
Macfarlane, & Lewis 1997), and another finds that only 9 of the 160 
repeat consultations were due to the adverse effects of antibiotics (Davey 
et al. 1994). Therefore, I will omit this potential effect from the analysis. I 
will also ignore sensitivity and specificity issues, and base the estimates 
directly on the findings of the trial where a 40% reduction in antibiotic 
prescription was achieved with no effect on outcome.  
 
 




3. Market size  As LRTIs are so broad in definition, it is very difficult to estimate the 
number of episodes per year.  One UK study estimated (by extrapolating 
data from one general practice) that there are around 1,700,000 LTRI 
cases in England & Wales between the ages of 16 and 79 (Macfarlane et 
al. 1993). 
Market size per year (NHS England & Wales: Adults) : 1.7 million 
 
4. Health Service 
 
Changes in resource use.  Any changes in 
service delivery costs to the NHS that will 
result from the application of the new 
technology, including the disinvestment in 
previous practice.  This could include: Staff 
time, hospital bed days, GP visits, A&E visits, 
etc.  It should not include services for which 
the NHS (and personal social services) is not 
financially liable (e.g. lost productivity and 
[non-health] social care costs), but these 
should be noted in writing below to add to 
the verbal case for the product (NICE may 
incorporate social care costs into cost-
effectiveness estimates in the near future). 
 
 If relevant and not included in service cost 
impact above, search for price of the 
currently used product (P1). 
 
Use HCHS index to inflate estimates to 

















One cost-of-illness study estimated that LRTIs cost 
the NHS £1,364 million a year: 0.5% of the NHS 
budget (Guest JF & Morris A 1996).  
Antibiotic cost per patient is likely to vary greatly 
according to type and severity of LRTI; the antibiotic 
cost of a patient admitted to hospital for community-
acquired pneumonia was on average £155 in 1997 
(Guest & Morris 1997); whereas the cost of one 
course of Amoxicillin (first-line treatment of a chest 
infection) is only £1.85 (Prodigy 2005a).  
 
As indicated above from the RCT reported by Christ-
Crain et al., antibiotic prescription was reduced by 
about 40% (Christ-Crain et al. 2004). For those in the 
procalcitonin-guided group who were prescribed 
antibiotics, treatment duration was also shorter (10.9 
days versus 12.8) than the standard treatment group.  
This all led to total mean antibiotic cost per LRTI 
patient of $96.3 (£50) for the procalcitonin-guided 
group versus $202.5 (£106)28 for the control group (a 
52% reduction). 
 
Another study finds an average cost per treatment 
across the various antibiotics treatment options of 
£19.37 (Lavoie et al. 2005)29. 
 
Estimates of antibiotic treatment cost seem to vary 
greatly according to source of information (probably 
due to the different settings in which they were 
acquired). I will use the 52% reduction in antibiotic 
cost found per LRTI patient (as shown by the Kryptor 
assay RCT (Christ-Crain et al. 2004)) to assess the 
value of this prognostic test given varying 
assumptions of antibiotics cost.  As this cost 
reduction was found for the average LRTI patient 
(rather than the average per patient treated with 
antibiotics), I will multiply the assumed antibiotic 
costs by 0.8 to estimate the initial ‘average cost of 
antibiotics per LRTI patient’ (assuming that about 
                                                          
28
 Converted to pounds sterling at the exchange rate in Jan 2005: $1.9129 
29
 $37.06 converted to pounds sterling at the exchange rate in Jan 2005: $1.9129 









































Describe any potential costs/savings that 
you haven’t quantified.  
80% of patients are initially prescribed antibiotics, as 
per trial data), and multiply this by 0.52 in order to 
estimate the costs saved per LRTI patient. 
 
Cost per antibiotic course (in bold): 
- £2: (£2*0.8)*0.52 = £0.83 saved per patient 
- £10: (£10*0.8)*0.52= £4.16 saved per patient 
- £20: (£20*0.8)*0.52= £8.32 saved per patient 
- £50: (£50*0.8)*0.52= £20.80 saved per patient 
- £100: (£100*0.8)*0.52= £41.60 saved per patient 
- £150: (£150*0.8)*0.52= £62.40 saved per patient 
 
The ‘saved per patient’ figures above thus represent 
the NHS resource savings in antibiotic costs, resulting 
from reduced antibiotics prescriptions (and according 
to the initial cost of those antibiotics).  To estimate 
the yearly total resource saving, the appropriate 
figure would be multiplied by the total number of 
LRTI patients seen by clinicians in a given year.  This is 
likely to be in-between the extremes presented. 
 
Cost of average antibiotic course for LRTIs: £2 
(Total) ∆SC= £1,411,000 




Cost of average antibiotic course for LRTIs: £150 
(Total) ∆SC= £106,080,000 




These represent the total and per patient savings 
considering the number of (adult) LRTI episodes in 
England & Wales per year. 
  
Another important benefit of reducing antibiotic 
prescriptions, aside from the direct cost savings 
estimated above, is the antibiotics resistance 
problem.  Where antibiotics are prescribed 
unnecessarily, the body can be at further risk of later 
developing bacterial infections that are resistant to 
antibiotics. This causes problems when trying to treat 
subsequent infections, but the precise cost of this in 
terms of increased medication and treatment costs 
would be very difficult to define.  The fact that 
antibiotic costs should include consideration of side-
effects of treatment and long term costs resulting 




from bacteria resistance to antibiotics is emphasised 
in a pharmaco-economic paper by Delporte (Delporte 




Potential impact of the new device on 
patient health, as compared to current 
practice (preferred method of elicitation is 
from studies using the EQ-5D).   
Where NICE have not produced relevant 
economic analyses, search for cost-
effectiveness studies or systematic reviews 
within the disease area (the CEA registry 

























Describe any impact on patient health that 
you haven’t quantified.  
The hypothesis upon which this analysis is based, is 
that by making sure antibiotics are prescribed 
appropriately, antibiotics use will go down but with 
no impact on outcome (i.e. those patients that would 
previously have received antibiotics but whose 
infection is of a viral nature, will not experience any 
reduced therapeutic benefit by not receiving the 
medicine).  This was confirmed in the trial which used 
the Kryptor assay to guide antibiotic prescriptions.  It 
has also been argued though that outcomes could 
actually be improved, given the side-effects that can 
be caused by antibiotics which could be avoided 
where unnecessary, as determined by the Kryptor 
assay.  As described in section 2, I have decided to 
omit these from this analysis on both the cost and 
patient benefit fronts, as the literature seems to 
indicate that this does not have an obvious impact on 
the health service.  The effect of procalcitonin-guided 
therapy from a patient’s perspective was investigated 
in the RCT reported by Christ-Crain.  As part of the 
study they had all patients fill in a QoL questionnaire 
and visual analogue scale (marking how they felt 
between 0% [feeling very ill] and 100% [feeling 
completely healthy]) on admission and at follow-up.  
The HRQoL estimated, and changes in this from 
before and after treatment, were not significantly 
different between the two treatment groups.  Adding 
to this the fact that potential side-effects are very 
diverse in nature and impact, it does not seem 




(Av. per person) ∆QALY= 
 
The potential for reduced morbidity from limiting 
antibiotics side-effects (although not identified in the 
RCT), have been ignored here, as has the reduced risk 
of patients being faced with future infections that are 
resistant to treatment. 
 
6. Developments (clinical & healthcare 
context) 
 
 [GREEN] LRTI accounts for a greater number of 
GP consultations each year than any other illness. 
Many of these cases are self-limiting and can be 




Consider the following questions to help you 
think about the space for your product 
within the market.  
 
Does the technology address any key national 
objectives for improving care in this area? 
 
How will the technology complement current 
practice? Is current practice likely to change? 
 
Are there any indications in the literature of 
potential effectiveness? 
 
Have you identified any direct competitors? (This 
could be another specific technology, or simply a 
different technique)  
 
 RED: Poses a significant threat to the 
opportunity identified in the market (i.e. 
works against current health service 
objectives, or there are other products 
being developed that are associated with 
better outcomes or are at a more advanced 
stage of development). 
 
AMBER: Potential threat 
 
GREEN: Further supports the case for the 
new technology  
managed at home, but antibiotics are often 
prescribed for clinical reasons that have no 
evidence-base, or non-clinical reasons such as 
patient expectation, or to reduce re-attendance 
(SIGN (Scottish Intercollegiate Guidelines 
Network) 2002). 
 
 [GREEN] The overuse of antibiotics, leading to 
antimicrobial resistance, is now a world-wide 
phenomenon which must be controlled. A 
message from the director-general of the World 
Health Organization in 2000 emphasised the 
need for a global effort to tackle this issue 
(Brundtland 2000).  
 
 [AMBER] Some experts propose that antibiotics 
are not even always necessary for patients with 
bacterial infections (Hopstaken, Coenen, & Butler 
2005). 
 
 [AMBER] One retrospective analysis conducted in 
2004 showed that winter antibiotic prescribing 
for LRTIs in England and Wales had shown a 30% 
decline since 1995/6.  They found that this 
reduction had a small but significant association 
with the increase in pneumonia mortality (Price 
et al. 2004). This puts into question the 
assumption that a reduction in antibiotics 
prescriptions will have no effect on outcome, 
though it could be argued that this change was 
made in the absence of effective guidance, which 
the Kryptor compact could provide.  The general 
decline in antibiotic use described in the report, if 
found to be generalisable, could reduce the 
impact of the Kryptor assay. 
 
7. Research questions 
 
This should be a list of the things that the 
developer needs to find out or monitor 
during the process of development, relating 
to the function of the device or how it fits 
into the market place. 
 
From the research undertaken and reported 
above, what are the most important 
questions or uncertainties that must be 
addressed / tested? What factors or 
 This analysis has been based on the efficacy 
results from a trial on the Kryptor assay, Brahm’s 
original model.  It has been assumed that the 
new model (Kryptor compact) has the same 
impact as the original model.  Is this an 
appropriate assumption? 
 The reason that the MRP has not been taken as 
simply the price of the original Kryptor assay, is 
that it is not used as part of widespread clinical 
practice, and so is not the appropriate 
comparator in terms of its value proposition to 
the NHS.  Why is the original Kryptor assay not 




assumptions have the calculations / 
economic or clinical case hinged upon? 
What potential benefits or threats have you 
ignored in the calculation (see italicised 
points in Qs 4&5, and ‘developments’ 
section)?  
used in routine clinical practice?  Is it anything to 
do with issues that the new model (supposedly 
cheaper, smaller, and easier to maintain) would 
address / change?    
 Is the proposition of this new development to the 
company more an issue of simple product 
evolution, and changes that the company must 
make to keep their products up to date or 
dominant in the market place? It its 
consideration in terms of clinical value 
inappropriate? 
 Does the estimated reduction in antibiotic 
prescription as a result of the Kryptor assay, that 
was found from a trial based in Switzerland, 
seem appropriate and relatable to the situation 
in the UK? 
 To what extent might these parameters (cost and 
rate of antibiotic prescription) change according 
to setting? (primary/secondary care?) 
 The estimated patient population includes adults 
aged between 16 and 79. What about patients 
outside of this age bracket? This could widen the 
market. 
 Is the introduction of such a diagnostic test 
feasible in a primary care setting? To what extent 
would the service need be centralised? 
 How many devices would be required to service 
all LRTI episodes, and how long would the piece 
of equipment last? Estimates of these would be 
required in order to calculate a maximum 
reimbursable price (MRP) per device. 
 Could the cost and patient value of antibiotics 
side-effects, and later treatment resistance, be 
quantified? If it could, then this may well add to 
the headroom for the Kryptor compact. 
 Is standard practice likely to change? All relevant 
LRTI guidance proposes the careful use of 
antibiotics for LRTI patients. Is this changing the 
landscape for antibiotics prescription of the 
future? This may affect the impact of the Kryptor 
compact. 
 Although in most cases the LRTI is self-limiting, it 
is indicated in the literature that a big reason for 
over prescription of antibiotics is patient 
expectations (patients want to feel like they are 
being treated).  Clinicians are bound to respond 
to this expectation and also feel like they should 
be actively treating the patient’s symptoms.  Is 
this phenomenon likely to change, and to what 




extent might the initiation of the serum test 
(Kryptor compact assay) be likely to overcome 
this?  
 This analysis looks only at the value of the 
Kryptor compact in this specific market (LRTIs).  
The company are already aware that the 
technology is in demand in this context of other 
disease areas, so the value to the NHS of this 
device is by no means limited to this market. 
Headroom Notes (KRYPTOR compact) 
The headroom analysis allowed me to estimate the value to the health service per patient of the 
more appropriate prescription of antibiotics using the Kryptor compact assay.  As the average cost of 
antibiotics per LRTI treatment to the NHS was uncertain, the value across a range of estimates was 
calculated.  These are three of these estimates: 
Cost per antibiotic course  Headroom per LRTI patient (i.e. 
value to NHS of the Kryptor 
compact, on a per patient 
basis) 
Total headroom (value to the 
NHS of using the Kryptor 
compact to guide antibiotic 
treatment, based on an adult 
LRTI incidence of 1.7 million per 
year) 
£2 £0.83 £1,411,000 
£20 £8.32 £14,144,000 
£150 £62.40 £106,080,000 
 
The basis of this value is the reduced spending on antibiotics.  Considering this information in the 
context of a development decision would require the developer to have an understanding of the 
average cost of antibiotics, and what the best estimate might be across the whole LRTI population 
(assuming that the device is to be marketed across all NHS services).  The value described by the 
numbers presented must cover the cost to the health service of consumables such as materials, 
technician time etc. per test. 
In order to calculate an MRP per device, we would need an understanding of how many of the 
devices would be needed to service all LRTI patient serum samples, the consumables cost per test, 
and the number of years that one Kryptor compact system is likely to last.      
In terms of a development decision, even if we were able to estimate an MRP per device, and the 
cost of consumables, it would not be considered in the same way as other examples.  The baseline in 
terms of NHS value is ‘no useful test’, but for Brahms the baseline in terms of development is their 
previous model of the Kryptor assay.  This means that development costs are likely to be relatively 
minimal, and such an evolution may in any case be natural (not requiring a value analysis of this 
sort). 




As indicated by the wide-ranging estimates of headroom above, the value of such a device would 
probably vary greatly according to treatment setting.  If, as indicated by the literature, cost of 
antibiotic treatment is greater in a hospital setting, then the value created by the Kryptor compact is 
going to be greater in this setting.  This may be of consideration in development/distribution 
decisions. 
Follow-up (KRYPTOR compact)  
Headroom Outcome and Market success 
Does the MRP look realistic? Would it have indicated yes or no to development? 
The headroom analysis could not deliver an MRP per device, due to the lack of information regarding 
the likely / feasible distribution strategy for the Kryptor compact (i.e. how many samples would each 
device process per year?), and also how long it is likely to last.  However, by using estimates of 
antibiotics prescription impact from an RCT of the Kryptor compact’s predecessor (the classic Kryptor 
assay), the value per patient was calculated. A range of values was presented, assuming different 
antibiotics cost. This ranged from a value per patient of 83 pence up to £62.40.  The lower of these 
values was based on an antibiotic treatment course cost of £2 (supposedly the first-line treatment 
for LRTI), whereas the higher estimate was based an antibiotic cost of £150, which is close to that 
estimated for hospitalised pneumonia patients. 
 
The “average” antibiotics cost per patient is likely to fall somewhere in-between these two extremes, 
but will certainly vary in relation to clinical setting.  The cost of antibiotics for patients who are more 
severely ill from their respiratory infection will on average be higher than those who go to their GP 
with mild symptoms. It is probable, therefore, that the Kryptor compact could fetch a higher price if 
aimed at a secondary care setting.  Although I cannot anticipate the likely cost per patient for 
diagnosing patients with the Kryptor assay (especially given my lack of understanding of the number 
of samples processed by each device), 83 pence seems like a small reimbursement opportunity, 
especially as this would have to cover the service costs involved in the process e.g. lab costs, 
transport if required, time, etc.  Therefore, the reimbursement opportunity seems much greater/ 
more likely in situations where the cost of antibiotics is relatively high.   
 
In terms of the ‘yes or no to development’ aspect of this headroom analysis, this represents a bit of a 
special case.  The baseline in terms of clinical value was ‘nothing’ (i.e. no other useful diagnostic test 
is used to determine bacterial/viral cause of infections), and that’s why the Kryptor compact 
represented a ‘new indication’ in this respect.  However for the company, the Kryptor compact is an 
incremental development of their previous model.  Therefore, the development costs are likely to be 
minimal.   Also, the Kryptor can be / is already used for several diagnostic purposes, such as in 
prenatal setting; this will at least increase the market for the Kryptor compact, but it could also scale-
up the value of the device dramatically if one unit can serve several different indications.   
 
The actual cost per procalcitonin measurement using the Brahms Kryptor is about £15 according to 
the company, as reported by a PASA economic report (CEP 2010) (this includes assay material, 
reagents, technician time, and purchase / maintenance of bench-top analyser).  However, the use of 
procalcitonin testing usually requires repeat testing within 6 to 24 hours, and Brahms indicates that 
two tests are likely to be sufficient. This means an actual cost of about £30 per patient tested.  This 
indicates that at the lower estimate of antibiotics cost, the reimbursement opportunity per test as 




indicated by the headroom analysis would have fallen far short of what would be required to support 
the test in clinical practice.  The upper range of these estimates, however (i.e. where the cost of 




Headroom unfavourable for situations where antibiotics are likely to cost under £70 per course 
(assuming negligible development costs being needed to be made back).  Headroom seems 
favourable for cases where antibiotics costs are high. This may indicate that the secondary care 
setting might provide a viable setting for the Kryptor compact. 
Has there been a decision made on it by NICE? What was the outcome? 
No NICE guidance has been issued for this technology specifically.  In 2008, NICE produced a clinical 
guideline on ‘Prescribing antibiotics for self-limiting respiratory tract infections in adults and children 
in primary care’ (NICE 2008a).  In this guideline they emphasise that whilst prompt antibiotic 
treatment may have been relevant in the past, in modern times rates of complication are low; the 
fact that most people presenting in primary care with an acute uncomplicated RTI receive antibiotics, 
is no longer appropriate.  They recommend a strategy of no antibiotic / delayed antibiotic prescribing 
in all cases except for: bilateral acute otitis media in children under 2 years of age or in children with 
otorrhoeia, or acute sore throat/phayngitis/tonsillitis when three or more Centor criteria are present. 
In these cases, antibiotics should be prescribed immediately.  In a costing report that was issued as 
part of this guideline, it was estimated that, if implemented, £3,678,000 of savings could be realised 
due to the reduced antibiotics costs. 
In May 2007 NICE issued a clinical guideline for ‘Feverish illness in children’ (NICE 2007a).  A research 
recommendation was that the performance and cost-effectiveness of procalcitonin versus C-reactive 
protein (another inflammatory marker) for identifying serious bacterial infection in children with 
fever without apparent source should be investigated. 
In July 2007 the topic of serum procalcitonin as a marker for respiratory LRTI was considered by the 
NICE TA committee but was referred to the national coordinating centre for HTA (NCCHTA).  
 
Is it sold in the UK or the rest of the world?(Or has it in the past) If so, who is it bought by? 
When looking up the Brahms product range it is clear that the Kryptor assay has been developed for 
many indications, the list of which includes Intensive care and emergency medicine, Thyroid diseases, 
Tumour markers and Prenatal screening (categories which comprise 5 to 14 individual tests). In fact, 
the procalcitonin test is only listed as one of the three products in ‘Other Parameters’ (BRAHMS 
2011b).  On their own website, they describe the Kryptor compact as ‘a fully automated random-
access immunoassay system, offering optimal analytical precision as well as maximum economic 
efficiency’ which was developed ‘to meet the needs of today’s laboratories’ (BRAHMS 2011a).  The 
company has distribution partners across the world. As well as Brahms PCT assay for the Kryptor 
system, the company also have agreements with other companies (DiaSorin S.p.A, bioMerieux A.A., 
Siemens Medical Solutions Diagnostics and Roche Diagnostics GmbH) to provide / distribute the PCT 
assay compatible with these various other systems (BRAHMS 2008;Thermo Scientific 2011). 





Have there been investigations into its clinical / cost effectiveness? 
A news article published on several biomedical websites in July 2009 reported that the Kryptor 
Compact had been successfully proven in the context of risk assessment for Down’s syndrome in first 
trimester screening; the King George hospital in Essex conducted an evaluation of the Kryptor 
Compact and found the results to be interchangeable with the classic system, with performance 
“equally as good”, being the instrument of choice for 1st and 2nd trimester screening (Buchholzer 
2009).  Apart from this article, I have not found the Kryptor compact mentioned specifically (the 
system is simply referred to as the Brahms Kryptor system).  This is not surprising, but we are at least 
assured that the assumption of equivalent performance seems to be well founded. 
Clinical effectiveness 
There have been five major RCTs which have tested the use of procalcitonin-guidance for antibiotic 
prescription versus standard care in a clinical setting, one of which was discussed in the headroom 
analysis (Christ-Crain, 2004).  The other four RCTs were also all based in Switzerland, and all used the 
Brahms Kryptor assay for treatment guidance.  The following is a summary of findings: 
 Briel  (2008, LRTIs, primary care) found an absolute reduction in antibiotic use of 72% (Briel 
et al. 2008). 
 Christ-Crain  (2006, community-acquired pneumonia, emergency department) found an 
absolute reduction in antibiotic use of 14% (Christ-Crain et al. 2006). 
 Stolz  (2007, COPD exacerbations, emergency department) found an absolute reduction in 
antibiotic use of 32% (Stolz et al. 2007). 
  Schuetz  (2009, LRTI admissions, tertiary care hospitals) found an absolute reduction in 
antibiotic use of 13% (Schuetz et al. 2009). 
These show variable results, and the trial results that I used sit somewhere in between these 
estimates (I used results from the RCT reported by Christ-Crain in 2004 which found a 39% reduction 
in antibiotic use, which translated into a cost-saving for antibiotic spend of on average 52% per 
patient admitted). None report any changes in outcome. 
Cost-effectiveness 
An economic report was produced by the NHS purchasing and supply agency (PASA) in March 2010 
(CEP 2010) (presumably the result of the referral by NICE of the topic to the NCCHTA).  Their analysis 
uses the following assumptions: 
 Average cost of antibiotics: £16.63,  
 86% of patients are prescribed antibiotics in routine clinical practice, 
 Cost per tested patient is £30 (based on estimate by Brahms), 
 Sensitivity & specificity are 76%, and 
 20% of LRTIs have a bacterial cause. 
They calculate that it costs an additional £51 to correctly treat (by either giving or withholding 
antibiotics) a patient using the procalcitonin test (as compared with standard care).  Like the 
headroom analysis, the report does not quantify any outcome measures, but urges the reader to 




consider this cost alongside potential benefits achieved, which include the reduction in side-effects 
of antibiotics and the reduced likelihood of further antibiotic-resistant strains of bacteria (CEP 2010).   
A more recent cost-effectiveness analysis which uses published estimates of the impact of 
procalcitonin guidance on antibiotic usage, calculates that the point at which the cost of testing 
equals the cost of antibiotics saved is when daily antibiotics cost Can$148.26 (about £80)30 (Heyland, 
Johnson, Reynolds, & Muscedere 2011).   
I found two UK based (non-randomised) studies. Bignardi et al. applied the Kryptor analyser for two 
months and found that savings in antibiotic use (£1,306) did not cover the cost of testing (£6,570) 
(Bignardi et al. 2006). The reason for this was that the antibiotics discontinued were mainly 
inexpensive oral antibiotics (e.g. doxycycline and amoxicillin).  By contrast, Saeed et al. found that, by 
applying the PCT test to those admitted to the intensive care unit of The Royal Hampshire County 
Hospital in Winchester, there was a net saving of about 17% (Saeed et al. 2011).  
The results of these clinical and cost-effectiveness analyses confirm the headroom analysis results; 
that the test would only be cost-effective where the antibiotics courses that are discontinued as a 
result of the test are expensive. The literature also supports the decision to leave aside outcome 
issues from the quantified analysis, leaving these for ‘value judgement’ only.    
Has the landscape described changed significantly? 
What is current gold standard clinical practice now? Has this changed? 
In their clinical guideline on prescribing antibiotics for respiratory tract infections, NICE indicates that 
a no antibiotic / delayed antibiotic strategy should be applied where patients in primary care present 
with acute otitis media, acute sore throat/phatyngitis/tonsillitis, common cold, acute rhinosinusitis, 
or acute cough / acute bronchitis (NICE 2008a).   If this were to be systematically undertaken across 
the health service, it is likely to reduce the overall prescription rates of antibiotics under ‘standard 
clinical practice’, and thus reduce the savings that could result from the Kryptor compact (or any PCT 
test).     
Blood tests taken for procalcitonin analysis do not seem to be widely applied in clinical practice in the 
UK.  NICE guidelines do not mention the use of serum tests, and advice to patients presented by ‘NHS 
Choices’ indicates that clinical diagnoses of chest infections still rely predominantly on symptom 
analysis (NHS Choices 2010a); blood tests (‘to identify the germ that is causing your infection’) is only 
mentioned among the list of ‘further testing’, which may be required only if chest infection 
symptoms are severe. 
 
Are there now many direct competitors? 
Although all of the RCTs identified considered PCT testing using the Brahms Kryptor assay, the 
economic report by CEP identified other suppliers: Siemens, Roche and BioMerieux (though I found 
that Brahms appears to hold license agreements with these companies).   
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 Cost results from this study were reported in Canadian dollars at 2009 prices. In December 2009 
the exchange rate was 1.8573CAD to the pound. 




C-reactive protein (CRP) is another biomarker that has been found to be associated with bacterial 
infection, and has also undergone trials.  However, a meta-analysis conducted by Simon et al find 
procalcitonin to be more accurate (more sensitive and specific) than CRP in the diagnosis of bacterial 
infection (Simon L et al. 2004).  
Conclusions: How useful might the headroom exercise have been? 
 
The headroom analysis considered the case for developing the Kryptor Compact, which was 
described in the NHSC briefing and became available in 2007.  Although this model was an update of 
a previous version from the same company, from a health economic perspective the base-line 
comparator was standard clinical practice, which did not appropriately discriminate between 
bacterial and viral infections, and thus led to a situation of over-prescription of antibiotics.   
 
As the classic Kryptor assay had already been tested in a clinical trial, I was able to use the results of 
this directly to estimate the headroom per LRTI patient for the Kryptor Compact. Relating this to the 
actual cost per patient tested with the Kryptor of £30 (though it is unclear which model this is based 
on), the result of the headroom would have been that the device only looked cost-effective to the 
NHS if antibiotic costs were over £70 (development costs may be minimal, as the Kryptor compact 
represents an incremental change to a previous model).  This would have indicated to the company 
that the test may be appropriate for high-risk infections where antibiotic prescription costs are large, 
but not as part of general routine clinical practice.   
 
Indeed, blood tests are not recommended in current clinical guidelines for the routine management 
of LRTI patients in the community (NICE 2008a).  
 
Although the headroom analysis reflected reasonably well the clinical and economic studies that 
have since been published on the Kryptor system, taking the entire follow-up into consideration, it 
may be that the headroom method was not relevant / well suited to this case, for the following 
reasons: 
 
1. The Kryptor compact has a wide spectrum of clinical applications.  The headroom 
analysis considered its clinical and economic value in relation to this specific market 
which, although perhaps useful for the company in understanding reimbursement 
opportunity for this particular indication, is not useful as the sole determinant of a 
Go/No-Go development decision. 
2. The decision to develop the Kryptor Compact probably represented a natural evolution 
of the company’s product portfolio, and the desire to keep their technologies up-to-date 
and competitive.  A headroom analysis may have seemed redundant if this is the case. 
3. The business and implementation context of this diagnostic test is clearly much more 
complicated than a headroom analysis can fathom/reflect.  Not only is the question of 
number-needed (to serve whole population) a problem, but the follow-up has brought to 
light that the company have licence agreements with other companies and providers, 
and that distribution is not straightforward.  
 
 













No NICE follow-up. 
 
Date of briefing: Dec 
2006 
 
Time perspective of this 
analysis: 2004 
 
Acute decompensated heart failure (ADHF) is a common cause of acute 
respiratory distress, and is often associated with an accumulation of fluid 
(‘volume overloaded state’). A sufferer of congestive heart failure (CHF) 
may easily decompensate (where the heart fails to maintain adequate 
blood circulation).   It is thought that approximately 1-2% of healthcare 
budgets in developed countries are spent on heart failure, and that in the 
UK, 66% of this spend is accounted for by hospitalisations (Varney 2001). 
 
Ultrafiltration using the Aquadex FlexFlow aquapheresis system (by CHF 
solutions) is for patients with ADHF who are unresponsive to 
‘conventional therapies’, or those with very severe peripheral oedema 
and fluid overload.  
 
It is a portable, trolley based device which removes excess water and salt 
from a patient’s circulation (much like the set-up of a dialysis system), and 
can be performed in a hospital ward or outpatient department.  Each 
treatment lasts approximately 24 hours (multiple treatments may be 
required per patient). 
 
Being able to reduce the fluid overload associated with ADHF will help the 
heart to work more efficiently, and thus maintain perfusion to vital organs 
(Southworth 2003). 
 
2. Comparator  
 
Diuretics are the first-line management for patients with ADHF; they are 
the cornerstone therapy for these patients as they help to manage fluid 
overload.  Two types of drugs, IV vasodilators and IV inotropes, are used 
as adjunct therapy for patients hospitalised with ADHF.  Treatment of the 
precipitating cause is also important.  
When patients do not respond to diuretics therapy, management can also 
include conventional ultrafiltration which, unlike the Aquadex FlexFlow, 
requires high blood flow rates and is used mainly in intensive care units.  
 
Although diuretics are usually effective in controlling fluid overload, the 
management of patients who do not respond to conventional drug 
treatment is presenting an increasing problem for clinicians (Lécluse et al. 
1999).  It is thought that as many as a third of CHF patients become 
resistant to diuretics; what’s more, resistance occurs most frequently in 
moderate and severe CHF patients, making this a serious problem 
(Ravnan, Ravnan, & Deedwania 2002). Although trying different 
combinations of drug therapies can help to overcome this resistance, 
including inotropic support (though the effectiveness of this drug in 
diuretic resistance is not well established), the issue makes the need for 
an alternative ever more important.      
 
It is difficult to know in this case whether to consider the standard 
pharmacological therapy (diuretics, with vasodilators or inotropes added 




in hospital care) as the gold standard of clinical practice, and thus the 
appropriate comparator for this analysis, or whether to take as a baseline 
conventional ultrafiltration (which must be carried out in an intensive care 
unit).  On the one hand, ultrafiltration/aquapheresis is not included in the 
“treatment options” of a review by Southworth (Southworth 2003) and 
other recent summaries of treatment for refractory patients (Ravnan, 
Ravnan, & Deedwania 2002), is not mentioned in the NICE clinical 
guideline for heart failure produced in 2003 (NICE 2003a), nor is it 
included in the guidelines produced by the American College of 
Cardiology for the Evaluation and Management of heart failure (Williams, 
Bristow, Fowler, & et.al. 1995). 
On the other hand, in 2007 this technology was submitted to the 
technology appraisal team within NICE but rejected, and Ultrafiltration 
seems additionally to have been submitted to the Interventional 
Procedures team, but was rejected as it was ‘not in remit’; the reason for 
this was that ultrafiltration / aquapheresis was regarded as a “minor 
modification of an existing procedure which is considered established 
clinical practice with risks and benefits that are sufficiently well 
known”(NICE 2010f).  They do not, however, explain the context of this 
statement, and whether they refer to its use in ADHF patients.    
 
The NHSC document refers to the Aquadex  in relation to both of these 
potential comparators: 
 Conventional ultrafiltration requires high blood-flow rates and large 
bore vascular access, and is therefore mainly used in intensive care or 
renal departments.  Aquadex can be used in a normal ward 
environment, or outpatient department. 
 Compared with standard care, it is thought that the Aquadex could 
reduce length of stay in hospital and reduce readmission rates. 
 
Small clinical studies of ultrafiltration (sometimes referred to as 
haemofiltration or peritoneal dialysis [though this is slightly different]) 
date back many years to at least the 1960s (Cairns et al. 1968), but the 
principles of ultrafiltration were described even earlier in the 1940s.  
There were many publications through the 1970s, 80s and early 90s of 
individual patient cases (Morgan, Mansell, & Thompson 1985) and very 
small clinical studies (Asaba et al. 1978;Kramer et al. 1980;Sagliaschi et al. 
1992;Simpson et al. 1987;Simpson & Hutton 1987),  which showed the 
usefulness of ultrafiltration in refractory ADHF patients (diuretic-
resistant).  In 2001 Ellison (Ellison 2001) mentions mechanical 
ultrafiltration for the treatment of diuretic resistant CHF patients, but 
more recent literature on this has been limited.  In the literature that 
relates to ADHF treatments more widely, ultrafiltration is either not 
mentioned, or mentioned in passing and without great detail relating to 
the extent to which it is actually used in clinical practice. 
 
So, whilst it has been around a long time, conventional ultrafiltration still 
does not seem to be part of mainstay clinical practice. I found one paper 
from 1989 that related to the cost-effectiveness of ultrafiltration (said to 




be “highly cost-effective), but could only access the abstract, and got no 
indication of what this statement was based on (L'Abbate et al. 1989). 
One paper considers why ultrafiltration has tended to be overlooked, and 
why official clinical guidelines have tended to ignore the management of 
refractory patients. Sackner-Bernstein and Obeleniene (Sackner-Bernstein 
& Obeleniene 2003) propose three reasons: firstly, the requirement of 
central access has meant that ultrafiltration has needed to be delivered in 
an intensive care unit (putting a strain on resources); secondly, this type 
of intervention has tended to be focused toward nephrology (kidneys) 
rather than used by cardiologists (so might be met with some resistance), 
and; thirdly, clinical cardiologists are used to considering pharmacological 
rather than mechanical treatments for their patients.  The Aquadex 
FlexFlow could overcome the first barrier by allowing ultrafiltration to be 
offered in more a accessible and less expensive setting (the ward or 
outpatient department), and if it can be proven to be both effective and 
cost-effective, then clinicians may embrace such a procedure, as a way to 
treat their refractory patients for whom currently there are few options.  
 
The Aquadex FlexFlow is intended as a treatment option for those who do 
not respond to diuretics, rather than a complete replacement of diuretic 
therapy, which is relatively cheap and well supported by evidence. 
Therefore, it would be appropriate to conceptually place the Aquadex in 
the context of diuretic resistance, and the outcome of those patients who 
are not well managed by current therapy. However, I have found no 
assessment of the impact of diuretic resistance on outcomes.   
 
3. Market size  It is estimated that as many as one third of patients develop resistance to 
diuretic therapy.  Lloyd et al. estimate that there are about 181,000 
hospitalised CHF events every year (Lloyd, Schmieder, & Marchant 2003). 
This means that a potential 60,000 could be indicated for ultrafiltration 
using the Aquadex FlexFlow.   
 
Market size (UK) per year: 60,000 
 
I have rounded this estimate down, as the NHS hospital cost of an acute 
CHF event that was reported alongside this incidence figure, was £1,337.  
This seems very low for ADHF events compared with estimates I have 
found in the literature. Therefore, it may include a wider range of CHF 
events than those that could be relevant for the Aquadex. This may still 
be a very optimistic estimate considering the low current uptake of 
ultrafiltration in clinical practice. 
 
4. Health Service 
 
Changes in resource use.  Any changes in 
service delivery costs to the NHS that will 
result from the application of the new 
technology, including the disinvestment in 
Although the literature does not facilitate a precise 
estimate of potential costs that may be saved by 
treating patients with a new intervention like the 
Aquadex, either compared to conventional 
ultrafiltration or to conventional pharmacotherapy, 
one study indicates that the effect of Aquadex 




previous practice.  This could include: Staff 
time, hospital bed days, GP visits, A&E visits, 
etc.  It should not include services for which 
the NHS (and personal social services) is not 
financially liable (e.g. lost productivity and 
[non-health] social care costs), but these 
should be noted in writing below to add to 
the verbal case for the product (NICE may 
incorporate social care costs into cost-
effectiveness estimates in the near future). 
 
 If relevant and not included in service cost 
impact above, search for price of the 
currently used product (P1). 
 
Use HCHS index to inflate estimates to 































treatment might be comparable for both of these 
baseline comparaotors (in terms of the incremental 
effect on hospital resources, not taking into account 
the costs of the interventions themselves).  
 
As indicated in the NHSC briefing, the Aquadex would 
allow for treatment in the ward environment rather 
than in an intensive care setting; hospital costs could 
be saved by the relocation of treatment. A cost-
effectiveness study of a new drug (nesiritide) for 
ADHF patients showed that, when compared to 
standard (milrinone) treatment, length of stay in the 
intensive care unit was reduced by 2 days, though 
overall length of stay was not statistically different 
(Lewis, Gurram, Abraham, & Akers 2003).   
 
So, to roughly estimate the impact of: a) moving 
ultrafiltration from an ICU setting to a ward, or b) 
simply providing more appropriate therapy to 
refractory patients than that offered by current 
management: I will assume a reduction in ICU length 
of stay by two days31. 
 
The PSSRU’s ‘Unit Costs of Health and Social Care 
2004’ (which draws its data from DH reference costs) 
indicates that the national average cost per bed day 
in an Intensive Therapy Unit / Intensive Care Unit is 
£1,330; a bed day in a Coronary Care Unit (ward) is 
£437 (PSSRU 2004).  Treating a patient in the ward 
rather than an ICU would save the service 
approximately £893 per day.   
 
I could find no cost estimates of conventional 
ultrafiltration, nor could I identify the cost of 
hospitalisation attributable to the medication that 
would be replaced by Aquadex (although one study 
found diuretic cost to represent just 2% of total drug 
expenditure for HF hospital admissions, less than 
0.001% of the total admission cost (McGowan, 
Heerey, Ryan, & Barry 2000)).  Therefore, the 
peripheral service cost implications must be 
considered alongside the headroom estimated. 
 
Service costs saved by reduction of LOS in ICU: 
(Total) ∆SC= 107 million  
(Av. Per person) ∆SC= £1,786 
 
                                                          
31
 The NHSC briefing indicates that for severe cases of fluid overload, ‗multiple‘ treatments may be 
required, each typically lasting 24 hours. 







Describe any potential costs/savings that 














































PConventional Ultrafiltration= ? 
 
Intuitively, this seems like it could be an 
overestimation of the hospital costs. This may be 
because the costs per bed day of ICU and Coronary 
Care unit were derived from an NHS reference cost 
database, and did not represent ‘cost per excess bed 
day’ (as they are too generic to have an HRG), but 
were the national average unit cost, presumably 
encompassing the total cost of treating those 
patients admitted to that unit. This is not ideal, as the 
high cost for an ICU day will probably cover the cost 
of those expensive treatments used in ICU, which I do 
not want to capture when looking simply at the effect 
of changing location of a treatment.    
 
The ‘total’ service cost impact is speculative, given 
the uncertain number of refractory ADHF patients. 
  
 
Something not incorporated above is the potential 
reduction of hospital readmission rates (I have 
included this separately as the sources indicate quite 
different hospitalisation costs, so aggregating them 
seems inappropriate).  An Irish study which 
estimated the cost of hospital treatment arrived at 
an average cost per heart failure patient of £2,774 (i)    
(this might be quite low because the sample of 30 
patients may not have included those patients 
serious enough to warrant ultrafiltration).  Another 
study based in the U.S. finds an overall cost of £3,085 
(ii) (also an estimate that is not based specifically on 
patients resistant to diuretics). 
 
The average of the above estimates is £2,930 (cost 
per hospital admission). If half (speculative 
assumption) of current readmissions could be 
avoided per Aquadex use, then on average this could 
lead to a £1,465 reduction in health service cost per 
patient (of the ‘readmitted’ population: I don’t know 
how big this population is), additional to any cost 
saving in the initial visit. 
 
Service costs saved by reducing readmission rate by 
half: 
 (Av. Per person of the ‘readmitted’ population) 
∆SC= £1,465 
 




Describe any potential costs/savings that 
you haven’t quantified. 
This is all speculative, but was included as the briefing 
indicated that readmission rates could be reduced. 
Adding these two effects together, if deemed 
appropriate, would lead to an average service cost 
saved for some patients of up to £3,251. (This 




Potential impact of the new device on 
patient health, as compared to current 
practice (preferred method of elicitation is 
from studies using the EQ-5D).   
Where NICE have not produced relevant 
economic analyses, search for cost-
effectiveness studies or systematic reviews 
within the disease area (the CEA registry 
































I could not identify any HRQoL studies using an 
accepted method such as the EQ-5D. 
One cost-utility analysis of CHF patients delivered by 
Capomolla et al. used the time trade-off method to 
compare the costs and utilities of patients managed 
according to ‘usual care’ or ‘day hospital’ (Capomolla 
et al. 2002).  Usual care was a management strategy 
whereby care was driven by the patients’ needs, 
encompassing emergency room management, 
hospital admission, and outpatient access.  Although 
the method and results for utility elicitation are not 
well documented, the utility weighting estimated for 
the usual care group could be used as a proxy for 
baseline utility of heart failure patients: this was 0.63.  
Other estimates using time trade-off to  estimate the 
mean utility of heart failure patients are 0.76 
(Havranek et al. 2004) and 0.77 (Havranek et al. 
1999). 
 
What would be useful to identify is the impact of an 
acute exacerbation of CHF (resulting in 
hospitalisation) on HRQoL. One study elicited the 
HRQoL of heart failure patients using the Cantril Self-
Anchoring Scale (Welsh et al. 2002), and on a scale of 
1 to 10 found an average QoL of 5.1 at time of visit to 
the emergency department.  However, the 8.0 found 
at ‘baseline’ was derived from patients being asked 
about their QoL before heart failure diagnosis. 
A study by Jaagosild et al. used the time trade-off 
method to measure the utility of severe CHF patients 
at hospital admission (0.84) , at 60 days (0.93), and at 
180 days (0.94) (Jaagosild et al. 1998).  Although 
these utility weights are very high and probably 
reflect the method of elicitation, we could use the % 
change in utility found (an 11% reduction) or the 
absolute reduction (about 0.1) to estimate the 
impact of hospitalisation on HRQoL.  Taking baseline 
to be about 0.7 (from the three estimates mentioned 
above), this would imply a utility at hospitalisation of 
about 0.6.  
 
However, in this analysis the only variable we are 


























Describe any impact on patient health that 
you haven’t quantified.  
changing is the length of stay in ICU rather than 
overall length of stay.  As such, it would seem too 
speculative to try and imagine an impact on HRQoL in 
that respect.   
The NHSC briefing indicates that the Aquadex 
FlexFlow may be able to reduce length of hospital 
stay, and readmission. If readmissions were to be 
reduced by half, and the average length of hospital 
stay is 8 days (Lewis, Gurram, Abraham, & Akers 
2003) (0.022 years), then a drop in utility of 0.1 for 
the hospitalisation itself (as outlined above) could be 
used to estimate the reduction in QALY loss: 
 
0.1*0.022 years = 0.0022 QALYS per patient that 
avoids a hospital readmission, which is half of those 
currently readmitted. 
 
∆QALY= ?  




(This also presumes a single readmission).  I’ve not 
considered issues of survival and impact on mortality. 
One paper suggests that prognosis remains negative 
for those treated with ultrafiltration, but it may allow 
those waiting for heart transplant to survive, and 
improve their chances of surviving heart surgery as 
well (Sagliaschi et al. 1992). I have also not 
considered that length of stay of subsequent visits 
might be reduced.  
 
 6. Developments (clinical & healthcare 
context) 
 
Consider the following questions to help you 
think about the space for your product 
within the market.  
 
Does the technology address any key national 
objectives for improving care in this area? 
 
How will the technology complement current 
practice? Is current practice likely to change? 
 
Are there any indications in the literature of 
potential effectiveness? 
 
Have you identified any direct competitors? (This 
 [GREEN] Congestive heart failure is the most 
common reason for fluid overload, but is by no 
means the only cause (liver cirrhosis, kidney 
disease, hypertension, certain surgical 
procedures, etc).  This may mean that the 
potential market for Aquadex FlexFlow is large, 
and that that if a hospital were to invest in the 
unit (trolley-based and portable), it could provide 
value to patients and the NHS through its use in 
other areas as well.   
 
 [GREEN] The small studies that have tested 
ultrafiltration as a way to treat diuretic-resistant 
ADHF patients have all been positive, indicating 
that the therapy is effective.  
 




could be another specific technology, or simply a 
different technique)  
 
 RED: Poses a significant threat to the 
opportunity identified in the market (i.e. 
works against current health service 
objectives, or there are other products 
being developed that are associated with 
better outcomes or are at a more advanced 
stage of development). 
 
AMBER: Potential threat 
 
GREEN: Further supports the case for the 
new technology  
 [AMBER] Even though ultrafiltration has been 
around for many years, it is still not part of 
mainstay clinical practice, and is omitted from 
various national guidelines. Although the 
Aquadex may help to overcome the logistical / 
financial barrier to the use of ultrafiltration in 
clinical practice, whatever else has inhibited the 
therapy’s use until now (e.g. clinician reluctance) 
may remain. 
 
 [AMBER] As the use of ultrafiltration has existed 
in the context of CHF since the 1970s, it seems 
feasible to assume other companies will easily fill 
the market if it becomes a viable product. 
 
 [AMBER] Combining classes of diuretics is the 
normal strategy adopted to combat diuretic 
resistance (De Bruyne 2003;Paul 2003).  Many 
recent reviews do not indicate that any other 
strategy is necessary. 
 
7. Research questions 
 
This should be a list of the things that the 
developer needs to find out or monitor 
during the process of development, relating 
to the function of the device or how it fits 
into the market place. 
 
From the research undertaken and reported 
above, what are the most important 
questions or uncertainties that must be 
addressed / tested? What factors or 
assumptions have the calculations / 
economic or clinical case hinged upon? 
What potential benefits or threats have you 
ignored in the calculation (see italicised 
points in Qs 4&5, and ‘developments’ 
section)?  
 As described, diuretic resistance is usually tackled 
by using a variety of available drug therapies. For 
what proportion of patients does this still not 
offer adequate control of symptoms? 
 What proportion of patients are currently 
readmitted? 
 If possible, find the cost associated with 
conventional ultrafiltration, and diuretic therapy. 
 What is the likely impact of the Aquadex on 
overall length of stay? Does it have the potential 
to reduce more than just ICU stay? 
 How many courses of treatment are typically 
required? 
 How many machines would be required to equip 
a cardiac ward so that all relevant patients could 
receive the therapy when needed? 
 Are other products (haemodialysis products?) 
able to perform the same function as the 
Aquadex FlexFlow? If so, how is the Aquadex 
better? 
 The main difficulties in eliciting the ‘headroom’ 
for this product, were: 
o Not understanding the most appropriate 
comparator 
o Having no estimates of the extent of 
potential impact (an idea of this is likely 
to have been present if this were to be 




filled in by the developer themselves) 
o In the absence of this, inadequate 
information in the literature upon which 
to base these assumptions. 
As such, the analysis should be updated once 
more is known or a greater understanding has 
been developed of the potential impact of 
Aquadex on outcome and cost parameters. 
 
 
Notes by AC 
(i) The cost reported in the Irish study for a heart failure admission was IR£2,146, for which 
the data was collected in 1999/2000 (McGowan, Heerey, Ryan, & Barry 2000).  
Converting this to pound sterling gives a cost of £2,331.  To convert to today’s (2004) 
prices, I inflated this according to the HCHS ‘Pay and Prices’ Index: 
HCHS P&P Index 1999/00: 188.5 
HCHS P&P Index 2003/4: 225.6 
Inflation rate: 1.119 
£2,331 * 1.19= £2,774 
(ii) The cost reported for the control arm of this trial (overall cost of ADHF admission per 
patient) was $4553, and the paper was published in 2003. The exchange rate at this time 
was $1.5495 to the £, resulting in a pound value of £2,938. To convert to today’s (2004) 
prices, I inflated this according to the HCHS ‘Pay and Prices’ Index: 
HCHS P&P Index 2002/3: 213.7 
HCHS P&P Index 2003/4: 224.8 
Inflation rate: 1.05 
£2,938* 1.05= £3,085 
Headroom Notes (Aquadex FlexFlow) 
The only numbers to be estimated from this analysis were: 
1) The saved service costs that could result if the Aquadex FlexFlow were to reduce length of 
stay in ICU by 2 days compared with conventional ultrafiltration or conventional 
pharmacologic treatment. This saving was £1,786. 
2) An estimate of the service costs saved by halving readmission rates. This saving was £1,465 
Together, these would lead to a headroom in service costs of £3,251, but only in patients who would 
currently experience a re-admission; as these are quite speculative it would be down to the 
developer to decide if either or both of these estimates would be appropriate.  The QALY impact of 
reducing readmissions was not included in the headroom calculation, as it is not known for what 
proportion of patients this would apply, so it is impossible to know the average per patient. However, 
the QALYs generated for those patients who are no longer readmitted to hospital would be 0.0022, 
for which the NHS should be willing to pay £44 to £66 per patient (but this cannot be aggregated 
across the whole ADHF population without knowing more about the total incidence of readmission).  




What must be considered alongside these savings is the cost of provision of this service.  As well as 
estimating the cost saved from disinvesting in current practice, the extra cost implications must also 
be accounted for.  Nurse time will be required in order to empty the ultrafiltration bag (every three 
hours), and to attend if an alarm is raised. 
An MRP can only be delivered with an understanding of how many patients one unit could serve, and 
the likely cost of consumables per course. 
 
Follow-up (Aquadex FlexFlow) 
Headroom Outcome and Market success 
Does the MRP look realistic? Would it have indicated yes or no to development? 
The difficulty that arose from trying to estimate a headroom for development for the Aquadex 
FlexFlow by CHF Technologies was that the potential benefits projected in the NHSC briefing 
document were not specific enough and, in the absence of these estimates, the literature on ADHF 
and ultrafiltration (at least that which I was able to access within a reasonably short time frame), did 
not offer much help in informing these estimations.  
What I did find was that in one drug study, improved therapeutic benefit resulted in a reduced ICU 
stay (by two days).  So, I hypothesised that if ultrafiltration could improve outcome for those who do 
not respond to drug therapy, then a similar benefit could be achieved.  Also, I knew that the benefit 
over conventional ultrafiltration was that it could be carried out in a ward rather than ICU setting, so 
this also fit into that comparison. This would lead to a reduced hospital cost (from the marginal 
difference in the cost of a bed day) of £1,786 per patient.  I also presented the effect of reducing 
readmissions by half, both in terms of costs (£2,930 per readmission avoided; £1,465 on average for 
the cohort of patients who would otherwise be readmitted), and in terms of QALYs (which would 
generate a reimbursement of £44-£66 per readmission avoided; £22-£33 on average for the cohort 
of patients who would otherwise be readmitted).  However, I could not aggregate these effects as: a) 
the costs used for the two seemed quite different in magnitude, and b) I could not find an estimate 
of % readmission, meaning I could not find the average costs or QALYs saved across the whole ADHF 
population.  
The actual cost of the Aquadex FlexFlow system is approximately £12,000 (though it can be loaned or 
leased to hospitals).  For each ultrafiltration course, a new filter and blood circuit is required; these 
cost about £600 (leasing costs are £500 a month, and leasing reduces circuit costs from £600 to 
£450).  Multiple treatments may be required per patient for severe cases.  Depending on how many 
courses each patient would require, this may or may not exceed the estimated headroom.   
Of the economic analyses that I have found, one implies the use of only one filter system per treated 
patient (CEP 2007b), and one (that uses unpublished findings from the UNLOAD trial (Costanzo et al. 
2007)) indicates that the average patient treated with ultrafiltration (using Aquadex) underwent two 




treatments with an average of 1.2 filters per treatment (Bradley, Levy, & Veenstra 2009).  If patients 
did only undergo one session of ultrafiltration (with £600 consumables cost and the amortised cost 
of equipment presumably relatively small), then the reimbursement opportunity presented by the 
headroom may well have seemed attractive.  Using the estimate of 2.4 filters (at a cost of £1,440 per 
patient) would mean that the prospect for profit would be reduced, but may still seem viable given 
the potential opportunity of reimbursement estimated.  However, this would have depended on the 
developer’s estimates of effect, which I found difficult to guess when undertaking the headroom 
analysis.        
Given the exploratory estimates of potential reimbursement opportunity (and comparing this to 
the actual cost of the device), the headroom analysis may have indicated a positive development 
decision. However, the analysis undertaken and assumptions made were highly speculative; the 
developer’s input of early estimates of potential effectiveness would have been useful. 
 
Has there been a decision made on it by NICE? What was the outcome? 
As described in the pro forma, this technology was put forward for evaluation by the Interventional 
Procedures team, but rejected on the basis of being a ‘minor modification’ of established clinical 
practice.  It was also submitted for technology appraisal but rejected by the panel (“to be considered 
for inclusion in future update of Heart Failure clinical guideline) (NICE 2009b).  Ultrafiltration is not 
mentioned at all in the NICE Clinical Guideline, either in its original publication (NICE 2003a) or the 
updated version published in August 2010 (NICE 2011a).   
 
Is it sold in the UK or the rest of the world?(Or has it in the past) If so, who is it bought by? 
The  Aquadex FlexFlow System (CHF Solutions) received FDA approval in September 2006 (FDA 
2006a).  The device is distributed in the UK by Kimal Plc.  (Gambro is another supplier). A ‘case study’ 
on the Aquadex ultrafiltration system, presented by the ABHI, indicated that the system was being 
evaluated in three UK hospitals (the date of issue is not detailed, but appears to be post-2008) (ABHI 
2011).  It is not clear whether the treatment is widely used by the NHS, though an evaluation report 
for the Aquadex FlexFlow was produced for the NHS Purchasing and Supply Agency by CEP (Centre 
for Evidence based Purchasing) (CEP 2008). Early user experience from NHS consultants was 
favourable. 
The CHF Solutions brochure for Aquadex FlexFlow ‘How Are You Treating Fluid Overload?’ (CHF 
Solutions 2011) indicates that the device is aimed not only toward the treatment of heart failure, but 
also fluid overload caused by problems with the kidneys, lungs, after surgical operations, burns, and 
trauma.  Therefore, the market size and potential clinical utility derived from this ultrafiltration is 
wider than that estimated in the headroom analysis. 
 
Have there been investigations into its clinical / cost effectiveness? 
There are now many clinical investigations and publications for ultrafiltration, and many of them 
relate to the Aquadex system specifically.  In 2007 CEP produced an evidence review for 
ultrafiltration, which included an economic evaluation of the Aquadex FlexFlow (CEP 2007b). They 




used effectiveness results from the UNLOAD (Ultrafiltration versus Intravenous Diuretics for Patients 
Hospitalized for Acute Decompensated Congestive Heart Failure) trial (Costanzo et al. 2007), and NHS 
costs. They use the estimated difference between ultrafiltration and IV diuretics in the following 
parameters (all from the UNLOAD trial): 
- Length of stay (LOS) (6.3 days vs. 5.8 days),  
-Rate of rehospitalisation (18% vs. 32%),  
-LOS for rehospitalisation (1.4 days vs. 3.8 days), and 
-Rate of emergency hospital visits (21% vs. 44%),   
The total cost per patient treated is found to be £1,379.39 for Aquadex and £771.39 for diuretics.  
However, they acknowledge that the effectiveness parameters did not relate specifically to diuretic 
resistant patients, whose baseline costs are likely to be much higher than the average (and thus 
stand far more to gain clinically and economically with ultrafiltration than the average ADHF patient).   
I found two problems with the analysis undertaken by CEP, the first relating to NHS unit costs used 
(the costs per bed day for the various settings described were much lower than those I found during 
my analysis, and since) and the second relating to Aquadex costs.  The authors find bed day costs (for 
cardiac ward and ICU) from the Unit costs of health and social care 2006 from the PSSRU (PSSRU 
2006).  A read of the document reveals that the £464 estimate used for an ICU bed day is actually for 
an ICU attendance associated with mental health services, and the £101 cardiac ward cost used by 
CEP is actually the cost per bed day of patient rehabilitation in cardiology—the costs that should 
have been used, from the NHS reference costs pertaining to the same year are £450 for the coronary 
care unit and £907 for the cardiac intensive care unit (Department of Health 2007).  Secondly, the 
‘Aquadex equipment and consumables’ costs used (per patient treated) was £621.97.  Considering 
that just the filter costs £600 (and assuming that the rest is made up of the amortised cost of 
equipment), this assumes an average of just one filter required per patient treated.  This does not 
seem likely, given trial results and manufacturer estimates. 
Costanzo et al. published the results of the large clinical trial UNLOAD (Costanzo et al. 2007). They 
found that ultrafiltration (using the Aquadex system) was safe, produced greater weight and fluid 
loss than intravenous diuretics, and reduced 90-day resource utilisation.  The same author published 
another study in 2010 (Costanzo et al. 2010), which found similar fluid removal results between 
ultrafiltration and diuretics, but fewer heart failure rehospitalisations were associated with 
ultrafiltration.  Also, it more effectively reduced sodium levels in congested HF patients. 
Bradley et al. presented a decision-analytic model in 2009 in a U.S. setting, finding that although 
rehospitalisation rates are reduced, ultrafiltration is unlikely to be cost saving (Bradley, Levy, & 
Veenstra 2009).  They approached the model from various perspectives, and found that from a 
societal perspective, treatment with ultrafiltration had an 86% probability of being more expensive 
than IV diuretics (base case: $13,469 versus $11,610), from a Medicare payer perspective it had a 
greater than 99% chance of being cost saving (due to the set reimbursement model for CHF 
hospitalisation) ($7,230 versus $8,652), and from a hospital perspective there was a 97% probability 
that ultrafiltration was more expensive (ultrafiltration was associated with a $6,157 shortfall 
between costs and revenues whereas IV diuretics were associated with a shortfall of $2,820).    The 




model was based on the results of the UNLOAD trial (Costanzo et al. 2007), so related to the Aquadex 
system. 
 
The Aquadex FlexFlow is indicated for those who have failedto respond to diuretic therapy (CHF 
Solutions 2011). I found just one study that looked at the use of ultrafiltration for refractory HF 
patients (non-responsive to diuretics and other management strategies), though the ultrafiltration 
was carried out by peritoneal ultrafiltration (from the abdomen rather than peripherally like the 
Aquadex), and used a haemodialysis device to do this (Sánchez et al. 2010). It was a Spanish single 
centre, prospective, non-randomized study of 17 patients, which tested the use of the intervention 
not just in an acute setting, but whenever symptoms required it (12 of the patients were still 
undergoing the treatment at the end of follow-up, which lasted between 6 and 35 months). Sánchez 
et al. report that for these refractory HF patients, use of ultrafiltration increased life expectancy by 
82% after 12 months (56% after 24 months).  They also provide the only estimate I have found of 
utility, as measured with the EQ-5D using the time trade-off method, which was 0.6727 for 
ultrafiltration versus 0.4035 for conservative therapy. This indicates that I may have underestimated 
impact on health (as I only considered the intervention in the context of an acute setting). They 
conclude that the intervention is highly cost-effective, both leading to improved quality of life and 
reduced health care costs (though as mentioned, they use a haemodialysis device to do this, which is 
likely to be much cheaper) (Sánchez et al. 2010). 
There are many additional non-randomized, single centre studies, which tend to be positive about 
the treatment (though one found worsening renal function during ultrafiltration therapy (Liang et al. 
2006).  It can be concluded that ultrafiltration does have an impact on rehospitalisation (of nearly 
50% according to one RCT (Costanzo et al. 2007), so very similar to the assumption used in the 
headroom analysis), but I have not seen any analysis of impact on ICU LOS.  LOS for re-admissions 
seems to be reduced by ultrafiltration (not considered in the headroom analysis), and the rate of 
emergency hospital visits are also lower.  I did not find any comparisons between conventional 
ultrafiltration and ultrafiltration with Aquadex.  
Has the landscape described changed significantly? 
What is current gold standard clinical practice now? Has this changed? 
In 2004 (time perspective of headroom analysis) there was little mention of ultrafiltration in any 
clinical guidelines that I came across. Although diuretics are still the clinical gold standard for the 
treatment of ADHF patients, there are many treatment guidelines that now support ultrafiltration for 
the management of refractory patients: Heart Failure Society of America 2010, American College of 
Cardiology / American Heart Association 2009, The Canadian Cardiovascular Society 2009, and the 
European Society of Cardiology (CHF Solutions 2011). 
One review (Kazory & Ross 2008) describes the growing role of haemofiltration approaches in the 
management of heart failure. 




Are there now many direct competitors? 
One issue brought up in the ‘research questions’ was whether the function of ultrafiltration could be 
achieved by machines currently used in other areas, like renal dialysis.  Ross et al (Ross, Bellamy, 
Hawig, & Kazory 2011) describe the cost, reimbursement, and financial impacts of ultrafiltration for 
ADHF, and note that the costs associated with ultrafiltration are highly variable depending on brand 
and type of equipment used.  They say that traditional haemodialysis machines and supplies can be 
used, and due to their mass production, are much less expensive than those devices designed 
specifically for ultrafiltration / aquapheresis only. They indicate that just the disposables can cost up 
to 50 times those used for haemodialysis equipment (Ross, Bellamy, Hawig, & Kazory 2011). 
However, these lower disposable costs should be balanced against the nurse and ICU expense of 
operating dialysis devices.  The authors also indicate that re-calculating the results presented by 
Bradley et al (Bradley, Levy, & Veenstra 2009) (see above) swings further in favour of ultrafiltration 
when switching to lower-cost haemodialysis technology. 
To my knowledge, this is the only commercial device marketed specifically for this indication. 
Conclusions: How useful might the headroom exercise have been? 
In this case, the headroom analysis felt highly speculative, and would have benefited from a greater 
understanding of the developer’s expectations around potential impact. The literature available in 
2004 was not sufficiently detailed to inform very precise estimations. However, what the analysis did 
achieve was to identify some sources of cost and QALY estimations, which could have been used or 
manipulated according to the expectations of the developer.   
The cost savings presented by the headroom analysis were reduced LOS in intensive care (which was 
derived from a study of an alternative drug therapy), and reduction in readmissions.  Evidence has 
since emerged on the second of these but not the first.  As for quality of life, there has only been one 
QALY estimate for ultrafiltration, which indicates that the potential for improvement in HRQoL may 
be substantial. 
Overall, the headroom method (although not presenting a definitive MRP or ‘headroom’ value) 
painted a fairly positive picture for the reimbursement opportunity of Aquadex.  The device has 
received much attention in the literature, and ultrafiltration seems to be increasingly utilised 
(though, in time this may generate a switch to cheaper available equipment, such as dialysis 
systems). 
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The Electronic Medical Integrated Care System (e-medICS) is a device 
intended for pre-hospital care; it is a touch screen panel PC (and wireless 
headset) with voice-enabled commands, which provides online decision 
support for paramedics at the scene of emergencies.   
 
The paramedics at the scene of an incident can feed information into the 
system (through touch screen or voice activation).  The e-medICS then 
provides information on diagnostic aids and treatment protocols across 
the spectrum of acute medical emergencies and trauma (a decision 
support that incorporates ‘Joint Royal College Ambulance Liaison 
Committee [JRALC] National Treatment Guidelines). This intuitive icon 
driven interface is from the Unified Emergency Care System (Morgan-
Jones & Hodgetts 1999a;Morgan-Jones & Hodgetts 1999b).  It also acts as 
an electronic patient report form, so a patient’s vital signs and digital 
images can be relayed to A&E before a patient’s arrival.  The two way 
communication system can also allow specialists to give detailed advice to 
paramedics on the scene. 
 
According to the Department of Health Statistical bulletin (Department of 
Health 1999), in 1998-99 the number of emergency calls to NHS 
ambulance services in England was 3.8 million (rising from 3.6 million for 
last year 1997-98, an 8% increase). The number of emergency patient 
journeys rose by 2% from last year, representing 2.7 million emergency 
journeys (total patient journeys were 18.6 million, with 1.1 million 
‘urgent’ journeys and 14.8 million ‘special/planned’).  
 
2. Comparator  
 
There are a number of electronic patient report forms (ePRF) being 
developed to meet the needs of the NHS in this context. In their report 
‘Information for Health: An Information strategy for the Modern NHS 
1998-2005’(NHS Executive 1998), the Government set out specific 
objectives to be achieved over the period 1998 to 2005. The thrust of this 
strategy is the movement towards developing and maintaining a system 
of electronic patient records.  The e-medICS system could support this 
strategy.  Other ePRF forms are being developed; these are commonly 
referred to as pen-tablet computers, and have been shown in Germany 
and the US to improve data recording in medical emergency files (Balaban 
1998;Ellinger, Luiz, & Obenauer 1997). However, unlike the e-medICS 
device, these do not improve patient care at the road-side by providing 
electronic operational support and guidance at the scene of a major 
incident.  This is the first system to offer this comprehensive support to 
paramedic teams. 
 
Rather than changing pre-hospital care, the e-medICS system would serve 
as an addition to current clinical practice, providing the tools to ensure 
that gold standard clinical guidelines are adhered to. 
 




In order to understand the health economic case for e-medICS, we need 
to understand the deficiencies in current clinical practice.  One study of 
the warning times for A&E departments by ambulance services, carried 
out in the West Midlands, found that in many cases A&E departments 
should be alerted much earlier by the ambulance service (Harrison & 
Cooke 1999).  It can take some time to for the A&E department to 
prepare and assemble the appropriate facilities, equipment, and 
personnel required to attend to a major casualty.  An earlier and more 
informed warning (which could be facilitated by e-medICS) could improve 
the speed and effectiveness of treatment on arrival at the hospital. 
 
3. Market size  The NHSC briefing indicates that, if the e-medICS is widely accepted, it 
could be incorporated into 2,900 emergency ambulances across England 
and Wales, with the potential to benefit up to one million patients a year 
(there was no source given for this estimate, so it is assumed to come 
from the expectations of the manufacturer).   
 
Market size per year (NHS England and Wales):     2,900 ambulances 
1 million patients 
 
4. Health Service 
 
Changes in resource use.  Any changes in 
service delivery costs to the NHS that will 
result from the application of the new 
technology, including the disinvestment in 
previous practice.  This could include: Staff 
time, hospital bed days, GP visits, A&E visits, 
etc.  It should not include services for which 
the NHS (and personal social services) is not 
financially liable (e.g. lost productivity and 
[non-health] social care costs), but these 
should be noted in writing below to add to 
the verbal case for the product (NICE may 
incorporate social care costs into cost-
effectiveness estimates in the near future). 
 
 If relevant and not included in service cost 
impact above, search for price of the 
currently used product (P1). 
 
Use HCHS index to inflate estimates to 






As outlined above, advantages to the health service 
of the e-medICS system in ambulances would be: 
1. To make sure that paramedics are able to 
access decision-support enabling them to 
offer the appropriate treatment to patients, 
adhering to current guidelines and protocol.  
If patients receive the most appropriate 
treatment initially, then their outcomes 
should be improved and cost of subsequent 
treatment in hospital reduced. 
2. Better warning system to the hospitals.  If the 
paramedics input the patient’s vital signs 
(and even digital images of the patient), then 
the hospital is likely to be better prepared for 
the patient on arrival. This could mean more 
effective and efficient treatment in hospital. 
3. E-medICS could facilitate better record 
keeping, which not only plays towards the 
national movement to electronic records, but 
also allows for improved evaluation of the 
service. 
 
Aside from the ‘warning system’ element, the 
principal benefit of the product is to empower 
medical staff to make treatment decisions that are in 
line with clinical guidelines (which presumably 
represent the most appropriate way to manage 
patients).  In other words, it should mean that 





















































ambulance staff are equipped with the tools to do 
their job more effectively.  This would be very 
difficult to evaluate from a health service cost 
perspective, as the spectrum of patients and ailments 
treated by ambulance staff is very wide, and we do 
not know the extent to which protocols are not 
adhered to currently.  
However, probably the most appropriate type of 
evidence to draw upon is from investigations that 
have considered the impact of extra staff training.  
All of the studies I have found that examine this issue 
of extended training for ambulance staff, are within 
the context of specific conditions or types of calls 
attended.   
One study considered the effect of training 
ambulance staff to carry out endotracheal intubation, 
intravenous infusion, and ventricular defibrillation 
(for cardio-pulmonary arrest) (Wright 1985).  Wright 
proposed that one fully equipped ambulance that 
was permanently available and manned by personnel 
with extended training would save 3 to 4 lives per 
year, with a cost per life year of about £2000 (1981 
prices) (Wright 1985).    
Brazier et al. provide a brief review of all the RCTs 
that have considered and provided evidence for pre-
hospital care, but this was not restricted to 
ambulance care (Brazier, Murphy, Lynch, & Bury 
1999). 
 
One comprehensive HTA based on a large UK study 
(2,076 patients in all), presented by Nicholl et al., has 
been presented from an NHS perspective for pre-
hospital care of serious trauma patients (Nicholl et al. 
1998).  They compared the outcomes and costs of 
trauma patients who received pre-hospital care by 
either emergency medical technicians (EMTs) or 
crews with at least one paramedic (who receive 
further training than EMTs, called ‘advanced life 
support’ training).    The results in terms of 
parameters that might affect health service costs 
were the following: 
 Mean length of stay in hospital (15.2 nights) and 
percentage admitted to intensive care (5.9%) 
were not significantly different between the 
paramedic and EMT groups. Readmissions, 
outpatient attendances, and GP contacts were 
also similar between the groups.  
 Paramedics spent two minutes longer on scene 
than EMTs (even after case-mix adjustment). 






















































Overall, the paramedic group cost £22 more per 
patient (£2231 versus £2209 per patient), but this 
difference was not statistically significant (p=0.814). 
 
It may be reasonable to assume that if patients are 
treated with the most appropriate care initially 
(facilitated by E-medICS), subsequent treatment 
costs would be reduced. Although one would 
presume that paramedics (as opposed to EMTs) 
would have a stronger basis to implement the most 
appropriate care for patients, the UK HTA found no 
difference between the two groups in this respect 
(cost of care upon arrival at hospital and 
subsequently).  However, it would be inappropriate 
to generalise these findings, as they relate to a 
specific cohort of patients that receive pre-hospital 
care by the ambulance service (trauma patients), and 
the results may not be replicated elsewhere.   
Indeed, one review of the literature for ‘The efficacy 
of advanced life support (ALS)’ (Bissell, Eslinger, & 
Zimmerman 1998) concludes that of the 51 articles 
reviewed, 8 had concluded that ALS care is no more 
effective than basic life support, 7 concluded that it is 
effective in some applications but not others, and the 
rest found evidence of improved effectiveness.  They 
found that the strongest support for ALS was in 
cardiac arrest victims, whereas trauma studies and 
non condition-specific studies had more divergent 
results (Bissell, Eslinger, & Zimmerman 1998). 
 
It would be very difficult to try and estimate the 
impact of e-medICS on health service costs. One NHS-
specific study found that for trauma patients, 
subsequent hospital costs were not affected, but this 
result cannot be generalised across the whole 
ambulance service. In the absence of specific 
monetary estimates, the economic case should be 
made with careful consideration of points 1 to 3 
above.  
 
The extra costs  associated with E-medICS include 
installation into emergency vehicles, as well as staff 
training on the use of the system.  
 
(Total) ∆SC=? 
(Av. Per person) ∆SC=? 
 
P1≈ £2230 per patient 





Describe any potential costs/savings that 
you haven’t quantified.  
 
The HTA presented by Nicholl et al (Nicholl et al. 
1998) found significantly reduced indirect costs for 
the paramedic group, in relation to productivity loss 
from time off work. This probably relates to the 
improved outcome of survivors (see below); it could 





Potential impact of the new device on 
patient health, as compared to current 
practice (preferred method of elicitation is 
from studies using the EQ-5D).   
Where NICE have not produced relevant 
economic analyses, search for cost-
effectiveness studies or systematic reviews 
within the disease area (the CEA registry 
offers a useful platform to identify these 
studies). 
 
Describe any impact on patient health that 
you haven’t quantified.  
In terms of patient health, the e-medICS system aims 
to improve patient outcomes by: 
1. Improving the management of patients at the 
scene, by ensuring that medical staff have access 
to national treatment guidelines (and potential 
for two-way communication with specialists in 
the hospital). 
2. Allowing A&E departments to have access to an 
incoming patient’s vital signs, digital images, and 
summary reports, so that they are better 
prepared for the admission, thus improving the 
likelihood of quick and appropriate treatment in 
hospital. 
3. Providing a means by which to electronically 
manage patient records, which should improve 
the management of patients across the spectrum 
of health service interaction.  
 
The third of these points would be very difficult to 
assess in terms of health impact.  The first two, 
however, should lead to a direct improvement of 
patient outcomes.  
 
Returning to the British HTA conducted by Nicholl et 
al. (for trauma patients), patient outcomes were 
measured and the following were the headline 
effects of paramedic treatment versus EMT 
attendance (Nicholl et al. 1998) (which I propose 
might represent the type of change that could be 
envisaged for e-medICS) : 
 Higher rate of mortality (6% for paramedic 
attendance versus 4.6% for EMTs), and, adjusting 
for case-mix, an increased risk of death from 
4.5% (EMT) to 8.7% (paramedics). 
 An increase in avoidable deaths: 14.2% in deaths 
attended by paramedics, and 6.8% in those 
attended by EMTs.  
 Significantly improved outcomes for survivors. 
Treatment by paramedics was associated with 




better scores on all of the SF-36 health 
dimensions32 (5 of the 8 were significant once 
adjusting for case-mix).  No aggregate score was 
provided.  
A trade-off between morbidity and mortality is 
apparent. For survivors, residual health was markedly 
improved in those receiving initial treatment from 
more highly trained staff.   The noted mortality effect 
for paramedic-treated patients was observed in 
those patients with bleeding injuries, and could be 
related to the increased length of time at the scene 
that was associated with the paramedic group.  The 
integration of the e-medICS could feasibly be 
associated with increased time at the incident before 
transportation to hospital (speculative), and so this 
effect might be worth considering. 
 
In her review of the literature of advanced training 
versus basic training, Bissell (Bissell, Eslinger, & 
Zimmerman 1998) finds that, whilst not unanimous, 
research tends to indicate a positive effect of further 
staff training on clinical effectiveness, presumably 
indicating better patient outcomes.  
 
As there was no summary health value reported in 
this or any other HTA (and in any case it would be 
wrong to presume that this trauma-specific example 
would be indicative of the general service), we 
cannot use this to estimate QALYs.  It would be 
impossible to try and estimate this effect with no 
data, as the breadth of patients that would need to 
be considered would make the problem very difficult 
to pin down.   
 
Like the question of health service cost impact, the 
rationale for e-medICS in terms of patient health 
should be viewed with points 1 to 3 (above) in mind, 
but with the awareness of the generally positive QoL 
results for patients treated by more informed 
healthcare staff, but also the potential for adverse 
mortality effects when treatment is delayed (at least 





(Av. per person) ∆QALY= 
                                                          
32
 SF-36 health dimensions: Physical functioning, Social functioning, Role —physical,  Role —
emotional,   Mental health, Energy/vitality, Pain, and General health perceptions. 




6. Developments (clinical & healthcare 
context) 
 
Consider the following questions to help you 
think about the space for your product 
within the market.  
 
Does the technology address any key national 
objectives for improving care in this area? 
 
How will the technology complement current 
practice? Is current practice likely to change? 
 
Are there any indications in the literature of 
potential effectiveness? 
 
Have you identified any direct competitors? (This 
could be another specific technology, or simply a 
different technique)  
 
 RED: Poses a significant threat to the 
opportunity identified in the market (i.e. 
works against current health service 
objectives, or there are other products 
being developed that are associated with 
better outcomes or are at a more advanced 
stage of development). 
 
AMBER: Potential threat 
 
GREEN: Further supports the case for the 









 [GREEN] Patient journeys in ambulances rose 2% 
from last year (Department of Health 1999). This 
upward trend in ambulance attendances 
enhances the need for more effective and 
efficient services.  If e-medICS were to have the 
anticipated effect on patient treatment, it could 
help the service to cope with this rising demand. 
 
 [GREEN] The interface that will be utilised by e-
medICS (the Unified Emergency Care System) 
was designed in the context of providing pre-
hospital care to those injured on the battlefield; 
the interface developed utilises the experience of 
those medics who were required to provide a 
pre-hospital level of care comparable to that 
which a patient should expect to receive on the 
NHS (Morgan-Jones & Hodgetts 1999b).  
 
 [GREEN] In the ‘Information strategy for the 
modern NHS’ issued by the NHS executive / 
Department of Health (NHS Executive 1998), it is 
asserted that telemedicine and telecare “will 
undoubtedly come to the fore as a way of 
providing services in the future” (p.8, (NHS 
Executive 1998)).  They go on to explain that one 
of the greatest potential benefits of new 
technology in the NHS is improving quality of 
care by allowing better access to information, 
specialist advice, and support for both medical 
professionals and patients.  It is in this way that 
e-medICS would facilitate improved patient care.  
In the same report, one of the stated objectives 
to be achieved before 2005 is “to provide every 
NHS professional with on-line access to the latest 
local guidance and national evidence on 
treatment…” (p.3, (NHS Executive 1998)).  E-
medICS could facilitate the provision of this 
resource in ambulances.  
 
 [GREEN] The NHS wish to create an Electronic 
Health record, which could allow for 24 hour 
access to clinical records.  This should improve 
patient management, and the e-medICS would 
work toward this goal.  The e-medICS thus 
complements various wider NHS goals: 1) 
electronic patient records, 2) incorporating 
JRCALC (ambulance treatment guidelines) 
strategies into practice, and 3) improving 
treatment equity.   





 [GREEN] Technological advances in modern day 
life are such that many things that a few years 
ago seemed impossible are now facilitated by 
modern technology and gadgets.  It seems 
appropriate that the NHS should make use of 
these advances to progress its own system of 
managing patients and improving care. 
 
 [AMBER] Having said that the NHS should move 
with the times in order to get the most out of 
advances in the technology sector, it must be 
kept in mind that this is not a consumer 
purchase.  Buying a new gadget or mobile phone 
because it is clever and has improved capabilities 
might be a reason to make a consumer goods 
purchase, but in order to justify reimbursement 
from a publicly funded health service, it must 
prove to deliver value in terms of patient health 
and service costs.        
 
 [AMBER] As this device is based on technological 
rather than medical advances, it may attract 
competitors from the wider technology sector. 
 
 [AMBER] 1500 emergency ambulance journeys 
made over 2.5 years were investigated by P.S. 
London (London 1972) in 1972. He found that, 
whilst there were some respects in which 
equipment or performance by the ambulance 
service could be improved, there was no 
unnecessary life loss. 
 
 [GREEN] As in any public facing role, especially 
where the stakes are so high, paramedics are 
vulnerable to patient/family accusations and 
legal action when things go wrong.  If the e-
medICS system is employed, the actions of the 
medical team may be more defendable (if 
following the stated guidelines); the upload of 
patient data and images could also provide 
evidence of the medical team’s handling of the 
situation.   
 
 [GREEN] One published letter regarding the 
collection of uniform cardiac arrest data by the 
UK ambulance service (Goodacre, Gray, & 
McGowan 1997), notes that without uniformity 
of data collection for pre-hospital cardiac arrest, 




the data is of little value when assessing the 
performance of the service.  The e-medICS 
system could systematise that process. 
 
 [AMBER] The success of e-medICS would be 
reliant on its acceptance by the ambulance 
service community.  It may be that some staff 
(especially experienced staff) might think it 
unnecessary or even a hindrance, if every 
decision should be run through the computer.  
Acceptance by the whole medical team is 
essential for the system to work, including: the 
medical staff in the hospital to which the patient 
will be admitted, specialists who might be called 
upon to give the paramedic advice at the scene, 
as well as the ambulance staff themselves.  
Additionally, in order to achieve its intended 
impact, uptake should not be isolated to 
individual ambulances, but e-medICS should be 
disseminated across the whole service.  This 
means the case for e-medICS would need to 
prove to be very strong in order to warrant the 
huge investment that would be required to set 
the system up across all 2,900 ambulances in 
England and Wales. 
 
 [AMBER] Initial barriers to uptake that could be 
envisaged are that: 
o Training of all ambulance as well as the 
relevant hospital staff would be required. 
o The need for staff at the hospital to be 
responsive to incoming information and 
images may require some reorganisation 
of A&E services. 
o The NHS is generally a slow adopter of 
new technology, and it would take time 
for ambulance staff to get used to the 
new system.  Benefits may therefore take 
some time to be realised. 
o A large up-front cost would be required 
for installation of the equipment. 
o It may be that over time the system 
would require systematic upgrading (in 
order to reflect changes in practice or 
advances in technology), so investment 
would not be one-off. 
 
 




7. Research questions 
 
This should be a list of the things that the 
developer needs to find out or monitor 
during the process of development, relating 
to the function of the device or how it fits 
into the market place. 
 
From the research undertaken and reported 
above, what are the most important 
questions or uncertainties that must be 
addressed / tested? What factors or 
assumptions have the calculations / 
economic or clinical case hinged upon? 
What potential benefits or threats have you 
ignored in the calculation (see italicised 
points in Qs 4&5, and ‘developments’ 
section)?  
 The first proposition of this system is to improve 
patient care at the scene of emergencies, by 
ensuring that paramedics have access to clinical 
support and guidelines. Whether this would 
enhance current practice would hinge on the 
following questions: 
o To what extent do ambulance staff not 
adhere to best practice guidelines, due to 
not knowing or not having access to what 
these are?  
o Would paramedics be willing to adjust 
their actions even if they didn’t adhere to 
current guidelines? 
This would be difficult to investigate, and may 
not be fathomable until something like this 
system is tested, and outcomes do or do not 
change as a result. 
 The second proposition is that the A&E 
department has advanced and more detailed 
warning of the incoming patient. 
o Would staff in the hospital be 
willing/able to receive and respond to 
this information? 
o In the case of the two-way 
communication system, is it feasible that 
specialists at the hospital could respond 
to calls? 
 Would the electronic patient record element of 
e-medICS be compatible with the NHS’s system 
for data collection? 
 The NHSC briefing does not indicate that the 
system could be used for the paramedics to 
access information and records of the patient’s 
medical history. Might this be feasible to 
incorporate in the future? Would this provide a 
useful and valuable function?  
 How much time (if any) would be added to pre-
hospital treatment, by consulting with the e-
medICS system before / during patient 
treatment?  If more appropriate treatment is at 
the expense of more minutes at the incident 
scene, then these (even small) delays may have 
an impact on mortality rates.  
 What is the reaction of the ambulance service 
community to this sort of device?  The response 
of the medical staff that would be involved in its 
operation, and their engagement in the process, 
would be absolutely key for the success, and 
indeed the uptake of the e-medICS. Therefore, 




this must be gauged as soon as possible.  
Probably more so than any other medical 
technologies, its impact is completely reliant on 
the input by medical staff.  If they are not on 
board, the investment might have been wasted.  
Additionally, this acceptance needs to be 
widespread in order to achieve maximum 
efficacy. Is this feasible? 
 The currently available evidence might indicate 
that improved medical skills / awareness of 
clinical guidelines may have a more positive 
impact in some clinical areas than others (e.g. 
cardiac arrest). Might it be feasible emphasise 
the use of e-medICS more urgently in those 
scenarios for which it would have the greatest 
impact?  
 The e-medICS system is a piece of technology 
that will likely have to compete in the highly 
dynamic and fast-moving technology sector.  
Does QinetiQ have the capacity and resources to 
keep the device up-to-date and competitive, so it 
is not overtaken by competitors?  More so than 
many other devices, this will probably not be a 
question of a one-off development process. 
 Any clinical trial or investigations of the product 
must explicitly focus on the specific effect of e-
medICS on subsequent hospital costs, and 
patient outcome in terms of mortality as well as 
morbidity. 
 
Headroom Notes (E-medICS) 
No ‘headroom’ was delivered by this analysis.  This was principally because of the very wide 
spectrum of patients, ailments, and costs, and the (unsurprising) lack of evidence upon which to base 
impact estimates.  Instead, the bulk of the analysis is presented by section 6&7 of the pro forma, 
which provide some detailed factors/questions that the success of such a system as the e-medICS 
might rest upon.  These should be considered, with the potential barriers weighed against the 
potential benefits.  Especially important in this case would be the widespread acceptance by the 
ambulance community; this should be investigated carefully. 
In terms of a development decision, as pointed out in the pro forma, it is probable that to stay 
competitive the process of development will need to be continuous.  
 





Headroom Outcome and Market success 
Does the MRP look realistic? Would it have indicated yes or no to development? 
The e-medICS innovation raises many interesting clinical, economic, and practical questions that 
should be considered when deciding whether the system might present an attractive offer to the 
NHS, and thus whether it will warrant a sufficient level of reimbursement.  As the type of incidents 
and patients attended by the ambulatory service are so broad in nature, severity, and cost, 
estimating the service cost and health impact of the e-medICS system would be very difficult.  The 
analysis therefore focused on presenting the important factors upon which the health economic case 
for the product would hinge, along with evidence or trends picked up in the literature that might 
help the developer to consider the likelihood of reimbursement prospects.  As a result, parts 6 and 7 
of the pro forma were extensive, as they outlined the current developments, trends, or issues in the 
market context which might work towards or against the case for adoption.  These would have been 
important for a product such as this which would require the backing of staff and a major investment 
by the service.  The ‘research questions’ section outlined the things that the developer would need 
to know in order to make an informed development decision, and begin to quantify the 
reimbursement opportunity.  However, this topic is such that these questions are likely to remain 
largely unanswered until the system were to actually be put in place and used widely (e.g. to what 
extent do paramedics not follow guidelines, would their behaviour change, would it lead to longer 
time spent at the scene of the injury, would staff in the A&E department be receptive to incoming 
information, etc).  Therefore, the developer would have to have considered these and the other 
research questions very carefully, and made a judgement call on likely reimbursement with all these 
factors (and evidence presented from specific emergency situations) in mind.   
I am not able to guess what the result of that process would be, especially as a certain part of it 
related to the capacity of the company itself to manage the continual development of the system 
and the investment this would require, as well as the elicitation of user (paramedic) feedback.       
Headroom decision unknown 
 
Has there been a decision made on it by NICE? What was the outcome? 
NICE has not issued any guidance on the (generic) topic of emergency care / ambulance services for 
the NHS.  This is unsurprising given its very wide scope, and is reflective of why it also posed 
difficulties from a headroom perspective. 
 
Is it sold in the UK or the rest of the world?(Or has it in the past) If so, who is it bought by? 
In 2002, at the time the NHSC document was written, e-medICS was being trialled (a two year 
project) with the Surrey Ambulance Service NHS Trust.  The project was funded by HM Treasury – 
Capital Modernisation Fund (Smith 2004).  A brief report on this project (not a clinical trial as such) 




was issued on the website of the ‘Telecare Knowledge Network (TKN)’.  They emphasise that there 
was much national and international enthusiasm for the project, and note that the UECS system (the 
interface used for e-medICS) has been shown in the military to improve treatment of patients, and 
has potential for mass use in the military environment (Smith 2004).  As for its use by NHS 
ambulances, it is reported that “the volume of clinical evidence has not been generated to prove the 
clinical efficacy of the computerised UECS” (Smith 2004).  However, much was learnt about 
implementation issues: “There are significant cultural and change management issues to be 
overcome before such a system becomes commonplace”, but there is a big pressure on the NHS to 
realise the potential of modern technology to support decision making and flexible protocol delivery. 
In 2003, QinetiQ joined forces with an Australian company called HAS Solutions (who are Australian 
IT providers in health care) to develop the e-medICS further (Worcester News Archive 2003).  
I have not found any mention of e-medICS in the context of the NHS since the early 2000s in its trial 
with the Surrey Ambulance Service, and the product is not mentioned on QinetiQ’s website.  
 
Have there been investigations into its clinical / cost effectiveness? 
This specific device is not mentioned in any clinical or economic literature that I have found. Of those 
papers I have found, pre-hospital care is considered in the context of specific clinical problems (e.g. 
trauma and cardiac arrest) rather than effectiveness of practice in general. 
One Australian study published in 2006 considered ambulance officers’ use of online clinical evidence 
(Westbrook, Westbrook, & Gosling 2006).  They found that over half of ambulance officers 
questioned had not heard to the Clinical Information Access Program (CIAP, an Australian online 
evidence system), and those who used the system was low.  It was reported that lack of access in the 
work place deprives ambulance staff of the benefits of this system, and those that did use it (mainly 
at home) valued it highly. However, there was no link made in the study of CIAP use and 
performance / patient outcomes. 
 
Has the landscape described changed significantly? 
What is current gold standard clinical practice now? Has this changed? 
In response to the NHS white paper published in 2010, ‘Equity and excellence: Liberating the NHS’ 
(Department of Health 2010), the Department of Health developed clinical and quality indicators for 
urgent and emergency care, where response time guidelines are set, but it was emphasised that 
performance will be measured on quality and patient outcomes rather than times alone (Department 
of Health 2011e).   
The value proposition for e-medICS was based on some guiding principles, which were that:  
1) paramedic performance would benefit from access to a decision support device,  
2) patient outcomes would be improved if their treatment was guided by national treatment 
guidelines, and if A&E departments could be better prepared for their arrival in hospital, 




3) E-medICS could facilitate the movement toward an electronic health record system, 
4) A resource such as e-medICS could make care more systematic an equitable. 
As there is no evidence that e-medICS has been picked up by the NHS, do these factors still present 
an unmet need to the emergency care system?  Points 1 and 2 above cannot be answered, and 
would not be answered until such a system is rolled out. 
Some of the problems with clinical practice that probably inspired the development of e-medICS still 
exist, for example, there is still a great variation in the quality of ambulance care across the country 
(Department of Health 2011b).   As for the general move toward an electronic health record system, 
progress was slow; a House of Commons health committee report published in 2007 revealed that 
just a few ‘early adopter sites’ were starting to trial the very basic form of electronic patient record 
(EPR), the ‘Summary Care Record’ (which includes information on things like allergies, adverse 
reactions and current medications) (House of Commons Health Committee 2007).  Since this time, 
the whole NHS National Programme for IT (of which the electronic patient record plan was a major 
part) has been largely dismantled, the acceleration of which was announced by the government in 
September 2011 (Department of Health 2011d).  It is said that some aspects of the programme have 
achieved a lot and that this will be maintained, such as the Summary Care Record. However, this 
goes no-where near what was envisaged back in 1998, toward which e-medICS could have played a 
role in the context of emergency ambulance care, and which formed a strong part of its case for 
adoption.  The system of electronic patient records has been widely discussed and debated, with 
many claiming it to be less efficient than paper records or systems that are based locally (Quinn 
2009), that the benefits are limited, that concerns of confidentiality and safety are an issue (Triggle 
2010), and that clinicians may not even access them (Greenhalgh et al. 2010).    
  
Are there now many direct competitors? 
The NHS is renowned for being a slow adopter of new technology. Despite the fact that e-medICS 
was first presented over a decade ago, when electronic patient record forms (e-PRFs) were being 
developed by many to fulfil the stated need by the NHS, such devices are still not in widespread 
clinical use.  At the 2011 NHS Innovation Expo, a new device was presented as the ‘Introduction of 
Electronic Patient Report Form (ePRF) to emergency care’ using ‘ToughBook’ laptops (Healthcare 
Innovation 2011).  This product also proposes the facilitation of patient recording, incident data 
transmission, and access to JRCALC guidelines.  These are apparently being rolled out by the East 
Midlands Ambulance Service (NHS East Midlands 2011). 
 
Conclusions: How useful might the headroom exercise have been? 
Although no monetary value was presented for this ‘headroom’, thinking about the device in terms 
of its potential impact on patients and the health service allowed for the identification of various 
sources of relevant evidence in the literature, and potential barriers to uptake.  Many of the factors 
identified in sections 6 and 7 of the pro forma turned out to be very relevant for e-medICS, including 




the main point made which was that, disregarding all other factors, the system would only work in 
practice if it had the backing of the clinical staff that would use it.  From the small trial results, it 
seems that this is what has scuppered that adoption case for e-medICS.  However, there has been 
one substantial development in the clinical context that may not have been predictable a decade 
ago; in 1999, the NHS was vey keen to create a centralised bank of electronic health records, and the 
vision was that this would transform the way that patients were managed, making the most of the 
technology that is now available to us.  The e-medICS was put forward as a way to optimise the 
management of patients and allow for patient records to be managed electronically.  The company 
would probably not have been able to predict that, a decade later, this would still not have been 
rolled out nationally.  This shows how important the clinical landscape is for the business proposition 
of a new product, and that sometimes it can change unpredictably. 
Combining from the pro forma the ‘developments’, potential barriers to adoption, and ‘research 
questions’ identified, with the evidence identified from a UK trial on the emergency care of trauma 
patients, the case for e-medICS may have appeared at worst unlikely or at best uncertain (though I 
cannot judge what the developer would have made of these factors / questions, if indeed he had not 
considered them anyway).  From the information I have found, e-medICS has not proven itself be a 
cost-effective or efficient alternative to current management , and does not seem to have achieved 
widespread coverage in NHS ambulances.  
This was an interesting example as in some ways e-medICS is a product delivered by the technology 
sector, and whilst it is important that the NHS makes the most of the technology that is available to 
improve patient management, procurement from this publicly funded service must be based on the 
value it creates for patients and the NHS.  This was uncertain when carrying out the headroom 
analysis, and seems to be uncertain still. 
It is difficult to know whether consideration of the headroom output would have influenced the 
decision of QinetiQ to develop e-medICS, but many of the questions were significant.    
 
 











No NICE follow-up. 
 
Date of briefing: 
October 2007 
 




Patients who undergo major surgery or are being treated in intensive care 
units often require cardiac monitoring, due to the strain that these 
procedures place of the patient’s heart. Cardiac output (which is 
sometimes called CO, or simply ‘Q’) is defined as the volume of blood that 
is pumped by the heart in one minute. 
 
The HeartSmart is a piece of software that uses algorithms to perform 
cardiac dynamic monitoring; results are reported in real time. The 
physician will input physiological readings into the software that are 
measured by standard pre-existing hospital equipment (e.g. a central 
venous catheter (CVC)). The physiological parameters required are: heart 
rate, central venous pressure, blood pressure and core body temperature. 
 
HeartSmart uses encoded algorithms defining the relationship between all 
key blood flow variables in order to produce important indexes of cardiac 
output, pressures and haemodynamic variables. These can be used to 
optimise patient blood flow and fluid management whilst the patient is in 
intensive care or undergoing surgery. 
 
The company envisages that HeartSmart could later be developed and 
marketed as hardware (where the algorithms are embedded into a 
microchip).   
 
2. Comparator  
 
Many methods have been developed to measure cardiac output, and 
increasingly the emphasis of these developments has been on non-
invasive methods. 
The reference standard for cardiac haemodynamic monitoring is 
pulmonary artery catheter thermodilution (PACTD).  This is an invasive 
procedure, which involves a pulmonary artery catheter (PAC) (which is 
sometimes called the Swan-Ganz catheter) being inserted directly into the 
pulmonary artery to measure temperature. There are considerable risks 
associated with the technique, including arrhythmias, infections, 
thrombotic complications, and sometimes pulmonary artery rupture.  An 
investigation by Walker and Waldmann (Walker & Waldmann 1994) found 
that in the UK, there is considerable lack of standardisation for PAC use; 
this may impact its clinical utility.  
 
‘Dilution’ refers to the technique of measuring cardiac output by injecting 
an indicator and measuring its concentration in the blood after one 
circulation through the heart.  Dye was initially the ‘indicator’ of choice. 
The PACTD technique uses temperature measurements, by using heated 
or cooled fluid as the indicator and measuring temperature change at 
different stages of the circulation. 
 
There are many alternative methods of cardiac output monitoring, 
including the following: 




 Other indicator dilution techniques: 
o Arterial (or ‘transpulmonary’) thermodilution: a less invasive 
method of thermodilution, where a thermistor-tipped 
catheter is inserted via the femoral artery. This has been 
found to be effective for burns patients, for whom fluid shifts 
can be great (Holm et al. 2001). 
o Transpulmonary lithium dilution techniques. 
o Pulmonary artery catheter based continuous thermodilution. 
Several products have been commercialised for this: Vigilance 
(Baxter), Opti-Q (Abbott), and TruCCOMs (Aortech). This 
continuous method was found to be effective compared with 
standard (‘bolus’) PACTD in a small trial by Medin et al (Medin 
et al. 1998). 
 Echo-Doppler ultrasound: Measures blood velocity through the heart 
using ultrasound waves (‘doppler shift’).  
 Impedance cardiography (ICG): An electric current is used to measure 
resistance changes after each heart beat, which can be used with an 
ECG to generate haemodynamic data.  A systematic search of the 
literature by Dark and Singer (Dark & Singer 2004) for esophageal 
Doppler monitors found them to have high validity and high clinical 
agreement with PATCD in the monitoring of changes in cardiac 
output. 
  The Fick Principle: This describes the rate at which oxygen is 
consumed, and relates this to blood flow. A device (called NICO) has 
been developed by Novametrix which uses this principle to non-
invasively estimate cardiac output, just using measurements of airway 
gas. 
 Arterial Pulse Contour Analysis: Pulse pressure is (invasively) 
measured and used to estimate cardiac performance. Commercialised 
products that can achieve continuous cardiac monitoring using this 
method include PiCCO (Pulsion), PulseCO (LiDCO), and Modelflow 
(TNO/BMI).  
 Other comparators include MRI, electrical cardiometry, ultrasound 
dilution, and Finapres Methodology (‘volume clamp’ method).  
 
Despite this wide range of invasive, minimally invasive and non-invasive 
alternatives to PACTD, the consensus in the literature seems to be that 
PACTD is the established ‘gold standard’ for cardiac output estimation in 
critical care.   
 
The need for coronary output monitoring spans across many medical 
situations, in which a patient’s blood flow and fluid need to be optimised, 
including general intensive and neuro-intensive care units, open heart 
surgery, sepsis or shock, major general surgery, and the assessment of 
pressure in the pulmonary artery prior to liver operations.  Clinical studies 
that investigate the outcome of patients that undergo cardiac monitoring     
using a pulmonary artery catheter (PAC) consider specific contexts 
(conditions or procedures).  However, we can use these to give us some 
indication of the potential outcome of PACTD (our baseline) and to 




speculate on the differences that could be made by HeartSmart.  
 
One cost-effectiveness study considered the hypothetical incremental 
cost/QALY of a PAC versus a no PAC strategy for patients experiencing 
COPD exacerbations that require mechanical ventilation, under the 
scenario that PAC-driven management results in a 5% improvement in 
survival (a speculative assumption) (Smith & Pesce 1994).  They calculate 
an ICER of $77,407 and conclude that PAC for COPD exacerbations is 
expensive compared to alternative management strategies, unless PAC 
guided management were to improve survival by 8.7% or more.   
 
However, there is much discussion in the literature regarding whether 
PAC is in fact of any benefit in the management of patients. 
A cost-effectiveness study presented by Ramsey et al. (retrospective 
cohort study) looked at the use of PAC for patients undergoing coronary 
artery bypass graft surgery (Ramsey et al. 2000).  They found that, after 
adjustment, the relative risk of in-hospital mortality was 2.10 for the PAC 
group versus the non-PAC group, total length of stay was 0.26 days longer 
for the PAC group, and hospital costs were $1,402 higher (Ramsey et al. 
2000). 
 
Sandham and colleagues (Sandham et al. 2003) report on an RCT 
conducted to examine the use of PAC in high risk surgical patients (60 
years of age or older).  They find no clinical benefit from PAC-guided 
therapy over standard care (which was allowed to include measurement 
of central venous pressure with a CVC).  They found differences for in-
hospital mortality or morbidity. 
 
Connors et al. (Connors, Jr. et al. 1996) present the findings of an 
observational study of the effectiveness of PAC in the care of critically ill 
patients (a mixed population, including medical and surgical patients in 
the ICU).  Case-matching analysis was performed, and they found that 
patients that were catheterised had increased 30 day mortality (odds 
ratio of 1.24), an increased mean cost per hospital stay of $13,600, and 
1.8 more days in ICU.   
In response to these findings, Murdoch et al. examined the effect of PAC 
on mortality over 7 years in an ICU of a large British teaching hospital 
(Murdoch, Cohen, & Bellamy 2000).  They found that the use of PAC had a 
strong impact on mortality (42.9% versus 12.6% without PAC) if no 
adjustment was made for severity of illness. After adjustment, PAC had no 
association with increased mortality (Murdoch, Cohen, & Bellamy 2000).  
 
On the other hand, a meta-analysis of the incidence of major morbidity in 
critically ill patients that are managed with PACs found that, in the studies 
considered, there was a statistically significant reduction in morbidity for 
PAC-guided management (Ivanov, Allen, & Calvin 2000). 
 
Some of these studies question the usefulness of using cardiac monitoring 
to manage patients (at least using PACTD).  The NHSC brief does not 




indicate that, aside from reduced invasiveness / complications, 
HeartSmart would function any better than PACTD in its capacity to 
monitor cardiac output.  Therefore, we must assume equivalent 
effectiveness, but that the risks posed by PACTD would be avoided by 
using the HeartSmart software instead of this procedure.  
 
By using PACTD as our baseline comparator, we assume that this is what 
is used in clinical practice, and thus what HeartSmart would replace.  The 
literature varies in its assessment of PACTD, at best implying that 
morbidity is reduced, and at worst describing its use being associated with 
higher mortality, morbidity, and increased length of stay in hospital.  The 
headroom method seeks to quantify the potential monetary opportunity 
for a new product within a specific market.  This will be best explored in 
this case by considering two scenarios: 
 
1) Patient outcomes and cost of hospitalisation are equivalent for 
PACTD-monitored patients and HeartSmart monitored patients.  
Thus the only difference is the procedural cost of PACTD that is 
avoided    
2) The negative impact of PACTD on patient outcome (mortality) and 
hospitalisation costs (length of stay) may be avoided by using 
HeartSmart for cardiac output monitoring. 
 
3. Market size  What we would ideally use for this estimation is the number of PACTDs 
that are undertaken in the NHS every year; I could not find this.  The 
NHSC briefing indicates in its ‘clinical need and burden of disease section’ 
that 200,000 central venous catheters (CVCs) are placed in the NHS every 
year (this estimate comes from NICE’s TA49 (NICE 2002)), but that the 
company believe this figure to actually be much higher.  The 
measurements taken by CVC provide some of the required input 
measurements for HeartSmart, though their use seems to be associated 
with many motivations: haemodynamic monitoring, intravenous delivery 
(blood, drugs, etc), haemodialysis, nutrition, management of 
perioperative fluids etc.  The placement of a pulmonary artery catheter 
seems to be diagnostic only, so it could be that a CVC is required 
alongside the PAC to make the indicated changes to optimise fluid and 
blood flow management. 
Although one might assume that the use of CVC would go beyond the use 
of PACTD for cardiac monitoring, I will use this estimate of 200,000 as the 
potential market sixe for HeartSmart, as this is what seems to be 
indicated by the NHSC briefing. 
Market size per year (NHS): 200,000 
 
4. Health Service 
 
Changes in resource use.  Any changes in 
service delivery costs to the NHS that will 
result from the application of the new 
I am not sure whether CVCs are generally indicated 
for patients who undergo cardiac monitoring by 
PACTD.  Therefore, I will show the health service cost 
effect in both cases.  
 




technology, including the disinvestment in 
previous practice.  This could include: Staff 
time, hospital bed days, GP visits, A&E visits, 
etc.  It should not include services for which 
the NHS (and personal social services) is not 
financially liable (e.g. lost productivity and 
[non-health] social care costs), but these 
should be noted in writing below to add to 
the verbal case for the product (NICE may 
incorporate social care costs into cost-
effectiveness estimates in the near future). 
 
 If relevant and not included in service cost 
impact above, search for price of the 
currently used product (P1). 
 
Use HCHS index to inflate estimates to 



























According to the NHSC briefing, the total equipment 
cost of PACTD is £145 (‘cost plus consumables’) (no 
source was given, so it is assumed that this was 
company-knowledge). Besides this, the NHSC offers 
total monitor costs (£11,000-£15,000) and the cost of 
a service contract (£40,000)(no time span offered).  
Without more details of this cost (i.e. what does it 
include, does the headline figure of £145 include the 
amortised monitor/service costs, is the procedural 
cost of insertion included? etc), it is difficult to 
understand the true cost of PACTD to the NHS in the 
absence of any other estimate from the literature. 
Therefore, I will use the £145 ‘total equipment cost’ 
figure offered by the NHSC as the estimate of PACTD 
cost per patient, whilst considering that, if not 
included, the monitor and service costs could add 
considerably to the headroom.  
 
Assuming that a CVC is normally used alongside 
PACTD, then the headroom in equipment costs would 
be the full £145. 
 
The cost of a CVC is also estimated in the NHSC 
briefing. The ‘cost’ is added to the ‘consumables’, to 
arrive at a ‘total equipment cost’ of £27. Alongside 
this, they present monitor costs of £3,800-£5,500 
(again, no sources indicated or indication of what the 
figure of £27 includes).  Therefore, per unit33 there 
would be a saving of about £118 in switching from 
PACTD to CVC in cases where CVC would not be used 
concurrently with PACTD. 
 
For scenario 1 (outcomes and hospital costs of PACTD 
and HeartSmart are equivalent), this £145 (if CVC 
already used alongside PACTD) or £118 (CVC not used 
alongside PACTD) would be the headroom in health 
service costs. 
 
For scenario 2, we must add the health service costs 
associated with the adverse impact of PACTD on 
hospital length of stay.  I will use the findings 
retrieved by Connors et al. where mean cost of 
hospital stay was raised by $13,600 in PAC patients, 
equating to about £12,111 today (i)34.   
                                                          
33
 As CVCs are used for various purposes, it may be inappropriate to include the monitor costs for 
CVC anyway, as these may be needed in any case. 
34
 The study by Connors et al (Connors, Jr. et al. 1996) included a mixed cohort of patients that 
attended ITU, including medical and surgical critically ill patients.  Therefore, it may offer a more 
appropriate estimate than those studies that have considered a specific group of patients.  However, it 
























Describe any potential costs/savings that 
you haven’t quantified.  
 
Scenario 1 & CVC used with PACTD already: 
(Av. Per person) ∆SC= £0 
P1= £145 
 
Scenario 1 & and CVC investment required: 
(Av. Per person) ∆SC= £27 
P1= £145 
 
Scenario 2 & CVC used with PACTD already: 




Scenario 2 & and CVC investment required: 





I can’t tell whether or not monitor costs are included 
in the cost estimate of PACTD. If it isn’t, then – as 
HeartSmart requires no investment in any capital 
equipment — this cost should be added to the 
headroom. As the monitor and service costs 
combined were up to £55,000, this indicates that 
these costs may not have been included in the ‘total 
equipment cost’ estimate.  If this is the case, then this 




Potential impact of the new device on 
patient health, as compared to current 
practice (preferred method of elicitation is 
from studies using the EQ-5D).   
Where NICE have not produced relevant 
economic analyses, search for cost-
effectiveness studies or systematic reviews 
within the disease area (the CEA registry 





The results of studies that consider the mortality 
effect of PAC vary greatly in result. Of those studies 
presented briefly above, Sandham (Sandham et al. 
2003) finds no mortality impact, Ramsey (Ramsey et 
al. 2000) finds an increased relative risk of in-hospital 
mortality from PAC of 2.1, Connors (Connors, Jr. et al. 
1996) presents an increase in 30 day mortality with 
an odds ratio of 1.24 compared with the no-PAC 
group, and Murdoch (Murdoch, Cohen, & Bellamy 
2000) finds that, after adjustment, PAC has no impact 
on mortality.   
Chittock and colleagues (Chittock et al. 2004) find 
that the use of a PAC may decrease mortality rates in 
those who are most severely ill, and increase it in 
those who are less ill.  Yu et al. find no mortality 
                                                                                                                                                                                     
should be noted that this was the highest cost saving estimate that I found which, whilst maybe 
appropriate in the calculation of a ‗headroom‘, may not be regarded as the most realistic estimate 
necessarily (as indicated, others found more moderate estimates). 


















































impact from PAC in patients with severe sepsis (Yu et 
al. 2003), and Affesa and colleagues detect no 
mortality effect of PAC use on patients in intensive 
care either (Afessa et al. 2001).   
 
As we can see, these results are very variable.  For 
Scenario one, we assume no impact on mortality 
(which seems to be the finding for most clinical 
studies).  For Scenario 2, however, we want to model 
the monetary value of eliminating the risk that 
PACTD may pose on patients’ lives due to its invasive 
nature, which could be avoided using HeartSmart.  As 
we did with the service cost impact, it seems 
appropriate to take the most optimistic view for the 
value of HeartSmart, by taking the estimate from the 
literature that demonstrates the highest benefit to 
patients and the NHS from moving away from the use 
of PACs.  It is Ramsey who provides the strongest 
case in this respect showing that, after adjustment, 
in-hospital mortality increased two fold for the PAC 
group. 2.8% of patients in the PAC group died, so let’s 
assume that cardiac monitoring with HeartSmart 
rather than PACTD halves the mortality rate to 1.4%. 
 
To account for the quality of those lives saved 
accurately would be difficult as monitoring of cardiac 
output spans so many types of patients and illnesses.  
The median age of those patients (who underwent 
coronary artery bypass graft surgery) in the Ramsey 
study seemed to lie in the 60-69 bracket35.  The 
median age of those admitted to the ICU of St 
James’s University Hospital, Leeds between January 
1990 and December 1996 (44% of which received 
PAC) was 56.3 years (Murdoch, Cohen, & Bellamy 
2000).  Therefore, let’s assume an average age of 
about 60.  The Office of National Statistics (ONS) 
provide interim life tables which present the average 
person’s expected years of life left at any given age 
(Office for National Statistics 2011).  For expectation 
of life based on data for the years 2002-04, a 60 year 
old should expect to live a further 20.18 years if male 
or 23.43 years for women; let’s assume a life 
expectancy of 22 years at the age of 60 for the 
general population.  Of course, the underlying 
conditions which have led the patient to require the 
surgery or episode in ICU may mean that their life 
                                                          
35
 It should be noted that the use of this study is a proxy for potential impact, as this study related 
specifically to coronary artery bypass surgery rather than a more general investigation of cardiac 
output monitoring. 














































Describe any impact on patient health that 
you haven’t quantified.  
expectancy should be reduced when compared to 
that of the general population. Let’s speculatively 
consider that this figure is halved, so that the average 
life expectancy of a patient having received the 
intervention (cardiac monitoring) is around 11 years 
(underlying health condition will of course vary 
greatly among the target population, which makes 
this analysis highly speculative). 
 
To turn these into QALYs, we must apply a weighting 
to this estimate to account for the HRQoL 
experienced by the patients who are saved.  For the 
general population, the weighted health state index 
for 55-64 year olds is 0.8, and 0.78 for 65-74 year 
olds (EQ-5D value sets) (Kind, Hardman, & Macran 
1999). Although this does not account for the 
underlying health condition of these survivors, I will 
not try to manipulate this figure given the lack of 
information upon which to base such a manipulation.   
 
However, as per NICE’s reference case, life years 
gained in the future should be discounted at a rate of 
3.5%.  According to this principle, 11 years of life with 
a weighting of 0.8 is worth about 7.5 years today (ii). 
 
Overall, use of HeartSmart rather than PACTD could 
reduce in-hospital mortality from 2.8% to 1.4%, 
saving on average: 
7.5 years x 1.4% = 0.11 QALYs per patient.   
 
(This is all highly speculative, but is only illustrative 
anyway, as really we can see enough potential in the 
service costs alone to justify development) 
 
Scenario 1: 
∆QALY= 0  
(Av. per person) ∆QALY= 0 
 
Scenario 2: 
∆QALY= 22,000   
(Av. per person) ∆QALY= 0.11 
 
Pulmonary artery rupture as a result of PAC is a rare 
but fatal complication.  An analysis of case reports to 
the U.S. FDA indicated 71 cases in the U.S. between 
1991 and 2001, and found that the risk is greater in 
women than in men (Kaczmarek, Liu, & Gross 2003).  
One study that explored the risk of pulmonary artery 
perforation advises that caution should be taken in 




inserting PACs, and that their use should be avoided 
unless absolutely necessary (Sirivella, Gielchinsky, & 
Parsonnet 2001).  
 
6. Developments (clinical & healthcare 
context) 
 
Consider the following questions to help you 
think about the space for your product 
within the market.  
 
Does the technology address any key national 
objectives for improving care in this area? 
 
How will the technology complement current 
practice? Is current practice likely to change? 
 
Are there any indications in the literature of 
potential effectiveness? 
 
Have you identified any direct competitors? (This 
could be another specific technology, or simply a 
different technique)  
 
 RED: Poses a significant threat to the 
opportunity identified in the market (i.e. 
works against current health service 
objectives, or there are other products 
being developed that are associated with 
better outcomes or are at a more advanced 
stage of development). 
 
AMBER: Potential threat 
 
GREEN: Further supports the case for the 
new technology  
 [RED] There seem to be a great number of 
options for cardiac monitoring, and many more 
on the horizon (see section 2).  The literature for 
cardiac output monitoring is extensive, and many 
clinical studies relate to specific technologies of 
the sort described in section 2.  This shows that 
they are at an advanced stage of development, 
and are already looking to fill the space that 
PACTD now fills.  Therefore, HeartSmart will be 
competing against all of these options rather 
than PACTD alone.  A change in baseline 
comparator is likely to have a dramatic effect on 
the perceived headroom, especially if a non-
invasive option were to prove effective and gain 
the favour of the clinical community. 
 
 [GREEN] It is unlikely that any other option for 
cardiac output monitoring is as cheap as what 
HeartSmart should turn out to be, as it requires 
no investment in capital equipment, no 
consumable costs, and no maintenance 
requirements. 
 
 [AMBER] The basis of this headroom analysis is 
the proposed avoidance of the potential 
complications associated with placement of a 
pulmonary artery catheter.  However, there are 
also risks associated with placement of CVCs 
(pneumothorax, central-line associated 
bloodstream infections, thorombosis, arterial 
punctures, arteriovenous fistula, nerve injury, 
etc.) (NICE 2002).  If these are in fact not used 
alongside PACTDs in the base case, then this 
could have a negative impact on the value 
generated by HeartSmart for patients and the 
health service. Cobb et al. find that both PACs 
and CVCs pose the risk of infection (Cobb et al. 
1992).  NICE seem to consider the reduction in 
CVC use to be a favourable outcome for an 
intervention.  
 
 [GREEN] NICE has issued guidance relating to the 
placement of CVCs in order to reduce 
complications associated with it (NICE 2002).  




This could reduce the effect decribed above. 
 
 [AMBER] In one European study regarding the 
use / misuse of PAC, the authors suggest that: 
“As an alternative to expensive clinical trials on 
the pulmonary artery catheter, we propose that 
our limited financial resources for clinical 
investigation be invested in the development of 
innovative techniques that may reduce the need 
for pulmonary artery catheter in the future” 
(Vincent, Dhainaut, Perret, & Suter 1998).  This 
emphasises the potential space for HeartSmart, 
and its capacity to replace a procedure which is 
expensive and for which the evidence does not 
seem convincing. 
 
 [AMBER] In April 2002 ‘Pulse pressure wave 
monitoring for measurement of cardiac output’ 
was notified to NICE but was declared ‘not in 
remit’, and the reason given was that it was 
already an established procedure (NICE 2010e). 
This re-emphasises that the reference standard is 
not straightforward, and there are actually lots of 
options that are employed for cardiac 
monitoring. 
 
 [AMBER] Unlike other options that have been / 
are being developed for cardiac monitoring, I 
assume that the readings given will not be 
continuous (and will only update when the 
clinician re-enters the relevant physiological 
data).  This may be seen as a disadvantage of 
HeartSmart compared with its competitors. 
Medin et al (Medin et al. 1998) find that 
continuous monitoring of cardiac output (using 
thermodilution) shows increased effectiveness 
over bolus comparators.  
 
 [AMBER] As HeartSmart is based simply on an 
encoded formula, then it may be that this is easy 
to replicate by another company or within the 
NHS.  It may even seem unethical to be charged 
for the output of HeartSmart for each set of 
measurements.  
 
 [GREEN] The simplicity of HeartSmart is also a 
benefit, as there would be no significant change 
in clinical practice, and so no learning curve for 
staff or significant investment in training. 





7. Research questions 
 
This should be a list of the things that the 
developer needs to find out or monitor 
during the process of development, relating 
to the function of the device or how it fits 
into the market place. 
 
From the research undertaken and reported 
above, what are the most important 
questions or uncertainties that must be 
addressed / tested? What factors or 
assumptions have the calculations / 
economic or clinical case hinged upon? 
What potential benefits or threats have you 
ignored in the calculation (see italicised 
points in Qs 4&5, and ‘developments’ 
section)?  
 Physiological parameters and CVC readings are to 
be inputted into the HeartSmart software 
manually. Is this a time intensive process? 
 
 A big risk that has been identified for this 
technology is the threat of a changing baseline.  
How does HeartSmart compare in cost and 
effectiveness with other up and coming options 
for cardiac monitoring? Is PACTD the relevant 
comparator (especially given the accumulation of 
literature that questions its usefulness)?  
Innovation in this area should be monitored.  
 
 If continued research into the clinical utility of 
PACTD confirms that PACTD does not have a 
beneficial impact on the management of patients 
during surgery or critical care, could HeartSmart 
be considered useful? What does it add to 
cardiac monitoring that is not achieved by CVC 
alone? (CVC alone is sometimes used as a 
comparator for PACTD in clinical studies). 
 
 How realistic is the market size estimated? 
 Update estimates of patient numbers if/when 
they become available. 
 
 Is CVC usually used alongside PACTD or not? 
 
 How much does PACTD cost? If the estimate used 
in this analysis is not correct, then so is the 
headroom. 
 
Notes by AC 
(i) The difference in hospital costs for PAC and non-PAC patients was $13,600 in 1996 
prices. 
The exchange rate in 1996 was about £0.65 to the US$: $13,600 = £8,840. 
This must be inflated to today’s (2004) prices using HCHS price inflator: 
 
HCHS P&P Index 1996/7: 170.6 
HCHS P&P Index 2004/5: 234.2 
Inflation rate: 1.37 
 
Hospital costs saved: £8,840 * 1.37 = £12,111 
 




(ii) In order to express the QALY gain with today’s reference point in mind, we must apply a 
discount rate of 3.5%.  If every remaining year of life is experienced at a QALY of 0.8, 
then the total value of 11 years in this state would equate to the following: 
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= 7.46 QALYs  
Headroom Notes (HeartSmart) 
Here, the MRP represented the maximum reimbursable price for cardiac monitoring per patient.  
Without understanding the intended organisation / marketing of HeartSmart, I do not know how this 
relates to the reimbursement structure of the finished product (i.e. will the health service be charged 
per patient (as explored with headroom)? Per reading? Per license bought?)  Unlike many services of 
this nature, the use of HeartSmart does not depend on an investment in capital equipment, and as 
such it is difficult to know how the company will choose to price the product. 
In the least optimistic case (switching to HeartSmart would lead to no change in patient outcome or 
services costs in terms of patient stay etc, and placement of CVC (previously not indicated) would be 
required) the headroom per patient who needed cardiac monitoring was £118. This was simply the 
cost saving from no longer placing the PAC (minus the cost of placing the CVC).  It should be noted 
that the cost of PACTD as expressed in the NHSC briefing was quite unclear, and that the equipment 
and service costs for PACTD (which could reach up to £55,000, but which would need to be 
amortised to reach a per patient figure) may need to be added.  This could increase the Headroom 
figure further. 
In the most optimistic scenario (switching to HeartSmart would reduce length of stay in hospital and 
reduce inpatient mortality, CVC is already used at baseline, and the NHS would be willing to pay 
£30,000 per QALY) the headroom per patient was £15,556.  
This very wide gap in estimation shows the uncertainty in the assumptions made, which reflects the 
wide and divergent literature base for PACTD. 
As for allowable development costs, even considering the least optimistic scenario these seem to be 
very large (in the region of £20 million), especially given the fact that the variable costs would be 
minimal for a piece of software. 






Headroom Outcome and Market success 
Does the MRP look realistic? Would it have indicated yes or no to development? 
The headroom calculated per patient ranged from £118 to £15,556, depending on assumptions used 
for reduced length of stay, the need to apply a CVC where it was not used before, mortality, and WTP 
per QALY. The allowable development costs were very large (ranging from £3 million to £23 million).  
However, these supposed development costs should be taken with a pinch of salt as the estimated 
number of units was based on the use of CVCs in the NHS which, although indicated in the NHSC 
briefing as a proxy for HeartSmart use, may be an overestimate.  
The information base to inform headroom assumptions was either sparse or inconsistent.  This is 
why the estimates used were quite speculative, and why the range of headroom for most and least 
optimistic was so large, and why the exercise should be viewed as exploratory rather than definitive.   
Without getting too wrapped up in the detail, though, the health economic case for HeartSmart 
seems convincing when compared to what the company charge for the product.  We knew that 
PACTD cost £145 a go (and this probably did not include the equipment and service costs which could 
reach £55,000 per unit), so even ignoring any of the potential benefits to arise from HeartSmart, it 
would be unlikely that the cost to produce the software for HeartSmart would exceed this value.  
Indeed, HeartSmart costs about £400 for set-up and installation, and £10-£15 per HeartSmart 
measurement (it is indicated that 3 to 4 measurements may be required). With no capital equipment 
costs, disposables, or maintenance required, the health economic case seems to be an obvious one if 

































Variable cost per device (including consumables) 
Most optimistic 
Least optimistic 




Having demonstrated the potential value to the NHS presented by HeartSmart it seems that, under 
the assumptions considered, the headroom would have indicated plenty of room for development.   
Headroom would have indicated a positive development decision 
 
Has there been a decision made on it by NICE? What was the outcome? 
NICE have not considered this particular device.  NICE have produced guidance on other technologies 
for cardiac monitoring (see below). 
 
Is it sold in the UK or the rest of the world?(Or has it in the past) If so, who is it bought by? 
HeartSmart is distributed in the UK by APC Cardiovascular, a UK based supplier of medical products.  
Dr Kenneth Warring-Davies, who is based at Bradford Royal Infirmary, was the inventor of the 
continuous cardiac dynamic monitoring (CCDM) software, HeartSmart36.  Based on the locations of 
clinical trial data, it seems that HeartSmart has been used at least alongside PACTD (in order to check 
concordance of output) in 7 NHS trust hospitals (London, Cambridge, Bradford, Leeds, Sheffield, 
Scunthorpe and Grimsby).  I have not been able to identify the extent to which it has or has not 
become part of routine clinical practice as an alternative to PACTD or other techniques.  
Warring-Davies applied for a patent in 2003 (Berridge, Warring-Davies, Bland, & Quinn 2009), 
indicating that the 2004 time perspective may not have been the most appropriate. 
HeartSmart is not mentioned in a ‘Review of emerging cardiac technologies’ provided by the 
Department of Health (Department of Health 2011a) (though this may be because this document is 
focused on services for sufferers of cardiac diseases, toward which cardiac dynamic monitoring is not 
exclusively focused).  
 
Have there been investigations into its clinical / cost effectiveness? 
I have found two journal publications relating to HeartSmart in the literature (both of which are 
authored or co-authored by HeartSmart’s inventor Warring-Davies).  Both consider the use of 
HeartSmart in a clinical setting by estimating cardiac output using standard PACTD and HeartSmart 
simultaneously, and comparing the results.  The first, published in 2009,  considers 45 patients 
undergoing cardiac surgery (Berridge, Warring-Davies, Bland, & Quinn 2009).  They find that PACTD is 
in ‘good agreement’ with cardiac output monitoring using HeartSmart.  The second paper (in Open 
Access Journal of Clinical Trials, 2010) considers trial data from 268 adult surgery or ICU patients that 
required PAC placement across 7 NHS trust hospitals, which allowed for the comparison of 2720 
paired sets of cardiac index estimations (Warring-Davies & Bland 2010).  Results suggest that 95% of 
paired measurements found HeartSmart values to be between 57% - 164% of PAC measurements 
                                                          
36
 It was noted in the fill-in sheet that other cardiac monitoring options allowed monitoring to be continuous, 
and that HeartSmart not doing so may be perceived as a disadvantage.  I am not sure whether the capacity for 
HeartSmart to offer continuous monitoring of cardiac variables is something that has since is been 
incorporated, or whether it was simply not well described in the NHSC briefing. 




(and that using the larger limit of agreement estimated between the two would imply that 
HeartSmart agrees with PAC as closely as it agrees with itself) (Warring-Davies & Bland 2010).   
We can see from these trials that HeartSmart output generally agrees with the gold-standard.  As 
trials have only tested the use of HeartSmart alongside PACTD, we are not able to observe the impact 
on clinical outcome of HeartSmart.  However, if the accuracy of HeartSmart were to be deemed 
sufficient and it would require no investment in equipment or major re-training of staff, and would 
reduce the invasiveness (and presumably risks) of cardiac monitoring, then its case could only be 
favourable (in relation to PACTD). 
In 2006 Harvey et al. produced an HTA on the clinical and cost-effectiveness of pulmonary artery 
catheters in patient management in intensive care (Harvey et al. 2006a). The study was a large 
multicentre RCT in a mixed setting across the UK, accompanied by an economic evaluation which was 
undertaken from an NHS perspective. PAC was compared with no PAC; in the control group patients 
were allowed to undergo cardiac monitoring by alternative means, which were employed in 66% of 
control group patients.  The results corroborated the more conservative findings identified in the 
literature during the headroom analysis.  There was no difference in hospital mortality or length of 
stay in hospital between the two groups, and the economic evaluation found that the expected 
cost/QALY that could be gained from withdrawing PAC from clinical practice would be £2,985 (this is 
because in the analysis the PAC group was associated with a slightly shorter LOS and slightly higher 
mortality).  However, the cost of the PAC procedure itself does not seem to have been incorporated, 
only the time in ICU or the ward (this is not explained).  In a cost-effectiveness study reported in the 
year prior to the full HTA (same data and results), the authors conclude that the withdrawal of PAC 
from routine clinical practice would be cost-effective (Stevens et al. 2005).  This HTA suggests that 
‘scenario 1’ in the headroom analysis may have been the most realistic. 
Some of the same authors as the HTA (including Harvey S, lead author of both) provide a Cochrane 
review of the evidence for pulmonary artery catheters in the same year, 2006 (Harvey et al. 2006b).  
The results re-emphasise the variable findings of studies in the literature. 
 
Has the landscape described changed significantly? 
What is current gold standard clinical practice now? Has this changed? 
It seems that PACTD is still considered the gold standard in clinical practice for haemodynamic 
monitoring; new technologies compare themselves with this technique (Warring-Davies & Bland 
2010).  However, the literature still indicates that new techniques and technologies continue to 
emerge and seem to be providing viable and effective alternatives to this ‘reference standard’.   
One technology in particular has shown particular potential, being recommended in March 2011 by 
NICE in a medical technologies guidance (NICE [Medical Technology Guidance] 2011) (though the 
committee note at the top of every report produced that “The specific recommendations on 
individual technologies are not intended to limit the use of other relevant technologies which may 
offer similar advantages”). The CardioQ-ODM oesophageal Doppler monitor uses a probe that is 




placed in the oesophagus via the mouth or nose, which generates low-frequency ultrasound.  The 
reflected signal can help determine flow velocity, and from this, other data can be generated.  The 
CarioQ-ODM costs £11,000, plus the cost of a probe which is £67 to £118 per patient. Through 
reductions in hospital length of stay and complications due to better fluid management and a less 
invasive monitoring method, NICE estimate that implementing the guidance could generate 
£80,800,000,000 for the NHS (NICE 2011c).  Interestingly, the comparator used by the committee 
seemed to be central venous pressure monitoring, against which CardioQ-ODM was said to generate 
£1,062 to £1,285 in savings.   
This and other techniques seem to have become more common practice in recent years.  Funk and 
colleagues (Funk, Moretti, & Gan 2009) wrote a review article in 2009 that considered the various 
options for minimally invasive cardiac output monitoring in the perioperative setting. They 
emphasise that the need for cardiac monitoring is strong and getting stronger, and that the 
limitations and complications inherent to PAC mean that clinicians are seeking minimally or non-
invasive methods of monitoring cardiac output.  They outline the advantages and disadvantages of 
esophogeal Doppler, thoracic electrical bioimpedance, partial non-rebreathing systems, arterial pulse 
contour, lithium dilution, and trans-pulmonary thermodilution techniques (Funk, Moretti, & Gan 
2009). 
Given the far reaching research that is being undertaken in this area on alternative means of cardiac 
monitoring, and the largely neutral impact of PAC as presented by the literature, it seems that the 
appropriate baseline for HeartSmart is now not one, but many techniques.  
 
Are there now many direct competitors? 
In their review (in which HeartSmart is not mentioned), Funk et al. conclude that of the monitors that 
are now available, the oesophageal Doppler and arterial pulse contour devices have the greatest 
potential for replacing PAC in standard practice.  The arterial pulse contour method only requires an 
arterial line (rather than a central line [as used for CVCs], arterial lines are usually placed in smaller 
veins, for example in the wrist).  Like HeartSmart, this works by using an algorithm in order to 
calculate the required indexes; though, signal processing and display devices seem to be required for 
this method. 
 
Conclusions: How useful might the headroom exercise have been? 
As the information base for cardiac monitoring was in some areas sparse and in others plentiful but 
inconsistent, the resultant headroom analysis did not produce a definitive monetary opportunity for 
HeartSmart.  It did, however, allow me to explore the potential health service value of the device, 
and how this would change when the assumptions used are manipulated.  Hopefully this would have 
given the developer some appreciation of the important factors in the analysis, and how they can 
affect the overall health economic case for HeartSmart.  As it happened, the health economic case 
under the perspective taken was an obvious one, as even the least optimistic scenario seemed to 
provide adequate headroom for HeartSmart.   The perspective that was taken (regarding the 




appropriate baseline) was challenged in sections 6 and 7 of the pro forma, and it is this that may be 
the most pertinent reason that HeartSmart does not seem to have a well established presence in the 
literature for cardiac monitoring.  In the years since 2004, the alternatives to PAC have continued to 
grow, and the guidance recommending the use of the Doppler monitor actually indicated that CVC 
use alone was the relevant comparator.  
As for the specific assumptions used, it seems that scenario 1 may have been the most relevant, as 
RCTs and systematic reviews that have since been produced for PAC have indicated that it is most 
likely to provide no benefit or harm for patient treatment.  The HTA based on the large UK RCT 
(Harvey et al. 2006a) did not include the cost of PAC itself but did not indicate why; the basis of the 
headroom analysis for scenario 1 was simply the cost of PAC, which the NHSC indicated was 
substantial.  
HeartSmart seems to be available in the UK (the company offer free trials), and used by various 
isolated centres (APC Cardiovascular 2011).  The reason that is hasn’t achieved widespread adoption 
across the NHS is likely to be because of the plethora of other options, one of which now has NICE 
approval, and also the requirement of CVC insertion (which seem to be out of favour given its 
inherent risks to the patient).  Such barriers were identified in sections 6 and 7 of the pro forma. The 
‘headroom’ for development would probably have been considered adequate without spending the 
hours trying to put a number to this, given the (relatively) high cost of PACTD and the low cost of a 
piece of software with encoded algorithms.  Also, an expert in the area is likely to be aware of all of 
the other developments in the field.   
The headroom method may have been a useful exercise for the developer of HeartSmart. 
 
 











NICE CG follow-up. 
 
Date of briefing: 
December 2006 
 
Time perspective of this 
report: 2003 
Coronary Artery Disease (CAD) is the leading cause of death worldwide. It 
describes a condition where coronary arteries, which supply oxygen and 
nutrients to the myocardium (the muscle of the heart), become blocked.  
In England, angina (chest pain due to ischaemia of the heart generally 
caused by CAD) affects more than 1.4 million people, 300,000 suffer from 
heart attacks every year, and more than 110,000 people die from heart 
problems per year (Department of Health 2000). Coronary Heart Disease 
(CHD) accounts for about 3% of hospital admissions in England 
(Department of Health 2000), costs the UK £3.5 billion in health care costs 
(£7.9 billion including productivity losses and informal care) (British Heart 
Foundation 2003d), 79% of which is attributable to inpatient care (British 
Heart Foundation 2003a).  
In 2003 there were 53,261 percutaneous coronary intervention (PCI) 37 
procedures undertaken in the UK (British Heart Foundation 2003c), and 
about 28,000 coronary artery bypass grafts (CABGs)38 (British Heart 
Foundation 2003b).  Angiography is the term used to describe the medical 
imaging technique that allows for investigation of coronary artery 




Multi-detector (or ‘multi-slice’) CT angiography (MDCTA) can measure the 
presence of coronary artery calcification, which indicates the presence of 
atherosclerosis – artery hardening.  It combines the use of X-rays with 
advanced computer analysis, and allows for visualisation of the coronary 
arteries (non-invasively).  MDCTA could produce a 3D image of the heart 
in less than 10 seconds, which can help the medical team detect the 
presence or lack of significant coronary stenosis (occlusion).  It is thought 
that MDCTA could be used to diagnose CAD in patients with chest pain, 
and who have an intermediate pre-test probability of CAD; they may have 
no changes in ECG or an un-interpretable ECG.  It could also be used for 
those patients that require angiographic data before surgery, in whom 
invasive angiography is not appropriate.     
 
 
2. Comparator  
 
The reference standard for evaluation of CAD is invasive coronary 
angiography (ICA) which involves coronary catheterisation.  A catheter is 
inserted via the forearm, through the arterial system and into the major 
coronary artery. An x-ray contrast agent is then administered into the 
desired area to assess blood flow and visualise the artery openings (to 
assess occlusion, stenosis, thrombosis, etc) with an X-ray. 
The following is a list of other options: 
                                                          
37
 PCI is more commonly known as angioplasty, and is the therapeutic procedure used to treat 
stenosis (narrowing) of the coronary arteries.  
38
 CABG is a different therapeutic procedure whereby the stenotic arteries are bypassed by grafting by 
grafting vessels from elsewhere in the body. 





 Magnetic resonance angiography (MRA). This technique is already 
used for the evaluation of ventricular function, myocardial perfusion 
and mass. The test is non-invasive and does not use radiation, but for 
this indication would produce images of lower resolution and 
accuracy.  
 Electron beam computed tomography (EBCT). Also non-invasive and 
uses lower radiation doses than MDCTA, but would have lower 
power. 
 
In the national service framework produced for CHD in 2000 (Department 
of Health 2000), it is said that candidates for revascularisation who have 
evidence of extensive ischaemia or angina that persists despite medical 
therapy, should be referred for angiography (an ECG can help to 
determine these parameters, which records the electrical activity of the 
heart).  Angiography would be followed by a quantitative assessment of 
urgency/risk/priority, which may be followed by revascularisation (either 
by CABG or PCTA (percutaneous transluminal coronary angioplasty)).  
 
MDCTA could offer a less invasive, lower risk, and probably much cheaper 
alternative to ICA.  The reason that it is not being proposed for wider use 
(i.e. only in patients who have an intermediate pre-test probability of 
significant coronary stenosis, and for whom ICA would otherwise be 
indicated) is because of the risk of high-dose radiation involved.   
 
Diagnostic imaging is constantly evolving, with techniques continually 
improving in speed and accuracy; CT scanners are no exception to this.  
MDCTA is therefore not a brand new technology (which would be rare in 
the area of diagnostic imaging), but is being proposed for diagnostic 
imaging of CAD where an invasive ICA would otherwise be indicated.  
Therefore, this headroom analysis (which does not relate to one particular 
scanner, but to the practice of MDCTA more widely) investigates the 
monetary opportunity for MDCTA, and so explores whether there is 
enough of a reimbursement opportunity in the market to support the 
development of new and improved MDCTAs.  It could be that 
developments / advances in this technology are what is needed in order 
to make them acceptably accurate and able to replace the reference 
standard in clinical practice, ICA. 
Therefore, this analysis could be seen as providing the maximum 
reimbursement opportunity for MDCTAs that perform as well as the 
reference standard, from which a developer could determine the 
feasibility of development.   
 
There is already some early data on the use of CT for non-invasive 
angiography (Achenbach et al. 2000;Harbel R & Steinbigler P 2001).  Some 
results of trials comparing invasive to non-invasive CT angiography 
demonstrate a sensitivity of 76-91% and a specificity of 84-97% (Harbel R 
& Steinbigler P 2001). De Feyter et al, in a recent (2003) review of multi-
slice CT conclude that “further technical improvements are necessary to 




make CT a clinically reliable diagnostic tool” (de Feyter et al. 2003). By 
comparing MDCTAs directly to ICAs in their performance (and ignoring 
issues of sensitivity and specificity), we will be exploring the economic 
case for these further development (using the top end of the possible 
performance of MDCTAs). 
      
The need for non-invasive angiography was highlighted by a study by 
Haberl et al, in which only 53% of those investigated by means of invasive 
coronary angiography actually had significant stenosis (Haberl et al. 2001). 
This is supported by a postal questionnaire that was undertaken to survey 
directors of public health in the UK, which found that the mean ratio of 
invasive treatment to angiography was 1:2 (Gunnell & Harvey 1996). 
 
The NHSC briefing is not absolutely clear whether ICA would still be 
indicated for those patients in whom CAD is detected non-invasively. In 
other words, the brief does not make clear whether MDCTA would be 
used as a ‘rule out’ method to ensure that those that don’t have 
significant CAD  do not undergo invasive angiography, or whether it is 
proposed to work just as well as ICA in the assessment of the heart prior 
to revascularisation.  One cost-effectiveness analysis for alternative test 
strategies for CAD models a situation where if non-invasive tests are 
positive than they would be followed by ICA (Garber & Solomon 1999).  
With regards to angiography prior to cardiac surgery, the NHSC briefing 
indicates that MDCTA could be used in patients for whom invasive 
angiography has either not worked or is unsafe.  Therefore, I will assume 
that the assessment of a patient with MDCTA (which would replace 
current ICA as first-line investigation CAD) would be followed by an ICA 
for those patients where severe occlusion is indicated and therefore who 
would require revascularisation. The sources cited above indicate that 
about half of those currently investigated with ICA result in cardiac 
surgery.  Therefore, I will assume that by investigating all CAD patients 
(that currently undergo ICA) with MDCTA first, half of these patients will 
avoid ICA and the other half will have to undergo ICA subsequently.   
 
3. Market size  The NHSC indicates that around 93,470 ICAs are performed per year in 
England.  However, this was based on 2005 data (beyond my time 
frame).  Assessing the Department of Health’s schedule of reference 
costs for the year 2002 (published 2003) (Department of Health 2003), 
‘Angiography’ comes under a couple of seemingly relevant HRG code 
labels: ‘Cardiology’ which had 22,311 attendances, and ‘Vascular Surgery’ 
which had 8,532 attendances’. The sum of these is 30,843, which is only a 
third of those reported by the NHSC for 2005.  The only thing that brings 
the estimate up to the 90,000 level is by including the 50,275 
Ophthalmology (eye) angiographies, which are clearly not relevant.  
Gunnel and Harvey (Gunnell & Harvey 1996) estimate that in 1996 in the 
UK, coronary angiographies were undertaken at a mean rate of 1,010 per 
million of the population, indicating that about 50,500 ICAs are 
undertaken every year in England (considering a population of about 50 
million). 




On the other hand, these figures would seem to underestimate the 
market size if we are considering that half of ICAs lead to 
revascularisation, and that about 81,261 revascularisation procedures are 
undertaken every year in the UK (adding together CABG and angioplasty 
statistics from the British Heart Foundation reported above). 
 
Therefore, it seems to be difficult to obtain a clear picture of market size.  
Also, it may not be appropriate to consider the market size in its absolute 
sense, as this headroom analysis sets itself within the space for MDCTAs 
in general, a space which is likely to be filled by many different 
companies.  Therefore, it would be more appropriate to consider this 
example exclusively on a per unit basis.  It is clear from the estimates 
above that there is a large market for imaging for the diagnosis and 
management of CAD.  
Market size per year: ? (large) 
 
4. Health Service 
 
Changes in resource use.  Any changes in 
service delivery costs to the NHS that will 
result from the application of the new 
technology, including the disinvestment in 
previous practice.  This could include: Staff 
time, hospital bed days, GP visits, A&E visits, 
etc.  It should not include services for which 
the NHS (and personal social services) is not 
financially liable (e.g. lost productivity and 
[non-health] social care costs), but these 
should be noted in writing below to add to 
the verbal case for the product (NICE may 
incorporate social care costs into cost-
effectiveness estimates in the near future). 
 
 If relevant and not included in service cost 
impact above, search for price of the 
currently used product (P1). 
 
Use HCHS index to inflate estimates to 










The potential headline advantages of MDCTA over 
ICA are that it would be less invasive, lower risk, 
quicker, and probably cheaper.  The baseline 
assumption form a healthcare cost perspective for 
this analysis is that half ICAs can be avoided by first 
using MDCTA to assess CAD.   
 
The important input for this is therefore the cost to 
the NHS of an ICA procedure.  The NHS reference 
cost database for 2002 (Department of Health 2003) 
provides the national average unit cost for specific 
HRG-coded interventions.  For ‘angiography’ under 
the cardiology label (HRG code E02op) and vascular 
surgery label (HRG code Q02op), the average cost is 
£278 and £379 respectively.  The NHSC briefing 
indicated that ICAs could cost between £134 and 
£1,600.  With the reference cost data being at the 
lower end of this range, and not knowing what was 
included in these costs, an estimate from a UK-based 
study in the literature was sought. 
 
Underwood and colleagues (Underwood et al. 1999) 
investigated the economics of myocardial perfusion 
imaging in various centres across Europe. For the cost 
of coronary angiography (ICA), they used the average 
costs from three UK centres (judged to be the most 
consistent from the study), which included the cost 
to the NHS of consumables, labour, fixed costs 
(amortised according to patient throughput, and 
including maintenance of equipment), capital 
charges, and also overnight stay (1996 figures).  The 
total cost of ICA was £1,100, which in today’s (2003) 















Describe any potential costs/savings that 
you haven’t quantified.  
prices, is £1,419 (i). 
 
If half of ICA procedures can be avoided, then the 
average cost per patient of those who now undergo 
ICA would be halved. 
 
(Total) ∆SC= - 




Use of MDCTA rather than ICA for those patients who 
do not turn out to have severe CAD, may mean that 
the complications associated with ICA are reduced.  I 
have not found any estimates that monetarise these 
complications, but the case for MDCTA should be 





Potential impact of the new device on 
patient health, as compared to current 
practice (preferred method of elicitation is 
from studies using the EQ-5D).   
Where NICE have not produced relevant 
economic analyses, search for cost-
effectiveness studies or systematic reviews 
within the disease area (the CEA registry 




















CAD is associated with significant risk to life (it is the 
leading cause of mortality in the UK) as well as a 
reduced QoL. 
 
Kuntz et al. describe quality adjustment weights for 
sufferers of angina (a major outcome of CAD), which 
ranges from 0.89 for mild to 0.78 for severe (Kuntz, 
Tsevat, Goldman, & Weinstein 1996). 
 
Another cost-effectiveness study that considers 
different diagnostic strategies for CAD uses standard 
gamble to assign health utilities of 0.87 for no 
symptoms, 0.81 for mild symptoms, and 0.67 for 
severe symptoms (Kuntz, Fleischmann, Hunink, & 
Douglas 1999). 
 
However, these QoL indicators have only been used 
to compare the outcome of patients that undergo 
different diagnostic tests that, due to variable 
performance, lead to different treatment strategies 
(which impact the quality and length of life of the 
patient).  I have found no cost-effectiveness analyses 
that have considered any QALY loss for the procedure 
itself.  Therefore, as I am assuming that treatment 
outcome would be the same for MCDTA + ICA 
(proposed strategy) and ICA alone (current practice), 
then I will assume that there is no effect on patient 
outcome.  
 
∆QALY= -  






Describe any impact on patient health that 
you haven’t quantified.  
(Av. per person) ∆QALY= - 
 
Intuitively, there is a great advantage in presenting a 
strategy whereby all those patients that currently 
undergo invasive angiography unnecessarily no 
longer will. The risk to patients that is inherent to 
invasive procedures would be reduced significantly, 
but again, I have found no figures to quantify this 
risk.  It should be noted, though, that there may be 
some safety issues with the high doses of radiation 
associated with MDCTA. 
 
6. Developments (clinical & healthcare 
context) 
 
Consider the following questions to help you 
think about the space for your product 
within the market.  
 
Does the technology address any key national 
objectives for improving care in this area? 
 
How will the technology complement current 
practice? Is current practice likely to change? 
 
Are there any indications in the literature of 
potential effectiveness? 
 
Have you identified any direct competitors? (This 
could be another specific technology, or simply a 
different technique)  
 
 RED: Poses a significant threat to the 
opportunity identified in the market (i.e. 
works against current health service 
objectives, or there are other products 
being developed that are associated with 
better outcomes or are at a more advanced 
stage of development). 
 
AMBER: Potential threat 
 
GREEN: Further supports the case for the 
new technology  
 [AMBER] If the treatment strategy following 
diagnostic imaging is revascularisation (e.g. by 
angioplasty), then it may be that the intervention 
could be performed straight after the diagnostic 
test.  If the diagnostic test were to be 
conventional invasive angiography, then this 
transition may be swifter and more cost-effective 
(avoiding the full cost of ICA plus 
revascularisation).  An investigation by 
Panchamukhi and Flaker (Panchamukhi & Flaker 
2000) found that catheter intervention 
(angioplasty) performed at the same time as the 
diagnostic cardiac catheterization, is safe, 
effective, and significantly reduces hospital stay 
and costs.  Indeed, interest has been raised in 
“diaventioanal” catheters that can function in 
both diagnostic and interventional capacities 
(Chatelain et al. 1994).  This would not be 
possible for MDCTA, as the procedure is 
dissimilar. 
 
 [AMBER] There are actually lots of alternative 
strategies of non-invasive angiography in 
development.  The NHSC produced a technology 
briefing on these emerging imaging techniques 
for coronary heart disease in 2001, of which 
MDCTA was one. Others included: myocardial 
ultrasound, nuclear medicine (SPECT, Pet) and 
MRI (MR spectroscopy, contrast MRI, coronary 
MR angiography).  This headroom analysis can 
really be seen as an analysis for any of these 
options, depending on which turns out to be the 
most effective (which, as it happens, seems to be 
MDCTA).  However, it is important to note that in 
such a busy area of development, any single 
technique is unlikely to achieve universal 






 [GREEN] The results presented by Underwood et 
al (Underwood et al. 1999) for myocardial 
perfusion as a non-invasive imaging test showed 
that savings arose mainly from excluding CAD 
without the need for invasive angiography, 
supporting the hypothesis for this headroom 
analysis. 
 
 [AMBER] However, this and other cost-
effectiveness analyses demonstrate the potential 
of other methods of non-invasive imaging for 
CAD (Garber & Solomon 1999;Kuntz, 
Fleischmann, Hunink, & Douglas 1999;Patterson, 
Eisner, & Horowitz 1995;Underwood et al. 1999).  
Whilst the case for these other techniques has 
not, it seems, been deemed sufficiently 
convincing to replace ICA as the gold standard at 
the moment, this may change in the future.   
 
 [AMBER] One cost-effectiveness analysis 
comparing exercise ECG, single photon emission 
computed tomography, positron emission 
tomography, and coronary angiography for the 
diagnosis of CAD find that, for patients with a 
high pre-test likelihood of CAD (>0.7), (invasive) 
coronary angiography shows the lowest 
cost/effect or cost/utility given current levels of 
diagnostic accuracy and resulting outcomes. Non-
invasive tests showed lower costs than 
angiography when pre-test CAD was < 0.5 
(Patterson, Eisner, & Horowitz 1995).  This makes 
sense when considering that those with a greater 
likelihood of significant CAD and therefore 
surgical treatment may need an ICA anyway.  This 
may indicate that MDCTA would be indicated for 
a smaller number of patients than what is 
presumed in this analysis.  This notion is upheld 
by Bohme et al who indicate that some CAD 
patients would need to be assessed invasively, 
and so would not profit from the CT scan (Böhme 
et al. 2003).   
 
7. Research questions 
 
This should be a list of the things that the 
developer needs to find out or monitor 
 Given the fact that innovation in this area is 
constantly moving; will future changes in current 
practice change the baseline for coronary 
angiography? 




during the process of development, relating 
to the function of the device or how it fits 
into the market place. 
 
From the research undertaken and reported 
above, what are the most important 
questions or uncertainties that must be 
addressed / tested? What factors or 
assumptions have the calculations / 
economic or clinical case hinged upon? 
What potential benefits or threats have you 
ignored in the calculation (see italicised 
points in Qs 4&5, and ‘developments’ 
section)?  
 Would these scanners be used in areas other 
than CAD? This would change the context of the 
analysis and significantly widen the relevant 
market. The headroom analysis just considers the 
use of a device in a specific context. 
 
 How quickly and to what extent will MDCTA be 
further developed / improved over time?  
 
 To what extent are angiography and angioplasty 
conducted in the same sitting? This may have an 
effect on the supposed cost-effectiveness of non-
invasive imaging like MDCTA. 
 
 To what extent does the risks associated with ICA 
impact NHS costs and patient outcome? Is there 
a significant mortality risk? 
 
 What are the risks of the high-dose radiation 
associated with MDCTA, and can these be 
quantified?  Would they be sufficiently great so 
at to reduce the chances of adoption? 
 
 How realistic is it to assume that MDCTA would 
work as well as ICA in the detection of CAD?  For 
the purposes of this analysis we have ignored 
issues of sensitivity and specificity.  Lee et al (Lee 
et al. 2002) show that the rate of false negatives 
in diagnostic strategies for CAD is very important 
when considering the cost-effectiveness of these 
strategies.  
 
 For what proportion of patients is invasive CA not 
appropriate? 
 
 Would there be any patients for whom imaging 
with CT angiography weren’t possible? 
 
 It may be that MDCTA is most cost-effective 
when acting as a ‘rule out’ tool for those patients 
who do not have high probability of CAD.  What 
proportion of those currently undergoing ICA 
does that represent? 
 
 The whole monetary valuation in this headroom 
analysis is based on the supposed cost of ICA.  Is 
the figure of £1,100 that was employed (as 
indicated by Underwood and colleagues) the best 
estimate? If instead I were to have used the cost 




indicated by the NHS reference cost database, 
which was about £330 on average, then the 
headroom for MDCTA would have become just 
£165 per test.  
Notes by AC 
(iii) The total cost of ICA in 1996 prices was £1,100.  This can be inflated to today’s prices 
using the HCHS price inflator: 
 
HCHS P&P Index 1995/6: 166.0 
HCHS P&P Index 2002/3: 213.8 
Inflation rate: 1.29 
 
Cost of ICA (2003): £1,100 * 1.29 = £1,419 
Headroom Notes (CT Angiography) 
Given the fact that... 
1. The total market size was uncertain 
2. There may be many products that fill the space in the market for MDCTA, and 
3. MDCTA is a piece of equipment, and understanding the allowable headroom per device 
rather than per person would require an understanding of the machine’s throughput... 
...I did not relate the headroom to the implied allowable development costs. I was also unable to 
derive an MRP (maximum reimbursable price per device) because of point 3.   
What the headroom analysis does deliver is, under the assumptions outlined, the headroom per 
patient of a strategy using MDCTA before ICA.  This headroom was £710, and represents the 
maximum cost that the NHS should be willing to pay to put one patient through a scan with a MDCTA 
machine.  As the cost estimate used for ICA was inclusive of all component costs of the procedure, 
this £710 must include total NHS costs for the new imaging technique including hospitalisation, 
labour costs, equipment etc.  Although the equipment costs for MDCTA are not likely to be small 
(and may take up most of this ‘headroom’), the total service costs implicated for the use of MDCTA, 
which must also be considered within this £710 figure, may be reasonably modest as the process is 
said to deliver results in just 10 minutes and, given its non-invasive nature, patient recovery time it 
likely to be short.  
The issues raised in the ‘developments’ and ‘research questions’ sections should be considered 
alongside this figure in order to appreciate the likelihood of this ‘maximum reimbursement’ being 
achieved.  Especially worth considering is the research question which examines the effect of taking a 
different estimate of ICA cost. This may reduce the headroom per patient dramatically, to just £165. 
The developer should consider which of these is the more likely / appropriate estimate.  
 




Follow-up (CT Angiography) 
Headroom Outcome and Market success 
Does the MRP look realistic? Would it have indicated yes or no to development? 
No MRP per se was delivered (as the MDCTA scanner would be a piece of equipment that would be 
used by an unknown number of patients), but a headroom was found of £710 per patient.  This 
represented the cost saving to the NHS of avoiding half of the invasive coronary angioplasties (ICAs) 
that were previously undertaken.   
As described in the pro forma, this headroom analysis was performed not on the basis of one 
particular product to have been invented by one particular company, but on the monetary 
opportunity in the market for developments in CT angiography. Indeed, the NHSC technology briefing 
that was produced in 2006 provided information on four developers of these scanners: LightSpeed 
VCT from GE Healthcare, Brilliance 64 from Philips Medical Systems, Somatom Sensation 64 from 
Siemens Medical Solutions, and Aquillon 64 from Toshiba America Medical Systems. There are likely 
to be others.  All present the same offering in general terms, with slight variations in slice number, 
resolution and reconstruction time.   
The NHSC briefing indicates that the purchase cost of a MDCTA (64-detector (or ‘slice’) CT scanner) is 
around £600,000 to £1.2 million.  Considering the equipment costs alone and relating this to the 
headroom calculated, this would require a throughput of about 170 to 340 patients per year per 
scanner to recover costs, if the machine were to last 5 years (completely speculative, and ignores 
service costs involved in undertaking the scan and reviewing the results).  The feasibility of this would 
depend on distribution-level decisions, and how many scanners would be required to practically 
service all patients (in their respective locations) that would require it.  
An HTA that was conducted from a UK perspective which presented a systematic review of the 
clinical and cost effectiveness of CT angiography, used in its modelling a cost of £206 per test with 
MDCTA (Mowatt et al. 2008).  This is well below the headline headroom of £710, indicating ample 
room for development.  If, however (as presented in the ‘research questions’) we were to have used 
the cost estimate for ICA from the NHS reference costs, then the headroom would have been just 
£165; this is below the transpiring cost of MDCTA, indicating that under that assumption, the 
reimbursement opportunity may not have been deemed sufficient (depending on how close to the 
unit cost to the manufacturer the £206 is).  
Headline headroom estimation would most likely have indicated ample room for development.  
However, the output of sections 6 and 7 should have also been considered alongside this in the 
development decision; one issue to be presented was the effect of using a different source for the 
estimation of ICA cost.  If this had been considered appropriate, then this might have changed the 
decision outcome. 





Has there been a decision made on it by NICE? What was the outcome? 
In 2010 NICE produced a clinical guideline (95) for ‘Chest Pain of Recent onset’ (NICE 2010a).  In it, 
they recommend that for high risk CAD, ICA should be used as the first-line diagnostic investigation. 
CT angiography is recommended to assess people with a probability of CAD of 10-29% and a calcium 
score of 400 or less.  Those patients with a calcium score of 400 or more were deemed too difficult to 
image with the earlier generation (64-slice) CT scanners that were assessed. It was noted in a 
research recommendation that the use of CT angiography should be investigated as a more general 
‘rule out’ strategy for CAD. 
It has become clear upon follow-up that the ‘64 slice’ MDCTAs, which did not yet exist at the time of 
headroom (and indeed were the newest version at the time of the NHSC briefing publication in 
2006), are now labelled ‘earlier generation’ CT scanners.  NICE’s new diagnostic assessment 
programme have drafted guidance for new generation cardiac CT scanners (consultation period 
ended October 2010, and it is due for publication in January 2012).  They (provisionally) support their 
use in the NHS in England as first-line imaging of people with suspected or known CAD, in whom 
imaging is difficult with earlier generation CT scanners, and whose estimated probability of CAD is 20-
29% (NICE 2011d).   
 
Is it sold in the UK or the rest of the world?(Or has it in the past) If so, who is it bought by? 
I assume that CT angiography has been (or at least will be) incorporated into clinical practice in the 
NHS, as per NICE recommendations. 
An internet search for the MDCTAs that were indicated in the NHSC brief indicate that they seem 
successful (and have since been upgraded), for not only CAD but also other diagnostic capacities. As 
described above, the systems have already moved on and developed, and the NICE diagnostics 
guidance in fact considers the use of the very four products that were presented by the NHSC, but 
updated and advanced: 
Company 64-slice MDCTA ‘New generation’ CT 
GE Healthcare LightSpeed VCT Discovery CT750 
Phillips Healthcare Brilliance 64 Brilliance iCT 
Siemens AG Healthcare Somatom Sensation 64 Somatom Definition Flash CT 
Scanner 
Toshiba Medical Systems Aquillon 64 Aquillon ONE 
 
When examining patient-facing websites such as the information offered to CAD patients by NHS 
choices (NHS Choices 2011b) and the British Heart Foundation (British Heart Foundation 2011), CT 
angiography is not mentioned under the possible diagnostic tests outlined.  In both, those that are 
mentioned are ECG, x-rays, echocardiogram, blood tests, (invasive) coronary angiography, 
radionuclide tests, and MRI scans.  As there are so many different alternatives in coronary imaging, 
and each seem to have specific advantages or disadvantages in particular settings, it may just be that 
the list is too long and indications too specific to incorporate all of these potential options at a 




general level (or that the official guidelines that incorporate these other techniques are less than a 
year old).     
Have there been investigations into its clinical / cost effectiveness? 
There continues to be a strong presence in the literature of imaging techniques for CAD. 
In 2008 the NIHR produced an UK-based HTA which involved a systematic review of the clinical and 
cost-effectiveness of CT angiography against ICA (Mowatt et al. 2008).  The authors, Mowatt and 
colleagues, conclude that the proportion of ICA that might be replaced by MDCTA is uncertain, but 
that it would mainly be at the diagnostic end (rather than for revascularisation assessment). They 
find that its main use would be to rule out significant CAD, and that it is unlikely to replace ICA in the 
assessment of patients for revascularisation, especially as angiography and angioplasty are often 
conducted at the same time (Mowatt et al. 2008) (as noted as a potential factor in the headroom 
analysis).  They found CT angiography to be highly sensitive in pooled estimates (99%), and a high 
negative predictive value. Results varied between studies, with one finding that the use of MDCTA 
did not significantly affect the number of ICAs undertaken subsequently, and another finding that in 
the 6 months following MDCTA, ICA was avoided in 82% of those patients who would otherwise have 
undergone ICA.  On the cost side, Mowatt et al. use as a base case cost for ICA of £320 (very close to 
the estimate derived from the NHS reference cost database in the headroom analysis).  They do 
acknowledge that higher estimates have been identified in the literature, and use the same source 
that I did (Underwood) in a sensitivity analysis.  They conclude that the results suggest a scope for 
avoiding unnecessary ICAs. 
Cost-effectiveness analyses for MDCTA are generally positive.  One study by Amemiya &Takao use a 
Markov model to explore its cost-effectiveness and find that using CT angiography as first-line 
examination for men of 60 years of age at risk of stable CAD achieved similar QALY gains to 
conventional ICA, but cost less (Amemiya & Takao 2009).   Kreisz et al (Kreisz et al. 2009) find that CT 
angiography is a cost-effective rule-out strategy for symptomatic patients who are at 
low/intermediate risk of CAD.  Two decision analytic cost-effectiveness analyses that were 
undertaken from a U.S. healthcare payer perspective (Khare et al. 2008;Ladapo et al. 2008) find CT 
angiography to be either cost-effective or (more often) cost saving for patients with low-risk chest 
pain. 
There are a multitude of papers comparing the various imaging technologies to each other in the 
context of CAD, but perhaps the most relevant, up to date, and inclusive study into the clinical and 
cost-effectiveness of CT angiography is that presented by the diagnostics assessment programme 
within NICE (to be published officially January 2012). This assessment was performed with data 
pertaining to the new generation scanners listed above, which are quicker, involve a reduced 
radiation dose, and are more accurate in specific patient groups than the older 64-slice versions.  The 
scanners were investigated in terms of their cost and effectiveness for the imaging of patients for 
whom it was difficult or impossible to image, reasons for which include patients who are obese, have 
high heart rates, arrhythmias, intolerance to β-blockers, or previous stent implants or bypass grafts.  
ICA was considered to be associated with a (small) risk of complications such as stroke, non-fatal 
myocardial infarction and death. The results of the economic evaluation show that these new 




generation cardiac CTs are cost-effective for difficult to image CAD patients, and that strategies that 
include them yield equivalent QALYs and are cost saving (NICE 2011d).  
 
 
Has the landscape described changed significantly? 
What is current gold standard clinical practice now? Has this changed? 
There are many imaging technologies for CAD, which have an increasing role to play in this area, and 
which are being constantly developed and advanced.  Although ACI seems to be the main technique 
used in many cases (i.e. where likelihood of CAD is high, and especially where revascularisation is 
being planned), various imaging options are employed, and have a role to play / are recommended 
for particular circumstances.  Clinical Guideline 95 (NICE 2010a) for ‘Chest pain of acute onset’ 
describes the role of the various techniques, including CT angiography, and the role of new 
generation CT scanners is described in the Diagnostic guideline (NICE 2011d).   
Are there now many direct competitors? 
There are many other techniques, many of which have a specific role to play in the imaging of CAD 
patients who fulfil certain criteria (see CG 95 (NICE 2010a)).  Indeed, many of these are described by 
the National Horizon Scanning Centre.  In 2001 a briefing was published for ‘Imaging in Coronary 
Heart Disease’ which described many of these (NHSC 2001a), and subsequently MRI imaging (NHSC 
2007b) and MRA  imaging (NHSC 2007a) have been considered specifically by the NHSC (in 2007) for 
CAD patients.  This indicates that the sector is continually developing, and that the available 
technology comes in a variety of forms.  In essence, the headroom analysis (being non-specific in its 
nature) was relevant to them all. 
 
Conclusions: How useful might the headroom exercise have been? 
In the headroom pro forma, it was noted that MDCTA was not a brand new technology, having been 
developed from earlier CT scanners (even though these weren’t in relation to CAD specifically).  
Therefore, the purpose of the headroom analysis was to evaluate the space for developing the 
technology further, on the basis that advancing the technology to a level that could bring its 
performance closer to that of ICA may be what is required to achieve market coverage.  By 
considering the role of invasive CA as the mainstay of clinical practice in this area, MDCTA was tested 
in the headroom analysis as a ‘replacement’ of this as the first-line imaging strategy.  As the 
headroom analysis considered only the factors and costs associated with ICA, which could be avoided 
if the technique were to be replaced, it could be applicable for any of the non-invasive angiographies 
that are being developed.   
It has become clear in following up the device that technological developments in this area is very 
fast moving, and even the CT angiographies that were ‘on the horizon’ in 2007 have already been 




improved and updated to newer versions which are quicker, more accurate, and produce less 
radiation.  The headroom approach took the optimistic view that CT angiography could replace ICA in 
its first-line diagnostic capacity (whilst noting that ICA would still be required for those patients being 
considered for revascularisation). However, it was also indicated in the ‘developments’ and ‘research 
questions’ sections why this might not be the case, e.g. that for those with higher risk CAD it might 
be more appropriate to proceed straight to ICA, or for those cases where angiography and 
angioplasty might be conducted at the same time, etc. These considerations turned out to be 
completely relevant.   
By presenting the monetary value of the ‘best-case’, the value of iterative developments, which may 
eventually achieve diagnostic equivalence between CT and ICA, is articulated.  This seems to make 
sense in a market of continual development.   
The headroom, which overall seemed conducive to a positive development decision, relates 
favourably to subsequent cost-effectiveness analyses that have found MDCTA to be cost-effective 
(albeit in relation to specific sub-populations).  It was also encouraging to note that the large UK-
based HTA considered many of the same sources of evidence that had been identified for the 
headroom analysis in a short time-frame and with a date restriction of 2003 for searches.  Also, most 
of the issues / uncertainties that were articulated by the ‘research questions’ were appropriate and 
important. 
What isn’t considered by a headroom analysis is that, in this sort of area, developments are likely to 
be organic rather than the result of a specific early economic evaluation; companies are likely to 
want to ensure that they stay at the forefront of technological innovation.  Also, in this particular 
case, the technology involved is useful not only for imaging CAD patients, but would most likely be 
useful in a much wider set of diagnostic capacities.   The headroom method focuses on its application 
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Haemorrhoids, sometimes referred to as piles, are swollen or inflamed 
blood vessels that are located in or around the anus or lower rectum 
which can be internal or external.  They are often associated with itching, 
mucus discharge, pain, and bleeding when passing stools.   
Haemorrhoids are classified into stages of severity, of which there are 
four. Third and fourth degree haemorrhoids involve prolapse of the 
haemorrhoids, and may indicate the need for surgical removal (usually 
after having tried less invasive management methods). 
 
Prevalence of haemorrhoids is very difficult to ascertain and estimates 
vary greatly.  Johanson and Sonnenberg estimate a prevalence rate of 
4.4% among U.S. citizens (Johanson & Sonnenberg 1990).   They tend to 
occur in older people (though not exclusively), and certain risk factors 
including diet and specific events like childbirth increase the likelihood of 
haemorrhoids (a study of women at Birmingham maternity hospital found 
that 18% of women reported haemorrhoids following childbirth, half of 
which reported them occurring for the first time (MacArthur C, Lewis M, 
& Knoz E G 1991)). 
 
Stapled haemorrhoidectomy40 uses an intraluminal circular stapling device 
which is introduced into the anal canal; the staples are applied and the 
redundant tissue is removed.  It is intended for third and fourth degree 
haemorrhoids.   It is thought that procedure could be carried out as a day-
case, be less painful than conventional haemorrhoidectomy, and reduce 
recovery time. 
 
2. Comparator  
 
Small haemorrhoids are quite common and often don’t require any 
treatment at all.  For those that do require treatment, the options 
available vary in type and invasiveness depending on the severity of the 
haemorrhoid. Treatment could start with the administration of creams or 
the prescription of laxatives.   
For grade two or three haemorrhoids, the following strategies are 
sometimes employed. They all aim to reduce symptoms and obstruct the 
blood flow to the haemorrhoid: 
 Banding:  A very tight elastic band is placed around the 
haemorrhoid inside the anus in order to cut off the blood supply, 
allowing it to fall off within about seven days of treatment.  
 Sclerotherapy: An injection is administered into the blood vessels 
around the anus, which reduces the swelling. 
 Infrared coagulation: A probe is inserted into the anus and emits 
infrared light onto the affected tissue, which burns and shrinks 
the haemorrhoid (often used for grade one or two haemorrhoids. 
 
Surgery is usually reserved for grade three or four haemorrhoids.  
                                                          
39
 A date limit of 1995 has been chosen as the device was introduced into the UK in 1998 
40
 Haemorrhoidectomy is also known as haemorrhoidopexy.  




The main method employed is standard haemorrhoidectomy, which 
involves the surgical removal of the haemorrhoid, with or without closing 
the wound that is left.  The gold standard in UK clinical practice, and thus 
the most appropriate ‘comparator’ for this new device, is 
haemorrhoidectomy using the Milligan-Morgan technique.  The operation 
is generally performed under general anaesthetic.  It can be performed as 
a day-case procedure, but normally requires an inpatient stay (of about 3 
days, according to the NHSC briefing).  
 
3. Market size  In the NHSC briefing, the estimated number of haemorrhoid removal 
operations is 26,514, over half of which (14,373) are undertaken as day-
case procedures (according to 1998/99 HES data).  This does not seem to 
uphold the assertion made in the briefing that most conventional 
haemorrhoidectomies require an inpatient stay of around 3 days.  Being 
unable to identify the source for the 98/99 estimates, I searched the 
hospital episode statistics (HES) database to find an estimate of 
haemorrhoidectomies undertaken and the proportion of these that are 
undertaken as day-case procedures.  The first date for which 
haemorrhoid procedure data was available that I could find was for 
1999/2000.  Although this was past my date restriction, I thought it 
would be important for the headroom analysis to understand the likely / 
feasible effect size of stapled haemorrhoidectomy, by making sure I 
understood the current landscape for current treatment.  
For 1999/2000, HES data indicates that 10,292 excision procedures for 
haemorrhoids were undertaken (HES code H51); there were 22,772 
‘destruction of haemorrhoid’ procedures (H52) and 1,676 ‘other’ 
surgeries for haemorrhoids (H53) (HES 2000b).  Codes H52 and H53 must 
relate to procedures such as rubber banding, sceloptherapy, and 
coagulation.  The day-case count for all excision operations in 1999/2000 
was 12%, indicating that 88% involved an inpatient stay.   
 
This obviously differs from the information given in the NHSC briefing, 
but it may be that they considered the summary data file that reports 
headline figures (including other types of haemorrhoid treatment) rather 
than the break-down of interventions.  The main procedures database 
includes ‘Operations on haemorrhoid (H51-H53)’, which in 1999/2000 
was 27,392, of which 57% were day case (HES 2000a).  This is very similar 
to the figures used in the NHSC briefing, and would be inappropriate to 
use as this would include data for non-excision surgery, thus inflating the 
relevant market size as well as providing an inaccurate estimation of day-
case procedures in current surgical haemorrhoidectomy.  Therefore, I will 
use the estimations presented above for haemorrhoid excision 
procedures.   
Market size per year: 10,300 
 
4. Health Service 
 
Changes in resource use.  Any changes in 
The principle proposition of stapled 
haemorrhoidectomy on the health service costs is the 
reduced time in hospital for patients.   




service delivery costs to the NHS that will 
result from the application of the new 
technology, including the disinvestment in 
previous practice.  This could include: Staff 
time, hospital bed days, GP visits, A&E visits, 
etc.  It should not include services for which 
the NHS (and personal social services) is not 
financially liable (e.g. lost productivity and 
[non-health] social care costs), but these 
should be noted in writing below to add to 
the verbal case for the product (NICE may 
incorporate social care costs into cost-
effectiveness estimates in the near future). 
 
 If relevant and not included in service cost 
impact above, search for price of the 
currently used product (P1). 
 
Use HCHS index to inflate estimates to 






























The NHSC indicates that theatre time for stapled 
haemorrhoidectomy and the conventional method 
would be approximately the same, so I will assume 
that the operating theatre costs for the two 
procedures are equivalent.  Aside from the cost of 
the device itself (for which we are finding the 
headroom), the following factors would impact 
positively or negatively on service costs to the NHS: 
 (Saving) The cost of sutures used for 
conventional haemorrhoidectomy is 
approximately £1. 
 (Cost) Surgeons may recommend the use of 
prophylactic (preventative) antibiotics prior to 
stapled haemorrhoidectomy. 
 (Cost) Training of surgeons would be required for 
stapled haemorrhoidectomy. 
 (Saving) Stapled haemorrhoidectomy can be 
undertaken as a day-case. 
 
Without knowing the type of antibiotic that might 
potentially be prescribed (cheap or expensive), and 
to what extent they would be prescribed, I will ignore 
this potential cost, and presume it to cancel the 
saving from sutures that are used for conventional 
haemorrhoidectomy. 
Training of staff will be required, and must be 
conceptually incorporated into the headroom 
calculated (it is often the case that training is 
provided by the manufacturers of a new device 
anyway).  
 
So, the most important cost-saving factor that must 
be calculated is the potential impact of stapled 
haemorrhoidectomy on the cost of hospital stay for 
recovery post-surgery.  By reducing the level of pain 
and shortening recovery time, it is thought that 
stapled haemorrhoidectomy could be carried out as a 
day-case (the patient does not require the use of a 
hospital bed overnight).  
 
An article published in the Lancet in 1964 discussing 
hospital length of stay for patients undergoing 
surgical procedures at the Aberdeen Royal Infirmary 
(Campbell & Dudley 1964) found an average 
inpatient stay after a haemorrhoid operation of 5.4 
days.  As hospital care and the surgical procedure for 
haemorrhoids has improved over the years, so has 
the recovery prospects for patients undergoing 
haemorrhoidectomy.  The NHSC briefing indicates 














































that the average LOS for those undergoing a 
conventional haemorrhoidectomy who require an in-
patient stay is about 3 days.  Conventional 
haemorrhoidectomy can also be carried out as a day-
case, but the proportion of operations for which this 
happens is uncertain.  
 
Given the estimations presented in section 3, I will 
use the assumption that currently, conventional 
haemorrhoidectomy is performed as a day-case 
procedure in about 10% of cases (baseline estimate).  
I will also test the assumption that 50% of current 
haemorrhoidectomies are undertaken as day-cases 
to account for possible improvements in current 
practice. 
  
It is unlikely that a patient will be sent home straight 
after a haemorrhoidectomy even in a day-case 
scenario, so I will assume that on average two days’ 
worth of hospital costs would be saved by a patient 
being operated on in a day-case scenario as 
compared with an in-patient stay, at a price of £300 
per day (as indicated by the NHSC)41.  I will also 
assume that all stapled haemorrhoidectomies are 
performed as day-cases42.   
 
If one patient who would currently undergo 
conventional haemorrhoidectomy with a 3 day in-
patient stay, were to instead receive stapled 
haemorrhoidectomy which is performed as a day 
case, £600 in hospital costs would be saved. 
 
If 10% of those currently undergoing conventional 
haemorrhoidectomy are treated as day-case 
procedures (Scenario 1), then switching all patients 
to stapled haemorrhoidectomy would save the 
following in hospital costs for the ‘average’ patient: 
£600*0.9 = £540 
 
If 50% of those currently undergoing conventional 
haemorrhoidectomy are treated as day-case 
procedures (Scenario 2), then switching all patients 
                                                          
41
 The NHSC indicates that much of the information provided in the briefing is from Ethicon.  Without 
having provided a source for the £300 cost estimate for a hospital day, I will presume this to be a 
company estimation.  The estimate is comparable to other estimates in the literature (NHS reference 
costs started being reported in 1998) 
42
 The briefing indicates that in cases where in-patient hospital stay is required, stapled 
haemorrhoidectomy would reduce the length of this hospital stay. However, it is implied that most will 
be day-case procedures, and two days of hospital stay saved seems like a reasonable average 
marginal impact under either scenario. 

















Describe any potential costs/savings that 
you haven’t quantified.  
to stapled haemorrhoidectomy would save the 
following in hospital costs for the ‘average’ patient: 
£600*0.5= £300 
 
Scenario 1 (basecase etimate) 
(Total) ∆SC= £5.56 million  
(Av. Per person) ∆SC= £540 
 
Scenario 2 (testing the effect of improvements in 
current practice) 
(Total) ∆SC= £3.09 million 
(Av. Per person) ∆SC= £300 
 
The cost of antibiotics which may potentially be 
prescribed with stapled haemorrhoidectomy has not 




Potential impact of the new device on 
patient health, as compared to current 
practice (preferred method of elicitation is 
from studies using the EQ-5D).   
Where NICE have not produced relevant 
economic analyses, search for cost-
effectiveness studies or systematic reviews 
within the disease area (the CEA registry 
offers a useful platform to identify these 
studies). 
 
Describe any impact on patient health that 
you haven’t quantified.  
The reason that surgery is only indicated for those 
patients with third or fourth degree haemorrhoids is 
that, as well as the associated costs, the procedure 
can be very painful.  It is thought that stapled 
haemorrhoidectomy would be less painful for 
patients, reduce recovery time, and return patients 
to their normal activities quicker. 
 
It is recommended that patients take a week or so off 
work for the wounds to heal after having undergone 
surgical haemorrhoidectomy, and that pain may last 
for a few weeks43. 
 
After stapled haemorrhoidectomy, it is likely that 
patients will still need some recovery time, but that 
the period of pain experienced would be shorter and 
less acute.  I found no estimations of QoL for 
haemorrhoids or related procedures in the literature.     
In order to estimate the effect of this in terms of 
QALYS, I use the findings of Williams (Williams 1995), 
who presents the time trade-off tariff for each 
combination of health states within the EQ-5D 
questionnaire, which was estimated from a large 
study of the UK population (3,395 people).  For each 
of the five health dimensions (mobility, self-care, 
usual activity, pain/discomfort and 
anxiety/depression), there are three levels (no 
problems, some / moderate, or extreme problems).  
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 I could not find any precise estimation of recovery duration in the clinical literature.  Therefore, this 
information was retrieved from a patient-facing website (NHS Choices).  This information should easily 
have been accessible in 1995 for those working in the field.   





To get a rough estimate of the additional QALYs 
associated with an improved recovery period, let’s 
assume that stapled haemorrhoidectomy is 
associated with two fewer weeks in a health state of 
11221 (perfect health apart from ‘some problems 
performing usual activities’ and ‘moderate pain or 
discomfort’). This health state is said to be associated 
with a quality of life tariff of 0.76.  To translate this 
into QALYS we must multiply the impact on QoL 
(QoL2-QoL1) by the time in which this improvement is 
experienced (2 weeks = 0.038 years): 
 
(1 - 0.76) * 0.038 = 0.00912 QALYs.  
 
This would be gained by all patients.  
∆QALY= 94 QALYS 
(Av. per person) ∆QALY= 0.00912 
 
6. Developments (clinical & healthcare 
context) 
 
Consider the following questions to help you 
think about the space for your product 
within the market.  
 
Does the technology address any key national 
objectives for improving care in this area? 
 
How will the technology complement current 
practice? Is current practice likely to change? 
 
Are there any indications in the literature of 
potential effectiveness? 
 
Have you identified any direct competitors? (This 
could be another specific technology, or simply a 
different technique)  
 
 RED: Poses a significant threat to the 
opportunity identified in the market (i.e. 
works against current health service 
objectives, or there are other products 
being developed that are associated with 
better outcomes or are at a more advanced 
stage of development). 
 [GREEN] A meta-analysis of haemorrhoidal 
treatment modalities found haemorrhoidectomy 
to be significantly more effective than manual 
dilation of the anus, rubber band litigation and 
scelotherapy (MacRae & McLeod 1995).  The 
authors conclude that rubber band litigation 
should be used in the first instance; 
haemorrhoidectomy shows better response rates 
but is associated with more pain and 
complications. This recommendation is upheld by 
others (Murie, Mackenzie, & Sim 1980).  If 
stapled haemorrhoidectomy could reduce the 
pain experienced by patients and complications 
associated with the procedure, then it may 
overcome this barrier, and be recommended in 
more cases than haemorrhoidectomy is 
currently.  
 
 [AMBER] A clinical trial and economic evaluation 
conducted in 1977 which considered day-case 
surgery for haemorrhoidectomy, found that 
complications were twice as likely in the day-case 
group compared with the long-stay patients 
(Russell et al. 1977).  Day patients also received 
more visits from the district nurse, and had more 





AMBER: Potential threat 
 
GREEN: Further supports the case for the 
new technology  
GP consultations following the surgery. Although 
the economic evaluation was old-fashioned44, 
this may indicate that further care outside the 
hospital setting may be required for day-case 
patients.  However, rather than simply reducing 
the length of stay in hospital for patients 
undergoing the same procedure (as in the study 
by Russell and colleagues), the assumption made 
in this analysis is that stapled 
haemorrhoidectomy reduces length of hospital 
stay because its impact on patients in terms of 
morbidity and complications is lower than 
conventional haemorrhoidectomy. 
 
 [GREEN] Drug costs may be reduced for stapled 
haemorrhoidectomy patients due to its lower 
morbidity implications (patients are often 
prescribed narcotics following haemorrhoid 
surgery) (Kilbride, Morse, & Senagore 1994). Cost 
of pain management in primary care may be 
reduced following stapled haemorrhoidectomy.  
 
7. Research questions 
 
This should be a list of the things that the 
developer needs to find out or monitor 
during the process of development, relating 
to the function of the device or how it fits 
into the market place. 
 
From the research undertaken and reported 
above, what are the most important 
questions or uncertainties that must be 
addressed / tested? What factors or 
assumptions have the calculations / 
economic or clinical case hinged upon? 
What potential benefits or threats have you 
ignored in the calculation (see italicised 
points in Qs 4&5, and ‘developments’ 
section)?  
 Is it sensible to assume that all stapled 
haemorrhoidectomy procedures are undertaken 
as a day-case procedure?  If not, what 
assumption would be more appropriate, and how 
would this impact the estimation of 2 hospital 
days saved per patient? 
 
 What are the quality of life implications for pain 
following surgery, and how would this be altered 
with the new procedure? Search for any 
developments in the literature that test for this 
parameter, and adjust the QALY estimates 
accordingly. 
 
 What is the likely cost of antibiotics that might be 
prescribed before stapled haemorrhoidectomy? 
If these costs are significant, then they should be 
subtracted from the headroom figure. 
 
 This analysis has assumed that conventional and 
stapled haemorrhoidectomy are equally as 
                                                          
44 For example, it was suggested that the cost saving from reduced length of stay could be limited to 
the expenditure on provisions and laundry, and that this net saving could be cancelled out if actually 
the recovering surgical patients help nursing staff by carrying out small tasks on the ward (Russell et 
al. 1977). 




effective as each other at removing the 
haemorrhoid, by implicitly assuming equivalent 
complication and recurrence rate.  Is this 
appropriate, or could stapled 
haemorrhoidectomy be associated with 
increased / decreased complications and later 
recurrence? 
 
 Would the device be easy to copy? 
 
Headroom Notes (Stapled Haemorrhoidectomy) 
By considering the possible cost-saving and QoL-enhancing effect of stapled haemorrhoidectomy 
versus conventional haemorrhoidectomy, the MRP in the basecase is £772 to £814 (depending on a 
£20/£30,000 WTP).  This assumes the following things about stapled haemorrhoidectomy versus 
conventional haemorrhoidectomy: 
 2 hospital days are saved, 
 Recovery time is 1 week rather than 3, and 
 Conventional haemorrhoidectomy is undertaken as a day case in 10% of cases, and 
 All stapled haemorrhoidectomy procedures are undertaken as a day-case. 
To examine the effect of stapled haemorrhoidectomy in the context of improved current practice, I 
also tested the effect of assuming that half of all current procedures are undertaken as a day-case, in 
which case the headroom was £482 to £574.  
These figures must include the provision by the company (or NHS) of training to hospital staff on the 
use of the product, calculated on a per unit basis.  Also, if antibiotics will be used systematically with 
the procedure, then this should also be subtracted from these figures. 
The analysis yielded the following prospects for development costs / profit. 
 





Follow-up (Stapled Haemorrhoidectomy) 
Headroom Outcome and Market success 
Does the MRP look realistic? Would it have indicated yes or no to development? 
The MRP for stapled haemorrhoidectomy under the basecase was £772 to £814.  Incorporating an 
improvement in current practice resulted in a minimum MRP of £482 (see pro forma sheet and 
headroom notes for assumptions made).  Assuming that variable costs of production were £100 or 
under, then the maximum allowable development costs would have been at least £7.4 million in the 
basecase (assuming full market coverage). 
The NHSC briefing indicates that the price of the Ethicon stapling device is £256 per unit.  Unless the 
cost of training staff (and possibly antibiotics if indicated) were more than £200 for each procedure 
undertaken, then even when incorporating huge improvements in the current procedure, the MRP 
would still have been sufficient to cover what is now charged for the device.  In the technology 
appraisal conducted by NICE for the device, a price of £420 is indicated.  The basecase headroom 
(£772 to £814) would likely still have left ample room for development at this price, but depending 
on changes in assumptions made about impact on hospital length of stay, this (probably more 
reliable) estimated price of £420 for the stapler device would make it a closer call. 





























Variable cost per device (including consumables) 
Scenario 1: MRP = £814 
Scenario 2: MRP = £482 




Has there been a decision made on it by NICE? What was the outcome? 
In December 2003, NICE produced an Interventional Procedure Guidance (IPG 34) on the use of 
circular stapled haemorrhoidectomy. In it they conclude that “Current evidence on the safety and 
efficacy of circular stapled haemorrhoidectomy appears adequate to support the use of the 
procedure, provided that normal arrangements are in place for consent, audit and clinical 
governance” (NICE 2003b).  They emphasise that clinicians wishing to undertake the procedure 
should be trained and mentored.  
NICE have also produced a technology appraisal for the device, which was published in September 
2007 (NICE 2007b).  In their list of ‘consultees and commentators’, there are two companies under 
manufacturers/sponsors: Ethicon Endo-Surgery (Johnson&Johnson), and Tyco Healthcare UK Ltd.  
Upon reading the appraisal, the committee make it clear that the recommendations refer to the 
circular stapler produced by Ethicon Endo-Surgery, and that there was no evidence to recommend 
the Autosuture stapler with STRAM kit adaptor (which is the model produced by Tyco Healthcare).   
Stapled haemorrhoidectomy is recommended as an option for people in whom surgical intervention 
is appropriate in the treatment of prolapsed internal haemorrhoids.   
Is it sold in the UK or the rest of the world?(Or has it in the past) If so, who is it bought by? 
In 2000, the Australian Safety and Efficacy Register of New Interventional Procedures- Surgical 
(ASERNIP-S) produced a review of stapled haemorrhoidectomy and categorised the procedure as 
category C (safety and efficacy not proven) (NHSC 2001b).  Since, and with the increased availability 
of data, the device has been recommended by NICE as a safe and effective procedure (NICE 2003b), 
as well as a cost-effective one (NICE 2007b).   
Stapled haemorrhoidectomy is mentioned in all the patient-information websites that I have come 
across (Patient UK, NHS Choices, etc), and the device is presented, along with many other stapling 
devices, on the Ethicon Endo-Surgery website.  Given the plethora of clinical trials presented in the 
literature for stapled haemorrhoidectomy, I believe it to be used in many countries for the treatment 
of patients with haemorrhoids.  I don’t believe it to have replaced conventional haemorrhoidectomy 
entirely.  
 
Have there been investigations into its clinical / cost effectiveness? 
There is much literature on stapled haemorrhoidectomy. The following is a brief summary of some of 
the important research undertaken for the procedure. 
Clinical Effectiveness 
In the IPG NICE guidance published in 2003, specialist advisors to the committee indicated that 
stapled haemorrhoidectomy was as effective as the surgical alternative (but that long-term data was 
needed to confirm durability). They also suggested that safety concerns were theoretical and mostly 
unsupported by trials (NICE 2003b).   
The Cochrane collaboration produced an intervention review for stapled haemorrhoidectomy versus 
conventional surgery in 2006 (Jayaraman, Colquhoun, & Malthaner 2006).  In it, data was sought 
from all published RCTs. The main findings were that although pain seemed to be reduced (this effect 




was not always being significant), stapled haemorrhoidectomy was associated with higher risk of 
recurrence and prolapse; it was concluded that if recurrence and prolapse are the most significant 
clinical outcomes, then excision should remain the ‘gold standard’.  A review of this was produced in 
2010 to include more recent evidence (Lumb, Colquhoun, Malthaner, & Jayaraman 2010).  The 
conclusions of the previous review were upheld: stapled haemorrhoidectomy was associated with 
higher long-terms risk of recurrence and additional operations.  There were non-significant trends in 
favour of stapled haemorrhoidectomy in pain, pruritis ani and faecal urgency.  
Many individual studies confirmed the overall consensus that stapled haemorrhoidectomy carries a 
significantly higher risk of recurrence and additional operations (Giordano et al. 2009).  Individual 
studies also found that hospital stay and pain were significantly reduced with stapled 
haemorrhoidectomy versus conventional (Milligan-Morgan) haemorrhoidectomy (Khan et al. 2009).   
 
Cost-effectiveness 
The two main cost-effectiveness studies for stapled haemorrhoidectomy from an NHS perspective 
are those provided by NICE (NICE 2007b) and the NIHR HTA (Burch et al. 2008).   
In 2007, NICE provided a technology appraisal which recommended the use of stapled 
haemorrhoidectomy, as discussed above.  Upon reading the report in more detail, it is clear that 
many factors went into this decision from a cost-effectiveness perspective.  On the clinical 
effectiveness side, the committee found the following: 
- Less pain was associated with stapled versus conventional haemorrhoidectomy for the 14 
days post-procedure. 
- There was little difference long-term pain difference (21 days and 1 year or later)  
- Stapled haemorrhoidectomy was associated with shorter wound healing time and quicker 
return to normal activity. 
- Bleeding was reduced 14 days postoperatively, but not at 6 to 8 weeks or 12 weeks. 
- The evidence seems to indicate greater chances of prolapse and re-intervention. 
- Postoperative complications were not statistically different. 
- The overall message from QoL studies is that there is no statistically significant difference 
between stapled and conventional haemorrhoidectomy; 
- However, statements from patients and clinical specialists indicated that stapled 
haemorrhoidectomy was “considerably less painful” than the alternative, and that patients 
have a much speedier recovery time. 
On the cost-effectiveness side, NICE considered the cost-utility study submitted by the manufacturer, 
and also conducted their own.  That of the manufacturer, which took a one year time horizon and an 
NHS perspective, found a cost of £191 and an incremental QALY of 0.009 for stapled versus 
conventional haemorrhoidectomy, leading to an ICER of £22,416 per QALY.  The cost-utility analysis 
conducted by the NICE assessment group took a 3 year time horizon (and incorporated a wider 
definition of symptoms, complications and re-interventions) and found an incremental cost for 
stapled haemorrhoidectomy of £19, and 0.001 fewer QALYs.  Stapled haemorrhoidectomy was 




therefore dominated. However, NICE also considered the opinions of a ‘clinical specialist’ and 
‘patient expert’, who indicated the high value placed by patients on the benefits of stapled 
haemorrhoidectomy. As well as considering that patients who undergo conventional 
haemorrhoidectomy are probably more likely to seek pain management in primary care (leading to 
increased costs), they also considered the opinion of advisors that, for patients, the risk of re-
intervention was less important than the expectation of a high-level of postoperative pain.  They also 
heard that less time in hospital and an earlier return to normal activities was important for patients, 
and that according to the clinical expert “the recurrence of prolapse after haemorrhoidopexy varied 
on a case by case basis and in his experience of clinical practice recurrent prolapse was uncommon 
after stapled haemorrhoidopexy” (NICE 2007b).  Also, upon reconsideration of the important issue of 
utility (and the big impact this had on the overall ICER), they were persuaded that there was a clear 
utility benefit in favour of stapled haemorrhoidectomy, and therefore “on balance” the utility 
estimated by the manufacturer (0.009) was plausible.       
Burch and colleagues (Burch et al. 2008) produced a systematic review and economic evaluation for 
stapled haemorrhoidectomy from the perspective of the NHS in 2008. The findings are similar to 
those presented above.  The authors find that in the early postoperative period most trials find less 
pain following stapled haemorrhoidectomy, but that by day 21 the difference is minimal.  Healing 
was quicker, but prolapse was more likely. Stapled haemorrhoidectomy was associated with shorter 
operating times, hospital stay, and return to normal activity. There was no overall difference in the 
rate of complications between the two procedures. The cost and QALY implications calculated are 
exactly those used in the NICE guideline for the year before, indicating that this HTA fed into that 
decision making process.  The assessment concludes that conventional and stapled 
haemorrhoidectomy have very similar cost and QALYs. They indicate that the cost of the staple gun 
(£420) is offset by the savings in hospital stay; if this price were to change, then so would the 
conclusions of the economic analysis.  The authors conclude that the clinical evidence and economic 
evaluation indicate that the choice between the two procedures could be based primarily on the 
preferences and priorities of the patient and surgeon. 
 
Suitability of headroom assumptions 
By being able to examine the factors that went into the economic evaluation which was used by NICE 
to make a decision on whether to recommend stapled haemorrhoidectomy (by considering the full 
HTA that was published a year later), I can compare these parameter inputs to those presumed in the 










 Headroom HTA Comments 
Market size 10,300 8,000 The HTA also used HES data for code 
H51 (excision of haemorrhoid), but 
relating to the years 2004-2005. This 
shows that the decision to use my own 
search rather than the estimation in the 
NHSC briefing was appropriate.  
Impact of stapled 
haemorrhoidectomy 
on hospital LOS 
Reduction of 2 





Ethicon’s model: reduction 
of 1 day in those incurring 
hospital stay (57% vs. 27%) 
Assessment centre model: 
average reduction of LOS 
of 1.17 days (1.43 days 
rather than  2.66 days) 
The headroom analysis assumed that 
all stapled haemorrhoidectomies were 
conducted as a day-cases. This has 
turned out to be over-optimistic. 
Cost of a hospital 
day 
£300 Ethicon’s model: £224 
Assessment centre model: 
£256 
The cost estimation of a hospital day 
used in the headroom analysis was too 
large. 
QALY difference  +0.009 Ethicon’s model: +0.009 
Assessment centre model: 
-0.001 
Utility was estimated  in both HTA 
models by mapping visual analogue 
scale (VAS) scores to SF-36 data.  The 
NICE TA decision concluded that, based 
on the evidence presented by 
specialists as well as the output of the 
assessment centre model, the QALY 
gain estimated by Ethicon seemed 
feasible.  Amazingly, this was exactly 
the same QALY impact as that 
estimated in the headroom analysis.  
Although the basis upon which Ethicon 
estimated this QALY gain was very 
different, it was encouraging to see 
that, in this case, the very rough 
estimate derived in the headroom 
analysis using a simple manipulation of 
EQ-5D value inputs, was a match to 
what was subsequently found for utility 
effect
45
 .    
  
The main limitations in the headroom calculation were the assumptions that all stapled procedures 
would be undertaken as a day-case, and that effectiveness (in terms of subsequent prolapse and re-
intervention) would be the same.  Of course this sort of assumption is relevant for the headroom 
method as, before development, the effectiveness will be unknown and it is appropriate to estimate 
the value of what you think could be achieved. The factors that did transpire to negatively affect the 
economic case for stapled haemorrhoidectomy were raised as issues / questions in sections 6 and 7 
of the headroom analysis.  
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 It should be noted that the assumptions upon which the calculations were based were not the same, 
but it happened in this case that they led to exactly the same estimate of QALY gain. This at least 
shows that the rough method of QALY estimation proposed has the potential to be a useful judge of 
utility impact. 




Has the landscape described changed significantly? 
What is current gold standard clinical practice now? Has this changed? 
There is still plenty of literature being produced in relation to what I have considered in this analysis 
as ‘conventional’ haemorrhoidectomy – the Milligan-Morgan technique of open 
haemorrhoidectomy.  This includes a 2011 paper written on a study which looked at how to improve 
the pain prospects associated with the surgery (Ba-bai-ke-re et al. 2011). 
One 2010 paper considers excisional haemorrhoidectomy to still be the reference standard, being 
the most commonly performed procedure (McKenzie et al. 2010). However, the source used for this 
claim is a study from 1995 (which in fact I included as part of my headroom analysis (MacRae & 
McLeod 1995)).  However, the Cochrane review produced in 2010 also refers to the Milligan-Morgan 
open haemorrhoidectomy as the current ‘gold standard’.  Whilst stapled haemorrhoidectomy has 
gained worldwide approval over the last 10 years (Cosenza et al. 2011), it has not replaced 
conventional haemorrhoidectomy entirely.  This is also what is implied on patient-facing websites 
such as NHS choices. 
 
Are there now many direct competitors? 
There are still many options available for the treatment of haemorrhoids, and surgical intervention is 
still only considered for haemorrhoids of third/fourth degree, and usually where other less invasive 
methods have failed.  In terms of direct competitors, one other stapling device was identified (by 
Tyco Healthcare), but the use of this one does not seem so prevalent based on its coverage in the 
clinical literature. 
In May 2010 NICE issued an interventional procedures guidance suggesting that the use of 
haemorrhoidal artery ligation (also for grade 3 or 4 haemorrhoids) was an efficacious alternative to 
conventional / stapled haemorrhoidectomy (NICE 2010b).  The procedure ties off the blood supply to 
the haemorrhoids by stitching the blood vessels.  
 
Conclusions: How useful might the headroom exercise have been? 
The ‘headroom’ generated by the analysis is likely to have indicated a positive development decision 
(though this depends on whether my interpretation of potential effect was correct- if the developer 
actually had more reserved ideas for impact on LOS than I used, then the development case may 
have been less certain).  Stapled haemorrhoidectomy is used, but it has not replaced conventional 
haemorrhoidectomy entirely.    
What made this case interesting was the ability to follow-up with a NICE technology appraisal, and 
relate the headroom analysis to this subsequent appraisal.  The most important factors that were 
omitted from the (quantified) headroom analysis, which meant that the health economic effect was 
over estimated, were the incidence of prolapse and re-intervention, and the ability for stapled 
haemorrhoidectomy to be undertaken as a day case.  These issues were highlighted in the research 
questions section as topics that should be explored.  




Surprisingly, the estimate of QALY impact that was calculated by the manufacturers by extrapolating 
RCT data and converting to SF-36 scores was identical to that estimated in the headroom analysis 
(0.009 QALYs).  The assumptions that went into the estimations were not the same; in the headroom 
analysis I simply assumed that 2 week’s worth of ‘moderate pain’ and ‘some problems with normal 
activities’ were transformed into perfect health, whereas the Ethicon model took a year’s time 
horizon, incorporated probability of prolapse, and involved a complex mapping task to convert to a 
utility score.  Nevertheless, the fact that the estimate derived in the headroom analysis was in line 
with one that was later accepted by NICE as a plausible estimate of QALY impact for stapled 
haemorrhoidectomy, is encouraging (though with just this one case, the good prediction achieved 
with this method could be considered a fluke).  
A comparison between the assumptions made in the headroom analysis and those used in the HTA 
which were based on the clinical literature, is presented above.  An interesting finding from this 
follow-up is NICE’s decision to recommend the procedure despite showing that, health economically, 
it is most likely dominated by conventional haemorrhoidectomy (i.e. more expensive and worse) 
when using assumptions based on the current evidence base.        
Much like in a headroom evaluation, where the developer is encouraged to consider sections 6 and 7 
as additional un-quantified indicators of likely clinical / cost-effectiveness and incorporate 
consideration of these into their decision, NICE also seem to undertake such an exercise.  Even 
though the economic evaluation found that stapled haemorrhoidectomy was dominated by current 
practice, consideration of patient/clinician preference, as well as other factors such as the potential 
for reduced primary care costs for pain management (this was also flagged up in the headroom 
evaluation as a factor to consider), meant that NICE decided to recommend the procedure.  This 
demonstrates the importance of factors that can’t be quantified, which can still influence buying 
decisions, and should therefore also be considered in the development decision.   
Overall, I think the headroom analysis would have presented a useful insight into the market 


















NICE IPG follow-up. 
 
Date of briefing: July 
2002 
 





Age-related macular degeneration (AMD) is an affliction of the centre 
portion of the retina, the macula, and is responsible for the eye's detailed 
central vision.  It is one of the biggest causes of vision loss in people over 
50.  Degeneration of the macular occurs when small clot-like formations 
form in the cells below the retina, which can stop the flow of nutrients to 
the retina.  AMD can be dry form (all AMD starts as dry form), or wet 
form.  Although just 10% of AMD cases are wet form, they account for 
90% of blindness in the AMD population.  Wet-form occurs when tiny new 
blood vessels from the choroid (a deep layer of tissue) grow up beneath 
the retina and are very fragile (also called choroidal neovascularisation, 
CNV).  These fragile new vessels can leak and bleed, and eventually a scar 
forms in the middle of the central vision, causing a blind spot in a person's 
central vision.  AMD can affect just one eye, or both eyes at different 
rates. 
It is thought that over 30% of people over 75 years of age in England have 
AMD.  A paper published in 1996 estimated that about 50% of cases of 
registered blindness was attributable to AMD, and that the number of 
cases had an upward trend over time (Evans & Wormald 1996).  O’Shea 
describes AMD as accounting for 95% of blindness or partial sight 
registrations in the UK (O'Shea 1998).   CNV (wet-form AMD) affects 
247,000 people per annum in England.  Of these, only a small proportion 
suffer from classic CNV whilst 88% are afflicted with occult CNV, which is 
where the vessels may be growing in different directions and cannot be 
seen clearly upon examination (unlike classic CNV where there is a well 
defined stalk of vessels and a localised leak).  There are currently no 
treatment options for people with occult CNV, so prospects for these 
patients tend to be poor.   
Transpupillary thermotherapy (TTT) would be a new treatment option for 
AMD patients with CNV (i.e. wet-type AMD, classic or occult).  The 
particular benefit of this treatment would be that it could be used to treat 
those AMD patients for whom current methods of treatment are not 
viable (specifically, those with CNV of the occult type).  TTT uses a low 
intensity infrared laser beam (with an OcuLight SLx or OcuLight SL) with a 
large spot slit lamp adaptor, to heat the problematic blood vessels, with 
the objective of preserving central vision. 
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 I have chosen a timeframe of 2 years prior to the briefing because the laser equipment was actually 
CE marked in 1998, and is for use not just as part of the TTT procedure, but also for conventional 
photocoagulation.  It is to be paired with a large spot slit lamp adaptor for TTT, so really the headroom 
is for this new technique, for which the laser equipment must be bought.  As the laser equipment has 
already been developed and indicated for other ophthalmic uses, I will use a timeframe of the year 
2000. 




2. Comparator  
 
Conventional laser coagulation is the accepted treatment for CNV, which 
uses an intense light beam to burn the blood vessels and seal the leak.   
Photodynamic therapy is an emerging treatment for AMD, for which there 
is currently a lot of research being undertaken. This involves a drug called 
verteporfin being injected into the arm, which binds to the problematic 
blood vessels in the eye.  A low-energy laser is then directed at these 
vessels, which should clot them and prevent further damage by stopping 
the leakages.  The drug used for this is expensive.  Early results from trials 
have shown that photodynamic therapy can safely reduce the risk of 
vision loss for patients with classic CNV from AMD (Treatment of Age-
related Macular Degeneration With Photodynamic Therapy (TAP) Study 
Group 1999). 
 
The very important problem with the current options for CNV patients is 
that none are applicable for those with occult CNV, which represent about 
88% of all CNV patients. This is why I have described TTT as a ‘new 
indication’.   
 
3. Market size  In order to keep the analysis simple I will assume that treatment for 
patients with classic CNV, for whom conventional treatments are 
appropriate, will remain the same.  The impact of TTT will be considered 
for those 88% of CNV patients who suffer from occult CNV, a condition 
with no other treatment alternatives.   
Market size per year: 217,000 
 
4. Health Service 
 
Changes in resource use.  Any changes in 
service delivery costs to the NHS that will 
result from the application of the new 
technology, including the disinvestment in 
previous practice.  This could include: Staff 
time, hospital bed days, GP visits, A&E visits, 
etc.  It should not include services for which 
the NHS (and personal social services) is not 
financially liable (e.g. lost productivity and 
[non-health] social care costs), but these 
should be noted in writing below to add to 
the verbal case for the product (NICE may 
incorporate social care costs into cost-
effectiveness estimates in the near future). 
 
 If relevant and not included in service cost 
impact above, search for price of the 
currently used product (P1). 
 
Use HCHS index to inflate estimates to 
current prices  
Conventional laser photocoagulation is the mainstay 
in clinical practice for CNV patients.  Unfortunately, 
the majority of patients with this condition have 
occult CNV, which may not be treated with current 
methods.  The principal benefit of TTT is that it could 
treat the otherwise untreatable.  As there is no 
indication in the NSHC briefing that TTT would work 
better than current means of treatment, I will 
assume that TTT would be as useful for occult CNV 
patients as conventional laser photocoagulation is for 
patients with classic CNV.   
 
I have identified one cost-effectiveness study for 
conventional laser photocoagulation for subfoveal 
choroidal neovascularisation in patients with AMD. In 
it, the authors use markov modelling to compare 
laser photocoagulation therapy with the natural 
course of CNV (Brown et al. 2000).  The cost 
perspective taken for this analysis was that of the 
Health Care Finance Agency (U.S.).  The total cost 
estimation for laser photocoagulation was $1,047.  
This included initial outpatient consultation ($126), 
photocoagulation procedure ($733) and fluorescein 





































Describe any potential costs/savings that 
you haven’t quantified.  
angiography with interpretation and report, around 3 
weeks and 5 weeks after treatment (2x$94 = $188).   
 
As the process of treatment and patient care is likely 
to be similar for conventional laser and TTT 
treatment (the procedures are not dissimilar), the 
resource utilisation for the general patient pathway, 
outside of the treatment session itself, is likely to be 
similar.    
 
As we are considering TTT for the treatment of 
patients who would not otherwise be considered for 
treatment, all costs required to treat these patients 
would represent additional costs to the NHS, rather 
than a shift in the allocation of resources.  We can 
estimate the likely resource requirements for 
everything other than the procedure itself (for which 
we are estimating the ‘headroom’) using the costs 
reported above.  Outside of the TTT procedure itself, 
the cost to the health service of caring for a CNV 
patient undergoing treatment (assuming these would 
be similar across countries and health services) 
would be about $314 (initial consultation plus follow 
up appointments).  This is equivalent to £20747. 
 
These treatment costs are incurred in the initial year 
of treatment, so no discounting is required. 
 
(Total) ∆SC= £44,919,000 
(Av. Per person) ∆SC= £207 
 
P1= (not appropriate, as no disinvestment will occur)  
 
I have not added to this figure the procedural service 
costs associated with undergoing TTT.  Therefore, 
these would have to be considered within the 




Potential impact of the new device on 
patient health, as compared to current 
practice (preferred method of elicitation is 
from studies using the EQ-5D).   
Where NICE have not produced relevant 
economic analyses, search for cost-
There are some questions raised in the literature 
about how QoL (and the measurement of this 
parameter) and ophthalmology fit together.  A survey 
of experts conducted in 1998 found that UK 
Ophthalmologists appear to be unfamiliar with QoL 
measures, despite the fact that they have become 
the standard means of assessing and comparing 
health care interventions (Hart, Chakravarthy, & 
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 Using an exchange rate of $1.52 to the £ (the average across the 12 months of the year 2000) (HM 
Revenue & Customs 2011). 




effectiveness studies or systematic reviews 
within the disease area (the CEA registry 












































Stevenson 1998).  Most respondents deemed QoL 
measures to be of little importance for AMD, with 
distance and near visual acuity being the most highly 
rated measures.   
 
Brown (Brown 1999) presents the only attempt I 
have found in the literature within this timeframe of 
measuring the QoL associated with vision.  He 
presents an evaluation of various QoL measures for 
vision acuity loss, and finds the time trade-off 
method to be the most useful and appropriate. 
 
It is the same author that, a year later, produced the 
cost-effectiveness analysis for laser photocoagulation 
introduced above.  The extent to which TTT 
treatment of CNV could affect a patient’s QoL would 
be very difficult to guess / estimate by indirect 
means, as would the timeframe according to which 
these changes might happen.  Therefore, it seems 
appropriate to approximate this impact by using data 
obtained from treating classic CNV patients with 
conventional laser coagulation.  Brown et al. (Brown 
et al. 2000) use patient outcome data from a trial 
conducted by the Macular Photacoagulation Group 
(Macular Photocoagulation Study Group 1993), in 
which 371 patients were randomized to laser 
treatment or no treatment.  The mean age at 
randomization was 74.4 and follow up was available 
for 4 years.  The visual acuity data for these years 
showed that in the first three months, visual acuity 
was decreased in the treatment group compared 
with the control group, but that the net utility change 
from treatment was positive after the first year.  The 
change in visual acuity was reported over the four 
years, and these were converted into QALYs by 
Brown and colleagues by using the results of the QoL 
elicitation using the time trade-off method, as 
reported in his previous paper (Brown 1999).  The net 
utility change over the four years for treated versus 
non-treated CNV patients was 0.028, but markov 
modelling was used to extrapolate the results over 
the remaining years of expected life per patient (a 
further 7 years).  The overall QALYs gained from 
treatment versus no treatment was 0.257 which, 
discounted at a rate of 3%, is equivalent to 0.18648 
(Brown et al. 2000).   
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 The rate of discount that should be used is 3.5% (the same as the discount rate for costs).  
However, the authors only provide the QALY gain discounted at the rates of 1%, 3%, 5% and 10%.  








Describe any impact on patient health that 
you haven’t quantified.  
 
∆QALY= 40,362  
(Av. per person) ∆QALY=  0.186 
 
The most important aspect of this technology is that 
it may offer the opportunity to treat patient who at 
the moment have no hope of vision preservation.  Any 
reimbursement decision is likely to consider this 
proposition favourably, and may be willing to pay a 
premium for this.  
 
6. Developments (clinical & healthcare 
context) 
 
Consider the following questions to help you 
think about the space for your product 
within the market.  
 
Does the technology address any key national 
objectives for improving care in this area? 
 
How will the technology complement current 
practice? Is current practice likely to change? 
 
Are there any indications in the literature of 
potential effectiveness? 
 
Have you identified any direct competitors? (This 
could be another specific technology, or simply a 
different technique)  
 
 RED: Poses a significant threat to the 
opportunity identified in the market (i.e. 
works against current health service 
objectives, or there are other products 
being developed that are associated with 
better outcomes or are at a more advanced 
stage of development). 
 
AMBER: Potential threat 
 
GREEN: Further supports the case for the 
new technology  
 [GREEN] There is much emphasis in the literature 
on the lack of treatment options for patients with 
occult CNV (Howe 1995).  A technique (like TTT) 
that could overcome this big gap in current care 
for patients with AMD should be very sought 
after and well received by the health service.  
 
 [AMBER] The OcuLight laser instrument that has 
recently been developed by the company is for 
use in various clinical applications including, it 
seems, conventional laser coagulation.  It is very 
likely that others do or can produce very similar 
devices, and so the TTT technique may be 
mimicked and marketed by others if it proves to 
be successful in the treatment of CNV patients.        
 
 [AMBER] There seems to be plenty of innovation 
in the area of CNV treatment.  Treatments 
identified in the literature search include 
teletherapy (Hart et al. 1996) and proton beam 
irradiation (Flaxel et al. 2000).  With much 
development in the area, it may be sooner rather 
than later that other methods are found to treat 
occult CNV by other means. 
 
 [AMBER] A (small) number of investigations in 
the literature consider other options for the 
treatment of patients with occult CNV, for whom 
current treatment offers limited benefit.  One 
study finds that radiation therapy should not be 
generally used for patients with occult CNV 
(Weinberger et al. 1999).  Another such 
investigation is into the efficacy of indocyanine 
green angiography (ICGA)-guided laser 
photocoagulation. Brancato and colleagues 
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2000), I cannot calculate accumulated discounted value myself.  




(Brancato et al. 2000) find that  the technique 
may improve or stabilise visual acuity in some 
eyes with occult CNV, but that further 
investigation is needed. Weinberger et al show 
similar preliminary findings (Weinberger, 
Knabben, Solbach, & Wolf 1999).  
 
 [AMBER] Transpupillary thermotherapy is already 
referenced in the literature in relation to the 
treatment of choroidal melanoma.  This indicates 
potentially a much wider market, but also raises 
the issue that this is probably a technique that 
may be performed by a number of different 
devices. 
 
7. Research questions 
 
This should be a list of the things that the 
developer needs to find out or monitor 
during the process of development, relating 
to the function of the device or how it fits 
into the market place. 
 
From the research undertaken and reported 
above, what are the most important 
questions or uncertainties that must be 
addressed / tested? What factors or 
assumptions have the calculations / 
economic or clinical case hinged upon? 
What potential benefits or threats have you 
ignored in the calculation (see italicised 
points in Qs 4&5, and ‘developments’ 
section)?  
 How would the cost of performing TTT relate to 
the cost of conventional laser coagulation and 
photodynamic therapy?  If costs could be 
reduced and effectiveness is equivalent or better, 
then TTT could overtake these other techniques 
as the treatment of choice for all CNV patients. 
 For what other indications might the equipment 
be used?  This will affect market size. 
 Is it feasible to assume that the vision gain 
associated with treating occult CNV patients with 
TTT is equivalent to that gained treating classic 
CNV patients with laser coagulation? (this is the 
assumption that we make in this analysis) 
 Would there be any other costs involved in the 
application of TTT that have been omitted here? 
 Would just one treatment be necessary or would 
multiple treatments be required? 
 
Headroom Notes (Transpupillary thermotherapy) 
 
Headroom 
WTP: £20,000 WTP: £30,000 
£3,513 £5,373 
 
The ‘headroom’ presented above represents the value that the NHS should place on improving the 
vision prospects of occult CNV patients.  Netted from this are some of the service costs that would be 
involved in pre and post care for TTT.  




In this example, the service costs estimated are all incurred rather than saved as in most other 
examples.  This is because TTT offers a treatment option for those patients who were previously 
untreatable.   Although some service costs have been accounted for, those that would be associated 
with the procedure itself have not been accounted for, so must be considered within this figure.  In 
other words, the developer must ask himself whether £3,513 - £5,373 would reasonably cover the 
cost to the health service of carrying out the procedure itself (i.e. the clinician and theatre time 
involved) and whether what is left over of this ‘headroom’ figure would be sufficient to cover what 
would be the amortised cost of using the device.  Again, this is difficult for me to consider in concrete 
terms without understanding the likely throughput of the device, and so the ‘cost per patient’ of 
using it.  
Note: This estimation represents a headroom ‘per patient’.  If multiple procedures would be 
required, then this figure would have to cover all of these. 
 
Follow-up (Transpupillary thermotherapy) 
Headroom Outcome and Market success 
Does the MRP look realistic? Would it have indicated yes or no to development? 
A per patient headroom of £3,513 - £5,373 was calculated for Transpupillary thermotherapy (TTT).  
This represents what the NHS should be willing to pay to treat one patient with TTT, given the 
assumptions used in the headroom analysis, but should include the service costs associated with the 
procedure itself.   
The NHSC briefing indicates that the laser and delivery device would cost £25,000 as a one off lump 
sum.  A cost estimate per individual treatment/patient is not given.  I have found no other cost 
estimates for TTT, and without understanding the distributional and patient throughput implications 
of treating all occult CNV patients, I do not know if this would have covered costs (one device would 
have to treat at least 8 patients in its lifetime).  An economic evaluation undertaken from an NHS 
perspective for photodynamic therapy (PDT) (which was to inform NICE’s technology appraisal for 
the procedure) estimated that the cost per treatment was £1,181 (Meads et al. 2003).  Given the 
high cost of the verteporfin drug required for this procedure (£850), the cost of TTT would be very 
unlikely to exceed this cost, indicating that the headroom presented may well have shown ample 
room for development.  Having said this, the HTA seems to indicate that for PDT, patients would 
undergo at least 3 PDT treatments in the first year alone.  If this is the case for TTT, then the 
headroom must cover all treatments. 
An announcement by IRIDEX that TTT had achieved Medicare reimbursement (U.S.) in Mississippi 
detailed that the allowable cost (from a reimbursement perspective) for the procedure was $800 
(Internet Wire 2004).  Again, interpretation of this in relation to the headroom calculated would 
require knowledge of how many procedures would be required it total per patient, but it seems likely 
to fit within the headroom indicated (assuming that procedures required per patient are less than 




five or six, which seems likely).  Given the cost per patient treated with PDT fits within the headroom 
(which is likely to be more expensive than TTT given the drug required), and that the device would 
hopefully be used to treat more than seven or eight patients in its lifetime, headroom is likely to have 
indicated a positive development decision.  
Headroom result uncertain due to lack of information, but is likely to have indicated a positive 
development decision. 
 
Has there been a decision made on it by NICE? What was the outcome? 
As indicated by early research outlined in the pro forma, there is a lot of treatment innovation in the 
area of AMD.  This is reflected in the number of NICE appraisals / guidelines that are relevant to this 
disease.  To date there have been two technology appraisals (photodynamic therapy, and 
ranibizumab and pegaptanib) and six interventional procedures guidance (epiretinal brachytherapy, 
implantation of miniature lens systems, limited macular translocation, macular translocation with 
360°  retinotomy, radiotherapy, and Transpupillary thermotherapy).  
The interventional procedures guidance for TTT, IPG 58, was produced in May 2004 (NICE 2011e).  
Current safety and efficacy evidence for TTT was insufficient to allow the procedure to be 
recommended.   
 
Is it sold in the UK or the rest of the world?(Or has it in the past) If so, who is it bought by? 
I have found evidence that TTT is reimbursed for wet AMD in some parts of the U.S. (at least 17 
states as of 2003) (Business Wire 2003;Internet Wire 2004). However, some recommend TTT for 
different indications.  For example, the CIGNA49 medical coverage policy stipulates that TTT is 
provided but only for retinoblastoma or small choroidal melanomas; they do not cover TTT for the 
treatment of CNV associated with AMD as “such treatment is considered experimental, 
investigational or unproven”(CIGNA HealthCare 2008). Other health insurance providers have the 
same policy for TTT (Aetna 2011). 
From the Iridex website, it is clear they produce many laser devices, including the OcuLight SL/SLx 
(used for the delivery of TTT).  However, these infrared laser devices are for use not only for TTT but 
also other retinal treatment procedures, like photocoagulation.  
I have found no clinical literature on the use of TTT in a UK setting.  On the NHS choices website 
which provides patient information for the treatment of macular degeneration, TTT is not mentioned 
as one of the potential options to be considered (NHS Choices 2010c).  For wet AMD, the first 
treatment described is PDT, followed by drugs, followed by a list of ‘possible treatments’ which 
include implanting lens systems, macular translocation, and laser photocoagulation.  
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 CIGNA is a private healthcare provider, based mainly in the UK and large providers of managed 
employee healthcare benefits and services. 




Have there been investigations into its clinical / cost effectiveness? 
I have found no cost-effectiveness analyses or economic evaluations for TTT.   
As for the clinical effectiveness of the procedure, with the information available in 2004, NICE were 
unable to recommend the procedure for use in CNV patients (NICE 2011e).  Therefore I will briefly 
summarise the important results of clinical effectiveness since that time.  
As indicated in the NHSC briefing and therefore in the headroom analysis, the real benefit of TTT 
would have been to allow for the treatment of patients with occult CNV.  It was thought that no 
other therapy was relevant to this population.  However, a study presented by Odergren and 
colleagues in 2010 (Odergren et al. 2010) finds that TTT and PDT appear to be equally as effective for 
stabilising visual function for patients with occult CNV.  It is noted, however, that the study was 
underpowered and also that the drug ranibizumab has shown impressive results for all types of CNV, 
so neither laser procedure should be considered as first-line treatment (Odergren et al. 2010).  
One study reports that TTT carries a small but significant risk of immediate and severe vision loss—
risk factors identified were haemorrhage disc size and laser power (Mason, III et al. 2008). 
A prospective randomised controlled pilot study for the use of TTT in occult CNV patients (full text 
unavailable so I was unable to see whether Iridex equipment was used) was conducted in 2006 
(Myint, Armbrecht, Mon, & Dhillon 2006).  The authors concluded that TTT appeared to have no 
benefit in preventing vision loss.  
During my follow up searches, I found reference to TTT (using the OcuLight laser by Iridex) being 
tested for use in AMD in 1999 (Reichel et al. 1999), indicating that my time frame was not as early as 
it should have been.   
Has the landscape described changed significantly? 
What is current gold standard clinical practice now? Has this changed? 
In 2000 (the time perspective of the headroom analysis), conventional laser photocoagulation was 
considered the ‘gold standard’ for AMD patients.  This is no longer the case.  A Cochrane review 
produced in 2007 (and reviewed in 2009 with the same conclusions) considers laser 
photocoagulation for the treatment of neovascular AMD, and concludes that whilst being the first 
treatment in this area, laser photocoagulation should no longer be recommended for CNV patients 
given the risks attached to the procedure and the appearance of newer and better treatment 
modalities or different laser techniques (Virgili & Bini 2007).  PDT seems to be the most widely 
referenced treatment on patient information sites like NHS Choices. In September 2003 NICE 
recommended PDT for wet AMD patients, but only those with no sign of occult CNV (NICE 2003c).   
As mentioned, there was no gold standard in 2000 for patients with occult CNV.  This seems to have 
changed as well, with PDT proving to be just as effective for these patients in one study undertaken 
(see above).  In a technology appraisal produced for the drug ranibizumab, NICE recommend it as a 
treatment option for all wet AMD patients (NICE 2008b).  Ranibizumab has generated positive results 
in clinical trials for all types of CNV; more effective than another type of drug verteporfin (Brown et 




al. 2006).  A study that compared ranibizumab to a placebo found that after 2 years, vision loss was 
prevented in the treatment group and visual acuity rose; patients in the study included those with 
classic and occult CNV (Rosenfeld et al. 2006).  
The appearance of new treatment options in this area seems to be common, as well as the further 
development of current treatments, including TTT.  A 2011 publication considers the functional 
outcome of TTT with different spot sizes using the OcuLight by Iridex (though for the treatment of a 
different condition) (Shah, Narendran, & Kalpana 2011).   
Are there now many direct competitors? 
As of 2002, the FDA had approved three ophthalmic lasers for TTT: the OcuLight SLx (Iridex Corp, CA), 
the Nidek DC-3000 (Nidek Inc, CA) and the GaAIAs diode laser (Candela USA, MA) (CIGNA HealthCare 
2008).   
The main source of competition for TTT therapy are other forms of treatment, which at the moment 
appear to have a stronger clinical grounding for use in wet AMD patients.   
Conclusions: How useful might the headroom exercise have been? 
The source of ‘headroom’ in this example was predominantly the QoL benefit to patients, who 
currently had no treatment options.  Unfortunately it was difficult to interpret this headroom 
without information on the procedural service cost implications of the therapy (on the day of 
treatment), how many treatments would be needed per patient, and the distributional and 
equipment longevity details (and what this would mean for the equipment cost per patient).   
Although it was difficult to interpret the economic analysis from information provided in the NHSC 
briefing alone (this may have been a more informative process to the manufacturer), the main 
reason for its poor uptake in the UK is its limited clinical efficacy; I did not identify any economic 
analyses, presumably due to the limited clinical support for the procedure.   The headroom method 
economically evaluates a new device by considering the price it might fetch under the assumption 
that it will work.  In this case, TTT doesn’t produce the clinical outcomes it set out to, and other 
treatment options seem to be more viable.  The baseline has changed as other treatments have now 
been recommended for patients with occult CNV.  Although the efficacy of other new treatments 
can’t be predicted from an early stage, it was clear from the literature at the time that there were 
many new treatment options on the horizon.   
However, as indicated, the device (rather than the technique specifically) is used for a wider range of 
ophthalmic applications, and as such still appears to be a viable product. 




17.  Citrasate dialysate. Health Tec Medical Ltd. (License from Advanced Renal 








No NICE follow-up. 
 
Date of briefing: August 
2006 
 




People that require haemodialysis are those with chronic or acute renal 
failure who require the assistance of a dialysis machine to remove waste 
products and water from their blood.  A dialysis solution is used as part of 
the extracorporeal circuit, which often contains heparin.  Heparin is an 
anticoagulant and prevents clotting in the dialyser circuit, which can lead 
to a reduced dose of dialysis delivered and increased blood loss.  Heparin, 
however, is contraindicated in some patients.  
 
Citrasate dialysate is a citric acid concentrate which can be used as part of 
standard bicarbonate dialysis solutions.  It represents an incremental 
development to standard dialysis solutions, which could improve 
efficiency of dialysis and lead to fewer complications than standard acetic 
acid-based dialysate fluids.  It can also work as an anticoagulant for those 
patients who can’t tolerate heparin. There would be no changes to all 
other dialysate chemicals, and no system or equipment changes would be 
required. 
 
2. Comparator  
 
Comparator dialysate fluids include standard acetic acid or bicarbonate 
dialysate formulations (of which there are many types).  Heparin is added 
where anticoagulation is needed because there is a clotting risk, and is 
used routinely (SIGN (Scottish Intercollegiate Guidelines Network) 1999). 
Low molecular weight heparins are starting to emerge as an alternative to 
heparin, which are considered to potentially offer therapeutic benefit and 
reduced complications.  Heparin is considered to be relatively safe and 
effective, though its long term use can be associated with complications 
including thrombocytopenia (heparin-associated thrombocytopenia: HIT), 
lipid abnormalities, increased risk of haemorrhage, and allergic reactions 
(Saltissi, Morgan, Westhuyzen, & Healy 1999).    
Where heparin anticoagulation is contraindicated, measures that can be 
used are:  
 Periodic line flushes.  This is thought to be relatively ineffective and 
cumbersome.  
 Regional citrate anticoagulation.  High concentrations of citric acid are 
infused into the venous line to prevent and clear blockages. This can 
be difficult to administer, expensive, and unsuitable for out-patients. 
 Danaparoid can be used in patients where heparin is contraindicated.  
It is thought not to be suitable for all patients, and is expensive.  One 
clinical study from 1997 compares heparin to Danaparoid and 
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 There is some confusion in the literature regarding the categorisation of dialysis fluids.  However, 
within the rules set out for the classification of medical devices by the European Commission 
(European Commission 2010), ‗haemodialysis concentrates‘ are included under Rule 3: Non-invasive 
devices that modify biological or chemical composition of blood, body liquids, other liquids intended for 
infusion.  These belong to Class IIb. 
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 I have found trials for Citrasate dating back to the year 2000, so I have chosen to predate this by 
one year. 




concludes that Danaparoid is the drug of choice (van Barlingen, van 
Beek, Erkelens, & de Bruin 1997).  Another small study of two 
individual cases finds that Danaparoid is a safe and effective 
substitute for heparin as an anticoagulant in haemodialysis (in this 
case where that patient had developed HIT) (Ben Ami, Rachmimov, & 
Berliner 1999).   
 
3. Market size  According to the NHSC briefing, the company estimate that about 35% of 
patients on dialysis could receive Citrasate.  Approximately 13,000 people 
are on haemodialysis in England and Wales, which implies a potential 
market of approximately 4,500.   
There are probably only around 100 patients in the UK in whom heparin 
is contraindicated, but these patients need to use (heparin-free) dialysis 
throughout their lives.   
Market size per year:  
4,500 (if used for all relevant patients) 
100 (if used only for those who cannot use heparin) 
 
4. Health Service 
 
Changes in resource use.  Any changes in 
service delivery costs to the NHS that will 
result from the application of the new 
technology, including the disinvestment in 
previous practice.  This could include: Staff 
time, hospital bed days, GP visits, A&E visits, 
etc.  It should not include services for which 
the NHS (and personal social services) is not 
financially liable (e.g. lost productivity and 
[non-health] social care costs), but these 
should be noted in writing below to add to 
the verbal case for the product (NICE may 
incorporate social care costs into cost-
effectiveness estimates in the near future). 
 
 If relevant and not included in service cost 
impact above, search for price of the 
currently used product (P1). 
 
Use HCHS index to inflate estimates to 








I have found only a limited number of cost estimates 
for dialysate fluids: 
 The NHSC briefing indicates that the lowest price 
for acetate acid dialysate is 35p/litre. 
 One study which compares heparin with low-
molecular-weight heparin (LMW) reports a cost 
per treatment of US$24.22 for Clexane (LMW) 
and US$20.51 with sodium heparin (standard 
heparin) (Saltissi, Morgan, Westhuyzen, & Healy 
1999).  It is not clear what these costs include. 
 A review produced by the NHS HTA programme 
(MacLeod et al. 1998) presents a cost analysis for 
bicarbonate dialysate (to which Citrasate would 
theoretically be added) and acetate dialysate.  
They conclude that bicarbonate dialysate is both 
the most widely used and the most preferable, 
being of similar cost and associated with fewer 
complications.  The total cost of the bicarbonate 
dialysate fluid ranges from £5.40 to £9.45 per 
session (depending on type) and £4.90 to £6.30 
for the acetate dialysate.  However, this 
difference is neutralised when considering the 
cost to the health service of complications. 
 
In its costing analysis, the HTA implies that acid must 
be added to the bicarbonate dialysate but not to the 
acetate dialysate (the cost for this was included in 
the estimates above).   
I will assume that it is this acid addition that Citrasate 





















































dialysate is proposing to replace.  The cost for this 
acid element of the dialysate fluid in the HTA was 
£2.45 to £3.15 per session.   
 
There are two elements to the health economic case 
for Citrasate.  The first is to be a more efficient and 
effective dialysis fluid than standard acetic based 
ones.  The second is for it to act as an anticoagulant.  
As heparin is considered to be effective and 
inexpensive, I will assume that this would be 
continued to be employed for anticoagulation in 
haemodialysis.  However, for those in whom heparin 
is contraindicated, Citrasate could replace heparin-
substitute strategies, such as the use of danaparnoid. 
 
Scenario 1(a): Citrasate dialysate is to be used with 
standard bicarbonate dialysis solutions for 
haemodialysis (no specific targeting of the therapy to 
patients in whom heparin is contraindicated). 
 
For this scenario, I will simply assume that Citrasate is 
to be used as the ‘acid’ addition to bicarbonate 
dialysate solutions.  The headroom for this will simply 
be the cost of current acid required for the dialysate, 
which is about £3 per session (MacLeod et al. 1998) 
    
Market size = 4,500 
P1= £3 
Scenario 1(b): The NHSC briefing implies that the 
incorporation of Citrasate could promote more 
efficient dialysis (though is in reference to acetate 
fluids rather than bicarbonate).  If it is intended that 
the addition of Citrasate could further improve the 
efficiency of bicarbonate solutions, one could 
reasonably assume that the difference in cost of 
complications to staff etc. may be similar to the 
difference in complication cost between standard 
acetic and standard bicarbonate fluids (which 
perform better than acetic ones).  The maximum 
difference in cost of complications (provided in the 
HTA (MacLeod et al. 1998)) between these two 
standard dialysates is £0.62 (highest estimate for 
acetate) minus £0.11 (lowest estimate for 
bicarbonate).  Therefore, we will assume that, in the 
best case scenario, Citrasate might save about 50p in 
complications costs per patient per session. 
Market size = 4,500 
∆SC= £0.50 
P1= £3 




























Describe any potential costs/savings that 
you haven’t quantified.  
 
Scenario 2: Citrasate dialysate is directed at those 
who cannot use heparin and who require 
anticoagulation; this is relevant for about 100 
patients in the UK.   
 
Danaparoid seems to be the most widely recognised 
means to treat these patients, so provides the 
relevant comparator for Citrasate.  According to the 
NHSC briefing, one expert has suggested that 
replacing danaparoid in the small number of patients 
who use it could save their unit around £10,000 per 
year. 
 Although in many publications it is referred to as 
‘expensive’, I have found no direct estimate of the 
cost of danaparoid per session. As all other 
components of the procedure remain the same, the 
cost of danaparoid itself would be the only cost saved 
if Citrasate could replace it with equal effectiveness. 
Therefore, the cost of danaparoid would represent 
the headroom for Citrasate within this scenario, but I 
can find no details of this price.   
Market size ≈ 100 
P1= £? 
If Citrasate can improve the efficiency of dialysis over 
and above that of other bicarbonate dialysis fluids, 
then this could imply reduced extracorporeal flushing 
(saving staff time),and reduce the time required to 




Potential impact of the new device on 
patient health, as compared to current 
practice (preferred method of elicitation is 
from studies using the EQ-5D).   
Where NICE have not produced relevant 
economic analyses, search for cost-
effectiveness studies or systematic reviews 
within the disease area (the CEA registry 






Describe any impact on patient health that 
you haven’t quantified.  
Haemodialysis presents an interesting and difficult 
challenge for QoL measurements; whilst this renal 
replacement therapy acts as a lifeline for the many 
patients that use it, the impact of this very regular 
and intensive therapy on the lives of those that use it 
is substantial. There have been many attempts in the 
literature to address this issue (Killingworth & van 
den Akker 1996;Maxwell & Fitzpatrick 1998). 
 
As Citrasate dialysate represents an incremental 
development of currently used dialysate fluids, it is 
unlikely to pose any significant and measurable 
impact on QoL.   
∆QALY= -  
(Av. per person) ∆QALY= - 
 
If Citrasate were to work more effectively than 
current fluids, this could mean shorter dialysis 
sessions, and also reduced blood loss.  





6. Developments (clinical & healthcare 
context) 
 
Consider the following questions to help you 
think about the space for your product 
within the market.  
 
Does the technology address any key national 
objectives for improving care in this area? 
 
How will the technology complement current 
practice? Is current practice likely to change? 
 
Are there any indications in the literature of 
potential effectiveness? 
 
Have you identified any direct competitors? (This 
could be another specific technology, or simply a 
different technique)  
 
 RED: Poses a significant threat to the 
opportunity identified in the market (i.e. 
works against current health service 
objectives, or there are other products 
being developed that are associated with 
better outcomes or are at a more advanced 
stage of development). 
 
AMBER: Potential threat 
 
GREEN: Further supports the case for the 
new technology  
 [GREEN] Citrasate dialysate is to be added to 
standard bicarbonate dialysis solutions.  A 
comprehensive review of the literature 
undertaken form an NHS perspective was 
produced last year, 1998.  The systematic review 
indicated that bicarbonate has largely replaced 
acetate solutions in haemodialysis in the UK 
(MacLeod et al. 1998). The report indicates that 
bicarbonate dialysis is preferable due to its 
associated reduction in adverse symptoms, and 
similar costs.  Citrasate dialysate is compatible 
with these recommended solutions, and aims to 
promote their efficiency further. 
 
 [AMBER] There are other alternatives to heparin 
that are being investigated and could prove to be 
more effective: low molecular weight heparins 
LMW). A review produced two years ago in 1997 
outlines their benefit over unfractioned heparin 
(Nurmohamed, ten Cate, & ten Cate 1997). There 
may be some therapeutic advantages over 
unfractioned heparin, and possibly fewer 
complications.  Citrasate may need to prove itself 
to be as effective an anticoagulant as these.  
 
 [AMBER] Some of these low molecular weight 
heparins have been shown to provide a safe and 
effective anticoagulation for those in whom 
heparin has caused HIT (heparin induced 
thrombocytopenia) (Rowlings et al. 1991), and to 
show a lower complications rate (Warkentin et 
al. 1995).  This may change the treatment option 
for those in whom heparin is contradicted, 
moving away from danaparoid (supposedly very 
expensive) to other, perhaps cheaper modes of 
treatment, such as low molecular weight 
heparins.   
 
 [AMBER] Some authors find ‘no anticoagulation’ 
to be safe and effective in some cases. 
 
7. Research questions 
 
This should be a list of the things that the 
developer needs to find out or monitor 
during the process of development, relating 
 The main assumption made is that, in the case of 
scenario 2, Citrasate will work equally as well as 
other more expensive anticoagulants such as 
danaparoid. The feasibility of this assertion must 
be investigated. 




to the function of the device or how it fits 
into the market place. 
 
From the research undertaken and reported 
above, what are the most important 
questions or uncertainties that must be 
addressed / tested? What factors or 
assumptions have the calculations / 
economic or clinical case hinged upon? 
What potential benefits or threats have you 
ignored in the calculation (see italicised 
points in Qs 4&5, and ‘developments’ 
section)?  
 What is the cost of danaparoid?  Given that the 
above can be qualified, this will be the 
‘headroom’ in scenario 2.  
 Is it thought that Citrasate could improve the 
efficiency of dialysis as compared with 
bicarbonate dialysis, or acetic dialysis? (I.e. is 
scenario 1(a) or 1(b) the more likely? 
 Could the improvements brought about by 
Citrasate translate into any quality of life 
improvements for patients?  
 Would standard heparin still be used in patients 
who use Citrasate dialysate? If not, then a small 
premium may be added to represent the 
disinvestment in heparin when using Citrasate.  
 
Headroom Notes (Citrasate dialysate) 
There were many unknowns for this case, including, crucially, the price of the danaparoid, which is 
what Citrasate may possibly replace for anticoagulation in those who cannot use heparin.   
In the straightforward case of Citrasate replacing the acid that is added to standard bicarbonate 
solutions, the headroom (and indeed the MRP, as there would probably be no impact on service 
costs) would be about £3.  If the developers believed this to be a reasonable price, then this would 
be likely to justify a development decision.  If it is thought that Citrasate could improve the efficiency 
of dialysis compared with bicarbonate dialysate, then the MRP would be £3.50.  This is in reference 
to the price that could be charged per patient per session.   
To consider allowable development costs would require information on the number of haemodialysis 
sessions a patient will go through in a lifetime.  
Follow-up (Citrasate dialysate) 
Headroom Outcome and Market success 
Does the MRP look realistic? Would it have indicated yes or no to development? 
The headroom analysis in this case was fraught with uncertainties, and the benefits that could be 
brought about by Citrasate dialysate (as compared with standard bicarbonate rather than acetic 
solutions) was not clear.  However, under various assumptions / scenarios, the MRP of Citrasate 
dialysate per patient per session was estimated.   
Presuming that Citrasate incorporated into the to the haemodialysis process for all relevant patients, 
then some 4,500 patients may use Citrasate.  Without knowing more about the number of sessions 
undertaken by the average patient over their lifetime, I cannot calculate how many sessions this 
would equate to in total.  Per patient per session, the MRP was estimated to be about £3, and this 




was simply based on the price of the acid that is currently added to bicarbonate dialysate solutions.  
If it were thought that Citrasate could improve the efficiency of dialysis further, then it was estimated 
that it would fetch a price of around £3.50. 
One major proposition of Citrasate in terms of value was its capacity to act as an anticoagulant for 
patients in whom heparin was contraindicated, as current means of treating these patients are 
expensive.  However, I was unable to identify the price of danaparoid, the main (and probably most 
expensive) alternative.  I assume that this information would have been more accessible to the 
developer of Citrasate.  In this context, it would simply have been assumed that the NHS should be 
willing to pay up to what they already pay for danaparoid.  Of course, the prospect of cost-saving 
would be attractive for uptake, and it is unlikely that the developer could choose to set a different 
price according to who it was being used for.   
The NHSC briefing indicates that Citrasate dialysate would cost £1-2 per litre. They do not make clear 
how much fluid is required per session.  Various anti-coagulation strategies are discussed in one 
paper that was published in 2008, which includes Citrasate and danaparoid (Faratro, D'Gama, & Chan 
2008).  The cost of both is presented: Citrasate being $6.75 ‘per jug’ and danaparoid being $18.78 
‘each’.  Units are unclear.  On one medical supplies website, Citrasate is priced at about $40, based 
on ’48 cases’(Dial Medical Supply 2011).  Again, it is difficult to know how these would translate into 
a cost per haemodialysis session. The company’s own website indicates that Citrasate liquid is 
available in individual-dose gallon jugs, packaged four per case (Advanced Renal Technologies 2009).  
This would imply a cost of $40 / (48*4) = $0.21.  This is much lower than the estimate ‘per jug’ used 
in the study reported above. 
Headroom unclear given lack of detailed pricing knowledge (both for the estimation of headroom 
and for the assessment of its adequacy). If it is produced at a price of under £3 per session, then 
headroom would probably have been favourable. 
Has there been a decision made on it by NICE? What was the outcome? 
Citrasate for renal dialysis was considered for potential technology appraisal but was rejected by the 
panel in July 2007 (NICE 2009b).  NICE has produced various appraisals and guidelines for kidney 
failure and haemodialysis, but none deal specifically with dialysis fluids.  
 
Is it sold in the UK or the rest of the world?(Or has it in the past) If so, who is it bought by? 
Citrasate dialysate received FDA approval in June 2000 (FDA 2000), but did not receive EU regulatory 
clearance (by issue of a CE mark) until 2007.  In the FDA approval letter Citrasate dialysate is referred 
to as a device, but it is viewed by others as a drug (Flanigan 2000).  
The product was developed by Advanced Renal Technologies (ART) in the U.S., and Health Tec 
Medical Ltd. has exclusive rights for its sale in the UK.  Citrasate seems to be on the product list of 
many medical suppliers, who are located across the world. Uptake seems to have been quite slow, 
with the EU clearing Citrasate 7 years after it was available in the U.S.  A publication from 2008, in 
which Citrasate was used for nocturnal haemodialysis, indicated that the product was still not 
approved by ‘Health Canada’ (Faratro, D'Gama, & Chan 2008).   




Citrasate dialysate is not mentioned in a number of relevant guidelines (at least in its anticoagulant 
capacity), such as that produced by The Renal Association (UK) in 2009 (Mactier, Hoenich, & Breen 
2009).  They mention that bicarbonate dialysate should be used as the buffer.  Although its presence 
in the literature is reasonably limited (though there have been some publications which include the 
use of Citrasate, including one published in 2010 (Hanevold, Lu, & Yonekawa 2010)), it has a strong 
online presence.  This may be unsurprising given its very specific nature.  Health Tec Medical Ltd. (the 
UK supplier) confirmed by telephone that they supply Citrasate to 6 NHS units, and that this user 
base is expected to grow. 
 
Have there been investigations into its clinical / cost effectiveness? 
On sales websites for Citrasate, ‘tangible’ benefits that are emphasised are reduced clotting (and 
subsequent equipment changes) and reduced heparin use and nursing time.  Under the ‘intangible’ 
benefits are improved patient treatment, decreased time, lower blood loss and adverse side effects, 
and fewer saline flushes (Dial Medical Supply 2011).  They also emphasise the ‘costly pharmaceutical 
alternatives to heparin’.   
Whilst the product is marketed with its capacity for anticoagulation at the forefront of benefits, 
Citrasate is not included in most of the literature that addresses anticoagulation in haemodialysis.  
Most of the literature addresses heparin and low-molecular-weight (LMW) heparin.  Many articles 
refer to regional citrate infusion among the other treatment options, rather than Citrasate dialysate 
(Fischer 2007;Hetzel et al. 2011;Mactier, Hoenich, & Breen 2009).     
There are some clinical trials that consider Citrasate specifically.  One is by Ahmad and colleagues, 
who find that that use of Citrasate dialysate increases the delivered dose of dialysis (Ahmad, Callan, 
Cole, & Blagg 2000).  The same author has been involved in many poster presentations and other 
papers that report positive Citrasate results (he has ‘equity interests’ in the company ART).  The 
other published paper declares that Citrasate dialysate is associated with increased solute removal 
(Kossmann, Gonzales, Callan, & Ahmad 2009).  A different paper that considers the use of Citrasate in 
relation to haemodialysis in children, concluded that Citrasate was well tolerated and reduced but 
did not eliminate the need for heparin (Hanevold, Lu, & Yonekawa 2010).  Cheng and colleagues find 
in a feasibility study that citrate-enriched dialysate (using Citrasate) is feasible, and offers a simpler 
approach compared with intermittent saline flushing (Cheng et al. 2011). 
One review of the literature which concludes that (although heparin should remain the mainstay of 
clinical practice for anticoagulation in haemodialysis), after development of HIT (heparin-induced 
thrombocytopenia) it is appropriate to use one of the following: direct thrombin inhibitors, regional 
citrate infusion, citrate dialysate, or heparin-free dialysis (Cronin & Reilly 2010). 
In clinical studies that do not focus specifically on anticoagulation in haemodialysis, Citrasate tends to 
have positive results.  One study concludes that whilst coagulation was not affected by citrate-based 
versus acetate-based bicarbonate haemodialysis, efficiency was improved, as was acid-base status, 
haemodynamics and tolerance (Gabutti et al. 2009).   




The only study I have found which relates to the cost of Citrasate is not a cost-effectiveness study per 
se, but reports on the treatment outcomes and costs for one patient who tried many alternatives to 
heparin  for home haemodialysis, after having developed HIT (Faratro, D'Gama, & Chan 2008).   The 
cost per patient per treatment for home haemodialysis (including staffing time and supplies) was 
$103.85 for standard heparin, $127.37 for Citrasate dialysate, and $141.41 with danaparoid (Faratro, 
D'Gama, & Chan 2008). 
 
Has the landscape described changed significantly? 
What is current gold standard clinical practice now? Has this changed? 
Most of the literature addresses heparin and low-molecular-weight (LMW) heparin, many finding 
that healthcare resource use is reduced with LMW heparin, which makes up part of the price 
differential (Pettigrew et al. 2011); one study conducted from a UK perspective found that, although 
LMW heparins had been recommended over unfractioned heparin in the European Best Practice 
Guideliens, the LMW heparin Tinzaparin achieved comparable safety and efficacy compared with 
standard heparin, and equal total cost of therapy (Bramham, Varrier, Asgari, & Makanjuola 2008).   
One review published in 2010 concludes that unfractioned heparin is still the treatment of choice as 
the performance of LMW does not justify its extra cost (Cronin & Reilly 2010).  It was noted that 
although LMW heparin was not used widely in the U.S., in Western Europe it is the ‘norm’ (Cronin & 
Reilly 2010).  A Cochrane review is currently under development comparing the two.  
As for patients in whom heparin is contraindicated, various methods seem to be employed (as 
outlined in the headroom analysis).  A large survey sent to all renal units in the UK was reviewed in a 
study published in 2007, which found that for patients with HIT, the most commonly used treatment 
method was with Danaparoid (Hutchison & Dasgupta 2007).  This was the same baseline as that 
which was considered in the headroom analysis.  However, it wasn’t until 2007 that Citrasate 
dialysate was available in the UK.  
The gold standard of clinical practice seems to be similar to what it was in 1999 (the time perspective 
of the headroom analysis, apart from the increased use of LMW heparins. 
Are there now many direct competitors? 
All of the studies that I have identified (and websites that I have found) that relate to citrate fluids in 
general have all been in relation to Citrasate dialysate.  As expected, the use of LMW heparins has 
increased, and in some cases are employed where unfractioned heparin is contraindicated.  There 








Conclusions: How useful might the headroom exercise have been? 
The results of the headroom method were difficult to interpret given the lack of precise costing, 
price, and procedure data.  Whilst the potential for reimbursement was outlined, it could not be 
quantified (at least under scenario 2) without knowing the price of danaparoid.  There was no cost-
effectiveness study for Citrasate in the literature to compare assumptions and findings with the 
headroom analysis.  
The literature search undertaken for the headroom analysis identified one source for service cost 
saving estimates, which could potentially have been considered, but otherwise it was simply the 
price of current options that was used (one of which could not be found).  This would probably have 
been useful, but is likely to have been considered in any case. 
Citrasate dialysate is not used systematically across the NHS, but is employed by some units and 
















NICE follow up (CG) 
 
Date of briefing: June 
2000 
 
Time perspective of this 
report: 1996 52  
  
TVT is a minimally invasive technique which seeks to eliminate urinary 
incontinence.  It will be performed under local anaesthesia, take 25-30 
minutes and require an average of 6 hours in hospital. 
 
Stress incontinence (the most common cause of urinary incontinence (UI) 
in women) is the involuntary loss of urine upon physical exertion, which 
could simply be coughing or changing position. It is defined by the 
International Continence Society as the involuntary loss of urine occurring 
when, in the absence of bladder wall contraction, the bladder pressure 
exceeds the urethral pressure.  The condition can cause significant 
physical and psychological difficulties, thus reducing QoL.  It is thought 
that around 2.5 million women in the UK suffer from stress incontinence. 
 
TVT reinforces the pubourethral ligaments.  A mesh tape is attached 
under the urethra (like a sling / hammock) to keep it in the right position. 
It is inserted via the vaginal wall, looped in a u-shape around the mid-
urethra, and the ends are cut off in abdominal subcutaneous tissue 
(accessed through the abdomen). 
 
2. Comparator  Colposuspension surgery is the relevant comparator for treatment of 
stress incontinence after conservative treatments (pelvic floor muscle 
training, electrical stimulation, and pharmacological intervention) have 
failed.  The Burch colposuspension is the gold standard - a surgical 
intervention which involves repositioning the bladder neck by lifting and 
stitching the front wall of the vagina onto a ligament behind the pubic 
bone. 
 
TVT is less invasive and takes less time, and so is likely to be better 
accepted by patients, and reduce service delivery costs.  A recent study 
(1996) found significant changes in voiding function after Burch 
colposuspension, and outflow obstruction appeared to be a significant 
potential complication (Wall & Hewitt 1996).  A systematic review of the 
effectiveness of current surgical management for stress incontinence 
indicates that about 85% of women are continent one year following 
colposuspension (Black & Downs 1996).   We will assume that the TVT 
procedure will have the same outcomes as this more invasive surgical 
intervention (there is nothing in the briefing to suggest that it would work 
better). 
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 The three year rule I have employed elsewhere has been extended to four years in this case. This is 
because the briefing has been written on what seems to be a well established technique in 2000. The 
briefing refers to a publication which is a 3 year follow up of TVT, published in late 1999 (Ulmsten, 
Johnson, & Rezapour 1999). A publication from 1995 on non-surgical therapy for stress incontinence 
did not include this new sling procedure (Bourcier & Juras 1995). Therefore, I choose the year 1996 
for my time perspective. 




3. Market size  Around 4,000 ‘stand-alone’ colposuspensions are carried out each year, 
and it is thought that all women undergoing these procedures could be 
considered for TVT. 
 
Market size (NHS England) per year: 4,000 
 
However, it is thought that if this procedure were to be taken up, then 
the threshold for patients being referred to surgical intervention may 
become lower as TVT offers a much less invasive option compared to 
current surgical intervention.  The upper estimate of this population size 
is the following, as presented in the NHSC briefing: 
 
Market size (NHS England) per year: 100,000 
 
4. Health Service 
 
Changes in resource use.  Any changes in 
service delivery costs to the NHS that will 
result from the application of the new 
technology, including the disinvestment in 
previous practice.  This could include: Staff 
time, hospital bed days, GP visits, A&E visits, 
etc.  It should not include services for which 
the NHS (and personal social services) is not 
financially liable (e.g. lost productivity and 
[non-health] social care costs), but these 
should be noted in writing below to add to 
the verbal case for the product (NICE may 
incorporate social care costs into cost-
effectiveness estimates in the near future). 
 
 If relevant and not included in service cost 
impact above, search for price of the 
currently used product (P1). 
 
Use HCHS index to inflate estimates to 










There are only a limited number of cost estimates in 
the literature for open Burch colposuspension 
(assumed to be the ‘gold standard’) predating 1996.  
One estimates that the procedure is associated with 
a direct cost to the health service (U.S.) of $6,370 
(Hannah & Chin 1996), or £4,08553.  They find that an 
average hospital stay of three days is required for this 
procedure.  
Another estimate is made by Kung and colleagues 
(Kung, Lie, Lee, & Drutz 1996), who find that 
abdominal colposuspension costs Can$5692.3 (1994 
Canadian dollars), which is £2,852 in today’s (1996) 
prices (i).  
The NHSC briefing provides a couple of estimates for 
the cost of open colposuspension, one being £1,350 
(what is included in the figure is not detailed) and the 
other being £2,500 (according to the ‘consulted 
expert’).   
 
Colposuspension is performed whilst the patient is 
under general anaesthesia and looks to involve an 
inpatient stay of about 3 days.  This is in contrast to 
TVT, which is performed under local anaesthesia, 
takes about 30 minutes, and is performed as a day 
case (time in hospital should be limited to around 6 
hours).   
 
With cost estimates of current practice ranging from 
£1,350 to £4,085, and with no access to the full 
reports and details of these figures, I will assume that 
a colposuspension costs the NHS about £2,700 – the 
average of these four estimates.  
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 This was converted using the average exchange rate across the 12 months of 1996 retrieved from 
(X-rates 2011), which was $0.64132 to the £. 















































By switching from colposuspension to TVT, the 
majority of this cost should be avoided, as a large 
portion of it is made up by the hospital stay that is 
required following major surgery.   
 
Without having access to a comprehensive 
evaluation of the costs of colposuspension in order to 
help me isolate the costs associated with the various 
aspects of patient care, I will assume that the overall 
cost for the colposuspension procedure that is 
avoided is £2,700 (as described above), and this 
whole cost would be avoided with TVT.  The total 
headroom must therefore include the cost of 




Of course, for those who would not have initially 
undergone surgery for UI, the redirected costs would 
be much smaller, and are likely to be surpassed by 
the cost of TVT.  The QALY impact of undergoing TVT 
rather than more conservative treatments must 
make this monetary difference up.  A trial which 
compared the costs and outcomes associated with 
inpatient and outpatient continence programmes for 
UI  (bladder retraining and physiotherapy) found that 
the costs associated with the outpatient programme 
were much smaller (£66 per patient treated versus 
£126) and the outcomes just as good (Ramsay et al. 
1996). 
Assuming that some of the patients who would 
otherwise undergo conservative management such 
as that described by Ramsay and colleagues now 
undergo TVT, we may assume that £66 could be 
saved per patient per year55 (assuming that the 
health service employs this more efficient means of 
treating patients— in an outpatient setting).   
 
 
1: TVT replaces colposuspension.  
Patients: 4,000 
 
(Total) ∆SC= £10,800,000 
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 I have been unable to isolate these procedural costs from the headroom estimate due to the lack of 
NHS reference costs or other UK cost information that I have been able to find from sources that were 
available in 1996. 
55
 I choose a one year time frame for this scenario, as it may be that a patient‘s symptoms would have 
progressed such that surgery would have been considered in time: as I do not know the relevant time 
frame, I consider its value over a one year time period only.  














Describe any potential costs/savings that 
you haven’t quantified.  
(Av. Per person) ∆SC= £2,700 
 
 
2: Patients who would otherwise be treated by 
conservative means may now be treated surgically 
with TVT. Patients: 96,000 
 
(Total) ∆SC= £6,336,000 
(Av. Per person) ∆SC= £66 
 
The above figures must include the procedural cost 
implications of TV, including staff time, equipment, 
etc.  The training of staff to use this technique must 




Potential impact of the new device on 
patient health, as compared to current 
practice (preferred method of elicitation is 
from studies using the EQ-5D).   
Where NICE have not produced relevant 
economic analyses, search for cost-
effectiveness studies or systematic reviews 
within the disease area (the CEA registry 
















In the case of application 1, we assume that TVT 
simply replaces all current colposuspension 
procedures, with the same effectiveness.  For this, I 
assume that the QALYs implicated are the same56.  
 
For those who relied previously on conservative 
management alone, but who would benefit from 
surgery with TVT, there is likely to be a QoL 
implication.  The assumption here is that previously 
symptoms would have needed to be strong before 
surgery was considered.  With TVT, the (milder) UI 
symptoms of the 96,000 who could now be treated 
with TVT, could be alleviated.   
In the absence of any QoL assessments in the 
literature of this or comparable ailments, I estimate 
the impact of urinary incontinence by manipulating 
what may be the relevant EQ-5D parameters and 
estimating their value using the study presented by 
Williams (Williams 1995).  Of the five health 
parameters in the EQ-5D questionnaire57, those that 
seem to be the most pertinent for urinary 
incontinence are probably ‘usual activities’ 
‘pain/discomfort’ and ‘anxiety/depression’.  
Assuming that in all other ways the patient is in full 
health, the range of utility values that one could 
attribute to urinary incontinence ranges from 0.883 
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 Although recovery time is likely to be much shorter for TVT versus open colposuspension (and thus 
have a positive impact on QALYs), to estimate this may be impractical, especially given my lack of 
understanding of the recovery prospects for patients having undergone TVT.   The developer is likely 
to have had a better idea of this, even at this very early stage.  However, this is probably not crucial at 
this stage, given the fact that the case for development is likely to be an obvious one, given the cost 
saving potential of the procedure alone. 
57
 Mobility, Self-care, Usual activities, Pain/discomfort, Anxiety/depression. Note- manipulation of 
these parameters is speculative. 
















































to 0.689, assuming that any problems in these areas 
are moderate rather than severe58 (ii).  By simply 
adding the value of a shift change from level two to 
level one in the three potentially relevant health 
categories, this would lead to an impact of 0.23 on 
the QoL scale.  Therefore, I will assume that TVT for 
patients who would have previously been managed 
conservatively would lead to an incremental QALY of 
0.2 per year.  This means that if the patient is 
otherwise in full health, urinary incontinence might 
be associated with a QoL weighting of 0.8.   
This, however, assumes that patients gain no useful 
control of their symptoms after being treated by 
conservative therapy.  Although the NHSC brief 
indicates that those extra 96,000 patients who could 
now be treated with TVT are those who do not 
respond to conservative therapy, I will also test the 
headroom result for a more modest gain of 0.1 per 
year, to account for where conservative management 
leads to some symptom improvements (but only half 
of what could be achieved by undergoing TVT), or 
accounting for a more modest baseline level of 
health.  
 
TVT is intended as a permanent treatment for UI.  
However, without knowing the clinical pathway and 
progression of those that would before have been 
treated conservatively (e.g. average age of the 
patient, percentage recovery rate of those treated 
conservatively, or proportion of those patients who 
would develop further symptoms and subsequently 
be referred to colposuspension), I will take just a one 
year timeframe.   
 
 
1: TVT replaces colposuspension.  
Patients: 4,000 
 
∆QALY= -  
(Av. per person) ∆QALY= - 
 
2(a): Patients who would otherwise be treated by 
conservative means may now be treated surgically 
with TVT. Patients: 96,000 
                                                          
58
 If patients had symptoms within the ‗severe‘ category for any of these QoL parameters, the patient 
would probably have been within the group of 4,000 patients already being treated with surgical 
colposuspension. 



















Describe any impact on patient health that 
you haven’t quantified.  
 
∆QALY= 19,200 59  
(Av. per person) ∆QALY= 0.2 
 
2(b): Patients who would otherwise be treated by 
conservative means may now be treated surgically 
with TVT.  Conservative therapy improves UI 
symptoms but only half as much as TVT would. 
Patients: 96,000 
 
∆QALY= 9,600  




Due to the invasive nature of the current gold 
standard, patients are likely to prefer TVT to 
colposuspension. Although this preference is difficult 
to capture in a QALY (and so has been ignored), it is 
likely to have an impact on the clinician’s / patient’s 
decision. Also, the recovery time is likely to be much 
shorter.   On the other hand, for those who would 
otherwise have been treated conservatively TVT is 
unlikely to be pain-free, but the disutility associated 
with the procedure itself has been ignored by this 
analysis. 
Another potentially problematic assumption is that 
patients treated with TVT (who were previously 
managed conservatively) will resume a status of ‘full 
health’.  Given the likely age of the patients treated 
and other co-morbidities they might suffer from, this 
might not be appropriate.  
 
6. Developments (clinical & healthcare 
context) 
 
Consider the following questions to help you 
think about the space for your product 
within the market.  
 
Does the technology address any key national 
objectives for improving care in this area? 
 
How will the technology complement current 
practice? Is current practice likely to change? 
 
 [GREEN] In 1996 the Department of Health 
instigated and reported on a research project for 
the development of methodologies to identify 
urinary incontinence and set targets for health 
gain. Also in this year they published “Costs of 
incontinence to individuals and to services, and 
users’ perceptions of quality and effectiveness of 
services. Second stage feasibility study”. 
(Unfortunately neither report is electronically 
downloadable). This demonstrates current 
interest in improving outcomes for these patients 
(Department of Health 2011c). 
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 This is 96,000 * 0.2 (as I treat the replacement of colposuspension with TVT as simply a cost-saving 
enterprise for those other 4,000 patients). 




Are there any indications in the literature of 
potential effectiveness? 
 
Have you identified any direct competitors? (This 
could be another specific technology, or simply a 
different technique)  
 
 RED: Poses a significant threat to the 
opportunity identified in the market (i.e. 
works against current health service 
objectives, or there are other products 
being developed that are associated with 
better outcomes or are at a more advanced 
stage of development). 
 
AMBER: Potential threat 
 
GREEN: Further supports the case for the 
new technology  
 [AMBER] Other techniques are being investigated 
as alternatives to open Burch colposuspension.  
One such technique is a modification to the 
standard treatment: laparoscopic 
colposuspension, where the operation is 
performed through small keyhole cuts in the 
abdomen.  One cost-effectiveness study finds 
laparoscopic Burch to be more cost-effective 
than open abdominal Burch, costing Can$2,938 
rather than Can$5,692 (Kung, Lie, Lee, & Drutz 
1996).  Developments in this area may shift the 
comparator for TVT to a procedure that is 
relatively less invasive than open Burch 
colposuspension. 
 
 [AMBER] There may be other relevant treatment 
comparators or competitors for TVT.  The most 
directly relevant of these ‘other options’ 
identified in the literature seem to be those that 
are referred to as Sling procedures (Falconer, 
Ekman-Ordeberg, Malmström, & Ulmsten 
1996;Zaragoza 1996).  Without knowing more 
about the technicalities of either TVT or these 
other sling procedures, I do not know how (or if) 
these will differ. 
 
7. Research questions 
 
This should be a list of the things that the 
developer needs to find out or monitor 
during the process of development, relating 
to the function of the device or how it fits 
into the market place. 
 
From the research undertaken and reported 
above, what are the most important 
questions or uncertainties that must be 
addressed / tested? What factors or 
assumptions have the calculations / 
economic or clinical case hinged upon?  
 The analysis presented here assumes that TVT is 
equally as effective as our comparator, Burch 
colposuspension surgery.  Is this appropriate? 
Might complications be reduced by TVT?  
 In order to keep the analysis relatively simple, 
and to take an optimistic view at this very early 
stage, the analysis assumes that where TVT is 
used to treat patients who would previously have 
undergone conservative management, success 
rate is 100%.  Is this realistic, or should a down-
weighting be applied to account for those 
patients who may not respond positively to the 
procedure? 
 Is a one year time frame for the QoL benefits 
associated with TVT as compared to the current 
clinical pathway for moderate UI patients 
appropriate? 
 To what extent is conservative management 
successful?  The two estimates made in this 
analysis assume either a null (patients begin and 
end the year with a QoL weighting of 0.8 with 
conservative management) or modest success 




rate (that conservative management would raise 
QoL by 0.1, half the change that could be 
achieved by TVT).  The study I have found that 
estimates the success rate of conservative 
management is by Ramsay et al. who estimated 
that 63% of women were cured (or improved 
such that they required no further treatment) 
(Ramsay et al. 1996).  This many indicate that this 
analysis has overestimated with incremental 
effect of TVT on patient QoL over conservative 
management techniques.  This should be 
investigated in the light of continually evolving 
research.     
 Is ‘full health’ an appropriate baseline for QoL 
esimations? 
 To what extent would the less invasive nature of 
TVT provide an incentive to switch from 
colposuspension to TVT? By considering this 
change as cost-saving only (for those 4,000 who 
will currently be managed surgically), the value of 
TVT may be underestimated. 
 Is a potential patient population of 100,000 too 
optimistic? 
 The estimated QoL gain associated with switching 
from conservative treatment to TVT is very 
speculative.  The literature should be monitored 
regularly for QALY estimates of UI treatment.  
 It was also difficult to obtain a reliable and 
consistent picture of costs for colposuspension.  
The literature should be monitored for more data 
as it becomes available, particularly any attempts 
to estimate this from a UK perspective. The DH 
project mentioned above may prove useful in this 
respect (Department of Health 2011c). 
 How does TVT differ from other sling procedures 
currently being investigated in the literature? 
Notes by AC on workings 
Information used is from the NHSC briefing notes unless otherwise stated 
(i) The cost of colposuspension according to Kung and colleagues (Kung, Lie, Lee, & Drutz 
1996) needs inflating to 1996 prices as well as converting from Canadian dollars to pound 
sterling.  
The average exchange rate for the 12 months of 1994 was 0.4795 Can$ to the £ (X-rates 
2011). 
Can$5692.3 (1994 Canadian dollars) was equal to £2,729 in 1994 
 
This must be inflated to 1996 prices, which is done using the HCHS price inflator: 




The earliest date I can find for the HCHS index is 1995/6.  In order to try to estimate the 
inflation index between 1994 and 1996, and will use the inflation rate between 1995 and 
1997 as a proxy: 
 
HCHS P&P Index 1995/6: 166.0 
HCHS P&P Index 1997/8: 173.5 
Inflation rate: 1.045 
 
Cost of abdominal colposuspension (1996): £2,729 * 1.045 = £2,852 
 
(ii) By manipulating what seem to be the relevant health parameters within the EQ-5D 
framework, we get the following utility values: 
11112: 0.848 ‘Moderately anxious or depressed’ 
11121: 0.796 ‘Moderate pain or discomfort’ 
11211: 0.883 ‘Some problems performing usual activities’ 
11212: 0.812 ‘Some problems performing usual activities’ ‘Moderately anxious or depressed’ 
11221: 0.760 ‘Some problems performing usual activities’ ‘Moderate pain or discomfort’ 
11122: 0.725 ‘Moderate pain or discomfort’  ‘Moderately anxious or depressed’ 
11222: 0.689 ‘Some problems performing usual activities’ ‘Moderate pain or discomfort’ 
‘Moderately anxious or depressed’ 
Headroom Notes (TVT) 
For TVT, two ‘headroom’ scenarios were presented. The first was for where TVT would directly 
replace colposuspension, the current gold standard.  For this (which would be applicable for about 
4,000 patients), the headroom was £2,700, which is simply the estimated cost of a colposuspension 
procedure.   
For the other 96,000 of the potential 100,000 market in the UK, TVT would be replacing conservative 
management. To estimate the potential value of this to the health service, the cost of conservative 
management was added to the value of the estimated QALY gain.  This would be £4,066 if the NHS 
were willing to pay £20,000 per QALY and £6,066 if the tariff were £30,000 per QALY60.  However, 
this assumes that conservative management does not significantly improve UI symptoms.  If we 
assume that conservative management does improve symptoms, but only half as much as TVT 
would, then the headroom changes to £2,066 - £3,066. 
The headroom estimates must cover the cost to the health service of implementing the TVT 
procedure, and therefore should be considered as the headroom per procedure rather than per 
device per se (i.e. not an MRP).  Thus, as well as the device itself, this must cover the cost to the 
                                                          
60
 The fact that the headroom for treating those patients who currently do not undergo costly surgical 
procedures is larger than the headroom for those that do does not seem completely logical.  The 
reason for this result is that I have assumed a substantial QALY gain for these patients.  I have also 
presented the headroom for a more modest QALY gain.   




health service of staff time, hospital stay (about 6 hours), other equipment or local anaesthesia costs, 
as well as staff training etc.  
Extrapolation into development decision analysis was not undertaken due to the inability to identify 
the potential heath service procedural costs, and therefore lack of MRP.   
The analysis has been presented in two parts, according to style of current management, but of 
course these would not be considered by the company in isolation.  For example, it is unlikely to be 
the case that TVT be directed only to those 96,000 patients for whom the procedure may be 
relevant, but who do not currently undergo colposuspension.  Therefore, these figures should be 
considered side-by-side and not as absolute values; price discrimination for TVT according to the 
patient and their current treatment alternative is unfeasible. 
Follow-up (TVT) 
Headroom Outcome and Market success 
Does the MRP look realistic? Would it have indicated yes or no to development? 
The headroom analysis seems to present a favourable opportunity for TVT.  Having considered the 
cost of colposuspension, as well as the potential for increased QoL for those who would previously 
have received conservative management, the minimum headroom estimated was £2,066, but 
reached £2,700 for those who would currently undergo colposuspension treatment, and just over 
£6000 under very favourable assumptions of QoL gain for those who are currently managed by 
conservative treatment.  This was to cover all of the hospital costs for the procedure as well as any 
device used that is supplied by Ethicon for the TVT procedure.  Given the high estimated cost of 
colposuspension, the much shorter hospital stay that would probably result from TVT, and what is 
likely to be a relatively simple piece of kit, the economic case for TVT at this the development stage 
seems to be a relatively straightforward one.  Cost estimates of the procedure in the literature from 
a UK NHS perspective include estimates of £1,058 (Kilonzo et al. 2004;Manca, Sculpher, Ward, & 
Hilton 2003), £1,114 (Cody et al. 2003),  £1,135 (Imamura et al. 2010), and £2,044 (Jacklin, Duckett, & 
Renganathan 2010).  These mainly fall below even the minimum headroom figure, indicating that the 
headroom would have presented adequate room for development.   
Thinking about the problem on a more primitive level, comparing TVT directly to colposuspension 
and noting the shorter hospital stay and less invasive nature of the procedure, the saving in health 
service cost would seem very likely to outweigh the cost to the company of producing the tape and 
application device required to apply TVT (especially if it can be performed as a day case, as indicated 
in the NHSC briefing).  
Interpretive answer: Headroom appears adequate to support a development decision.  
Has there been a decision made on it by NICE? What was the outcome? 
In February 2003 NICE produced a technology appraisal for TVT for use in women with stress 
incontinence.  This was replaced in October 2006 by a clinical guideline on the management of 
urinary incontinence in women, CG40 (NICE 2006a).  In this guideline, retropubic mid-urethral tape 




procedures using a ‘bottom-up’ approach with macroporous polypropylene meshes (i.e.TVT) are 
recommended for the treatment of UI where conservative management has failed.  Open 
colposuspension, and autologous rectus fascial sling are the recommended alternatives ‘when 
clinically appropriate’ (NICE 2006a).  This indicates that TVT has replaced colposuspension as the gold 
standard method of surgical intervention. Sacral nerve stimulation is recommended for UI due to 
detrusor over activity (again, where conservative management has failed).  Also recommended 
within this guideline (to be considered after traditional TVT due to less outcome data) are synthetic 
slings with a retropubic ‘top-down’ or transobturator foramen approach.  Ethicon produces TVT-
Obturator (TVT-O) which matches this description. 
Is it sold in the UK or the rest of the world?(Or has it in the past) If so, who is it bought by? 
TVT was launched by Ethicon in 1999, and was one of the first minimally-invasive surgical treatments 
for stress UI (Ethicon 2010a).  In England, uptake has been fast.  In 1997/8, 8,000 surgical operations 
were undertaken for stress UI over a 12 month period.  Annual surgical interventions increased by 
16% for 2004-2005, despite a 90% fall in the number of colposuspensions and needle suspensions 
and a 50% reduction in bladder neck buttress, sling and periurethral injections (NICE 2006a).  This 
difference has been made up by the rapid introduction of TVT, and other similar tape procedures.  
This has also led to a decrease in hospital bed days for UI surgery, falling from over 5 days in 1998/9 
to under 3 days in 2004/5.   
HES data (hospital episode statistics for the NHS) for the year 2010-11 shows that TVT was carried 
out on the NHS for 6,451 patients (HES 2012).  This shows that surgical intervention for stress UI has 
risen (TVT is just one of the options), but not to the extent of what was considered possible in the 
NHSC briefing and headroom analysis, which was 100,000 relevant patients.  
From the Ethicon website, it is clear that the company have since expanded their portfolio of 
products in this area, with five variations of the TVT.  The ‘gold standard’ retropubic TVT system is 
the product that was first introduced and to which most clinical data seem to relate.  The product(s) 
are said to be used worldwide, in treating over one million women for stress UI (Ethicon 2010b). 
 
Have there been investigations into its clinical / cost effectiveness? 
There has been much investigation in the literature on the clinical and cost-effectiveness of TVT.   
As indicated by NICE’s positive recommendation decision, the clinical data indicates that TVT is a safe 
and effective way to treat women with stress UI.  The study with the longest follow-up period (11 
years) shows that TVT is safe and effective, with 77% being (subjectively) ‘cured’, 20% improved, and 
3% that were failures (Nilsson, Palva, Rezapour, & Falconer 2008).  In the studies reviewed by NICE 
that went into the decision to recommend TVT over colposuspension, TVT tended to perform in a 
similar way or slightly better than colposuspension, but TVT procedures consumed fewer hospital 
resources (hospital stay, duration of catheterisation and operating time) and were associated with a 
faster recovery (NICE 2006a).  The model presented by the systematic review and HTA that NICE used 
for its technology appraisal projected the cost and QALY implications of TVT and colposuspension 
over 10 years after surgery, and showed the QALY implication to be very similar, but that TVT was  a 
cost saver (Cody et al. 2003).  This supports the perspective taken by the headroom analysis for these 




patients (the 4,000 who would otherwise undergo colposuspension).  Given the paucity of data 
available in 1996, the exact cost of colposuspension to the NHS was difficult to find; the £2,700 
estimate that was used seems to overestimate its actual cost, which is about half this amount.  The 
average cost of colposuspension among the UK studies that I have found since is about £1,340.  
However, this is not likely to have had an impact on the economic case for TVT, as the potential 
saving in healthcare resources was clear.  Having said this, the proposal made in the NHSC briefing 
that TVT might require an average LOS of 6 hours seems overly optimistic; Manca and colleagues 
(Manca, Sculpher, Ward, & Hilton 2003) find an average LOS for TVT of 2.29 days, versus 
colposuspension which involved an average LOS of 6.67 days (study published in 2003). 
The mean length of stay presented in the HES data from 2010-11 for TVT was 1.4 days (median: 1 
day) (HES 2012).  About a third of all cases (2,125 out of 6,451) were treated as a day case.  This 
shows that as time has gone the procedure has become much faster. 
Manca and colleagues (Manca, Sculpher, Ward, & Hilton 2003) find that there is a mean cost saving 
of £243 with TVT as compared to colposuspension, that the QALY differential between the two 
procedures is 0.01, and that TVT had a 95% chance of being more cost-effective than 
colposuspension (at a WTP of £30,000).   Kilonzo et al. (Kilonzo et al. 2004), Wu et al. (Wu, Visco, 
Weidner, & Myers 2007), and Valpas. et al (Valpas, Rissanen, Kujansuu, & Nilsson 2006) all conclude 
that TVT is more cost-effective than colposuspension (though the comparison for Valpas is 
laparoscopic colposuspension rather than open).    
The more difficult of the perspectives taken in the headroom analysis was that of the patients who 
were currently managed conservatively.  The data for TVT procedures shows that the 100,000 
estimate for potential patient population is, at the moment, a huge overestimation, though TVT does 
seem to have lowered the threshold for surgical intervention (with 4,000 patients undergoing the 
‘gold standard’ colposuspension back then and 6,500 now undergoing TVT, notwithstanding the 
other types of surgical intervention that are currently also undertaken).  For this, what were 
regarded as the relevant EQ-5D parameters were manipulated and an impact of 0.2 was estimated 
for the cure of stress UI (an impact of 0.1 to the QoL weighting was also considered).  Research in the 
literature into the patients’ QoL before and after treatment for stress UI indicates that this 
presumption of a return to ‘full health’ in all of these parameters was overoptimistic.  Whilst in other 
headroom analyses I have used QoL data for the UK population according to age as the baseline, this 
was more difficult in this case as I was trying to measure a difference rather than an absolute.   The 
literature upholds the estimate made in the headroom analysis for the QoL value for women with 
incontinence: about 0.8.   In the systematic review used by NICE to assess the cost-effectiveness of 
TVT, a value of 0.8 was used for incontinent women, and 0.85 for continent women (Cody et al. 
2003).  These figures are around the same ballpark as QALY numbers estimated by others, for 
example Kilonzo et al. (Kilonzo et al. 2004) who find a utility value of 0.82 with cure and 0.78 with 
incontinence, and Manca et al. who (using the EQ-5D questionnaire) find a EQ-5D value at baseline of 
0.778 and 0.806 at 6 months after treatment.  Tincello and colleagues (Tincello et al. 2010) describe 
the characteristics and comorbidities of stress UI patients, which may go some way to describing the 
baseline health state of these patients.  




Has the landscape described changed significantly? 
What is current gold standard clinical practice now? Has this changed? 
The clinical landscape for stress UI has changed somewhat since 1996; open colposuspension is no 
longer the ‘gold standard’ treatment (though it remains an option).  There has been no update to the 
NICE clinical guideline since it was published in 2006.  NICE recommend that where conservative 
management does not offer the patient symptom control, a ‘bottom-up’ tape procedure (such as 
TVT) should be considered; open colposuspension and fascial sling procedures are recommended as 
alternatives where appropriate.  Other forms of tape procedures (e.g. TVT-O) are also considered to 
be appropriate options.  Laparoscopic colposuspension is not recommended by NICE.  
Tape procedures such as TVT are also described as the first-line surgical option on the patient-facing 
website NHS Choices (NHS Choices 2010b).   
Are there now many direct competitors? 
I have not seen the use of the term TVT in relation to any other medical companies.  Without a better 
knowledge of the area, I am uncertain to what extent direct competition is a factor.  When searching 
the NHS supply chain catalogue (NHS 2012) for TVT, only Johnson & Johnson products are brought up 
(Ethicon is a subsidiary of Johnson & Johnson).  Ethicon seem to have developed (and continue to 
develop) many variations of the device, with minor changes / enhancements to its user control, mesh 
used, precision, allowing for a single incision, etc.  There are now five products within Ethicon’s TVT 
range, which reflects the company’s work to stay dominant in the field (Ethicon 2010b).     
Conclusions: How useful might the headroom exercise have been? 
For TVT, a range of headroom values were presented based on various assumptions made and 
populations described.  For the simplest case, where TVT would simply replace the current gold-
standard at the time (colposuspension) the headroom was relatively straightforward and was simply 
the cost of colposuspension surgery to the NHS.  Although the relevant NHS costing estimates could 
not be disaggregated from this, the potential for the cost saving was clear, and given the relatively 
straightforward nature of the device itself, the case for development seemed to be a clear one.  
Indeed, the potential for cost saving has come to bear in reality, with TVT now having overtaken 
colposuspension as the first-line surgical treatment for stress UI. 
In the headroom analysis, the more conceptually difficult population to consider were those not 
currently managed surgically.  For these patients, QoL estimates had to be made (subjectively, given 
the lack of data in the literature).  Although the estimate of the QoL weighting associated with stress 
UI turned out to be remarkably accurate, the return to ‘baseline’ was misjudged in the headroom 
analysis, and the incremental benefit created by TVT (or any ‘cure’) was overestimated (see above for 
discussion of this).   
As the economic case for TVT was quite strong and, in the end, straightforward (in its cost saving 
potential alone), it is difficult to say whether the headroom approach would have contributed any 
novelty or extra information to the decision-making process.  Many of the difficult or pertinent 
factors that were raised in the research questions were pertinent to this example upon follow-up. 
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 Lower Urinary Tract Symptoms (LUTS) are a common problem for men; 
incidence increases with age.  Symptoms include problems with both 
storing and voiding urine.  The most common cause of LUTS is benign 
prostatic hyperplasia which, whilst not malignant, can cause significant 
morbidity.  The decision to intervene medically or surgically is dependent 
on severity of symptoms and responsiveness to alternative means of 
management. 
 
The CT300 is a non-invasive pressure flow analysis for men, which 
indirectly measures intra-vesical pressure using controlled inflation of a 
flexible cuff which is placed around the penis during the voiding of urine, 
until the flow is interrupted. Cuff pressure at this point reflects bladder 
contraction pressure. The CT3000 is thus a diagnostic technique that 
could be used to screen men with lower urinary tract symptoms (LUTS) 
before more lengthy, invasive and expensive studies are undertaken.   The 
results of the test can indicate suitability for prostatectomy.  
 
The CT300 system would consist of a PC, printer, customised trolley, flow 
meter, and the CT300 machine itself.  A single disposable penile cuff 
would be required per test. 
 
2. Comparator  
 
The current ‘gold standard’ diagnostic tests for obstruction of the bladder 
outlet are invasive urodynamic studies (sometimes called cystometry).  
These invasive and costly investigations involve urinary catheterisation 
and a rectal manometer. 
 
Currently, the best non-invasive method is peak urinary flow rates, but 
these cannot distinguish between obstruction and bladder muscle 
weakness (detrusor hypocontractility). It is thought that the presence of 
detrusor hypocontractility (rather than obstruction) is often a reason for 
prostatectomy failure, and thus part of the reason for poor success rates 
for prostatectomy.  
 
Other types of non-invasive test identified in the literature include: 
 Total prostate volume, or central zone prostatic volume (though the 
latter has been found by Corica et al. to be no more useful than the 
former (Corica et al. 1999)). 
 Imaging techniques.  These are outlined by the American College of 
Radiology (Bluth et al. 2000).  However, imaging does not play a major 
role in the current assessment of patients with LUTS (though it may 
play a larger role in the future) (Grossfeld & Coakley 2000). Imaging is 
mainly used to exclude the presence of malignant prostate tumour 
(Aarnink & Wijkstra 1999). 
 
The use of current testing methods (notably the two main ones: 
cystometry and peak flow rates) varies greatly according to location / 




urologist.  One study of men who underwent prostatectomy in four 
regions of England in the mid 1990s found that only 50% had their urinary 
flow rates measured (despite the fact that this is recommended) 
(Emberton et al. 1995), and a much smaller percentage undergo invasive 
testing.   This variable (and often underused) screening approach is 
further exemplified by a survey of the management of patients presenting 
with bladder outflow obstruction conducted in Scotland in 1991 (Lloyd & 
Kirk 1991).  Of the 46 respondents to the postal questionnaire, 36 (78%) 
had access to a urine flow meter, and 32 (70%) had facilities for 
cystometry.  Of those that did have access to a urine flow meter, 13 (36%) 
measured urine flow rates in all patients, and 14 (39%) said they did so 
frequently.  Of those with the facilities required to undertake cystometry, 
all used it ‘only occasionally’ in men with suspected outflow obstruction 
(Lloyd & Kirk 1991) (this was, however, 10 years ago).   
 
It is thought that around a third of men who currently undergo 
prostatectomy do not benefit from the procedure (Emberton et al. 1996) .  
Bladder pressure flow analysis using the CT3000 is proposed to increase 
the overall success rate of prostatectomy by improving the targeting of 
prostatectomy, as compared with current diagnostic strategies (which 
sometimes involves neither flow rates nor invasive urodynamic studies).   
 
The reason that I have decided to call the CT3000 non-invasive bladder 
pressure test ‘another option’ in relation to current practice, it that the 
briefing is not absolutely clear how the CT3000 would replace or add to 
the diagnostic strategies that are used at the moment.  The fact that the 
number of invasive tests performed by urologists could be reduced is 
mentioned, but it is not proposed to replace them entirely, and the device 
is also mentioned in its use as an addition to other non-invasive tests.  
Therefore, I assume that the CT3000 offers urologists another way in 
which bladder obstruction can be diagnosed (either with or instead of 
current bladder function tests), and that as a result the success rate of 
prostatectomy is increased from 70% (as is the case currently) to 90% 
(assumption provided by the NHSC briefing, presumably stipulated by the 
developer).  With the current number of prostatectomy procedures being 
around 30,000 per year in England and Wales, this could lead to 6,667 
procedures being prevented each year (assuming that the number of 
successful procedures remains constant)61.   
 
3. Market size  In England and Wales 30,000 prostatectomy procedures are currently 
undertaken each year.  It could be assumed that this corresponds to the 
approximate number of patients eligible for the CT3000 penile cuff test, 
though without understanding how exactly the device would be 
incorporated into current practice, this may be difficult to approximate.  
However, if it is to be incorporated into the management of patients 
across the NHS, then we may assume that all (approx.) 550 urologists 
should purchase one system.  As the main cost element of the CT3000 
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 This estimate was provided by the developer in the NHSC briefing. 




would be the piece of equipment itself rather than the disposable ‘cuff’, 
it makes sense to consider the investment on a per unit rather than per 
patient basis. 
 
Market size per year (NHS England & Wales, number of units required 
to cover all relevant patients ):  550 
 
4. Health Service 
 
Changes in resource use.  Any changes in 
service delivery costs to the NHS that will 
result from the application of the new 
technology, including the disinvestment in 
previous practice.  This could include: Staff 
time, hospital bed days, GP visits, A&E visits, 
etc.  It should not include services for which 
the NHS (and personal social services) is not 
financially liable (e.g. lost productivity and 
[non-health] social care costs), but these 
should be noted in writing below to add to 
the verbal case for the product (NICE may 
incorporate social care costs into cost-
effectiveness estimates in the near future). 
 
 If relevant and not included in service cost 
impact above, search for price of the 
currently used product (P1). 
 
Use HCHS index to inflate estimates to 















The main assumption for this headroom analysis is 
that 6,667 prostatectomy procedures could be 
avoided each year if the CT300 penile cuff test were 
available to urologists for the diagnosis of bladder 
obstruction (thus increasing the chance of a good 
outcome from prostatectomy).  According to the 
Department of Health’s NHS Reference costs for 
2000-2001, a prostate transurethral resection 
procedure costs a mean of between £1,411 and 
£1,592 (according to recipient age and presence of 
complications or comorbidities) (Department of 
Health 2002).  I will therefore assume that a 
prostatectomy costs the NHS about £1,500 per 
procedure.  
 
The CT3000 test requires around 15 minutes of 
preparation/operation time by a junior technician or 
health care assistant per test, costing the health 
service around £3.5062.  It will require 5 minutes a 
day from a senior technician for calibration.  Half a 
day of training would be required when the 
equipment is first introduced.  As these service costs 
are all relatively small, and are very likely to be 
outweighed by disinvestment in other bladder 
function tests that would result from the introduction 
of the CT3000 (which are not being quantified here), I 
will ignore these costs.  However, these should be 
considered in relation to the headroom that is 
identified; if the headroom is modest, then these 
may have an impact on a development decision. 
 
(Total) ∆SC per year= £10,000,500 
(Av. Per unit) ∆SC per year= £18,183  
 
P1= - 
(ignoring the potential for displaced cost of current 
tests) 
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 The first year for which Unit cost of health and social care data is freely available online is 2004 
(PSSRU 2004) (the 2002 version is not accessible).  Although out of the time scale of this analysis, I 
sought data for this in order to gain a general impression of scale, but will not include this in the 
headroom analysis.   




Describe any potential costs/savings that 
you haven’t quantified.  
As indicated, I am ignoring for the purposes of this 
headroom analysis any potential cost savings that the 
CT3000 could stimulate by allowing urologists to 
conduct fewer of the current tests.  However, this 
could be especially important if invasive cystometry 
procedures were reduced; a urodynamic investigation 
costs the NHS an average of £114 (Department of 
Health 2002) . 
Considering the approach taken, a potential for 
reduced service costs that is also being ignored is 
that, by reducing the number of unsuccessful 
prostatectomy procedures, the treatment costs for 
complications of prostatectomy would also be 
reduced, including urinary tract infection.  The costs 
involved in patient follow-up for all men who undergo 
the prostatectomy would also be reduced.   
As mentioned in the text above, service costs for the 




Potential impact of the new device on 
patient health, as compared to current 
practice (preferred method of elicitation is 
from studies using the EQ-5D).   
Where NICE have not produced relevant 
economic analyses, search for cost-
effectiveness studies or systematic reviews 
within the disease area (the CEA registry 




















A QoL study conducted on a subsample of those 
involved in the U.S. Health Professionals Follow-up 
Study (HPFS) investigated the QoL implications of 
LUTS according to severity of symptoms (Welch, 
Weinger, & Barry 2002).  The most important health 
parameters affected by LUTS were (in order of 
impact): a) the impact of a patient’s physical 
condition on his ability to carry out work or other 
usual activities, b) vitality or energy level, c) being 
depressed or anxious, d) general health perceptions 
and e) physical functioning.   
 
By taking the approach outlined above, we are 
assuming that the CT3000 results in an improvement 
in the success rate of prostatectomy procedures; this 
means that the same number of successful surgeries 
are undertaken, but that there are fewer 
unsuccessful ones.  Although overall the long term 
health of patients would be the same before and 
after the introduction of CT3000, the disutility 
associated with the procedure itself would be 
avoided for those 6,667 patients who no longer 
undergo it.  Whilst an important consideration for 
patients and those that manage their care, this would 
be difficult to translate into QALYs. 
 
As the cost saving impact of CT3000 is likely to 
represent sufficient reimbursement opportunity in 
itself, I will not spend the time trying to quantify this 
benefit. 







Describe any impact on patient health that 
you haven’t quantified.  
∆QALY= -  
(Av. per person) ∆QALY= - 
 
While this benefit to patients is left unquantified in 
this analysis, this would be an important 
consideration for patients and the clinicians that 
manage them.  
 
6. Developments (clinical & healthcare 
context) 
 
Consider the following questions to help you 
think about the space for your product 
within the market.  
 
Does the technology address any key national 
objectives for improving care in this area? 
 
How will the technology complement current 
practice? Is current practice likely to change? 
 
Are there any indications in the literature of 
potential effectiveness? 
 
Have you identified any direct competitors? (This 
could be another specific technology, or simply a 
different technique)  
 
 RED: Poses a significant threat to the 
opportunity identified in the market (i.e. 
works against current health service 
objectives, or there are other products 
being developed that are associated with 
better outcomes or are at a more advanced 
stage of development). 
 
AMBER: Potential threat 
 
GREEN: Further supports the case for the 
new technology  
 [AMBER] One of the key advantages of the 
CT3000 would be its non-invasive nature, and its 
ability to identify bladder obstruction more 
accurately than other current non-invasive 
methods.  Although not used systematically at 
the moment, other non-invasive tests for bladder 
function include imaging techniques (Bluth et al. 
2000;Grossfeld & Coakley 2000). 
 
 [GREEN] The literature indicates that bladder 
function testing before prostatectomy is not 
carried out enough (Emberton et al. 1995;Lloyd & 
Kirk 1991).  If it proves to be as effective as 
anticipated, an easy non-invasive method by 
which this can be done could instil more 
systematic testing of patients into current 
practice. 
 
 [GREEN] Although rare, prostatectomy 
procedures (as with any form of surgery) carry 
with them the risk of operative complications 
and death (Lertakyamanee et al. 2002).  Reducing 
the number of surgeries and ensuring they are 







7. Research questions 
 
This should be a list of the things that the 
developer needs to find out or monitor 
during the process of development, relating 
to the function of the device or how it fits 
into the market place. 
 
From the research undertaken and reported 
 The sensitivity and specificity of the CT3000 
penile cuff test has been assumed to be such that 
the success rate of prostatectomy procedures is 
improved from 70% to 90%. Does this seem 
feasible?  The appropriateness of this assumption 
should be tested during clinical investigations, by 
comparing the test to current means of 
investigation.   




above, what are the most important 
questions or uncertainties that must be 
addressed / tested? What factors or 
assumptions have the calculations / 
economic or clinical case hinged upon? 
What potential benefits or threats have you 
ignored in the calculation (see italicised 
points in Qs 4&5, and ‘developments’ 
section)?  
 The analysis is based principally on the 
proposition that a large number of patients do 
not benefit from prostatectomy.  This, and the 
specific number that was estimated, should be 
investigated further and verified by other studies 
if possible. 
 Would 550 units be sufficient to cover all patients 
for whom the test would be indicated? 
 The cost saving that may arise from 
disinvestment in other tests has been ignored.  
How exactly would the CT3000 be used in 
relation to current methods: alongside? Instead 
of?  Where the test would replace other 
methods, there could be a significant saving for 
the health service. 
 Currently, it is thought that 50% of patients that 
undergo prostatectomy do not even have their 
flow rates measured (Emberton et al. 1995).  
Given the relatively straightforward nature of 
peak flow tests, why is this the case?  Might the 
uptake of the CT3000 bladder function test be 
affected in the same way? 
 Does the introduction of the penile cuff test 
require any infrastructure or equipment in place 
that is not provided by Mediplus? If so, how 
much would this cost?  
 
Headroom Notes (Penile cuff test, CT3000) 
The approach taken to estimate the headroom for reimbursement for this bladder function test was 
to estimate the overall cost saving to the health service that could be achieved, and to divide this by 
the number of machines required to service all patients (thought to be 550).  This seems intuitive, 
given that: 
a) From a development perspective, it makes more sense to estimate the reimbursement 
opportunity per unit rather than per patient tested.   
b) It is not absolutely clear at this stage how the test would be employed and for how many 
patients. 
c) The main cost element of the CT3000 would be the piece of equipment itself, rather than the 
consumables associated with its use. 
The headroom identified was £18,183 per unit per year.  I was unable to translate this into a 
‘development decision’ as I have no information regarding how long each device will last.  If there 
were no yearly service or maintenance costs, this headroom should simply be multiplied by the 
number of years it is thought that the CT3000 could work.  




The CT3000 test requires around 15 minutes of preparation/operation time by a junior technician or 
health care assistant per day, and 5 minutes a day from a senior technician for calibration.  Half a day 
of training would be required when the device is first introduced into a practice.  These costs, as well 
as the disposable costs of the penile cuff (one required per test) will need to be considered, and need 
to fit within this headroom. 
Follow-up (Penile cuff test, CT3000) 
Headroom Outcome and Market success 
Does the MRP look realistic? Would it have indicated yes or no to development? 
The headroom estimated per device per year was £18,183, based on the total reduction in 
prostatectomy procedures that could result from better targeting, divided by the number of units 
required to service all relevant patients.  Left out of this estimation were the potential cost savings in 
other types of urodynamic tests that might ensue from the uptake of CT3000.  In order to inspire a 
positive development decision, this £18,183 needed to at least cover the cost of consumables, the 
equipment required to use the test, and service costs involved in carrying out each test. 
The NHSC briefing indicates that the cost of the CT3000 system is £11,000.  Single use disposables 
cost £5.50 per test.  I have found no estimation of the NHS service costs (in terms of staff time), for 
providing the test, but these are likely to be quite modest given its simplicity and speed of use.  The 
total yearly consumables cost per device clearly depends on its throughput.  If throughput were 
30,000 / 550, then this would be about 55 tests per year, indicating a consumables cost to the NHS of 
around £300 per year (55*£5.50).  The NHSC briefing indicates that the whole CT300 system, which 
apparently consists of PC, printer, trolley, flow meter, and CT300 ‘back box’, costs £11,000.  A CEP 
report published in 2007 for the Mediplus CT3000 (CEP 2007a), provides an evidence review for the 
device.  Whilst an economic evaluation is not presented, the authors indicate that: ‘the additional 
cost of specialised equipment associated with introducing the cuff method is estimated to be 
£5,000’.  With no indication of what this refers to (no other prices or costs are provided at all) and 
whether this is on top of the CT3000 system price indicated above, it is difficult to know whether this 
should also be covered by the headroom. 
Even with the inclusion of a potential extra £5,000, the headroom of £18,183 is likely to cover all 
equipment and consumable costs that have been identified since the device has come onto market.  
This, and the fact that this headroom should actually be multiplied by the number of years of service 
each CT3000 could provide, seems to provide sufficient potential for reimbursement, and thus is 
likely to have indicated a positive development decision63.  
Headroom would probably have indicated a positive development decision. 
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 An analysis of the development decision in terms of overall costs and allowable development costs 
could not be conducted without information regarding the longevity of the device.   





Has there been a decision made on it by NICE? What was the outcome? 
NICE have not issued any guidance on the CT3000 penile cuff test.    
Is it sold in the UK or the rest of the world?(Or has it in the past) If so, who is it bought by? 
The CTP3000 received a CE mark and was launched in the UK in 2005, as the first non-invasive 
method of measuring bladder pressure in men (Mediplus 2005).  Mediplus Ltd is a privately owned 
manufacturer of medical devices, based in the UK, which specialises principally in urology products 
but also for urogynaecology, gynaecology, gastroenterology, anaesthetics, and general surgery 
(Mediplus 2012a).  On their website, Mediplus indicate that the first centres using the CT3000 are 
located in: Newcastle-Upon-Tyne, London, Bristol, Exeter, Leeds, Norfolk, Spain, Switzerland, USA, 
and Canada (Mediplus 2012c).   I have found no further evidence of how widespread the use of 
CT3000 is.  The CEP report published in 2007 indicates that the Mediplus CT3000 system shows 
significant potential for use in outpatient urology clinics (CEP 2007a).   The outline of diagnostic tests 
employed to diagnose prostate enlargement on NHS Choices does not mention non-invasive bladder 
pressure tests. 
 
Have there been investigations into its clinical / cost effectiveness? 
The principal assumption used to inform the headroom analysis was that the CT3000 cuff test would 
improve the success rate of prostatectomy from 70% to 90%.  A study reported by Harding et al. 
showed that, using the CT3000 to target prostatectomy, there was a surgical success rate of 87% 
(Harding et al. 2007).  This indicates that the estimate used for the headroom analysis was 
appropriate (though CEP note that it remains to be seen whether these findings can translate to the 
population beyond that of that particular study).   
I found no economic evaluation. The CEP report deemed there to be too many unknowns.  
An early study of the cuff test found that the device, when combined with information provided by 
flow rate, can classify more than two thirds of patients without the need for invasive testing; the 
system identified obstruction with 68% positive predictive value and 75% negative predictive value 
(Griffiths et al. 2005).   One study published in the Journal of Urology assessed the usability of the 
cuff test by testing the variability in interpreting the results between experienced and novice users of 
the test (McArdle et al. 2009).  The authors find good concordance of results, and conclude that 
introducing the penile cuff test into the routine assessment of men with LUTS would be 
straightforward.  A study of repeatability found that diagnostic category repeatability (using the test 
on the test on the same man with a month’s interval) was similar to that of conventional 
urodynamics (Clarkson et al. 2008).  Another study tested pressure flow measurements (using the 
cuff test) before and after the removal of the obstruction (prostatectomy) (Sajeel et al. 2007).  The 
study found that the test was sensitive to change following the removal of the obstruction.  CEP 
provides details of further clinical investigations. 
The extent of possible reductions in other tests is still unclear (CEP 2007a).  Mediplus indicate that 
the test is not to be used as a replacement of other urodynamic tests, but as an adjunct (Mediplus 
2012b).  This supports the decision to leave this potential for cost saving out of the headroom 




estimates. Also, when using CT3000 to make a referral for surgery, a high proportion (87%) of 
patients had a good outcome from the TURP procedure (3). This ability to predict surgical outcome is 
equivalent to that offered by invasive urodynamic studies, though it remains to be proven whether 
this finding can be generalised beyond the population of that particular study. 
The degree of accuracy offered by the Mediplus CT3000 system, in two clinical trials (144 and 193 
patients), is greater than the accuracy achieved by flow rate measurement and symptomatic 
assessment (see refs in CEP report).  
Has the landscape described changed significantly? 
What is current gold standard clinical practice now? Has this changed? 
The gold standard in urodynamic assessment for patients with LUTS seems to still be cystometry.  
Peak flow rate still seems to be an important tool for urologists.  Whilst it is clear that the CT3000 has 
been picked up, it is difficult to know how wide spread its application has become.  On their website, 
Mediplus emphasise that the CT3000 is to be used alongside standard flow study, and not as a 
replacement to conventional urodynamic investigation, which remains the ‘gold standard’.  The 
penile cuff test provides useful extra information for urologists. 
Are there now many direct competitors? 
I have come across no other version of the penile cuff test in my internet and literature searches. 
Conclusions: How useful might the headroom exercise have been? 
The headroom analysis indicated adequate room for development of the CT3000 bladder function 
test.  The value estimation was drawn from the assumption that the CT3000 could improve the 
success rate of prostatectomy by more accurately targeting the procedure.  Whilst some studies 
indicate that the system does indeed have the potential to improve the success rate of surgery, this 
remains to be tested on a large scale.  There are no published economic evaluations for the product 
in order to test the assumptions made, but the system does seem to provide good value, and this is 
indicated by its uptake so far.  











NICE IPG for follow-up 
 
Date of briefing: 
January 2006 
 
Time perspective of this 
report: 200564 
Migraine is a common headache disorder, which is neurobiological in 
origin and manifests as recurrent attacks lasting anywhere between four 
and seventy-two hours.  Migraine episodes are associated with headache 
pain and are sometimes accompanied by nausea, vomiting, and sensitivity 
to light or sound.  The World Health Organisation estimate that migraine 
is 19th among the causes of years lived with disability (WHO 2004); social 
and work capacity can be significantly reduced.  
 
About 15% of people who have migraine have migraine with aura, which 
represents about 500,000 to 750,000 people in England and Wales.  Those 
who have migraine with aura additionally experience visual (light flashes, 
clouded vision, etc) or other neurological disturbances (pins and needles, 
hearing, vertigo, sensitivity to touch, etc). 
 
A patent foramen ovale (PFO) is the presence of a hole in the wall 
between the two upper chambers of the heart.  In the womb, a baby will 
have a small opening between the left and right atria (which allows blood 
to bypass the lungs); this hole should close by itself soon after the baby is 
born. PFO is present when this hole does not close fully and remains 
patent throughout a person’s life.  As many as one in four people have 
PFO, but for most this causes no complications. 
 
Although PFO is a well-established risk factor for ischaemic stroke (Del 
Sette et al. 1998), there is said to be an increased prevalence of PFO 
among those with migraine (especially with aura).  Although a causal link 
has yet to be proven, various studies show there to be a relationship here.  
In one study, it was found that 47% of those with migraine with aura had 
PFO, and just 17% of the control subjects (Schwerzmann et al. 2005).  
Another study found that 41% of patients who had migraine with aura 
had PFO versus 16% of the controls (Del Sette et al. 1998).  Yet another 
study that investigates this relationship is presented by Anzola et al. 
(Anzola et al. 1999), who found that PFO was present in 48% of patients 
with migraine w/aura, 23% of patients who had migraine without aura, 
and 20% in the age-matched non-migraine controls.  We can deduce from 
these studies that people who have migraine with aura seem to be about 
two to three times more likely to have PFO than the general population.   
 
The patent foramen ovale (PFO) closure procedure is suggested for 
people who suffer from refractory migraine with aura, i.e.  for those who 
do not respond to conservative treatment.  This procedure is already 
established as a treatment option for patients with stroke or transient 
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 I have back-dated the perspective of this analysis from the publication of the NHSC briefing by just 
one year.  The reason for this is that for this particular case, the device that is being proposed for this 
indication already exists and is used to treat patients but for a different clinical problem.  Therefore, the 
question becomes whether this particular indication is worth pursuing not in terms of developing a 
device from scratch, but for investing in the research required to prove its worth clinically, and 
marketing the device toward this particular group of patients and their clinicians. 




ischaemic attacks, and aims to prevent recurrent events.  379 PFO closure 
procedures took place in Britain in 2004. 
Percutaneous PFO closure involves placing an umbrella-like closure device 
to seal the PFO.   NMT Medical (STARFlex septal repair implant) and St 
Jude Medical (Premere PFO closure device) have PFO closure devices that 
are already CE marked.  NICE issued an interventional procedures 
guidance for PFO closure in the prevention of cerebral embolic stroke in 
January 2005 (NICE 2005a).  NICE find that there are no major safety 
concerns and that the procedure is efficacious in achieving closure of the 
foramen.  However, they are unable to confirm (due to insufficient 
evidence) that PFO closure prevents future strokes. 
 
PFO closure is suggested as a treatment option for patients whose 
symptoms do not respond to current medical management.  It is thought 
that this could reduce the frequency and impact of migraine attacks. 
 
2. Comparator  
 
There is no absolute cure for people who have a tendency to experience 
migraines.  However, lifestyle modification and the use of medicines can 
reduce their frequency / impact.  Pharmacological therapy includes that 
which is intended to alleviate symptoms (analgesics, anti-emetics, 5-HT1 
etc), and those that are designed to prevent future attacks (pizotifen, 
beta-blockers, sodium valproate, amitriptylline, topiramate, etc).  
Relaxation therapy and acupuncture are also considered beneficial. 
 
There are no other treatment options for migraine with aura patients who 
do not respond to any of these treatments.   
 
3. Market size  PFO closure would be indicated for refractory migraine with aura 
patients, whose symptoms are relatively severe.  It is thought that 500-
750,000 people have migraine with aura in England and Wales.  Of these, 
at least 10-15% (50-75,000) have weekly attacks.  The NHSC briefing 
indicates that this might represent the relevant patient population.  
However, it is difficult to know whether all of these patients would be 
relevant for PFO closure, given the uncertainty surrounding how many of 
these patients actually have PFO (under half of migraine with aura 
patients have PFO), and how many might respond adequately to current 
symptom-alleviating medication.  Given the uncertainty in the number of 
relevant patients, as well as the presence of many existing competitors, I 
will consider this problem on a per unit basis rather than extrapolating 
any calculations by considering the likely number of procedures.  Also, 
this parameter would be less crucial than it would be in a ‘to develop or 
not to develop’ decision (the PFO closure devices already exist). 
 
Market size per year: - 
 
4. Health Service 
 
Over 10 years ago, it was estimated that migraines 
cost the NHS about £23 million ([No authors listed] 




Changes in resource use.  Any changes in 
service delivery costs to the NHS that will 
result from the application of the new 
technology, including the disinvestment in 
previous practice.  This could include: Staff 
time, hospital bed days, GP visits, A&E visits, 
etc.  It should not include services for which 
the NHS (and personal social services) is not 
financially liable (e.g. lost productivity and 
[non-health] social care costs), but these 
should be noted in writing below to add to 
the verbal case for the product (NICE may 
incorporate social care costs into cost-
effectiveness estimates in the near future). 
 
 If relevant and not included in service cost 
impact above, search for price of the 
currently used product (P1). 
 
Use HCHS index to inflate estimates to 





























1992) (probably worth nearly £40 million after 
inflating to today’s prices).  
 
I have identified two economic evaluations 
conducted from the perspective of the NHS for 
migraines: one that investigates the cost-
effectiveness of acupuncture (Vickers et al. 
2004;Wonderling, Vickers, Grieve, & McCarney 2004) 
and another that compares the cost-effectiveness of 
various management strategies for the acute 
treatment of migraine (Sculpher, Millson, Meddis, & 
Poole 2002). 
Although the HTA on acupuncture is very 
comprehensive and offers a breakdown of NHS as 
well as personal costs of migraine, the patient 
population under investigation is that of ‘chronic 
headache’, which included tension-type headache, 
and the costs associated with medicines were not 
clear. 
The study comparing management strategies looks at 
the direct healthcare costs of the acute treatment of 
migraine using three approaches: stratified, and two 
stepped care approaches (across attacks and within 
attacks).  Costs are provided in relation to total 
health service costs over six attacks, including rescue 
medications and adverse events (which included GP, 
A&E or consultant neurologist costs where relevant).    
The highest cost strategy was stratified care, which 
was £28.25 for six attacks.  I will use this, the highest 
estimate of migraine cost (as those serious migraines 
with aura patients who would be considered for PFO 
closure are likely to be the most costly patients).  
Assuming weekly attacks, this equates to a yearly 
cost of £245. 
 
Missing from the estimate above is the cost of 
preventative medicine that may be prescribed to 
patients.  According to UK clinical guidelines, 
preventative treatment for migraines should be 
considered where migraine attacks cause significant 
disability, are regular (more than two or three per 
month), or where there is over-use of current 
medication (Prodigy 2005b).  The severity of migraine 
patients that are likely be indicated for PFO closure 
would fulfil these criteria.  The guidelines 
recommend that first-line preventative treatment 
should be beta-blockers such as propranolol, 
metoprolol, timolol and atenolol (Prodigy 2005b).  
Information on the cost of these drugs in the UK has 





















































been difficult to obtain.  One appraisal of migraine 
drugs in the U.S. presented the wholesale cost for 
one month of preventative medicine according to 
type (Adelman et al. 1998).  The average monthly 
cost of the four beta-blockers recommended by the 
PRODIGY guidelines was $24.60- about £15.  This 
equates to a yearly cost of about £180. 
 
However, the difficulty is knowing whether and to 
what extent the medicines for acute headache 
symptoms would be prescribed alongside these 
preventative drugs. Although it may be the case that 
both are used in some instances, I will simply take 
the medication cost associated with those severely 
affected by migraine with aura, which is £245 per 
year. 
 
It is thought that PFO closure could reduce the 
frequency and impact of migraines.  Without having 
been given an estimate of the extent of this 
reduction, I will apply the assumption that the 
positive impact on migraines reduction will reduce 
health service costs by half each year: £123. 
 
In the NHSC briefing, it is proposed that implantation 
of the STARFlex by NMT Medical would use similar 
facilities and take a similar amount of time as an 
angiography; it would require access to 
echocardiography, (light) general anaesthetic, and 
could involve a hospital bed stay.  NHS reference 
costs for 2003-2004 indicate that HRG Code E14 
[Cardiac Catheterisation and Angiography without 
complications] has a national average unit cost of 
£1,221 (Department of Health 2005).  The NHS 
reference cost database indicates that angiography is 
associated with a length of stay of two days.  In order 
to approximate the procedural service costs 
associated with PFO closure, I will use the cost of 
angiography (£1,221) minus one day’s worth of 
hospital costs, as according to the briefing it is likely 
to involve just one overnight hospital stay.  The cost 
of an excess bed day for angiography is £255 
(Department of Health 2005).   The resultant service 
cost of providing the PFO closure would be 
approximately £966.   This would be a one off cost. 
 
The net impact of PFO closure on service costs would 
depend on the time scale chosen; whilst the 
procedural costs associated with its closure would be 
























Describe any potential costs/savings that 
you haven’t quantified.  
a one-off investment, the potential cost savings from 
reduced drug costs should last for the remainder of a 
patient’s lifetime.  In order to demonstrate the 
impact of the timescale taken, I will present the 
results according to a time horizon of: one year, five 
years, ten years and twenty years (see note (i) for 
workings). 
 
TIME HORIZON: 1 Year 
 (Av. Per person) ∆SC= £843  
 
TIME HORIZON: 5 Years  
 (Av. Per person) ∆SC= £391 
 
TIME HORIZON: 10 Years  
 (Av. Per person) ∆SC= -£93 (saving) 
 
TIME HORIZON: 20 Years  
 (Av. Per person) ∆SC= -£843 (saving) 
 
A major issue for sufferers of migraine is the impact 
of migraine episodes on productivity (ability to go to 
work and effectiveness whilst at work), and the 
knock-on effect this has on the economy.  Some 
estimates value these productivity losses at around 
ten times that incurred by the NHS to treat migraines 
([No authors listed] 1992).  One study of the direct 
and indirect costs of migraine found that in the UK, 
the average total cost per migraine patient per year 
was €543; just €12 was accounted for by direct 
medical costs, and the remaining €520 by indirect 
costs (€156 for work absence and €375 for reduced 
productivity at work)(Berg & Stovner 2005).  Whilst 
not within the remit of an economic evaluation 
conducted from a health service perspective, this 
strong association with loss in productivity is likely to 
favour any treatment that can help those whose 
symptoms are not adequately controlled by current 
care options. 
One potential service cost that has not been 
considered is the investigation and clinical decision-
making that would be involved pre- procedure, to 
decide whether the patient is suitable for PFO closure.  





Potential impact of the new device on 
Migraine significantly affects a person’s QoL and 
ability to work, as well as having a big impact on 
social and family life (Silberstein 2004).  A means of 




patient health, as compared to current 
practice (preferred method of elicitation is 
from studies using the EQ-5D).   
Where NICE have not produced relevant 
economic analyses, search for cost-
effectiveness studies or systematic reviews 
within the disease area (the CEA registry 







































Describe any impact on patient health that 
you haven’t quantified.  
reducing the impact of migraines for those who 
suffer from them severely and who currently are not 
well managed by medicines and alternative therapies 
could have a significant positive impact on the HRQoL 
of those patients for the better. 
 
To estimate the QoL impact of a reduction in 
frequency and severity of migraines with no data on 
which to base these estimates would be highly 
speculative, given the uncertainty surrounding the 
current level of QoL of those patients, and how PFO 
closure might impact this. 
The HTA undertaken from an NHS perspective on 
acupuncture for migraine estimated the QALY impact 
of acupuncture on patients with chronic headache 
(Vickers et al. 2004;Wonderling, Vickers, Grieve, & 
McCarney 2004).  The patient characteristics are 
presented, which show that about 95% of 
participants were sufferers of migraine (Wonderling, 
Vickers, Grieve, & McCarney 2004).  The QALY impact 
of acupuncture on patients was found to be 0.021 
over a 12 month time period (from 0.708 to 0.727).  
Given the paucity of information in the literature, I 
will use this QALY difference of 0.021 per year as an 
estimate of the impact that PFO closure might have 
on patient QoL.  It should be noted though that this 
may well be an underestimate, considering the fact 
that those severe sufferers of migraine with aura that 
may be referred for PFO closure may well stand more 
to gain from symptom relief.  Again, I will present this 
potential QALY impact over one, five, ten and twenty 
years (see note (ii) for calculations). 
 
TIME HORIZON: 1 Year 
(Av. per person) ∆QALY= 0.021 
 
TIME HORIZON: 5 Years 
(Av. per person) ∆QALY= 0.0981  
 
TIME HORIZON: 10 Years 
(Av. per person) ∆QALY= 0.1808 
 
TIME HORIZON: 20 Years 
(Av. per person) ∆QALY= 0.3089 
 
 
As mentioned previously, migraine has a big impact 
on a person’s productivity, both inside and outside of 
the workplace.  As well as the huge impact this can 




have on the economy and a person’s own finances, it 
can also interfere a great deal with non-work 
activities.  More so than in many clinical areas, costs 
are often borne by patients.  This is so much the case 
that some studies consider it more appropriate to 
value medicines by the willingness to pay of the 
patient rather than the health service.  One particular 
study by Hamelsky and colleagues tries to assess the 
burden of migraine using a WTP model for migraine 
treatment (Hamelsky, Lipton, & Stewart 2005).  This 
highlights the fact that an economic evaluation 
undertaken from a health care perspective is likely to 
underestimate the true societal value of a treatment 
for migraine.  
 
6. Developments (clinical & healthcare 
context) 
 
Consider the following questions to help you 
think about the space for your product 
within the market.  
 
Does the technology address any key national 
objectives for improving care in this area? 
 
How will the technology complement current 
practice? Is current practice likely to change? 
 
Are there any indications in the literature of 
potential effectiveness? 
 
Have you identified any direct competitors? (This 
could be another specific technology, or simply a 
different technique)  
 
 RED: Poses a significant threat to the 
opportunity identified in the market (i.e. 
works against current health service 
objectives, or there are other products 
being developed that are associated with 
better outcomes or are at a more advanced 
stage of development). 
 
AMBER: Potential threat 
 
GREEN: Further supports the case for the 
new technology  
 [GREEN] A review of the available evidence by 
NICE has shown that PFO closure devices are 
successful in closing the PFO, and seem to be safe 
(NICE 2005a). 
 
 [AMBER] The literature has indicated that there is 
a true association between PFO and migraine 
(Anzola et al. 1999;Del Sette et al. 
1998;Schwerzmann et al. 2005).  [RED] However, 
whether there is an actual cause/effect 
relationship has yet to be proven.  [AMBER] This 
will be crucial in predicting the effectiveness of 
PFO closure for migraine.  This may be of some 
concern given the fact that in their interventional 
procedures guidance (NICE 2005a), NICE 
indicated that the evidence was not sufficient to 
say with certainty that PFO closure reduces the 
risk of stroke, even though intuitively the 
association between PFO and stroke would seem 
more logical than PFO and migraine. 
 
 [AMBER] Diffusion could be limited by the 
available number of neurologists and 
interventional cardiologists that would be 
required to screen patients with migraine for 
PFO, and for the suitability of PFO closure. 
 
 [RED] Presence of PFO is not information that is 
routinely collected.  In order to integrate PFO 
closure into clinical practice for refractory 
migraine with aura patients, investigative 
screening would need to be incorporated into the 
clinical pathway for these patients.  This may 




substantially increase costs.  
 
 [RED] There are likely to be many competitors, as 
the intervention is already established. 
 
 [GREEN] Many economic evaluations in the area 
of migraine and headache include an estimation 
of productivity loss, which usually far outweighs 
any outlay by the NHS.  The importance of 
patient-incurred costs in this area means that any 
treatments that can reduce this impact would be 
regarded favourably.  
 
7. Research questions 
 
This should be a list of the things that the 
developer needs to find out or monitor 
during the process of development, relating 
to the function of the device or how it fits 
into the market place. 
 
From the research undertaken and reported 
above, what are the most important 
questions or uncertainties that must be 
addressed / tested? What factors or 
assumptions have the calculations / 
economic or clinical case hinged upon? 
What potential benefits or threats have you 
ignored in the calculation (see italicised 
points in Qs 4&5, and ‘developments’ 
section)?  
 The most crucial assumption that has been made 
is that there is a cause effect relationship 
between PFO and migraine.  Above all else, this 
direct causal link will need to be proven. 
 Selection is likely to be important.  How will this 
be done? Would there be any extra service costs 
involved in this?  
 The potential market size should be investigated 
in more detail, as well as an investigation into the 
acceptability of the procedure for patients who 
suffer from migraine with aura.   
 To what extent will patients who have undergone 
the procedure still rely on medication for 
symptom relief? Is it appropriate to assume these 
costs will be halved, or does this 
over/underestimate its potential? 
 No cost analysis was found in the literature 
relating specifically to patients who suffer from 
migraine with aura.  Is this significant, and has 
this resulted in the saved costs of patient 
management being underestimated? 
 Was it appropriate to assume similar costs as 
angiography? Were there any potential costs 
incurred that were missed? 
 Although the service costs used for the 
management of acute symptoms included the 
GP, A&E and consultant costs that result from 
adverse events, does this cover any changes that 
might result from the decrease in general access 
to health services, such as routine appointments 
with a GP/clinic?  
 
 




Notes by AC 
(i) Discounting cost savings. 
One-off procedural cost of PFO closure: £966 
Yearly savings in healthcare resources (mainly medication): £123 
 
In the first year, the net impact of PFO closure on costs to the NHS would be:  
£966 - £123 = £843 
 
Any costs incurred or saved in the future must be discounted in order to account for the 
time value of money.  The rate that is used by NICE for this is 3.5% 
Time Horizon: 5 years 
           
    
     
 + 
    
        
 + 
    
        
 + 
    
        
  = £574.79
 
£966 - £575 = £391 
Time horizon: 10 years  
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£966 - £1,059 = - £93 (saving) 
Time horizon: 20 years 
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             = £1809.31 
= £966 - £ 1809 = - £843 (saving) 
It can be observed that by applying the discount rate to calculate the value of savings a long way 
into the future has a big effect on the present value of those savings.  Had we not applied a 
discount rate to the savings in medication costs, the net service cost impact for 20 years would 
have been calculated at (£966 – (20*123)) =  - £1,494 (saving).  
 
(ii) Discounting QALY benefit. 
As well as costs, QALY benefit accrued in the future must also be discounted at a rate of 
3.5% 
 
Time Horizon: 5 years 
             
     
     
 + 
     
        
 + 
     
        
 + 
     
        
  = 0.0981 QALYs
 




Time horizon: 10 years  
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Time horizon: 20 years 
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             = 0.3089 QALYs 
Headroom Notes (PFO Closure) 
In order to calculate the headroom for PFO closure, the main assumptions were: 
- Half of current medication costs could be saved 
- The procedural costs involved would be similar to that of a coronary angiography (minus one 
hospital bed day) 
- The QALY benefit would be similar to that of acupuncture, giving rise to an extra 0.021 QALYs 
per year. 
Under these assumptions, the maximum reimbursable price was calculated according to various time 
horizons: 
 MRP 
WTP: £20,000 WTP: £30,000 
Time Horizon: 1 year -£423  -£213 
Time Horizon: 5 years £1,571 £2,552 
Time Horizon: 10 years £3,709 £5,517 
Time Horizon: 20 years £7,021 £10,110 
 
We can see from the above MRP figures that in the first year, the NHS would not be willing to spend 
any money on the PFO closure device; in fact, it would have to be given £213-£423 to even consider 
undertaking it.  This means that the initial investment required to undertake the procedure more 
than outweighs the combined value of health benefit and saved medication costs that are seen in the 
first year.  Considering a time horizon of 5 years renders a positive willingness to pay for the device, 
of £1,571 to £2,552.   A time horizon of 10 years leads to an MRP of £3,709 to £5,517 and of 20 years: 
£7,021 to £10,110.   
Clearly, the time perspective the health service is willing to adopt is very important here.  The 
research questions should also be considered, including the appropriateness of assumptions made.  
One area of particular concern is the screening/ decision-making process, which has not been 




considered in the health economic analysis.  If deemed appropriate, this means that any 
investigational time / processes must be considered within the headroom calculated.  
Follow-up (PFO Closure) 
Headroom Outcome and Market success 
Does the MRP look realistic? Would it have indicated yes or no to development? 
The question relating to the feasibility of these devices must be posed slightly differently than it has 
done for previous examples.  The headroom analysis would be used in this instance to indicate the 
potential value of PFO closure devices for this particular market.  Although the calculation of 
headroom is exactly the same as it has been for other examples (except that we know that the device 
does work in closing the PFO), the way in which the resulting headroom and MRP should be 
considered is different.  The devices for PFO closure (we have considered two specific ones here) 
have already been developed, and implanted into people with PFO – mainly in people at risk of 
stroke or TIA.  By considering the value of the procedure for use in people who have refractory 
migraine with aura, the question becomes whether enough value could be generated to support the 
actual price of the device.  This would inform the decision of whether to pursue this market 
(considering the costs involved in undertaking clinical trials, marketing, etc.). 
The magnitude of costs that would have to fit into the estimated headroom would be much more 
tangible than if this were a development decision.  At the time of analysis, the device would already 
have had a price, making the comparison between that price and the estimated headroom much 
more straightforward to conceptualise.  The NHSC briefing indicated that the STARFlex (NMT 
Medical) and Premere (St Jude Medical) devices cost just over £4,000 (£3,500 + VAT).  This did not 
include procedural costs (which is why procedural costs were incorporated into the headroom 
analysis).   
Depending on the time horizon taken, the MRP of the PFO closure devices varied greatly.  The 
relatively high procedural costs were incurred in year 1, whereas the health gain and treatment 
savings accumulated over time.  In year one, PFO closure would be associated with a net health 
economic loss (WTP per QALY by the NHS would have to have been over £40,000 before you would 
see a net gain in year one).  The MRP associated with a 5 year perspective for service costs and 
health gain would be £1,571 to £2,552; £3,709 to £5,517 for 10 years; and £7,021 to £10,110 for 20 
years.  This means that given the actual price of the PFO closure devices, a time horizon of at least 10 
years would be required in order for the procedure to be reimbursable.  
However, one important caveat is the question of how patients are identified and screened for the 
procedure.  This was not mentioned in the NHSC briefing, but there is likely to be significant 
investment required for PFO investigation and organisational change required to incorporate this 
into routine clinical practice.  Depending on how much this would cost the NHS, it is likely that an 
even longer time perspective would be required for the procedure to be cost-effective (i.e. over ten 
years).  Unfortunately, I have identified no economic evaluations for the procedure that I can 
compare this with.  




The favourability of headroom would depend on the time horizon that the reimbureser was willing to 
consider, and the magnitude of investment required for the developer to carry out clinical trials.  The 
time perspective would need to be at least 10 years (which sounds feasible, given the effects of the 
procedure should last for the remaining life expectancy of the patient; the mean age of one migraine 
study that I considered was around 46 (Wonderling, Vickers, Grieve, & McCarney 2004)).  However, 
this is without considering the investment required on the part of the NHS for screening, which may 
increase the cost per patient considerably.  This is difficult to quantify, without understanding the 
scale of this upfront cost given the uncertainty of market size.  Tentatively: if 50,000 people have 
migraine with aura symptoms that may warrant such invasive treatment (as suggested in the NHSC 
briefing), these patients would all need to be investigated for PFO, even though it is likely that under 
half will actually have PFO.  NICE IPG guidance indicates that echocardiography is used to confirm 
PFO closure after a closure device is inserted (NICE 2010d); it may therefore be reasonable to assume 
that this type of investigation would also be used to diagnose PFO in the first place.  According to a 
costing report by NICE (NICE 2011b), Echocardiography has a unit cost of £86.  If this is used to 
investigate all 50,000 patients (total cost: £4,300,000), and around half of these go on to undertake 
the procedure as PFO was identified (Schwerzmann et al. 2005), then this would add £172 per 
patient treated. Whilst this seems reasonably modest, the structures that must be put in place to 
incorporate this front-line investigation into clinical practice may be significant and costly, and this 
large up-front cost may pose a barrier to uptake.  This, in addition to the uncertain health benefit 
even if PFO closure did work (without consideration of which the procedure would certainly be 
extremely un cost-effective), presents significant potential barriers to the health economic case for 
PFO closure devices.  
Although these barriers have been identified, I cannot say for sure whether the company would have 
perceived this assessment to be prohibitive.  It should be noted, however, that even if the procedure 
works as well as hoped, its health economic case for uptake may be marginal. 
Headroom development decision result: uncertain.   
 
Has there been a decision made on it by NICE? What was the outcome? 
NICE have issued guidance on the use of PFO closure for various indications: for the prevention of 
recurrent paradoxical embolism (NICE 2005a) in 2005, and now also for recurrent migraine (NICE 
2010d) and for the prevention of recurrent paradoxical embolism in divers (NICE 2012), both issued 
in December 2010.  NICE have indicated that the current evidence on the efficacy of PFO closure for 
recurrent migraine is not adequate, neither in quantity nor quality.  Evidence of safety has shown a 
small incidence of serious adverse events, including device prolapse and embolism.  NICE 
recommend that the procedure should only be undertaken with special arrangements for clinical 
governance, consent, and audit/research.  Guidance for its use in divers is similar. 
 
Is it sold in the UK or the rest of the world?(Or has it in the past) If so, who is it bought by? 
The STARFlex device, produced by NMT Medical, was the first to be tested in a large RCT for PFO 
closure in Migraine patients (the MIST- Migraine Intervention with STARFlex technology- trial).  The 
results were not favourable, and there was a lot of controversy surrounding their presentation 




(allegations of bias and non-disclosure of important information, see section below).  The company 
went into liquidation in 2011 (NMT Medical 2011;Wood 2011). 
St Jude Medical, a medical technology company specialising in cardiac, neurological and chronic pain 
products, had at the time of the headroom analysis a device called Premere PFO Closure System.  
This product is still advertised on their website (St.Jude Medical 2012b).  The information relating to 
the Premere device relates only to its design and use, rather than what/who it is used for.  The 
website indicates that the product is available for use in select international markets, but not in the 
U.S.  The company have another product for PFO closure—AMPLATZER PFO Occluder— for which 
there is more information (St.Jude Medical 2012a); it is assumed that this is the updated version of 
their previous model (though the device also seems to be associated with a company called AGA 
Medical Corp). The device is also said to be available to use in select international markets, but upon 
examination of its instructions for use, the device is intended for the closure of PFO in patients with a 
history of stroke or TIA.  Migraine is not mentioned.  The ESCAPE Migraine trial for the Premere PFO 
closure device, which started recruitment in 2005 and was due to complete in 2012 was terminated 
due to insufficient enrolment (ClinicalTrials.gov 2012). 
 
Have there been investigations into its clinical / cost effectiveness? 
The parimary question for the whole headroom analysis was whether or not a causal link could be 
found between PFO and migraine / migraine with aura.  Although the increased prevalence of PFO 
among migraine sufferers has been confirmed, the presence of a direct relationship between these 
and the proposed benefit of a PFO closure intervention are still controversial and unconfirmed, 
despite the intense investigation in the area (Sharma, Gheewala, & Silver 2011).   
Clinical results seem to vary greatly from trial to trial.  This is exemplified by two studies, one of 
which is a systematic review that concludes that patients who have migraine with aura are likely to 
represent a subset of patients in whom PFO closure has no impact (as opposed to other migraine 
patients who may benefit) (Butera et al. 2010), whereas another study finds that, after PFO closure, 
migraineurs with aura are 4.5 times more likely to experience migraine relief than those who had 
migraine without aura (despite residual shunt) (Jesurum et al. 2008).   
The only RCT that has been completed for PFO closure in migraine patients is the MIST (Migraine 
Intervention With STARFlex Technology) trial, which randomly assigned patients who had migraine 
with aura to PFO closure, or a sham procedure (Dowson et al. 2008).  The results of the trial indicated 
there to be no significant effect of PFO closure on migraine cessation or frequency/severity of 
migraine attacks.  The results and how they have been presented by Dowson and colleagues 
(Dowson et al. 2008) have caused much controversy.  One paper published later in 2008 discusses 
the allegations of misrepresentation of the effectiveness data (Tobis 2008).  Tobis suggests that UK 
and U.S. governmental agencies should hold the company responsible for the publication of all data, 
and for providing an independent review of the data.  Dr.Wilmshurst, the Co-PI of the MIST study and 
a cardiologist from Royal Shrewsbury hospital (a centre participating in the trial) alleged that NMT 
were withholding critical information that had been agreed in the trial design, and failing to disclose 
unfavourable data.  For example, two patients with very unfavourable results were labelled as 




‘outliers’ and omitted from the analysis with no real justification (Wood 2007).  He also claimed that 
30-40% of patients assigned to the intervention had large residual shunts (holes) following the 
procedure (Tobis 2008).  NMT Medical subsequently denied that Wilmshurst was ever co-PI, 
threatened him with legal action for discussing the results of the trial with the press, and was 
dropped from the trial for ‘comitting protocol violaitons’ (Wood 2007).  In April 2011, after three and 
a half years of NMT Medical attempting to bring an expensive libel suit against Wilmshurst in the UK 
high court, the company went into liquidation (Boseley 2011;NMT Medical 2011;Wood 2011).   
As mentioned above, the ESCAPE trial for St. Jude Medical’s PFO closure device was terminated, 
many years into the study, due to insufficient enrolment, and information regarding the devices 
relate only to their use for stroke and TIA patients.    
The fact that the MIST trial represents the only RCT in this area is indicative of the uncertainly around 
the procedure, as well as the relative difficulty in undertaking this sort of trial (which involves half of 
all the recruited patients having to undergo sham surgery).  In their interventional procedure 
overview of PFO closure for recurrent migraine, NICE evaluate the current evidence for the 
procedure.  The mixed results that are reported in the other studies (non-randomized comparative 
studies, comparative case series, studies of registry databases, and case reports of safety) do not 
provide sufficient evidence to support the efficacy of PFO closure for migraine patients, despite the 
fact that some non-randomised studies look favourable (NICE 2010d).   
I found no health economic studies for PFO closure.  
Has the landscape described changed significantly? 
What is current gold standard clinical practice now? Has this changed? 
Given the lack of conclusive data for PFO closure, the intervention has not been recommended for 
the treatment of patients who have refractory migraine with aura.  No interventional procedures are 
mentioned on patient-facing websites for migraine sufferers.   
Are there now many direct competitors? 
As indicated in the headroom analysis, various developers have produced PFO closure devices.  
Direct competitors include AGA Medical Corporation, Gore Medical and Applied Biometrics.  
Conclusions: How useful might the headroom exercise have been? 
For this example, in which the health economic case for PFO closure was investigated in relation to 
Migraine with aura, the headroom that was calculated would not have been used to inform a 
development decision per se, but to support the decision of whether to pursue this market, and 
invest in clinical trials etc.  The results of the headroom analysis indicated that the time perspective 
required to be taken by the reimburser would need to be at least 10 years, but probably more 
considering the likely investment required to screen patients, that had not been incorporated into 
the analysis.  Whether the results of the headroom analysis would have indicated a favourable 
decision to pursue this market or not is difficult to say, but the case for investment is certainly not an 
obvious one.  Headroom calculations are based on a scenario in which the device works as intended.  




The economic analysis brought up some interesting questions (and highlighted the importance of the 
timeframe considered).  Unfortunately these could not be tested, as the clinical effectiveness of the 
procedure has not been proven, which is clearly a prerequisite for any reimbursement 
considerations! No health economic studies were found relating to PFO closure for migraine patients. 
The literature has shown that the clinical efficacy of PFO closure for migraine has not been proven.  
During the headroom analysis, the question of efficacy and the causal link between PFO and migraine 
was highlighted as the crucial factor, and the non-recommendation of PFO closure for stroke patients 
offered a potential warning sign.   
There may well have been some elements of the decision to pursue this market that would not have 
been addressed by the headroom analysis, such as strategic consideration relating to, for example, 
the free-riding of research (though in this case it may well have been that research by others 
worsened the prospects for other companies).   
The headroom analysis (which in this case would principally have been used to explore the worth of 
investing in clinical trials) was uncertain, but this turned out not to matter as it was the clinical 
effectiveness that was its downfall.  NMT performed an RCT which did not produce favourable 
results; the company has since gone bust.  St. Jude Medical have a larger portfolio of products, so 
this was likely to have been less critical for them. They started a trial which was subsequently 
terminated due to insufficient enrolment (probably a results of other trials, as its status was only 
modified in 2011, and in 2008 the trial was still ‘ongoing’ (Wood 2008)). 
The main research question identified was whether PFO closure would work in reducing the burden 
of migraine.   This, as with any headroom analysis, of course turned out to be pertinent.  The other 
questions related to the adequacy and appropriateness of the assumptions that were made.  
Unfortunately, these cannot be tested.  Although the health economic case was uncertain, and the 
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Appendix 8: Participant Information Sheet and Consent Form 
Project Title: The Headroom Method of early economic evaluation of medical devices 
Dear Participant, 
You are being asked to take part in some interview research, the aim of which is to compliment and 
further explore the usefulness of the Headroom Method of early economic evaluation of medical 
devices.  The Headroom Method is intended to aid early decision making in the development of new 
devices, by exploring the potential health economic value of a new product.  The main aim of the 
study is to apply the method to specific medical devices.  These interviews are being undertaken in 
order to gain a deeper insight into the aptness and feasibility of applying the method, by discussing 
the process with its intended user: the developer.  The study has received ethical approval from the 
University’s Science, Technology, Engineering and Mathematics Ethical Review Committee. 
What will be involved in the interview? 
After having discussed with you some of the theory behind the headroom method and talked 
through some worked examples, you will be asked a series of general questions which will relate to 
the method itself and its application (rather than any specific medical device).  The interview will last 
no longer than 20-30 minutes, and will be tape recorded.    
How will the interview be used? 
Where relevant, your anonymity will be conserved in the recording of findings within the research 
project (in which case, you will be referred to by job title e.g. clinician, medical device company, etc).    
Your participation is voluntary and you have the right to withdraw at any time, in which case any 
data collected will be destroyed, and will not be used in the project.  
Where can I get more information? 
If at any time you have questions about the study or about how the information / views you provide 
will be used, then please contact the primary researcher (Amanda Chapman) at any time.  Details of 
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The Headroom Method of early economic evaluation of medical 
devices 
Consent for participation in Interview Research 
Name of Researcher: Amanda Chapman, PhD Student, University of Birmingham 
1. I confirm that I have discussed what will be involved in the interview and read the 
participant information sheet.  I understand the intent and purpose of the 
research.  
  
2. I am happy with how the information discussed will be used and presented as part 
of an academic piece of work (to be published within the researcher’s thesis). 
Where relevant, this will include anonymity of views offered. I have had the 
opportunity to discuss any questions I might have and these have been answered 
to my satisfaction. 
 
3. I have the right to request to be shown the format in which the research will be 
presented. 
 
4. I understand that my interview will be audio recorded, and that this recording will 
be stored securely. 
 
5. I understand that my participation is voluntary, and I have the right to decline to 
answer any question or terminate the interview at any time (without having to 
offer an explanation).  I also have the right to withdraw from the study at any 
time during or after the interview, in which case my data will not be used. 
 
I have read and understood the explanation provided to me, and I consent to participate 
in today’s interview. 
 
Name of Participant   Date   Signature 
……………………………….   ………………  …………………….. 
Name of Researcher   Date   Signature 





Appendix 9: Semi-structured Interviews: Question Topics 
What you do at the moment 
 What are the main drivers in your decision to develop (/advise clients to develop) a new 
medical device? What gets you excited about a new idea? 
 To what extent and at what stage do you formally consider the value that the product could 
provide for the NHS? 
 To what extent were you familiar with health economics before? Did you / how did you 
explore the reimbursement prospects? 
Thoughts on the headroom method 
 As an approach, do you understand the headroom method? 
 Do you agree with its suggested application (e.g. early)? 
  Does it involve an oversimplification of the situation (clinical or reimbursement)? 
 I’ve shown you that I’ve put together a guide to go about identifying headroom.  Do you 
think you could apply the method yourself / incorporate it into your approach? 
 What would the barriers be? 
The headroom method in practice 
 Is the output useful? (MRP).. i.e. can costs be conceptualized at such an early stage? 
 Is it very different to the sorts of things you think about already? (Did you learn anything 
new?)  
 Do you think it is a good use of time? 
 Would you let the results influence your perception of viability of the product? 
 What has been left out?  Do you think there are more important factors that should prevail 
at an early stage? 
 Scope: is it too UK focused? To what extent is your market focus a global one?  
 Who do you think this would be most useful for? 
 
Any other comments, or concerns about the headroom method, how it might be used, difficulties 
that may arise?  
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Appendix 10: Presentation slides for interview sessions 
 
The Headroom Method of early 
economic evaluation for medical devices





• What is it?  A simple health economic decision 
making tool, to identify the innovations that have the 
potential to represent value for the end buyer, and so a 
good investment for you
• When should it be applied? At ‘concept’ stage of 
a new device. i.e. Before decision to develop
• Why is it valuable? To avoid wasting resources on 
devices that will never be cost-effective
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Early Expectations / Lack of data
• At this stage, what we DON’T have is:
– Probability data
– Comprehensive idea of spectrum of outcomes
– Sensitivity analysis
– Exact costs of production
• What we DO have is an idea of what we hope the device 
will achieve for patients and for the health service.  
Headroom 
method
•Will the NHS buy it?





Why is early economic evaluation important?
• To check the commercial viability of a new technology
• To avoid wasting resources on devices that will never be 
cost effective and so never make it to market
• To be a ‘predictor’ of later coverage decisions
– Decision-makers use ‘economic evaluation’ to determine 
whether a new healthcare product represents value to the 
NHS, by comparing it to current practice in terms of:
– Impact on healthcare resources (∆cost) and...
– Impact on patient health (∆ effectiveness)
– The Headroom Method is a way to incorporate this demand-
side reimbursement process (decision to buy) into supply-side 
investment decisions (decision to develop). 
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How do we do this?
• A manipulation of the ‘ICER’ equation 
• NICE ‘threshold’ ICER: £20,000 - £30,000 
ICER< £20,000 – favourable (buy)
ICER>£30,000 – unfavourable (reject)
• Therefore...    Max WTP= £20,000 =
• Max ∆ Cost = £20,000  x ∆QALY
New device




Headroom: An estimate of the maximum additional cost (to 
the health service) over the comparator, at which the 





Max ∆ Cost = £20,000  x  ∆QALY
Headroom: An estimate of the maximum additional cost (to the 
health service) over the comparator, at which the technology is 
considered cost-effective
The Decision: Does the manufacturer deem it 
feasible to produce the new device at a price which 
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The headroom method in graphs
• Isolating maximum reimbursable price (MRP): 
‘Commercial Headroom’
• Examples
1. Device that saves service costs and improves health
2. Device that costs more but improves health






1. Device that saves service costs and improves health
Comparator device / procedure: 
Has a known associated Cost1 and         
QALY1 , that places it here and     
becomes our ‘baseline’
New device: 
No set P2 But..
Potential impact on service costs
Potential health benefit
Cost2, QALY2 
We use these to plot... 
1.Impact on health ∆QALY (QALY2-QALY1) and






•a) Healthcare service costs: SC
•b) Price of device: P
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• Multiply ∆QALY by WTP (In order to put cost impact and 
health benefit on the same scale- £)
∆ Cost
∆ QALY
•a) Healthcare service costs: SC





WTP per QALY: £20,000
Maximum WTP for extra health 
generated:  ∆QALY x £20,000
Maximum WTP for reduced 
service costs (∆SC) and 








•a) Healthcare service costs: SC
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• Thus, the Headroom quantifies the maximum the NHS will pay for 




Adds to headroom, 
because represents a 
disinvestment









Agento IC for VAP
50% ↓ likelihood of VAP
1.   Device that saves service costs and improves health (summary)
∆ Cost
∆ QALY
•a) Healthcare service costs: SC





WTP per QALY: £20,000
Commercial 
Headroom
P2 = (∆QALY x £20,000) + ∆SC + P1
∆QALY (0.00025) * £20,000
∆SC £1,556 (hospital costs)
+ £55 (price of current tubes)
= £1,616
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2.    Device that costs more but improves health
∆ Cost
∆ QALY
•a) Healthcare service costs: SC




WTP per QALY: £20,000
Commercial 
Headroom





3.   Device that reduces costs, with no impact on outcome
∆ Cost
∆ QALY
•a) Healthcare service costs: SC




WTP per QALY: £20,000
Commercial 
Headroom
P2 = ∆SC + P1
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• Does the MRP represent a feasible price for your 
product, when considering the costs of 
production, profit, selling costs, and also the 
need to recover ‘sunk’ development costs?
• By asking this question early on, investment 
decisions can be as informed as possible at this 
early stage
• The headroom method offers a framework for 







The Headroom method allows us to 
estimate the height of the future 
reimbursement opportunity...£ £ £  
An early warning 
signal for industry
Stops manufacturers 
wasting resources on 
devices that will never 
be cost effective so 
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Appendix 11: Thematic analysis codes 
The following table provides a summary and description of all codes used for the coding of data 























BD Burden of Disease The importance of how many people 
the problem affects 
IDHS Impact of disease on health 
service 
Consideration of the impact on NHS 
services or service organization 
DCP Deficiencies in current practice What’s wrong with how things work at 
the moment (thereby justifying the 
space for the new device) 
Costly The clinical problem is costly to 
the health service 
An account of how much the problem 
costs the health service 
IPC A focus on improving patient 
care 
An account of how patient care or the 
patient pathway could be improved 
SOP Statement of own perspective Bringing in own perspective, in terms of 
experience, outlook, past, etc. 
CV  Concept of value An example of the interviewee’s 
concept of value 
BIP  Belief in product Demonstration of interviewee’s belief 
in their own product 
BS Business sense Reference to business opportunity/ 
profit 
CFC Current feasibility check Procedures or ways they make 
decisions at the moment 
IDM Influencing Decision-Making Ability to influence decisions 



















-UND Understanding (negative) Difficulty understanding method 
+UND Understanding (positive) Good understanding of method 
WF Where do I find the figures? Articulating difficulty or uncertainty 
surrounding the finding of figures to 
furnish headroom 
assumptions/calculations 
HA How do I make the assumptions? Uncertainty re appropriate 
assumptions 
ASS Appropriateness of assumptions Whether or not the assumptions made 
in the headroom analysis were 
appropriate 
INAD Information is readily available 
now-a-days 
A recognition that information / 
numbers are easier to find now 
F Figures Reference to the figures used in 
headroom (outside: ‘where do I find 
them?’) 
TM Target market Target market reference. Stratification 
of the potential patient population 
COST Understanding of own costs Ability to weigh up future costs with 
the headroom presented  
PRAC Practicality of doing it yourself How practical / feasible the method 
would be to carry out without me 















SIMPL Simplifying Reference to the simplifications process 
of headroom 
COMPL ‘Completeness’ of the headroom 
analysis 
The fullness of the headroom message. 
To what extent the benefits were 
captured. 
NS Narrow scope of headroom 
method 
Scope too narrow. Not enough 
considered. Factors left out (e.g. global, 
other buyers) 
AR Actual reimbursement How the reimbursement scene actually 
works! 
UNDER Underestimate of 
problem/potential impact 
A belief that the headroom analysis 
may (have) underestimate(d) the true 
benefit of the product 
DD Devices are different An appreciation of devices being 
different to evaluate / considers (e.g 
comparison with pharmaceuticals) 
IHE Importance of health economics The relative importance of the health 
economic case to the interviewee 
COMP Competitors Consideration of competitors 
PvsA Product vs. Application Reference to these not being the same.  
E.g. multiple applications, product then 
application etc. 
TIM Timing  When these ideas (economic 
evaluation) should be considered 
SI Suggested Improvements Things to change about / to add to the 
tool 
ES Extra Scope Wider scope of headroom method 













MOTH Motivation for conducting 
h/room 
The reason health economic ‘value’ is 
being considered 
WUF Who useful for Who would benefit most from the 
method 
SUB Subconscious use of same 
principles 
Basic elements of headroom 
considered pre-headroom 
education‘..although you might not 
know that you’re doing that’ 
KHE Knowledge of health economics 
(before) 
How new are the principles? 
ART Articulating a general notion into 
something concrete 
A tool to hone in on the value 
PS Price setting How the price will actually be set 
IFI Informing future investigation Use to shape future research 
LEARN A learning experience Having learnt from the headroom 
method (e.g. about NICE) 
COMM A tool to help communicate 
value 
Use of output as a communication tool 
with the relevant stakeholders 
ACT Action  What the method has / will be used for 
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